

# 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer

Matthew D. Ringel,<sup>1,\*</sup> Julie Ann Sosa,<sup>2,\*</sup> Zubair Baloch,<sup>3</sup> Lindsay Bischoff,<sup>4</sup> Gary Bloom,<sup>5</sup> Gregory A. Brent,<sup>6</sup> Pamela L. Brock,<sup>7</sup> Roger Chou,<sup>8</sup> Robert R. Flavell,<sup>9</sup> Whitney Goldner,<sup>10</sup> Elizabeth G. Grubbs,<sup>11</sup> Megan Haymart,<sup>12</sup> Steven M. Larson,<sup>13</sup> Angela M. Leung,<sup>5,14</sup> Joseph Osborne,<sup>15</sup> John A. Ridge,<sup>16</sup> Bruce Robinson,<sup>17</sup> David L. Steward,<sup>18</sup> Ralph P. Tufano,<sup>19</sup> and Lori J. Wirth<sup>20</sup>

**Background:** Differentiated thyroid cancer (DTC) is the most prevalent cancer of thyroid and is among the most frequently diagnosed cancers in the United States. The practice guidelines of the American Thyroid Association (ATA) for DTC management in adult patients (previously combined with thyroid nodules) were published initially in 1996, with subsequent revisions based on advances in the field. The goal of this update is to provide clinicians, patients, researchers, and those involved in health policy with rigorous, comprehensive, and contemporary guidelines to assist in the management of adult patients with DTC, emphasizing the patient journey beginning with a thyroid cancer diagnosis.

**Methods:** The questions addressed were based, in part, on prior versions of the guidelines, with input from a larger, more diverse complement of stakeholders. The panel included members from multiple specialties involved in thyroid cancer care, including a patient advocate and an expert in systematic reviews/meta-analyses/guidelines who educated and supported task force members. The panel conducted systematic literature reviews to inform the recommendations and commissioned two additional systematic reviews. Published English-language articles were eligible for inclusion, with a final search date of July 1, 2024. A modified Grading of Recommendations Assessment, Development and Evaluation system was used for critical

<sup>1</sup>Department of Molecular Medicine and Therapeutics, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio, USA.

<sup>2</sup>Department of Surgery, University of California San Francisco (UCSF), San Francisco, California, USA.

<sup>3</sup>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

<sup>4</sup>Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

<sup>5</sup>ThyCa: Thyroid Cancer Survivors' Association, Inc., Olney, Maryland, USA.

<sup>6</sup>Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA.

<sup>7</sup>Division of Human Genetics, Department of Internal Medicine, The Ohio State University College of Medicine, Wexner Medical Center, and Comprehensive Cancer Center, Columbus, Ohio, USA.

<sup>8</sup>Department of Medical Informatics and Clinical Epidemiology and Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA.

<sup>9</sup>Departments of Radiology and Biomedical Imaging and Pharmaceutical Chemistry, University of California, San Francisco, California, USA.

<sup>10</sup>Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado Anschutz Medical Campus, Denver, Colorado, USA.

<sup>11</sup>Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

<sup>12</sup>Department of Medicine, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, Michigan, USA.

<sup>13</sup>Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

<sup>14</sup>Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA.

<sup>15</sup>Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, New York, USA.

<sup>16</sup>Department of Surgical Oncology, Fox Chase Cancer Center, Lewis Katz School of Medicine, Temple University Philadelphia, Philadelphia, Pennsylvania, USA.

<sup>17</sup>Department of Endocrinology, Royal North Shore Hospital and University of Sydney, Sydney, Australia.

<sup>18</sup>Department of Otolaryngology – Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

<sup>19</sup>Division of Otolaryngology-Head and Neck Surgery, Sarasota Memorial Health Care System, The Florida State University College of Medicine, Sarasota, Florida, USA.

<sup>20</sup>Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

\*Drs. Ringel and Sosa were co-leaders of the task force and are co-first authors, contributing equally to the manuscript. After the co-leaders, the authors are listed in alphabetical order.

appraisal of evidence and determining the quality of data. The guidelines panel had editorial independence from the ATA. Competing interests of task force members were pre-vetted, regularly updated, communicated with task force members, and assessed and managed by ATA leadership and the Clinical Practice Guidelines and Statements Committee.

**Results:** These revised guidelines begin with the initial cancer diagnosis and continue with recommendations for staging and risk assessment, initial treatment decisions, assessment of treatment responses, monitoring approaches, diagnostic testing, and subsequent therapies based on the strength of evidence for response and consideration of side effects and outcomes. Patient-reported outcomes and identified areas of need for additional high-quality research are highlighted.

**Conclusions:** These revised evidence-based recommendations inform clinical decision-making in the management of DTC that reflect the changing science and optimize the evidence-based clinical care of patients throughout their journey with DTC. Critical areas of need for additional research are highlighted.

**Keywords:** thyroidectomy, thyroid cancer, radioactive iodine, thyroglobulin, targeted therapy, active surveillance

#### TABLE OF CONTENTS 2025 ATA GUIDELINES FOR DTC

Page number	Sections and subsections	Item
	2025 AMERICAN THYROID ASSOCIATION MANAGEMENT GUIDELINES FOR ADULT PATIENTS WITH DIFFERENTIATED THYROID CANCER	
843	INTRODUCTION	T1, F1
845	AIM AND TARGET AUDIENCE	
845	METHODS	
847	CLINICAL MANAGEMENT PRINCIPLES: DICTIONARY AND DEFINITIONS	
847	<i>General Definitions</i>	T9, F3
847	<i>Treatment Definitions</i>	F2, F3
848	INITIAL DTC MANAGEMENT	
849	<i>Thyroid Cancer Pathology</i>	T2, T3
851	<i>Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features</i>	T3, F4
851	<i>Is NIFTP considered thyroid cancer?</i>	R1
851	<i>Thyroid Cancer Epidemiology</i>	
852	<i>Genetic Predisposition to Follicular Cell-Derived Thyroid Cancer and Genetic Counseling</i>	
852	<i>Which patients with DTC should be offered germline genetic testing?</i>	R2, T4
853	<i>Should patients with non-syndromic FNMTc receive genetic testing?</i>	R3
854	<i>Should family members of patients with FNMTc be screened for thyroid cancer?</i>	R4
854	<i>When should germline genetic testing be offered to patients with DTC with alterations detected on tumor samples (somatic testing)?</i>	R5
855	<i>Initial Management of Thyroid Cancer</i>	
855	<i>Does surgical experience influence complication rates for thyroidectomy?</i>	R6
856	<i>What is the role of preoperative staging with diagnostic imaging and laboratory tests?</i>	R7, F3
857	<i>When should preoperative cross-sectional or <sup>18</sup>F-fluorodeoxyglucose-PET imaging be performed?</i>	R8
858	<i>Should a serum Tg level be measured prior to surgery?</i>	R9
858	<i>Should preoperative somatic genomic testing be performed to inform the extent of surgery?</i>	R10
859	<i>Are there patients in whom active surveillance and percutaneous ablation are appropriate management options?</i>	R11
861	<i>What is the optimal approach for patients undergoing active surveillance?</i>	R12
861	<i>Should serum Tg and TgAb levels be measured during active surveillance?</i>	R13
861	<i>Are there clear indications for when patients undergoing active surveillance should pursue resection?</i>	R14
861	<i>What is the optimal operative approach for DTC?</i>	R15
		T5
864	<i>When should completion thyroidectomy be performed?</i>	R16
866	<i>What is the surgical approach to thyroglossal duct carcinoma?</i>	R17
866	<i>When should completion thyroidectomy following Sistrunk procedure be performed?</i>	R18
866	<i>When should prophylactic central-compartment lymph node resection be performed?</i>	R19
867	<i>What is the best approach for therapeutic central and lateral compartment node resections?</i>	R20
868	<i>What is the appropriate perioperative approach to voice and parathyroid issues?</i>	R21
869	<i>Should the patient undergo voice or laryngeal examination prior to surgery?</i>	R22
869	<i>How should the recurrent laryngeal nerves be assessed intraoperatively?</i>	R23
872	<i>How should the parathyroid glands be managed intraoperatively and perioperatively?</i>	R24
872	<i>Should drainage of the thyroidectomy bed be performed?</i>	R25
872	<i>How should the surgeon manage postoperative voice changes and symptoms after surgery if they occur?</i>	R26
873	<i>What are the basic principles of histopathologic evaluation of thyroidectomy samples?</i>	R27
874	<i>How should risk of recurrence and initial assessment be performed after surgery?</i>	R28
		T6, T7, T8, F2
881	<i>How should clinical response to surgery be assessed?</i>	R29
881	<i>When should Tg levels be measured after surgery?</i>	R30
883	<i>What is the role of ultrasound and other imaging techniques (CT, MRI, <sup>18</sup>FDG-PET-CT) after primary resection?</i>	R31, T9
884	<i>What is the role of RAI after thyroidectomy in the primary management of DTC?</i>	R32, F2
		T10

(continued)

(CONTINUED)

Page number	Sections and subsections	Item
887	Should radioiodine be administered for OTC treatment?	R33
887	How should patients be prepared for RAI administration?	R34
889	Should a low-iodine diet be prescribed prior to RAI administration?	R35
889	When and how should diagnostic radioiodine WBS be performed?	R36
890	Should post-therapy WBS be performed?	R37
890	Should single photon emission computed tomography with computed tomography be performed with the WBS?	R38
890	How should patients be educated regarding radiation safety?	R39
891	How do you counsel and minimize risks of RAI side effects to the salivary glands and lacrimal ducts?	R40
891	How should patients be counseled regarding the risk of second primary malignancy after receiving RAI therapy?	R41
892	What other testing should patients receiving RAI therapy undergo?	R42
892	How should patients be counseled about RAI therapy and pregnancy, nursing, and gonadal function?	R43
893	What is the role of radiotherapy, with or without chemotherapy, in patients with DTC?	R44
895	LONG-TERM MANAGEMENT AND ADVANCED DTC MANAGEMENT	F5
895	What Are the Appropriate Features of Long-Term Management of Patients with DTC?	F6
895	What is the appropriate degree of TSH suppression in patients treated for DTC?	R45, T9
896	How long should TSH suppression to below the reference range be maintained?	R46, T9
897	What is the role of serum Tg measurement in the follow-up of DTC?	R47
899	Can monitoring be de-escalated or discontinued in patients with low-risk DTC?	R48, T11
900	Introduction to de-escalation of long-term monitoring in low-risk DTC.	
900	Ultrasound monitoring after total thyroidectomy for patients with low-risk DTC.	
902	When should neck ultrasound and other imaging techniques (WBS, SPECT-CT, and <sup>18</sup> F-DG-PET-CT) be performed during follow-up?	R49
902	Diagnostic RAI WBS	R50
903	<sup>18</sup> F-DG-PET/CT scanning	
903	Is ongoing risk stratification (response to therapy) useful in guiding long-term disease surveillance and therapeutic management decisions?	R51, F5, F6, F8
906	When and what type of treatment should be performed when there is evidence for locoregional residual, clinically recurrent, or progressive DTC?	R52, F7
908	Should RAI therapy be used for the treatment of isolated cervical lymph node metastases?	R53
908	Should external beam radiation therapy be used in isolated cervical node metastases?	R54
908	What preparation and dosing strategies should be used for RAI therapy for locoregional and/or distant metastases?	R55
910	What RAI dosing strategies should be used for patients with pulmonary metastases?	R56
910	What RAI dosing strategies should be used for patients with bony metastases?	R57
911	When should empiric RAI be considered for Tg-positive, RAI diagnostic scan-negative patients?	R58
911	How is radioiodine-refractory DTC classified?	R59
912	Supplemental criteria suggesting less RAI sensitivity	
912	Which patients with metastatic DTC can be followed without additional therapy?	R60
912	For patients with RAIR DTC deemed appropriate for systemic treatment, what is the optimal approach to choosing the best therapy?	R61, F8
913	What is the general approach for first-line therapy for patients with progressive RAIR DTC?	
913	When patients with RAIR DTC without an actionable driver alteration need systemic therapy, what is the best initial treatment?	R62
915	What is the best timing for the initiation of MKIs in patients with RAIR DTC?	R63
916	When initiating lenvatinib treatment for RAIR DTC, what is the best starting dose?	R64
916	How should adverse events in patients receiving VEGFR MKI therapy be managed?	R65
917	What is the preferred approach to second-line therapy for patients with RAIR DTC?	R66
918	For patients with NTRK fusion-positive RAIR DTC, what is the optimal first-line therapy?	R67
919	For patients with RET fusion-positive RAIR DTC, what is the optimal first-line therapy?	R68
920	For patients with ALK fusion-positive RAIR DTC, what is the optimal first-line therapy?	R69
920	For patients with BRAF <sup>V600E</sup> mutation-positive RAIR DTC, what is the optimal first-line therapy?	R70
921	For patients with RAIR DTC harboring other potentially actionable targets, what is the optimal first-line therapy?	R71, F9
922	What is the approach for patients with progressive RAIR DTC who progress on first-line therapy or cannot tolerate first-line therapy?	F9
922	What is the optimal approach to address disease progression in RAIR DTC on gene-specific therapy?	R72
923	What is the role of immunotherapy in RAIR DTC?	R73
924	For patients with RAIR DTC, what is the role for kinase inhibitor redifferentiation therapy?	R74
925	What is the role of cytotoxic chemotherapy in RAIR DTC?	R75
925	What is the optimal approach for patients with oligometastatic RAIR DTC?	R76
926	What is the optimal treatment approach for patients with site-specific symptomatic RAIR DTC?	R77
927	When should bone-directed agents be considered for patients with DTC?	R78
928	What is the best treatment for patients with brain metastases?	R79
928	Who should be considered for clinical trials?	R80
929	Considerations managing pregnant patients with DTC	R81
930	Cancer Survivorship	
930	What are long-term survivorship concerns related to initial thyroid cancer therapy?	R82
931	How should financial hardship caused by thyroid cancer be addressed?	R83
931	What are the critical psychosocial concerns of thyroid cancer survivors?	R84

F, Figure; R, recommendation; T, Table.

## Introduction

Differentiated thyroid cancer (DTC) includes papillary, follicular, and oncocytic carcinomas, comprising the vast majority (>90%) of all thyroid cancers.<sup>1</sup> In the United States, it is estimated that there were 44,020 new cases of thyroid cancer in 2024,<sup>2,3</sup> compared with 37,200 in 2015 when the last American Thyroid Association (ATA) guidelines were


published. The yearly incidence tripled from 4.9 per 100,000 in 1975 to 14.3 per 100,000 in 2015.<sup>4</sup> Approximately 25% of the new thyroid cancers diagnosed in 1988–1989 were <1 cm, compared with 39% of the new thyroid cancer diagnoses in 2008–2009.<sup>4</sup> This shift to earlier detection/diagnosis correlates with the increasing use of neck ultrasonography and other imaging along with the advent of ultrasound-guided fine needle aspiration (FNA).<sup>5</sup> The incidence of thyroid cancer,

and particularly small thyroid cancers, has reduced in the United States since 2014.<sup>2,6</sup> This change in incidence trajectory is likely a reflection of the adoption of guidelines' recommendations from the ATA and other organizations discouraging FNA of small nodules <1 cm in the absence of abnormal lymph nodes or local invasion, due to the overall outstanding prognosis associated with these tumors and weighed against the potential risks of unnecessary treatment. In addition to changes in the management of early-stage thyroid cancer, prior guidelines introduced criteria to enhance initial decision-making and a response framework following interventions to facilitate further management decisions. These have been validated since the prior guidelines, enabling adoption in clinical practice. There have been major advances in understanding the molecular causes of thyroid cancer development and progression that have created newly approved treatment options for subsets of patients. Published data in these and other areas require serial updates of existing guidelines to facilitate clinical care. In the current guidelines, an approach to clinical decision-making is introduced based upon the individual patient and clinician journey with thyroid cancer, which we term DATA: **D**agnosis, **r**isk/benefit **A**ssessment, **T**reatment decisions, and **r**esponse **A**ssessment (Fig. 1). This approach begins at the initial diagnosis of thyroid cancer, the diagnosis of residual disease or a clinical

recurrence, and it includes assessment to determine whether a particular intervention is appropriate based on risks and benefits as well as individual patient factors. When multiple possible management strategies are available, the framework supports identification of the best treatment option. Then, after intervention, an assessment of response using the 2025 ATA risk assessment tool is deployed to determine whether more treatment or monitoring is appropriate. The clinician and the patient can use this DATA framework to help make clinical decisions from diagnosis through the patient's entire disease course.

In 1996, the ATA published treatment guidelines for patients with thyroid nodules and DTC.<sup>7</sup> Over the last 25–30 years, there have been remarkable advances in knowledge affecting the diagnosis and treatment of DTC, but clinical controversy continues to exist in many areas. In the end, the goal is to provide individualized therapy for each patient based on the best application of clinical data to their unique case. For example, a less aggressive approach would be recommended for individuals with early-stage DTC who have an excellent prognosis or for individuals at higher risk of side effects, while a more aggressive approach would be recommended for those patients with higher risk disease or those with inadequate response to initial therapy. Overall, there are too few high-quality clinical trials in thyroid cancer, contributing to uncertainty and controversy surrounding

## DATA Framework



**FIG. 1.** Overall DATA framework for clinical management.

several important areas of clinical management. As a group, specific areas where future research is felt to be essential to support data-informed clinical care are noted in the text.

Finally, as clinical decisions in the office are made jointly by patients and clinicians (i.e., shared decision-making), we provide specific sections regarding survivorship concerns from patient advocates and point to areas where patient-reported outcomes research is needed. In situations where clinicians from multiple disciplines are managing patients, a transdisciplinary approach is recommended to optimize collaborative clinical care and communication with the patient and between physicians. Examples may include multidisciplinary tumor boards, co-located clinics, and direct communication between clinicians.

### Aim and Target Audience

The objective in these guidelines is to inform clinicians, patients, researchers, and health policy makers about the best available evidence (and its limitations) relating to the diagnosis and treatment of adult patients (over 18 years of age) with DTC. ATA guidelines for pediatric thyroid cancer have been published and/or are under development.<sup>8</sup> Compared with prior guidelines, this document applies only to patients with DTC, including individuals diagnosed with noninvasive follicular tumors with papillary-like nuclear features (NIFTP) and follicular tumors with uncertain malignant potential (FUMP), extremely low-risk lesions with diagnosis possible only after surgical excision.

This document is intended to inform clinical decision-making using the DATA framework for patients as they proceed through their individual journey with thyroid cancer, minimizing potential harm from overtreatment in patients at low risk for disease-specific mortality and morbidity while more intensively monitoring and treating patients at higher risk, including those with aggressive forms of DTC. These guidelines should not be interpreted as a replacement for clinical judgment and should be used to complement informed, shared patient–clinician consideration of complex issues. It should also be recognized that specific recommendations apply most to those patients reflected by participants in the studies referenced and therefore may or may not be applicable to individuals with unique demographic, clinical, and pathological characteristics. National clinical practice guidelines may not necessarily constitute a legal standard of care in all jurisdictions.<sup>9</sup> If important differences in practice settings present barriers to meaningful implementation of the recommendations of these guidelines, interested physicians or groups (in or outside of the United States) may consider adapting the guidelines using established methods<sup>10,11</sup> (ADAPTE Collaboration, 2009, <http://www.gi-n.net>). ADAPTE Collaboration is an international group of researchers, guideline developers, and guideline implementors who aim to promote the development and use of clinical practice guidelines through the adaptation of existing guidelines. As our primary focus was reviewing the quality of evidence related to health outcomes and diagnostic testing, we have decided *a priori* not to focus on economic resources and financial implications within specific recommendations. However, with attention to survivorship and with participation of a patient advocate, we include a section on this

important topic (i.e., “financial toxicity”) as an emerging area of research and attention.

It is recognized that other groups have developed clinical practice guidelines for DTC in the United States and worldwide. While there are many similarities in approaches and recommendations across guidelines, there also are many controversies, differences in critical appraisal approaches and in clinical practice patterns across geographic regions and clinician specialties, as well as inconsistency in available testing and treatment approvals in different countries. In the end, it is not surprising that organizational guidelines will not completely agree for all issues. These differences highlight the importance of clarifying evidential uncertainties with additional research.

### Methods

The first ATA Thyroid Nodules and Differentiated Thyroid Cancer guidelines were published in 1996<sup>7</sup> and revised in 2006,<sup>12</sup> 2009,<sup>13</sup> and 2015.<sup>14</sup> Due to the expansion of knowledge concerning the management of thyroid nodules and DTC, a decision was made to separate the topics into two sets of updated guidelines. Task force chairs were appointed by the ATA President with approval of the Board of Directors (BOD). A committee of specialists with complementary expertise was appointed representing Endocrinology, Surgery (endocrine surgery and otolaryngology—head and neck surgery), Nuclear Medicine, Pathology, Medical Oncology, Cancer Genetics, and Medical Informatics/Clinical Epidemiology. For the first time, a patient advocate was included. Conforming to ATA policy to ensure broad specialty and geographic representation with fresh perspectives, at least one-third of the task force was made up of new members who did not help to create prior ATA guidelines.

#### *Management of potential competing interests*

Task force chairs were proposed and vetted by the ATA Guidelines and Statements Committee (GSC) and then confirmed by the ATA BOD. Potential conflicts of interest (COI) also were assessed by the ATA GSC and BOD. Task force chairs were selected for their expertise, and 11 proposed task force members were evaluated for COI prior to invitations to serve on the committee. Any potential financial competing interests were declared (see COI section), and, where appropriate, individuals were not involved in the final approval of recommendations for which a potential or perceived conflict was identified. Competing interests were re-evaluated annually by the task force chairs and members. The opinions expressed herein are those of the authors, and the task force had complete editorial independence from the ATA. Except for the methodology consultant (R.C.), who received payments from the ATA, no individual task force members received funding from the ATA or from industry for work on these guidelines.

#### *Systematic review methods*

A series of systematic reviews were conducted to inform these guidelines. The key questions used to guide the systematic reviews were developed by the guidelines task force

using the PICO (Population, Interventions, Comparisons, and Outcomes) framework. The population was people with DTC, as described above. Outcomes were prioritized through discussion and consensus of the group. Survival or mortality outcomes (all-cause and/or cancer-specific) were prioritized most highly, followed by other oncologic (e.g., metastasis, progression, recurrence) and clinical ones (e.g., quality of life [QoL], function, adverse events). Intermediate (e.g., radiological or laboratory) outcomes were assigned lower priority.

For key questions addressing active surveillance versus immediate surgery and diagnostic accuracy of serum thyroglobulin (Tg) management following partial thyroidectomy or total/near-total thyroidectomy without radioactive iodine (RAI), the guidelines task force commissioned systematic reviews from the Pacific Northwest Evidence-based Practice Center at Oregon Health & Science University.<sup>15,16</sup> For these systematic reviews, searches were conducted by an information specialist on Ovid MEDLINE, Embase, and Cochrane Central for relevant studies using search terms based on the corresponding prespecified inclusion criteria (PICO). Searches were supplemented by reference list review for additional studies. Inclusion was restricted to English-language studies, and studies published only as conference abstracts were excluded. Two investigators independently reviewed titles, abstracts, and full-text articles for eligibility for inclusion. Data on study characteristics, patient and tumor characteristics, and results were extracted by one investigator and verified by a second. The quality (risk of bias) of each study was assessed using study-design specific criteria adapted from the U.S. Preventive Services Task Force Procedure Manual. The overall quality of evidence was assessed using methods adapted from the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group, based on risk of bias, consistency, directness, precision, and reporting bias. Evidence was graded as “high,” “moderate,” “low,” or “very low” certainty, indicating the confidence in the findings; in accordance with the adapted approach to GRADE developed by the Clinical Guidelines Committee of the American College of Physicians,<sup>17</sup> evidence too limited to permit reliable conclusions was graded as “insufficient.”

For the other Key Questions, task force members also conducted searches of electronic databases (Medline using PubMed or OVID) with assistance from an information specialist, selected articles using prespecified eligibility criteria, and assessed the quality of evidence using methods adapted from GRADE and the American College of Physicians.

#### Guideline development methods

Each recommendation was developed by a subgroup of members based on the findings of the systematic reviews. Draft recommendations were reviewed by the full committee and revised based on full committee input prior to final voting. Approval of recommendations was by group discussion and an informal consensus process in meetings led by the co-chairs<sup>17–19</sup>; final recommendations required majority approval from all nonconflicted task force members. Task force members used criteria adapted from methods developed by the U.S. Preventive Services Task Force and the Cochrane Collaboration to assess the quality of included papers.<sup>20,21</sup>

Each recommendation was graded as strong or conditional (Table 1).<sup>22</sup> Strong recommendations are applicable to all or nearly all persons or situations and are indicated when benefits clearly outweigh harms with at least moderate certainty. Other factors supporting strong recommendations are non-sensitivity to values/preferences regarding outcomes, high feasibility and acceptability, low or efficient costs or use of resources, and anticipated positive impacts on equity. When certainty is low, strong recommendations require a strong rationale for benefit despite uncertainty in the evidence and strong supporting considerations (e.g., low cost, high feasibility, high acceptability, and/or likely positive impacts on equity). Conditional recommendations are applicable to most people or situations, though other courses of action might be appropriate in certain circumstances or under certain conditions. Conditional recommendations are indicated when the balance of benefits to harm is relatively close, when there is lower certainty about benefits and/or harms, when decisions are preference-sensitive, or when there are important concerns about feasibility, acceptability, resource use, or equity impact.

When the quality of evidence was low or insufficient, a Good Practice Statement (GPS) served as an alternative to a graded recommendation in selected situations.<sup>23</sup> A GPS is not GRADE-d but is like a strong recommendation, in that it is applicable to all or nearly all persons or situations; not following a GPS would be considered outside of usual clinical practice. To be a GPS, the benefits of the recommended intervention must be obvious and actual certainty of benefits must be high despite the lack of direct evidence demonstrating benefits. In many cases, collecting direct evidence showing benefits may not be feasible. Rather, inferred benefits are based on a compelling chain of indirect evidence that must be clearly described. In general, to qualify as a GPS, there must be consensus from the guidelines group. A unanimous consensus was required for all GPS included in these guidelines.

After completion of approved recommendations, a final literature review was performed by each group, including manuscripts published and available electronically or in print through July 1, 2024. A single exception was made to include the recently published updated World Health Organization’s (WHO) classification of tumors or endocrine organs in 2025.<sup>24</sup> Once the article was drafted, all recommendations were re-reviewed by all panel members until no further suggestions for revisions were requested by any panel members. Thus, consensus on acceptability of recommendations and article text was reached for all recommendations. This approach adheres to best practices in guideline consensus statements. Patient representative input was requested for all recommendations; the

TABLE 1. GRADE RECOMMENDATION GRID

<i>Strength of recommendation</i>	<i>Certainty of evidence</i>			
Strong	High	Moderate	Low <sup>a</sup>	Very low <sup>a</sup>
Conditional	High	Moderate	Low	Very low
<i>No recommendation</i>	Insufficient evidence to determine benefits and/or harms			

<sup>a</sup>Strong recommendations are only indicated when certainty is low or very low in limited circumstances.

patient representative was a full member of the committee and included in all consensus discussions.

The guidelines article was reviewed and approved by the ATA Clinical Practice Guidelines and Statements Committee and the ATA BOD and then made available to the entire ATA membership for review and comments in the Fall of 2024. Feedback and suggestions were discussed by the task force, and revisions were made to the article prior to journal submission. The organization of management guideline recommendations is shown in the table of contents.

### Clinical Management Principles: Dictionary and Definitions

Several terms are utilized throughout the guidelines in different sections and recommendations. Important definitions used by the committee are included below:

#### General definitions

**Active surveillance.** The ongoing observation or active monitoring of a known or suspected primary, intrathyroidal, low-risk DTC with serial imaging as an alternative to upfront surgical intervention. This is a type of expectant management and is only appropriate for a subset of low-risk DTCs (see **Recommendation 11**). This does not pertain to persistent or recurrent thyroid cancer, in which case the term “monitoring” is employed (see below). Some proportion of patients who undergo active surveillance may be recommended to pursue thyroid surgery if there is concern for disease progression or based on patient preference.

**Disease monitoring.** Monitoring for biochemical (elevated level of serum Tg) and/or structural persistence or recurrence of disease (as confirmed by imaging and/or biopsy) following the diagnosis and initial treatment (surgery ± RAI) of thyroid cancer. It is deployed to evaluate patients for disease progression and inform the type and timing of interventions deemed appropriate.

**Response to therapy.** Response assessment is performed after intervention, either for initial or clinically persistent/recurrent disease<sup>14,16,25</sup> (see **Recommendation 29** and Table 9).

**Excellent response.** No biochemical or structural evidence of persistent thyroid cancer (i.e., remission).

**Indeterminate response.** The presence of nonspecific findings on imaging; mildly elevated serum Tg levels; or positive, but stable or declining, anti-Tg antibody (TgAb) levels in persons who have undergone total thyroidectomy with or without RAI. Most patients in this category prove to have a “good” clinical response to therapy, especially if they have a low risk of clinical recurrence, and findings are nonspecific. However, those at intermediate or high risk of clinical recurrence based on histopathologic and staging characteristics in this category may have higher rates of recurrence.

**Biochemically incomplete response.** Elevated serum Tg concentrations or rising TgAb levels without radiological evidence of structural recurrence in persons who have undergone total thyroidectomy with or without RAI.

**Structurally incomplete response.** Structural evidence of disease recurrence (by imaging or biopsy), usually in conjunction with elevated Tg and/or TgAb levels.

**Persistent or recurrent disease.** See **Recommendation 29** and Table 9.<sup>26</sup>

**Clinically persistent disease.** Biochemical or structural evidence of disease within 90 days of initial therapy (or intervention for persistent disease).

**Clinically recurrent disease.** Biochemical or structural disease subsequently identified in patients previously deemed to have an excellent response following therapy. Clinically recurrent disease likely represents progression of residual disease that is below the lower limits of detection.

**Risk of recurrence.** We use the term “recurrence” to mean clinical recurrence, recognizing that most recurrences reflect growth of residual disease to clinically detectable levels (Fig. 2). An overall assessment of risk of biochemical or structural recurrence determined by incorporating a combination of factors: histopathologic characteristics of the resected tumor, American Joint Committee on Cancer (AJCC) staging, imaging, molecular analysis of tumor, and response to therapy at subsequent evaluation.<sup>27</sup> For the purpose of these guidelines, categories are designated as low (<10%), low-intermediate (10–15%), intermediate-high (≥16–30%), and high (>30%) risk of recurrence.

#### Treatment definitions

**Extent of surgery definitions (ATA website definitions).** **Total thyroidectomy:** Surgical removal of the entire thyroid gland.

**Near-total thyroidectomy:** Intended extent of resection for thyroid cancer is total thyroidectomy, but a small remnant may be left for a specific reason (usually confidence in nerve preservation).

**Lobectomy or hemithyroidectomy with or without isthmusectomy:** Surgical removal of one lobe (half) of the thyroid with or without the isthmus.


**Subtotal thyroidectomy:** Surgical removal of almost all of the thyroid gland, leaving 3–5 g of thyroid tissue with the intent of maintaining adequate thyroid hormone production.<sup>28</sup> This operation is not recommended if the diagnosis of thyroid cancer is known preoperatively.

**Completion thyroidectomy:** Surgical removal of the remnant thyroid tissue following procedures of less than total or near-total thyroidectomy.

#### Extent of lymphadenectomy definitions

**Central neck dissection.** Central neck lymph nodes include Levels VI and VII (Fig. 3).<sup>29–33</sup> Central neck dissection is a comprehensive removal of pretracheal and prelaryngeal lymph nodes, along with at least one paratracheal nodal basin. It can be unilateral or bilateral; the laterality and extent of dissection should be documented at the time of operation in addition to surgical intent (therapeutic vs. prophylactic).

**Therapeutic.** It implies that metastatic nodal disease is apparent clinically preoperatively or intraoperatively by examination and/or imaging, cN1a.



**FIG. 2.** ATA 2025 Risk of Recurrence for PTC, FTC, and OTC. \*Lymph metastases are uncommon in OTC and FTC/IEFVPTC. FTC, follicular thyroid carcinoma; IEFVPTC, invasive encapsulated follicular variant of papillary thyroid carcinoma; OTC, oncocytic thyroid carcinoma; PTC, papillary thyroid carcinoma.

*Prophylactic.* It implies that no metastatic nodes are detected by examination or imaging preoperatively or intraoperatively, cN0.

*Lateral neck dissection.* Full compartment dissection of the lateral cervical neck lymph nodes in Levels IIA, III, IV, and VB ipsilateral to the tumor and performed for clinical evidence of metastatic involvement. Dissection of Levels I, IIB, and VA are not regularly performed but can be considered based on findings suggestive of metastatic disease in these compartments (Fig. 3).

*Completeness of surgical resection.* The goal of surgery is to remove safely as much thyroid cancer as possible. To define the completeness of resection, the AJCC created definitions that are used in these guidelines to facilitate communications. An R0 resection means that the surgical margin is microscopically negative for residual tumor. An R1 resection means that there is no residual macroscopic tumor but that microscopically positive margins still demonstrate the presence of tumor. R2 resection means that gross (macroscopic) disease remains post-surgery.

<sup>131</sup>I, RAI administration

*Remnant ablation.* RAI administration to destroy benign remnant thyroid tissue following total or near-total thyroidectomy.<sup>26</sup>


*Adjuvant therapy.* RAI administration to destroy suspected (but not identified) remaining thyroid cancer following total or near-total thyroidectomy.

*Therapeutic treatment.* RAI administration to treat known residual or recurrent thyroid cancer, either initially or with subsequent progression of thyroid cancer after total or near-total thyroidectomy.

*Thyrotropin suppression therapy.* Use of thyroid hormone to suppress serum thyrotropin (TSH) concentrations below the normal range based on the risk of recurrence and/or response to therapy.

**Initial DTC Management**

The DTC guidelines begin with a certain or near-certain diagnosis of thyroid cancer on preoperative FNA testing (Bethesda VI cytology and/or molecular results with high certainty of malignancy) as reviewed in the thyroid nodule guidelines, or after initial surgery based on surgical histopathology analysis. We also include a discussion of the NIFTP and FUMP due to their malignant potential. Recent updates were made to the histological criteria, subtypes of thyroid cancer, and staging. They are summarized in the following section.



**FIG. 3.** Nodal levels with corresponding anatomical landmarks (used with permission from R. Udelsman, MD).

#### Thyroid cancer pathology

Throughout this document, the 5th edition of the WHO Classification of Thyroid Tumors has been utilized for descriptions of the types of non-anaplastic follicular cell-derived thyroid carcinomas and NIFTP (Tables 2 and 3).<sup>24</sup> Approximately 90% of thyroid cancer cases are well differentiated and are classified based on the predominant histomorphology; however, they now also can be categorized based on their molecular profiles. Four main types of DTC include follicular thyroid carcinoma (FTC), invasive encapsulated follicular variant of papillary thyroid carcinoma (IEFVPTC), papillary thyroid carcinoma (PTC), and oncocytic thyroid carcinoma (OTC).<sup>24,34–36</sup>

PTC is the most common type of DTC. PTC is typically indolent and associated with excellent long-term survival:

**TABLE 2. PATHOLOGICAL DIAGNOSTIC CRITERIA OF NIFTP**

A. Encapsulation or clear demarcation <sup>a</sup>
B. Follicular growth pattern, including: Absent papillae <sup>b</sup>
Absent psammoma bodies (reminiscent of dead papillae)
<30% solid, trabecular, or insular growth pattern
C. Nuclear features of papillary thyroid carcinoma
D. No invasive characteristics (no capsular or vascular invasion) <sup>b</sup>
E. No tumor necrosis
F. No high mitotic activity, defined as <3 mitoses per 10 high-power field

<sup>a</sup>Tumors are well demarcated from the surrounding thyroid parenchyma and can be thinly or partially encapsulated.

<sup>b</sup>Features requiring histopathologic examination of the entire tumor capsule and tumor.

NIFTP, noninvasive follicular tumors with papillary-like nuclear features.

96% at 5 years, 93% at 10 years, and >90% at 20 years. Overall, mortality rates for PTC are 1–6.5%, with an overall recurrence rate of 15–35%; tumor recurrence typically occurs in the tumor bed, cervical lymph nodes, or (rarely) distant sites.<sup>14,37</sup> PTCs have characteristic nuclear features and can present as infiltrative and encapsulated tumors. Molecular studies have shown that most PTCs (90%) develop by the activation of a Mitogen-activated protein kinase (MAPK) pathway-event.<sup>38,39</sup> This activation occurs via mutually exclusive mutations in *BRAF* or *RAS* oncogenes. A subset of PTCs is acquired by gene fusions involving rearranged during transfection (*RET*) or (less commonly) other receptor tyrosine kinases. Oncogenic mutations at *BRAF*<sup>V600E</sup> are the most common in PTC; a minority can show *non-V600E* mutations, such as *BRAF*<sup>K601E</sup> or *BRAF* fusions. The IEFVPTC is an encapsulated and invasive follicular-patterned tumor. Based on its tendency for vascular invasion, distant metastasis, and molecular profile, it can behave similarly to FTC.<sup>26–32</sup>

Histologically, FTCs are encapsulated follicular patterned tumors without the nuclear features of PTC; they are characterized by the presence of vascular (limited or extensive) and capsular invasion (vascular invasion involving vessels within the tumor capsule) and widely invasive (extensive invasion of the thyroid parenchyma beyond the tumor capsule).<sup>24</sup> These tumors are mostly driven by activating mutations in *RAS* oncogenes (*NRAS*>*HRAS*>*KRAS*), *PAX8::PPAR* $\gamma$  fusions, *EIF1AX* mutations, *PIK3CA* mutations, or loss of *PTEN* expression. *BRAF*<sup>V600E</sup> and *RET* fusions typically are not seen in FTC. Expression of *PAX8::PPAR* $\gamma$  fusions oncoprotein occur in 25% of FTC, in which the thyroid transcription factor PAX8 drives the expression of PPAR $\gamma$ ,<sup>38,40</sup> a receptor involved in adipocyte biology. Mutations in *DICER1*, which encodes a ribonuclease in the processing of microRNA precursors, occur in *RAS*-like thyroid neoplasms and are prevalent in FTC. *DICER1* mutations can also be seen in subsets of PTC, differentiated high-grade thyroid carcinoma (DHGTC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC).

With greater recognition of the unique genomic features of OTC (previously known as Hürthle cell carcinoma) and different clinical behavior from classical forms of FTC, these tumors are now considered a third form of DTC rather than a subtype of FTC in the current WHO classification; they account for ~3% of all DTC.<sup>24,41,42</sup> An “oncocyte” is an enlarged polygonal cell with an abundant granular eosinophilic cytoplasm, round nuclei with even chromatin pattern, and prominent nucleoli. As defined by WHO, oncocytic neoplasms are usually encapsulated and composed of  $\geq 75\%$  oncocytic cells.<sup>24,36,43</sup> Oncocytic features can be identified in some PTC or FTC cells at lower frequencies. Most of these tumors are larger in size; however, smaller tumors can be identified. Like FTC, the presence of invasive characteristics (i.e., tumor capsule and/or vascular invasion in an encapsulated oncocytic neoplasm) is diagnostic of OTC, and OTCs can be classified as minimally invasive, encapsulated angio-invasive, and widely invasive.

Genomically, OTCs are characterized typically by a near-haploid genome, mitochondrial DNA mutations commonly involving genes encoding Complex I of the mitochondrial respiratory chain, and mutations in *DAXX* and *ATRX* involved in telomere length. OTCs can also have mutations that activate mammalian target of rapamycin (mTOR) and MAPK signaling,

TABLE 3. WHO PATHOLOGICAL CLASSIFICATION OF DIFFERENTIATED THYROID CARCINOMA (WHO, 5TH EDITION)<sup>24</sup>

<i>Follicular cell-derived neoplasms</i>	<i>Subtypes</i>
Low-risk neoplasms	<ol style="list-style-type: none"> <li>1. NIFTP<sup>a,b</sup></li> <li>2. Follicular tumor of uncertain malignant potential</li> <li>3. Hyalinizing trabecular tumor</li> </ol>
Malignant neoplasms	<ol style="list-style-type: none"> <li>1. Follicular thyroid carcinoma               <ol style="list-style-type: none"> <li>a. Minimally invasive</li> <li>b. Encapsulated angioinvasive</li> <li>c. Widely invasive</li> </ol> </li> <li>2. Invasive encapsulated follicular variant papillary carcinoma</li> <li>3. Papillary thyroid carcinoma-subtypes               <ol style="list-style-type: none"> <li>a. Classical</li> <li>b. Encapsulated classical</li> <li>c. Infiltrative follicular</li> <li>d. Tall cell</li> <li>e. Columnar cell</li> <li>f. Hobnail</li> <li>g. Diffuse sclerosing</li> <li>h. Solid / trabecular</li> <li>i. Warthin-like</li> <li>j. Oncocytic</li> <li>k. Others<sup>c</sup></li> </ol> </li> <li>4. Oncocytic carcinoma               <ol style="list-style-type: none"> <li>a. Minimally invasive</li> <li>b. Encapsulated angioinvasive</li> <li>c. Widely invasive</li> </ol> </li> </ol>
Malignant neoplasms—high-grade follicular-cell derived non-anaplastic carcinoma	<ol style="list-style-type: none"> <li>1. Poorly differentiated carcinoma (Turin-criteria):               <ol style="list-style-type: none"> <li>a. Solid/trabecular architecture</li> <li>b. Absence of nuclear features of papillary thyroid carcinoma</li> <li>c. Tumor necrosis</li> <li>d. Mitotic index <math>\geq 3/10</math> high power fields (HPFs)</li> <li>e. And/or convoluted tumor nuclei</li> </ol> </li> <li>2. Differentiated high-grade thyroid carcinoma               <ol style="list-style-type: none"> <li>a. Differentiated cytological and architectural features</li> <li>b. At least one the following two histomorphologic features</li> <li>c. Mitotic count <math>\geq 5/2</math> mm<sup>2</sup> and/or tumor necrosis</li> </ol> </li> </ol>
Other rare neoplasms	<ol style="list-style-type: none"> <li>1. Salivary gland-type carcinomas               <ol style="list-style-type: none"> <li>a. Mucoepidermoid carcinoma of the thyroid</li> <li>b. Secretory carcinoma of salivary gland type</li> </ol> </li> <li>2. Thyroid tumors of uncertain histogenesis               <ol style="list-style-type: none"> <li>a. Sclerosing mucoepidermoid carcinoma with eosinophilia</li> <li>b. Cribriform morular thyroid carcinoma</li> </ol> </li> <li>3. Thymic tumors within the thyroid</li> </ol>

<sup>a</sup>Formerly classified as noninvasive and encapsulated follicular variant of papillary thyroid carcinoma.

<sup>b</sup>See Table 2.

<sup>c</sup>Includes rare subtypes such as PTC with fibromatosis/fasciitis-like stroma, clear cell subtype, spindle cell subtype, and so forth. PTC, papillary thyroid carcinoma; WHO, World Health Organization.

and like PTC and FTC, more aggressive OTCs can have mutations in the *TERT* promoter or *TP53*.<sup>44,45</sup> Clinically, some studies have shown that OTCs have a greater tendency toward lymph node metastases while retaining a predilection for distant metastases, and unlike FTC, OTCs often are not radioiodine-avid despite retaining other differentiated features, such as Tg secretion and TSH receptor expression.<sup>46–55</sup>

The 5th edition of the WHO Classification of Thyroid Tumors also introduces a new category of high-grade follicular cell derived, non-anaplastic carcinoma that includes PDTC and DHGTC.<sup>24</sup> By molecular analysis, poorly

differentiated thyroid cancer and DHGTC harbor driver mutations in *BRAF* (*BRAF*<sup>V600E</sup>) and *RAS* genes, and some cases may show gene fusions (often *RET* and *NTRK3*). Additional mutations in the *TERT* promoter, *PIK3CA*, and *TP53* are commonly identified.<sup>36,43,56–59</sup>

DHGTC has been defined by certain authors as a “thyroid malignancy” that is recognized as DTC but in which certain histological and cytopathologic features are present that justify the lesion being classified as “high-grade.”<sup>37,60–67</sup> The DHGTCs are invasive, high-grade carcinomas that show one of the following two histological features: mitotic count

$\geq 5$  per 2 mm<sup>2</sup> and tumor necrosis.<sup>36,43,56,58,68–70</sup> By contrast, thyroid carcinomas classified as PDTC are follicular cell-derived tumors that show a minor component of DTC (papillary, follicular, oncocytic), show solid and/or insular growth pattern with presence of either necrosis or  $\geq 3$  per 2 mm<sup>2</sup>, and lack the usual histological characteristics and aggressiveness of ATC. In both cases, clinical behavior is considered intermediate between DTC and ATC.<sup>24,36,65,71–75</sup>

*Non-invasive follicular thyroid neoplasm with papillary-like nuclear features*

NIFTP is the pathological definition of a type of noninvasive follicular cell-derived thyroid neoplasm that was first described in 2016.<sup>76</sup> This topic post-dated the 2015 ATA thyroid nodule and DTC guidelines, but a subsequent ATA task force statement in 2017 supported adoption of the NIFTP nomenclature for this entity.<sup>77</sup> In 2017, NIFTP were classified as a distinct category in the revised WHO Classification of Tumors of Endocrine Organs, corresponding to a neoplasm with very low malignant potential.<sup>24</sup>

NIFTP comprise approximately 2.1–9.6% of follicular cell-derived thyroid neoplasms, with relatively lower incidence in Asia than in North America and Europe.<sup>78–82</sup> NIFTP are characterized by validated histological inclusion and exclusion features (Table 3). The original NIFTP validation study excluded tumors measuring  $\leq 1$  cm and those with oncocytic features.<sup>76</sup> However, as subsequent literature has shown that tumors measuring  $\leq 1$  cm (micro-NIFTPs) or with oncocytic features (oncocytic-NIFTPs) demonstrate similar clinical behavior to those of original NIFTP,<sup>62,76,83–85</sup> these features also are included in the tumor's current pathological definition. The initial definition of NIFTP had required the presence of  $< 1\%$  papillae,<sup>76</sup> but subsequent experience<sup>83,86,87</sup> has shown this feature can be associated with lymph node metastases; therefore, the diagnostic criteria have been revised to require that papillae are absent.<sup>83</sup> It is recommended to carefully examine the entire tumor capsule interface and tumor to exclude the possibility of invasive features and presence of papillae.<sup>76</sup> NIFTPs often coexist with one or more NIFTPs or other thyroid malignancies in the ipsilateral or contralateral lobes.

Studies assessing the molecular profile of NIFTPs have shown them to be clonal neoplasms.<sup>88–91</sup> Molecular alterations are present in approximately 78% of cases, with approximately 30–54% of NIFTP tumors harboring a *RAS* mutation (*NRAS* mutations most common, followed by *HRAS* and rarely *KRAS* mutations).<sup>89,92</sup> However, the *NRAS* mutations seen in NIFTPs may also be identified in FTCs and IEFVPTC; therefore, they are nonspecific. A small subset of NIFTP cases have been shown to harbor *PAX8::PPAR $\gamma$*  fusions, *THADA* fusions, and *BRAF*<sup>K601E</sup> mutations.<sup>89,93</sup> Some studies also have explored miRNA expression in NIFTP cases, demonstrating that two mi-RNAs (miR-10a05p and miR-320e) can effectively discriminate between NIFTP and the infiltrative follicular variant of PTC.<sup>94</sup> Further studies are required to validate these findings.

While NIFTPs are characterized by a follicular growth pattern and nuclear features of PTC (Fig. 4), they are associated with extremely low malignant potential.<sup>76,95,96</sup> Several multi-institutional series (largest sample,  $n = 363$ ), including several that reclassified DTCs as NIFTP upon retrospective analyses, have mostly reported zero risk of disease persistence/

recurrence over a mean or median follow-up of up to 11.8 years.<sup>97</sup> Lymph node metastases have been seen in  $< 5\%$  of the total cohort and in only a few series.<sup>80,87,98,99</sup> Only one retrospective analysis of 102 cases showed the presence of distant metastases (to the lungs) in one case, although this study was limited by incomplete follow-up (80%) and a high proportion of patients who received more aggressive care (total thyroidectomy and radioiodine ablation).<sup>80</sup> At present, there are no available data comparing the clinical benefits and harms of various short- and long-term monitoring strategies in patients with NIFTP tumors.

Is NIFTP considered thyroid cancer?

■ **RECOMMENDATION 1**

NIFTP and other tumors of uncertain malignant potential (Follicular Tumor of Uncertain Malignant Potential and Hyalinizing Trabecular Tumor) are diagnosed pathologically and have a very low malignant potential (lower than the lowest-risk DTC). Further treatment with completion thyroidectomy/lymphadenectomy and/or RAI is not advised routinely. The optimal approach to postoperative monitoring of these tumors is uncertain. (*Good Practice Statement*)

*Thyroid cancer epidemiology*

After rising for three decades, thyroid cancer incidence peaked in 2015 at 14.9 per 100,000. Then, between 2015 and 2017, a decline was observed for the first time in 30 years.<sup>100</sup> The initial increase in incidence was thought to be related to a true increase in the incidence of PTC as well as widespread use of diagnostic imaging and FNA of thyroid nodules leading to potential “overdiagnosis.”<sup>101–104</sup> “Overdiagnosis” is defined as the diagnosis of cancers that would not, if left in place, result in symptoms or death.<sup>105</sup> The decline in incidence may be due to a heightened awareness of the potential harms of overdiagnosis.<sup>106</sup> The observed decrease has correlated temporally with clinical management recommendations from the 2009 and 2015 ATA guidelines, which suggested a larger nodule size threshold and higher ultrasound suspicion for biopsy of thyroid nodules and use of molecular markers for small, indeterminate nodules.<sup>13,14</sup> Similar recommendations were published by the American College of Radiology with its thyroid imaging reporting and data system.<sup>107</sup> In 2017, the U.S. Preventative Services Task Force (USPSTF) recommended against thyroid cancer screening in asymptomatic adults. This also might have contributed to decreasing thyroid cancer incidence.<sup>108,109</sup> The 2016 reclassification of NIFTP also is reported to have contributed to the observed decline.<sup>104</sup> Notably, the increase in thyroid cancer incidence observed from 1974 to 2013 occurred for all stages of disease, and the mortality rate from that same period increased annually by 1.1% in advanced disease.<sup>109,110</sup>

Accepted risk factors for thyroid cancer include a history of childhood head and neck radiation, total body radiation for bone marrow transplantation,<sup>111</sup> and exposure to ionizing radiation from fallout in childhood or adolescence.<sup>112</sup> Adult occupational radiation exposure in the low-to-moderate dose range ( $< 0.5$  Gy) has not been associated with a significantly increased risk of thyroid cancer.<sup>113,114</sup>

Additional potential risk factors have been identified, and further study is necessary to determine their

causative relationship with thyroid malignancy. As outlined in **Recommendation 28**, obesity has been reported to be positively associated with PTC and FTC. Flame retardants (FR) alter thyroid hormone homeostasis, and a relationship between environmental exposure and risk of thyroid cancer has been considered. Common FR include polybrominated diphenyl ethers, which began to be phased out in the early-2000s<sup>115</sup> due to possible toxicity, and more recent alternatives such as brominated FRs and organophosphate FRs (PFR).<sup>116,117</sup> Aschebrook-Kilfoy et al. reported no association between exposure to Penta-BDEs and PTC through a nested, case-control study evaluating serum concentrations of FRs.<sup>118</sup> In another case-control study, greater exposure measured by household dust levels of the Deca-BDE, BDE-209, and the PFR, tris(2-chloroethyl) phosphate was associated with an increased odds of having PTC.<sup>119</sup> Since FR utilization is expected to increase in the future,<sup>120</sup> continued study of a potential causative relationship is important.

DTC can occur in families, which is termed familial non-medullary thyroid cancer (FNMTC). FNMTC is further classified as “syndromic” when it is one of a constellation of tumors (e.g., PTEN [phosphatase and tensin homolog] hamartoma tumor syndrome [Cowden disease], familial adenomatous polyposis [FAP], Carney complex, Werner syndrome/progeria) or “non-syndromic,” when DTC is the single or prevailing inherited malignancy. Specific approaches and recommendations for both syndromic and non-syndromic forms of DTC are discussed below.

It has been shown that Ki-67/MIB-1 as a marker for cell proliferation can be used to assess clinical behavior in numerous malignancies. Ki67 is expressed in all cell proliferation stages except G0 and can be easily evaluated immunohistochemically in tissue samples. High Ki-67 proliferation index correlates with poor prognosis in thyroid carcinomas; however, additional studies are needed to make this an essential step in the pathological assessment of well-differentiated thyroid carcinomas.<sup>121–123</sup>

#### *Genetic predisposition to follicular cell-derived thyroid cancer and genetic counseling*

**Principles of germline genetic testing.** The genetic testing process involves pre-test counseling, identification of the most appropriate testing options, and post-test result disclosure. Ideally, this is conducted by a certified genetic counselor and/or other provider (endocrinologist, oncologist, geneticist, etc.) with expertise and experience in cancer genetics and thyroid cancer. Clinicians without direct referral access to the appropriate expertise should be aware of the telehealth genetic counseling options available. In the United States, both in-person and telehealth resources can be found through the National Society of Genetic Counselors “Find a Genetic Counselor” tool ([www.nsgc.org](http://www.nsgc.org)).

Pre-test counseling components should include the following: (i) a carefully performed three- to four-generation pedigree of the patient’s family; (ii) assessment of the patient’s risk to carry a heritable cancer susceptibility gene variant, as well as the patient’s absolute risks to develop various types of cancer, given the patient’s family history; (iii) psychosocial assessment and counseling of the patient; (iv) education of the patient regarding the suspected hereditary cancer syndrome (e.g., inheritance, penetrance); (v) implications of

having genetic testing from the personal, family, and insurance perspectives; and (vi) informed consent prior to obtaining a sample for genetic testing.

Due to overlapping phenotypes of hereditary predisposition conditions, genetic testing often utilizes multigene panel testing. Once test results are back, the post-test genetic counseling visit should include not only disclosure of the results in verbal and written form but also verbal and written information regarding the significance of the test results about cancer risk and the medical management options based on the estimated cancer risk to the patient. It also should include verbal and written discussions of the implications of the test results for family members, identification of resources for psychosocial support and future decision-making related to medical management, and results should be communicated to the treating physicians, particularly if counseling is performed by a genetic counselor rather than the treating physician.

Which patients with DTC should be offered germline genetic testing?

#### ■ **RECOMMENDATION 2**

Germline genetic testing may be offered in the following scenarios (Table 4):

- A. Clinical suspicion for Cowden/PTEN hamartoma tumor syndrome (PHTS) due to a combination of DTC and non-thyroid malignancy/tumors/features (**Conditional recommendation, Moderate certainty evidence**)
- B. In patients who were diagnosed with FNMTC as children, clinical and family history should be evaluated for features of *DICER1* tumor predisposition. Consideration may be given to germline *DICER1* testing in patients from families with pediatric patients with DTC. (**Conditional recommendation, Very low certainty evidence**)
- C. Pathologic diagnosis of cribriform morular thyroid carcinoma (*APC* gene) (**Conditional recommendation, Moderate certainty evidence**)
- D. Other combinations of tumors and/or cancers in a patient and/or their family members may raise concern for a hereditary predisposition condition, including rare conditions such as Carney complex or Werner syndrome. In these patients, genetic counseling and testing may be offered. (**Conditional recommendation, Moderate certainty evidence**)

The National Comprehensive Cancer Network (NCCN) regularly updates testing guidelines for Cowden syndrome/PHTS. These criteria require a combination of major and minor criteria, with FTC (and presumably OTC) serving as a major criterion and PTC (including FVPTC) and structural thyroid lesions serving as minor criteria.<sup>127</sup> As a result, numerous clinical presentations can fulfill *PTEN* testing criteria. The spectrum of conditions resulting from pathogenic variants in *PTEN* is referred to as PHTS. Cowden syndrome is a part of this spectrum and characterized by an increased risk for thyroid, breast, endometrial, and (to a lesser degree) colon and renal cancers. Benign thyroid and breast tumors, other tumors such as trichilemmomas, papillomatous papules, lipomas, gastrointestinal hamartomas, or ganglioneuromas, and macrocephaly, intellectual disabilities, or autism spectrum disorders are common manifestations.<sup>128</sup> In *PTEN*-related disorders, there is an

TABLE 4. SYNDROMES ASSOCIATED WITH DTC

Syndrome (gene)	Histology	Lifetime risk	Other features	Screening guidance
Cowden syndrome/PHTS ( <i>PTEN</i> )	FTC, <sup>a</sup> PTC	3–10%	Breast cancer, endometrial cancer, goiter, macrocephaly	NCCN—Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic
Familial adenomatous polyposis ( <i>APC</i> )	CMTC, PTC	Up to 12%	Colon polyposis, CHRPE, desmoids	NCCN—Genetic/Familial High-Risk Assessment: Colorectal Schultz et al. <sup>124</sup>
DICER1 tumor predisposition ( <i>DICER1</i> )	PTC, FTC, <sup>a</sup> PDTC	OR, 9.2 [CI 2.1–34.7]	Pleuropulmonary blastoma, cystic nephroma, ovarian sex cord stromal tumors	
Carney complex ( <i>PRKARIA</i> )	FTC, <sup>a</sup> PTC	Unknown	Pigmented abnormalities of the skin, myxomas, schwannomas, and endocrine tumors	Correa et al. <sup>125</sup>
Werner syndrome ( <i>WRN</i> )	FTC, <sup>a</sup> PTC	Unknown	Premature aging, cataracts, DM, other cancers	Takemoto et al. <sup>126</sup>

<sup>a</sup>OTC was previously included as a subtype of FTC and is likely also associated with these hereditary predispositions.

CHRPE, congenital hypertrophy of the retinal pigment epithelium; CI, confidence interval; CMTC, cribriform-morular thyroid carcinoma; DM, diabetes mellitus; DTC, differentiated thyroid cancer; FTC, follicular thyroid carcinoma; NCCN, National Comprehensive Cancer Network; OR, odds ratio; OTC, oncocytic thyroid carcinoma; PDTC, poorly differentiated thyroid carcinoma; PHTS, *PTEN* hamartoma tumor syndrome.

enrichment of FTC, but PTC remains the most common histology. PTC (including IEFVPTC) represents 56–60%, while FTC accounts for 25–45% of reported *PTEN*-related thyroid cancers.<sup>129,130</sup>

*DICER1* tumor predisposition is characterized by an increased risk for pleuropulmonary blastoma, pulmonary cysts, thyroid neoplasia, ovarian tumors, and cystic nephroma. Germline pathogenic *DICER1* variants were seen in 1 of 6 pediatric patients with PDTC,<sup>131</sup> 4 of 15 pediatric patients with FTC,<sup>132</sup> and 0 of 20 pediatric patients with PTC.<sup>133</sup> However, other reports do suggest a relationship between germline *DICER1* variants and pediatric PTC.<sup>134,135</sup> The recommendations put forth by the International *DICER1* Symposium suggest that germline *DICER1* testing be considered based on the presence of multinodular goiter or thyroid cancer in two or more first-degree relatives.<sup>124</sup> However, given the commonality of this presentation in adults and the relative rarity of germline pathogenic variants in *DICER1*, the yield in this scenario may be low. Further research is required to determine the best screening strategy.

Cribriform-morular thyroid carcinoma (CMTC) is a rare malignancy that is frequently identified in patients with FAP due to a germline pathogenic variant in *APC*.<sup>136–138</sup> It is characterized by a prominent cribriform architecture and formation of whorls or morules composed of spindle cells. The presence of aberrant beta-catenin immunoreactivity provides strong evidence for this cancer type.<sup>139–141</sup> The cancer cells typically stain for NKX2-1 (TTF1) but are negative for Tg, raising the hypothesis that the tumor morules seen in this cancer are of thymic/ultimobranchial pouch origin.<sup>142</sup> Approximately 40% of patients with CMTC are found to have FAP. Although no microscopic tumor features can distinguish between familial and sporadic disease, tumor multifocality is more common in the setting of familial disease.<sup>139,143</sup> Since many patients with CMTC have FAP, and thyroid cancer can precede clinically detectable colonic abnormalities in up to

40% of patients,<sup>143</sup> this diagnosis should raise the possibility of a hereditary predisposition and prompt consideration for genetic testing/counseling. Established syndromes associated with DTC are summarized in Table 4.

Recently, it has been reported that individuals with long telomeres due to variants in genes encoding components of the shelterin complex have a clinically identifiable multi-cancer predisposition that may include PTC.<sup>144</sup> Component cancers of the syndrome include melanoma, leukemia, and sarcoma, and the syndrome has been termed long telomere syndrome.<sup>144–147</sup> PTC also was identified as being one of the 12 cancers associated with genetically determined long telomere length in a systematic review.<sup>148</sup> Interestingly, short telomeres also have been reported to predispose to thyroid cancer, and a U-shape relationship has been reported.<sup>149</sup> Further research in this area is needed to inform genetic screening recommendations.

Should patients with non-syndromic FNMTTC receive genetic testing?

### ■ RECOMMENDATION 3

There is a lack of evidence to suggest the utility of clinical germline genetic testing in non-syndromic FNMTTC. In non-syndromic FNMTTC, the non-thyroid malignancies in the family may drive decision-making regarding genetic testing. (*Conditional recommendation, Moderate certainty evidence*)

Several studies have been performed in multigenerational kindreds with DTC (mostly PTC); in some families candidate genes have been identified through a combination of linkage analyses and sequencing.<sup>150–152</sup> To date, variants in these candidate genes, while important for individual families, are nonrecurring and appear to be “private” to those families. Therefore, data do not support their inclusion in clinical panel testing. Because of the autosomal dominant inheritance pattern in most families, there may be a role for thyroid cancer screening in selected non-syndromic FNMTTC

in which there appears to be high penetrance, early age onset thyroid cancer, or aggressive disease (see below).

Some families with FNMTC may have enrichment of non-thyroid malignancies, which may be an indication for germline genetic testing. Therefore, some patients with sporadic DTC can also have a documented pathogenic variant in a cancer predisposition gene for other tumor types. Whether or not the DTC in those patients is related to their cancer predisposition is not always certain. For example, pathogenic variants (PV) in *CHEK2* are a relatively common finding on clinical multigene panel testing and are associated with an increased risk for a variety of cancers.<sup>153</sup> Most notably, *CHEK2* PVs are associated with a moderate increase in the risk for breast cancer. While associations with DTC have been suggested,<sup>154</sup> the magnitude of risk is modest, with an approximately two-fold risk for PTC associated with common *CHEK2* variants.<sup>155</sup>

Should family members of patients with FNMTC be screened for thyroid cancer?

#### ■ RECOMMENDATION 4

Individuals with a family history of FNMTC should have a careful history and directed neck examination as a part of regular health maintenance. Ultrasound screening may be considered in first-degree family members of individuals who meet criteria for a clinical diagnosis of FNMTC due to the presence of three or more (first or second degree) related individuals with diagnoses of NMTC. Ultrasound screening may also be considered in families with only two affected individuals showing other concerning features (such as particularly young ages of diagnosis) or with limited family structure. The age for initiation of such screening requires further study and should be carefully weighed against the risk of overtreatment. (*Conditional recommendation, Very low certainty evidence*)

Family members of patients with FNMTC may be considered at risk for disease based on epidemiological evidence showing that 5–10% of NMTC have a familial occurrence. However, in most of these families, only two members are affected. There is controversy about whether two family members are sufficient to define familial disease rather than a coincidental or screening-related association. Estimates suggest that when only two first-degree family members are affected, the probability that the disease is sporadic is 62%, with the probability decreasing to ≤6% when the number of affected family members is three or more.<sup>156</sup> However, while controversial, stratification of families with two first-degree family members based on age of diagnosis (both ≤45 years vs. one or both >45 years) has been reported to predict subsets of individuals with more frequent multifocal/bilateral cancers, more extrathyroidal extension, and compromised outcomes when compared to matched sporadic NMTC, and no significant differences when comparing families with one or more members with older ages at diagnosis.<sup>157</sup>

A prospective interventional screening program investigated the impact of yearly screening in a cohort of 109 individuals from 25 kindreds (12 with two members affected and 13 with ≥3 members affected). Screening started as early as 7 years of age and included neck ultrasound and FNA of thyroid nodule(s) >0.5 cm. This led to the detection of thyroid cancer in 4.6% (2/43) of at-risk individuals from families with two members affected and in 22.7% (15/66) of at-

risk members from families with ≥3 patients affected ( $p=0.01$ ). The youngest age of thyroid nodule detection was 7 years, and the youngest age of thyroid cancer diagnosis was 18 years.<sup>158</sup> Based on these data, Capezzone et al. suggest consideration of screening with yearly ultrasound in kindreds with ≥3 affected family members, starting from the age of 20 years, or 10 years before the earliest age of diagnosis in the family.<sup>159</sup> Further studies are needed to determine the optimal approach to family screening that address costs and the potential risks of overtreatment.

The USPSTF discourages screening for thyroid cancer in asymptomatic adults.<sup>108</sup> However, this recommendation was aimed at population-based screening. Screening programs in the setting of FNMTC should be initiated with caution, as there are no data regarding the impact of screening on outcomes in FNMTC, and the frequency of ultrasound is inconsistently applied. Several studies have suggested that FNMTC is associated with earlier age-of-onset and more aggressive behavior,<sup>143,160–163</sup> although others have not demonstrated this relationship.<sup>164,165</sup>

When should germline genetic testing be offered to patients with DTC with alterations detected on tumor samples (somatic testing)?

#### ■ RECOMMENDATION 5

When genomic testing is performed on tumor samples for clinical purposes, both somatic and germline genetic alterations can be detected. If a potentially clinically relevant germline cancer-predisposing variant is detected, evaluate patients and their family histories for clinical correlation, and consider referral for genetic counseling for possible germline testing. (*Conditional recommendation, Moderate certainty evidence*)

Sequencing of thyroid cancer specimens can occur at initial diagnosis as part of thyroid nodule evaluation, or later in the course of the disease to assist in determining treatment options. In both cases, pathogenic variants identified through sequence analysis of a tumor sample are either acquired somatic events or may be of germline origin. These tests are optimized for somatic variant detection. While paired tumor and analysis of normal tissue can help distinguish variant origin, such analysis is not a reliable method to detect germline variants, and studies have shown that up to 8.1% of pathogenic germline variants are missed on standard tumor sequencing assays.<sup>166</sup> Therefore, tumor analysis is not a replacement for germline testing, and confirmatory germline testing in the context of genetic counseling should be performed prior to further evaluation of a family. The potential to identify germline variants ideally should be considered when consenting patients for tumor sequencing.

Guidelines for the optimal approach to identify germline pathogenic variants based on somatic tissue analysis have been developed outside the specific context of thyroid cancer. For example, the NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic Guideline states that a likely pathogenic variant or known pathogenic variant in *PTEN* detected by tumor profiling of any tumor type should prompt careful evaluation of personal and family history of the individual to determine the yield of germline sequencing.<sup>127</sup> If personal or family history consistent with PHTS is present, genetic counseling/testing should be offered. Furthermore, the European

Society for Medical Oncology Precision Medicine Workgroup recommends focused germline testing for up to 40 genes if somatic mutations are identified in any tumor type, especially for seven genes deemed “most actionable,” which include *BRCA1*, *BRCA2*, *MLH1*, *MSH2*, *MSH6*, *PALB2*, and *RET*. This recommendation is based on a >5–10% tumor-to-germline conversion rate for variants with variant allele fractions >30% in a cohort of 49,264 cancer samples with paired sequencing data. Thyroid cancers constituted approximately 2% of this cohort.<sup>167</sup>

#### Initial management of DTC

Shared decision-making between patients and their treating clinicians is paramount in determining the goals of initial therapy for patients with DTC. The preference of the patient must be considered when recommending the following, as appropriate:

1. In patients selected for thyroid surgery, the initial goal is to resect the primary tumor, any disease that has extended beyond the thyroid, and clinically significant lymph node metastases. Completeness of surgical resection is an important determinant of outcome, as lymph nodes represent the most common site (74%) of neck disease persistence/recurrence, followed by the thyroid remnant (20%) and the trachea and adjacent muscle (6%).<sup>168</sup>
2. Consider which of the available multimodal treatment options is appropriate, to (a) decrease the risk of disease persistence/recurrence and metastatic spread and (b) minimize treatment-related morbidity. In addition to initial surgery, postoperative RAI administration, serum TSH suppression, and other management strategies may be appropriate in selected patients. However, it is important to balance the benefits and risks of the treatment(s), which may outweigh the burden imposed by the disease itself.
3. Determine staging and risk stratification to estimate prognosis. Cancer staging is useful to estimate risks of disease-specific mortality, while initial risk stratification can be used to estimate short- and long-term risks of disease persistence/recurrence.

Does surgical experience influence complication rates for thyroidectomy?

#### ■ RECOMMENDATION 6

Due to lower complication rates and improved outcomes on average associated with high volume thyroid surgeons (>25–50 thyroidectomies/year), patients with thyroid cancer should be offered referral to a high-volume surgeon, particularly for tumors requiring more extensive surgery. (*Strong recommendation, Moderate certainty evidence*)

Physician experience and expertise have long been revered in patient care, but quantifying the benefits can be challenging, particularly at an individual provider level. There are many aspects of care where physician expertise is important in the diagnosis, staging, and management of patients with thyroid cancer, including sonography, pathology, surgery, endocrinology, nuclear medicine, oncology, and radiation therapy. Ultrasound of the neck is a prime example, due to its well-documented dependence on the skill and experience of the sonographer coupled with its importance for preoperative

diagnosis, staging, and surveillance.<sup>169–173</sup> The experience of the cytopathologist also has been demonstrated to improve the accuracy of ultrasound-guided FNA biopsy diagnosis.<sup>174</sup> The evidence supporting improved outcomes at the hands of experienced surgeons is most compelling.

The relationship between thyroid surgery case volume and patient outcomes has been studied extensively during the past 20 years. In one of the first studies examining the relationship between surgeon volume and thyroidectomy outcomes, Sosa et al.<sup>175</sup> found a strong association between higher surgeon volume and favorable patient outcomes, especially with respect to recurrent laryngeal nerve injury and wound complications. This was most pronounced for patients undergoing total thyroidectomy for thyroid cancer. Others have made similar observations on a larger scale.<sup>176–179</sup> In a study of the Health Care Utilization Project Nationwide Inpatient Sample (HCUP-NIS),<sup>180</sup> over 80% of thyroidectomies were performed by low- and intermediate-volume surgeons ( $\leq 29$  thyroidectomies/year). On average, high-volume surgeons ( $\geq 30$  thyroidectomies/year) had the lowest complication rates for patients who underwent total thyroidectomy for cancer (high 7.5% vs. intermediate 13.4% vs. low 18.9%;  $p < 0.001$ ). A recent meta-analysis including 22 studies found unanimity in the association of lower complication rates with higher thyroid surgery volume.<sup>181</sup>

When hospital volume and surgeon volume are both considered, on average, high-volume surgeons are associated with lower complication rates, lower hospital mortality, and lower cost, whereas high-volume centers are associated primarily with lower cost and shorter lengths of stay.<sup>181–183</sup> Estimates of the annual thyroid surgical volume necessary to achieve lower complication rates range from 25 to 50,<sup>181,184–187</sup> with one series suggesting >50 cases for more advanced thyroid cancer.<sup>188</sup> A study specifically designed to address this number concluded that annual total thyroidectomy case volume >25/year was associated with improved outcomes. Patients have an 87% increase in the odds of having a complication if the surgeon performed just 1 case/year, 68% for 2–5 cases/year, 42% for 6–10 cases/year, 22% for 11–15 cases/year, 10% for 16–20 cases/year, and 3% for 21–25 cases/year.<sup>189</sup> Patients undergoing total thyroidectomy for cancer at the hands of high-volume surgeons also are reported to have significantly less thyroid remnant tissue after resection, resulting in a reduced radioiodine dose requirement for remnant ablation (if indicated).<sup>188,190</sup> Finally, patients having thyroid cancer surgery at low-volume centers were significantly more likely to have an involved tumor margin compared to those treated at high-volume centers.<sup>191</sup> An overwhelming body of evidence demonstrates improved outcomes for patients undergoing thyroid cancer surgery with higher-volume surgeons.

Referral of patients to high-volume thyroid surgeons is associated with, on average, superior outcomes. However, referral is not always possible, in view of the relative scarcity of high-volume surgeons and their geographic concentration in larger urban areas. Conclusions at an overall population level cannot always be applied to individual surgeons and patient circumstances. It seems reasonable to encourage referral of patients with grossly invasive and/or extensive disease to a high-volume surgeon experienced in the management of advanced thyroid cancer, and perhaps even to refer those patients undergoing total thyroidectomy for low- to intermediate-risk cancers.

It is important to recognize that even high-volume surgeons have a higher overall postoperative complication rate when performing total thyroidectomy (when compared with lobectomy).<sup>192</sup> In the HCUP-NIS study, high-volume thyroid surgeons had a complication rate of 7.6% following thyroid lobectomy compared with a rate of 14.5% following total thyroidectomy. For low-volume surgeons, the complication rates were 11.8% and 24.1%, respectively.<sup>192</sup> Older patients with thyroid cancer generally have a worse prognosis and higher rates of complications than younger patients; therefore, they may benefit from referral. Decision-making regarding extent of surgery, role of radioiodine therapy, and referral to high-volume surgeons or centers for thyroid cancer has many facets, and patient preference is an important component.<sup>193–198</sup>

What is the role of preoperative staging with diagnostic imaging and laboratory tests?

#### ■ RECOMMENDATION 7

- A. Preoperative neck ultrasound to evaluate cervical lymph nodes in the central and lateral neck compartments as well as for gross extrathyroidal extension is recommended for all patients undergoing surgery for malignant cytologic or molecular findings. (*Strong recommendation, Moderate certainty evidence*)
- B. Ultrasound-guided FNA of sonographically suspicious lymph nodes greater than 8–10 mm in the smallest diameter should be performed to confirm malignancy if this would change management. (*Strong recommendation, Moderate certainty evidence*)
- C. The addition of FNA-Tg washout in the evaluation of suspicious cervical lymph nodes may be performed in select preoperative patients, but interpretation may be difficult in patients with an intact thyroid gland. (*Conditional recommendation, Low certainty evidence*)

DTC (and particularly PTC) involves cervical lymph nodes in 20–50% of patients in most series using standard pathological techniques,<sup>199–203</sup> and these metastases may be present even when the primary tumor is small and intrathyroidal.<sup>204</sup> The frequency of micrometastases (less than 2 mm) may approach 90%, depending on the sensitivity of the detection method.<sup>205,206</sup> However, the clinical implications of micrometastases are likely less significant compared with macrometastases, and they do not appear to affect survival<sup>207</sup>; when they are in the central neck, they also do not appear to increase recurrence.<sup>208</sup> Preoperative ultrasound identifies suspicious cervical adenopathy in 20–31% of cases, potentially altering the surgical approach<sup>209,210</sup> in as many as 20% of patients.<sup>211–213</sup> It has significantly less clinical utility in identifying central neck lymph nodes due to the presence of the overlying thyroid gland.<sup>214</sup>

Sonographic features suggestive of abnormal metastatic lymph nodes include enlargement, loss of the fatty hilum (odds ratio [OR] 1.9), a rounded rather than oval shape (long axis/short axis  $\leq 2$ ; OR 1.6), hyper-echogenicity (OR 5.4), cystic change (OR 71.8), calcifications (OR 6.2), and peripheral vascularity or abnormal blood flow (OR 3.8).<sup>215</sup> No single sonographic feature has adequate sensitivity for detecting lymph nodes with metastatic thyroid cancer; however, cystic change has the highest odds of malignancy.<sup>215</sup> Absence of a

fatty hilum, cystic changes, microcalcifications, abnormal vascularity, and cortical hyper-echogenicity are all independent features of metastatic lymph nodes with a high specificity of 87–99.6%. Absence of a fatty hilum has the highest sensitivity but low specificity at 66.4%.<sup>216</sup>

The location of the lymph nodes also may be useful for decision-making. Figure 3 illustrates the delineation of Levels I through VI cervical lymph nodes. Metastatic lymph nodes are much more likely to occur in Levels III, IV, and VI than in Level II,<sup>214,217</sup> although this may not be true for PTC tumors arising in the upper pole of the thyroid, which have a higher propensity to produce skip metastases to Levels II and III.<sup>218</sup> Confirmation of malignancy in lymph nodes with a suspicious sonographic appearance is achieved by ultrasound-guided FNA aspiration for cytology and/or measurement of Tg in the needle washout (FNA-Tg). Tg washout is a helpful adjunct to FNA, particularly in cases where the lymph nodes are cystic, or the cytological and sonographic evaluations disagree (e.g., normal cytological biopsy of a large lymph node with microcalcifications).<sup>219</sup> False positive Tg washout may occur, particularly in lymph nodes in the central compartment when the thyroid gland is still present,<sup>220,221</sup> but it remains valid in the presence of positive serum TgAb. **Recommendation 31** reviews the role of FNA-Tg washout in lymph nodes in the postoperative setting.

Data are limited to support a definitive FNA-Tg threshold for diagnosis of a metastatic lymph node. A systematic review and meta-analysis showed that FNA cytology with FNA-Tg washout has a negative predictive value (NPV) of 99.4% and accuracy of 86.8% in the evaluation of pathological-appearing lymph nodes.<sup>222</sup> If the FNA-Tg level is 1.0 ng/mL or lower, then the NPV approximates 100%. However, non-metastatic lymph nodes can have concentrations as high as 32 ng/mL. Accuracy, specificity, positive predictive value (PPV), and NPV are significantly higher if the FNA-Tg threshold is 28.5 ng/mL.<sup>222</sup> Another systematic review analyzed 22 studies with 2,670 suspicious lymph nodes during thyroid nodule workup or PTC follow-up and found that the highest sensitivity was observed with a FNA-Tg cut-off of 1 ng/mL and the highest specificity was observed with a cutoff of 40 ng/mL. In this study, other factors that influenced the accuracy of FNA-Tg included TSH suppression, presence of serum Tg, and methodologic differences in Tg measurement.<sup>223</sup> Another study found the presence of serum TgAb interferes with circulating serum Tg measurement but does not appear to interfere with FNA-Tg measurements.<sup>224–226</sup> Further studies are needed to determine an optimal FNA-Tg threshold to diagnose metastatic lymph nodes.<sup>222</sup>

In addition to assessing for pathological lymph nodes, ultrasound evaluation of the thyroid gland to gauge gross extrathyroidal extension is important for surgical planning, as this typically demonstrates indication for RAI and therefore total thyroidectomy.<sup>227</sup> If there is evidence of more advanced locoregional disease, additional imaging with computed tomography (CT) may be useful. While ultrasound is more specific for nodal disease, CT is more sensitive, and the combination of both may increase diagnostic accuracy.<sup>228,229</sup> In view of the higher cost of CT compared with ultrasound, the associated radiation exposure, and potential

risks of intravenous contrast administration in specific populations, it is important to determine the imaging needs on an individual patient basis.

Accurate staging is important for determining the prognosis and tailoring treatment for patients with DTC. However, unlike many tumor types, the presence of metastatic disease does not obviate the need for thyroidectomy.<sup>230</sup> Because distant metastatic disease may respond to RAI therapy, removal of the thyroid as well as the primary tumor and accessible loco-regional disease is an important component of initial treatment for most patients with distant metastatic disease.

When should preoperative cross-sectional or <sup>18</sup>F-fluorodeoxyglucose-PET imaging be performed?

#### ■ RECOMMENDATION 8

- Preoperative use of cross-sectional imaging studies (CT, magnetic resonance imaging [MRI]) of the neck and mediastinum with intravenous contrast is recommended as an adjunct to physical examination and ultrasound for patients with clinical suspicion for advanced or invasive disease, including primary tumors with gross extrathyroidal extension, extensive (e.g. bulky or invasive) adenopathy, or disease concerning for aerodigestive tract and/or thoracic involvement (*Strong recommendation, Moderate certainty evidence*)
- Performing preoperative cross-sectional imaging of the chest, abdomen, and pelvis in search for distant metastases is recommended in situations when results will influence extent of surgery. (*Good Practice Statement*)
- Routine preoperative <sup>18</sup>F-fluorodeoxyglucose (FDG)-PET/CT is not recommended prior to surgery. (*Strong recommendation, Moderate certainty evidence*)

Since ultrasound evaluation is operator-dependent and cannot always adequately image deep anatomical structures or those acoustically shadowed by bone or air, alternative imaging procedures may be preferable or useful adjuncts in some clinical settings. Patients displaying bulky or widely distributed nodal disease on initial ultrasound may have nodal regions involved beyond typical cervical stations (some of which may be difficult to evaluate by ultrasound, including the mediastinum, infra-clavicular, retropharyngeal, and parapharyngeal regions).

In a systematic review and meta-analysis of 6378 patients with thyroid cancer assessing the diagnostic performance of CT in the detection of metastatic cervical lymph nodes, the pooled sensitivity was 55%, and the pooled specificity was 87%; however, there was considerable variation based on different CT protocols.<sup>231</sup> A meta-analysis of ultrasound and CT diagnosis with 5656 patients with thyroid cancer showed that CT had a higher sensitivity than ultrasound for assessment of cervical lymph nodes in the central and lateral compartments but that ultrasound has a higher specificity. Neither modality performed well in the central compartment (sensitivity of CT 40% vs. 28% for ultrasound).<sup>228</sup> While ultrasound had a higher specificity, the addition of CT reduces the rate of missed disease and improves surgical planning.<sup>228</sup>

MRI does not entail exposure to ionizing radiation, and its contrast agents are less nephrotoxic than those employed in

CT scanning. However, MRI is more subject to motion artifacts during the scan, though there have been recent advances in rapid acquisition of MRI images. In a meta-analysis of 504 patients with thyroid cancers, the pooled sensitivity of MRI for the diagnosis of metastatic cervical nodes was 80% and the specificity was 85%, but there was considerable heterogeneity, here reflecting fat-suppressed imaging and analytic techniques.<sup>232</sup> CT and MRI with intravenous (IV) contrast probably perform comparably in the detection of cervical nodal disease.

When cross-sectional imaging is performed, use of IV contrast is important, as it helps to delineate the anatomical relationship between the primary tumor or metastatic disease and other structures. If a retroesophageal innominate artery is identified, a right nonrecurrent laryngeal nerve should be suspected. Iodine is cleared within 4–6 weeks in most patients, so concern about iodine burden from IV contrast causing a clinically significant delay in subsequent whole body scans or RAI treatment after preoperative imaging is unfounded for most patients.<sup>233–235</sup> The benefit gained from improved anatomical imaging almost invariably outweighs any potential risk of deferring RAI imaging or therapy. When there is a clearance concern, a spot urinary iodine level can be measured.

<sup>18</sup>Fluorodeoxyglucose positron emission tomography (<sup>18</sup>FDG-PET) has been employed preoperatively for lymph node staging. However, a meta-analysis of 759 patients with thyroid cancer showed a pooled sensitivity of only 30% despite a high specificity of 94%.<sup>236</sup> The findings are reinforced by a network meta-analysis of 3571 patients from 19 direct comparison studies using two or more different imaging modalities (ultrasound, CT, <sup>18</sup>FDG-PET, or <sup>18</sup>FDG-PET/CT).<sup>237</sup> This showed that the imaging studies afford comparable detection of lymph node metastases. For all lymph node levels, ultrasound is superior in terms of PPV, NPV, and accuracy. Sensitivity and specificity of the three modalities vary when considering the lateral neck nodes, central compartment, and all lymph node levels, but none is significantly superior to ultrasound. Therefore, <sup>18</sup>FDG-PET or <sup>18</sup>FDG-PET/CT should not regularly be undertaken prior to initial treatment.

Locally invasive DTC has been reported to occur in 10–15% of patients at the time of diagnosis.<sup>238,239</sup> For this group of patients, if suspected preoperatively, cross-sectional imaging can be useful for surgical planning to delineate the extent of laryngeal, tracheal, esophageal, or vascular involvement.<sup>240,241</sup> Prior to resection, tracheoscopy and/or esophagoscopy, with/out ultrasonography, looking for evidence of intraluminal extension also may be helpful in cases of suspected aerodigestive tract invasion.

Locally invasive primary cancers may be associated with characteristic signs and symptoms, including rapid tumor enlargement, vocal cord paralysis, tumor fixation to the airway or neck structures, progressive dysphagia, respiratory compromise, hemoptysis, and significant voice change. Sonographic features of the primary tumor, including extrathyroidal extension (especially with posterior capsular penetration and disease reaching the mediastinum), also may prompt axial imaging. Chest CT can be useful in defining the inferior border of disease (and determining the extent to which

mediastinal structures are involved) in cases with significant caudal spread. CT findings may influence management by suggesting the uncommon need for sternotomy and/or tracheal or laryngeal resection/reconstruction, which often would require assembling additional resources and personnel in preparation for the operation. Neck CT or MRI with contrast may define the extent of laryngeal, tracheal, and/or esophageal involvement in tumors displaying aggressive local invasion, as well as delineating bulky lymphadenopathy with clinical extranodal extension that involves adjacent structures. Preoperative appreciation of these features of the primary tumor or metastases has the potential to influence the surgical plan.<sup>241</sup>

Should a serum Tg level be measured prior to surgery?

#### ■ RECOMMENDATION 9

Routine preoperative measurement of serum Tg or TgAb levels is not recommended. (*Conditional recommendation, Low certainty evidence*)

Data from a systematic review and meta-analysis suggested that high preoperative concentrations of serum Tg may predict a higher sensitivity for postoperative surveillance with serum Tg.<sup>242</sup> In a prospective, observational study of patients undergoing total thyroidectomy, preoperative serum Tg was not a significant predictor of malignancy.<sup>243</sup> Similarly, in a retrospective review of 131 patients who underwent surgery for benign multinodular goiter or indeterminate thyroid nodules, Tg levels did not significantly differ between those proving to have benign and malignant histologies.<sup>244</sup> In contrast, Scheffler and co-workers reported that the addition of preoperative serum Tg to the McGill Thyroid Nodule Score for Well-Differentiated Thyroid Cancer improved its sensitivity in predicting malignancy in thyroid nodules.<sup>245</sup>

A related issue is whether preoperative Tg levels can predict the extent of disease in patients with a preoperative diagnosis of thyroid cancer. Kim et al. performed a retrospective review of 4029 DTC cases between 1994 and 2006.<sup>246</sup> They report a linear association between preoperative Tg level and size of primary tumor and number of lymph node metastasis, with a threshold of 13.15 ng/mL as a predictor of ipsilateral lateral lymph node metastasis, 30.05 ng/mL for contralateral lateral lymph node metastasis, and 62.9 for distant metastasis. However, in a retrospective review of 422 patients with thyroid cancer who had preoperative Tg levels, Patell and co-workers found that while preoperative Tg was significantly correlated with size of the gland and T category, it did not correlate with presence of metastasis and was of low utility in the preoperative evaluation of thyroid cancer.<sup>247</sup>

While the presence of TgAbs preoperatively do not appear to be an independent preoperative predictor of stage in patients with DTC, evidence is limited. In a cross-sectional analysis of 1770 patients with perioperative TgAb level data in the National Thyroid Cancer Treatment Cooperative Study (NTCTC, a thyroid cancer registry that included 11 North American centers and enrolled patients between 1987 and 2011), serum TgAb status was not significantly associated with the stage of disease on multivariable analysis, nor was it associated with disease-free or overall survival on univariate or multivariable analyses.<sup>248</sup>

Should preoperative somatic genomic testing be performed to inform the extent of surgery?

#### ■ RECOMMENDATION 10

Genomic evaluation of confirmed DTC prior to surgery is not recommended routinely. However, if the genomic profile is known or performed, the presence or absence of specific combinations of abnormalities may be considered in the context of clinical, radiographical, and cytopathologic data to inform extent of surgery. (*Conditional recommendation, Low certainty evidence*)

Several groups have studied whether incorporation of molecular results using different preoperative tests might have a role in guiding surgical planning for preoperatively defined thyroid cancers. The basis for these studies is summarized in **Recommendation 28** in which associations between individual and/or combinations of genomic features and risk of recurrence are described. Several studies have indicated that the combination of *TERT* promoter and *BRAF*<sup>V600E</sup> mutations correlates with worse prognosis.<sup>249–252</sup> However, it is uncertain if a somatic *TERT* promoter mutation, with or without a concomitant *BRAF*<sup>V600E</sup> or *RAS* mutation, is associated with aggressive disease in smaller DTCs.<sup>253,254</sup> *BRAF*<sup>V600E</sup> mutations are commonly found in both small and large DTCs, and their presence in isolation is not clearly associated with more aggressive disease or worse outcomes.<sup>252</sup> While some studies show that higher risk tumors are more likely to have *BRAF*<sup>V600E</sup> mutations than low-risk tumors, low-risk tumors still harbor *BRAF*<sup>V600E</sup> at a high frequency.<sup>255</sup> It is possible that a higher allelic frequency of *BRAF*<sup>V600E</sup> mutation may be related to more aggressive tumor behavior.<sup>256</sup> Other combinations of mutations that include *TP53*, *PIK3CA*, and *AKT1* also are associated with aggressive disease and differentiation.<sup>257,258</sup> The presence of multiple mutations such as *BRAF*<sup>V600E</sup> with *TERT* promoter, *TP53*, or *AKT1* has been associated with more aggressive disease and is more common in surgically resected metastatic lesions, clinical trial populations, and with dedifferentiation in retrospective cohort studies.<sup>259,260</sup> *RAS* genes (most commonly *NRAS*), *PIK3CA*, *PTEN*, and *PAX8/PPAR $\gamma$*  fusions are more common in follicular variants of PTC or FTC<sup>261</sup> but can be found in benign follicular adenomas and NIFTP; therefore, they are not specific for thyroid cancer.<sup>76,262</sup> FTCs with *RAS* mutations have been reported to have a higher incidence of metastases, but this has not been verified in large population studies.<sup>263</sup> The frequencies of these mutations are variable between populations, with *BRAF*<sup>V600E</sup> mutation frequencies ranging from 46% to 90% of diagnosed PTCs on cytology, while *TERT* promoter and *TP53* mutations are significantly less common.<sup>264,265</sup> Expression of specific miRNAs also may be associated with increased risk of locoregional disease; however, robust data are lacking.<sup>255</sup>

Several molecular tests have been developed to improve diagnostic accuracy of thyroid nodule FNA cytology. These approaches have been studied to determine if they can predict tumor behavior to guide preoperative surgical planning.<sup>257,266–269</sup> Categories (low-, intermediate-, and high-risk) have been developed based on clinical outcomes on retrospective analyses.<sup>267–269</sup> In these studies, patients with high-risk molecular profiles had more extensive initial surgery, larger cancers, a higher frequency of nodal metastasis, and vascular invasion as well as shorter recurrence-free survival than those with low-risk molecular profiles. Features included in the low-risk

categories included *RAS* and *RAS*-like mutations (i.e., *BRAF*<sup>K601E</sup>, *PAX8/PPAR $\gamma$*  fusions), intermediate risk categories including *BRAF*-like alterations (i.e., *BRAF*<sup>V600E</sup>, *NTRK3* fusions, and *RET* fusions), and high-risk categories including *TERT* promoter, *TP53*, *AKT1*, and *PIK3CA* mutations.

One study<sup>269</sup> retrospectively reviewed patients who underwent total thyroidectomy for DTCs between 1 and 4 cm without nodal disease and reviewed available molecular testing results grouped into low-risk (*RAS* and *RAS*-like alterations and gene expressions) or intermediate risk (*BRAF*-like alterations and gene expressions and copy number alterations). T3a tumors were excluded, while T3b and T4 <4 cm were included. Molecular results in the high-risk category were excluded, as the assay used to assess high-risk genomic features was not available at the time that many in the cohort were tested. In multivariable analysis, both intermediate-risk and low-risk molecular categories predicted recurrence, as did pN1a disease. Because preoperative ultrasound was not included in the analysis, and molecular testing was not performed in consecutive patients, but rather in those selected by their treating clinicians, it is not possible to directly correlate preoperative clinical findings with molecular markers. Few patients in the cohort underwent lobectomy, none of whom recurred, making it impossible to compare outcomes from total thyroidectomy versus lobectomy by molecular assessment. In this same cohort, the association between molecular classification and recurrence was compared with the 2015 postoperative ATA risk stratification system. In this analysis, the preoperative molecular associations were like those of the 2015 postoperative ATA Risk of Recurrence.<sup>270</sup> Another study approach has been to categorize tumors by their *BRAF* and *RAS*-like expression profiles.<sup>266</sup> When retrospectively analyzed, the *BRAF*-like tumors were more associated with extrathyroidal extension, lymph node metastases, and multifocality.

In addition to identifying patients who might benefit from total thyroidectomy based on high-risk molecular testing, it also has been suggested that patients with low-risk molecular results might be selected for lobectomy. One group reported on 685 consecutive patients who underwent surgery for PTC of which 78.5% had a *BRAF*<sup>V600E</sup> mutation and 19.4% had a *TERT* promoter mutation.<sup>252</sup> Patients with *TERT* promoter mutations had worse outcomes than those who did not. Isolated *BRAF*<sup>V600E</sup> mutations did not impact outcome. In those who were *TERT* promoter mutation-negative, there was no difference in 10-year disease-free or cancer-specific survival among patients with intrathyroidal tumors 1–4 cm. In another retrospective study tumors were categorized by molecular risk profiles on testing performed preoperatively in clinically selected patients.<sup>269</sup> DTCs in the intermediate molecular risk category were more likely to recur than those in the low-risk category (7.2% vs. 0.7%, retrospectively). Recurrence rates for the intermediate-risk group were influenced by tumor size. Patients with tumors >2 and <4 cm recurred more frequently than those with tumors between 1 and 2 cm. Recurrence was low at 3.8% for the entire cohort. Because most patients underwent total thyroidectomy (85.6%), it is not possible to know if extent of surgery would have impacted outcomes.

Several retrospective studies assessing a possible role for molecular testing among patients being considered for active

surveillance (T1a PTC) have conflicting results.<sup>253,271</sup> Thus, there are insufficient data to support use of molecular testing to stratify the approach for patients with T1a PTC.

The potential application of molecular testing for preoperatively defined DTC to individualize initial therapy may be particularly relevant for select patients with cT2N0 DTC for whom extent of surgery is not clear after consideration of clinical and radiographical features, and patient preferences (see **Recommendation 15**). Further studies are needed in consecutive, non-selected patients with T2N0 DTCs to fully assess the potential role of molecular testing to guide initial extent of surgery. In addition, cost–benefit analyses are necessary, particularly given the relatively low frequency of higher risk molecular profiles in cT2N0 DTCs that would lead to total thyroidectomy (e.g., combinations of *BRAF*<sup>V600E</sup> and *TERT* promoter or *TP53* mutations). Clinical trials of neoadjuvant therapy for very large invasive DTCs are ongoing; therefore, molecular tests in such patients are best utilized in the context of a clinical trial.

Are there patients in whom active surveillance and percutaneous ablation are appropriate management options?

#### ■ RECOMMENDATION 11

- A. Active surveillance may be offered as an appropriate management option for some patients with cT1aN0M0 PTCs. Shared clinical decision-making between the patient and clinical team regarding risks and benefits of this approach is essential. (*Conditional recommendation, Low certainty evidence*)
- B. Ultrasound-guided percutaneous ablation may be considered as an alternative to active surveillance or resection for cT1aN0M0 PTC in selected patients. Shared clinical decision-making between the patient and clinical team regarding risks and benefits of this approach is essential. (*Conditional recommendation, Low certainty evidence*)

*Active surveillance.* FNA is not routinely recommended for thyroid nodules  $\leq 1$  cm with low-risk features. However, if thyroid cancer is diagnosed in a tumor  $\leq 1$  cm by FNA, active surveillance is an acceptable management option in selected patients. A systematic review published by a subgroup of this guidelines task force reviewed the published literature regarding active surveillance versus immediate resection and found low-certainty evidence that in adults with small, low-risk DTC, active surveillance and immediate resection are associated with similar, low risk of all-cause or cancer-specific mortality, distant metastasis, and recurrence after thyroidectomy.<sup>15,202,272–290</sup> In patients managed with active surveillance, rates of tumor growth were low. Data on harms were limited, but temporary vocal fold paralysis and hypoparathyroidism were complications from thyroid surgery.<sup>15</sup> Rates of later surgery varied and were driven more by patient choice than signs of progression. Evidence regarding QoL or functional outcomes also was limited but indicated small or no differences. Cohort studies found that surgery was associated with improved all-cause or thyroid cancer mortality, but findings were potentially influenced by patient age, tumor risk category, and eligibility for, and actual receipt of, active surveillance.<sup>291–294</sup>

TSH goals in the setting of active surveillance are discussed in **Recommendation 46**.

There are limited data on the role of active surveillance in cancers >1 cm, as most of the existing studies have focused on enrollment for tumor sizes ≤1 cm.<sup>202,272–298</sup> One study evaluated 77 patients with tumor size ≤1.2 cm who underwent active surveillance and 18 who underwent immediate operation. Of the patients undergoing active surveillance, only one had progression of disease requiring surgery after 30 months of follow up; in that case, tumor growth was associated with suspicion of extrathyroidal invasion.<sup>279</sup> A study that included 392 patients with tumors ≤2 cm (T1bN0M0) found that only 61 (16%) of the patients with tumors ≤2 cm selected active surveillance as management over immediate surgery, whereas 360 (89%) of those with tumor size ≤1 cm chose active surveillance. During a mean follow-up of 7.4 years (range 0.5–25 years), no significant difference was seen in the tumor progression of patients with tumor sizes ≤1 cm versus ≤2 cm; however, the cohort was small, and there was a risk of selection bias.<sup>280</sup> More recently, a prospective, nonrandomized controlled trial of 222 patients with Bethesda V and VI nodules that were ≤2 cm over a mean follow-up of 37.1 months found equivalent disease-specific and overall survival.<sup>299</sup> Of the 112 patients who underwent active surveillance, 90% continued, 41% experienced tumor shrinkage, and none developed regional/distant metastases. Size growth of >5 mm was observed in 4% of those undergoing active surveillance, and volumetric growth of >100% was seen in 7%.

Determining which patients are candidates for active surveillance involves shared decision-making among the patient, endocrinologist, surgeon, and other clinicians involved in the patient's care. Some patients may not want active surveillance, whereas for others the benefit of avoiding surgical complications, which may be higher in some settings versus others, is a priority.<sup>300,301</sup> In addition to patient preferences regarding surgery versus active surveillance, consideration should be given to the tumor and patient characteristics and the medical team's ability to provide long-term observation. For patients considering an active surveillance approach, it is important that clinicians provide a description of the "unknown." For example, the risk of tumors growing or dedifferentiating over time could narrow the window of earlier effective treatment if they are not properly monitored. Practitioners should stress the critical need for long-term follow-up and how non-compliance with such follow-up invalidates claims for safety of this approach.<sup>302</sup> In this context, some patients may choose earlier treatment rather than active surveillance. Patients who have evidence of aggressive histology on review of cytopathology; patients with cancers that on imaging studies appear to invade the recurrent laryngeal nerve, trachea, or esophagus, or exhibit visible extrathyroidal extension; or regional or distant metastases are not candidates for active surveillance. Due to concern for tumor growth near critical local structures, active surveillance for cancers that abut the posterior capsule/trachea have been excluded from studies. Although this exclusion limits our ability to draw conclusions from existing data, it is reasonable to infer that active surveillance of posteriorly located tumors may be inappropriate due to the risk of invasion into vital structures.<sup>15,303</sup> A cohort study from Japan ( $N = 1235$ , mean follow-up

75 months) suggested that older patients (i.e., patient age >60 years) with T1a PTCs may be better candidates for active surveillance because they are significantly less likely to experience tumor size increase of ≥3 mm, new lymph node metastases, or new clinical disease compared to young adults (age <40 years).<sup>273</sup>

**Percutaneous ablation.** Thermal ablation using radiofrequency (RFA), microwave (MWA), and laser (LA) and ethanol ablation have been studied as primary treatment of low-risk PTC in carefully selected patients. Selection criteria are similar to those employed for active surveillance. Patients who are uncomfortable with active surveillance or with surgery may prefer a percutaneous ultrasound-guided ablative treatment for their cancer. Compared with lobectomy, ablation has a lower likelihood of resultant hypothyroidism, but it affords less certainty of complete tumor eradication, and it does not permit histopathologic evaluation.<sup>304–306</sup> A meta-analysis on the subject included 11 studies involving 715 patients from Asia, with significant heterogeneity between the studies.<sup>307</sup> The pooled rate of complete tumor disappearance was 57.6% [confidence interval (CI) 35–80%] with a pooled recurrence rate of 0.4% [CI 0.0–1.1%]. Complication rates were 3.2% overall and 0.7% for major events, the latter of which consisted mostly of temporary voice changes. Subset analysis comparing modalities revealed no significant difference in rates of complete tumor disappearance ( $p = 0.35$ ) or complications; however, there was a significant difference in volume reduction rates (RFA 99%, MWA 95%, and LA 89%,  $p < 0.001$ ).<sup>299</sup>

Another more recent meta-analysis of thermal ablation for cT1N0M0 included 36 studies with a pooled complete tumor disappearance rate of 91% [CI 83–97%] for cT1a and 60% [CI 50–70%] for cT1b carcinomas using RFA.<sup>308</sup> The local recurrence rates were 2–3% with nodal metastasis rates of 1–2%, across three thermal ablation techniques (RFA, LA, and MWA). Minor complication rates varied from 3% to 13%, and major complications were not reported. Comparisons of effectiveness between techniques were difficult to perform due to potential different tumor sizes.<sup>308</sup>

A single-institution, prospective study of RFA for low-risk cT1a PTC included 98 tumors in 92 patients with complete tumor disappearance in 42% at 6 months and 96% at 1 year. At 18 months, no recurrences or nodal metastases were identified.<sup>309</sup> Another single-institution, retrospective study with at least 5 years of follow-up from RFA for cT1a PTC, including 84 nodules in 74 patients, found 99% and 100% complete tumor disappearance rates at 2 and 5 years.<sup>310–312</sup> Fifteen percent of nodules required repeat RFA.<sup>310</sup> Four additional cancers developed in three patients; they were successfully ablated, and no patients developed metastases. The major complication rate was 1.4%.

A larger retrospective study of 414 patients with low-risk, unifocal cT1a PTC treated with RFA found a complete tumor disappearance rate of 88%, with 3% of patients requiring additional ablation.<sup>313</sup> The overall rate of local tumor progression was 4%. Local recurrence occurred in 2.4% of patients, and 1% developed nodal metastasis with an average follow-up of 3.5 years (range 2–5 years). No life-threatening complications were observed.

A single-institution, retrospective cohort study of 1613 individuals with PTC ≤2 cm treated with RFA had a

median follow-up of 58.5 months.<sup>314</sup> During this follow-up, local tumor progression was observed in 69 of 1613 (4.3%) patients, tumor recurrence occurred in 42 (2.6%) patients, and persistence occurred in 27 (1.7%) patients. Mean time after RFA to development of local tumor progression was 21.5 months. The disease-free survival rate differed based on tumor size (T1a vs. T1b), number of tumors (unifocal vs. multifocal), and subcapsular tumor location distance from the capsule or trachea ( $\leq 2$  mm or  $>2$  mm).

Yan et al. retrospectively evaluated RFA for patients with unifocal ( $n = 432$ ) versus multifocal ( $n = 55$ ) cT1a PTC and found no significant differences in outcomes between the two groups with a mean follow-up of 4 years. Complete disappearance rates were reported as 89% versus 96% ( $p = 0.2$ ). There were no significant differences between the two groups in rates of local progression, nodal metastasis rates, local recurrence, disease persistence, and recurrence-free survival.<sup>315</sup> However, another study demonstrated better outcomes for unifocal versus multifocal PTC with RFA (hazard ratio [HR] 0.5,  $p < 0.001$ ), as well as for T1a versus T1b PTC (HR 0.4,  $p < 0.001$ ).<sup>314</sup>

Yang et al. reported retrospective results evaluating RFA for cT1a PTC in 91 patients with tumors adjacent to the tracheoesophageal groove and anticipated location of recurrent laryngeal nerve (“danger triangle”) and found no significant difference in complete tumor disappearance rates between those located near or away from that region (74% vs. 78%,  $p = 0.5$ ) with no difference in disease progression (2% vs. 2%,  $p = 0.99$ ) and no significant difference in complications (3.3% vs. 1.7%,  $p = 0.65$ ) but may have been underpowered to show a difference.<sup>316</sup>

A retrospective study of MWA for multifocal, cT1a PTC in 66 patients with 158 tumors and 5 years of follow-up found complete tumor resolution in all lesions with tumor progression in 3%, nodal metastases in one patient, and development of a new cancer in another. Repeat MWA was successful, and the complication rate was 3%.<sup>317</sup>

Retrospective results using ultrasound-guided percutaneous ethanol ablation for cT1aN0M0 papillary thyroid cancer were reported from a single center involving 15 patients with 17 tumors utilizing injections on two successive days. Forty-seven percent of cancers completely resolved with median tumor volume reduction of 80–90%. No new cancers developed, and no nodal metastasis occurred with a median 5-year follow-up.<sup>318</sup>

A retrospective study comparing individuals who underwent RFA versus surgery for unilateral multifocal papillary microcarcinoma with over a 5-year follow up period showed no statistically significant differences in disease progression (4.5% vs. 3.8%;  $p > 0.99$ ), lymph node metastasis (2.3% vs. 3.8%;  $p > 0.99$ ), persistent lesions (2.3% vs. 0%;  $p = 0.27$ ) and RFS rates (97.7% vs. 96.2%;  $p = 0.67$ ).<sup>312</sup> The data suggest that percutaneous ablation may represent an alternative to active surveillance or resection in selected patients. Additional studies are needed to assess widespread applicability,<sup>304</sup> particularly given that many of the referenced studies are subgroup analyses from a single group.<sup>309,312–315</sup>

What is the optimal approach for patients undergoing active surveillance?

#### ■ RECOMMENDATION 12

For patients undergoing active surveillance, neck ultrasound should be used to monitor disease progression. (*Good Practice Statement*)

It is important that members of the medical team offering active surveillance have experience and confidence in their use of neck ultrasound.<sup>171</sup> Neck ultrasound, assessing the thyroid gland and all cervical lymph node compartments, is key to monitoring for cancer progression. Based on prior studies addressing active surveillance, neck ultrasound should be performed every 6 months for 1–2 years and then annually.<sup>202,273,274,290</sup> The length of necessary follow-up remains unknown. None of the prior studies on active surveillance used neck CT for routine follow-up.

Should serum Tg and TgAb levels be measured during active surveillance?

#### ■ RECOMMENDATION 13

For patients undergoing active surveillance, routine measurement of serum Tg and/or TgAb levels is not recommended. (*Good Practice Statement*)

Data are lacking on the role of serum Tg levels when the entire thyroid is intact, as is the case during active surveillance. Since there is no clear role for measuring serum Tg levels preoperatively or postoperatively after lobectomy for thyroid cancer monitoring (**Recommendation 9**), serial serum Tg levels are unlikely to prove meaningful during active surveillance.

Are there clear indications for when patients undergoing active surveillance should pursue resection?

#### ■ RECOMMENDATION 14

In patients undergoing active surveillance, surgical resection is indicated if there is evidence of new biopsy-proven lymph node metastases, growth of the primary tumor by  $\geq 3$  mm, distant metastases, evidence of extrathyroidal extension, posterior growth, when there is patient anxiety, inability to follow-up, and/or expressed preference for surgery. (*Good Practice Statement*)

Since patients with regional or distant metastases would not routinely be candidates for active surveillance, initial or follow-up surgical consultation is indicated when patients who are undergoing active surveillance develop new (not previously observed), biopsy-proven lymph node metastases, ultrasound evidence of extrathyroidal extension, or distant metastases. Since surgical timing is relevant, discussion with their surgeon would be appropriate for patients considering active surveillance, particularly those with tumor adjacent to, but not invading, the recurrent laryngeal nerve, trachea, or esophagus. Invasion into the recurrent laryngeal nerve, trachea, or esophagus should prompt the patient to visit their surgeon, as patients with cancers with these features would not be appropriate for active surveillance.

Based on prior studies, prompt initial or follow-up consultation with the involved thyroid surgeon is indicated if there is clinically significant increase in tumor size described as cancer growth by  $\geq 3$  mm in any dimension.<sup>274,280,290</sup> Patient preference for pursuing surgery after a period of active surveillance, as well as the patient’s inability to follow-up regularly for monitoring (risk of non-compliance), also are appropriate indications for another consultation with their surgeon.

What is the optimal operative approach for DTC?

#### ■ RECOMMENDATION 15

A. When resection is performed for patients with thyroid cancer  $\leq 2$  cm without gross extra-thyroidal extension

(cT1) and without metastases (cN0M0), the initial surgical procedure should be a thyroid lobectomy unless there are bilateral cancers or other indications to remove the contralateral lobe. (**Strong recommendation, Moderate certainty evidence**)

- B. For patients with low risk, unilateral thyroid cancer >2 and ≤4 cm (cT2N0M0), thyroid lobectomy may be the preferred initial surgical treatment due to significantly lower risk and side effects. However, the patient and treatment team may adopt total thyroidectomy to enable RAI administration and/or enhance follow-up based on disease features, suspicious contralateral nodularity, and/or patient preferences. When thyroid lobectomy is offered as initial treatment, counsel the patient about the possibility of conversion to total thyroidectomy or need for subsequent completion thyroidectomy if higher-risk factors emerge intraoperatively or postoperatively. (**Conditional recommendation, Low-moderate certainty evidence**)
- C. For patients with thyroid cancer >4 cm (cT3a), cancer of any size with gross extra-thyroidal extension (cT3b or cT4), or clinically apparent metastatic disease to lymph nodes (cN1) or distant sites (cM1), the initial surgical procedure should include a total thyroidectomy with gross removal of all primary tumor and node dissection unless there are contraindications to this procedure. (**Strong recommendation, Moderate certainty evidence**)

A preoperative FNA biopsy diagnostic for DTC is almost always interpreted as conventional PTC based upon cytology (Bethesda VI), whereas IEFVPTC, FTC, and OTC more often fall into one of the indeterminate categories (Bethesda III, IV, or V). The identification of a *BRAF*<sup>V600E</sup> mutation or *RET* fusion on molecular testing of a thyroid nodule FNA sample, if performed, is diagnostic of PTC. Thus, in the absence of clinical features confirming malignancy with indeterminate cytology, the preoperative diagnosis of DTC typically involves classical PTC. Surgery for thyroid cancer is an important element of an often straightforward but potentially complex treatment approach, best coordinated preoperatively with a multidisciplinary team and reflecting patient desires. The operation should be compatible with the overall treatment strategy and follow-up plan recommended by the managing team, understood by the patient and respecting their personal preference(s).<sup>319</sup>

Earlier ATA guidelines<sup>12,13</sup> endorsed total thyroidectomy as the primary initial surgical treatment option for nearly all DTCs >1 cm with or without evidence of loco-regional or distant metastases, with lobectomy sufficient for unilateral T1a carcinomas (T1a PTC) without metastasis. The recommendation was based on data suggesting that for cancers >1 cm, a bilateral surgical procedure was associated with improved survival,<sup>320</sup> decreased recurrence rates,<sup>321–323</sup> allowed routine use of RAI remnant,<sup>168,324</sup> and facilitated detection of recurrent/persistent disease during follow-up. However, the 2015 ATA guidelines<sup>14</sup> suggested lobectomy as an alternative to total thyroidectomy for cT1b-T2N0M0, low risk, unilateral PTCs (particularly follicular variant) and FTCs. This change was based on data demonstrating that for properly selected patients, clinical outcomes are very similar following unilateral or bilateral thyroid surgery.<sup>325–330</sup> There has been a trend

away from routine use of RAI for remnant ablation (which requires total thyroidectomy), and there are higher rates of complications following total thyroidectomy versus thyroid lobectomy (see **Recommendation 6**).<sup>168,324,331</sup> In view of the generally favorable outcomes of low-risk DTC and lack of randomized controlled trials, large database studies were deemed necessary to identify statistically significant differences in outcomes between lobectomy and total thyroidectomy.<sup>332</sup>

Near total or total thyroidectomy is necessary if the overall strategy is to include RAI therapy post-operatively. Therefore, near-total or total thyroidectomy was recommended in prior ATA guidelines in situations where postoperative RAI therapy was recommended: that is, for primary DTCs >4 cm (cT3a), with gross extrathyroidal extension (cT3b or T4), and/or regional (cN1) or distant metastases (cM1). For tumors between 1 and 4 cm and without evidence of metastasis (cT1b-2, N0, M0), prior ATA guidelines suggested that patient age >45 years, contralateral thyroid nodules, a personal history of radiation therapy to the head and neck, or FNMTc might prompt recommendations for total thyroidectomy because of plans for RAI therapy, to facilitate follow-up strategies, or to address greater suspicion of bilateral disease.<sup>325,329,333,334</sup> Ultrasound-guided FNA of significant/suspicious contralateral nodule(s) helped inform a recommendation for total thyroidectomy.

Since publication of the 2015 guidelines suggesting that thyroid lobectomy/hemi-thyroidectomy may be sufficient for low risk (cT1-2N0M0) DTC, numerous studies have been published evaluating this recommendation. Several systematic reviews and meta-analyses have been performed, with approximately half showing no difference in recurrence or survival but with higher complication rates for total thyroidectomy.<sup>335–337</sup> The other approximate half demonstrate statistically significant, lower recurrence rates with total thyroidectomy compared with lobectomy alone.<sup>338–340</sup> Only one meta-analysis found improved overall survival with total thyroidectomy over lobectomy, but the benefit was confined to T2 primary tumors.<sup>340</sup> This result is influenced by a National Cancer Database (NCDB) study analyzing PTC (1–4 cm, T1b-2) demonstrating significantly better survival with total thyroidectomy for classical PTC but not FVPTC; however, in subset analysis, this seemed to be true only for T2 (not T1b) classical variant PTC.<sup>341</sup> A recent narrative review of these studies and published guidelines concluded that lobectomy was sufficient for low-risk T1 tumors and that either lobectomy or total thyroidectomy would be reasonable treatment alternatives for low-risk T2 tumors. They recommended that patients with cT2N0M0 tumors should be informed that lobectomy has a significantly lower risk of complications and side effects but carries a slightly higher risk of locoregional recurrence and possibly reduced overall survival.<sup>342</sup> This conclusion was supported by another recent systematic, qualitative narrative review.<sup>343</sup> Most recurrences following lobectomy alone appear to occur in the contralateral lobe and are successfully salvaged with completion thyroidectomy.<sup>339,340</sup> A Surveillance, Epidemiology and End Results (SEER) database study involving only FTC without extrathyroidal extension or metastasis (cT1a-T3aN0M0) found no difference in 15-year disease-specific survival between lobectomy and total thyroidectomy (98% vs. 97%,

respectively), but it did not evaluate recurrence.<sup>344</sup> A large, single-institution study of minimally invasive FTC found patient age >55 years and tumor size >4 cm were both independently associated with higher 10-year risk of recurrence on multivariable analysis.<sup>345</sup> Results of single-institution studies of primarily PTC are mixed.<sup>346–353</sup>

A few studies have addressed the issue of multifocality with lobectomy versus total thyroidectomy for PTC <1cm (T1a). One found a significantly higher recurrence rate with lobectomy versus total thyroidectomy (26% vs. 5%, respectively), with lower disease-free survival at 5 and 10 years, particularly in male patients with a sum of all tumors >1 cm.<sup>354</sup> Another study found a higher recurrence rate for lobectomy in patients with PTC T1a tumors, with a higher rate of recurrence beyond the contralateral lobe in the presence of multifocality.<sup>355</sup> Additional studies looked specifically at pathologically node positive disease discovered in the central compartment at the time of lobectomy (cN0 but pN1a); one demonstrated no significant difference in recurrence-free survival at 15 years between total thyroidectomy and less than total thyroidectomy,<sup>356</sup> but the other showed a significantly lower recurrence rate but higher complication rate with total thyroidectomy compared with lobectomy, with no difference in recurrence if pN0.<sup>357</sup> A study examining the impact of minimal extra-thyroidal extension in T1N0 PTC tumors found no difference in recurrence rates between lobectomy and total thyroidectomy (3% vs. 2%, respectively).<sup>358</sup> A recent SEER database study of patients with unilateral T1a PTCs found no difference in overall or disease-specific survival between lobectomy and total thyroidectomy after propensity matching; a subset analysis revealed lower disease-specific survival for younger patients (<55 years) and those with multifocality and/or extra-thyroidal extension treated with lobectomy alone.<sup>359</sup> Another database study involving a Chinese cohort suggested younger patients (<35 years) benefit from total thyroidectomy over lobectomy, and particularly for T3 (>4 cm) cancers.<sup>360</sup>

Recent studies of intermediate-risk (see **Recommendation 28**) PTC have demonstrated conflicting results, with two finding no significant difference in recurrence- or disease-specific survival<sup>361,362</sup> but another demonstrating significantly reduced recurrence with total thyroidectomy versus lobectomy (0% vs. 8%, respectively) but no significant difference in overall survival.<sup>363</sup> A NCDB study demonstrated reduced survival among patients undergoing lobectomy alone versus total thyroidectomy with RAI for T1b-T2 DTCs with intermediate- or high-risk features.<sup>364</sup> A recent report of high-risk patients confirmed a survival advantage associated with total thyroidectomy and adjuvant RAI therapy.<sup>365</sup>

Several retrospective studies have examined the estimated proportion of patients who might require completion thyroidectomy after initial lobectomy for clinically low-risk, unilateral, intrathyroidal, node-negative DTCs; estimates ranged greatly, from 5% to 43%.<sup>366–369</sup> of patients, which is similar to a meta-analysis estimate of 11–34%.<sup>339</sup> Two additional studies found a 21% rate of conversion to total thyroidectomy from lobectomy based on high risk findings identified intraoperatively and a 27–30% rate of completion thyroidectomy based on pathologically higher-risk findings.<sup>370,371</sup> More important, one study that compared actual rates of initial total thyroidectomy versus lobectomy and rates of completion thyroidectomy after initial lobectomy (before and

after publication and implementation of the 2015 ATA guidelines) found a reduction in the utilization of total thyroidectomy (from 61% to 31% of all initial operations) and also completion thyroidectomy (from 74% to 20%), suggesting that doing more lobectomies for lower-risk cancers does not result in a higher rate of completion thyroidectomy.<sup>372</sup> Several additional studies<sup>373–375</sup> document increased use of lobectomy for cancer after publication of the 2015 ATA guidelines, as well as lower rates of completion thyroidectomy (from 50% to 25%).<sup>374,376</sup> However, total thyroidectomy remains the more commonly performed initial operation (70–88%), even for cT1-2N0M0 cancers, despite significantly higher postoperative morbidity.<sup>373–375,377</sup> Increasing primary tumor size from T1a-T1b to T2 was associated with increased utilization of initial total thyroidectomy<sup>375</sup> and completion thyroidectomy.<sup>377</sup> The one prospective study of lobectomy for T1a PTC found only a 3% conversion rate to total thyroidectomy due to higher risk intraoperative findings and a 20% salvage surgery rate, with resultant 99% disease-free survival (similar to a retrospective cohort treated with initial total thyroidectomy and central neck dissection).<sup>378</sup> Accurate preoperative ultrasound<sup>227,379</sup> and targeted use of frozen section<sup>380–382</sup> can help identify patients best treated with total thyroidectomy, reducing the need for subsequent completion thyroidectomy. Cost-effectiveness assessment found greater utility with lobectomy over total thyroidectomy for PTCs that are 1–4 cm (T1b-2N0M0).<sup>343,367</sup>

The risks of total thyroidectomy are significantly greater than those for thyroid lobectomy, with a meta-analysis suggesting a relative risk (RR) significantly greater for all complications, including recurrent laryngeal nerve injury (transient RR = 1.7, permanent RR = 1.9), hypocalcemia (transient RR = 10.7, permanent RR = 3.2), and hemorrhage/hematoma (RR = 2.6).<sup>383</sup> Total thyroidectomy is associated with the rare risk of bilateral recurrent laryngeal nerve injury necessitating tracheostomy. Surgeon experience likely influences the risks of thyroidectomy, with higher-volume surgeons having lower complication rates.<sup>175,176,178,384,385</sup> However, as noted above, even high-volume surgeons still have a higher complication rate when performing total thyroidectomy versus lobectomy (14.5% vs. 7.6%, respectively), which is higher on average than the complication rate for lobectomy undertaken by low-volume surgeons (11.8%). Highest risk is associated with total thyroidectomy at the hands of a low-volume surgeon (24.1%).<sup>192</sup> Therefore, patients should carefully weigh the relative benefits and risks of total thyroidectomy versus thyroid lobectomy, even when the operation is performed by high-volume surgeons. Total thyroidectomy necessitates thyroid hormone replacement, while lobectomy is associated with postoperative biochemical hypothyroidism estimated on average to be 22%, with clinical or overt hypothyroidism estimated at 4%.<sup>386</sup>

A significantly increased risk of hypothyroidism following lobectomy has been reported in the presence of autoimmune thyroid disease (e.g., as reflected by the presence of thyroid antibodies) or high normal/elevated preoperative TSH.<sup>383,386</sup> Hypothyroidism is not an indication for thyroidectomy, and its use as justification for total thyroidectomy over lobectomy should be weighed against the other higher risks associated with total thyroidectomy. In contrast, coexistent hyperthyroidism may be an indication for

total thyroidectomy, depending upon the etiology. Patients with high-normal TSH levels following lobectomy for cancer may still need thyroid hormone supplementation to reduce TSH levels into their target range (see TSH target section).<sup>387–395</sup> Regardless, two recent studies confirm significantly better quality-of-life measures in patients undergoing lobectomy compared with total thyroidectomy for cancer.<sup>396,397</sup> A third found this was only true for the first few months postoperatively, with no significant differences at 6–12 months.<sup>398</sup> A separate report found a decreased rate of chronic asthenia (generalized weakness) with lobectomy.<sup>399</sup>

*Preoperative somatic molecular testing and neoadjuvant therapy.* Preoperative molecular testing obtained from FNA has been proposed to help determine extent of initial thyroid surgery in selected patients with cT1–cT2 cN0 DTC (see **Recommendation 10**). Retrospective studies have demonstrated that high-risk molecular test results (*BRAF*<sup>V600E</sup> or *RAS* mutations with a *TERT* promoter and/or *TP53* mutations) correlate with postoperative ATA Risk of Recurrence assessment. These studies included patients with cytologically indeterminate nodules (66% Bethesda III–IV) not addressed in these thyroid cancer guidelines. In addition, patients with ATC and/or advanced DTC that was evident preoperatively were included without adjusting for clinical TNM staging.<sup>267,268</sup> Finally, many of the patients only had postoperative molecular testing (i.e., not on preoperative FNA). Another study from the same team reported on a cohort that included many of the same patients with tumors 1–4 cm.<sup>269</sup> This series excluded patients with cT3, cN1, and/or cM1 disease but did not appear to have excluded patients with locally advanced (cT3b–4) disease. There were no recurrences in the lobectomy group during follow-up, suggesting that preoperative clinical risk assessment was sufficient. Molecular high-risk assessment could not be evaluated due to differences in the clinically available molecular tests over time. Intermediate molecular risk (*BRAF*<sup>V600E</sup>-like) and the presence of pN1a disease both predicted recurrence with estimates of 11% for 2–4 cm and 6% for 1–2 cm tumors, respectively, in patients treated with total thyroidectomy.<sup>269</sup>

In contrast, another study of 1–4 cm DTCs in which cT4, cN1, or cM1 disease were excluded (but included cT3b tumors) found no difference between lobectomy and total thyroidectomy in 10-year cause-specific survival for *BRAF* and/or *TERT* promoter-mutated tumors.<sup>252</sup> No patients died of their disease. Disease-free survival was not significantly better in patients with *TERT* promoter-mutated tumors (predominately also *BRAF*-mutated) treated with total thyroidectomy versus lobectomy (100% vs. 65%,  $p = 0.09$ ). There was no difference in disease-free survival for patients whose tumors were *TERT* promoter-negative and predominantly *BRAF* mutation-positive treated with total thyroidectomy versus lobectomy (97% vs. 97%,  $p = \text{NS}$ ).<sup>252</sup>

Another retrospective study of 105 patients with PTC and Bethesda V or VI cytologies (85% Bethesda VI) found high-risk mutations in 6%, all of whom underwent total thyroidectomy and had T3b–4 and/or N1 and/or M1 disease.<sup>400</sup> An increased recurrence rate was observed for patients with high-risk molecular tumors versus low- and intermediate-genomic risk groups, although the number of patients in the high-risk group was small ( $n = 6$ ).<sup>400</sup> Of the 19% of patients who underwent initial lobectomy, 21% underwent completion

thyroidectomy based upon postoperative risk of recurrence assessment. None had a high-risk mutation, and no comparison between low- or intermediate-risk mutations was performed.<sup>400</sup>

In summary, high-risk mutations appear to be uncommon in patients with cT1b–2N0M0 DTC. *BRAF*<sup>V600E</sup> and *BRAF*<sup>V600E</sup>-like mutations are common in these tumors, as most patients with Bethesda VI cytology have classical PTC. Because low-risk mutations (*RAS*-like) occur primarily in cytologically indeterminate (Bethesda III–V) nodules, data for these nodules may not be as applicable for patients with Bethesda VI cytology on preoperative FNA. Thus, routine use of molecular testing is not recommended for patients with these smaller intrathyroidal DTCs as prospective studies that included cost analyses have not yet been performed (see **Recommendation 10**).

For patients with large, locally invasive DTC in whom high-risk mutations are more common and a R0 or R1 resection is unlikely without high morbidity, use of systemic multi-kinase or targeted therapy with or without immunotherapy in the neoadjuvant setting has been reported. These reports thus far show variable results depending on the type and side effects of therapy.<sup>401,402</sup> Results from larger prospective clinical trials are needed to determine for whom such a strategy may be appropriate to consider.

In view of the significantly lower risk of complications and better QoL with lobectomy in comparison to total thyroidectomy, and limited oncologic benefit of total thyroidectomy, it appears that lobectomy for low-risk DTC is the preferred initial operation when the primary tumor is clinically small, unilateral, intrathyroidal, and without evidence of regional or distant metastasis. However, patients must be aware of a  $\geq 20\%$  possibility of conversion to total thyroidectomy intraoperatively, or subsequent completion thyroidectomy. Multifocality with clinically significant contralateral nodularity may make total thyroidectomy the preferred initial operation for some patients to reduce the risk of recurrence and need for additional surgery. Most recurrences in the setting of multifocality/contralateral nodularity can be successfully salvaged with completion thyroidectomy if the patient is compliant with sonographic surveillance. With appropriate follow-up, deferral of completion thyroidectomy has little to no impact on survival. Patients with larger cT2N0M0 classical PTC are also good candidates for lobectomy but may prefer to undergo total thyroidectomy and RAI postoperatively to possibly reduce their risk of recurrence and improve survival.<sup>340–343</sup> Patients with clinically more advanced primary tumors (cT3–4), nodal involvement (cN1), and/or distant metastasis (cM1) are generally best treated with total thyroidectomy to facilitate RAI and biomarker surveillance (Table 5). Decisions regarding the extent of initial thyroidectomy should be part of a patient-centered, multidisciplinary treatment plan; patient preference serves as a very important component. Clinical risk factors such as age, male sex, family history of thyroid cancer, and/or history of radiation exposure may further influence decision-making regarding total thyroidectomy.

When should completion thyroidectomy be performed?

#### ■ RECOMMENDATION 16

- A. Completion thyroidectomy for cancer following initial lobectomy may be considered to address persistent

TABLE 5. EXTENT OF INITIAL THYROID SURGERY FOR DTC

Clinical stage	Extent of thyroidectomy <sup>a</sup>
cT1N0M0 (Unilateral)	Lobectomy
cT1 (m) N0M0 (Bilateral)	Total thyroidectomy
cT2N0M0 (Unilateral)	Lobectomy or Total thyroidectomy
cT2 (m) N0M0 (Bilateral)	Total Thyroidectomy
cT3-4 or cN1 or cM1	Total thyroidectomy

Clinical stage based upon AJCC 8th edition.

<sup>a</sup>If surgery chosen for initial therapy.

AJCC, American Joint Committee on Cancer.

primary malignancy, facilitate RAI administration, and/or enhance follow-up based upon higher estimated risk of recurrence identified postoperatively, accounting for recurrent laryngeal nerve function. (**Conditional recommendation, Low-moderate certainty evidence**)

- B. Completion thyroidectomy for OTC may be considered based on indications like other histological types of DTC. (**Conditional recommendation, Very low certainty evidence**)

Completion thyroidectomy after initial lobectomy may be indicated when the diagnosis of DTC was not known preoperatively or recognized intraoperatively. However, most cytologically indeterminate cases that prove to be malignant on final histology are low-risk cancers adequately treated with lobectomy alone. When final histology reveals heightened risk factors for recurrence (see Pathology section and **Recommendation 28**), completion thyroidectomy may be desired (1) to ensure complete removal of persistent primary cancer following inadequate initial resection (cR2) or in the presence of suspected bilateral cancers following initial lobectomy, (2) to facilitate RAI therapy, and/or (3) to facilitate biochemical follow-up. Decision-making regarding completion thyroidectomy should be made as part of a patient-centered, transdisciplinary management plan with patient preference an important component. Postoperative estimated risk of recurrence should be balanced with potential risks of nerve injury and hypoparathyroidism from additional surgery. Prior to considering completion thyroidectomy, the functional status of the recurrent laryngeal nerves should be evaluated, and if an injury is present, contralateral resection should be deferred until the ipsilateral nerve has recovered. The surgical risks and side effects of two-stage thyroidectomy (lobectomy followed by completion thyroidectomy) are similar to those of initial near-total/total thyroidectomy<sup>403–405</sup> although possibly with reduced rates of transient hypoparathyroidism<sup>406</sup> and lower rates of readmission and return to the operating room.<sup>407</sup> Bilateral recurrent laryngeal nerve injury may be avoided if ipsilateral nerve function is confirmed prior to undertaking thyroidectomy on the contralateral side. In cases that require completion thyroidectomy in the face of permanent ipsilateral recurrent laryngeal paralysis, referral of the patient to a high-volume thyroid surgeon is recommended (see **Recommendation 6**). Ablation of the remaining lobe with RAI in the absence of residual nodules has been employed as an alternative to completion thyroidectomy for patients with contraindications to completion thyroidectomy.<sup>408,409</sup> Like total thyroidectomy, completion

thyroidectomy results in hypothyroidism, and need for thyroid hormone replacement. Patients should be informed of this prior to the completion thyroidectomy.

**Recommendation 28** highlights histological features associated with higher recurrence rates, which may inform decisions regarding completion thyroidectomy if the treatment goal is to facilitate RAI administration and/or enhance serum biomarker surveillance. The presence of multifocality and contralateral nodularity alone may warrant either completion thyroidectomy<sup>354,355</sup> or close sonographic surveillance with deferred completion thyroidectomy if concerns for contralateral malignancy emerge.<sup>410,411</sup> Ultrasound-guided FNA biopsy of contralateral nodules may inform a recommendation for/against completion thyroidectomy. Multifocal cancer is more common in classical PTC and is often associated with higher recurrence rates, commonly presenting with other higher risk factors that warrant completion thyroidectomy.<sup>411–413</sup> In contrast, follicular variants of PTC, FTC, and OTC are less often associated with multifocality, and they typically would not require completion thyroidectomy in the absence of other higher-risk features. OTCs are rarely iodine-avid; therefore, the benefit of RAI treatment of OTC is uncertain.<sup>46,414–417</sup> Facilitating RAI is a less compelling rationale for completion thyroidectomy for patients with OTC.

Minimal/microscopic extrathyroidal extension no longer promotes tumors to T3 in the AJCC 8th edition staging system<sup>418</sup> and may not require completion thyroidectomy, particularly for T1 and small T2 unifocal tumors,<sup>358</sup> unless there is clinical concern for involvement of the nerve, trachea, or esophagus with involved posterior margins.<sup>419</sup> In contrast, gross extrathyroidal extension is associated with higher risk of recurrence<sup>354,397,420</sup> and warrants conversion of lobectomy to total thyroidectomy, with complete tumor resection to grossly free margin. With uncertainty about whether there is extrathyroidal tumor extension into overlying strap musculature versus scarring from needle biopsy, leaving a cuff of sternothyroid muscle at the area of concern and deferring to final histology may be a more prudent approach than pursuing total thyroidectomy because minimal/microscopic extrathyroidal extension into strap musculature with a clearly negative margin does not mandate completion thyroidectomy. The microscopic histological finding of tumor transgressing the thyroid capsule and/or a microscopically positive margin (in the absence of clinical concern for extrathyroidal extension) does not mandate completion thyroidectomy, particularly if the finding is noted anteriorly.<sup>366,419,421,422</sup>

Microscopic, pathologically involved central compartment lymph nodes (cN0 but pN1a) identified incidentally after lobectomy or as part of ipsilateral central neck dissection may prompt completion thyroidectomy, but the procedure is not necessary for all patients.<sup>356,357,423</sup> A larger number of nodes (more than three to five nodes),<sup>424–426</sup> higher lymph node ratio (LNR, >0.3),<sup>426–428</sup> or presence of extranodal extension<sup>429–431</sup> suggests possible higher risk of recurrence and therefore potential benefit from completion thyroidectomy. Clinically evident nodal metastasis (cN1a) noted during lobectomy warrants conversion to total thyroidectomy with central lymph node dissection. Targeted frozen section of clinically suspicious nodes may aid intraoperative decision-making.<sup>380–382</sup>

Vascular invasion, particularly when extensive vascular invasion is identified in FTC or OTC, is associated with increased risk of distant metastasis<sup>432,433</sup> and may warrant completion thyroidectomy. Vascular invasion in PTC is also associated with increased risk of distant metastasis and may warrant completion thyroidectomy.<sup>432,434</sup>

Some histological tumor variants also influence risk (see Pathology and Risk of Recurrence sections): minimally invasive FTC, OTC, and minimally invasive IEFVPTC generally have the lowest risk and would not typically warrant completion thyroidectomy in the absence of high-risk findings. In contrast, higher-risk variants of PTC (e.g., tall cell, hobnail, and solid variant and diffuse sclerosing) and widely invasive FTC, OTC, and PDTC (or a poorly differentiated component) are associated with higher risk of recurrence and may warrant completion thyroidectomy.<sup>341</sup> Noninvasive, encapsulated follicular variant of PTC, now known as NIFTP, is considered very low risk from a clinical perspective, and while it requires surgery for definitive diagnosis, it does not typically warrant completion thyroidectomy, although further data are needed, particularly for larger tumors (see **Recommendation 1**).<sup>76,77</sup>

Clinical risk factors such as patient age, male sex, family history of thyroid cancer, and/or history of radiation exposure may influence decision-making regarding completion thyroidectomy. Patient preference is critical, and decisions always should be made by a patient-centered multidisciplinary clinical team informed by knowledge of recurrent laryngeal nerve function.

What is the surgical approach to thyroglossal duct carcinoma?

#### ■ RECOMMENDATION 17

- A. Initial surgical therapy for thyroid carcinoma arising within a thyroglossal duct (TGDCa) should include complete tumor/cyst excision along with the central portion of the hyoid bone (Sistrunk procedure). (*Conditional recommendation, Low certainty evidence*)
- B. A Sistrunk procedure and thyroidectomy may be considered for TGDCa with significant/suspicious thyroid nodularity to ensure complete resection of possible multicentric disease and/or for larger tumors, particularly in older patients, to facilitate RAI and/or enhance follow-up. (*Conditional recommendation, Low certainty evidence*)
- C. A Sistrunk procedure and total thyroidectomy should be performed for TGDCa with evidence of more advanced disease (e.g., gross extension of tumor into surrounding tissues, nodal or distant metastasis). (*Strong recommendation, Moderate certainty evidence*)

When should completion thyroidectomy following Sistrunk procedure be performed?

#### ■ RECOMMENDATION 18

- A. Completion (total) thyroidectomy may be considered following resection of TGDCa with higher-risk factors (similar to completion thyroidectomy after lobectomy) or that proves to be a metastasis to the Delphian/prelaryngeal lymph node(s). (*Conditional recommendation, Moderate certainty evidence*)

- B. Completion thyroidectomy may be considered following resection of lower-risk TGDCa associated with significant/suspicious thyroid nodularity to ensure complete resection of possible multicentric disease, or for larger tumors, particularly in older patients, to facilitate RAI and/or enhance follow-up. (*Conditional recommendation, Low certainty evidence*)

The diagnosis of TGDCa arising in association within a TGD cyst should only be rendered upon presence of a TGD cyst remnant, which shows squamous/columnar epithelium lining cysts and ectopic thyroid tissue in the cyst wall. The cyst wall can be of variable thickness, and the carcinomatous component is usually solid and/or nodular.<sup>435</sup> Almost 50% of all thyroid glands exhibit a pyramidal lobe (a remnant of the inferior portion of a TGD), which extends superiorly from the isthmus<sup>436</sup> and can be connected to the hyoid bone with fibrous tissue. A carcinoma arising in the pyramidal lobe should be staged as usual.<sup>435</sup> The Delphian or prelaryngeal lymph node(s) is/are located anterior to the cricothyroid membrane and superior to the isthmus. This is a common site for nodal metastasis from PTCs arising in the isthmus. In some cases, the Delphian node(s) can be completely replaced by metastatic PTC with cystic degeneration, which may pose difficulties in distinguishing it from PTC arising in a TGD cyst.

Rather than devising a separate definition and/or staging system for this rare carcinoma, it seems reasonable to apply the current TNM staging system in view of studies demonstrating increased rates of recurrence with larger tumors, “extrathyroidal” extension of the primary tumor, nodal metastasis, and/or older patient age. For TGDCas diagnosed preoperatively and without sonographic evidence of tumor extension beyond the cyst, suspicious thyroid nodules, or suspicious lymph nodes, the Sistrunk<sup>437–439</sup> procedure alone is a reasonable initial treatment option, especially for younger patients. Patients should understand the potential need for conversion to total thyroidectomy or subsequent completion thyroidectomy if high-risk factors are appreciated intra- or postoperatively.<sup>418–420,422,425,426</sup> A Sistrunk procedure in concert with total thyroidectomy may be reasonable initial therapy when suspicious/significant thyroid nodularity is present or for older patients with larger tumors.<sup>420,421,427</sup> When there is nodal involvement, a compartment-oriented central lymph node dissection should accompany a Sistrunk procedure and total thyroidectomy.<sup>440,441</sup> Completion thyroidectomy following an initial Sistrunk procedure may be warranted when the diagnosis of TGDCa was not assigned preoperatively and significant/suspicious thyroid nodularity is present, to facilitate RAI administration and/or enhance follow-up in the presence of gross tumor extension into surrounding tissues, or other higher-risk features.

When should prophylactic central-compartment lymph node resection be performed?

#### ■ RECOMMENDATION 19

- A. Prophylactic central-compartment lymph node dissection should not be performed for most small, noninvasive, clinically node-negative PTC (cT1-T2, cN0) and for most FTCs. (*Strong recommendation, Moderate certainty evidence*)
- B. Prophylactic central-compartment neck dissection may be considered in patients with PTC and

clinically uninvolved lymph nodes (cN0) who have advanced primary tumors (T3 or T4) or for whom the information will be used to plan further steps in therapy, but this approach should be weighed against the risks as they evolve during thyroidectomy. (**Conditional recommendation, Low certainty evidence**)

The value of prophylactic central lymph neck dissection (pCLND) for clinically N0 (cN0) DTC remains unproven. Chen and co-workers<sup>442</sup> performed a meta-analysis on this topic that included 23 retrospective and prospective cohort studies with a total of 18,376 patients. Locoregional recurrence occurred in 280 (2.52% of 11,098) patients in the pCLND group and 254 (4.59% of 5583) patients in the non-pCLND group. Patients who underwent pCLND had a significantly lower locoregional recurrence rate (OR 0.65 [CI 0.48–0.88]) but significantly higher rates of transient recurrent laryngeal nerve injury (OR 2.03 [CI 1.32–3.13]), transient (OR 2.23 [CI 1.84–2.70]), and permanent hypocalcemia (OR 2.22 [CI 1.58–3.13]) versus the non-pCLND group. In contrast, Lee and co-workers<sup>428</sup> in a study assessing rates of occult lymph node metastasis and risk of regional recurrence in PTC after bilateral CLND saw no association between occult lymph node metastasis and regional recurrence. They concluded that the LNR, which is the ratio of the number of malignant lymph nodes excised to the total number of excised lymph nodes that exceeds 0.26, was an independent predictor of regional lymph node recurrence, especially in the lateral neck. Wang and co-workers<sup>443</sup> performed a meta-analysis and reported an overall recurrence rate of 3.8% for patients undergoing total thyroidectomy plus pCLND [CI 2.3–5.8]. In the six comparative studies that included 1740 patients, 995 patients undergoing total thyroidectomy and 745 patients undergoing total thyroidectomy with pCLND, the overall recurrence rate was 7.6%: 7.9% in the total thyroidectomy group and 4.7% in the total thyroidectomy plus pCLND group. The RR of recurrence was 0.59 [CI 0.33–1.07], favoring a lower recurrence rate in the total thyroidectomy plus pCLND arm. They concluded that it would be necessary to treat 31 patients with pCLND to prevent a single recurrence. Hence, the benefits of pCLND should be weighed against the risks, especially when a surgeon's experience is limited.

Overall, expectant management of the central compartment when a patient is deemed cN0 seems prudent. Hughes et al.<sup>444</sup> examined 14 studies and evaluated the effect of pCLND on locoregional recurrence. They found that it was 6.75% for total thyroidectomy alone versus 4.55% for total thyroidectomy and pCLND<sup>445</sup> and found that the 5-year recurrence-free survival and central neck recurrence-free survival rates were 96.6% and 99.1%, respectively. The authors concluded that observation of the central neck is safe and should be recommended for all patients with PTC thought before and during surgery to be free of central compartment metastasis. Zhao et al.<sup>446</sup> performed a meta-analysis that included 17 studies comprising 4437 patients. Although the total thyroidectomy with pCLND group had a significantly reduced risk of loco-regional recurrence (risk ratio = 0.66 [CI 0.49–0.90];  $p = 0.008$ ) when compared with total

thyroidectomy alone, they received higher RAI doses (74.6% vs. 59.9%); experienced more temporary hypocalcemia

(OR = 2.37 [CI 1.89–2.96];  $p < 0.00001$ ), permanent hypocalcemia (OR = 1.93 [CI 1.05–3.57];  $p = 0.03$ ), and increased overall morbidity (OR = 2.56 [CI 1.75–3.74];  $p < 0.00001$ ). All these studies suggest equipoise when considering a pCLND, especially with T3 and T4 tumors.

The role of pCLND for patients treated with lobectomy alone has not been extensively studied. Choi et al. reviewed their outcomes for thyroid lobectomy with prophylactic ipsilateral CLND for low-risk PTC. Nine hundred and six patients were reviewed, with 52 experiencing recurrences (5.7%) during 10 years of follow-up. Thirty-two (61.5%) patients experienced recurrence in the remaining thyroid lobe, 11 (21.2%) in a lymph node only, and 9 (17.3%) in both. The recurrence-free survival rates at 5 and 10 years were 97.1% and 81%, respectively. There was no comparison group, and future studies are needed to evaluate the utility of pCLND in this scenario.

What is the best approach for therapeutic central and lateral compartment node resections?

#### ■ RECOMMENDATION 20

- A. Therapeutic central-compartment (Level VI and upper Level VII) neck dissection for patients with clinically involved central nodes (cN1a) should accompany thyroidectomy to clear disease from the central neck. (**Strong recommendation, Moderate certainty evidence**)
- B. Therapeutic CLND with dissection of the ipsilateral central compartment lymph nodes is recommended to accompany lateral-compartment neck dissection and thyroidectomy for patients with clinically involved lateral neck lymph nodes (cN1b). (**Conditional recommendation, Low certainty evidence**)
- C. Therapeutic lateral neck compartmental lymph node dissection, typically including Levels IIa, III, IV and Vb, should be performed as part of initial surgical therapy for patients with biopsy-proven or clinically obvious metastatic lateral compartment cervical lymphadenopathy. (**Strong recommendation, Moderate certainty evidence**)

It is generally accepted that compartmental dissection of lymph nodes known or suspected to be involved with DTC provides a recurrence-free advantage.<sup>14</sup> In the central neck, a compartmental dissection of at least the prelaryngeal, pretracheal, and involved paratracheal lymph node areas should be performed.<sup>32</sup> Recognizing the limitations of imaging (and especially ultrasound in detecting lymph node metastases with the thyroid present) and the increased risks associated with central compartment dissection especially when the surgery is bilateral, the question of whether to dissect a cN0 *contralateral* paratracheal compartment is pertinent. Yeh et al.<sup>241</sup> highlighted that in the absence of bilateral primary tumors >1 cm, contralateral Level VI is less commonly affected (prevalence 5–25%). Qu et al.<sup>447</sup> performed a systematic review and meta-analysis of the clinical risk factors for central compartment lymph node metastasis in PTC. Three studies assessed the association between lateral versus the central

compartment lymph node metastasis.<sup>448–450</sup> Central compartment lymph node metastases were significantly more frequent among patients with lateral compartment disease (88.7% vs. 31.1%) overall, with an OR obtained through analysis of these three studies of 14.33 ([CI 5.34–38.50];  $p < 0.001$ ). Likhterov et al.<sup>451</sup> reported that of patients with lateral neck nodal metastases, only 5% had “skip” metastases, leading the authors to advocate for ipsilateral central compartment neck dissection when lateral neck nodes are involved. Decision-making reflecting the circumstances that evolve during an operation should be an underlying guiding principle when performing a central compartment neck dissection. For example, if the initial side of the thyroidectomy for the primary tumor and involved paratracheal lymph nodes results in an injured recurrent laryngeal nerve and/or compromised parathyroid glands, it would be prudent to avoid the contralateral paratracheal compartmental dissection when it is cN0 to minimize the risk of possible bilateral vocal fold paralysis and hypoparathyroidism.

Miller et al.<sup>452</sup> demonstrated that half of residual lymph node metastases are due to failure to recognize the extent of nodal involvement preoperatively, while the other half result from incomplete nodal dissection. Improvements in nodal imaging protocols and standardization of nodal dissection technique with adherence to formal compartmental nodal dissections should reduce the risk of persistent disease and the need for further treatment. Consideration of removing lymph nodes along the transverse cervical artery and vein, the superior thyroid artery and vein, and behind the head of the clavicle when performing a lateral neck dissection will help reduce the risk of recurrence in these regions.

The concept of lymph node yield (LNY), the total number of excised lymph nodes (whether benign or malignant) examined, to determine adequacy of the nodal dissection and how it relates to prognosis may further support formal compartmental nodal dissections. LNY is relevant to risk of recurrence in many other malignancies. Robinson et al.<sup>453</sup> reviewed the NCDB (1998–2012) to characterize the distribution of involved lymph nodes among adult patients diagnosed with localized  $\geq 1$  cm PTC who underwent thyroidectomy with one or more lymph nodes examined. To rule out occult nodal disease with 90% confidence, 6, 9, and 18 lymph nodes would need to be examined for patients with T1b, T2, and T3 diseases, respectively. Sensitivity analyses limited to patients likely undergoing prophylactic central compartmental neck dissection resulted in need to assess three, four, and eight nodes to provide comparable adequacy of lymph node evaluation for T1b, T2, and T3 diseases, respectively. Heaton et al.<sup>454</sup> evaluated 125 patients who underwent CLND, of whom 20 had a nodal recurrence. The LNY of patients subsequently developing central neck recurrence was significantly less than that of those who experienced no recurrence (2.5 vs. 10.3, respectively;  $p < 0.0001$ ). Of 71 patients who underwent lateral neck dissection, 23 had ipsilateral lateral neck disease recurrence. The LNY of patients with lateral neck recurrence had been significantly less than those who did not recur (10.5 vs. 24.6, respectively;  $p < 0.0001$ ). Higher rates of recurrence were associated with smaller lymph node yield in both groups. LNY remains predictive of recurrence on multivariable analysis controlling for pT categories, pN categories, AJCC stage, and RAI treatment.

Amit et al.<sup>455</sup> studied 2542 patients (1801 [71%] males; median age, 48 years [range, 18–97 years]) with a median follow-up of 55 months (range, 4–192 months). The 10-year disease-specific survival rate was 98% for patients with an LNR<sup>450</sup> of  $\leq 0.19$ , compared with 90% for those with an LNR  $> 0.19$  (effect size, 8% [CI 4–15%]). The 10-year overall survival was 87% for patients with an LNR of  $\leq 0.19$ , compared with 79% for patients with LNR  $> 0.19$  (effect size, 8% [CI 3–15%]). Multivariable analysis revealed that LNR  $> 0.19$  was independently associated with an adverse disease-specific survival (HR 4.11 [CI 2.11–8.97]) and overall survival (HR 1.96 [CI 1.24–4.11]). Subgroup analysis of patients with  $\geq 18$  lymph nodes analyzed revealed that LNR  $> 0.19$  remained a significant marker for disease-specific survival (HR 2.94 [CI 1.36–9.81]) and overall survival (HR 2.26 [CI 1.12–5.34]). Lee et al. found that an LNR  $> 0.42$  had an HR of 3.35 for locoregional recurrence.<sup>456</sup> Multivariable analysis of 1082 PTC patients who underwent total thyroidectomy and prophylactic central compartment lymph node dissection (pCCLND) had an LNR of  $> 0.5$  and an HR of 1.794 ( $p < 0.001$ ) for recurrence.<sup>457</sup> Multivariable analysis of 390 patients with PTC who underwent total thyroidectomy, CLND, and ipsilateral or bilateral modified radical neck dissection demonstrated that a central neck LNR of 0.44 had an HR for recurrence of 2.35, while a lateral neck LNR  $> 0.29$  had an HR for recurrence of 1.58.<sup>427</sup> A multivariable analysis of 437 patients with N1b reported that an LNR  $> 0.25$  in the lateral neck had an HR for recurrence of 2.09.<sup>428,458</sup> Lee et al. evaluated 211 patients who underwent total thyroidectomy and bilateral pCCLND and reported an LNR  $> 0.26$  associated with an HR for recurrence of 11.49.<sup>428,459</sup> In a retrospective multivariable analysis, Kim reported an LNR  $> 0.5$  as a risk factor for recurrence in T1a PTC.<sup>426</sup> Lee et al. proposed the LNR of 0.17857 should be used in combination with the ATA Risk of Recurrence category to determine overall risk of recurrence.<sup>460</sup>

Griffin et al.<sup>461</sup> conducted a retrospective review of cases in which five lymph nodes or more were removed during thyroidectomy and five or fewer lymph nodes were found to be involved with PTC. Step-sectioning was performed on original tumor blocks, and all slides were re-reviewed by a senior pathologist. Step-sectioning significantly increased LNY compared with standard sectioning. In total, they found 12 new involved lymph nodes; 7 (58%) were in totally new lymph nodes, while 5 (42%) were in lymph nodes previously believed to be uninvolved. All were classified as micrometastases ( $\leq 2$  mm). These data support using consistent standards of assiduous pathology specimen handling and sectioning related to lymph node assessment in DTC. This is relevant because future studies evaluating the number of lymph nodes resected and LNR as parameters for prognosis should include a description of the techniques used to harvest and analyze lymph nodes as well as the size of the focus of DTC in the lymph node(s).

What is the appropriate perioperative approach to voice and parathyroid issues?

#### ■ RECOMMENDATION 21

Prior to surgery, the surgeon should review surgical risks with the patient, including potential for nerve and parathyroid injury, through the informed consent process and communicate with associated physicians, including anesthesia

colleagues, important findings elicited during the preoperative evaluation. (*Good Practice Statement*)

The preoperative consent process should include explicit discussion of the potential for temporary or permanent nerve injury (and its clinical sequelae, including voice change, swallowing disability, risk of aspiration, and tracheostomy) as well as hypoparathyroidism, discomfort, risks of anesthesia, bleeding, scarring, disease recurrence, reoperation, need for additional postoperative treatment, need for thyroid hormone supplementation/replacement, and surveillance thyroid function tests. The conversation should be informed by the operating surgeon's own rates of complications. Results of the preoperative evaluation regarding extent of disease, risk stratification, and integrity of the airway should include findings from imaging, cytology, and physical examination.<sup>462–466</sup>

Should the patient undergo voice or laryngeal examination prior to surgery?

#### ■ RECOMMENDATION 22

- A. All patients undergoing thyroid surgery should undergo voice assessment as part of their preoperative physical examination. This should include the patient's description of vocal changes and the physician's assessment of voice. (*Strong recommendation, Moderate certainty evidence*)
- B. Preoperative laryngeal exam should be performed in all patients with:
  - a. Preoperative dysphonia (*Strong recommendation, Moderate certainty evidence*)
  - b. History of cervical or upper chest surgery, which places the recurrent laryngeal nerve or vagus nerve at risk (*Strong recommendation, Moderate certainty evidence*)
  - c. Known thyroid cancer with posterior extrathyroidal extension or extensive central compartment or jugular chain nodal metastases (*Strong recommendation, Low certainty evidence*)

Voice alteration is an important potential complication of thyroid surgery affecting patients' QoL (with regard to voice, swallowing, and airway domains), and it has medico-legal and cost implications.<sup>467–475</sup>

Preoperative assessment provides a necessary baseline reference from which to establish subsequent expectations.<sup>476</sup> Also, preoperative voice assessment may lead to identification of vocal cord paralysis or paresis, which provides presumptive evidence of invasive thyroid malignancy and is important in planning extent of surgery and perioperative airway management.<sup>477–479</sup> Contralateral surgical nerve injury in such patients could cause bilateral cord paralysis with airway implications.

Preoperative voice assessment should include the patient's subjective response to questions regarding voice abnormalities or changes, as well as the physician's objective assessment of voice, and should be documented in the medical record.<sup>480</sup> Voice and laryngeal function may be further assessed through laryngoscopy and the application of validated QoL and auditory perceptual assessment voice instruments.<sup>476</sup> Transcutaneous laryngeal ultrasound to evaluate laryngeal function gained popularity during the COVID-19 pandemic, but evaluation

can be limited in some patients, particularly older males with calcified thyroid cartilage. It is important to appreciate that vocal cord paralysis, especially when chronic, may not be associated with significant voice symptoms due to a variety of mechanisms, including contralateral vocal cord compensation. Voice assessment alone may not identify such individuals.<sup>476</sup>

Incidence rates for preoperative vocal cord paresis or paralysis for patients with benign thyroid disease at preoperative laryngoscopy range from 0% to 3.5% and up to 8% in patients with thyroid cancer.<sup>481–485</sup> Finding vocal cord paralysis on preoperative examination strongly suggests the presence of locally invasive disease. Approximately 10–15% of thyroid cancers present with extrathyroidal extension, with the most common structures involved including strap muscle (53%), the recurrent laryngeal nerve (47%), trachea (30%), esophagus (21%), and larynx (12%).<sup>479,486–488</sup> Undiagnosed preoperative laryngeal nerve dysfunction conveys greater risks of bilateral nerve paralysis during total thyroidectomy, respiratory distress, and need for tracheostomy.<sup>489</sup> Preoperative identification of vocal cord paralysis is important because surgical approaches to the management of the invaded nerve incorporate functional status.<sup>490</sup>

A laryngeal exam should be performed if the voice is abnormal during preoperative voice evaluation. Any patient with a history of neck surgery which placed either the recurrent laryngeal nerve (such as past thyroid or parathyroid surgery) or the vagus nerve (such as carotid endarterectomy, cervical esophagectomy, and anterior approach to the cervical spine) at risk or with a history of prior external beam radiation to the neck should have laryngeal exam even if the voice is normal. Correlation between vocal symptoms and actual vocal cord function is poor due to the potential for (i) variation in paralytic cord position, (ii) degree of partial nerve function, and (iii) contralateral cord function/compensation. Therefore, voice symptoms may be absent in patients with vocal cord paralysis. Vocal cord paralysis may be present in 1.5–30% of such postsurgical patients; it can be asymptomatic in up to one third of the patients.<sup>477,491–497</sup>

A laryngeal exam is recommended in patients with the preoperative diagnosis of thyroid cancer if there is evidence for gross extrathyroidal extension of cancer, which extends posteriorly or if there is extensive nodal involvement, even with normal voice. The laryngeal exam should be performed in the above noted high-risk settings but may be performed on other patients based on the surgeon's judgment.

How should the recurrent laryngeal nerves be assessed intraoperatively?

#### ■ RECOMMENDATION 23

- A. Visual identification of the recurrent laryngeal nerve (s) (RLN) should be performed during thyroidectomy and/or para-tracheal node dissection, to preserve nerve integrity and function. (*Good Practice Statement*)
- B. Intraoperative neurophysiological monitoring of the RLN may be performed during thyroidectomy for malignancy in an effort to reduce the risk of RLN injury, particularly during total or re-operative thyroidectomy. (*Conditional recommendation, Low-moderate certainty evidence*)

- C. Intraoperative identification and neurophysiological monitoring of the external branch of the superior laryngeal nerve (EBSLN) may be performed during thyroidectomy for malignancy in an effort to improve accurate nerve identification and improve voice outcomes. (*Conditional recommendation, Moderate-high certainty evidence*)
- D. Intraoperative vagal nerve or proximal RLN stimulation (with monitoring or laryngeal palpation) should be performed after initial lobectomy to assess RLN integrity and function prior to removing the contralateral lobe in an effort to avoid possible bilateral nerve injury. (*Good Practice Statement*)

RLN injury rates are lower when the nerve is regularly seen in comparison to operations in which the nerve is simply avoided,<sup>480,495,498</sup> and prior ATA guidelines have strongly recommended visual identification. No formal recommendation was made for nerve integrity monitoring (NIM) to prevent RLN injury, as the evidence confirming a benefit at the time was equivocal for routine use,<sup>492,499–501</sup> but its use appeared beneficial for complex and re-operative thyroid surgery.<sup>479,502–506</sup> Nerve stimulation (with or without monitoring) was recommended to confirm accurate identification and nerve function.<sup>14</sup>

Subsequently, several meta-analyses have considered the subject. A Cochrane meta-analysis restricted to five randomized controlled trials ( $n = 5$ ) found NIM and visual nerve identification alone are associated with similar rates of permanent RLN paralysis (0.7% vs. 0.9%, RR 0.77 [CI 0.33–1.77]); however, NIM was associated with a trend toward decreased RR of transient RLN injury that was not statistically significant (2.1% vs. 3.6%; RR 0.62 [CI 0.35–1.08];  $p = 0.09$ ).<sup>507</sup> In the Cochrane meta-analysis, there was also no statistically significant difference in risk of the composite outcome of permanent or temporary RLN paralysis (2.7% vs. 4.4%; RR 0.70 [CI 0.38–1.30];  $p = 0.21$ ). However, the absolute risk difference (2%) was statistically significant, with the number of nerves needed to treat/monitor (NNT) estimated to be about 50 to prevent one event (risk difference  $-2.0\%$  [CI  $-3.0$  to  $0.0\%$ ];  $p = 0.03$ ). Our panel identified a small ( $n = 72$ ) randomized trial<sup>498</sup> not included in the Cochrane review, which showed a nonsignificant difference in transient RLN injury of 2.7% in the NIM group versus 8.3% in the control group. Another meta-analysis including 24 randomized and nonrandomized trials found a significant reduction in overall (3.2% vs. 4.4%,  $p = 0.04$ ) and transient (1.8% vs. 2.6%,  $p = 0.01$ ) RLN injury rates with a possible reduction in permanent (0.7% vs. 1.1%,  $p = 0.15$ ) RLN injury and a risk difference of 1.2% for overall rates, which suggests an NNT of about 80.<sup>499</sup> In the subset of four studies limited to patients with thyroid cancer, a significant reduction with NIM was noted for overall (3.9% vs. 6.6%,  $p < 0.05$ ) and transient (3.0% vs. 5.0%,  $p < 0.05$ ) but not permanent RLN injury (0.9% vs. 1.6%,  $p > 0.05$ ), which translates into a NNT of approximately 30 patients. Another meta-analysis including 34 studies found significant reductions in overall (3.0% vs. 3.9%,  $p = 0.0002$ ), transient (2.3% vs. 2.8%,  $p = 0.002$ ), and permanent (0.7% vs. 1.0%,  $p = 0.003$ ) nerve injury rates with NIM. This was significant in the subgroups undergoing total thyroidectomy (1.5% vs. 3.0%,  $p < 0.05$ ; 1.1% vs. 2.1%,  $p < 0.05$ ; 0.5% vs. 0.8%,  $p < 0.05$ ) or thyroid surgery for cancer (2.6% vs. 4.4%,

$p = 0.02$ ; 2.0% vs. 3.4%,  $p = 0.04$ ; 1.2% vs. 1.1%,  $p = 0.73$ ), for overall, transient, and permanent nerve injury rates, respectively. The authors recommended NIM for bilateral thyroidectomy (NNT approximately 70) and/or cancer (NNT approximately 60). A meta-analysis limited to high-risk thyroid surgery that included 10 studies found significant reduction in overall (2.5% vs. 4.5%,  $p = 0.003$ ), transient (2.4% vs. 3.9%,  $p = 0.02$ ), and permanent (0.1% vs. 0.6%,  $p = 0.10$ ) RLN injury rates, with subgroup analysis demonstrating significantly lower overall RLN injury rates for cancer (2.1% vs. 3.5%,  $p = 0.03$ ) and reoperation (4.5% vs. 7.6%,  $p = 0.02$ ). The authors recommended NIM, particularly in these two situations, with estimates of NNT of approximately 70 and 30, respectively.<sup>501</sup> Results of subsequent individual studies vary, but the majority demonstrate a significant benefit of nerve monitoring to prevent RLN injury.<sup>508–521</sup>

These reports are supported by several recent large database studies demonstrating significant reduction in RLN injury rates with NIM. A National Surgical Quality Improvement Program (NSQIP) study involving nearly 10,000 patients found a significant reduction in RLN injury with NIM use, particularly for thyroid cancer (OR 0.76,  $p = 0.01$ ).<sup>522</sup> This is confirmed by an even larger NSQIP study of nearly 18,000 patients showing significant reduction in RLN injury with NIM use (5.7% vs. 6.8%, OR 0.67,  $p = 0.00001$ )<sup>523</sup> and verified by a third NSQIP study.<sup>524</sup> These results were recapitulated in a large endocrine and thyroid registry from the United Kingdom, with a significant reduction in both transient and permanent RLN injury with NIM use (OR 0.63 and OR 0.47, respectively, both  $p < 0.0001$ ).<sup>525</sup>

Studies comparing automatic persistent (often termed “continuous”) vagal nerve stimulation with monitoring versus conventional laryngeal NIM with intermittent stimulation have been conflicting.<sup>523,526–529</sup> Further study may be warranted to determine whether the potential advantage of continuous vagal nerve stimulation with monitoring is worth the potential added risk of device placement compared with traditional NIM.

Evaluation of NIM cost-effectiveness suggested a benefit in two<sup>520,530</sup> but not a third publication.<sup>531</sup> Results of the later publication would change if the RR reduction were  $\geq 50\%$  (as shown in the meta-analyses above). Studies<sup>517,532</sup> including a randomized controlled trial<sup>533</sup> have shown a reduction in time to find the nerve with NIM use, but the differences may not be clinically meaningful ( $< 5$  minutes). A recent survey of North American surgeons revealed increasing utilization of NIM, with 70% using NIM always, 15% sometimes, and 13% never.<sup>534</sup> One percent reported it was not available at their institution. Of those using it sometimes, indications included reoperation (94%), preoperative RLN paralysis or dysphonia (84%), patient preference (46%), and cancer (34%). Commercially available NIM endotracheal tubes were used most (89%), regular endotracheal tubes with electromyography adhesive (8%), or palpation of laryngeal twitch alone (2.5%). Only 0.4% employ persistent stimulation for vagus nerve monitoring.<sup>534</sup>

The ATA 2015 guidelines suggested deploying RLN stimulation at the completion of lobectomy to determine the safety of contralateral resection to avert bilateral vocal cord paralysis and resultant airway compromise.<sup>14,504,535–537</sup> Subsequently, the International Nerve Monitoring Study Group

(INMSG) recommended deferring completion thyroidectomy in cases with loss of nerve function on the first side, thus preventing bilateral RLN paralysis; most RLN injuries are temporary and will usually resolve within a few months.<sup>538</sup> This approach is supported by recently published surgical thyroidectomy guidelines of the American Head and Neck Society (AHNS)<sup>539</sup> and the American Association of Endocrine Surgeons (AAES).<sup>540</sup> Several studies have evaluated the results of such an approach. Reported NPV, confirming intact RLN function postoperatively when nerve stimulation shows appropriate NIM signal and/or palpable laryngeal twitch of the arytenoid, are remarkably high at 99–99.9%, with specificity of 99%.<sup>508,541,542</sup> The PPV confirming RLN paralysis postoperatively is somewhat lower but has been considered acceptably high at 77–78%, with sensitivity of 90–94%.<sup>508,541–544</sup> In practice, this has resulted in a two-stage procedure in 4–5% of planned total thyroidectomies following lobectomy accompanied by loss of stimulation NIM signal or laryngeal twitch. Approximately 80% of those cases demonstrate early postoperative RLN palsy with subsequent recovery in 90% of those cases.<sup>541,544,545</sup> Another team eliminated bilateral RLN paralysis completely (0% vs. 2.7%,  $p = 0.03$ ) after adoption of the approach.<sup>546</sup> A recent analysis evaluating NIM to prevent bilateral RLN paralysis demonstrated cost-effectiveness of this approach.<sup>547</sup> A protocol evaluating the potential for intraoperative return of signal within 20 minutes of its loss, either spontaneously or following treatment with 4 mg dexamethasone found a significantly greater rate of intraoperative return of signal (18% vs. 88%,  $p < 0.001$ ) with significantly lower rates of transient (82% vs. 6%,  $p < 0.001$ ) and permanent (50% vs. 0%,  $p < 0.001$ ) postoperative RLN paralysis in the dexamethasone-treated group.<sup>548</sup>

Management of invasive thyroid cancer involving the RLN is challenging, and the topic of several recently published statements/guidelines from the AHNS,<sup>488,539</sup> AAES,<sup>540</sup> and INMSG.<sup>549</sup> Knowing the preoperative functional status of the nerve is critical to intraoperative management. When the nerve is functioning preoperatively, removal of all gross tumor with the nerve dissected intact is preferable. When the nerve is encased in tumor and/or paralyzed preoperatively, then nerve sacrifice to ensure complete tumor removal should be undertaken. In cases of nerve sacrifice, primary anastomosis is ideal if feasible. Otherwise ansa cervicalis nerve anastomosis to the distal segment may be performed. Primary or delayed vocal fold medialization is another option.<sup>488,539,540,549</sup>

The EBSLN is small. It innervates the cricothyroid muscle and facilitates tensing the vocal folds to raise voice pitch, which is particularly important to singers and other professional voice users. The EBSLN is vulnerable to injury during thyroid surgery, and traditional surgical strategies to avoid injury include visual identification and/or ligation of the superior pole vasculature as close to the superior pole capsule as possible (as recommended in the prior ATA guidelines). Cernea, who developed the first classification system for EBSLN anatomy in relation to the thyroid gland,<sup>550</sup> was also the first to report a lower rate of EBSLN injury with stimulation of the nerve compared to the traditional approach.<sup>551</sup> A recent study of post-thyroidectomy patients revealed that 15–20% of patients had a change in their speaking fundamental frequency because of EBSLN injury, highlighting the importance of this

problem.<sup>552</sup> A recent monograph documented a significant association between decreased EBSLN stimulation response after superior pole dissection and worse voice outcomes.<sup>553</sup>

The INMSG has published guidelines suggesting EBSLN stimulation/monitoring to reduce the risk of injury.<sup>506</sup> A recent meta-analysis revealed a significantly greater rate of EBSLN identification with nerve stimulation compared to visual identification alone (96% [CI 94–97] vs. 77% [CI 69–83]).<sup>554</sup> A randomized controlled trial of NIM-based stimulation versus conventional technique aided by a widely available battery-powered nerve stimulator demonstrated a greater rate of nerve identification and preservation with NIM than with the battery-powered device (89% vs. 18%,  $p < 0.001$ ). Fewer female patients experienced postoperative voice impairment in the NIM group (3% vs. 11%,  $p = 0.02$ ).<sup>555</sup> Another randomized controlled trial comparing the use of NIM-supported stimulation to traditional ligation of the superior pole vessels close to the capsule revealed a lower EBSLN injury rate (9% vs. 1%,  $p = 0.01$ ) and lower voice impairment scores 1 and ( $p = 0.02$ ) 3 ( $p = 0.03$ ) months postoperatively in the NIM-supported stimulation group.<sup>556,557</sup> This is supported by another randomized controlled trial of NIM versus traditional ligation of the superior pole vessels with lower rates of EBSLN injury (9% vs. 1%,  $p = 0.01$ ) and lower voice impairment scores 1 ( $p = 0.012$ ), 3 ( $p = 0.015$ ), and 6 months postoperatively ( $p = 0.02$ ) in the NIM group.<sup>558</sup> These results are similar to an earlier randomized controlled trial of NIM versus visualization alone with higher rates of EBSLN identification in the NIM group (84% vs. 34%,  $p < 0.001$ ); lower rates of EBSLN injury (1.5% vs. 6%,  $p = 0.02$ )<sup>559</sup>; and lower early postoperative rates of diminished mean phonation time (2% vs. 10%,  $p = 0.018$ ), voice level (2% vs. 13%,  $p = 0.003$ ), and fundamental frequency (1% vs. 9%,  $p = 0.03$ ).<sup>559</sup> Several recent studies have confirmed higher rates of nerve identification with the use of NIM-supported stimulation (94–98%) compared with visual identification (28–82%).<sup>556,560–566</sup> In one study with a relatively high rate (79%) of visual identification of the EBSLN, nerve stimulation showed the impression to be erroneous in 21%.<sup>565</sup>

In sum, visual identification of the RLN during operations for thyroid cancer remains the gold standard for prevention of injury. Laryngeal NIM appears to reduce risk of RLN injury during thyroid surgery, particularly for total thyroidectomy, cancer, or reoperation for recurrent disease with estimated NNT/monitor ranging from 30 to 70 to prevent one injury. Visual identification of the EBSLN is challenging due to the size of the nerve so that accurate identification and preservation are significantly improved with NIM-supported stimulation, resulting in better voice outcomes. In fact, the evidence supporting NIM use appears even stronger for EBSLN than RLN. Commercially available NIM systems seem available in approximately 99% of institutions performing thyroid surgery in North America. Some 70% of surgeons always use them, and another 15% employ NIM systems selectively. Common indications for selective use include reoperation, preoperative dysphonia/paralysis, patient preference, and thyroid cancer. The predictive value of a response to vagal and/or proximal RLN stimulation confirming a functioning RLN after completion of dissection is on the order of 99% and proceeding to the contralateral side in planned total thyroidectomy under this circumstance is exceedingly unlikely to

result in bilateral cord paralysis with attendant airway compromise. The predictive value of loss of response to stimulation suggesting RLN injury is also high at 75–80%. Deferring resection of the contralateral side (when oncologically sound) to allow a likely transient RLN injury to resolve seems to prevent bilateral injury with need for tracheostomy. Initiating resection on the side of the cancer during planned total thyroidectomy for unilateral disease is imperative when employing this strategy. Palpation of arytenoid/laryngeal twitch with vagal/RLN stimulation is a long-standing and acceptable alternative to the use of NIM endotracheal tubes to confirm RLN function at the completion of dissection.

How should the parathyroid glands be managed intraoperatively and perioperatively?.

#### ■ RECOMMENDATION 24

- A. The parathyroid glands and their blood supply should be preserved during thyroid surgery to reduce the risk of hypoparathyroidism. Parathyroid glands, if devascularized or removed, should be auto-transplanted into nearby muscle after frozen section (of a portion) confirms benign parathyroid tissue. (*Good Practice Statement*)
- B. After total thyroidectomy and/or central lymph node dissection, or after unilateral operations that follow prior contralateral thyroid resections, parathyroid hormone-directed calcium and vitamin D supplementation (regular or selective) should be provided to reduce rates of hypocalcemia and shorten hospital stays compared with observation with serial calcium measurement alone. (*Strong recommendation, Moderate certainty evidence*)

Typically, parathyroid gland preservation is enhanced by gland identification benefiting from meticulous dissection.<sup>535,567</sup> If the parathyroid(s) cannot be located, the surgeon should attempt to dissect on the thyroid capsule and ligate the inferior thyroid artery very close to the thyroid, since most parathyroid glands receive their blood supply from this vessel. Superior glands may receive blood supply from the superior thyroid artery. If the parathyroid glands are discovered to have been inadvertently or unavoidably removed during thyroidectomy or central lymph node dissection, or if devascularized, then frozen section confirmation (of a portion) of the suspected parathyroid gland should be performed to confirm parathyroid tissue without evidence of cancer. Then, the remainder of the parathyroid can be auto-transplanted into strap or sternocleidomastoid muscles. It is important to inspect the thyroidectomy and/or central lymphadenectomy specimen after resection and before passing it off the sterile field to find parathyroid glands that can be salvaged for auto-transplantation. This is particularly important if the parathyroid glands were not identified during dissection. Regular sacrifice of a parathyroid gland for auto-transplantation may increase transient hypoparathyroidism without improving long-term outcomes,<sup>568</sup> but there is no firm consensus in the literature,<sup>569,570</sup> and interpretation is obscured by need to reimplant ischemic and excised glands. Intraoperative adjuncts designed to aid in parathyroid gland identification remain investigational in the

United States. Optical technologies, such as near-infrared autofluorescence and near-infrared fluorescence imaging with indocyanine green, seem promising and potentially superior to employing the naked eye for parathyroid identification,<sup>571–576</sup> as do carbon nanoparticles, which are not widely available.<sup>577–579</sup>

Hypocalcemia resulting from hypoparathyroidism is a risk primarily following total or completion thyroidectomy, as well as central compartment lymph node dissection involving both paratracheal basins and unilateral central lymphadenectomy after contralateral operations. Symptoms of hypocalcemia can progress to tetany if left untreated. Strategies to prevent development of hypocalcemia, rather than awaiting the onset of symptoms, include selective supplementation based upon early rapid postoperative parathyroid hormone testing regular use of postoperative calcium and vitamin D supplementation or selective supplementation based upon early rapid postoperative parathyroid hormone testing and are supported by ATA and surgical society guidance, and in more recent prospective randomized study addressing universal versus symptomatic-driven treatment.<sup>540,580,581</sup>

Should drainage of the thyroidectomy bed be performed?

#### ■ RECOMMENDATION 25

Under most circumstances, drainage of the thyroidectomy bed is not recommended; it is associated with increased length of stay, may increase infections, and does not reduce the incidence of hematoma. (*Conditional recommendation, High certainty evidence*)

Drainage of the surgical bed after thyroidectomy was once common. Proponents expressed concerns surrounding ready detection of postoperative hemorrhage and prevention of fluid collections. Opponents have cited drains as a potential source of infection. Meta-analyses and randomized trials have been undertaken. In a meta-analysis of more than 1900 patients, drainage of the thyroid bed was associated with increased length of stay, increased infection rate, and increased incidence of hematoma.<sup>582</sup> Selective use may be reasonable with very large (chiefly retrosternal) glands, excessive intraoperative bleeding, and/or bleeding disorders. In contrast, due to lymphatic disruption following comprehensive lateral neck dissection for nodal disease, drain placement is typically employed to reduce seroma formation and to aid adherence of elevated flaps.

How should the surgeon manage postoperative voice changes and symptoms after surgery if they occur?

#### ■ RECOMMENDATION 26

- A. Patients should have their voice assessed in the postoperative period. Formal laryngeal exam should be performed if the voice is abnormal. (*Good Practice Statement*)
- B. Important intraoperative findings and details of postoperative care should be communicated by the surgeon to the patient and other physicians who are important in the patient's postoperative care. (*Good Practice Statement*)
- C. If there is known recurrent laryngeal nerve injury from surgery, timely referral to a speech language

pathologist and physician specializing in voice is recommended. (*Good Practice Statement*)

Voice assessment should occur after surgery and should be based on the patient's subjective report and physician's objective assessment of voice in the office.<sup>14</sup> Typically, this assessment can be performed at 2 weeks to 2 months after surgery. Early detection of vocal fold motion abnormalities after thyroidectomy is important for facilitating prompt intervention (typically through early injection and/or vocal fold medialization), which is associated with better long-term outcome, including a lower rate of formal open thyroplasty repair.<sup>583</sup> There are many options for the management of RLN paralysis, including voice therapy, vocal fold injection techniques, and open vocal fold medialization. Rates of vocal fold paralysis after thyroid surgery can only be assessed by laryngeal exam postoperatively.<sup>583</sup>

Effective thyroid cancer management requires a highly collaborative, interdisciplinary effort centered around the patient, starting with issues surgeons face related to the wound and postoperative neck. The cervical scar that results after thyroid surgery is a result of multiple factors that are both surgical technique and patient related. Many studies have reported that the appearance of the cervical scar after thyroid surgery has a significant quality of life (QoL) impact on patients, especially within the first few years after surgery.<sup>584,585</sup> Management of the scar and lessening its impact should be a focus for the thyroid surgeon. Some patients experience a "tight neck" after thyroid surgery that is most noticeable in the first 3 months but may persist even longer. This tightness may result in a globus sensation or dysphagia.<sup>586</sup> Massage and neck range of motion exercises in the immediate post-op period may help to minimize this effect for the short and long term.<sup>587</sup>

*Surgeon communication with the clinical teams.* Carty et al.<sup>588</sup> defined a multidisciplinary data set of essential perioperative information requiring documentation and communication in this process. Since their publication, the increasingly nuanced management recommendations should be carefully considered and discussed among all stakeholders involved in treatment decision-making. The discussion of risks, benefits, and alternatives to active surveillance for T1a PTC is one such feature (see Active Surveillance section). Another is the decision whether to perform a thyroid lobectomy only for T1 and T2 DTC that meets appropriate criteria. This requires shared decision-making. It is important for the team that will be performing surveillance after thyroid surgery to concur with the selected surgical option. Consensus for management that includes the patient's view should be achieved and documented through this interdisciplinary communication.

The AHNS Endocrine Section<sup>589</sup> developed a consensus-based, unified, preoperative, perioperative, and postoperative workflow for North American use. The AAES guidelines for thyroidectomy list key findings that should be communicated in an operative note. These should include information about indication(s), informed consent, surgical findings (e.g., extra-thyroidal extension, lymph node status, aberrant anatomy), parathyroid gland status, recurrent laryngeal nerve identification and preservation, attending surgeon presence during procedural steps, hemostasis, closure methods, and patient

disposition.<sup>540</sup> Electronic health records allow for computerized and/or synoptic operative reporting, which has the potential to improve documentation and efficiency.<sup>590,591</sup> The surgeon should also relay information regarding the completeness of resection and should help to reconcile pathology findings, especially as they relate to involved margins and whether the resection was R0 versus R1 versus R2. This may inform the need for more intense adjuvant treatments and monitoring.

Dos Reis et al.<sup>592</sup> examined the Memorial Sloan Kettering Thyroid Surgery e-Form, the Alberta WebSMR, and the Thyroid Cancer Care Collaborative (TCCC) electronic health records. Each met all the general recommendations for effective reporting of the domains that are specified in the management of thyroid cancer, as recommended by the ATA. However, the TCCC format was the most comprehensive. The TCCC is a web-based disease-specific database designed to enhance communication of patient information between clinicians in a Health Insurance Portability and Accountability Act-compliant manner. There should be consideration of coordinated care linkages between electronic medical record portals for the guidelines-based management of patients with thyroid cancer. The before and after results of adoption of guidelines-based thyroid cancer care should be studied. Better adherence to guidelines should reduce variation in care and improve value for all stakeholders. One starting point in these efforts would be creating an intra-institutional multidisciplinary thyroid conference (MDTC). Moore et al.<sup>593</sup> compared the postoperative RAI regimens for patients with thyroid cancer before and after instituting an MDTC. In the intermediate and high-risk patient groups, there was a significant decrease in the number of patients who received high-dose RAI after implementation of a MDTC compared with before initiation of an MDTC ( $p = 0.04$  and  $p < 0.01$ ) without an associated increase in tumor recurrence (11 vs. 7%,  $p = 0.74$ ). On multivariable analysis, presentation of a patient at MDTC was a negative predictor for receiving high-dose RAI noncompliant with guidelines ( $p = 0.002$ ).

What are the basic principles of histopathologic evaluation of thyroidectomy samples?

#### ■ RECOMMENDATION 27

1. In addition to the essential histopathologic features of the tumor required for the latest AJCC thyroid cancer staging (including status of resection margins), pathology reports should include additional information helpful for risk assessment, including the presence of vascular invasion and the number of invaded vessels, number of lymph nodes examined and involved with tumor, size of the largest metastatic focus to the lymph nodes, and presence or absence of extranodal extension of the metastatic tumor. (*Good Practice Statement*)
2. Histopathologic subtypes of DTC associated with unfavorable (e.g., tall cell, columnar cell, and hobnail subtypes of PTC; widely invasive FTC and OTC; high-grade follicular cell-derived non-ATC) or favorable (e.g., IEFVPTC with minimal invasion, minimally invasive FTC) outcomes should be identified



TABLE 6. AJCC/UICC TNM STAGING: THE 8TH EDITION TNM<sup>27,595</sup>

<i>TNM</i>			
<i>CATEGORY</i> <sup>a</sup>	<i>Code</i>	<i>Description</i>	
Primary tumor (pT)	TX	Primary tumor cannot be assessed	
	T0	No evidence of primary tumor	
	T1	Tumor ≤2 cm limited to thyroid	
	• T1a	Tumor ≤1 cm limited to thyroid	
	• T1b	Tumor >1 cm but ≤2 cm limited to thyroid	
	T2	Tumor >2 cm but ≤4 cm limited to thyroid	
	T3	Tumor >4 cm or minimal extrathyroidal extension	
	• T3a	Tumor >4 cm limited to thyroid	
	• T3b	Gross extrathyroidal extension to strap muscles	
	T4	Gross extrathyroidal extension to major neck structures	
	• T4a	Invading soft tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve	
	• T4b	Invading prevertebral fascia or encasing carotid/mediastinal vessels	
	Regional lymph node (pN)	NX	Regional lymph nodes cannot be assessed
		N0	No evidence of regional lymph node metastasis
• N0a		One or more cytological or histologically confirmed benign lymph nodes	
• N0b		No radiological/clinical evidence of metastasis	
N1		Metastasis to regional nodes	
• N1a		Metastasis to level VI or VII (pretracheal, paratracheal, prelaryngeal / Delphian or upper mediastinal) lymph nodes; this can be unilateral or bilateral disease	
• N1b		Metastasis to unilateral, bilateral or contralateral lateral neck lymph nodes (levels I, II, III, IV or V) or retropharyngeal lymph nodes	
Distant metastasis (M)	M0	No distant metastasis	
	M1	Distant metastasis present	
<b>STAGING</b>			
1. <55 YEARS	Stage I	Any T, Any N, M0	
	Stage II	Any T, Any N, M1	
2. ≥55 YEARS	Stage I	T1–T2, N0/NX, M0	
	Stage II	T1–T2, N1, M0 or T3a/T3b, Any N, M0	
	Stage III	T4a, Any N, M0	
	Stage IVA	T4b, Any N, M0	
	Stage IVB	Any T, Any N, M1	

<sup>a</sup>Categories may be subdivided: (s) solitary tumor and (m) multifocal tumor (the largest tumor determines the classification).  
UICC, Union for International Cancer Control.

T3 cancers that were >4 cm as well as those that were T3 due to microscopic extrathyroidal extension. They reported a risk of recurrence in cancers ≤1 cm with microscopic extrathyroidal extension that was 6%, cancers 1–4 cm with microscopic extrathyroidal extension had an 18% risk of recurrence, cancers >4 cm without extrathyroidal extension had a 12% risk of recurrence, and cancers >4 cm with microscopic extrathyroidal extension had

a 48% risk of recurrence.<sup>599</sup> AJCC/UICC staging is designed to predict disease-specific survival and thus does not predict overall risk of structural persistence/recurrence.

*2025. ATA Risk of Recurrence.* The 2015 ATA Risk of Recurrence stratification system has been reported to be a better predictor of structural persistence/recurrence than AJCC/UICC TNM staging, which predicts disease-specific

TABLE 7. MAJOR CHANGES IN AJCC/UICC TNM 8TH EDITION—DIFFERENTIATED THYROID CARCINOMA, COMPARED WITH THE 7TH EDITION<sup>595,596</sup>

- Age cutoff used for staging was increased from 45 to 55 years at diagnosis.
- Minimal extrathyroidal extension detected only on histological examination was removed from the definition of T3 disease and therefore has no impact on either T category or overall stage.
- N1 disease no longer upstages a patient to stage III; if the patient's age is <55 years at diagnosis, N1 disease is stage I; if age is ≥55 years, N1 disease is stage II.
- T3a is a new category for tumors >4 cm confined to the thyroid gland.
- T3b is a new category for tumors of any size demonstrating gross extrathyroidal extension into strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles).
- Level VII lymph nodes, previously classified as lateral neck lymph nodes (N1b), were reclassified as Central neck lymph nodes (N1a).
- In DTC, the presence of distant metastases in older patients is classified as stage IVB disease rather than stage IVC disease; distant metastasis in anaplastic thyroid cancer continues to be classified as stage IVC disease.

survival (Fig. 2).<sup>597</sup> Multivariable analysis of the 2015 ATA Risk of Recurrence categories in patients with PTC showed 1.5% recurrence in low-risk, 5.4% in intermediate-risk, and 25% in high-risk patients.<sup>600</sup> Similar rates of recurrence were seen when evaluating T1a PTC: 1.6% in low-risk, 7.4% in intermediate-risk, and 22.7% in high-risk disease.<sup>601</sup> Van Velsen et al. specifically addressed the 2015 ATA Risk of Recurrence stratification system in patients with high-risk PTC and FTC. They evaluated 236 patients with high-risk DTC (32% FTC) and found all the 2015 ATA high-risk criteria were associated with recurrence except pathological lymph nodes >3 cm. Twenty-nine percent had an excellent response, and 51% had structural persistence/recurrence; 4% had a biochemically incomplete response, and 16% had an indeterminate (16%) response. Of those that attained an excellent response, 14% developed structural recurrence.<sup>602</sup> Lee et al. evaluated ATA 2015 risk of recurrence, AJCC/UICC 8th edition staging, and LNR and found that using a combination of all three assessments most accurately predicted risk of recurrence.<sup>460</sup> Since the 2015 ATA DTC guidelines, additional features have been reported to influence overall risk of structural persistence/recurrence, and others have been refined. These features have been incorporated into the 2025 ATA Risk of Recurrence categories for PTC, FTC/IEFVPTC, and OTC.

**Tumor focality.** In the 2015 guidelines, unifocal T1a PTC and multifocal T1a PTC were both categorized as having a low risk of structural persistence/recurrence. However, multifocal T1a PTC with microscopic extrathyroidal extension is categorized as having intermediate risk of recurrence, and multifocality in T1a PTC is reported to have a higher risk of structural recurrence (4–6%) than unifocal disease (1–2%).<sup>14</sup> The data guiding the role of tumor focality are mixed. Multivariable analysis of 496 patients with PTCs >1 cm revealed structural recurrence in 21.4% of those with bilateral multifocality (HR = 4), 12.8% recurrence in those with unilateral multifocality, and 6.6% recurrence in those with unifocal disease.<sup>603</sup> However, additional retrospective multivariable analyses have not supported this association. Some studies report multifocality is not an independent predictor of structural recurrence but often is associated with other higher risk predictors of structural recurrence, such as extrathyroidal extension, lymph node metastases, and higher TNM stage.<sup>411,413</sup> Wang et al. performed a multicenter study of 2638 persons with PTC and reported recurrence in 21.2% of classical PTC with multifocality, as compared with 14.1% of unifocal classical PTC. However, when evaluating only T1a PTC, recurrence was lower at 13.7% in the multifocal and 5.1% in the unifocal groups. When evaluating FVPTC, those with multifocality had 13.7% recurrence, and patients with unifocal disease had 8.2% recurrence. Wang also evaluated patients with intrathyroidal tumors without any risk factors (such as extrathyroidal extension, lymph node metastases, or distant metastasis) and found that there was no difference in recurrence between multifocality (4.4%) and unifocality (4.2%), and overall rates of recurrence were much lower than those with multifocality in the presence of other risk factors.<sup>413</sup> In contrast, Genpeng et al. found multifocality was significantly associated with tumor capsular invasion (HR 1.5), T category (HR 1.87), and N category

(HR 1.8) in a multivariable analysis of 570 patients with PTC.<sup>604</sup> Woo et al. evaluated 1249 patients who had undergone total thyroidectomy for PTC and also found multifocality to be an independent predictor of structural recurrence (HR 1.986) using multivariable Cox regression analysis, but 10-year disease-free survival was also lower in those with multifocal tumors (93.3%) compared with 97.6% for unifocal tumors.<sup>605</sup> Four systematic reviews and meta-analyses support the association between multifocality and overall increased risk of recurrence in patients with PTC.<sup>606–609</sup> Zhang et al. performed a meta-analysis of 15 studies with a total of 9,665 patients and reported structural recurrence/persistence in 13% of unilateral multifocal cancers after total thyroidectomy versus 5.7% of unifocal cancers.<sup>607</sup> Kim et al. evaluated 26 studies with a total of 33,976 patients and reported that ≥3 foci of tumor was associated with a higher risk of recurrence (pooled HR 1.95).<sup>606</sup> Cui et al. also performed a systematic review and meta-analysis of 23 studies with 41,616 patients and reported increased risk of extrathyroidal extension (RR 1.38), central compartment lymph node metastases (RR 1.21), lateral compartment lymph node metastases (RR 1.86), distant metastasis (RR 1.35), and post-operative recurrence (HR 1.76) with multifocality when compared with unifocality.<sup>608</sup> Overall, most studies show that multifocality is an independent predictor of a higher risk of persistence/recurrence as compared with unifocal tumors >1 cm. The data are not as strong for multifocality as a predictor of structural persistence/recurrence in T1a PTCs.

**Vascular invasion.** Vascular invasion is defined as tumor cells invading through a vessel wall and the presence of a fibrin thrombus adherent to intravascular tumor.<sup>610</sup> On pathology reports, it is often referred to as “lymphovascular invasion” rather than identifying lymphatic or vascular (angioinvasion) invasion separately. Distinguishing between lymphovascular invasion and differentiating lymphatic from angioinvasion still remains controversial among pathologists. The main reason is that with routine hematoxylin and eosin staining, it is difficult to differentiate between small lymphatics, veins, and arteries. However, it is understood generally that psammoma bodies and viable tumor emboli seen within the thyroid parenchyma are within lymphatics. This has been shown by performing lymphatic-vessel-specific immunostains, such as D2-40.

The term “angioinvasion” is more applicable and diagnostically reproducible when there are sizable veins and arteries showing defined muscle structure and endothelial lining. These can be highlighted or confirmed by doing immunostains for ETS-related gene, factor VIII, and/or CD31. Angioinvasion detected in sizable (medium to large sized) vessels, seen in the tumor capsule, at the periphery of the thyroid gland or in the pseudo-capsule is significant and reproducible among pathologists. However, the criteria for diagnosing angioinvasion in thyroid carcinoma remain inconsistent. It has been shown that rigid criteria for angioinvasion (tumor cells invading through a vessel wall and covered with endothelium and tumor thrombus attached to the vessel wall) are associated with distant metastases.<sup>610</sup>

Based on these challenges, some authors recommend using the term “lymphovascular invasion.” However, for tumor staging, it is critical for synoptic reporting to

differentiate between angioinvasion and lymphatic invasion (as intra-lymphatic psammoma bodies or viable tumor emboli or both). Wagner et al. performed a single-institution retrospective analysis of 610 patients from 1987 to 2016 that included multivariable regression analysis. In this study, lymphovascular invasion was not an independent predictor of recurrence; however, it was associated with other adverse prognostic factors.<sup>611</sup> Since both lymphatic and vascular invasion were classified as the same entity, it is possible this explains the lack of association. When evaluating specifically for vascular invasion, studies have shown a significant association with risk of recurrence in all types of DTC (PTC, FTC, and OTC).<sup>434,610,612–618</sup>

**Papillary thyroid carcinoma.** In the 2015 ATA DTC guidelines, vascular invasion in PTC was associated with an intermediate risk of recurrence of 15–30%.<sup>14</sup> In retrospective multivariable analyses of 698 patients with DTC, Wreesman et al. found that vascular invasion was not an independent predictor of local recurrence but was associated with poor prognostic factors, including tumor size >4 cm, gross extrathyroidal extension, and distant metastasis.<sup>434</sup> Systematic review and meta-analysis of 26 studies with a total of 11,961 patients with all types of DTC (including PTC, FTC, minimally invasive FTC, and OTC) showed significant associations between vascular invasion and tumor persistence (OR 2.75), locoregional recurrence (OR 4.44), and distant recurrence (OR 5.08).<sup>619</sup> Pooled recurrence rates for those with vascular invasion was 21%, and for those without, it was 4%.<sup>619</sup> Subgroup analysis of just PTC showed vascular invasion significantly increased the risk of locoregional recurrence and distant recurrence. Newer literature suggests that vascular invasion is associated in general with an intermediate risk of structural recurrence but more commonly predicts distant metastasis rather than locoregional recurrence.<sup>434,610,612–619</sup>

**Follicular thyroid carcinoma.** The 2015 ATA guidelines classify FTC with extensive vascular invasion ( $\geq 4$  vessels) as high-risk with a 30–55% risk of recurrence and minimally invasive ( $< 4$  vessels) as low risk and a 2–3% risk of recurrence.<sup>14</sup> Recent studies have suggested that any vascular invasion may be associated with more aggressive behavior.<sup>620</sup> Extensive vascular invasion in FTC has been reported to be associated with a higher risk of distant metastasis than of locoregional recurrence.<sup>621</sup> Lee et al. evaluated 166 patients with FTC, and multivariable analysis showed the presence of any vascular invasion was associated with an HR of 29.06 for recurrence. However, when divided between  $< 4$  and  $\geq 4$  vessels,  $\geq 4$  vessels had an HR of 40.57 as compared with  $< 4$  vessels.<sup>433</sup> Xu et al. evaluated 276 patients with low grade encapsulated DTC and found overall higher rates of extensive vascular invasion in FTC and OTC compared with PTC. Those with focal ( $< 4$  vessels) vascular invasion had a 1% recurrence rate, but 26% of those with extensive vascular invasion developed recurrence.<sup>66</sup> Ito et al. evaluated 523 patients with FTC and compared those with no vascular invasion to those with  $< 4$  vessels and those  $\geq 4$  vessels and found a progressive increase in risk of distant metastatic disease with increasing vascular involvement, with an HR of 2.5 in those with  $< 4$  vessels ( $p = 0.021$ ) and HR of 8.03 in those with  $\geq 4$  vessels ( $p = 0.001$ ).<sup>622</sup> This also

was confirmed by systematic review and meta-analysis, specifically separating FTC from all patients with DTC. In the FTC subgroup analysis, vascular invasion was significantly associated with tumor persistence, locoregional recurrence, distant recurrence, and overall recurrence/persistence. Additional subgroup analysis looking at focal ( $< 4$  foci) versus extensive ( $\geq 4$  foci) vascular invasion demonstrated that extensive vascular invasion increased the risk of distant recurrence, with an OR of 26.38.<sup>619</sup>

**Oncocytic thyroid carcinoma.** OTC was previously considered a subset of FTC but more recently has been recognized as a distinct clinicopathologic and genomic entity. The Mayo Clinic retrospectively analyzed 173 OTC cases and through multivariable analysis found those with minimally invasive OTC had no clinical recurrences or death. In contrast, widely invasive OTC ( $\geq 4$  vessels or  $\geq 4$  foci of capsular invasion with minimal extrathyroidal extension), male sex, and higher TNM stage (III–IV) were significantly associated with clinical recurrence and death from OTC.<sup>623</sup> This is consistent with other studies reporting increased recurrence with widely invasive tumors.<sup>624–626</sup> In a retrospective multivariable analysis comparing 252 patients with FTC with 126 patients with OTC, Wenter et al. showed that recurrence was significantly more common in OTC at 17% versus FTC at 8%. OTC was an independent adverse prognostic factor for disease-free survival.<sup>627</sup> Bishop et al. also observed that locoregional recurrence associated with OTC more commonly presents as soft tissue implants because of spread within venous channels rather than true lymph node metastases.<sup>628</sup>

**Lymph node metastasis.** Metastatic lymph node size and number are important features when considering risk of structural recurrence.<sup>629</sup> In the 2015 ATA DTC guidelines, those with  $\leq 5$  micrometastases (defined as  $< 2$  mm) had a low risk of recurrence, and high risk included those with cN1  $> 3$  cm.<sup>14</sup> Since the 2015 guidelines, multiple retrospective analyses have evaluated these parameters. Multivariable analysis of 252 patients with multifocal T1a PTCCGR who had undergone total thyroidectomy and lateral compartment lymph node dissection reported cN1 or lymph node metastases  $> 5$  mm were associated with a 25.9% risk of recurrence and pN1  $> 3$  cm had an HR of 4.2 and a 50% risk of recurrence.<sup>630</sup> Multivariable analysis of 398 patients with N1a PTC reported size  $> 3.5$  mm, and  $\geq 4$  lymph node metastases had an HR of 3.76 for recurrence.<sup>424</sup> Bardet et al. studied 305 patients with micro- and macroscopic tumors (latter defined as cN1/pN1, i.e., when evident on clinical examination or ultrasound before surgery and/or clearly suspected by the surgeon) and found that tumor size  $> 2$  cm had a RR of recurrence of 2.4; macroscopic tumors had a RR of 4.5, and microscopic tumors had a RR of 2.5 for recurrence.<sup>631</sup> Lee et al. also challenged this size cutoff of 3 cm as a predictor of higher risk of recurrence. Multivariable analysis of 324 N1b tumors found that lymph node metastases  $> 2$  cm have an HR of 1.15 for recurrence.<sup>456</sup>

Further evaluating the number of lymph node metastases, Furtado et al. retrospectively evaluated 86 patients and reported  $\leq 5$  clinically evident lymph nodes in the central neck (cN1) predicted a lower risk of persistent disease. Three or fewer clinically metastatic lymph nodes were associated

with a 4.6% rate of recurrence, and 9% of those with four or five metastatic lymph nodes experienced recurrence ( $p = \text{NS}$ ).<sup>425</sup> Park et al. evaluated 1040 patients with PTC and reported the sensitivity and specificity of >3 lymph node metastases for predicting recurrence were 63.6% and 77%, respectively.<sup>632</sup> The association between lymph node metastases and survival is controversial. Adam et al. evaluated the association between number of lymph node metastases and survival using both the SEER (21,855 patients) and the NCDB (47,902 patients) and found that an increasing number of metastatic nodes up to six was associated with decreased survival (HR 1.12,  $p = 0.03$ ), but >6 did not add additional mortality risk ( $p = 0.75$ ).<sup>633</sup> Conversely, Ruel et al. also evaluated 39,301 patients with PTC  $\geq 1$  cm, cN0 or pN1a in the NCDB, and found increased use of RAI but no difference in overall survival if there were no clinically evident lymph nodes involved.<sup>423</sup>

LNR has emerged as a potential predictor of recurrence (see **Recommendation 20**). However, the LNR is largely dependent on the absolute number of metastatic and total lymph nodes studied, for which small alterations in either may substantially alter the LNR. Not all patients underwent the same procedure, with some undergoing prophylactic central and/or lateral neck dissection rather than therapeutic dissections for clinically evident disease, which significantly affects not only the total number of lymph nodes removed but also the potential number of microscopically involved lymph nodes. The studies evaluating LNR as a risk factor for structural recurrence report a range LNR depending on the conditions but consistently cite an elevated HR for recurrence with a LNR >0.25–0.5.<sup>424,426,427,433,456,457,459,634</sup>

LNY (see **Recommendation 20**), defined as the total number of excised lymph nodes (whether benign or malignant), also has been reported as a predictor of recurrence.<sup>454</sup> From these data, acceptable general minimum expectations of LNY adequacy are resection of at least five lymph nodes from the central neck and 20 lymph nodes from the lateral neck. Robinson et al. evaluated 78,724 patients from the NCDB (1998–2012) and estimated that the number of lymph nodes that needed to be removed to predict occult nodal disease was 6 lymph nodes in T1b, 9 lymph nodes in T2, and 19 lymph nodes in T3 disease.<sup>453</sup> This is an area of controversy because routine pCLND is not recommended in T1b and T2 disease. The number of lymph nodes seen can also be dependent on the extent of pathological examination. Some authors have reported comprehensive serial histological sectioning of the lymph nodes in PTC to identify metastatic deposits. However, the cost–benefit ratio and prognostic significance of this approach remain to be validated.<sup>635</sup>

**Extranodal extension.** According to the 2015 ATA DTC guidelines, pN1 tumors with extranodal extension and >3 metastatic lymph nodes have a risk of recurrence at 40% and suggest a high-risk category.<sup>14</sup> This has been confirmed in multiple studies since those guidelines were published. Roh et al. evaluated 2071 patients who had undergone thyroidectomy, and multivariable analysis showed that both micro- and macro-extranodal extension, the number of positive nodes (>5), LNR of >0.3, and ATA risk group all were independent variables associated with an increased risk of recurrence.<sup>431</sup> Chereau et al. evaluated 2518 patients who

underwent surgery for PTC between 1978 and 2014 and reported that extranodal extension and LNR in the lateral neck compartment were independent predictors of recurrence.<sup>636</sup> The association between extranodal extension and recurrence has been reported in many other studies.<sup>430,456,637</sup> Macroscopic extranodal extension also is associated with decreased survival.<sup>431</sup> Meta-analysis of 23 studies evaluating extranodal extension and recurrence found patients with extranodal extension had significantly higher rates of all-cause and cancer-specific mortality and recurrence.<sup>429</sup> Hence, extranodal extension appears to predict a high risk of both locoregional recurrence and distant metastasis. Reporting of extranodal extension is currently part of the pathology synoptic report ([www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates](http://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates)).

**Extrathyroidal extension.** In the 2015 ATA DTC guidelines and 7th edition AJCC/UICC staging,<sup>638</sup> microscopic extrathyroidal extension was sufficient for a tumor to be categorized as T3. AJCC 8th edition<sup>27</sup> guidelines no longer incorporate microscopic extrathyroidal extension into TNM staging. This change was made to avoid upstaging of small tumors without other risk factors for aggressive disease. The overall agreement among pathologists regarding identification and reporting minimal extrathyroidal extension is poor ( $\kappa = 0.14$ ).<sup>639</sup>

Microscopic (also referred to as minor or minimal) extrathyroidal extension is categorized as low-risk and is associated with a 3–9% risk of recurrence, but extrathyroidal extension into subcutaneous soft tissues, larynx, trachea, esophagus, or the recurrent laryngeal nerve PTC (gross extrathyroidal extension) has a 23–40% risk of recurrence according to the 2015 ATA guidelines.<sup>14</sup> Since the last guidelines, the role of minimal extrathyroidal extension and the risk of recurrence also has been debated. Retrospective analysis of 252 patients with T1a PTC who underwent total thyroidectomy and CLND showed a recurrence rate of 3.8% in those with capsular extrathyroidal extension, 6.6% in those with soft tissue extrathyroidal extension, and 13.3% among those with extrathyroidal extension and strap muscle involvement.<sup>630</sup> In a prospective analysis, Danilovic and colleagues analyzed 596 patients with PTC according to their degree of extrathyroidal extension. They found recurrence in 3% of ATA low-risk patients without extrathyroidal extension, 14% recurrence in ATA intermediate-risk patients without extrathyroidal extension, 14% recurrence in patients with minimal extrathyroidal extension, and 25% recurrence in those with gross extrathyroidal extension.<sup>420</sup> Li et al. retrospectively evaluated 4045 patients and reported recurrence in 22.5% of patients with extrathyroidal extension into strap muscles, and strap muscle invasion was significantly associated with multifocality, lymph node involvement, and distant metastasis; however, it was not independently associated with recurrence.<sup>640</sup> Retrospective review and multivariable analysis of 721 patients with T1a PTC by Seifert et al. reported a 13.1% lymph node recurrence rate in those with minimal extrathyroidal extension compared with those without minimal extrathyroidal extension (1.25%) and a 7.8% distant metastatic disease rate in those with minimal extrathyroidal extension when compared to those without (1.1%).<sup>641</sup> Systematic review and meta-analysis evaluating

the impact of strap muscle invasion versus gross extension into surrounding structures concluded that tumors exhibiting strap muscle invasion had a higher risk of recurrence compared with those without any extrathyroidal extension but lower risk than gross invasion. This analysis included six retrospective studies with 13,639 patients. They reported the local recurrence rate of those with strap muscle invasion to be 5–25.9%. The variability was attributed to the extent and location of invasion. There was significant heterogeneity, but even in subgroup analysis, the higher risk of recurrence persisted for strap muscle involvement. Further studies are needed to confirm these findings.<sup>239</sup> In contrast, Diker-Cohen et al. performed a meta-analysis that included 13 studies and concluded that minimal extrathyroidal extension is associated with a minimally increased risk of recurrence; the risk of recurrence was 7% with minimal extrathyroidal extension in tumors >1 cm, which is in the low risk of recurrence category.<sup>642</sup>

**Microscopically positive margin.** Incomplete tumor resection and residual gross disease (R2) are categorized as ATA high-risk.<sup>14</sup> However, the presence of microscopically positive margins (R1) was not a component of the 2015 ATA DTC risk stratification system. Multiple studies have retrospectively evaluated this question, and the majority have found no association between microscopically positive margins and local persistence/clinical recurrence.<sup>419,422,643</sup> Sanabria et al. performed a meta-analysis, evaluating six studies that included 7696 patients and found no association between microscopically positive margins and increased risk of locally persistent/recurrent disease.<sup>421</sup> Location of the positive margin (anterior vs. posterior) was not delineated in most of the reported studies, although Lang et al. retrospectively evaluated 1513 patients with DTC, and when they differentiated between the two margins, they found a 3.6% rate of recurrence in those patients with a positive anterior margin and 11.6% risk of recurrence in those patients with a positive posterior margin. This led the authors to conclude that a positive posterior margin is an independent risk factor for persistent/recurrent disease (HR = 22.95,  $p < 0.0001$ ).<sup>419</sup> Retrospective review of >14,000 patients in the NCDB showed that microscopically positive margins are associated with an increased risk of death in both T1a PTC<sup>644</sup> and PTCs 1–4 cm.<sup>645</sup> Mercado et al. reported that recurrence-free survival is lower among patients with positive margins at 71% versus 90% among those with negative margins, regardless of other favorable risk factors.<sup>646</sup> More studies need to be done in this area, with special attention to the difference between anterior and posterior microscopically positive margins to determine the true risk of structural recurrence.

**Subtypes of PTC.** Since the last ATA DTC guidelines, a new classification of encapsulated follicular variant of PTC has been created, termed NIFTP. Previously, NIFTPs were included as encapsulated variants in the FVPTC category, which could have affected overall risk estimates for recurrence. Henke et al. performed a single-institution, retrospective multivariable analysis evaluating 1293 patients treated for thyroid cancer between 1943 and 2009 comparing classical PTC versus FVPTC (specifically excluding NIFTP from the analysis). The authors found that thyroid capsule

invasion was associated with classical PTC and larger size, and tumors confined to the thyroid were associated with FVPTC. Overall, classical PTC was associated with a higher risk of recurrence compared with FVPTC.<sup>647</sup> Tunca et al. evaluated 258 patients with classical PTC and 153 patients with FVPTC and reported similar findings, with higher rates of capsular invasion, microscopic extrathyroidal extension, and lymph node metastases in classical PTC compared with FVPTC.<sup>648</sup> FVPTC had higher rates of multifocality and involvement of both lobes. Recurrence rates were higher in the classical PTC group  $\geq 45$  years, but there was no difference among those <45 years when compared with FVPTC.<sup>648</sup> Shi et al. compared classical PTC, FVPTC, and tall cell variant of PTC and found that recurrence was highest in the tall cell variant of PTC at 27.3%, 16.1% in classical PTC, and 9.1% in FVPTC.<sup>109</sup> It should be noted that in WHO 2022 FVPTC is now considered a separate category of DTC and is now termed IEFVPTC (see Pathology section).

**Age.** Patient age is included in the AJCC staging system and is believed to be a predictor of mortality. However, it has not been included among the ATA Risk of Recurrence predictors. Data are conflicting concerning the role of patient age at diagnosis and risk of recurrence and response to therapy. Several groups have reported older age (generally >45–55 years) in addition to the ATA Risk of Recurrence as predictors of recurrence for the high-risk categories.<sup>649–652</sup> Alzahrani and Mukhtar reviewed 287 patients with intermediate- or high-risk DTC and found that patient age  $\geq 55$  years was significantly associated with risk of having biochemically or structurally incomplete response to therapy.<sup>653</sup> In a prospective cohort study using the Italian Thyroid Cancer Observatory database, Grani et al. also reported patient age as a variable that, when combined with the ATA Risk of Recurrence stratification system, can more accurately predict rates of persistence and recurrence.<sup>654</sup> However, Pitoia et al. performed a retrospective analysis of 268 patients with DTC and reported age at diagnosis was not associated with structurally incomplete response to therapy.<sup>655</sup> Additionally, Banerjee and colleagues evaluated 9273 patients with thyroid cancer in the SEER-Medicare database to determine factors associated with treatment-free survival and did not see an association with age.<sup>656</sup> Additional studies are needed to determine the overall impact of patient age at diagnosis as an independent predictor of long term outcomes.

**Somatic genomic testing.** Since the 2015 ATA Guidelines, many investigators have evaluated the role of molecular testing in predicting tumor aggressiveness, response to therapy, and recurrence. Multiple studies and meta-analyses have shown that co-existent *BRAF*<sup>V600E</sup> and *TERT* promoter mutations are associated with more aggressive clinical behavior and a higher risk of recurrence.<sup>657–659</sup> A recent meta-analysis demonstrated the association of PTCs with a combination of *BRAF*<sup>V600E</sup> and *TERT* promoter mutations and more aggressive disease, including reduced disease-specific survival (RR 15.09 [CI 7.75–29.37]).<sup>657</sup> This association was more pronounced than for patients with a *BRAF*<sup>V600E</sup> mutation alone (RR 5.34 [CI 4.20–6.78]).

Recently, the trio of *TERT* promoter mutation, *BRAF*<sup>V600E</sup>, and a *BRAF* genotype TT of rs2853669 was reported to have an even higher risk of recurrence (76.5%) when compared with tumors with no mutations (8.4%).<sup>660</sup> *RAS* mutations, in combination with *TERT* promoter mutations, also have been shown to be a significant predictor of aggressiveness and higher risk of recurrence.<sup>254,661,662</sup> One study evaluated 388 patients with PTC from 19 centers within the Thyroid Cancer Genome Atlas (TCGA) thyroid cancer database and measured the outcomes association with *BRAF*<sup>V600E</sup>, *RAS*, and *TERT* promoter mutations. They reported an adjusted HR for recurrence of 106 [CI 15.3–744.49] for concurrent *RAS* and *TERT* promoter mutations and an HR of 6.59 [CI 1.55–27.94] for concurrent *BRAF*<sup>V600E</sup> and *TERT* promoter mutations.<sup>662</sup>


*RAS* mutations in conjunction with *EIF1AX* mutations also have been associated with PDTC and ATC.<sup>261,663–666</sup> In a multicenter retrospective review of 764 patients who underwent total or subtotal thyroidectomy and had molecular testing results, 42 patients (5.5%) were found to have an *EIF1AX* mutation, but an *EIF1AX* mutation alone was not predictive of malignancy (38% benign, 14% NIFTP, and 47% malignant). Thirty percent of the cancers had aggressive features; 83% of these were poorly differentiated. All the aggressive malignancies had an *EIF1AX* A113\_splice site mutation (*EIF1AX* c.338-2A>T, exon 6), and 50% had at least one additional mutation. The authors concluded the co-occurrence of *RAS* and *EIF1AX* was associated with more aggressive behavior.<sup>666</sup> Other combinations of mutations, including *RAS* and *BRAF*<sup>V600E</sup> in conjunction with *TP53*, *PIK3CA*, and *AKT1*, also are associated with more aggressive behavior.<sup>258</sup> Some groups have categorized specific mutations, fusions, and copy number alterations into molecular risk of recurrence categories, like the ATA Risk of Recurrence categories based on histology. As discussed in **Recommendation 10**,

these proposed molecular categories were similar in their ability to predict recurrence compared with the 2015 ATA Risk of Recurrence categories.<sup>268</sup>

Another study applied an algorithm to the RNA-Seq expression dataset from the TCGA and assessed progression-free survival in more than 7,500,000 combinations of genes.<sup>257</sup> In total, they identified 82 genes associated with prognosis and divided them into three groups. The group with the highest risk of recurrence had >50% with *BRAF*<sup>V600E</sup> mutations; all of those with *TERT* promoter mutations were in this category. This group also had the lowest tumor differentiation scores, high levels of immune cell infiltrate, and the highest expression of immunoregulatory molecules. Another study reported a gene expression-based score (Molecular Aggression and Prediction [MAP]) composed of markers for cell cycle, differentiation, extracellular matrix, and immune cell infiltrate.<sup>667</sup> A positive MAP score was associated with more aggressive disease. The authors proposed that a positive MAP score in combination with genomic alterations may better predict recurrence and aggressiveness. These reports highlight a fraction of the emerging evidence that the tumor microenvironment also plays an important role in DTC recurrence. More studies are needed to evaluate the predictive role of tumor microenvironment alterations (with or without genomic alterations) as a DTC biomarker.

Overall, these publications shed light on the behavior of tumors with specific molecular alterations and tumor microenvironment findings (Table 8).<sup>36,53,54,133,261,269,665,668–703</sup> The molecular risk of recurrence, if it was obtained, should be considered in conjunction with the ATA Risk of Recurrence categories, postoperative Tg levels, and imaging. Additional studies are needed to determine if routine postoperative genomic analysis of histological specimens improves

TABLE 8. GENOMIC CHANGES AND COMBINATIONS OF EVENTS ASSOCIATED WITH DTC



	Early Genomic Changes	Events in Combination with Early Changes Associated with Progression
<b>Papillary Carcinoma</b>	<p><b>Mutations:</b></p> <ul style="list-style-type: none"> <li>■ <i>BRAF</i><sup>V600E</sup></li> <li>■ <i>RAS</i></li> <li>■ <i>BRAF</i> (Non V600E)</li> </ul> <p><b>Fusions:</b></p> <ul style="list-style-type: none"> <li>■ <i>BRAF</i>, <i>RET</i>, <i>ALK</i>, <i>NTRK 1/3</i></li> </ul> <p><b>Other:</b></p> <ul style="list-style-type: none"> <li>■ 1q gain, 22q loss</li> </ul>	<p><b>Mutations:</b></p> <ul style="list-style-type: none"> <li>■ <i>TERT</i> promoter (C228T/C250T)</li> <li>■ <i>TP53</i>, <i>RBM10</i>, <i>CDKN2B</i>, <i>PIK3CA</i>, <i>PLEKSH1p</i>, <i>AKT1</i></li> </ul> <p><b>Other:</b></p> <ul style="list-style-type: none"> <li>■ <i>CDKN2A</i> and <i>CDKN2B</i> loss</li> <li>■ Increased APOBEC activity</li> <li>■ Global DNA hypomethylation</li> </ul>
<b>Follicular Carcinoma</b>	<p><b>Mutations:</b></p> <ul style="list-style-type: none"> <li>■ <i>RAS</i></li> <li>■ <i>DICER1</i>, <i>EIF1AX</i>, <i>PTEN</i>, <i>GNAS</i></li> <li>■ <i>BRAF</i> (Non V600E)</li> </ul> <p><b>Fusions:</b></p> <ul style="list-style-type: none"> <li>■ <i>PPARγ</i>, <i>THADA</i></li> </ul> <p><b>Other:</b></p> <ul style="list-style-type: none"> <li>■ 7q gain, 22q loss</li> </ul>	<p><b>Mutations:</b></p> <ul style="list-style-type: none"> <li>■ <i>TERT</i> promoter (C228T/C250T)</li> <li>■ <i>TP53</i>, <i>RBI</i>, <i>RBM10</i></li> <li>■ <i>CCNE1</i></li> </ul> <p><b>Other:</b></p> <ul style="list-style-type: none"> <li>■ <i>CDKN2A</i> and <i>CDKN2B</i> loss</li> <li>■ Global DNA hypomethylation</li> </ul>
<b>Oncocytic Carcinoma</b>	<p><b>Mutations:</b></p> <ul style="list-style-type: none"> <li>■ Mitochondrial DNA</li> <li>■ <i>RAS</i>, <i>DAXX</i>, <i>ARHGAP35</i>, <i>APC</i>, <i>FAT1</i>, <i>CDKN1A</i></li> <li>■ <i>PTEN</i>, <i>GNAS</i></li> </ul> <p><b>Fusions:</b></p> <ul style="list-style-type: none"> <li>■ <i>PRKAB1</i>, <i>VPRREB3</i>, <i>PANX1</i></li> </ul> <p><b>Other:</b></p> <ul style="list-style-type: none"> <li>■ Chromosomal loss, near haploid with or without genome wide duplication</li> </ul>	<p><b>Mutations:</b></p> <ul style="list-style-type: none"> <li>■ <i>TERT</i> promoter (C228T/C250T)</li> <li>■ <i>TP53</i>, <i>FAT1</i>, <i>AGAP2</i>, <i>MTOR</i>, <i>AKT2</i>, <i>MT2C</i></li> <li>■ <i>KEAP1</i>, <i>TBX3</i>, <i>CDKN1B</i>, <i>NFI</i>, <i>PDGFRA</i>, <i>CD274</i></li> <li>■ <i>JAK2</i></li> </ul> <p><b>Other:</b></p> <ul style="list-style-type: none"> <li>■ <i>CDKN2A</i> and <i>CDKN2B</i> loss</li> </ul>

the accuracy of the 2025 ATA Risk of Recurrence categories. Currently, the combination of 2025 ATA Risk of Recurrence category, AJCC staging, imaging, and laboratory results should be the primary approach to determine risk of recurrence. Use of somatic genomic testing to guide treatment for patients with progressive RAI resistant (RAIR) DTC is discussed in **Recommendation 61**.

*Sex.* Male sex has been associated with higher prevalence of advanced stage DTC.<sup>704</sup> Hence, there are questions regarding the role of sex in risk of recurrence. Multivariable analysis reported that sex was not an independent prognostic factor for disease-specific survival.<sup>704</sup> Park et al. evaluated 5566 patients with DTC between 2009 and 2015 in Seoul, Korea, and reported a significantly higher recurrence rate in males compared with females.<sup>705</sup> However, after matching and multivariable analysis, male sex was not an independent prognostic factor for DTC recurrence. In view of the lack of an independent association, sex is not one of the considerations in the ATA Risk of Recurrence prediction modeling.

*Body mass index.* Overweight, obesity, and elevated body mass index (BMI) have emerged as risk factors for DTC. Two systematic reviews and meta-analyses evaluating the role of BMI and clinicopathologic features of PTC found obesity to be associated with larger tumor size, increased rates of multifocality, extrathyroidal extension, and lymph node metastasis, and these associations increased with higher BMI.<sup>706–708</sup> In a prospective cohort study of 4713 patients with thyroid cancer using the Italian Thyroid Cancer Observatory database that includes patients from 40 centers, Grani et al. reported that body composition was predictive of response to therapy but had different impacts depending on the cluster or cohort of patients: it appeared to be protective in some and a risk factor for compromised outcome in others.<sup>654</sup> Greater waist circumference and adulthood weight gain also have been shown to be associated with thyroid cancers at higher risk for recurrence.<sup>709</sup> While not currently part of the ATA Risk of Recurrence predictors, overweight and obesity may play a role in future algorithms.

How should clinical response to surgery be assessed?

■ **RECOMMENDATION 29**

The ATA Response Criteria should be used to categorize response to surgery prior to determining intensity of additional therapy or monitoring in combination with the ATA Risk of Recurrence Estimates. (*Strong Recommendation, Moderate certainty evidence*)

While the ATA Risk of Recurrence and tumor staging estimates provide important insights into a patient's risk of clinical recurrence and disease-specific mortality, they are not designed for individualization of therapy based on response to treatment. In the 2015 guidelines, the ATA proposed a risk stratification system that incorporates individual response to therapy into a real-time, dynamic risk stratification scheme in order to provide an individualized approach to ongoing management.<sup>710,711</sup> While initially proposed for use during long-term follow-up, studies have shown now that many patients initially considered at intermediate- or high-risk of recurrence using the initial stratification systems can be re-classified

subsequently to low risk of recurrence based on their excellent response to initial therapy.<sup>712–728</sup>

With the reduced use of RAI for patients with low risk of recurrence and an increase in the use of thyroid lobectomy, we propose that the first assessment following initial therapy should occur within 3 months after resection. In this way, it can be used to inform patient and physician decision-making for use of RAI and/or to individualize the administered dose. For example, a patient with multiple lymph nodes at high risk of recurrence may be treated with a lower dose if the serum Tg is not detectable on a highly sensitive assay (e.g., lower limit of detection 0.1 ng/mL) in the absence of TgAb during levothyroxine (LT4) administration, and neck ultrasound does not reveal residual disease after operation. Conversely, for the same patient, an elevated Tg level might prompt chest imaging to identify metastases, thereby changing the goals of treatment. More prospective outcome studies are required to support this as an initial approach; retrospective data using the ATA dynamic risk stratification schema support this paradigm during follow-up. Proportion of variance explained values associated with risk stratification systems that incorporate response to therapy variables into revised risk estimates are significantly higher (62–84%) than those seen with initial classification systems.<sup>712,729</sup> These data indicate that long-term outcomes can be more reliably predictive using systems that respond to new data over time.<sup>710,712</sup>

The concept and initial validation of the four response categories presented here were described by Tuttle et al.<sup>712</sup> and modified by Vaisman et al.<sup>730</sup> As originally conceived, these clinical outcomes described the best response to initial therapy during the first 2 years of follow-up,<sup>710,712</sup> but they are now being used to describe the clinical status at any point during follow-up. Application of these definitions to the postoperative time frame is summarized in Table 9. As described in the Definitions section above, response following tumor resection is categorized as the following:

- A. **Excellent response:** no clinical, biochemical or structural evidence of disease.
- B. **Indeterminate response:** nonspecific biochemical or structural findings, which cannot be confidently classified as either benign or malignant. This includes patients with stable or declining TgAb levels without definitive structural evidence of disease.
- C. **Biochemical incomplete response:** abnormal Tg or rising TgAb levels in the absence of localizable disease.
- D. **Structural incomplete response:** persistent or newly identified locoregional or distant metastases on imaging.

When should Tg levels be measured after surgery?

■ **RECOMMENDATION 30**

- A. Measuring a postoperative serum Tg level 6–12 weeks after total thyroidectomy while on thyroid hormone therapy or after TSH stimulation is recommended. Such measurements may guide additional decision-making regarding clinical management. (*Strong recommendation, Low certainty evidence*)

TABLE 9. RESPONSE CRITERIA AFTER INITIAL THERAPY BASED ON TYPE OF INTERVENTION

Response to therapy	Post total thyroidectomy and/or neck dissection with RAI ablation or therapy	Post total thyroidectomy and/or neck dissection without RAI ablation	Post hemithyroidectomy	TSH goal
Excellent	Nonstimulated Tg <0.2 or stimulated Tg <1 and negative imaging	Nonstimulated Tg <2.5	Normal or low-risk nodules in the contralateral lobe, or contralateral lobe nodules with benign biopsy AND no abnormal lymph nodes on imaging	TSH within normal reference range
Indeterminate	Nonspecific findings on imaging studies or nonstimulated Tg 0.2–1 or stimulated Tg 1–10 or stable/ declining TgAb levels	Nonspecific findings on imaging studies or nonstimulated Tg 2.5–5, or stable/ declining TgAb levels	N/A <sup>a</sup>	TSH within normal reference range <sup>b</sup>
Biochemically incomplete	Non-stimulated Tg >1 or stimulated Tg >10 or increasing TgAb levels and negative imaging	Nonstimulated Tg >5 or increasing TgAb levels and negative imaging	N/A <sup>a</sup>	TSH below normal reference range <sup>c</sup>
Structurally incomplete	Structural evidence of disease (suspicious imaging or biopsy proven local or distant metastatic disease)	Structural evidence of disease (suspicious imaging or biopsy proven local or distant metastatic disease)	Structural evidence of disease (suspicious imaging or biopsy proven local or distant metastatic disease)	TSH below normal reference range <sup>c</sup>

<sup>a</sup>See Recommendation 48 for specific comments regarding Tg levels (ng/mL) in patients treated with hemithyroidectomy.

<sup>b</sup>Data on optimal TSH target range are inconclusive.

<sup>c</sup>Data on optimal TSH target range are inconclusive and/or conflicting. If there is progression of residual disease or development of new recurrence, targeting a TSH below normal reference range may be reasonable. However, comorbidities such as atrial fibrillation and osteoporosis should be factored into the decision making process.

RAI, radioactive iodine; Tg, thyroglobulin; TgAb, anti-thyroglobulin antibody; TSH, thyrotropin.

- B. Measurement of serum Tg on one occasion 6–12 weeks after thyroid lobectomy with a normal TSH may be helpful to ensure that it is not unexpectedly elevated; however, a specific cutoff value is uncertain. (*Good Practice Statement*)

Measurement of serum Tg is a fundamental tool for evaluating thyroid cancer tumor burden, assessing response to treatment, and monitoring for cancer recurrence. Details about assays and antibody interference are included in **Recommendation 47**. Normal thyroid tissue, as well as DTC, produces Tg, which is released into the circulation. Therefore, Tg produced by the normal thyroid is not distinguishable from Tg produced by DTC. In a prospective study of 50 patients with impending thyroidectomy, the preoperative serum Tg was lower in patients ultimately found to have thyroid cancer compared with those with benign disease, likely because those undergoing surgery for benign conditions had larger thyroid glands. The optimal background setting to utilize serum Tg to detect cancer persistence or recurrence is after a patient has had all normal thyroid tissue removed with a total thyroidectomy and ablative RAI treatment. The trends toward less frequent use of RAI and lobectomy, rather than total thyroidectomy, for many patients with DTC have raised questions about using serum Tg as a tumor marker in patients with DTC when a larger amount of normal thyroid tissue remains.

A serum Tg level is recommended in the postoperative period to inform treatment decisions. The timing of the initial

postoperative serum Tg measurement is guided by a study that performed preoperative and sequential postoperative serum Tg level measurements at multiple time points up to 1 year after surgery.<sup>243</sup> Preoperative serum Tg levels did not distinguish between patients with benign and malignant conditions. The median time to reach the nadir serum Tg after thyroidectomy in patients with both benign and malignant disease was 12 weeks, later than was previously thought.

Measurement of serum Tg after DTC treatment has the potential to provide highly sensitive detection of residual tumor. Serum Tg can be measured when the patient is euthyroid, either with an adequately functioning residual lobe after a thyroid lobectomy on LT4 replacement or while being treated with TSH suppressive doses of LT4. The other circumstances to measure serum Tg is a “TSH-stimulated” measurement, either achieved by stopping LT4 replacement (with or without temporary LT3) in an athyreotic patient and allowing the endogenous TSH to increase (usually >30 mIU/mL) or administering exogenous recombinant human TSH (rhTSH). TSH is a stimulant to Tg production; an individual patient may have a Tg that is in the reference range at baseline but that increases in response to rising TSH.

Both a stimulated Tg level and a basal Tg level have been used postoperatively to identify persistent and to predict recurrent disease, but a benefit of stimulated over basal Tg has not been consistently shown. A retrospective observational study evaluated 1093 patients with DTC with pre-RAI ablation, TSH-stimulated serum Tg and post-RAI, TSH-

stimulated serum Tg.<sup>731</sup> The endogenous pre-ablation, TSH-stimulated Tg and recombinant TSH, post-ablation, stimulated Tg levels, as well as an index of serum Tg reduction, were predictors of disease progression and recurrence. Use of unstimulated serum Tg to follow patients not treated with RAI was addressed in a retrospective series of 570 patients with DTC, 187 of whom underwent lobectomy and 320 of whom had total thyroidectomy but did not receive RAI.<sup>732</sup> At a mean follow-up of 8 years, patients who had total thyroidectomy and a serum Tg of <0.2 ng/mL and patients who had lobectomy and a serum Tg <30 ng/mL had an excellent response with no evidence of recurrent structural disease. In a study of 100 patients with DTC who were given additional RAI if they had an elevated serum Tg, 62% of patients had a complete response at one year. Patients were then followed for an average of 96 months. The authors concluded that additional RAI for a persistently elevated serum Tg was associated with improved long-term outcomes. In another small study, 63 patients with DTC had an endogenous TSH-stimulated serum Tg measurement after thyroidectomy but before RAI; a TSH-stimulated serum Tg below 4.4 ng/mL predicted successful response to RAI ablative therapy.

Few studies have examined the association between postoperative serum Tg and DTC survival. An observational study of 1093 patients with DTC who underwent total thyroidectomy and RAI ablation examined the relationship between pre-RAI ablation thyroid hormone withdrawal stimulated serum Tg and ATA risk stratification on 10-year survival.<sup>733</sup> Initial ATA high-risk classification, patient age >55 years, and pre-ablation Tg  $\geq 30$  ng/mL were the primary factors associated with reduced 10-year survival. Patients with a stimulated Tg  $\geq 30$  ng/mL had a 10-year survival of 78%, compared with 95% for those with a stimulated Tg <30 ng/mL.

Serum Tg has not been shown to predict recurrence in patients with DTC after thyroid lobectomy. A cohort study of 208 patients with low-risk PTC followed serum Tg in patients who underwent lobectomy and did not require LT4 therapy.<sup>734</sup> Postoperative serum Tg, Tg/TSH ratio, and neck ultrasound were followed regularly for a median follow-up period of 6.9 years. The mean serum Tg and Tg/TSH ratio increased gradually, but there was no difference in serum Tg or Tg/TSH ratio in the 19 patients with tumor recurrence. Of those who had recurrence, all but one had a Tg <30 ng/mL, similar to those who did not have a recurrence. The authors concluded that serum Tg level was not predictive of disease recurrence in patients with PTC after thyroid lobectomy. In a retrospective study, 167 patients with PTC who underwent lobectomy were followed with serum Tg and TgAb measurements.<sup>735</sup> At 2 years of follow-up, serum Tg declined in 42% of patients, was stable in 22%, and rose in 36%. After 6 and half years of follow-up, 18 patients required completion thyroidectomy for PTC in the contralateral lobe or had metastatic disease, and serum Tg rose in only 3 of the 18 patients. The authors concluded that serum Tg level was not useful for detecting recurrence in patients with PTC who initially underwent lobectomy.

In view of the importance of understanding the diagnostic accuracy of serum Tg following thyroid lobectomy and total/near-total thyroidectomy without RAI treatment, a subset of the guidelines task force members initiated a systematic

review to address this question.<sup>16</sup> A total of 37 studies met the inclusion criteria assessing the diagnostic accuracy of serum Tg in a variety of postoperative settings. Serum Tg measurement following partial thyroidectomy was not accurate for diagnosing DTC recurrence or metastasis. After total/near total thyroidectomy without RAI, there were few studies and very low rates of recurrence or metastasis, but serum Tg levels were usually stable and low. Since most patients who do not receive RAI are in lower risk groups for recurrence, it is difficult to compare the value of serum Tg in this group to the measurements in patients that receive RAI. The systematic review concluded that there was significant variability among the studies with respect to treatment protocols and approaches, but for patients who have undergone total or near-total thyroidectomy without RAI, serum Tg levels up to 1–2.5 ng/mL while on LT4 therapy generally identify patients at low risk for persistent or metastatic disease.

Finally, while it is acknowledged that the data do not support a firm cut-point for Tg monitoring after lobectomy, the task force unanimously felt that measuring a single Tg value  $\sim 12$  weeks after surgery with a normal TSH would be prudent to ensure it is not unexpectedly markedly elevated, whereupon further imaging would be appropriate. Additional studies are needed to clarify the optimal approach for monitoring patients after lobectomy.

What is the role of ultrasound and other imaging techniques (CT, MRI, <sup>18</sup>F-DG-PET-CT) after primary resection?

#### ■ RECOMMENDATION 31

- A. Ultrasound to evaluate the thyroid bed and central and lateral cervical lymph node compartments is the preferred method of imaging surveillance for most DTC. (*Strong recommendation, Moderate certainty evidence*)
- B. If the serum Tg level after surgery is above the excellent response range (see Table 9), and/or there are Tg Ab, cervical ultrasound and/or cross-sectional imaging should be performed prior to administering RAI. (*Good Practice Statement*)
- C. Six to 12 months following completion of initial therapy, cervical ultrasound to evaluate the thyroid bed and central and lateral cervical lymph node compartments should be performed. Timing and frequency thereafter are informed by the patient's risk for residual or recurrent disease and response to therapy. (*Good Practice Statement*)
- D. Suspicious lymph nodes or lesions <8–10 mm in shortest dimension may be followed without FNA unless they grow or threaten vital structures (such as the recurrent laryngeal nerve, trachea, esophagus, or great vessels). (*Conditional recommendation, Low certainty evidence*)
- E. If cytological diagnosis of recurrent or metastatic DTC would influence treatment decisions or change management, ultrasonographically suspicious lymph nodes or lesions  $\geq 8$ –10 mm in the shortest dimension should be assessed with FNA for cytology and measurement of Tg in the needle washout fluid. (*Good Practice Statement*)
- F. When Tg (or TgAb) levels rise following total thyroidectomy for DTC, and cervical ultrasound

demonstrates no structural disease or only minimal tumor burden, additional cross-sectional imaging to evaluate common metastatic sites (e.g. lungs and bone) should be performed. (**Good Practice Statement**)

- G. When Tg (or TgAb) levels rise following total thyroidectomy for OTC and PDTC, and cervical ultrasound demonstrates no structural disease or shows only minimal tumor burden, <sup>18</sup>FDG-PET/CT may be considered. (**Conditional recommendation, Low certainty of evidence**)

Cervical ultrasound is performed with a high-frequency probe (10 MHz) and is highly sensitive in the detection of cervical metastases in patients with DTC.<sup>736–738</sup> These studies primarily evaluated patients with PTC, and the utility of neck ultrasound for monitoring patients with low-risk FTC is not well established. Neck ultrasound should interrogate all lymph node compartments and the thyroid bed. Limitations of ultrasound in the central compartment with the thyroid in place<sup>738</sup> should not limit detection of central neck recurrences after thyroidectomy, but ultrasound may not distinguish thyroid bed recurrence or nodal progression from benign gland remnants.<sup>739,740</sup> Masses in the thyroid bed that are <6 mm in shortest dimension are seldom malignant; punctate echogenicity is worrisome.<sup>741</sup> During the first year after resection in patients with low serum Tg levels on thyroid hormone therapy (and without any other suspicious findings), if an ultrasound abnormality is found, then follow-up should be performed. Efficacy of ultrasound is operator-dependent; it is not uncommon for some team members involved to lack confidence in their ability to perform ultrasound.<sup>171,742</sup> Whether ultrasound is best undertaken by radiologists, endocrinologists, cytopathologists, or surgeons is likely to vary from one center to another. In patients with PTC found to be at low risk for recurrence after total thyroidectomy (based on serum Tg measures and first follow-up neck ultrasound), there is a high incidence of false positive findings that may engender additional fruitless testing.<sup>743</sup> While the utility of follow-up in young patients without biochemical or ultrasound evidence of recurrence at 12 months has been questioned in view of the low frequency of structural recurrence,<sup>744</sup> on 10-year follow-up of 253 patients with PTC, 5 of 11 recurrences developed between 20 and 60 months after total thyroidectomy.<sup>736</sup> Correlation between ultrasound findings and surgical pathology<sup>745</sup> has shown that for lymph nodes  $\geq 8$ –10 mm in shortest diameter, a cystic appearance or hyperechoic foci in patients with a history of DTC should be considered malignant. In addition, peripheral vascularity is worrisome, with a high sensitivity/specificity for malignancy. With such findings, FNA biopsy is justified. A hyperechoic hilum and central vascularity are reassuring. A round shape, hypoechoic appearance, or the loss of the hyperechoic hilum does not, as isolated findings, justify FNA biopsy.

Interpretation of neck ultrasound should reflect additional clinical and biological information. The risk of recurrence is closely related to the initial lymph node status. Most lymph node recurrences occur in already involved compartments; the risk increases with increasing number of involved lymph nodes and a greater number of lymph nodes with extranodal extension,<sup>746</sup> with macroscopic rather than microscopic lymph node metastases,<sup>629,747</sup> and with higher metastatic LNRs.<sup>748,749</sup>

In low- and intermediate-risk patients after total thyroidectomy, the risk of lymph node recurrence is low (<2%) if there is an undetectable serum Tg level; it is much higher in those patients with detectable/elevated serum Tg levels.<sup>750,751</sup> One gram of DTC should increase the serum Tg by  $\sim 1$  ng/mL during thyroid hormone treatment and by  $\sim 2$ –10 ng/mL following TSH stimulation.<sup>750</sup> Neck ultrasound can detect involved nodes as small as 2–3 mm in diameter (among patients where the serum Tg level may be low or undetectable) but benefit from early discovery (when the smallest diameter is  $\leq 8$ –10 mm) has not been demonstrated.

If diagnosing recurrent cancer will influence clinical decisions, then FNA biopsy for cytology and Tg measurement in the aspirated fluid generally should be performed for suspicious lymph nodes  $\geq 8$ –10 mm in their shortest dimension. Ultrasound guidance improves the results of FNA biopsy for small lymph nodes and those located deep in the neck. However, FNA cytology alone misses thyroid cancer in up to 20% of patients.<sup>752,753</sup> The combination of cytology and serum Tg determination in the aspirated fluid (which remains valid even if there is an environment of serum TgAb) increases sensitivity as described in **Recommendation 7**.<sup>220,752–756</sup>

Tg measurement in the aspirated fluid should be compared with serum Tg measurement (secured on the same day, prior to the FNA) in most patients. FNA for Tg determination is technically demanding and has not been standardized. Variations in needle gauge, diluent volume, processing time, and number of punctures all have the potential to limit accuracy and reproducibility.<sup>757,758</sup> Nodes without suspicious morphology and small, worrisome nodes (<8–10 mm in shortest dimension) can be managed expectantly.

Most patients with recurrent DTC will only have disease in the lymph nodes. The most common sites of extra-cervical metastases are the lung and bone, comprising more than 80%; pulmonary metastases represent the majority.<sup>759</sup> While well recognized, intra-abdominal and retroperitoneal disease is uncommon. Cutaneous metastases are detectable by examination. Hence, initial cross-sectional imaging should not be directed to sites other than lung and bone when screening for distant disease in the absence of ultrasound-detected cancer in cervical lymph nodes or the thyroid bed.

What is the role of RAI after thyroidectomy in the primary management of DTC?

#### ■ RECOMMENDATION 32

- A. Remnant ablation is not recommended routinely after total thyroidectomy for patients with ATA low-risk DTC. (**Strong recommendation, High certainty evidence**)
- B. RAI adjuvant therapy may be considered after total thyroidectomy in patients with ATA low-intermediate and intermediate-high risk of recurrent DTC. (**Conditional recommendation, Low certainty evidence**)
- C. RAI adjuvant therapy is recommended routinely after total thyroidectomy for patients with ATA high-risk DTC. (**Strong recommendation, Moderate certainty evidence**)
- D. In patients with an initial diagnosis of DTC with distant metastases, RAI therapy is recommended routinely after

total thyroidectomy. (*Strong recommendation, Moderate certainty evidence*)

Our recommendations regarding utilization of RAI and goals of therapy are adapted from the Martiniq guidelines<sup>760</sup> and are summarized in Table 10. Important definitions include the following:

**Remnant ablation.** Eliminate residual benign thyroid tissue in the thyroid bed to facilitate treatment monitoring.

**Adjuvant therapy.** Additional RAI administered to reduce the risk of recurrence.

**Treatment of known disease.** Treatment of known areas of residual/metastatic disease.

Postoperative RAI administration can be used to accomplish remnant ablation, adjuvant therapy, or treatment for known residual disease. When deciding if RAI is appropriate, a variety of patient- and tumor-specific features should be considered. These include the histopathology of the thyroid cancer, concurrent comorbidities, serological biomarkers and metabolic function panel, logistic feasibility for post-treatment isolation recommendations and follow-up evaluation, and patient concerns and preferences.

Imaging and molecular genetic profiles features have been associated with favorable response or treatment resistance. Notably, favorable response to RAI therapy has been observed in tumors harboring *RAS* mutations and *RET* fusions, while resistance is more frequently observed in DTCs harboring *BRAF*<sup>V600E</sup>, *TERT* promoter, and/or *TP53* mutations.<sup>761–763</sup> The presence of concomitant *BRAF*<sup>V600E</sup> and *TERT* promoter or *TP53* mutations is associated with loss of <sup>131</sup>I avidity and poor clinical outcomes.<sup>764,765</sup> These findings have motivated the development of strategies beyond administration of higher doses of <sup>131</sup>I to overcome resistance to RAI, such as redifferentiation therapy (see **Recommendation 74**).<sup>766</sup>

**ATA low-risk.** There is increasing evidence suggesting lack of a clinical benefit of RAI in ATA low-risk thyroid cancer, particularly for patients categorized as having an excellent response after surgery. A multi-institutional, retrospective study followed 1298 patients with ATA low-risk DTC for a median of 10.3 years and determined that there was no benefit of RAI therapy with respect to overall or disease-free survival.<sup>767</sup> The National Thyroid Cancer Treatment Cooperative Study Group (NTCTCSG) also found that

RAI treatment for patients with Stage I and II DTC does not influence disease-specific and disease-free survival.<sup>768,769</sup> However, it is important to note that studies are limited in truly determining RAI-associated outcomes due to the low incidence of disease-related mortality and morbidity in this cohort. As a result of these studies, the 2015 ATA guidelines determined that RAI should not be administered routinely for Stage I and II DTC. Since then, several prospective studies have been published regarding RAI administration in patients with low-risk DTC. A randomized Phase III trial (ESTIMABL2) evaluated 776 patients with low-risk DTC treated with total thyroidectomy with or without prophylactic lymph node dissection (pT1a N0 with a sum of the diameters of tumor lesions  $\geq 10$ mm, pT1b N0).<sup>770</sup> Two to 5 months after surgery, in the absence of suspicious lateral neck lymph nodes demonstrated on ultrasound, patients were randomized either to the follow-up group (no RAI) or to the ablation group (1.1 GBq following rhTSH stimulation). Of the 730 patients, the percentage of patients without an event was 95.6% in the non-RAI group compared with 95.9% in the RAI group, which met noninferiority criteria. This Phase III clinical trial demonstrated noninferiority of a follow-up strategy when compared with systematic adjuvant postoperative administration of RAI in patients with low-risk DTC.<sup>770</sup> One potential limitation of these studies is the relatively limited duration of follow-up.

In the select cases where RAI is employed in low-risk patients based on postoperative risk assessment, a low dose of 1.1–1.85 Gbq (30–50 mCi) of <sup>131</sup>I should be administered to reduce the potential for side effects. This conclusion is supported by another open label, randomized controlled factorial trial (HiLo). In this study, 438 patients were split evenly into two groups who received either low-activity RAI (1.1 GBq) or high-activity RAI (3.7 GBq, 100 mCi); they were followed for a median of 6.5 years. The authors found that the cumulative recurrence rates were similar between the low and high activity groups (3 years, 1.5% vs. 2.1%, respectively; 5 years, 2.1% vs. 2.7%; and 7 years, 5.9% vs. 7.3%; HR 1.10 [CI 0.47–2.59];  $p = 0.83$ ).<sup>771</sup> This suggested that use of low-dose RAI for patients with low-risk DTC is noninferior to use of a higher RAI dose as measured by risk of recurrence.<sup>763</sup> Similar findings were observed at 5 years of follow-up in the ESTIMABL1 trial.<sup>764</sup>

**ATA intermediate-risk (low-intermediate and high-intermediate).** Despite limited risk-group specific data examining

TABLE 10. SUMMARY OF RECOMMENDATIONS FOR INITIAL RAI FOLLOWING THYROIDECTOMY<sup>a</sup>

Risk category	Typical RAI recommendation	Recommended <sup>131</sup> I activity level	Goals of therapy
Low	No	1.1–1.85 GBq (30–50 mCi)	None or remnant ablation
Intermediate-low and intermediate-high	Consider	1.1–3.7 GBq (30–100 mCi)	Remnant ablation +/- adjuvant therapy
High	Yes	3.7–5.55 GBq (100–150 mCi)	Remnant ablation and adjuvant therapy
Distant metastases	Yes	3.7–7.4 GBq (100–200 mCi) or consider dosimetry	Treatment of known disease, remnant ablation

<sup>a</sup>Note that these recommendations represent guidelines and that a variety of additional features including patient preference, comorbid conditions, access to care, pre-therapy imaging, and others may influence the decision to treat with RAI as well as the resulting activity level. Consistent with the Martiniq documents, the final recommendation for administered activity should be based on multidisciplinary management recommendations.<sup>760</sup>

RAI, radioactive iodine.

RAI efficacy, RAI adjuvant therapy should be considered in patients with ATA intermediate-risk DTC. Data summarized in the 2015 ATA guidelines suggested that the greatest potential benefit of RAI in this patient cohort may be observed in those with adverse thyroid cancer histopathologies, extensive nodal disease including metastatic nodal disease outside the central neck, postoperative Tg level, and in older patients.<sup>772</sup> In the 2025 guidelines, we have divided this category into low-intermediate and high-intermediate, as not all criteria within the intermediate category predict the same risk of recurrence (Fig. 2 and **Recommendation 28**). These categories should be considered when assessing the potential benefits of RAI administration for an individual patient. Patients with higher risk of iodine-avid recurrent or persistent disease who receive RAI are expected to demonstrate improved outcomes based on retrospective studies. Multivariable-adjusted analyses from SEER suggest that postsurgical RAI treatment is associated with improved overall survival for patients with more aggressive thyroid cancer histologies, such as tall cell, diffuse sclerosing, and insular variants.<sup>773,774</sup> Multivariable-adjusted analyses from SEER also suggest that RAI treatment is associated with improved overall survival in node-positive adults with PTC or pT3 node-negative PTC when the primary tumor is >4 cm or there is evidence of extrathyroidal extension.<sup>775</sup> This study demonstrated that the overall survival rate was greatest in patients aged <45 years, such that over 98% of patients were alive after a median follow-up period of 6.8 years, regardless of RAI treatment status. Individuals over the age of 65 years experienced worse overall survival, such that 73% of patients with T3-node negative or node-positive PTC treated with RAI and 69% of those not treated with RAI were alive at the time of follow-up<sup>775</sup>; in this older subgroup, the absolute risk difference of 4% between the treated and nontreated groups was statistically significant. Lamartina et al. reported conflicting results around the impact of RAI treatment on disease recurrence; in a systematic review, 11 nonrandomized studies suggested benefit, whereas 13 studies did not.<sup>776</sup>

Recent studies support the guideline recommendations to administer RAI in this risk group. In a recent analysis of the NCDB, a total of 21,870 patients with intermediate-risk DTC who underwent total thyroidectomy with or without RAI administration were included and followed for an average of 6 years post-RAI. A total of 15,418 (70.5%) received RAI, and 6452 (29.5%) did not. In a multivariable logistic regression model, which adjusted for demographic and clinical factors, RAI treatment was associated with a 29% reduction in the risk of death, with a hazard risk of 0.71 [CI 0.62–0.82;  $p < 0.001$ ]. For those less than 45 years of age, RAI usage was associated with a 36% reduction in risk of death, with a hazard ratio of 0.64 [CI 0.45–0.92;  $p = 0.016$ ]. In contrast with the findings from prior literature, this study demonstrated improved overall survival in patients with intermediate-risk DTC treated with RAI in both younger (<45 years) and older (>65 years) patients.<sup>775</sup> Similarly, Verburg et al. evaluated 11 retrospective cohort studies in a systematic review, where some demonstrated a benefit of RAI treatment even in T1a PTCs, while others showed no benefit. The authors concluded that unless further randomized prospective studies are conducted which generate other findings, <sup>131</sup>I administration

should be considered in all patients with intermediate-risk DTC with a primary tumor diameter exceeding 1 cm.<sup>777</sup>

One additional benchmark comes from the prospective randomized Adjuvant Selumetinib for differentiated Thyroid cancer, Remission After RAI (ASTRA) trial designed to study use of redifferentiation therapy with selumetinib for first-line RAI treatment. In this study, 62% of patients treated without redifferentiation had persistent or recurrent structural disease after 18 months, raising concern about efficacy of such therapy.<sup>778</sup> However, this study was not designed to evaluate the efficacy of RAI alone. Finally, Tian et al. performed a retrospective analysis of 1349 patients who were treated with RAI versus 138 who were not; they found that not receiving RAI was an independent risk factor for structural and biochemical recurrence and that the non-RAI group had less favorable recurrence-free survival.<sup>779</sup> There are few studies that have evaluated RAI in a cohort of patients who are uniquely at intermediate risk or that can be classified as low-intermediate or intermediate-high risk of recurrence, limiting strong recommendations. Further studies are needed in this group of patients, including those that incorporate somatic genomic testing. RAI adjuvant treatment should be considered for intermediate-risk patients with an administered activity generally ranging from 1.1–3.7 Gbq (30–100 mCi) of <sup>131</sup>I, considering the potential survival and disease-free benefits and limited adverse effects.

**ATA high-risk.** Several prior studies have demonstrated the overall benefit and need for administration of RAI in high-risk patients, as was recommended in the 2015 ATA guidelines. Data from SEER suggest that postsurgical RAI therapy is associated with improved overall survival in patients with PTC and distant metastases (when distant metastases are combined with an age >45 years, tumor size >2 cm, and metastatic lymph nodes at primary diagnosis).<sup>780</sup> SEER data showed that patients with FTC with distant metastases who were treated with postsurgical RAI had double the overall survival when compared with their counterparts who did not receive RAI.<sup>773</sup> The recommendation therefore remains that postsurgical RAI should be administered to patients with ATA high-risk DTC. The suggested activity of <sup>131</sup>I for this group of patients when dosimetry is not available should be 3.7–5.55 GBq (100–150 mCi). For higher doses, especially doses greater than 7.4 GBq (200 mCi), dosimetry is recommended to reduce risk of adverse effects. When RAI is intended for initial adjuvant therapy to treat suspected microscopic residual disease, administered activities up to 5.55 GBq (150 mCi) are generally recommended (in the absence of known distant metastases).

**Patients with known distant metastases.** In patients with initial diagnosis of DTC and distant metastases, RAI therapy is routinely recommended after total thyroidectomy. In this cohort, <sup>131</sup>I activity of at least 3.7 GBq (100 mCi and often greater) is recommended to achieve tumor control. There are two main approaches to choosing the <sup>131</sup>I dose in patients with metastatic DTC: empirical and dosimetry-based treatment. In the first one, most delivered activities are 3.7 GBq (100 mCi), 5.6 GBq (150 mCi), or 7.4 GBq (200 mCi), and the dose is selected based on patient parameters, the nuclear medicine physician experience, and patient preferences. An

alternative strategy is the use of dosimetry employing either maximum tolerated activity (MTA) or lesional dosimetry methods.<sup>781</sup> The goal of MTA dosimetry is to identify the maximum dose that can be administered without exceeding empirically determined thresholds associated with higher risk of toxicity (a dose to the blood of 2 Gy or more, or whole body retained activity of 4.5 GBq or 3.0 GBq in the case of patients with diffuse lung metastases). The routine application of administered activities greater than 5.55–7.4 GBq (150–200 mCi) may exceed the MTA. Tuttle et al.<sup>782</sup> retrospectively analyzed 535 dosimetry studies performed as part of routine clinical care in 328 patients with hypothyroid with apparently normal renal function. They found that administration of 9.25 GBq (250 mCi) would exceed the MTA in 22% of patients <70 years and 50% of patients ≥70 years. Factors associated with a lowering of MTA to less than 9.25 GBq (250 mCi) were age at dosimetry >45 years, female sex, subtotal thyroidectomy, and <sup>131</sup>I-avid diffuse bilateral pulmonary metastases. In conclusion, they suggest that dosimetry-guided RAI therapy may be preferable to fixed-dose RAI treatment strategies in older patients with thyroid cancer and in patients with <sup>131</sup>I-avid diffuse bilateral pulmonary metastases (even when renal function is normal).<sup>782</sup> These results are further supported by Kulkarni et al.<sup>783</sup>

Klubo-Gwiedzinska et al. compared the treatment efficacy and side effects of dosimetry versus empirically guided therapy.<sup>784</sup> In this retrospective study, the authors found a lower rate of progression and a higher rate of remission in the dosimetry-guided group. Deandreis et al. retrospectively analyzed 352 patients with <sup>131</sup>I-avid metastatic DTC treated with RAI by an empirical fixed activity of 3.7 GBq (GR, *n* = 231) or by personalized activity (2.7–18.6 GBq) based on whole-body/blood clearance dosimetry at a single center (*n* = 121).<sup>778</sup> No difference was identified in 5-year overall survival, and they concluded that routine use of whole-body dosimetry without lesional dosimetry provided no overall survival advantage when compared with empirical, fixed RAI activity in the management of patients with DTC with <sup>131</sup>I-avid distant metastases.<sup>778</sup> There is a need for prospective clinical trials to evaluate the ideal RAI dose for metastatic DTC. Until further studies are completed, the suggested administered activity is 3.7–7.4 GBq (100–200 mCi), and dosimetry should be considered for appropriate cases, particularly for patients of advanced age and/or diffuse lung metastases or renal failure.

Should radioiodine be administered for OTC treatment?

#### ■ RECOMMENDATION 33

Outcome data are limited in OTC; thus, specific recommendations regarding use of RAI are not certain. If RAI is not administered empirically, evaluation of iodine avidity with a diagnostic whole-body scan (WBS) may be considered. (*Conditional recommendation, Very low certainty evidence*)

Several small retrospective studies have evaluated the impact of RAI treatment for patients with OTC with inconsistent results. One review of 32 patients with OTC and distant metastasis reported that 53% of the 30 patients (94%) who received RAI demonstrated iodine-avidity; over the 8.3 years reviewed in the study, the median number of RAI treatments was 4 (1–10 doses), with a median cumulative administered

activity of 34.1 GBq (922 mCi) (range, 8.5–56.4 GBq, 230–1523 mCi).<sup>785</sup> Two larger studies, one with 239 patients<sup>786</sup> and the other with 2799 patients,<sup>787</sup> showed conflicting results when comparing the impact of RAI on survival in patients with OTC. Oluic et al. reported no impact on overall survival or disease-specific survival with RAI; they suggested an impact on disease-free survival on univariable analysis but not multivariable analysis.<sup>786</sup> Yang et al. reported that RAI was associated with improved overall survival but not disease-specific survival.<sup>787</sup> NCDB review of 1909 patients with OTC reported that 60.9% received RAI therapy, with improved 5-year and 10-year overall survival.<sup>788</sup>

In contrast, three retrospective studies described below showed no benefit of RAI in patients with OTC. A single-institution review with 50 years of follow-up data reported 41% of the 48 patients with OTC after total thyroidectomy received RAI therapy, but this did not impact disease-free survival.<sup>625</sup> A SEER database review of 172 patients with OTC reported that RAI appeared to have no impact on survival for the 33% of patients who received RAI therapy.<sup>789</sup> A third study of 89 patients with OTC reported that RAI treatment had no impact on survival for the 16% of patients who received it. In this same report, all patients who had distant metastasis underwent initial iodine WBS, with only 3 of 33 patients (9%) with bone metastasis showing avidity and 2 of 27 patients (7%) with lung metastasis showing avidity.<sup>790</sup> Improved ability to employ Tg levels to facilitate monitoring in patients with low- and high-intermediate or high-risk OTC may serve as a potential rationale for RAI administration for individual patients. In sum, current data preclude a definitive recommendation with respect to RAI; further research is needed.

How should patients be prepared for RAI administration?

#### ■ RECOMMENDATION 34

- In patients with DTC in whom RAI remnant ablation or adjuvant therapy is planned, preparation with rhTSH stimulation is preferred over thyroid hormone withdrawal. (*Strong recommendation, High certainty evidence*)
- In patients with DTC of any risk level with significant comorbidity that may preclude thyroid hormone withdrawal prior to RAI administration, rhTSH preparation should be considered. (*Good Practice Statement*)
- If thyroid hormone withdrawal is planned prior to RAI therapy or diagnostic testing, LT4 should be withdrawn for 3–4 weeks. If LT4 is withdrawn for ≥4 weeks, substitution of LT4 with liothyronine (LT3) in the initial weeks should be considered. In such circumstances LT3 should be withdrawn for at least 2 weeks. Serum TSH should be measured prior to radioisotope administration to evaluate the degree of TSH elevation. (*Good Practice Statement*)
- A goal of TSH >30 mIU/L should be employed in preparation for RAI therapy or diagnostic testing. (*Good Practice Statement*)
- In patients with known distant metastases, either LT4 withdrawal or rhTSH can be used for preparation. (*Conditional recommendation, Low certainty evidence*)

Early observational research established that TSH stimulation is required before RAI ablation/therapy or scanning. It is recommended that a TSH level  $>30$  mIU/L be established in preparation for successful RAI absorption. TSH stimulation can be achieved by either thyroid hormone withdrawal or rhTSH stimulation. Lee et al. reported on an open-label, single-center study with 291 patients with DTC randomized to (a) withdrawal of LT4 for 4 weeks ( $n = 89$ ), or (b) withdrawal of LT4 for 4 weeks with substitution of LT3 for the first 2 weeks ( $n = 133$ ), or (c) recombinant human TSH (with withdrawal of LT4 for a few days from the time of the first rhTSH injection to radioisotope administration) ( $n = 69$ ).<sup>791</sup> All patients received RAI with 1.1 GBq (30 mCi) for remnant ablation and were prescribed a low-iodine diet pre-ablation for 2 weeks. The baseline characteristics (including pre-ablation urinary iodine measurements) were well balanced among groups. The pre-ablation TSH was  $>30$  in all patients in this trial, with no significant difference in mean pre-ablation TSH levels. The primary outcome, which was the rate of successful remnant ablation at 12 months, did not differ between groups (range, 91.0–91.7%). Administration of questionnaires in a double-blinded fashion found no significant difference in QoL during preparation for RAI ablation between the LT4 withdrawal group and the LT4 withdrawal with LT3 substitution group; however, QoL in both withdrawal groups before ablation was significantly worse than after rhTSH preparation.<sup>791</sup> Therefore, direct LT4 withdrawal or LT4 withdrawal with substitution of LT3 in initial weeks seem to be associated with similar short-term QoL and hypothyroidism symptoms; remnant ablation success rates appear to be comparable between all preparation methods.

There has been some uncertainty about the optimal TSH level following thyroid hormone withdrawal and before RAI administration when long-term outcome effects are considered. There is conflicting observational evidence surrounding whether any specific TSH level pre-RAI administration is associated with greater success at remnant ablation.<sup>792,793</sup> Fallahi et al. reported that a pre-RAI TSH level of  $>25$  mIU/L following LT4 and LT3 thyroid hormone withdrawal was associated with a significantly increased likelihood of successful remnant ablation (OR 2.36 [CI 1.28–4.35];  $p = 0.006$ ) after adjustment for RAI activity, baseline serum Tg, on-LT4 TSH level, patient sex, age, histology, baseline RAI uptake, and extent of surgery.<sup>792</sup> According to a more recent retrospective study, 689 patients were categorized into three groups (TSH levels of  $<30$ , 30–70, and  $\geq 70$  mIU/L), and the response to RAI was evaluated after a follow-up of 6–8 months. They found that a pre-RAI TSH level of 30–70 mIU/L has a higher rate of complete response compared with a TSH level of  $<30$  mIU/L.<sup>794</sup> However, in another recent retrospective study that included 1873 patients without distant metastases referred for postoperative adjuvant RAI, Vrachimis et al. reported that TSH levels at the time of RAI are not related to ablation success rates, recurrence-free survival, or DTC-related mortality.<sup>795</sup> Most patients enrolled in the previously mentioned study (around 80%) were low-risk, so findings should not be extended to other risk groups.

rhTSH is currently approved by the U.S. Food and Drug Administration (FDA) and Health Canada for use in preparation for RAI remnant ablation in patients who have undergone a near-total or total thyroidectomy for DTC and who do not have evidence of distant metastases. Data from a

compassionate use, observational study suggest that rhTSH raises serum TSH measurements in patients who are unable to mount an endogenous TSH increase and reduces the risk of hypothyroid-related complications in patients with significant medical or psychiatric comorbidities.<sup>796</sup> rhTSH therefore is the preferred approach for patients with significant medical (central nervous system or respiratory compromise, congestive heart failure, coronary artery disease) or psychiatric diseases in whom a hypothyroid state can produce serious complications.<sup>796</sup>

Preparation with rhTSH for RAI for adjuvant therapy also is the preferred method of preparation for such patients who do not have evidence of distant metastases based on data demonstrating similar efficacy and fewer side effects versus thyroid hormone withdrawal. Several randomized controlled trials in patients with low- and intermediate-risk DTC have measured remnant ablation outcomes using rhTSH compared with thyroid hormone withdrawal, concluding that there are no differences between the two methods.<sup>797</sup> Data from 1535 patients across seven clinical trials were described in a meta-analysis that suggested that the rates of remnant ablation success did not differ significantly using rhTSH compared with thyroid hormone withdrawal (risk ratio 0.97 [CI 0.94–1.01]).<sup>797</sup> A pooled analysis suggested that QoL was superior on the day of remnant ablation in the rhTSH group, with no significant difference between the groups 3 months later.<sup>797</sup> Another meta-analysis including six of the previously mentioned randomized controlled trials also suggested that the success of remnant ablation did not differ between patients prepared with rhTSH or thyroid hormone withdrawal.<sup>798</sup> Patients who underwent thyroid hormone withdrawal had a worse health-related QoL outcome, attributed to hypothyroid symptoms.<sup>798–800</sup>

Prospective data comparing rhTSH with thyroid hormone withdrawal are lacking for patients with DTC with distant metastases. However, in a retrospective analysis of 175 patients with iodine-avid metastatic disease to lungs and/or bone, the authors observed no significant difference in overall survival after a mean follow-up period of 5.5 years between patients prepared with rhTSH alone for all RAI treatments, thyroid hormone withdrawal for all RAI treatments, or thyroid hormone withdrawal for initial treatment followed by rhTSH for subsequent treatment(s).<sup>801</sup> In this study, whole-body and blood dosimetry studies were performed in all patients; therefore, the results should not be extrapolated to RAI fixed dosing. Some important differences between groups in this study that could have affected the findings included differences in cumulative RAI activities received and longer follow-up in groups who had thyroid hormone withdrawal.<sup>801</sup> Although the authors performed a multi-variable analysis examining predictors of overall survival (finding that the method of thyrotropin stimulation was not significant), their model did not adjust for all variables. In a two-center retrospective analysis comparing responses with treatment using RECIST 1.1 criteria in 56 patients with distant metastatic disease prepared with either rhTSH or thyroid hormone withdrawal prior to RAI administration, there were also no differences in outcomes between groups after a mean follow-up of about 6 years.<sup>802</sup> There were important baseline differences between groups, such as rates of use of dosimetry and mean cumulative RAI activity. Rates of xerostomia,

leukopenia, or thrombocytopenia did not differ significantly between treatment groups. The overall mortality rate was 20% in the rhTSH group (3/15) and 7.3% in the thyroid hormone withdrawal group (3/41,  $p = 0.188$ ),<sup>802</sup> although the study was probably not large enough to assess differences in this important outcome. The findings of the study cannot be readily extrapolated to fixed dosing RAI treatment regimens, because 80% of the individuals in the rhTSH group and 46% in the thyroid hormone withdrawal group received dosimetry-based RAI treatment. Randomized controlled trials comparing rhTSH with thyroid hormone withdrawal preparation pre-RAI treatment are needed to guide clinical care in patients with high-risk DTC.

Another scenario in which rhTSH is the preferred method of preparation is for patients with limited pituitary gland function due to previous head trauma/surgery/radiation and patients with obesity. In these settings, the patient would often have a suboptimal TSH elevation despite thyroid hormone withdrawal. It is important to consider that secretory metastatic DTC and large thyroid remnants may also cause suboptimal TSH response to hormone withdrawal; therefore, this uncommon possibility should be excluded.

Should a low-iodine diet be prescribed prior to RAI administration?

#### ■ RECOMMENDATION 35

A low-iodine diet for approximately 1–2 weeks should be used for patients undergoing RAI remnant ablation or treatment. (*Good Practice Statement*)

There are currently no randomized controlled trials that assess the impact of a low-iodine diet on the efficacy of RAI for any of its uses, limiting the strength of this recommendation. A low-iodine diet is generally defined as a restriction in iodine consumption to <50 mcg/day. Consultation prior to the administration of RAI should include a series of questions to confirm adherence to a low-iodine diet and exclude other known high-dose iodine sources (e.g., intravenous contrast within 3 months or amiodarone use) to prepare for the optimal timing of RAI imaging/therapy. Although urinary iodine should not be used to determine an individual's long-term iodine status, it can be employed as a measure of iodine intake over the prior several days to confirm patients' compliance with a low-iodine diet or to ensure clearance of amiodarone or IV contrast.

However, there are unresolved questions regarding the actual impact of a low-iodine diet on the outcome of remnant ablation,<sup>803</sup> with the best available evidence largely restricted to retrospective analyses using historical controls.<sup>804,805</sup> In a study including 120 patients, the use of a 4-day low-iodine diet (with seafood restriction for 1 week) was associated with a higher rate of remnant ablation success (defined by absent neck activity and stimulated Tg <2 ng/mL) compared with normal diet.<sup>804</sup> In a study of 94 patients comparing a more stringent low-iodine diet with a less stringent diet of restricted salt/vitamins/seafood, each for 10–14 days, there was no significant difference in the rate of successful remnant ablation, using a visually negative WBS to define outcome.<sup>805</sup> The optimal stringency and duration of a low-iodine diet (if any) prior to therapeutic RAI administration are not known. In a randomized controlled trial including 46 patients, the increase in uptake and reduction in urinary iodine excretion did not

significantly differ between patients who followed a low-iodine diet for 2 weeks compared with 3 weeks prior to RAI scanning,<sup>806</sup> suggesting that there may be little reason to extend the low-iodine diet beyond 2 weeks. A lack of association between urinary iodine excretion and the rate of successful thyroid ablation has been reported in patients not specifically prescribed a low-iodine diet<sup>807</sup>; absence of a specific low-iodine diet comparison group in this study may limit the generalizability of the findings to situations where a specific low-iodine diet is prescribed. Notably, high urinary iodine and excessive iodine uptake have been linked to failure of remnant ablation.<sup>808</sup> More recent studies support 1–2 weeks as the optimal duration for a low-iodine diet.<sup>809–811</sup>

Although low-iodine diets may be cumbersome or unpalatable, serious side effects are relatively infrequent,<sup>803</sup> with case reports of potentially life-threatening hyponatremia occurring most often in patients who (i) are elderly and subject to thyroid hormone withdrawal, (ii) have metastatic disease, (iii) are concurrently treated with thiazide diuretics, and (iv) are on a low-iodine diet for longer than a week.<sup>812</sup> It is important to avoid restriction of non-iodized salt during the low-iodine diet, since this may be associated with hyponatremia, especially in patients undergoing thyroid hormone withdrawal.

When and how should diagnostic radioiodine WBS be performed?

#### ■ RECOMMENDATION 36

Postoperative diagnostic <sup>123</sup>I or low-dose <sup>131</sup>I WBS may be considered for patients undergoing RAI treatment prior to their therapeutic (ablative, adjuvant, or treatment) administration to help guide treatment planning. (*Conditional recommendation, Low certainty evidence*)

RAI is a theranostic agent, as it provides both imaging and therapy in patients with DTC. Imaging with RAI is performed using either <sup>123</sup>I or low-dose <sup>131</sup>I WBS. Other methods including <sup>124</sup>I positron emission tomography (PET) are employed in investigational settings. A variety of methods for WBS with <sup>123</sup>I have been proposed and implemented. In many cases, <sup>123</sup>I may be preferred for scanning due to the lower radiation dose and less concern for “stunning,”<sup>813</sup> where diagnostic activity of RAI is thought to reduce subsequent uptake of the therapeutic dose. However, this concept is controversial and possibly related to destruction of thyroid tissue by the diagnostic dose of <sup>131</sup>I.<sup>814,815</sup> In some cases, <sup>131</sup>I may be preferred due to lower cost. In practice, both options are considered reasonable,<sup>816</sup> although <sup>123</sup>I may be preferable if it is available.<sup>817</sup> When performed, diagnostic WBS should follow patient preparation similar to RAI therapy.<sup>818</sup> Technical parameters for acquisition of these scans have been summarized in practice guidelines from the Society of Nuclear Medicine and Molecular Imaging (SNMMI).<sup>809</sup> Diagnostic WBS may be performed either as surveillance or as a part of RAI treatment protocols.

One of the common indications for WBS is to help guide subsequent treatment with RAI. In general, the WBS includes whole body images as well as a measurement of uptake in the thyroid bed. These scans can provide useful information about (i) the retained activity in the thyroid bed and (ii) the presence of regional or distant metastatic disease.

This information, in turn, can be used to inform the subsequent treatment dose along with standard clinical and laboratory assessment parameters as detailed in other sections. The value of pre-therapy diagnostic WBS has been documented in several prior studies that show diagnostic WBS may lead to changes in management at the time of RAI therapy.<sup>819–822</sup> For example, Van Nostrand et al. found that in a cohort of 355 patients, 29% had findings on diagnostic WBS that would alter management prior to treatment.<sup>823</sup> In a single-center study, Chen et al. found that a pre-therapy <sup>123</sup>I scan provided critical information in 31/122 (25%) patients.<sup>824</sup> More recently, in a retrospective review, Song et al. found that pre-therapy scanning altered the selected administered activity for RAI therapy in 49% of cases.<sup>825</sup> Use of pre-therapy imaging is particularly important when higher administered activities are considered. This is because higher activities, such as 7.4 GBq (200 mCi), will exceed safe MTA thresholds in some patients (e.g., the elderly and those with renal dysfunction).<sup>782</sup> For these higher doses, pre-therapy imaging is strongly recommended, combined with blood-based dosimetry, for better determination of a safe MTA.

Overall, representative changes in management that can be obtained with use of pre-therapy WBS include (i) detection of very large thyroid remnants with greater than 15% uptake, which may be an indication for additional surgery; (ii) detection of an insignificant thyroid remnant, which, when combined with a Tg level of <1 ng/mL, may obviate the need for RAI therapy or lead to a dose reduction; and (iii) the detection of clinically unsuspected nodal or distant metastatic disease. These findings may alter the decision to pursue RAI treatment and could result in the modification of the selected activity.

Should post-therapy WBS be performed?

■ **RECOMMENDATION 37**

Post-RAI therapy scans should be performed after RAI treatment. (*Strong recommendation, Moderate certainty evidence*)

When therapeutic <sup>131</sup>I is administered, a post-therapy WBS generally should be obtained, since it provides critical prognostic information about the iodine sensitivity of tissues as well as the presence or absence of residual or metastatic disease. This scan utilizes the RAI dose administered as part of therapy, so no additional radiopharmaceuticals are administered. Post-therapy imaging (generally 2–10 days after treatment dose administration) may identify sites of disease even among patients with negative Tg measurements.<sup>826</sup> For example, Park et al. found that in a cohort of 824 postoperative patients, 52 (6.3%) demonstrated functioning metastases on post-therapy scans despite negative serum Tg measurements.<sup>827</sup> Since larger activities of <sup>131</sup>I are administered at the time of therapy compared with the pre-treatment diagnostic scan, additional sites of disease may be identified on post-therapy scanning. Fatourechi et al. found that 13% of 117 post-treatment scans had abnormal uptake not identified on pre-therapy scan, and 9% experienced changes in management based on the differential biodistribution observed.<sup>828</sup> Therefore, a post-therapy scan after RAI treatment should be performed.

Should single photon emission computed tomography with computed tomography be performed with the WBS?

■ **RECOMMENDATION 38**

Single photon emission computed tomography with computed tomography (SPECT/CT) may be performed when available with diagnostic or post-treatment WBS. (*Conditional recommendation, Low certainty evidence*)

SPECT/CT enables more precise localization of areas of radionuclide uptake. This is because the tomographic map of the distribution of the radioactivity may be precisely overlaid upon the CT map, allowing more accurate localization than is possible with planar imaging alone. In many cases, the more accurate imaging provided with SPECT/CT enables discrimination between benign and malignant foci of RAI uptake. For example, Tharp et al. found that SPECT/CT imaging had an incremental diagnostic value over planar imaging alone in 41/71 (57%) patients by characterizing localization of regional or distant metastatic disease or identifying benign variants.<sup>829–831</sup> Similar findings have been replicated across a variety of studies, including systematic reviews.<sup>819,832–836</sup> While SPECT/CT is more accurate in providing diagnostic information, it may not be available at all centers, and it slightly increases the imaging time and cost. However, when available, it should be considered based on the additional information it provides.

How should patients be educated regarding radiation safety?

■ **RECOMMENDATION 39**

Patients should be provided oral and written instructions before preparation for RAI begins to minimize exposure to their families and members of the public, consistent with guidelines in the country where therapy is performed (e.g., in the United States, those of the Nuclear Regulatory Commission). (*Good Practice Statement*)

Administration of RAI generally is performed as an outpatient procedure. In this context, it is imperative to provide proper information to patients to minimize radiation exposure to their families and members of the public. For example, in the United States, release after RAI treatment is subject to regulatory control by the U.S. Nuclear Regulatory Commission, as stated in Code of Federal Regulations Title 10, Part 35, Section 35.75. All patients receiving RAI for DTC are subject to these regulations. Beyond these requirements, the principles of radiation safety are guided by ALARA (“as low as reasonably achievable”). This topic is reviewed extensively by the ATA,<sup>837</sup> the Nuclear Regulatory Commission,<sup>838</sup> the SNMMI,<sup>839</sup> the National Council on Radiation Protection and Measurements,<sup>840</sup> and the International Commission on Radiological Protection.<sup>841</sup> Since <sup>131</sup>I emits both gamma and beta radiation, there is potential for radiation exposure and contamination through bodily fluids. Models can be used to calculate the time during which a patient should follow precautions to protect others. Some controversy exists concerning which model most accurately predicts radiation exposure.<sup>842</sup> Broadly speaking, key parameters include biological half-life (determined by extent of disease, avidity for <sup>131</sup>I), time of exposure, distance from source, and shielding. A key assumption often used is an “occupancy factor” (i.e., time spent <1 m from the patient) of <0.25. Recent data indicate that more traditional models overestimate

radiation exposure contamination (i.e., produced by body fluids or waste).<sup>843</sup> Length of time precautions should be determined by calculations using an appropriate model. Breastfeeding and lactation must cease prior to treatment (see **Recommendation 43**). In general, release to home is preferred; release to hotel is discouraged. These instructions must be provided to patients in writing and documented in the medical record. If these instructions and regulations are followed, radiation exposure to family and friends of patients undergoing RAI, as well as to the public and health care personnel, is minimal.

How do you counsel and minimize risks of RAI side effects to the salivary glands and lacrimal ducts?

#### ■ RECOMMENDATION 40

- A. Patients should be counseled that RAI treatment may be associated with (acute and chronic) salivary gland morbidity, lacrimal duct stenosis, and potential risk of secondary malignancies. (*Good Practice Statement*)
- B. For prevention of salivary gland side effects after RAI, general measures including hydration are recommended.<sup>844</sup> (*Good Practice Statement*)
- C. Patients with xerostomia are at increased risk of dental caries and should discuss preventive strategies with their dental health professional. (*Good Practice Statement*)
- D. Surgical correction should be considered for nasolacrimal outflow obstruction, which often presents with excessive tearing (epiphora) but also predisposes to infection. (*Good Practice Statement*)

Salivary gland epithelium expresses the Na, I symporter (NIS). Therefore, it is not surprising that salivary gland side effects are common after RAI treatment, with both acute and chronic toxicity noted. For this reason, it is important to counsel patients before treatment that significant morbidity can occur in the weeks following RAI administration in the form of salivary gland swelling, salivary pain, and dryness of the mouth. Rarely, sequelae can become chronic and severe, associated with dry mouth and increase in dental caries and interference with taste.

Grewal et al. reported that in the first year after RAI ablation, acute salivary gland side effects occurred in 39% of a cohort of 262 patients (66% women, 93% PTC; single oral administration, median 5.21 GBq [141 mCi]).<sup>844</sup> There was recovery from these adverse effects in most patients; persistent side effects after a median of 7 years were observed in less than 5% of the cohort. A dose–response relationship was seen among this group. A statistically significant dose–response effect was seen between administered activity of RAI and development of salivary gland swelling ( $p = 0.001$ , logistic dose–response curve) but not with dry mouth ( $p = 0.63$ ), altered taste ( $p = 0.27$ ), or salivary gland pain ( $p = 0.152$ ). Salivary gland side effects developed in 14% of patients receiving administered activities of 1.1 GBq (30 mCi); administered activities of  $\geq 2.8$  GBq (75 mCi) were associated with symptoms in 40% of patients ( $p = 0.046$ ). Patients prepared with thyroid hormone withdrawal received higher <sup>131</sup>I activity than those prepared with rhTSH, yet thyroid hormone withdrawal was associated with a lower rate of salivary gland swelling

(10% vs. 20%,  $p = 0.017$ ). There were no differences in the development of dry mouth, altered taste, or salivary gland pain based on type of preparation for RAI.<sup>838</sup>

Some centers suggest use of sour lozenges to promote salivary secretion after RAI therapy, but other groups consider it harmful,<sup>845</sup> and there is no evidence of reduction in salivary gland radiation-absorbed dose with vitamin C tablets.<sup>846</sup> Hence, the role of sour candies to increase salivary secretion after RAI is uncertain. A recent study reported promising reduction in acute symptoms of xerostomia and sialadenitis with bethanechol, a parasympathomimetic, after thyroid ablation.<sup>847</sup> This drug also has shown promise in prevention of xerostomia and sialadenitis caused by external beam radiation of the head and neck.<sup>848</sup> For salivary gland pain and swelling (radiation-induced sialadenitis), most patients respond well to nonsteroidal anti-inflammatory drugs, but occasionally a short course of steroids is required for severe symptoms.

There is the possibility of cumulative dose-related early- and late-onset complications such as salivary gland damage, dental caries,<sup>849</sup> nasolacrimal duct obstruction,<sup>850</sup> secondary malignancies,<sup>851–855</sup> and (rarely) long-term dysphagia.<sup>856</sup> As a result, it is important to ensure that the benefits of RAI therapy (and its repeated use) outweigh the potential risks. There is probably no administered activity of RAI that is completely safe, nor is there any maximum cumulative administered dose that could not be used in selected situations. In general, with higher (single and aggregate) administered activities, there are increased risks of side effects.

For acute transient loss of taste or change in taste and sialadenitis, recommended measures to prevent damage to the salivary glands have included hydration, sour candies, amifostine, and cholinergic agents,<sup>857</sup> but evidence is insufficient to recommend for or against these modalities. One study suggested sour candy may increase salivary gland damage when given within one hour of RAI therapy, as compared to starting its use 24 hours post-therapy.<sup>845</sup> Another study showed that the use of lemon slices within 20 minutes of <sup>123</sup>I administration resulted in increased radiation absorbed dose to the salivary glands.<sup>858</sup> Other studies have suggested that early use and multiple administered doses of lemon juice transiently decreased radiation exposure to the parotid glands,<sup>859,860</sup> so the exact role and details of use of sialagogues to prevent salivary gland damage remain uncertain. Patients with painful sialadenitis may receive pain relief from local application of ice. For chronic salivary gland complications such as dry mouth and dental caries, cholinergic agents may increase salivary flow.<sup>857</sup> Interventional sialendoscopy has been shown in several small studies to be an effective treatment in patients with radioiodine-induced sialadenitis that is unresponsive to medical therapy.<sup>861–863</sup>

How should patients be counseled regarding the risk of second primary malignancy after receiving RAI therapy?

#### ■ RECOMMENDATION 41

Patients should be counseled about the risks of second primary malignancy (SPM) after RAI treatment for DTC. The absolute increase in risk attributable to RAI appears to be small and does not warrant additional screening for SPM. (*Good Practice Statement*)

Long-term follow-up studies report a low risk of SPM (e.g., breast, colorectal, kidney, salivary cancers, and

leukemia) in long-term survivors of DTC following treatment with RAI.<sup>851,852,864–866</sup> The incremental additional risk of SPM following RAI appears to be low<sup>864</sup> and does not justify enhanced cancer screening. One meta-analysis demonstrated a RR of 0.98 comparing RAI-treated with nontreated patients with DTC; an increased incidence of acute myeloid leukemia, a decreased incidence of multiple myeloma, and no change in the risk of solid tumors were reported.<sup>867</sup> A meta-analysis of two large multicenter studies showed that the risk of SPM was significantly increased with a RR of 1.19 ([CI 1.04–1.36];  $p < 0.010$ ) relative to patients with DTC not treated with RAI, although the absolute increase in risk attributable to RAI was small.<sup>853</sup> The risk of leukemia was increased in patients with DTC treated with RAI, with a RR of 2.5 ([CI 1.13–5.53];  $p < 0.024$ ).<sup>853</sup> A study from the SEER registry demonstrated a small but statistically significant increase in the risk of chronic and acute myeloid leukemia in patients treated with RAI.<sup>868</sup> The excess risk of leukemia was greater in patients aged <45 years (standardized incidence rate [SIR] 5.32 [CI 2.75–9.30] for those aged <45 years vs. an SIR of 2.26 [CI 1.43–3.39] in older individuals).<sup>869</sup> A population-based study of adults <30 years and children demonstrated an increased incidence of solid tumors following RAI treatment of 3.7 Gbq (100 mCi) or more.<sup>870</sup> The risk of SPM appears to be related to the administered activity of <sup>131</sup>I,<sup>852</sup> with an excess absolute risk of 14.4 for solid cancers and 0.8 for leukemias per GBq (1 GBq = 27 mCi) at 10,000 person-years of follow-up. Pasqual et al. suggested that RAI treatment for DTC diagnosed in childhood or young adulthood was associated with an increased risk of both leukemia and several solid tumors.<sup>866</sup> Studies by Teng et al. and Seo et al. also reported increased leukemia risk at doses above 5.5 GBq (150 mCi).<sup>871</sup> There also appears to be an increased risk of breast cancer in women with DTC; however, it is uncertain if this is due to RAI or other factors.<sup>851,855,872,873</sup> Reinecke et al. performed a systematic review and reported ranges of risk for SPM of 1.14–1.84 for patients with DTC treated with RAI versus those who did not receive RAI, but that quality of evidence was considered “very low.”<sup>864</sup> The risk of second hematological malignancies was higher (ranged from 1.30 to 2.50), and the quality of evidence was considered “low.”<sup>864</sup> Taken together, the evidence from studies with large number of patients suggests a small dose-related increase in SPM following RAI. Further studies to identify subgroups of patients at greatest versus lowest risk for SPM are needed to better individualize risk assessment for patients. The use of laxatives may decrease radiation exposure for the bowel, particularly in patients treated after prolonged thyroid hormone withdrawal; vigorous oral hydration reduces exposure of the bladder and gonads.<sup>809,839,874</sup>

What other testing should patients receiving RAI therapy undergo?

#### ■ RECOMMENDATION 42

Patients receiving therapeutic administration of RAI should have a baseline complete blood count and assessment of renal function. (*Good Practice Statement*)

Published data indicate that when administered activities remain below 200 cGy to the bone marrow, minimal transient effects are noted in white blood cell and platelet counts.<sup>875</sup> Transient abnormalities in blood counts may be seen after

RAI,<sup>870</sup> but they generally return to baseline. Persistent mild reductions in white blood cell counts and/or platelets have been seen in some patients who have received multiple RAI therapies. Radiation to the bone marrow is impacted by several factors, including renal function. The kidneys are a major means of iodine excretion from the body, and physiological radioisotope study research in non-thyroidectomized individuals has shown that renal impairment significantly reduces RAI excretion.<sup>871</sup> In patients with significant renal failure, dosimetry-guided therapy should be considered. Females of reproductive age should have a negative pregnancy test prior to receiving RAI (see **Recommendation 43**).

How should patients be counseled about RAI therapy and pregnancy, nursing, and gonadal function?

#### ■ RECOMMENDATION 43

- A. Female patients of reproductive age receiving RAI therapy should have a negative screening evaluation for pregnancy prior to RAI administration and avoid pregnancy for at least 6 months after receiving RAI. (*Good Practice Statement*)
- B. RAI should not be given to nursing female patients. Depending on the clinical situation, RAI therapy should be deferred until lactating women have stopped breast-feeding or pumping for at least 3 months. A diagnostic <sup>125</sup>I scan may be performed in recently lactating women to detect breast uptake that may warrant deferral of therapy. (*Good Practice Statement*)
- C. Male patients receiving cumulative radioiodine activities >14.8 GBq (400 mCi) should be counseled regarding potential risks of infertility. (*Good Practice Statement*)
- D. Female patients receiving RAI should be counseled that such therapy has not been shown to impact future fertility. (*Good Practice Statement*)

Female patients should undergo pregnancy testing prior to RAI treatment. Treatment with <sup>131</sup>I is contraindicated during pregnancy due to direct radiation to the developing embryo and fetus, as well as concentration and potential destruction of the developing fetal thyroid gland after about 12 weeks gestation. NIS is expressed in the placenta, and iodine is transported from the mother to the developing fetus; in addition to the direct effects of RAI in pregnancy from circulating <sup>131</sup>I on kidneys, bladder and bone marrow, there are recognized effects of radiation on the ovaries.<sup>876–878</sup> Temporary amenorrhea/oligomenorrhea occurs in 8–27% of menstruating women within the first year after RAI for DTC.<sup>879</sup> Although the numbers of patients studied are small, long-term rates of infertility, miscarriage, and fetal malformation do not appear to be elevated in women after RAI.<sup>879–881</sup> One recent large retrospective cohort study demonstrated that RAI treatment was associated with delayed childbearing and lower birth rates in later years, although it is unclear whether this is due to reproductive choice or reproductive health.<sup>882</sup> Another large retrospective study suggested that pregnancy should be postponed for 1 year after RAI administration because of an increased miscarriage rate,<sup>883</sup> although this was not confirmed in a subsequent study.<sup>884</sup>

A long-standing recommendation after RAI therapy for hyperthyroidism or thyroid cancer has been to wait at least 6 months after therapy before pregnancy. Several observational studies provide a basis for recommendations around the timing of pregnancy after  $^{131}\text{I}$  therapy. A large retrospective population-based cohort study from Korea utilizing the Health Insurance Review and Assessment database identified 10,842 women (out of 111,459 women of childbearing age) with thyroid cancer who then became pregnant. They assessed the impact of surgery or surgery and RAI on obstetrical complications and pregnancy outcomes. Overall, there were no differences in the assessed outcomes if pregnancy occurred more than 6 months after RAI was administered. When pregnancy occurred less than 6 months after RAI, there was a small but significant increase in congenital malformations in the offspring (OR 1.74 [CI 1.01–2.97]).<sup>885</sup>

RAI is also concentrated in lactating breast tissue. Therefore, RAI should not be given to females who are nursing.<sup>837,886–890</sup> In order to reduce radiation dose to the maternal breasts, cessation of breast feeding for 3 months prior to RAI therapy is recommended. A diagnostic  $^{123}\text{I}$  scan may be employed in recently lactating female patients to detect breast uptake that may warrant deferral of therapy, especially if more urgent treatment is desired.<sup>823</sup> Dopaminergic agents might be useful in decreasing breast exposure in recently lactating female patients, although caution should be exercised given the risk of serious, albeit rare, side effects, including cardiovascular, neurological, and psychiatric disorders associated with their routine use to suppress postpartum lactation.<sup>891</sup>

In males, RAI therapy may be associated with a temporary reduction in sperm counts and elevated serum follicle-stimulating hormone (FSH) levels.<sup>892,893</sup> A small study of thyroidectomized male patients receiving an ablative administration of  $^{131}\text{I}$  that averaged 1.256 GBq (33.9 mCi) measured total (beta and gamma) doses to the testes; these ranged from 30 to 43 uGy/MBq.<sup>894</sup> RAI therapy does not affect serum testosterone concentrations in males, but it is associated with a temporary elevation in serum FSH and a reduction in inhibin B levels.<sup>895–897</sup> In general, serum FSH and inhibin B levels normalize within 18 months from the last administration of RAI. Reduced normokinetic sperm counts after  $^{131}\text{I}$  therapy also have been reported, but they returned to normal when evaluated at 12 months.<sup>895</sup> A longitudinal prospective multicenter study observed no DNA fragmentation in sperm, but a statistically significant increase in chromosomal abnormalities 3 months after a single  $^{131}\text{I}$  ablative dose with activity of 3.7 GBq.<sup>896</sup> The slight increase in chromosomal abnormalities persisted 13 months after therapy.<sup>896</sup> Although data are limited, it has been recommended that males who receive  $^{131}\text{I}$  wait at least 120 days (the lifespan of sperm) after  $^{131}\text{I}$  therapy before attempting conception or providing a sperm sample for assisted reproduction.<sup>898</sup>

Higher cumulative activities (18.5–29.6 GBq, 500–800 mCi) in male patients are associated with an increased risk of persistent elevation of serum FSH levels, but fertility and risks of miscarriage or congenital abnormalities in subsequent pregnancies are not changed with moderate RAI activities (~7.4 GBq, 200 mCi).<sup>899</sup> Permanent male infertility is unlikely with a single ablative dose of RAI, but theoretically, there could be cumulative damage with multiple treatments.

It has been suggested that sperm banking be considered in males who receive cumulative RAI activities  $\geq 14.8$  GBq (400 mCi).<sup>893</sup> Gonadal radiation exposure is reduced with good hydration, frequent micturition to empty the bladder, and avoidance of constipation.<sup>900</sup>

A retrospective study among 64 women with a history of thyroid cancer treatment who underwent *in vitro* fertilization/intracytoplasmic sperm injection, compared with 320 matched control women, found no difference in fertility treatment success or pregnancy outcomes in women treated for thyroid cancer.<sup>901</sup> RAI therapy has been recognized as influencing long-term ovarian function, resulting in significant decreases in ovarian reserve.<sup>902–904</sup> A systematic review and meta-analysis examined 36 studies that compared pregnancy rates and ovarian function in menopause in thyroid cancer patients with and without RAI treatment to controls. There were no differences in pregnancy rates after RAI, but a slight reduction in anti-Müllerian hormone levels 1 year after RAI and a slightly earlier menopause, averaging 49.5 years old compared with 51 years old in controls.<sup>879</sup>

What is the role of radiotherapy, with or without chemotherapy, in patients with DTC?

#### ■ RECOMMENDATION 44

- A. Adjuvant external beam radiotherapy (EBRT) for patients with DTC with high-risk features for locoregional disease progression (such as aggressive histologic subtype, gross extrathyroidal extension, positive margins, and visceral or soft tissue invasion) may be considered in select cases, especially if the expected disease progression would not be amenable to salvage surgery. The potential benefit of improving locoregional relapse-free survival must be weighed against the absence of data demonstrating improvement in overall survival and the known risks of clinically meaningful toxicity. (**Conditional recommendation, Low certainty evidence**)
- B. EBRT with or without concurrent chemotherapy in patients with DTC with gross residual disease in the postoperative setting or with locally advanced unresectable disease may be considered in select patients who may benefit from improved locoregional control. EBRT with or without concurrent chemotherapy may increase locoregional control but also causes acute- and long-term treatment-related toxicity. (**Conditional recommendation, Low certainty evidence**)

Surgery is the mainstay of treatment for DTC, in part to achieve locoregional disease control and reduce the risk of recurrence, particularly involving critical anatomical structures, such as the larynx, trachea, esophagus, and recurrent laryngeal nerves. Surgery, with or without RAI administration, will achieve locoregional control in many patients with DTC. Risk factors for progression include older patient age, unfavorable histology, the presence of macroscopically positive margins or gross residual disease, tumor dissection off the recurrent laryngeal nerve, trachea or larynx, and gross extrathyroidal extension.<sup>905–907</sup> Locoregional recurrence can contribute significantly to morbidity and even mortality in patients with DTC. For patients with distant metastases, the

impact of locoregional disease progression must be considered in the context of the overall prognosis.

The role of EBRT to reduce the risk of locoregional recurrence or progression is debated, primarily because of the morbidity resulting from EBRT to the neck and lack of solid data demonstrating improvement in outcomes. Prospective data from clinical trials evaluating the benefits of EBRT weighed against its toxicities are limited. Only one multicenter randomized trial has been launched comparing RAI plus EBRT following thyroidectomy to RAI alone post-thyroidectomy in locally invasive DTC.<sup>908</sup> This study closed in 2003 due to slow accrual after only 45 patients were enrolled. Several single-institution retrospective reviews have examined the role of EBRT, primarily without concurrent chemotherapy, in heterogeneous groups of patients with DTC with varying risk factors for locoregional progression.<sup>909–919</sup> High-risk factors in DTC cases leading to EBRT have generally included aggressive histological subtype, gross extrathyroidal extension, positive margins, visceral or soft tissue invasion, and lymph node involvement. The range of radiation dose administered is primarily 6000–6600 cGy. Since the widespread adoption of intensity-modulated radiation therapy (IMRT) as a more precise technology for the delivery of radiation, it has replaced 3D conformal radiation as the standard approach.<sup>920</sup> The main advantage with IMRT is in reducing the radiation dose to normal structures, but acute and late radiation-related adverse events are still encountered. While grade 2 or less acute mucositis, esophagitis, xerostomia, dysphagia, dermatitis, and fatigue are quite common, grade 3 or higher acute and long-term toxicities, including dysphagia, gastrostomy tube-dependence, and tracheostomy, are rare.<sup>910,912–914,918</sup> In single-institution reviews, locoregional relapse-free, disease-specific, and overall survival rates were reported at varying time periods spanning 4–10 years and ranged from 79% to 95%, 71% to 76%, and 65% to 93%, respectively.

Of the single-institution retrospective reviews that compared EBRT-treated patients with matched historical controls, locoregional relapse-free survival was improved with treatment. However, no differences in overall survival were seen, likely due to similar rates of distant metastasis.<sup>910,912,914,918</sup> One single-institution phase II study of IMRT following surgery and RAI treatment in 65 patients with locoregionally advanced (pT4 or N1b) disease was performed.<sup>911</sup> No grade 3 or higher acute or long-term radiation-related adverse events were reported. The outcomes of the patients treated on study were compared to a propensity score-matched control group from the same period. Locoregional relapse-free survival at 4 years was 100% and 84.6% ( $p = 0.002$ ) in the IMRT-treated patients and controls, respectively, and 4-year overall survival was 100% in both. In view of the lack of randomized controlled trials investigating adjuvant EBRT in high-risk DTC, a comparative effectiveness analysis of observational data from 870 locally advanced T4 PTC cases from SEER from 1988 to 2013 was conducted.<sup>921</sup> Of note, EBRT was associated with worse overall survival (HR 1.60 [CI 1.18–2.16]) and disease-specific survival (HR 1.58 [CI 1.09–2.30]). Systematic reviews and NCDB reviews also have been published.<sup>920,922,923</sup> Despite data suggesting that locoregional relapse-free survival may be improved with adjuvant EBRT in high-risk DTC, disease-specific and overall survival were not improved. Adjuvant EBRT may be appropriate in select cases, such as in patients considered at high risk for an aggressive locoregional recurrence that could not be approached

with surgical salvage, but results available to date do not support the adoption of adjuvant EBRT as a standard of care in patients with high-risk locally advanced DTC, particularly in light of the risks of acute and long-term treatment-related adverse effects that may impact patient QoL and make future revision neck surgery for recurrent disease still more challenging.

In patients with DTC with postoperative gross residual disease or presenting with unresectable locoregional disease, several retrospective reviews suggest that EBRT with or without concurrent chemotherapy may decrease the risk of locoregional progression.<sup>917,919,924,925</sup> In treating gross disease, IMRT administered to 7000 cGy was most common, with evidence indicating that locoregional control is improved with doses higher than 5000 cGy.<sup>917,919,924</sup> Concurrent chemotherapy schedules, variously including doxorubicin, cisplatin, cisplatin/etoposide, and taxanes, have been employed<sup>917,924</sup>; treatment-related acute and long-term toxicities were acceptable with chemoradiotherapy compared with radiation alone, but rates of hoarseness, dermatitis, and gastrostomy-tube placement may be higher with chemoradiotherapy.<sup>905,912</sup> In these reports, locoregional control appeared to be improved with chemoradiotherapy compared with that seen with radiation alone, ranging from 86% to 90% at 3–4 years with chemoradiotherapy, versus 69–73% with radiation alone.

Data on differences in overall survival are conflicting. One multicenter retrospective review analyzed outcomes of patients initially presenting with unresectable DTC.<sup>925</sup> Patients were treated with EBRT, locoregional therapy of distant metastases, cytotoxic chemotherapy, and/or multi-kinase inhibitors (MKIs) such as sorafenib, pazopanib, or lenvatinib. Thirteen patients were treated initially with EBRT, resulting in disease stabilization in six patients. First-line MKI therapy was initiated in seven patients, yielding an overall RR of 29%. No responses to cytotoxic chemotherapy were reported. No difference in overall or disease-specific survival was found in comparing MKI-treated and non-MKI treated patients, or in EBRT-treated and non-EBRT treated patients. The authors concluded that initial MKI therapy may represent a promising treatment option for patients presenting with unresectable DTC, but more definitive data are needed. One single-institution phase II trial of IMRT with or without chemotherapy has been reported in the modern era.<sup>926</sup> Twenty-seven patients with gross residual or unresectable DTC were enrolled. The first eight patients were treated with IMRT (7000 cGy) alone before the protocol was amended to add concurrent weekly doxorubicin for the remaining 19 patients. Acute grade 3 or higher treatment-related adverse events were seen in one-third of patients. Chemoradiotherapy compared with IMRT alone was associated with higher rates of grade 2 or greater acute dermatitis (89.5% vs. 50.0%;  $p = 0.04$ ), mucositis (73.7% vs. 25.0%;  $p = 0.03$ ), and dysphagia (63.2% vs. 12.5%;  $p = 0.03$ ). No difference in long-term adverse events was observed, although two chemoradiotherapy patients required tracheostomy for laryngeal edema, two chemoradiotherapy patients required gastrostomy placement, and two IMRT-only patients required tracheostomy after experiencing locoregional recurrence. Locoregional control at 2 years was 100% with chemoradiotherapy and 50% with IMRT alone ( $p = 0.001$ ). In patients who were free of distant metastasis at enrollment, 23.5% developed distant metastasis by 2 years, and no difference was seen in the risk of distant metastases between chemoradiotherapy and IMRT alone. Two-year overall survival was 77.3% in all 27 patients, with no difference in overall survival between the two groups. The authors deemed chemoradiotherapy

promising due to the superior locoregional control achieved; however, with increased toxicity and no difference in overall survival observed in this small single-institution phase II trial, chemoradiotherapy cannot be recommended for all patients with gross residual or unresectable DTC. Randomized clinical trials investigating the clinical benefits of IMRT with or without concurrent chemotherapy in patients presenting with unresectable locoregional disease or with gross residual disease post-thyroidectomy are needed.

### Long-Term Management and Advanced DTC Management

*What are the appropriate features of long-term management of patients with DTC?*

Using the DATA framework, monitoring for possible clinical recurrence in patients thought to be free of disease and identifying progression in patients with suspected or diagnosed


residual thyroid cancer are the primary goals (Fig. 5). Tests with high specificity allow for the identification of patients unlikely to experience disease recurrence so that less aggressive management strategies that are safer and more cost-effective can be pursued. De-escalation of monitoring based on low rates of clinical recurrence is possible for low-risk patients many years after initial therapy when they have a persistent excellent response. Those patients with a higher risk of recurrence should be monitored more closely, since early detection of recurrent disease offers the best opportunity to achieve an excellent response. A shared decision-making model should be pursued in consultation with the patient and consideration of side effects as well as financial implications.

*What is the appropriate degree of TSH suppression in patients treated for DTC?*

#### RECOMMENDATION 45

Individualization of decisions to initiate TSH suppression to below the reference range is recommended based on

## DATA Framework for Initial Therapy



**FIG. 5.** DATA framework applied to the first 12 months after DTC diagnosis. Imaging timing and type depend on risk of recurrence, Tg levels, and pathology/clinical factors. DTC, differentiated thyroid cancer; Tg, thyroglobulin.

potential benefits and risks; recognizing that patients with high-risk disease may be more likely to benefit from a TSH in the subnormal range than those with low-risk disease (see Table 9). (*Conditional recommendation, Low certainty evidence*)

How long should TSH suppression to below the reference range be maintained?.

#### ■ RECOMMENDATION 46

- A. Long-term TSH suppression is not suggested for patients with low- or intermediate-risk disease who have no evidence of biochemical or structural recurrence. (*Conditional recommendation, Low certainty evidence*)
- B. Risks versus benefits of TSH suppression and TSH goals should be re-evaluated over time. (*Good Practice Statement*)

DTC cells express the TSH receptor on their membranes and respond to TSH stimulation by increasing the expression of several thyroid-specific proteins (e.g., Tg, NIS) and by increasing the rates of cell growth.<sup>927</sup> Suppression of TSH using supra-physiological doses of LT4 historically was used to treat patients with DTC to decrease the risk of recurrence or reduce the rate of disease progression.<sup>768,928–931</sup> Although there is a physiological rationale for why TSH suppression may be beneficial in some scenarios, there are mixed findings regarding which patients should or should not receive TSH suppression and the optimal degree of TSH suppression (see Table 9). The existing studies evaluating the role of TSH suppression in DTC management have many limitations, including small sample size for some studies and low event rates for many. Comparing and evaluating existing studies are complex due to variable length of follow-up, different disease severity in study cohorts, and approaches to categorizing TSH.

There have been several publications on TSH levels and DTC outcomes performed by the NTCTCSG.<sup>365,768,769,929</sup> The most recent NTCTCSG study was published in 2015. Mean TSH categories were created with specified ranges reportedly correlating with degree of thyroid hormone suppression: aggressive suppression (undetectable to subnormal TSH), moderate suppression (subnormal to normal TSH), and non-suppression (normal to elevated TSH). This study had a median of 6 years of follow-up and found that among 3238 patients with DTC, there was improved overall survival and disease-free survival across all stages for mean TSH scores in the moderate suppression range (i.e., subnormal to normal TSH) and no further improvement for any stage with TSH levels averaging in the undetectable subnormal range.<sup>365</sup>

Although there are conflicting data, evidence to support TSH suppression came from a meta-analysis from 2002 that described 4174 patients with thyroid cancer, of whom 2880 were on TSH suppression (defined as TSH below the lower limit of normal range, i.e., below 0.4–0.5 mIU/L). This study demonstrated an association between TSH suppression therapy and a reduced incidence of major adverse clinical events (defined as progression, recurrence, or death; RR = 0.73 [CI 0.60–0.88];  $p < 0.05$ ).<sup>928</sup> In a more recent retrospective single-center observational study of 366 consecutive patients with DTC who had a median follow-up of 8.85 years, there was a positive association

between serum TSH levels and risk of recurrent disease and cancer-related mortality, with a threshold of 2 mIU/L differentiating between disease-free survival and recurrence or death.<sup>932</sup> In a retrospective study of 141 patients with a mean of 95 months of follow-up, a constantly suppressed TSH (i.e., TSH  $\leq 0.05$  mIU/L) was found to be associated with a longer recurrence-free survival than when serum TSH levels were always  $\geq 1$  mIU/L, and degree of TSH suppression was an independent predictor of recurrence in multivariable analysis.<sup>933</sup> A retrospective patient chart study of 157 patients with distant metastases from DTC found improved thyroid cancer-specific survival if the median TSH level was  $\leq 0.1$  mIU/L as opposed to non-suppressed, but no further improvement in outcome was seen with TSH suppression to  $< 0.03$  mIU/L compared with  $\leq 0.1$  mIU/L.<sup>930</sup>

There also have been studies contesting the benefits of TSH suppression. A cohort study of 867 intermediate and high-risk patients with DTC treated with total thyroidectomy and RAI found that TSH suppression showed no association with progression-free survival at 5 years.<sup>934</sup> A similar retrospective series of 166 intermediate- and high-risk patients with pre-ablation Tg  $< 1$  ng/mL found that disease recurrence risk did not differ based on TSH  $< 0.1$  mIU/L, 0.1–0.5 mIU/L, 0.5–2.0 mIU/L, or  $> 2.0$  mIU/L, and only four patients experienced recurrences during a median follow-up of 5.8 years.<sup>935</sup>

There are also conflicting data surrounding TSH targets and the use of thyroid hormone in low-risk patients who have undergone lobectomy as described below. A small randomized controlled trial compared outcomes in 218 patients with PTC who were administered LT4 to keep their TSH levels suppressed versus 215 patients who had their TSH levels maintained in the normal range.<sup>936</sup> Most of the patients in this study did not undergo total thyroidectomy or RAI, and Tg levels were not monitored or reported.<sup>936</sup> This study showed that disease-free survival did not differ significantly between the cohort with normal TSH levels (TSH 0.4–5 mIU/L) compared with the cohort with suppressed TSH levels (TSH  $< 0.01$  mIU/L). Patients with T1a PTC, distant metastases, age  $\geq 80$  years, Graves' disease, ischemic heart disease/arrhythmia, or severe osteoporosis were not eligible for the trial. Another study retrospectively reviewed 1528 patients who underwent thyroid lobectomy for low-risk disease and found that during 5.6 years of follow-up, only 1.4% experienced recurrence.<sup>937</sup> There was no difference in recurrences among patients with TSH levels ranging across  $< 0.5$ , 0.5–1.9, 2.0–4.4, or  $> 4.5$  mIU/L. A separate retrospective study with 2297 low-, intermediate-, and high-risk patients who underwent lobectomy for DTC found that with a median follow-up of 70 months, mean TSH levels did not impact risk of recurrence.<sup>392</sup> In contrast, a retrospective study of 1047 patients who underwent thyroid lobectomy for low- or intermediate-risk PTC reported that a TSH level at 1 year was an independent risk factor for recurrence, with recurrence more frequently seen with a TSH  $> 1.85$  mIU/L.<sup>938</sup> A 2024 systematic review and meta-analysis evaluating the role of TSH suppression in patients with intermediate- and high-risk DTC found that progression-free survival, disease-free survival, and relapse-free survival were not significantly different between TSH suppression and non-suppression groups.<sup>939</sup>

Since the desire to avoid thyroid hormone replacement is a reason that some patients with low-risk disease choose

lobectomy over total thyroidectomy, optimal TSH goal is relevant to treatment decision-making. The TSH goal for those patients with low or intermediate risk for recurrence of thyroid cancer (after a total thyroidectomy or after a thyroid lobectomy) is in the normal reference range (Table 9). Prior studies suggest that if the TSH goal is within the normal range, about 70–80% of patients who undergo lobectomy can avoid thyroid hormone supplementation.<sup>940,941</sup> In contrast, if the goal TSH level is 0.5–2.0 mIU/L, only 20–30% of patients who undergo lobectomy can avoid thyroid hormone supplementation.<sup>388,942</sup> If TSH is above the normal reference range (after total thyroidectomy or after thyroid lobectomy), then thyroid hormone therapy should be initiated. Thyroid hormone replacement therapy is most frequently started in the first 2 years after thyroid lobectomy, but for up to a quarter of patients, it is started later.<sup>943</sup>

There have been recent studies exploring the role of TSH suppression during active surveillance, also resulting in conflicting findings.<sup>944,945</sup> In a study of 322 patients who had T1a PTC and who elected to pursue active surveillance, there was no significant association between mean TSH level and tumor growth.<sup>944</sup> However, a multicenter retrospective study of 234 patients with T1a PTC undergoing active surveillance used time-weighted average levels of TSH and found that for patients <50 years, a time-weighted average TSH >1.74 mIU/L was associated with disease progression (defined as tumor volume increase  $\geq 50\%$ , size increase  $\geq 3$  mm, or new lymph node metastases).<sup>945</sup> In addition, a prospective study from three referral hospitals in Korea included 699 participants who underwent active surveillance and found that serum TSH of 7 mU/mL or higher predicted tumor progression.<sup>946</sup> A study of 2509 patients with low-risk papillary thyroid microcarcinoma who underwent active surveillance, with only a subset receiving LT4, found that LT4 treatment may be associated with decreased tumor growth.<sup>947</sup> However, further research is needed.

When treating a patient with thyroid hormone replacement, it is critical to consider practical issues such as the ability to consistently maintain the goal TSH level without over- or under-replacing the patient, as well as clinically relevant issues such as balancing the benefits and risks of TSH suppression. It should be recognized that targeting and maintaining specific TSH goals can be difficult in real-world settings.<sup>948–950</sup> For example, with use of target TSH levels per the 2015 ATA guidelines, of 1125 patients with DTC who were treated at 21 medical centers, only 29% had TSH levels at target normal reference range despite 82.8% having good or moderate adherence to therapy. Approximately 50% of the patients were overtreated, and 20% were undertreated.<sup>950</sup>

The potential benefit of a suppressed TSH is greater in patients at high-risk for recurrence or death. When considering benefits and risks, there may be more benefits in patients with disease progression. In contrast, for patients at low-risk for recurrence, the risks of TSH suppression may exceed any potential benefit (Table 9). Some of the recognized adverse effects of TSH suppression are derived from studies of endogenous subclinical hyperthyroidism or from studies of exogenous subclinical hyperthyroidism that exclude patients with thyroid cancer. Based on these prior studies, recognized adverse outcomes of a low TSH include exacerbation of angina in patients with ischemic heart disease, increased risk

for atrial fibrillation and stroke (especially in older patients), increased risk for cardiovascular mortality, and increased risk of osteoporosis and possibly fracture in postmenopausal women.<sup>951–955</sup>

Similar risks, particularly surrounding bone health in older women, have been found in studies evaluating TSH suppression for thyroid cancer.<sup>956–961</sup> The importance of balancing benefits and risks is illustrated in a study of 771 patients with low- to intermediate-risk for recurrence who underwent total thyroidectomy.<sup>962</sup> Of this cohort, 5.6% had thyroid cancer recurrence, 3.9% were diagnosed with osteoporosis, and 2.3% were diagnosed with atrial fibrillation. Despite having similar risk of recurrence, patients with a TSH  $\leq 0.4$  mIU/L were at increased risk of atrial fibrillation and osteoporosis.<sup>962</sup> An observational study demonstrated increased risk of all-cause and cardiovascular mortality among patients with DTC compared with a control population.<sup>963</sup> The authors also showed that survival in the patients was lower when the serum TSH was  $<0.02$  mIU/L. Therefore, optimal TSH goals for individual patients balance the potential benefit of TSH suppression with the possible harm from subclinical thyrotoxicosis, especially in patients with medical conditions that can potentially be exacerbated by aggressive TSH suppression.

What is the role of serum Tg measurement in the follow-up of DTC?

#### ■ RECOMMENDATION 47

- A. Serum Tg should be measured by an assay that is calibrated against the BCR457 standard. Tg antibodies should be quantitatively assessed with every measurement of serum Tg. (*Good Practice Statement*)
- B. Measure serum Tg (on thyroid hormone therapy) after total thyroidectomy, with or without RAI, to monitor for response to therapy and to determine recurrence (although the predictive value is greater after RAI). (*Strong recommendation, Moderate certainty of evidence*)
- C. Measurement of serum Tg during initial follow-up while receiving thyroxine therapy should be undertaken every 6–12 months. More frequent serum Tg measurements may be appropriate for ATA intermediate-high or high-risk patients. (*Good Practice Statement*)
- D. Measurement of serum Tg on thyroid hormone in patients after lobectomy during initial follow-up is not recommended routinely (see **Recommendation 30**). (*Conditional recommendation, Very low certainty evidence*)
- E. In patients with circulating anti-Tg antibodies, trends of serial TgAb levels using the same assay may be useful to monitor disease. Current Tg immunometric assays (IMA) and radioimmunoassays (RIA) are often affected by TgAb, and Tg liquid chromatography-tandem mass spectrometry (LC-MS/MS) has low sensitivity. These should not be solely relied upon to monitor patients with circulating TgAb levels. Imaging is the primary modality for monitoring in this population. (*Conditional recommendation, Low certainty evidence*)

Serum Tg should be measured 6–12 weeks after total or near-total thyroidectomy in patients with DTC,<sup>243</sup> as

discussed in **Recommendation 30**. Serum Tg can be used to monitor tumor recurrence in patients who have undergone a total thyroidectomy, with or without receiving ablative RAI, although the sensitivity is improved in patients with DTC who have received RAI and is more limited in patients treated with lobectomy.<sup>16</sup>

Serum Tg is measured by immunometric assays, which include competitive RIA and IMA, or by LC-MS/MS assays.<sup>964</sup> In addition to sensitivity and specificity, these assays differ in ease of performance, instruments required, as well as interference from anti-Tg autoantibodies (TgAb), and heterophile antibodies (HAb).<sup>964</sup> The majority of clinical laboratories use Tg-IMA, which involves a solid phase antibody and a labeled antibody targeting a different Tg epitope and can be rapidly performed on an automated high-throughput instrument. It is recommended that Tg assays are calibrated with a standard traceable to the Certified Reference Material-457, now known as BCR-457, European Commission Institute for Reference materials.<sup>965</sup> The use of this Tg standard has significantly reduced the wide inter-assay variability, although even with use of these standards, mean Tg concentration in a cohort of TgAb-negative patients varied as much as two-fold.<sup>966</sup> The BCR-457 standard is a preparation of glandular Tg, and various Tg features, including glycosylation and iodine heterogeneity, can lead to differences in epitopes of circulating Tg detection.<sup>967</sup> Due to this intrinsic variability in Tg detection and the importance in postoperative follow-up, it is recommended that longitudinal measurements are made with the same manufacturers assay, and the same laboratory, if possible.

Immunometric assays are prone to interference from TgAb, which commonly cause falsely low serum Tg measurements. Moreover, variability in TgAb assays may result in falsely negative antibody levels associated with a misleadingly undetectable serum Tg due to the antibodies that are present but not detected.<sup>968</sup> Assays for TgAb have similar variability and lack of concordance, as do Tg assays,<sup>969</sup> and both Tg and TgAb assays may be affected by HAb.<sup>970</sup>

TSH-stimulated serum Tg measurements had been recommended to enhance the sensitivity for persistent or recurrent DTC. Most studies, though, have shown that a basal serum Tg (using assays with a sensitivity of 0.1 ng/mL or lower) on LT4 in patients after total thyroidectomy is adequately sensitive.<sup>971</sup> A meta-analysis of studies of DTC follow-up through 2013 concluded that an undetectable basal Tg level using modern highly sensitive assays had a high NPV, and TSH stimulation was not required. The authors recommended TSH stimulation when Tg levels were detectable.<sup>972</sup> A subsequent systematic review and meta-analysis from papers published from 2003 to 2018 addressed the NPV of serum Tg on LT4 in follow-up of DTC patients who had undergone total or near total thyroidectomy, with or without RAI.<sup>973</sup> The diagnostic performance of serum Tg on thyroid hormone was assessed versus anatomical imaging for structural recurrence both at the time of Tg and during follow-up. The NPV of serum Tg was 99.4% when undetectable on thyroxine treatment, providing support for adequate clinical sensitivity.

In patients with DTC treated with a total thyroidectomy with or without ablative RAI, a low or undetectable basal serum Tg is a reliable indicator of disease status. A

retrospective series of patients with low-risk DTC treated with total thyroidectomy but without ablative RAI demonstrated that an unstimulated Tg of <0.5 ng/mL on LT4 was achieved in all patients 2 years after treatment.<sup>974</sup> A retrospective database study examined 773 patients with DTC undergoing 3176 cervical ultrasounds from 1996 to 2012<sup>975</sup>; in the 6 months following the ultrasound, results were classified as true or false based on further evaluation and the sensitivity, specificity, and PPVs and NPVs. After 10 years, no true positive or false negative ultrasounds were found in patients with a basal Tg <1 ng/mL.

TgAb are present in about 20% of patients with DTC; thus, they have been the focus of several studies trying to identify the optimal approach to measuring serum Tg, minimizing the disruption from TgAb, understanding the significance of TgAb in the original assessment of DTC, and their impact on prognosis for tumor recurrence.<sup>976,977</sup> A variety of approaches have been proposed to improve the sensitivity and accuracy of serum Tg measurement,<sup>849</sup> especially in the presence of TgAb. A retrospective multi-institutional series studied 495 patients with Stage I-IV DTC (89% with PTC), comparing various Tg assays and determining the impact of TgAbs on the various assays.<sup>850</sup> The study compared four Tg immunoassays (IA), two Tg RIAs, and two Tg LC-MS/MS assays in patients with or without TgAb. TgAb positivity was observed in 27-58% of patients. The Tg IMA was most sensitive and specific in samples that were TgAb negative. In the presence of TgAb, Tg levels were underestimated by Tg IMA. Tg LC-MS/MS was most likely to measure Tg in the presence of TgAb and was felt to be the most accurate. TgRIA measured Tg in specimens that were TgAb positive, but there were false positives. A study to determine the benefit of Tg LC-MS/MS measurements examined patients with DTC who had undergone thyroidectomy and had a Tg measured by both immunoassay and LC-MS/MS no more than 1 month apart and examined those with TgAbs and with HAb.<sup>851</sup> The investigators observed that a falsely elevated TgIMA with undetectable Tg LC-MS/MS occurred with significant frequency. Tg LC-MS/MS, however, was useful to rule out HAb interference. Tg LC-MS/MS was not effective at detecting low levels of serum Tg in patients with TgAb and structural disease in this study, and the investigators concluded that no current assay design effectively measures serum Tg in the presence of TgAbs. The Tg mini-recovery system, which adds serum Tg with a concentration of about 5 ng/mL to samples with low native concentration to improve recovery, was assessed in 1120 samples from 798 patients with DTC, 20% of whom were TgAb positive.<sup>978</sup> The application of the mini-recovery system did not provide an overall clinical benefit in most patients. Thus, in clinical series, it is not clear that any Tg assay system is fully accurate in monitoring patients with circulating TgAb.

The significance of TgAb measurement in longitudinal follow-up has been assessed in patients treated with or without ablative RAI therapy. Notable is a study of 107 patients with DTC and positive TgAbs, all of whom had tumors <1 cm and who underwent total thyroidectomy without ablative RAI; they were followed for 6 years.<sup>979</sup> TgAb levels fell in most patients, and there was no tumor recurrence. TgAb levels declined even in the absence of RAI. A retrospective

review of a database that included 432 patients with DTC (all of whom underwent total thyroidectomy with or without ablative RAI, and 106 [24.5%] had detectable TgAb over a median follow-up of 53 months)<sup>980</sup> included patients from ATA low- (53.7%), intermediate- (26.8%), and high- (19.4%) risk groups. Disease progression in patients with TgAb positivity was compared with those who were TgAb negative. There was no association of initial TgAb positivity with disease progression and no association with response to therapy in the low-risk group. A rising TgAb level, more than an absolute level, was associated with an increased risk of a structurally incomplete response in the intermediate- and high-risk groups. A prospective study of 152 patients with DTC who underwent total thyroidectomy without RAI included patients with TgAbs (41 patients) and without TgAbs (111 patients) who were followed for a median of 2.3 years.<sup>981</sup> The overall risk of recurrence was similar in the two groups, and serum TgAb levels either decreased over time or were stable, increasing in just two patients.

In a study of 110 patients with positive TgAb levels treated with total thyroidectomy and ablative RAI,<sup>982</sup> an increase in the first 6–12 months was a risk factor for worse disease outcomes in patients <55 years, and the median time for TgAb levels to become negative was 15.8 months after surgery. A meta-analysis of 34 studies assessed whether TgAb levels are a reliable prognostic marker for DTC.<sup>981</sup> The studies included were those that had patients with DTC with known TgAb status and included prognostic outcomes. TgAb positive patients, in comparison to TgAb negative patients, had a higher risk of lymph node metastases and cancer persistence but no difference in tumor size, risk of extrathyroidal extension, or cancer mortality. Patients with persistent or increasing TgAb levels had a higher risk of cancer persistence and cancer mortality compared with patients with decreasing TgAb levels. A retrospective study of 76 patients with DTC with elevated TgAb levels after total thyroidectomy but without persistently raised serum Tg IMA level >1 ng/mL or RAI-avid disease examined the association of changes in TgAb levels and clinical outcome.<sup>983</sup> High postoperative TgAb levels and central compartment lymph node metastases were risk factors for an incomplete response, and low levels of TgAb were associated with an excellent outcome. Patients with low levels of TgAb had excellent outcomes, and patients with recurrences had very high baseline TgAb levels >1000 IU/mL. A study of 405 patients with DTC with preoperative TgAb positivity found that elevated TgAb levels were a risk factor for nodal metastases and extranodal extension, and elevated thyroid peroxidase antibodies (TPO) Ab levels were associated with a lower pathological tumor and nodal stage.<sup>984</sup>

The importance of *de novo* TgAbs in patients with DTC that are initially TgAb negative has been studied. The NTCTCSG reported on the significance of *de novo* TgAb detection from their DTC registry from 1996 to 2012, focusing on patients who were negative at their first postoperative follow-up and over the next 3 years without demonstrating evidence of persistent disease.<sup>985</sup> Overall, *de novo* TgAb were detected in 5% of patients with DTC, and there was no difference with respect to structural recurrence among these patients compared with patients who remained

TgAb negative. In the six patients from the *de novo* TgAb group who experienced structural recurrence, none were TgAb positive at the time of detection, and TgAbs became positive a median of 2.1 years later. Another retrospective study identified 119 patients with DTC with pre-ablation negative TgAb and evaluated 14 patients (11.7%) that developed *de novo* TgAbs.<sup>986</sup> The patients with *de novo* TgAbs did not differ from the TgAb negative patients regarding disease-free survival, although 2 of the 14 patients had structural recurrence.

In a limited number of patients with DTC, structural disease is present, but serum Tg is undetectable, and only TgAb levels are elevated. A retrospective review of 47 patients with PTC and lung metastases who had negative serum Tg and positive TgAb levels compared their outcomes with historical controls.<sup>987</sup> The 5- and 10-year rates of progression-free survival were not lower in the patients that were serum Tg negative and TgAb positive. The strongest predictor of a poor prognosis was loss of <sup>131</sup>I avidity in the lung metastases. Finally, as outlined in **Recommendation 30**, serum Tg has not been shown to predict recurrence in patients with DTC after thyroid lobectomy, but this is not well studied to date.

Can monitoring be de-escalated or discontinued in patients with low-risk DTC?

#### ■ RECOMMENDATION 48

1. For patients with low-risk DTC treated with total thyroidectomy and RAI and a sustained excellent response 5–8 years after initial therapy, routine ultrasound can be discontinued, and patients can be followed subsequently with biochemical markers alone every 1–2 years. (*Conditional recommendation, Low certainty of evidence*)
2. Patients with low-risk DTC treated with total thyroidectomy and RAI and sustained excellent response for 10–15 years do not require continued routine biochemical monitoring for thyroid cancer and should be considered to have achieved a complete remission. (*Good Practice Statement*)
3. For patients with low-risk DTC treated with a total thyroidectomy alone and a sustained excellent response 5–8 years after initial therapy, routine ultrasound can be discontinued, and patients can be followed subsequently with biochemical markers alone every 1–2 years. (*Conditional recommendation, Low certainty of evidence*)
4. Patients with low-risk DTC treated with total thyroidectomy alone and sustained excellent response for 10–15 years do not require continued routine biochemical monitoring for thyroid cancer and have achieved a complete remission. (*Good Practice Statement*)
5. For patients with low-risk DTC treated with lobectomy, if initial ultrasound is negative, subsequent ultrasounds should be performed every 1–3 years for 5–8 years after initial therapy. Nodules in the residual lobe should be monitored as per ATA thyroid nodule guidelines. (*Good Practice Statement*)
6. For patients with low-risk DTC treated with lobectomy, if postoperative Tg is not markedly

elevated (see **Recommendation 30**), additional Tg testing is not recommended routinely. (*Good Practice Statement*)

*Defining complete remission.* “Complete remission” is the term used in oncology to define the disappearance of all signs of cancer in response to treatment. This does not always mean that cancer has been cured or will not return.<sup>988</sup> Identifying patients to be in complete remission offers psychological, financial, and medical value to both patients and clinicians.

As recurrence risk declines over time, it is likely that most patients with DTC will achieve “complete remission”; however, this term has not been included in prior ATA DTC guidelines. Clear data to define this term in thyroid cancer are lacking and complicated by the heterogeneity of thyroid cancer management and differences in monitoring and response to therapy. However, the low rates of recurrence and outstanding survival statistics for patients with low-risk DTC support the general concept of de-escalating monitoring intensity over time. As summarized below, data are strongest for patients with low-risk DTC treated with total thyroidectomy, particularly those who also receive RAI. Data are more limited for patients treated with lobectomy, thereby providing a call for more research for this growing population of patients. Further validation studies will be crucial for all groups to help guide long-term monitoring so that we can better avoid unnecessary follow-up and interventions. A recommended approach is summarized in Table 11.

*Introduction to de-escalation of long-term monitoring in low-risk DTC.* In patients with low-risk PTC treated with total thyroidectomy who have achieved sustained excellent response, lifelong thyroid cancer monitoring is likely unnecessary due to the outstanding long-term prognosis. Lifelong biochemical assessments and neck ultrasounds are associated with financial and psychological burden that may not be justified in many patients in view of the extremely low risk of recurrence long after treatment.<sup>989,990</sup> There are no studies to compare lifelong monitoring with an

abbreviated course of follow-up, and specific timing of when to stop monitoring is not clear. Recent data on ultrasound monitoring in patients treated with total thyroidectomy for low- and intermediate-risk PTC and excellent biochemical response outlined below suggest that life-long monitoring with ultrasound is not necessary. There are patients in whom continued ultrasound monitoring is appropriate. Patients who have a history of clinical or radiographical recurrence and those with indeterminate or suspicious results on biochemical or imaging assessments should continue to undergo ultrasound monitoring. These data are limited to patients with PTC.

There are less data on de-escalating monitoring in patients with FTC or OTC, but it is important to recognize that recurrence rates are also very low for patients with low-risk FTC or OTC with undetectable Tg levels and negative imaging, as noted in **Recommendation 28**. The role of imaging has not been well studied in patients with low-risk FTC or OTC. Due to the predilection of some OTC to spread locally, ultrasound beyond the first year is reasonable to consider in these patients. The value of ultrasound in patients with FTC is uncertain. An approach to measuring Tg levels in patients treated with thyroid lobectomy is discussed in **Recommendations 30 and 47**.

*Ultrasound monitoring after total thyroidectomy for patients with low-risk DTC.* Neck ultrasound monitoring is recommended to identify residual and/or recurrent structural disease in the neck and has long been used for routine monitoring for locoregional recurrences. With the more sensitive Tg and TgAb assays (functional sensitivity of 0.1 and 0.9 ng/mL, respectively) now commonplace, the role of continued long-term ultrasound monitoring to detect structural recurrences in low-risk patients after total thyroidectomy for PTC who have excellent biochemical responses has been re-evaluated. Because of variability in both surgical approach and RAI use, it is not possible to formulate a single recommendation. As total thyroidectomy followed by RAI represented the historical standard of care, most of the data come from that patient population. However, more recent studies

TABLE 11. LOW-RISK DTC WITH EXCELLENT RESPONSE TO THERAPY DE-ESCALATION RECOMMENDATIONS

<i>Treatment and response to therapy</i>	<i>Unstimulated thyroglobulin</i>	<i>TSH</i>	<i>Suggested frequency of neck ultrasound</i>
Hemithyroidectomy	Once postoperatively (see <b>Recommendation 48</b> )	Normal	<sup>a</sup> Every 1–3 years for 5–8 years
Total thyroidectomy, no RAI Excellent response	<2.5 ng/mL with undetectable TgAb	Normal	Every 1–3 years for 5–8 years, then discontinue unless Tg level rises or TgAb becomes newly detectable
Total thyroidectomy + RAI Excellent response	<0.2 ng/mL with undetectable TgAb	Normal	Every 1–3 years for 5–8 years and then discontinue unless Tg level rises or TgAb becomes newly detectable

Recommendations on ultrasound monitoring in low-risk patients after total thyroidectomy with excellent biochemical response and no suspicious features on imaging. Imaging is indicated in patients with rising thyroglobulin (Tg), new development of anti-thyroglobulin antibodies (TgAb), concerning physical exam, or symptoms. Type and location of imaging depends on the histological type of thyroid cancer and other pathology features. Use of Tg levels following hemithyroidectomy, and use of neck ultrasound in patients with FTC and OTC require further study.

<sup>a</sup>Assuming no nodules in residual lobe requiring monitoring as per ATA thyroid nodule guidelines.

ATA, American Thyroid Association.

have demonstrated that total thyroidectomy without RAI in low-risk patients is non-inferior to total thyroidectomy with RAI; thus, fewer low-risk patients have been treated with RAI in recent years.<sup>770</sup>

DTC recurrence in the low-risk category is uncommon. When it occurs, the overwhelming majority occurs in the first 5 years after surgery.<sup>770,991–995</sup> In addition, patients who have excellent biochemical responses early on are unlikely to develop recurrences. Most of the data reflect monitoring patients with PTC. Some studies described below include patients with low-risk FTC and OTC.

A retrospective analysis reviewed 1020 patients who underwent total thyroidectomy with or without RAI for predominantly low- (61.3%) and intermediate- (35.5%) risk DTC, with 948 patients (93%) observed to be disease-free at initial post-treatment evaluation (<12 months). The duration of study follow-up was 5.1–20.4 years, with a median of 10.4 years. Of these 948 patients, structural recurrences were found in only 13 (1.4%), all of whom had disease confined to the cervical lymph nodes or thyroid bed. Ten of the 13 patients recurred in the first 5 years, and the remaining 3 within the first 8 years.<sup>991</sup>

A retrospective study of 501 patients with DTC who underwent total thyroidectomy and RAI found that of the 263 patients with excellent biochemical responses at 17 months (interquartile range [IQR] 14–22), only five (1.9%) patients developed structural disease at 101 months (IQR 71–126). All ATA risk groups were included in this study.<sup>993</sup> Another study retrospectively reviewed 2250 patients who had total thyroidectomy with or without RAI for PTC >1 cm who were biochemically and structurally disease-free on initial follow up. This cohort included higher-risk patients<sup>992</sup> and did not exclude patients with gross extrathyroidal extension (34%), positive surgical margins (9.3%), central (52.9%) or lateral compartment lymph node metastases (15.3%), or unfavorable histologies (1.8%). Structural recurrences were found in only 68 patients (3%), with a time to recurrence of 3.86 years in those with lymph node recurrences and 4.38 years in those with local soft-tissue recurrences or distant metastasis. In a prospective randomized trial of 726 patients with low-risk DTC after total thyroidectomy and RAI, 11 patients (2%) were found to have recurrences: 4 patients with structural disease, 5 patients with rising Tg levels but no evidence of structural disease, and 2 patients with indeterminate findings on ultrasound that were not sent for biopsy at a median of 5.4 years. All patients with structural recurrences had an elevated Tg level.<sup>994</sup> A randomized controlled trial of 730 low-risk patients after total thyroidectomy found recurrences in 31 patients (4%) at 3 years for both those who received RAI and those who did not, with no difference between the groups. Of these patients, five were found to have structural disease on ultrasound.<sup>770</sup> To investigate the need for long-term monitoring in low-risk DTC in patients with excellent biochemical response, 756 patients were retrospectively reviewed at a single institution, all of whom had low-risk DTC and achieved excellent biochemical response (stimulated Tg <1 mcg/L) with total thyroidectomy and RAI. Radiological recurrence was found in 13 (1.7%) patients, with the latest presentation of biochemical recurrence at 59 months. Only seven (54%) of the patients who recurred had a

histological diagnosis of PTC, representing <1% of the cohort.<sup>995</sup> While there are reports of recurrences after many more years, these are very rare.<sup>992</sup>

Ultrasound of patients at low risk for recurrence who have had excellent biochemical responses has not been found to identify clinically significant disease, but it can increase the number of interventions undertaken based on false positive findings.<sup>743,996–999</sup> While most data reflect patients who had RAI as part of their initial therapy, some data include patients who had not received RAI. Two hundred and 26 patients who had total thyroidectomy (with or without RAI) for PTC and who were at low- or intermediate-risk for recurrence with either excellent biochemical response or low-detectable Tg levels (0.21–0.99 ng/mL) at 1 year of follow-up were retrospectively reviewed. Of the 226 patients studied, 171 had (75.7%) an excellent biochemical response at the first year of follow-up. At 3 years of follow-up, only two (1.2%) patients developed indeterminate or suspicious features on ultrasound, and only three (1.8%) patients developed these ultrasound features at last follow-up (median 72 months; range 59–94 months), resulting in an NPV of 98.8% and 98.2%, respectively. Of the 55 patients who had low detectable Tg levels, one (1.8%) developed indeterminate or suspicious features on ultrasound at 3 years, and three patients (5%) had suspicious features at the last follow up (median 86 months; 59–99 months), resulting in an NPV of 98.7% and 94.5%, respectively. Of the six patients whose ultrasounds were not considered reassuring at last follow-up, only one was suspicious, while the other five were indeterminate. All six patients showed an increase in their Tg levels or developed TgAbs. No patient required treatment.<sup>997</sup>

Another retrospective cohort of 756 patients treated with total thyroidectomy and RAI for DTC were followed for 11.2 years; structural recurrence was found on imaging in 15 (2%) patients, 13 (85%) of whom experienced it within 5 years of surgery. All had rising Tg or TgAb levels. Six (40%) of the 15 patients who recurred had FTC or OTC. Of the nine (1.2%) patients with recurrence and PTC histology, two had high-risk disease, with the remaining seven having low- or intermediate-risk pathologies.<sup>1000</sup> A retrospective review of 76 patients with T1N0 to T4N1b PTCs followed by RAI with postoperative Tg levels <1 ng/mL and negative antibodies found 18 (23.7%) patients with suspicious ultrasound findings during 2–7 years of routine neck ultrasound monitoring. None of these patients proved to have recurrent disease by either pathological assessment or clinical follow-up and instead were determined to have false positive imaging results.<sup>996</sup>

Yang et al. reported a cohort of 90 patients with intermediate-risk PTC who underwent total thyroidectomy with RAI treatment and who had Tg levels <1 ng/mL in the absence of antibodies and either negative or atypical features on postoperative ultrasound. Over a median follow-up of 10 years (range 1–15 years), nine (10%) patients developed suspicious features on ultrasound that represented clinical disease requiring intervention, and none of these patients had ever attained excellent biochemical response as defined by the 2015 ATA guidelines. Fifty-one (56.7%) patients developed new atypical features on ultrasound in the course of follow-up that led to biopsy (3 patients, 3.3%), WBS (6 patients, 6.7%), cross-sectional imaging (10 patients, 11.1%), or further

ultrasound monitoring (47 patients, 52.2%), with none ultimately found to have recurrent disease.<sup>998</sup>

Just two studies have included patients who did not receive RAI. A review of 171 patients with low-risk PTC who underwent total thyroidectomy with or without RAI and excellent biochemical response reported one patient who experienced a structural recurrence, and there were 114 false positive findings; 61% of this study group did not have RAI as part of their initial therapy.<sup>743</sup> The other study retrospectively evaluated 93 patients with low- and intermediate-risk PTC treated with or without RAI with excellent biochemical response and found suspicious ultrasound findings in five patients (5.4%) over a mean follow-up of 2.5 years; all these patients had RAI as part of their initial therapy, and none ultimately were found to have clinically significant disease warranting treatment. Another 19 patients (20.4%) had indeterminate findings on ultrasound at a median follow-up of 4 years, none of whom ultimately demonstrated recurrence by clinical follow-up or on FNA cytology.<sup>999</sup> In a SEER review of 22,000 patients, more intense ultrasound imaging and surveillance were associated with increased intervention but with no impact on patient survival.<sup>1001</sup> Cost analyses of thyroid cancer surveillance have found that the cost to detect recurrence in low-risk patients is up to seven times higher than that performed for intermediate- and high-risk patients.<sup>1002</sup>

When should neck ultrasound and other imaging techniques (WBS, SPECT-CT, and <sup>18</sup>F-DG-PET-CT) be performed during follow-up?

*Neck ultrasound.* Considerations regarding neck ultrasound after surgery are reviewed in **Recommendation 31**.

#### *Diagnostic RAI WBS.*

#### ■ RECOMMENDATION 49

- A. Patients who have undergone lobectomy or total thyroidectomy without RAI should not undergo surveillance radioiodine WBS. (*Good Practice Statement*)
- B. Patients with DTC who are at low- and low-intermediate risk of recurrence and who have excellent response to therapy do not require routine diagnostic radioiodine WBS during follow-up. (*Conditional recommendation, Low certainty evidence*)
- C. Patients with DTC who are at intermediate-high and high risk of recurrence can be evaluated with diagnostic radioiodine WBS to evaluate for iodine-avid disease if there is clinical suspicion for recurrence. WBS, if undertaken, can be performed with <sup>123</sup>I or low activity <sup>131</sup>I. (*Conditional recommendation, Low certainty evidence*)
- D. SPECT-CT radioiodine imaging may be performed in addition to planar imaging to anatomically localize the radioiodine uptake and distinguish between likely cancer and nonspecific uptake. (*Conditional recommendation, Low certainty evidence*)

Patients whose native thyroid is still in place do not benefit from RAI WBS in efforts to detect recurrence, as the gland remnant is sufficiently iodine-avid to frustrate efforts to identify cancer in other sites. Thus, the utility of follow-up WBS is dubious in patients who have not received (and are not planned to receive) RAI as part of their treatment.

Following RAI ablation or adjuvant therapy, when the post-therapy WBS does not reveal uptake outside the thyroid bed, subsequent diagnostic WBS has low sensitivity and is usually unnecessary in patients who have achieved an excellent response as defined in the 2025 ATA guidelines, particularly for patients with low-risk DTC.<sup>1003–1005</sup>

A subsequent diagnostic WBS may be indicated primarily in three clinical settings: (i) for patients with abnormal uptake outside the thyroid bed on post-therapy WBS, (ii) for patients whose post-ablation WBS is of limited use because large thyroid remnants with high uptake of (>2% of the administered activity at the time of scan) obscure the detection of lower uptake in neck lymph nodes, and (iii) for patients with rising or elevated TgAb levels (who are at risk of false negative Tg measurement) even when neck ultrasound does not show any suspicious findings; <sup>123</sup>I is preferred generally over <sup>131</sup>I for these indications for diagnostic body scan because it delivers lower radiation doses to the body and provides better-quality images.

Scintigraphy (<sup>131</sup>I or <sup>123</sup>I) should include planar images of the whole body. These images may be supplemented with SPECT when available, or spot images of the neck, mediastinum, and on any abnormal focus of RAI uptake when SPECT is not available. A WBS may be performed after the administration of either a diagnostic dose (usually 74–185 MBq, 2–5 mCi of <sup>131</sup>I or <sup>123</sup>I) or therapeutic administration of <sup>131</sup>I. Because of the lack of anatomical landmarks on planar images, it may be difficult to differentiate (i) uptake in remnants of normal thyroid from lymph node metastases (especially when the remaining native thyroid is large), (ii) uptake in lung metastases from rib lesions, and (iii) accumulation of RAI in intestine or bladder from a pelvic bone lesion.

Hybrid cameras combine a dual-head SPECT gamma camera with a CT scanner in one gantry. This allows direct superimposition of functional and anatomical images. The radiation dose delivered to the patient by the low-dose CT scan is 2–5 mSv, which is much lower than the dose accompanied by the administration of 3.7 GBq (100 mCi) of <sup>131</sup>I (approximately 50 mSv). SPECT-CT performed after the administration of a diagnostic or a therapeutic dose (≥1.1 GBq, 30 mCi) of RAI is associated with an increased number of patients diagnosed with a metastatic lymph node and a decreased frequency of equivocal findings.<sup>830,832,1006–1010</sup> SPECT-CT may change tumor risk classifications according to the ATA Risk of Recurrence classification and change management in some patients by decreasing the rate of equivocal findings. However, the impact on clinical care in reported series varies widely, from a few percent up to one-third of patients.<sup>832,1008–1011</sup> Pursuit of additional imaging studies is not uncommon after identification of a likely disease site through SPECT-CT. As expected, cancers with low or absent uptake of RAI may yield a false negative SPECT-CT.

Positrons are emitted by <sup>124</sup>I, enabling PET/CT imaging in patients with DTC. It may be used as a dosimetric and diagnostic tool to localize disease; <sup>124</sup>I PET/CT permits accurate measurement of tumor volume and of the uptake and half-life of <sup>124</sup>I in each disease site, thereby allowing for a reliable dosimetric assessment. While these lesional dosimetry metrics have demonstrated promise, they have not yet found widespread use owing to the investigational nature of the <sup>124</sup>I

isotope.<sup>1012–1014</sup> Additionally, a few small single-center studies have examined the role of other positron-emitting radiopharmaceuticals in detecting DTC, including [<sup>18</sup>F]-tetrafluoroborate (TFB),<sup>1015</sup> [<sup>68</sup>Ga]PSMA-11,<sup>1016</sup> and [<sup>68</sup>Ga]DOTATATE/DOTANOC.<sup>1017</sup> The role of these novel agents in thyroid cancer remains undefined.

The sensitivity of <sup>124</sup>I PET for the detection of residual thyroid tissue and/or metastatic DTC is generally higher than that of a diagnostic planar WBS (99% vs. 66%, respectively).<sup>1018–1022</sup> These results were summarized in a meta-analysis, with a pooled sensitivity of 94.2% and specificity of 49.0%.<sup>1023</sup>; <sup>124</sup>I PET/CT has not yet been compared with SPECT-CT in a large series of patients; <sup>124</sup>I PET/CT is promising but not yet widely available for clinical use.

#### <sup>18</sup>FDG-PET/CT scanning.

#### ■ RECOMMENDATION 50

- A. Imaging using <sup>18</sup>FDG-PET/CT scanning may be performed in patients with DTC at high risk of recurrence with elevated serum Tg levels, particularly in patients with OTC or aggressive histologies and in patients who have a history of negative RAI imaging. (*Conditional recommendation, Moderate certainty evidence*)
- B. Imaging with <sup>18</sup>FDG-PET/CT scanning may also be employed: (i) as a prognostic tool in patients at highest risk for rapid disease progression and disease-specific mortality and (ii) as an evaluation of post-treatment response following systemic or local therapy of invasive disease. (*Conditional recommendation, Low certainty evidence*)

In patients with high-risk DTC with elevated serum Tg levels (generally >10 ng/mL), particularly those who have negative RAI imaging, <sup>18</sup>FDG-PET/CT is primarily employed. In a meta-analysis of 17 studies that included 1195 patients,<sup>1024</sup> the sensitivity of <sup>18</sup>FDG-PET/CT was 0.86, specificity was 0.84, and the diagnostic odds ratio was 31. There was high heterogeneity and possibly publication bias, but the reported values are similar to earlier reports in non-iodine-avid DTC.<sup>745</sup> Other factors influencing <sup>18</sup>FDG-PET/CT sensitivity include tumor de-differentiation, larger tumor burden, and serum Tg doubling time.<sup>1025–1027</sup>

In patients with an aggressive histological subtype (e.g., PDTC, tall cell cancers) and OTC, <sup>18</sup>FDG-PET/CT is more sensitive; <sup>18</sup>FDG uptake in patients with metastatic DTC is a major negative predictive factor for response to RAI treatment and an independent prognostic factor for diminished survival.<sup>1028,1029</sup> It may identify lesions with high <sup>18</sup>FDG uptake (SUV) that are more aggressive, warranting local treatment or more intensive monitoring. It is complementary to WBS even in the presence of detectable uptake in metastases, because <sup>18</sup>FDG uptake may be present in sites with or without <sup>131</sup>I uptake. However, <sup>18</sup>FDG-PET/CT for patients with recurrent <sup>131</sup>I-avid disease has not been widely undertaken, and so its benefit is uncertain.

Aggressive pathological variants may produce only small amounts of serum Tg, so this reference point may not be accurate for those cancers. Shorter Tg doubling time has

been associated with increased demonstration of disease through <sup>18</sup>FDG-PET/CT, but the “cut-points” vary across reports.<sup>1025,1027,1030</sup> For patients with undetectable serum Tg levels in the setting of persistent TgAbs, the “true” Tg cannot be reliably assessed; <sup>18</sup>FDG-PET/CT may demonstrate disease in some of these patients.

A meta-analysis from 2019 indicates that the sensitivity of TSH-stimulated <sup>18</sup>FDG-PET in detection of disease may not be superior to that of studies undertaken in an unstimulated setting.<sup>1024</sup> False positive results may be found with <sup>18</sup>FDG-PET imaging with TSH stimulation.<sup>1031</sup> The frequency of false positive lesions varies from 0% to 39% between series, even with TSH stimulation. These false positive rates justify a FNA biopsy with cytology and Tg measurement in the hub washout for cases where an accessible lymph node is identified by <sup>18</sup>FDG-PET/CT (to confirm the presence of thyroid cancer prior to initiating therapy). Detection of lesions in other locations should prompt dedicated cross-sectional imaging of those regions for confirmation and clinical decision-making. Finally, it is important to recognize that <sup>18</sup>FDG-PET is insensitive for detecting brain metastases and that standard imaging stops in the mid-thigh. Thus, if there is concern for metastases to brain or below the thighs, brain MRI and extension of images to the feet should be considered.

*Is ongoing risk stratification (response to therapy) useful in guiding long-term disease surveillance and therapeutic management decisions?*

#### ■ RECOMMENDATION 51

Ongoing risk stratification (dynamic risk assessment), when used in combination with the initial risk of recurrence, allows the clinician to provide individualized management recommendations while risk estimates evolve over time and should be used to inform timing and type of imaging. (*Good Practice Statement*)

The 2015 ATA guidelines defined an updated risk stratification system (RSS) that has been demonstrated in several studies to be predictive of recurrence. In addition, dynamic risk stratification, which assesses response to therapy over time, has been shown to correlate with initial risk category and initial response to therapy; it can predict future recurrence. The 2015 ATA RSS has been shown to be more predictive of recurrence than the original 2009 ATA RSS. A review of 2425 patients with PTC after total thyroidectomy and CLND at a single institution in South Korea between 1985 and 2009 found the accuracy of the 2015 ATA RSS was superior to the 2009 ATA RSS. Due to the inclusion of small volume micro-metastasis in cervical lymph nodes in the low-risk group by the 2015 guidelines, 258 out of 1913 (13.5%) patients who were designated as intermediate-risk by the 2009 RSS were low-risk according to the 2015 RSS. In the 2015 ATA low-risk group, only 1.1% of patients had recurrences.<sup>1032</sup>

In addition, the ATA RSS is a predictor of response to therapy. A retrospective review of 2071 patients in 40 centers with DTC (NIFTP was excluded) reviewed recurrences 1 year after surgery based on their 2015 risk groups. Most patients had a total thyroidectomy, with only 3.5% receiving a lobectomy. Of the entire cohort, 1109 (53.6%) had low-risk, 796 (38.4%) intermediate-risk, and 166 (8%) had high-risk disease. Biochemical recurrence was assessed in patients

who had a total thyroidectomy, and structural response was assessed for all patients. Overall, 76.1% of all patients had excellent responses at one year. Incomplete structural responses occurred in 1.5% of the low-risk group, 5.7% of the intermediate-risk group, and 14.5% of the high-risk group, indicating that the 2015 RSS is a strong predictor of response to therapy in the short term.<sup>1033</sup>

Data on long-term outcomes were reviewed from 674 patients between 2000 and 2020 with a mean follow-up duration of 6.17 years at a single institution in Saudi Arabia. Of this cohort, 60% were low-risk, 18.8% intermediate-, and 21.2% high-risk based on the 2009 ATA RSS. Of the entire cohort, 68.4% had excellent responses, 9.6% indeterminate responses, 12.3% biochemically incomplete responses, and 9.6% structurally incomplete responses. Of those with excellent response to therapy, 68.1% were low-risk. Those with high-risk disease had structurally incomplete responses at a rate of 61.5%.<sup>1034</sup>


Dynamic risk assessment during therapy or monitoring has been validated in several studies. In one review, 2184 patients treated with total thyroidectomy and RAI between 1998 and 2014 were classified by the 2009 ATA RSS and followed with dynamic risk assessment over an average of 7 years. Most patients in the initial high-risk category moved to the low-risk group with excellent responses, and only 6.4% of patients in the low-risk group were recategorized as high-risk during the follow-up period.<sup>1035</sup> Another study, with an average follow-up duration of 10.3 years, found that the dynamic risk stratification system was an independent predictor of structural recurrence. Structural recurrence occurred in 4.7% of patients with an initial excellent response to therapy compared with 17.1%, 58.4%, and 83.9% of patients with indeterminate, biochemically incomplete, and structurally incomplete initial responses, respectively.<sup>1036</sup>

In addition to validating the 2015 RSS, some data have indicated that the initial response to therapy may be a better

predictor of outcome than the 2015 ATA RSS.<sup>1037</sup> A retrospective cohort of 176 cases of PTC compared outcomes after a median of 7 years for patients stratified by recurrence risk and by initial response to therapy and found that the initial response to therapy had a higher NPV and PPV compared with the ATA RSS system.<sup>1037</sup>


Using the proposed integrated approach, most patients achieve excellent response to therapy over time, and their response can be predicted by both initial response and improved dynamically during therapy. A single-center, retrospective cohort of 501 patients with DTC was analyzed after treatment with total/near-total thyroidectomy and RAI ablation and initial follow-up of 6 to 18 months. They were grouped by initial postoperative response to therapy (excellent, indeterminate, biochemical incomplete, and structural incomplete) and followed for a mean duration of 101 months; 258 (66.7%) had excellent, 101 (26.1%) indeterminate, 17 (4.4%) biochemically incomplete, and 11 (2.8%) structurally incomplete responses to therapy. One hundred and fourteen patients (23%) underwent an additional intervention, with 52.6% achieving excellent biochemical responses by the last assessment. At the last assessment, 417 (83.2%) of the entire cohort achieved excellent biochemical response, 1% indeterminate response, 3.6% biochemically incomplete response, and 10.2% structurally incomplete responses.<sup>993</sup>

What does each category of dynamic risk assessment mean for patients' risk of long-term recurrence? At the time of diagnosis, the initial risk of recurrence (Low, Intermediate, High) is determined based on pathology, preoperative and postoperative imaging, and Tg/TgAb levels if applicable, using our DATA framework for initial therapy (Fig. 5). It is used to predict overall risk of recurrence and to help guide therapeutic decision-making and the need for additional surgery, RAI, or more extensive treatment. Over time, dynamic risk assessment performed during the second assessment phase in the DATA framework for monitoring after therapy (Figs. 6, 7) helps further refine risk of



**FIG. 6.** Dynamic risk stratification and DATA after initial therapy. After initial pathology, imaging, and clinical evaluations are used to estimate risk of recurrence (ROR), a treatment decision is made followed by assessing response to therapy leading to a re-estimation of ROR to inform monitoring approaches.

## DATA Framework for Persistent/Recurrent Disease



**FIG. 7.** DATA framework when a patient is diagnosed with residual or clinically recurrent localized DTC in the neck.

recurrence estimates. This can be assessed at every visit and may change over time. Since response to therapy differs for those who have undergone total thyroidectomy or lobectomy and for those treated with total thyroidectomy with or without RAI treatment, such categories have been evaluated separately in some papers, but additional studies are needed.

*For patients treated with total thyroidectomy and RAI.* When evaluating patients from all initial risk of recurrence categories, those who achieved an excellent response to therapy had recurrence rates of 1–4%.<sup>712,729,771,1036,1038–1042</sup> When specifically evaluating low-risk patients who achieved an excellent response, risk of recurrence was 0.2–2%.<sup>994,1043</sup> When evaluating intermediate-risk patients, 1–12% developed a structural recurrence.<sup>1043,1044</sup> Patients with high risk at initial assignment who achieved an excellent response experienced recurrences 3–15% of the time.<sup>602,652,712,1042,1045</sup>

For those with an indeterminate response to therapy, recurrence rates range from 5%<sup>1046</sup> to 15–20%.<sup>1043,1047,1048</sup> Patients with biochemically incomplete responses to therapy

experienced recurrences 20–53%<sup>1036,1046,1048</sup> of the time. For this category, it is harder to determine true structural disease rates, since biochemically incomplete response was also often combined with structurally incomplete responses to therapy. The combined recurrence rates were as high as 85%.<sup>712,729,1036,1038,1041,1043,1048</sup>

*For those who had total thyroidectomy without RAI.* All patients who undergo lobectomy or total thyroidectomy without RAI are low- or intermediate-risk, with rare exception. Hence, these studies do not represent high risk of recurrence patients. Those with excellent responses had recurrence rates of 0–1.6%<sup>732,1047,1049,1050</sup> in all studies except Lee et al., where a recurrence rate of 7.4% was observed.<sup>1036</sup>

Those with indeterminate responses experienced a 0–5.6% recurrence rate.<sup>732,1036,1042,1047,1049,1050</sup> Biochemically incomplete response to therapy was associated with a 0–31.6% rate of recurrence.<sup>732,1036,1042,1047,1049,1050</sup> All those categorized as structurally incomplete responses experienced continued presence of disease.<sup>732,1036,1042,1049,1050</sup>

As shown in Figure 6, recurrence rates for all initial risk of recurrence categories that derive excellent response to therapy are <15%. Those with initial low risk of recurrence with excellent response to therapy have a  $\leq 2\%$  chance of recurrence. Those with initially high risk of recurrence have higher recurrence rates (up to 15%), so they may warrant closer follow-up, but overall, this category experiences low rates of recurrence, which supports de-escalation of monitoring with continued excellent response to therapy. For those with indeterminate or biochemically incomplete responses to therapy, recurrence rates have been reported to be as high as 20% for indeterminate and 53% for biochemically incomplete responses. These data support continued biochemical and imaging follow-up. Those with stable Tg and/or TgAb levels should have ongoing imaging. In contrast, those with rising Tg or TgAb titers should have additional imaging, including cross sectional imaging or PET/CT, to evaluate for progressive structural disease that would warrant intervention.

When and what type of treatment should be performed when there is evidence for locoregional residual, clinically recurrent, or progressive DTC?

#### ■ RECOMMENDATION 52

1. A decision to perform a therapeutic compartmental or focused central and/or lateral neck operation in the reoperative setting should be based on a combination of factors. These include extent of prior operation(s), size and anatomic location of new disease, pace of growth, patient factors and preference, and context to overall disease management. (*Good Practice Statement*)
2. Percutaneous ethanol ablation may be considered an alternative therapy for recurrent or residual thyroid cancer, with greatest use in patients at high risk for complications from reoperation. (*Conditional recommendation, Low certainty evidence*)
3. RFA may be considered an alternative therapy in recurrent or residual thyroid cancer, with greatest use in patients at high risk for complications from reoperation. (*Conditional recommendation, Low certainty evidence*)

Depending on the initial tumor risk and the response to initial therapy, imaging-detected locoregional persistent or recurrent disease can occur in up to 30–40% of patients with PTC.<sup>168</sup> Risk for individual patients can be estimated based on the ATA Risk of Recurrence and by category of response to initial therapy (**Recommendations 31 and 51**). For example, in a 2023 study of 2302 patients with consecutive DTC treated at a single center who had an initially excellent response to primary treatment (as defined by the 2015 ATA guidelines), 32 (1.4%) experienced recurrence over a median follow up of 6.3 years. Clinical recurrence rates were 1.3%, 1.8%, 10%, and 14.3% for PTC, FTC, OTC, and PDTC, respectively.<sup>1051</sup> After initial resection with at least total thyroidectomy, patterns of locoregional recurrence requiring reoperation vary in the literature, with recent reports describing most recurrences transpiring in the lateral neck (66–78%).<sup>1052–1055</sup> For patients who underwent thyroid

lobectomy, recurrent disease often occurs in the contralateral lobe (35–56%) and lymph nodes (44–65%).<sup>325,346,349,1056</sup> Persistent or recurrent disease may result in local invasion and is the source of considerable patient and clinician anxiety.<sup>1057</sup> However, several observational studies suggest that low-volume recurrent nodal disease can be indolent and approached through active surveillance, although some lesions in these series are not malignant.<sup>739,1058</sup> An approach to patients with residual/recurrent DTC limited to the neck is depicted in Figure 7.

In prior ATA guidelines, size of a recurrent lymph nodes has been the primary determinant in consideration of surgical intervention. If a metastatic lymph node was >8 mm in the smallest dimension in the central neck or >10 mm in the lateral neck, reoperation was preferred over continued monitoring. The dimensions were selected because they represented the minimal size to be considered suspicious on imaging. Based on these recommendations, Lang et al. studied the effect of central compartment lymph node size on oncologic outcomes and morbidity of reoperative CLND.<sup>1055</sup> In this retrospective study of 130 patients who underwent reoperation, central compartment lymph nodes measuring >15 mm in smallest dimension represented an independent risk factor for biochemical incompleteness (compared to individuals with smaller disease); individuals grouped by disease <10 mm and between 10–15 mm did not differ from one another. Those patients with disease >15 mm had a significantly higher incidence of recurrent laryngeal nerve involvement and a higher rate of temporary, but not permanent, vocal cord paresis. These findings suggest that the previous threshold of 8 mm might potentially be increased to  $\geq 15$  mm in the central neck.

Multiple factors in addition to size should be considered when determining if reoperation is appropriate for recurrent disease in the neck, including proximity of metastatic lymph nodes to adjacent vital structures and the functional status of the vocal cords. Patient comorbidities, motivation, and emotional concerns also should be assessed, along with primary tumor factors (high-grade histology, Tg level doubling time, RAI avidity, and <sup>18</sup>FDG-PET avidity). In an environment of collaborative transdisciplinary management, metastatic lymph nodes can be monitored for progression in appropriately selected and counseled patients via serial clinical and radiographical monitoring. Surgery or other “rescue” interventions usually can be offered if progression is observed. If disease remains stable, then monitoring can continue. Decisions about when to monitor versus proceed with an intervention should use shared decision-making with the patient and include an experienced multidisciplinary team.

Bulky and/or invasive recurrent disease is generally best treated with surgery.<sup>321,1059–1062</sup> The judgment to offer surgery for recurrent nodal disease in the neck should compare two domains: (1) the (increased) risks of revision surgery balanced against (2) resection constituting optimal treatment for macroscopic (gross) nodal disease. An important element in this decision-making process is the availability of expertise in the performance of reoperative thyroid cancer surgery, which is chiefly to be found in referral centers. The decision to treat cervical lymph node recurrences with surgery should be made with consideration of the presence of distant disease and whether progression has been seen. Even in the setting of progressive distant disease, reoperative lymphadenectomy

may be indicated to palliate symptoms and/or prevent aerodigestive tract obstruction or invasion. Transdisciplinary coordination of care is key for such complicated patients. Patient perspective and preferences are of paramount importance when weighing risks and benefits.<sup>302</sup> Cytological confirmation of disease can be deferred if the findings will not change management. While cytological confirmation of abnormal radiographical findings prior to resection is generally advised, this may not be necessary (or possible) in every case (e.g., radiographical findings assigned a very high likelihood of malignancy based upon growth or symptoms, or the specific location of the lesion making it difficult/impossible to biopsy).

Reoperation is the most appropriate management for most patients with clinically apparent, macroscopic nodal disease identified via imaging rather than through serum Tg level elevation; meticulous anatomical characterization is crucial to inform the surgical approach.<sup>240,241,629</sup> In view of the increased risks of revision surgery, a clearly identified technical goal is mandatory. The risks of operations are strongly informed by the exact location of the recurrence/target node(s) and the extent to which the surgical field in question was previously manipulated. For example, the risks are elevated if there are recurrent central compartment lymph nodes after thyroidectomy, but typically less in the setting of lateral neck dissection following previous removal of a single node (berry-picking). The disease target must be defined by high-resolution anatomical studies such as ultrasound or CT with contrast, and by <sup>18</sup>FDG-PET/CT or RAI-SPECT/CT (as opposed to PET or RAI scan alone), to permit best preoperative planning. Ultrasound-guided FNA for cytology and Tg measurement in the aspiration sample should be performed to confirm the nodal recurrence prior to surgery when feasible.

Because of the increased risk of recurrence with ‘‘berry-picking,’’ compartmental dissection is recommended in the primary setting (Recommendation 20)<sup>1063,1064</sup> and during reoperation if it proves possible; recurrences in the environment of previous compartmental dissection usually are not amenable to formal lymphadenectomy because node-bearing tissues have been removed. Hence, planned reoperative dissection may be more limited, depending upon the surgeon’s assessment of the safety of the procedure in the context of scarring/distortion of anatomy (from prior surgery and/or radiation therapy) and the likelihood of complications. Revision lateral neck dissection involves Levels II, III, IV, and sometimes V, especially if a less than complete compartmental dissection was previously performed. Reoperative central neck dissection usually includes at least one paratracheal region with prelaryngeal and pretracheal sub-compartments. Bilateral central neck dissection is to be advised only when required by recurrence on both sides of the neck due to risks of bilateral recurrent nerve injury and permanent hypoparathyroidism. In modern series reported according to the most recent response nomenclature, reoperative surgery results in 27–63% excellent responses, 5.7–13.3% biochemically incomplete responses, 10–44% structurally incomplete responses, and 8.6–30% indeterminate responses.<sup>1065–1067</sup> Patient age >45 years, aggressive histology, and LNR >0.6 at initial resection were found to be independent risk factors for an incomplete response after reoperation.<sup>1067</sup> In these

reports, risk of permanent hypoparathyroidism ranged from 0% to 5.9%, and risk of permanent vocal cord paresis ranged from 0% to 1.3%, suggesting that reoperative central compartment surgery is safe in expert hands.

Percutaneous ethanol ablation for patients with metastatic lymph nodes has been employed as a nonsurgical directed therapy for patients with recurrent DTC. While no prospective comparisons between percutaneous ethanol ablation and surgery for recurrent disease have been performed, a meta-analysis of 27 studies including 1618 patients indicated that surgery has a success rate of 94.8% compared with 87.5% with percutaneous ethanol ablation, but that complications associated with surgery were slightly higher.<sup>1068</sup> Because percutaneous ethanol ablation encourages the clinical team to address an individual lesion rather than pursuing a compartmental approach, reoperative surgery is still considered the first-line therapy for patients with recurrent DTC. As is true with reoperative surgery, percutaneous ethanol ablation is best performed by clinicians with expertise in the technique and ideally should be performed for disease that is cytologically proven based on FNA.

Most published studies are limited to percutaneous ethanol ablation for patients who underwent prior neck dissections with RAI treatment and to individuals who have FNA-proven DTC in a lymph node. The largest study to date included 44 patients treated with ethanol injection for lymph nodes with metastatic PTC; it showed local control in 80% of patients, with a median follow-up of 11.3 years and no major complications.<sup>1069,1070</sup> A total of 13 recurrent lesions occurred in 10 patients at the previous ablation site (19% recurrence); most of these were found in the lateral neck. Another study retrospectively reviewed 25 patients who had 37 lymph nodes ablated with a mean follow-up of 65 months.<sup>1071</sup> Most of the lymph nodes shrank, and 46% completely disappeared. Serum Tg levels declined in most patients and entered an acceptable range (<2.4 ng/mL) in 82% of patients without TgAb. There were no serious or long-term complications. One series demonstrated durable responses following ethanol injection, reporting that 87% of 71 lesions responded completely at a mean of 40.5 months. Another study showed a decrease or no growth in 75.6% of the 46 lesions ablated over a mean of 74 months<sup>1072,1073</sup>; again, there were no long-term complications. Some patients required more than one percutaneous ethanol ablation treatment. These retrospective studies and reviews suggest that percutaneous ethanol ablation is a safe procedure warranting consideration in patients who are poor surgical candidates due to high anesthesia risk, multiple prior operations in the disease bed, or previous neck irradiation.

RFA under local anesthesia for the treatment of recurrent DTC also has been reported over the last several years. As might be expected, the overwhelming majority of studies were undertaken retrospectively. Short-term results (with follow-up periods ranging from 21 to 36 months) of RFA for nodules with a mean maximum diameter of 0.8–1.4 cm were associated with a mean volume reduction that has ranged between 95% and 98%, with complete disappearance of metastatic foci in 61–94% of the cases.<sup>1074–1078</sup> A recent meta-analysis revealed that the serum Tg level decreased after RFA; the pooled proportion of reduction in serum Tg levels after RFA was 71.6% [CI 63.5–79.7%].<sup>1079</sup> Chung et al.

reported an experience with 46 recurrent DTC lymph nodes (median largest diameter, 0.84 cm  $\pm$ 0.47) in 29 patients<sup>1080</sup> after a mean follow-up of 80 months. The study observed that the tumor volumes exhibited a mean reduction of 99.5% and complete tumor disappearance in 91.3% by the final evaluation. There were significant reductions in Tg levels, and there were no delayed complications noted.

Choi et al. examined patients with local recurrences after primary surgery and compared the efficacy and complication rates between the RFA ( $n = 96$ ; 67% central, 33% lateral) and revision surgery groups ( $n = 125$ ; 43% central, 57% lateral).<sup>1081</sup> After propensity score adjustment, the recurrence-free survival rates were similar between the two groups ( $p = 0.2$ ), as was the decrease in mean serum Tg levels post-treatment (RFA  $p = 0.891$  and surgery  $p = 0.963$ ). They showed no significant differences between groups with respect to procedural complications and voice changes. Overall complications were significantly more frequent in the surgery group (RFA,  $n = 7$ ; surgery,  $n = 27$ ;  $p < 0.001$ ); 13 of 70 surgical patients experienced permanent hypocalcemia, but no patient in the RFA cohort was similarly affected.

As with percutaneous ethanol ablation, multiple treatment sessions often are required. Immediate complications include discomfort, pain and sensation of heat, hematoma, and changes in voice.<sup>1082</sup> A meta-analysis evaluating safety of RFA in recurrent DTC found overall and major complication rates of 10.98% and 6.71%, respectively.<sup>1083</sup>

Both percutaneous ethanol ablation and RFA appear to be most useful for patients at high surgical risk rather than as an equivalent alternative to resection of metastatic disease.<sup>1082,1084</sup> Preliminary findings using ultrasound-guided laser ablation for treatment of cervical lymph node metastases have been reported.<sup>1085–1087</sup> There has not yet been a randomized trial comparing observation with these minimally invasive techniques in the setting of small lesions. Such studies are necessary to determine their optimal use. Additional experience is needed interpreting radiographical response to the therapies and whether they are superior to monitoring.

Should RAI therapy be used for the treatment of isolated cervical lymph node metastases?

#### ■ RECOMMENDATION 53

Additional RAI therapy for identified isolated cervical lymph node metastases may be considered after local therapy has been performed or if local therapy is not feasible. (*Conditional recommendation, Low certainty evidence*)

Hirsch et al. retrospectively studied the effect of a second RAI treatment in a cohort of patients with DTC with incomplete biochemical/structural response to initial treatment with surgery and RAI in the absence of distant metastases.<sup>1088</sup> For the incomplete biochemical response cohort, 44 of the 60 patients with evaluable data (73.3%) still had an elevated Tg level 1–2 years after the second RAI treatment. For the incomplete structural response cohort who underwent re-treatment with RAI alone (median lesion size 11.6 mm), no significant change in stimulated or unstimulated Tg levels ensued 1–2 years after the second RAI treatment. Three of 47 (17.6%) patients had resolution of their nodes based on imaging follow-up 1–2 years after the second RAI dose. Of the remaining 44 patients, 10 (22.7%) showed

locoregional structural progression, 2 (4.5%) showed a decrease in nodule size, and 26 (59.0%) experienced stable disease. These data suggest limited benefit of a second RAI treatment in patients with DTC with biochemical or structural evidence of persistent locoregional disease. Hung et al. retrospectively evaluated use of RAI after reoperation for recurrent or persistent disease.<sup>1089</sup> Of 102 patients undergoing reoperation, 50 (49.0%) received additional RAI. Median Tg levels at all timepoints studied were similar between the reoperation with RAI group and the reoperation without RAI group (Tg before reoperation, 3.3 ng/mL vs. 2.4 ng/mL, respectively; Tg after reoperation, 0.6 ng/mL vs. 0.2 ng/mL; and Tg after RAI, 0.5 ng/mL vs. 0.2 ng/mL; all differences were nonsignificant). Structural recurrence after reoperation occurred in 18 of 50 patients (36%) in the reoperation with RAI group and 10 of 52 patients (19%) in the reoperation without RAI group. In multivariable analysis accounting for clinicopathologic characteristics and Tg levels before reoperation, administration of RAI after reoperation was not associated with the rate of a second structural recurrence, suggesting limited benefit of this approach. Piccardo et al. found RAI after reoperation for DTC recurrence was significantly associated with better progression-free survival in patients with a suppressed Tg of  $>1$  ng/mL.<sup>1090</sup> It should be noted that the evidence to support this recommendation is low quality, and prospective studies could be helpful in identifying patients for whom repeated RAI may be appropriate.

Should external beam radiation therapy be used in isolated cervical node metastases?

#### ■ RECOMMENDATION 54

EBRT using modern techniques such as IMRT and stereotactic radiation may be considered for locoregional recurrences that are not surgically resectable or when there is extranodal extension or involvement of soft tissues. (*Conditional recommendation, Low certainty evidence*)

Stereotactic body radiotherapy (SBRT) can be used to treat isolated metastatic foci, but it does not have a role in most patients with resectable lymph node metastases. As outlined in detail in **Recommendation 44**, EBRT using modern techniques such as IMRT and stereotactic radiation should be considered for locoregional recurrences that are not surgically resectable; not responsive to other local therapy or RAI; or when there is extranodal extension or involvement of soft tissues, particularly in patients with no evidence of distant disease. The data supporting the use of radiation in this setting are discussed in detail in **Recommendation 44**. Side effects related to voice, swallowing, nutrition, and skin changes should be considered.

What preparation and dosing strategies should be used for RAI therapy for locoregional and/or distant metastases?

#### ■ RECOMMENDATION 55

- A. Empirically administered amounts of  $^{131}\text{I}$   $>5.5$  GBq (150 mCi) that have high potential to exceed toxicity parameters should be avoided in patients  $>70$  years or with renal failure. Such patients should be evaluated with dosimetry to confirm safety prior to RAI administration if doses  $>5.5$  GBq (150 mCi) are being

considered. (*Strong recommendation, Moderate certainty evidence*)

- B. Dosimetry-guided RAI (either lesional or maximum tolerated activity) may be considered in patients with locoregional or metastatic disease when administered activities >5.5 GBq (150 mCi) are considered. (*Conditional recommendation, Moderate certainty evidence*)
- C. rhTSH-mediated elevation or LT4 withdrawal may be utilized to prepare patients with distant metastatic disease who are being treated with RAI. (*Conditional recommendation, Low certainty evidence*)

The optimal therapeutic activity for treatment of locoregional or distant metastases remains controversial.<sup>760,1091–1094</sup> In general, activity selection strategies include imaging-adapted, risk-based fixed dosing, or dosimetric approaches including MTA or lesional dosimetric methods.<sup>781,1095–1100</sup> The primary advantage of a fixed dosing strategy is its relative ease and straightforward application, while use of lesional dosimetry potentially allows for more precise administration of biologically guided activity to be based on the patient's unique tumor burden and physiology. In the MTA dosimetry approach, serial blood sampling and/or imaging are used to determine the maximum safely administered activity, which has been empirically determined to be a dose not >2Gy (200 rads) to the blood, and not >4.44 GBq (120 mCi) retained in the whole body 48 hours post-administration (or 2.96 GBq, 80 mCi in the case of patients with diffuse lung metastases).<sup>781,875</sup> With the lesional dosimetry approach, pre-therapy imaging is used to prescribe a predicted radiation dose to thyroid remnants or sites of metastatic disease.<sup>1101</sup> Use of dosimetry for administered activity is favored in patients with renal insufficiency,<sup>1102,1103</sup> children,<sup>1104,1105</sup> older patients (>70 years of age), and/or patients with extensive pulmonary or bony metastases.

Comparison of outcomes among these methods is difficult, and no prospective randomized trial has delineated the optimal approach. One retrospective study concluded that patients with locoregional disease were more likely to respond after dosimetric therapy than after empirical dosing.<sup>784</sup> Another study demonstrated improved efficacy of administration of dosimetric maximal activity after failure of empirical dosage.<sup>1106</sup> Arguments in favor of higher activities cite a positive relationship between the total uptake per tumor mass and outcome,<sup>1107</sup> while others have not confirmed this association.<sup>1108</sup> The study by Deandreis et al. demonstrated equivalent overall survival benefit between MTA-guided dosimetry therapy and empirical treatment, although this work was limited by its retrospective design and major differences between the study populations.<sup>1109,1110</sup> In specific settings (i.e., patients with radiation-induced DTC after Chernobyl), radioiodine treatment may be associated with good outcomes even in high-risk patients with metastatic disease.<sup>1111</sup> In principle, improved imaging methods including <sup>124</sup>I PET and <sup>123</sup>I/<sup>131</sup>I SPECT have the potential to augment the accuracy of dosimetric methods.<sup>1112,1113</sup> Considering cost and logistics with multi-time point dosimetry, simplified dosimetry methods have been proposed.<sup>1112,1114,1115</sup> These typically employ a simplified single time-point measurement after administration of a diagnostic dose of <sup>123</sup>I, <sup>124</sup>I, or <sup>131</sup>I to estimate maximum tolerated dose.

The efficacy of RAI therapy is related to the mean radiation dose delivered to neoplastic foci and to the radiosensitivity of tumor.<sup>1116</sup> Radiosensitivity is higher in patients (i) who are younger, (ii) with small metastases from PTC or FTC, and/or (iii) with RAI uptake but no or low <sup>18</sup>FDG PET uptake.

The maximum tolerated absorbed radiation dose, commonly defined as 200 rads (cGy) to the blood, is potentially exceeded in a significant number of patients undergoing empirical treatment. In one study, 1–22% of patients treated with RAI according to dosimetry calculations would have theoretically exceeded the MTA had they been empirically treated with 3.7–11.1 GBq (100–300 mCi) of <sup>131</sup>I.<sup>783</sup> Another study found that an empirically administered activity of 7.4 GBq (200 mCi) would exceed the MTA in 8–15% of patients <70 years and 22–38% of patients ≥70 years.<sup>782</sup> Administering 9.25 GBq (250 mCi) empirically would have exceeded the MTA in 22% of patients <70 years and 50% of patients ≥70 years. These estimates suggest a need for caution when administering empirical activities >3.7–5.55 GBq (100–150 mCi) to older patients and those with renal failure; they support the recommendation that patients in this group undergo dosimetrically guided therapy. Patients should be counseled about the potential risks and benefits of RAI as noted in **Recommendations 39–43**. Decisions about dosing, timing, and preparation should all be made in a shared decision-making process, as patients may have important concerns.

While patients with distant metastases have traditionally been prepared for RAI therapy using thyroid hormone withdrawal, rhTSH can be used as an alternative for many patients. RhTSH preparation for RAI has been recommended for select patients with underlying comorbidities that make iatrogenic hypothyroidism potentially risky; these patients include those with pituitary disease who are unable to raise their serum TSH and patients for whom a delay in therapy must be avoided. Generally, such patients should be given the same or higher activity than would have been delivered had they been prepared with thyroid hormone withdrawal. This activity selection strategy is supported by studies demonstrating enhanced detection of metastases in patients undergoing thyroid hormone withdrawal compared to rhTSH preparation.<sup>1117,1118</sup> The amount of radiation delivered to a metastatic lesion per mCi administered may be different for preparation with thyroid hormone withdrawal versus rhTSH, but the amount of radiation delivered to the critical and noncritical organs also may be different. Plyku et al. performed a study in which both stimulation methods were deployed in four patients, with marked differences in absorbed radiation doses in normal tissues.<sup>1118</sup> These findings warrant further study.

There are no randomized controlled trials comparing outcomes of preparation with thyroid hormone withdrawal therapy to rhTSH-mediated therapy for treatment of distant metastatic disease, but there is a growing body of non-randomized studies reporting use of rhTSH to prepare patients in this context.<sup>1119</sup> Gomes-Lima et al. demonstrated similar survival in patients with metastatic DTC prepared with rhTSH and thyroid hormone withdrawal in a retrospective cohort study of 55 patients.<sup>1120</sup> Small comparative studies have suggested that the radiation dose to metastases is lower with

rhTSH than following withdrawal.<sup>1118,1121</sup> Many of these case reports and series report disease stabilization or improvement following rhTSH-mediated RAI, but it is unclear whether the efficacy of this preparation is comparable to that of thyroid hormone withdrawal. Extreme or prolonged elevations of TSH may acutely stimulate tumor growth and volume of metastatic disease.<sup>1122,1123</sup> With brain metastases or metastases close to the spinal cord or superior vena cava, swelling can compromise neurological function or produce superior vena cava syndrome. If brain or spinal canal metastases are detected, EBRT prior to RAI and high-dose corticosteroid therapy are recommended to limit the risk of acute tumor swelling (see **Recommendation 79**). For the timing before and after RAI, dexamethasone 2–4 mg can be administered every 8 hours starting 6–12 hours prior to rhTSH and RAI administration or after 10–12 days of thyroid hormone withdrawal; the steroid dosages can be tapered (i) over 1 week post-therapy, or (ii) for 48–72 hours after rhTSH administration, or (iii) for 72 hours after re-institution of thyroxine therapy when thyroid hormone withdrawal was employed.<sup>1119</sup> In these challenging situations, consideration should be given to attenuating the degree and duration of endogenous TSH elevation after thyroid hormone withdrawal by monitoring serum TSH levels. Satisfactory RAI treatment is generally thought to be feasible after achieving TSH levels of 30–50 mU/L. With thyroid hormone withdrawal, LT4 therapy should be recommended immediately after RAI is administered to reduce the duration of TSH elevation.

What RAI dosing strategies should be used for patients with pulmonary metastases?

■ **RECOMMENDATION 56**

- A. Pulmonary micrometastases can be treated with RAI therapy, and this may be repeated if the disease continues to concentrate RAI and clinically respond. (*Conditional recommendation, Low certainty evidence*)
- B. RAI dosing for pulmonary micrometastases should either be empiric (3.7–7.4 GBq, 100–200 mCi, or 3.7–5.55 GBq, 100–150 mCi for patients >70 years) or estimated by dosimetry to limit whole-body retention to 2.96 GBq (80 mCi) at 48 hours with 200 cGy to the bone marrow. (*Good Practice Statement*)
- C. Radioiodine-avid macronodular metastases can be treated with RAI, and treatment can be repeated when objective benefit is demonstrated. RAI dosing either may be empiric (3.7–7.4 GBq, 100–200 mCi, or 3.7–5.55 GBq, 100–150 mCi for patients >70 years) or informed by whole-body dosimetry to limit whole-body retention to 2.96 GBq (80 mCi) at 48 hours with 200 cGy to the bone marrow. (*Conditional recommendation, Low certainty evidence*)

For patients with pulmonary metastases, key criteria for therapeutic decisions include (i) size of metastatic lesions (e.g., macronodular typically detected by chest radiography, micronodular typically detected by CT, lesions beneath the resolution of CT); (ii) avidity for RAI and, if applicable, response to prior RAI therapy; and (iii) stability (or lack thereof) of metastatic lesions.<sup>1124</sup> Pulmonary pneumonitis

and fibrosis are rare complications of high activity treatment, and they can be severe or even fatal.<sup>1125</sup> Dosimetric approaches to the selection of therapeutic activity with a limit of 2.96 GBq (80 mCi) whole-body retention at 48 hours with 200 cGy to the bone marrow should be considered in patients with diffuse pulmonary uptake to reduce these risks.<sup>875</sup> If pulmonary fibrosis is suspected, then appropriate periodic pulmonary function testing and consultation should be obtained. Pulmonary fibrosis may limit the ability to retreat metastatic disease with RAI.<sup>1126</sup>

Patients with pulmonary micrometastases (<2 mm, generally not seen on CT imaging) that are RAI-avid have the highest rates of complete remission after treatment with <sup>131</sup>I.<sup>1127–1130</sup> These patients may be treated and re-treated with RAI up to every 6–12 months, if disease continues to concentrate RAI and to respond clinically, and if pulmonary side effects are not encountered.

Macronodular pulmonary metastases that are iodine-avid also may be treated with RAI. Factors to consider are disease response to treatment, patient age, and the presence or absence of other metastases.<sup>1127,1128</sup> Patients with solitary pulmonary metastases may be considered for surgical resection or radiation therapy, although the risk–benefit ratio for surgery is unclear.

A precise definition for “clinical response” is challenging in view of the wide variation observed in disease presentation and response to therapy. A meaningful response to RAI is generally a significant reduction in serum Tg level and/or the size (or rate of growth) of structurally apparent disease. Reduction in serum Tg level when RAI uptake does not fall or when there is a simultaneous increase in tumor size suggests cancer refractory to RAI or inadequate treatment. In the presence of widespread metastases, especially in bone, additional RAI may temporarily inhibit progression, but it is unlikely to result in cure, and the risks of bone marrow suppression or pulmonary fibrosis should engender caution when considering repeated RAI administrations. Absolute neutrophil count and platelet counts are markers of bone marrow suppression, and pulmonary function testing including diffusing capacity of the lungs for carbon monoxide can be markers of pulmonary toxicity. Other approaches should be employed once RAI disease is encountered (see **Recommendation 59**).

The likelihood of long-term benefit of RAI in patients with elevated Tg levels and negative diagnostic WBS is low.<sup>1131</sup> While some reduction in serum Tg may be observed after empirical therapy, one analysis concluded there was insufficient evidence to support this assertion.<sup>1132</sup> In one small retrospective series of patients with structural disease but negative diagnostic WBS, additional RAI therapy was associated with stability of disease in 44% of patients and progression of structural disease in 56% of patients.<sup>1133</sup>

What RAI dosing strategies should be used for patients with bone metastases?

■ **RECOMMENDATION 57**

- A. RAI for iodine-avid bone metastases has been associated with improved survival and should be employed. (*Strong recommendation, Low certainty evidence*)
- B. The activity administered could be given either empirically (3.7–7.4 GBq, 100–200 mCi) or as

determined by dosimetry. (*Conditional recommendation, Very low certainty evidence*)

RAI for patients with bone metastases is generally not curative, but many patients with RAI-avid bone metastases experience benefit.<sup>1128,1134,1135</sup> The dosimetrically determined administered activity of <sup>131</sup>I may be beneficial in comparison to empirical dosing,<sup>1107</sup> but this has not been shown in prospective, controlled studies. In addition to improved survival, some patients receiving RAI also may have palliation of bone pain.<sup>1136</sup> As outlined in **Recommendations 77 and 78** for patients with RAIR DTC, patients undergoing RAI therapy for RAI-avid bone metastases also should be considered for directed therapy when the metastases are visible on anatomical imaging. This recommendation is supported by Wu et al., who found that patients undergoing combination treatment (surgery, EBRT, other focal treatment modalities) in addition to RAI experienced superior outcomes compared to patients treated with RAI alone.<sup>1137</sup> Such patients also should be considered for systemic therapy with bone-directed agents as described in **Recommendation 78**.

When should empirical RAI be considered for Tg-positive, RAI diagnostic scan-negative patients?

#### ■ RECOMMENDATION 58

- A. In the absence of structurally demonstrable disease, patients with stimulated serum Tg <10 ng/mL after thyroid hormone withdrawal or <5 ng/mL with rhTSH (indeterminate response) can be followed with thyroid hormone therapy alone, reserving additional treatment for emergence of rising serum Tg levels over time or other evidence of structural disease progression. (*Conditional recommendation, Low certainty evidence*)
- B. Empiric (3.7–7.4 GBq, 100–200 mCi) or dosimetrically determined RAI therapy may be considered in patients with more significantly elevated or rapidly rising serum Tg levels where imaging (e.g., cross sectional imaging and/or <sup>18</sup>FDG-PET/CT) has failed to reveal tumor amenable to directed therapy. (*Conditional recommendation, Low certainty evidence*)
- C. If persistent nonresectable disease is localized after empiric administration of RAI, and there is objective evidence of significant tumor reduction, then repeated RAI therapy can be considered until the tumor has been eradicated or the tumor no longer responds to treatment. (*Conditional recommendation, Low certainty evidence*)

There is no recognized cutoff value for a serum Tg level above which a patient empirically should be treated with RAI. Most studies have reported primarily on patients after LT<sub>4</sub> withdrawal with Tg levels ≥10 ng/mL; it has been suggested that a corresponding level after rhTSH stimulation would be 5 ng/mL.<sup>1131,1138–1140</sup> Patients with a suppressed<sup>1141</sup> or stimulated<sup>1142</sup> serum Tg level of ≥5 ng/mL are unlikely to demonstrate decline without therapy, and they have higher rates of subsequent structural recurrence. In addition, a rising serum Tg level heralds clinically apparent disease, particularly if the rise is rapid.<sup>1143,1144</sup>

If serum Tg levels suggest persistent or recurrent disease but diagnostic RAI WBS is negative and structural or <sup>18</sup>FDG-

PET/CT imaging do not reveal disease amenable to directed therapy (surgery, thermal ablation, EBRT, alcohol ablation), then empirical therapy with RAI (3.7–7.4 GBq, 100–200 mCi) or dosimetrically determined RAI activities can be considered for two purposes: (i) to aid in disease localization and/or (ii) as therapy for unidentified disease. This approach may disclose the location of persistent disease in up to 50% of patients.<sup>1139,1145,1146</sup> However, the reported range of success is wide. From a therapeutic perspective, more than half of patients with negative diagnostic WBS experience a fall in serum Tg levels after empirical RAI therapy,<sup>1140,1147,1148</sup> but improved survival has not been shown with empirical therapy in this setting.<sup>1131,1138,1139</sup> There is evidence that Tg levels may decline without therapy in a proportion of patients with Tg levels <10 ng/mL.<sup>713,1094,1138,1141,1144,1149–1153</sup> The most compelling evidence for benefit from empirical RAI therapy is for multiple pulmonary metastases, which are typically not amenable to surgical management or EBRT.<sup>1138,1154</sup>

How is radioiodine-refractory DTC classified?

#### ■ RECOMMENDATION 59

- A. RAIR DTC (including OTC) cannot be diagnosed in patients who have not received an ablative or treatment dose of RAI. Patients who meet criteria for RAI should receive ablative or treatment administrations of RAI to determine status. (*Good Practice Statement*)
- B. Patients who have RAIR DTC should not receive additional empiric RAI therapy. Other treatments should be considered. (*Good Practice Statement*)

Strong criteria suggesting iodine-refractory DTC include (i) absence of <sup>131</sup>I uptake on a post-therapy scan (**Recommendation 37**) in the setting of confirmed disease visible on structural or <sup>18</sup>FDG-PET imaging. This may occur at the time of initial treatment of metastatic DTC or at the time of a subsequent RAI, and/or (ii) progression of disease less than 6 months after a treatment appropriate administration of therapeutic RAI demonstrated uptake on post-therapy scans.

Response to RAI therapy can be heterogeneous, and there is a spectrum of responsiveness. There has been controversy in defining response and refractoriness to RAI therapy.<sup>760,1155</sup> These controversies were summarized in a recent multidisciplinary meeting and publication that promoted the following statements<sup>1156</sup>:

- A. Characteristics used to classify patients as RAIR should be used to risk-stratify patients about the likelihood that their tumors will respond to RAI. They should not necessarily serve as definitive criteria to mandate whether RAI should be recommended.
- B. RAIR criteria will continue to evolve as (a) additional studies address important limitations and technical issues confounding the current literature, (b) techniques for RAI imaging are optimized and standardized, and (c) re-differentiation therapies enhance the effectiveness of RAI.

In clinical practice, patients and clinicians together must make judgments about the appropriateness of continued RAI, and so it is important to provide a framework for treatment planning. We propose the following criteria

which may suggest an iodine-refractory state in patients with metastatic DTC: When a patient does not have uptake on post-therapy scans in the setting of structurally apparent disease on imaging, and/or when there is progression of disease fewer than 6 months after treatment, such a patient is unlikely to receive benefit from additional RAI administration.

*Supplemental criteria suggesting less RAI sensitivity.*

- A. No uptake present on a diagnostic  $^{123}\text{I}$  or  $^{131}\text{I}$  WBS in the presence of otherwise detectable disease. This criterion is known to predict less favorable response to RAI, but some fraction of patients in this category will have a positive post-therapy scan and may still derive some clinical benefit from RAI.
- B. Uptake is present in some (but not all) tumor foci on post-therapy WBS. This criterion does not preclude use of RAI but instead suggests that a multimodal treatment approach could be appropriate depending on therapeutic response. RAI alone is not adequate treatment for this subgroup of patients.

Prognosis for patients with DTC is usually favorable, even when metastatic iodine-avid disease is present.<sup>1157</sup> For this reason, RAI is considered primary treatment for RAI-avid metastatic disease. However, a subgroup of patients with DTC with advanced disease do not respond, or become refractory, to RAI; while some of these patients die within 3–5 years, there are also long-term survivors with stable or very slowly progressive disease.

Predictors for tumor response to RAI treatment are presence of  $^{131}\text{I}$  uptake, younger patient age, well-differentiated histology, small metastases, and low  $^{18}\text{F}$ FDG uptake. These parameters are closely related<sup>1154,1158,1159</sup> and can predict response to treatment. About two-thirds of patients with metastases demonstrate  $^{131}\text{I}$  uptake in them, and only half of such individuals will be cured with repeated courses of RAI.

Less clear is the case of patients with uptake in all known lesions who do not achieve a complete response despite several treatment courses but whose disease remains stable and does not progress according to RECIST criteria (see below). In the absence of randomized studies, it remains controversial whether these patients should be considered iodine-refractory (and thus whether RAI treatment should be abandoned in favor of other treatment strategies). The probability of obtaining a cure with more RAI is low, and the risks of dose-related toxicities may increase (see above). There are several considerations, including response to treatment and absence of tumor progression since a prior treatment, a high or significant level of uptake on post-therapy WBS, low  $^{18}\text{F}$ FDG uptake, and good tolerance (absence of side effects) from the RAI therapy. It is important to consider patient preparation with low iodine diet and other confounding variables that may lead to misinterpreting the most recent scan as negative.

Which patients with metastatic DTC can be followed without additional therapy?

■ **RECOMMENDATION 60**

- A. Patients with RAIR metastatic DTC that is asymptomatic, stable, or minimally progressive, or who have clinically significant comorbidities, can be monitored on

TSH-suppressive thyroid hormone therapy with serial radiographic imaging every 3–12 months. (*Conditional recommendation, Low certainty evidence*)

- B. In the absence of planned systemic treatment or redifferentiation therapy, molecular testing is not routinely recommended in patients with RAIR residual DTC. (*Conditional recommendation, Moderate certainty evidence*)

Patients with metastatic RAIR DTC often have an indolent clinical course, with no apparent symptoms or adverse impact from their disease burden for many years. Once RAIR metastatic disease is identified, attention should be directed toward (i) determining the extent of metastasis on imaging studies such as CT,  $^{18}\text{F}$ FDG-PET/CT, or MRI; (ii) clinically assessing the patient for symptoms, risk of symptomatic progression, and comorbidities; and (iii) determining the rate of progression of radiographically evident lesions. Serial assessment of the size and development of metastatic lesions can be enhanced by applying criteria similar to RECIST version 1.1, as commonly used to assess tumor response in clinical trials.<sup>1160</sup> Representative soft tissue metastatic lesions, typically  $\geq 1$  cm, are identified as “targets” on cross-sectional imaging, with the longest diameter of each lesion measured. Disease extent is stable or minimally progressive if the sum of the longest diameters of the target lesions increases less than 20% in the absence of new metastatic foci on sequential imaging. Notably, RECIST 1.1 does not consider bone metastases (other than soft tissue components) to be measurable; thus, the growth of these lesions also should be assessed clinically. No study has identified an appropriate frequency for the optimal timing of serial imaging, but it is reasonable to repeat the imaging studies within 3–12 months based on the disease burden; location of lesions, and other clinical factors, such as histological subtype, rate of change in size over time, and Tg doubling time.<sup>1161,1162</sup> More frequent assessment may be considered when metastatic disease is initially identified (before a growth rate has been established) and/or there is a rapid rise in Tg level, and/or there is a change in patient symptoms. Less frequent imaging is possible if a pattern of stability is established. The development of worrisome progressive disease (whether by RECIST 1.1, the appearance of clinically significant new lesions, or impending disease-related symptoms) should prompt consideration of appropriate systemic therapy, optimally with a shared decision-making approach to individualize the treatment decisions (**Recommendation 64**). While biomarker monitoring of serum Tg can be undertaken at 3- to 12-month intervals, increasing Tg levels alone in the absence of structural disease progression should not be considered a criterion warranting the initiation of systemic therapy. Rather, increasing or accelerating Tg levels should lead to consideration of more frequent and/or comprehensive imaging in an effort to identify structural correlates.

For patients with RAIR DTC deemed appropriate for systemic treatment, what is the optimal approach to choosing the best therapy?

■ **RECOMMENDATION 61**

Tissue-based biomarker testing to identify actionable oncogenic driver alterations in RAIR DTC should be performed prior to initiating systemic therapy for progressive disease. (*Strong recommendation, Moderate certainty evidence*)

The treatment landscape for RAI-R DTC has evolved considerably over the last decade.<sup>1163,1164</sup> Effective systemic therapies for patients with progressive disease have emerged regardless of histological subtype, and new personalized treatments have emerged for genotype-specific subgroups of patients. Oncogenic driver alterations that are potentially amenable to FDA-approved drug treatments are found frequently in RAI-R DTC, including *NTRK 1&3* fusions, *RET* fusions, and *BRAF*<sup>V600E</sup> mutations.<sup>1165,1166</sup> In addition, other gene alterations, such as *N/H RAS* mutations and *ALK* fusions, may respond to targeted therapies. Thus, identification of an oncogenic driver may impact the choice of systemic therapy, whether treatment involves FDA-approved agents, clinical trial participation, or off-label treatment options. Toda et al. evaluated the frequency of identifying treatment-driving genomic changes in comprehensive genomic analysis of 552 patients with advanced thyroid cancer (ATC [*n* = 130], PDTC [*n* = 55], and DTC [*n* = 367]) using one of three testing options as part of a cancer-wide national study in Japan. Druggable genomic alterations were identified in 68/130 ATCs (52%), 16/55 PDTCs (29.1%), 1/55 FTC (1.8%), and 260/307 PTCs (85%), not only confirming the value of the testing but also pointing to therapeutic gaps for *RAS*-mutated thyroid cancers.<sup>1167</sup> This approach is supported by the American Society of Clinical Oncology Provisional Clinical Opinion on somatic genomic testing in patients with metastatic or advanced cancer, which states, "Patients with metastatic or advanced cancer should undergo genomic sequencing in a certified laboratory if the presence of one or more specific genomic alterations has regulatory approval as biomarkers to guide the use of or exclusion from certain treatments for their disease."<sup>1168</sup> Further support for conducting biomarker testing when considering treatment options (specifically for patients with RAI-R DTC) is provided by an AHSN Endocrine Surgery Section and International Thyroid Oncology Group consensus statement.<sup>1169</sup>

Several tissue-based multigene panels for next-generation sequencing (NGS) are FDA-approved for biomarker identification. Multigene panel-based NGS assays are recommended over sequential genomic biomarker testing because FDA-approved biomarker-linked therapy is available for more than one biomarker in RAI-R DTC.<sup>1168,1169</sup> If genomic sequencing results are used in clinical decision-making, such testing is best performed in a certified laboratory. Although concordance across NGS assays is high, platforms differ in the genes analyzed and techniques employed. Because oncogenic kinase fusions play a prominent role in DTC, NGS assays optimized to identify oncogenic kinase fusions, such as RNA-based sequencing and/or anchored multiplex polymerase chain reaction (PCR), are preferred.<sup>1170</sup> In the case of a rapidly progressive cancer, selection of the assay that will return results most promptly may be preferred over a more comprehensive NGS assay, depending on cost, time to obtain results, and availability. For example, rapid testing for a *BRAF*<sup>V600E</sup> mutation by either immunohistochemistry or PCR may be prudent in select cases.<sup>1171-1176</sup>

With the tumor-agnostic availability of immune checkpoint inhibitors (ICI) based on a high tumor mutational burden (TMB-H), NGS testing that provides TMB-H is preferred, although TMB-H DTCs are rare, even when they are RAI-R.<sup>1177-1179</sup> Similarly, tumor-agnostic indications for ICI therapy for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors

are also significant, even though MSI-H or dMMR DTCs are rare.<sup>1180</sup> IHC for PD-L1 to predict possible benefit from ICI therapy is not currently considered a routine biomarker in RAI-refractory DTC, but PD-L1 status may provide useful information in some cases.<sup>1181-1183</sup> The measurement of tumor DNA shed into the plasma (circulating tumor DNA [ctDNA]), or "liquid biopsy," is a powerful emerging tool in oncology, particularly for the identification of genomic driver alterations when tumor biopsy is insufficient for NGS testing.<sup>1184</sup> In the RAI-R DTC setting, large analyses validating the clinical utility of ctDNA testing have not yet been performed but may be limited by relatively sparse tumor cell shedding as compared to other cancers, and technical challenges in detecting the presence of kinase fusions.<sup>1185,1186</sup> More study, and possibly improved assays, will be needed before measurement of ctDNA in RAI-R DTC is validated. As a result, if an archival specimen adequate for tumor-based NGS testing is not available, biopsy of a locoregionally recurrent or metastatic lesion is preferred over ctDNA analysis for NGS testing.

What is the general approach for first-line therapy for patients with progressive RAI-R DTC?


While response rates to first-line therapies can be high, and medications can be well-tolerated, no current therapies are curative. The ability of patients to tolerate effective doses of therapies due to side-effects and/or toxicities varies without clear pre-treatment predictors other than known comorbidities. Thus, determination of the best treatment approach for each person with progressive RAI-refractory DTC should be individualized and determined in a shared decision-making model with the patient. Figure 8 outlines the general approach to assist in clinical decision-making as an application of the DATA framework.

When patients with RAI-R DTC without an actionable driver alteration need systemic therapy, what is the best initial treatment?

#### ■ RECOMMENDATION 62

For patients with progressive RAI-R DTC without an actionable biomarker-linked FDA-approved first-line therapy, MKI therapy with either lenvatinib or sorafenib is recommended. In most cases, lenvatinib is the preferred first-line MKI. (*Strong recommendation, High certainty evidence*)

Long-term survival outcomes following RAI treatment in patients with RAI-responsive metastatic DTC are excellent.<sup>1154</sup> Therefore, it is critical to confirm whether patients with DTC being considered for systemic therapy have defined RAI-R DTC. The DECISION trial was the first large multicenter double-blind placebo-controlled randomized clinical trial studying the MKI, sorafenib, in patients with progressive RAI-R DTC.<sup>1187</sup> Kinases inhibited by sorafenib include vascular endothelial growth factor receptors (VEGFR) 1-3, RET, c- and BRAF kinases, and platelet-derived growth factor receptor (PDGFR)  $\beta$ . Key elements of the study design included the enrollment of patients with RAI-R DTC with disease progression per RECIST criteria within the past 14 months. Participants were randomized to sorafenib or placebo and treated until they experienced disease progression per RECIST. At that point, participants' treatments were unblinded and those that had been randomized to placebo were offered crossover to open-label sorafenib. Progression-free survival was the study's primary endpoint. Secondary endpoints included the



**FIG. 8.** DATA framework for systemic treatment of patients with RAIR unresectable/metastatic DTC. 1) Initial staging may involve CT, MRI, and/or PET/CT. Consider brain MRI to rule out brain metastases. 2) First imaging and Tg monitoring after 2–6 months; timing thereafter is based on rate of progression and/or development of symptoms. 3) First-line gene-specific therapy in most patients with RET or NTRK fusion-positive disease is preferable. Multikinase inhibitors (MKIs) are recommended in general in patients with *BRAF*<sup>V600E</sup> or RAS-mutated DTC unless based on comorbidities/side effect concerns, patient preference, or clinical trial options. 4) When treatment is discontinued due to treatment related adverse events (TRAE), consider second-line therapy only after disease progression. CT, computed tomography; MRI, magnetic resonance imaging; NTRK, neurotrophic receptor tyrosine kinase; RAIR, radioactive iodine resistant.

adverse event profile, objective response rate and overall survival. DECISION was a positive study, with median progression-free survival significantly improved from 5.8 months with placebo to 10.8 months with sorafenib (HR 0.59 [CI 0.45–0.76];  $p < .0001$ ). The objective response rate (all partial responses) was 12.2%, and median duration of response was 10.2 months. There was no difference in overall survival between the two groups. Of note, 71.4% of patients randomized to placebo crossed over to receive sorafenib at the time of disease progression, which may have confounded the ability to detect a difference in overall survival. Adverse events were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v 3.0. The most common adverse events occurring in at least 15% of patients randomized to sorafenib were hand-foot syndrome (HFS), diarrhea, alopecia, rash, fatigue, weight loss, hypertension, anorexia, oral mucositis, pruritus, nausea, headache, cough, and constipation. Grade 3 or higher serious adverse events occurred in 37% of patients randomized to sorafenib. Dose interruption, reduction, and discontinuation occurred in 66.2%, 64.3%, and 18.8% of patients, respectively. Sorafenib was approved by the FDA and other health authorities for the treatment of progressive RAI-refractory DTC.

Exploratory analysis to identify biomarkers predictive of outcomes in DECISION evaluated tumor mutations (*BRAF* and *N/H/K RAS*), serum Tg, and plasma protein levels.<sup>1188</sup> No association between tumor mutational status and response to sorafenib was found; however, biomarkers associated with poor prognosis included elevated baseline VEGF and Tg levels, mutations in *RAS*, and the presence of wild-type *BRAF*. Additional real-world and pooled analyses detailing retrospective

series of patients with RAIR DTC treated with sorafenib generally reported similar efficacy and safety outcomes.<sup>1189–1193</sup>

SELECT, a randomized phase III trial comparing the MKI, lenvatinib, to placebo in patients with RECIST-measurable RAIR DTC, was conducted shortly after DECISION.<sup>1194</sup> Lenvatinib inhibits VEGF receptors 1–3, fibroblast growth factor receptors (FGFR) 1–4, PDGFR $\alpha$ , and RET and KIT. Three hundred and ninety-two participants with RAIR disease measurable by RECIST v1.1 and having progressed within 12 months were randomized in a 2:1 ratio to lenvatinib 24 mg daily versus placebo. Unlike the DECISION trial, participants were allowed to receive one prior MKI. At the time of disease progression, participant treatments were unblinded, and those receiving placebo were offered crossover to lenvatinib. Progression-free survival, the study's primary endpoint, was 18.3 months with lenvatinib compared with 3.6 months with placebo (HR 0.21 [CI 0.14–0.31];  $p < 0.001$ ). Progression-free survival was updated to 19.4 and 3.7 months, respectively, in a subsequent analysis.<sup>1195</sup> The objective response rate was 64.8% in the lenvatinib group, including four patients with a complete response. The difference in median overall survival between the two groups was not statistically significant (HR for death, 0.73 [CI 0.50–1.07];  $p = 0.10$ ), although evaluation of overall survival was confounded because 83% of placebo-arm patients crossed over to receive open-label lenvatinib at the time of disease progression. For patients who crossed over to lenvatinib following progression on placebo, the median progression-free survival on open-label lenvatinib was 10.1 months, and the objective response rate was 52.3%. The progression-free survival benefit with lenvatinib was seen across all histological subtypes and

sites of metastasis in subset analyses. Treatment-related adverse events were common and resembled those of sorafenib, with additional side effects such as hypertension, stomatitis, proteinuria, arthralgia, and dysgeusia. Serious adverse events occurred in 49.8% of patients on lenvatinib, six of which were fatal and attributed to lenvatinib. Increases in TSH also were common on lenvatinib, and dose increases in LT4 were common. QT prolongation, arterial and venous thrombotic events, renal and hepatic toxicity, gastrointestinal fistula, gallbladder toxicity and reversible posterior leukoencephalopathy syndrome (RPLS) occurred rarely. Dose interruption, reduction, and discontinuation occurred in 82.4%, 67.8%, and 14.2% of patients, respectively. Lenvatinib was approved by the FDA and other health authorities for the treatment of progressive, RAIR DTC.

In China, a phase III trial similar to the SELECT trial randomized 151 participants with progressive RAIR DTC to lenvatinib or placebo.<sup>1196</sup> Median progression-free survival was significantly longer with lenvatinib (23.9 vs. 3.7 months), and the objective response rate on lenvatinib was 69.9%. The safety profile in this study was like that seen in SELECT, apart from higher rates of hypertension, proteinuria, and dose reduction in the Chinese participants.

In SELECT, circulating cytokines, angiogenic factors, Tg, and tumor *BRAF* and *N/H/K RAS* mutational status were examined to identify biomarkers predictive of clinical outcomes.<sup>1197</sup> The lenvatinib progression-free survival benefit persisted across all factors examined. *BRAF* and *RAS* mutations were neither predictive nor prognostic in the overall study population; however, in patients on the placebo arm, wild-type *BRAF* was a poor prognostic factor.

Several “real-world” studies have reported outcomes of patients with RAIR DTC treated with lenvatinib.<sup>1191,1193,1198–1206</sup> Results generally have corroborated lenvatinib’s efficacy in terms of response rates and survival. Similar toxicity profiles were seen and considered manageable in most cases with supportive care, dose holds, and dose reductions. However, for older patients, heavily pre-treated patients and those with a poor performance status, dose reductions were more common, and efficacy was not as great as reported in SELECT.

While no randomized controlled trial has been conducted directly comparing sorafenib to lenvatinib in patients with progressive RAI-refractory DTC, attempts to identify the preferred first-line treatment have included systemic review and real-world comparisons.<sup>1193,1205,1207</sup> Results of these studies and expert opinion have led to a general consensus that lenvatinib is associated with a longer progression-free survival benefit and higher objective response rate. While the safety profiles of the two drugs are similar, lenvatinib is the preferred first-line drug for most patients in need of (and without contraindications to) treatment.<sup>1193,1205,1208</sup>

What is the best timing for the initiation of MKIs in patients with RAIR DTC?

#### ■ RECOMMENDATION 63

A. Lenvatinib or other therapy should be initiated without delay in patients with symptomatic RAIR DTC

for whom local therapy, such as radiation or surgery, is not appropriate. (*Strong recommendation, Moderate certainty evidence*)

B. For patients with asymptomatic RAIR DTC that has progressed over the prior 12–14 months and local therapy is not appropriate, if efficacy outcomes are the most important goal of treatment, earlier initiation of lenvatinib may be considered. For patients with asymptomatic progressive RAIR DTC for whom QoL is a major priority, delaying the initiation of lenvatinib and continuing disease monitoring may be most appropriate. (*Good Practice Statement*)

Decisions regarding the optimal timing of MKI initiation in patients with metastatic RAI-refractory DTC can be complex, and shared decision-making with the patient is critical. MKI therapy is not curative and causes toxicity that can affect QoL. In many cases, ongoing disease monitoring

by serial imaging and Tg testing, along with TSH suppression, may be appropriate, especially for patients with no impending symptoms and low-volume disease. Other individuals may have a more rapid pace of disease growth, and/or a higher volume of disease. When such patients are symptomatic (or thought to have impending symptoms), delaying the initiation of treatment may be unwise. However, there is a middle ground of patients with RAIR DTC whose disease is relatively aggressive and who will ultimately succumb to progressive disease but nevertheless have disease indolent enough that ongoing monitoring can be considered. To complicate matters, patients may hold different values. For example, some may strongly value QoL over length of life and wish to avoid adverse events from treatment as long as possible, while other patients may wish to treat their cancer aggressively. Multidisciplinary discussion may be useful; personalizing the decision on when to start MKI therapy (considering patient preferences, priorities, and concerns) is imperative.<sup>1164,1208</sup>

When considering the timing for initiating MKI therapy, one important factor is whether treatment improves overall survival. In the DECISION (sorafenib) and SELECT (lenvatinib) phase III trials, evaluation of the overall survival benefit with treatment is challenging, as both trial designs incorporated crossover to open-label MKI therapy for placebo patients at the time of disease progression. Nonetheless, two exploratory SELECT analyses indicated that an overall survival benefit was observed in two subsets of participants: namely, in patients age 65 and older and in patients with lung metastases.<sup>1209,1210</sup> In SELECT, 71 of the 392 participants enrolled were older than 65 years.<sup>1209</sup> The progression-free survival benefit from lenvatinib versus placebo was maintained for participants both  $\leq 65$  and  $>65$  years of age; however, an overall survival benefit was experienced in participants  $>65$  years, even though the rates of crossover from placebo to open-label lenvatinib were similarly high in both groups (85% and 89%, respectively). Two hundred and twenty-six participants enrolled in SELECT harbored lung metastases.<sup>1210</sup> In participants with lung metastases of any size, no overall survival difference was seen in the lenvatinib compared

with placebo arms. However, when a cutoff for lung metastasis of  $\geq 1$  cm was used, overall survival was significantly improved from 33.1 months in those randomized to placebo to 44.7 months in those randomized to receive lenvatinib (HR 0.63 [CI 0.47–0.85];  $p = 0.0025$ ).

Additional exploratory analyses from SELECT may provide further guidance related to the timing of initiation of lenvatinib. Performance status and neutrophil-to-lymphocyte ratio (NLR) are general markers of more advanced disease in patients with cancer. In SELECT participants randomized to lenvatinib, progression-free survival was improved in those with a performance status of 0 versus 1 and in participants with a low versus high NLR.<sup>1211</sup> Similarly, efficacy outcomes were superior in participants with a lower, compared with a higher, tumor burden.<sup>1212–1214</sup> These findings suggest that for patients with progressive RAI-R DTC who highly value the efficacy of treatment, it may be advantageous to initiate lenvatinib before the individual's performance status, NLR, and tumor burden worsen. This must be balanced against an individual patient's risk of side effects (which include treatment-related mortality), prior tumor treatments, comorbidities, and concerns regarding decline in QoL.

Patient-reported outcomes were evaluated in a multicenter expanded access program of lenvatinib among 39 patients with RAI-R DTC not included in SELECT.<sup>1215</sup> Patients completed the European Organization for Research and Treatment (EORTC) QoL Questionnaire-Core 30 and the pain visual analog scale (VAS) at baseline and monthly for 6 months. Adverse events were graded according to CTCAE v4.0. The most common adverse events were similar to those reported in SELECT. Overall, after initiating treatment no statistically significant difference in the QoL was found. Patients reported slight improvements in general health and in emotional and cognitive status, but also a slight worsening of physical role and social functioning. Pain, dyspnea, insomnia, and constipation improved, while fatigue, nausea and vomiting, appetite loss, and diarrhea worsened. An overall reduction of the level of pain was found on the Pain VAS. While this study did not reveal a clear adverse impact on patient QoL after initiating lenvatinib, the authors speculated that the impact of treatment-related fatigue, anorexia, weight loss, and stomatitis represented a major challenge for patients on treatment.

Further investigation is needed to define the optimal timing for initiating MKI therapy. For example, discrete-choice experiments and conjoint analysis are needed to ascertain patient preferences related to MKI therapy, including thoughts on the optimal time to initiate therapy, balancing the potential impact on QoL with efficacy benefits from treatment, and identifying desired supports to enhance the patient experience during therapy.

When initiating lenvatinib treatment for RAI-R DTC, what is the best starting dose?

#### ■ RECOMMENDATION 64

- A. For most patients with progressive RAI-refractory DTC initiating lenvatinib, 24 mg once daily is the

recommended starting dose; a lower starting dose may be indicated in selected patients. (*Strong recommendation, High certainty evidence*)

- B. Dose holds and dose reductions are important strategies for managing adverse events related to lenvatinib. (*Good Practice Statement*)

The high rates of treatment-related adverse events, dose holds, and dose reductions encountered in SELECT led to investigation of the best starting lenvatinib dose for patients with RAI-R DTC. A follow-up noninferiority study comparing the FDA-approved dose of 24 mg daily to 18 mg daily was performed, with a primary efficacy endpoint of objective response rate at 24 weeks, and primary safety endpoint of  $\geq$  grade 3 adverse events.<sup>1216</sup> One hundred and fifty-two participants with progressive RAI-R DTC were enrolled. At 24 weeks, the objective response rate in the 18 mg starting-dose arm was 40.3% [CI 29.3–51.2] compared with 57.3% [CI 46.1–68.5] in the 24 mg starting-dose arm. Surprisingly,  $\geq$  grade 3 treatment-emergent adverse event rates were similar in both treatment regimens: 61.3% in the 24 mg arm and 57.1% in the 18 mg arm, a difference of  $-4.2\%$  [CI  $-19.8$  to 11.4]. The authors concluded that the approved lenvatinib starting dose of 24 mg daily is important for optimizing lenvatinib treatment but should be accompanied by dose reductions when necessary. The best starting dose for lenvatinib should be individualized, particularly in patients with comorbidities. In patients with severe renal impairment (creatinine clearance  $<30$  mL/min) or liver dysfunction (Child-Pugh C), the recommended daily starting dose is 14 mg once daily. A lower recommended starting dose also may be advisable for patients with hypertension that is challenging to manage. Hypertension must be well controlled prior to initiating lenvatinib. Additional guidance on lenvatinib dosing was provided by an analysis of the impact of dose interruptions in SELECT.<sup>1217</sup> Scheduled planned drug holiday schedules also have been explored with some evidence for continued treatment efficacy, but this strategy has not been studied as a comparative trial.<sup>1218</sup> While lenvatinib improved progression-free survival compared with placebo regardless of the duration of dose interruptions, the magnitude of benefit was greater among patients for whom dose holds consumed less than 10% of the total treatment time (compared with those with dose holds longer than 10%) of total treatment duration. This highlights the importance of toxicity management so that dose interruptions are reduced to a minimum among those patients for whom the efficacy of treatment is the most important goal.

How should adverse events in patients receiving VEGFR MKI therapy be managed?

#### ■ RECOMMENDATION 65

Prevention, amelioration, and timely management of adverse events are required for patients treated with MKIs. Patients initiating MKI therapy should be evaluated at baseline and no less often than every 2 weeks for the first 2 months of treatment to manage adverse events and then generally at 1- or 2-month intervals thereafter. (*Good Practice Statement*)

Appropriate supportive care, including timely identification and management of adverse events, is essential to minimizing dose interruptions, dose reductions, and optimizing

treatment for patients with RAIR DTC during MKI therapy. Adverse event prevention and careful management reduce the impact of treatment-related adverse events on patient QoL.<sup>1208,1219</sup> Many of the MKI-related adverse events may be ameliorated by preventive care and proactive lifestyle modification.<sup>1220–1222</sup> Thus, there is emerging interest in “prehabilitation,” or proactive preparation for patients with RAIR DTC for whom MKI therapy is planned to improve patient QoL, facilitate adherence to treatment, minimize the need for dose holds and reductions, avoid treatment discontinuation, and thereby optimize patient outcomes. Specialized consultation, including dietary, dental, dermatology, podiatry, and psychosocial supportive care, may limit the risks and discomforts that patients experience.

Hypertension is a common complication of all VEGFR MKIs.<sup>1220–1222</sup> If untreated, MKI-associated hypertension can progress rapidly and lead to hypertensive emergencies, including RPLS. Blood pressure must be well controlled prior to initiating MKI therapy. In SELECT, treatment-emergent hypertension was found at a median of just 2 weeks after beginning lenvatinib.<sup>1223</sup> Thus, patients should monitor blood pressure at home daily after starting treatment. When hypertension does emerge, antihypertensive therapy should be initiated promptly to avoid RPLS, acute kidney injury, and heart failure. Studies evaluating the optimal approach to MKI treatment-emergent hypertension have not been conducted, but calcium channel blockers, angiotensin-converting enzyme inhibitors, beta blockers, diuretics, and angiotensin II antagonists all have been prescribed.<sup>1223</sup> Because treatment-emergent hypertension was associated with an overall survival benefit in SELECT, optimal medical management of this potentially serious adverse event is preferred over treatment discontinuation. Dose reductions may be needed in antihypertensive treatment-refractory cases. In patients with treatment-emergent hypertension for whom antihypertensive therapy has been initiated or increased, providers must remember to take the VEGFR MKI half-life into account when the MKI is held. The half-life of lenvatinib is short. When lenvatinib is held, even for a short period, antihypertensive therapy also may require adjustment.

HFS involves painful hyperkeratotic lesions and blistering concentrated on the palms of the hands and soles of the feet.<sup>1220–1222</sup> It is more common with sorafenib but also can be seen with lenvatinib, other VEGFR MKIs, and some other chemotherapeutic agents. Patient education regarding keeping hands well-moisturized (with fragrance- and alcohol-free products) and feet dry, avoiding sun exposure and extreme hot or cold temperatures, and wearing well-cushioned shoes can reduce exacerbation of MKI-related HFS. Treatment of hyperkeratotic areas and calluses on the hands and feet is essential. These lesions should be removed before treatment initiation and during therapy. The use of a 10% urea-based cream can be beneficial. If HFS emerges during treatment, 20–40% urea-based creams can be applied to affected areas, and periodic podiatry checks may be considered. In the case of more severe toxicity, topical or systemic glucocorticoids, antibiotics, and analgesics may be needed.

Diarrhea is a common adverse event with VEGFR MKIs<sup>1220–1222</sup> and when associated with anorexia, stomatitis, and weight loss, it can be particularly challenging for

patients. Patients should keep a symptom diary; alter diet to limit diarrheagenic foods; maximize intake of high-protein, low-fat, and low-fiber foods; and maintain hydration and electrolyte intake. Probiotics and consultation with a dietitian may be helpful. Over-the-counter anti-diarrheals, such as loperamide, may be needed. If loperamide is ineffective, diphenoxylate/atropine is recommended.

Because MKIs can alter TSH levels, particularly in patients who have undergone thyroidectomy, TSH and free T4 must be monitored periodically and thyroid hormone replacement therapy adjusted to maintain the appropriate level of TSH suppression. Serum electrolytes (including calcium) and blood counts also require monitoring. Proteinuria is a common MKI-related laboratory abnormality that should be monitored. QTc prolongation is a class effect of MKIs, necessitating EKG evaluation before initiating treatment and periodically during treatment. VEGFR MKIs may rarely cause cardiomyopathy. Baseline echocardiogram or other nuclear cardiac function study should be considered in selected patients at increased risk, such as those with significant histories of hypertension, coronary artery disease, or diabetes. Rare but potentially life-threatening treatment-related adverse events include gastrointestinal perforation, fistula formation, bleeding, and thromboembolic events. Patients with certain comorbid illnesses, such as poor cardiac function, recent acute cardiac syndrome or stroke, uncontrolled hypertension, colitis, diverticulitis, intestinal perforation, recent bowel surgery, tumor invasion of the trachea, esophagus or great vessels, hemoptysis, or other bleeding disorder, may be precluded from safely receiving a VEGFR MKI. Treatment alternatives may need to be considered.<sup>1221,1224</sup>

It is important for clinicians and patients to recognize that combined studies from patients with many cancers describe a 1–2% mortality rate from adverse events associated with lenvatinib. Several of these studies were collated from clinical trials for a variety of cancers using high-dose therapy and undertaken prior to gaining substantial clinical experience.<sup>1225</sup> Data from real-world thyroid cancer clinical practice are needed to optimize selection of patients for therapy and to enhance early recognition of symptoms.

What is the preferred approach to second-line therapy for patients with RAIR DTC?

#### ■ RECOMMENDATION 66

Cabozantinib should be offered as second-line therapy for patients with RAIR DTC without an actionable oncogenic driver alteration who have progressed on or did not tolerate, prior MKI therapy, if they desire ongoing treatment, and do not have a contraindication to therapy. (*Strong recommendation, High certainty evidence*)

The first evidence for clinical benefit with MKI treatment in the second line was demonstrated in SELECT.<sup>1194</sup> Ninety-three of the 392 participants enrolled (25.3%) had received one prior MKI. In this subset of second-line participants, efficacy of lenvatinib was similar to first-line participants, with median progression-free survival of 15.1 months and objective response rate of 62.1%. Cabozantinib, an MKI targeting VEGFR2, c-MET, RET, and other kinases, was studied in a single-arm, multicenter phase II trial enrolling participants with RAIR DTC who had progressed after no

more than two prior MKIs.<sup>1226</sup> The primary endpoint, objective response rate, was 40%. Following this, COSMIC-311, an international double-blind, phase III trial investigating cabozantinib in previously treated RAIR DTC, was launched.<sup>1227</sup> Participants were allowed to receive up to two prior VEGFR MKIs, and they were randomized in a 2:1 ratio to cabozantinib 60 mg daily or placebo. At the time of disease progression, treatments were unblinded, and those receiving placebo were offered crossover to open-label cabozantinib. The study design incorporated two primary endpoints, objective response rate per RECIST v1.1 and progression-free survival. One hundred and eighty-seven participants were enrolled. Most had received either lenvatinib or sorafenib as their most recent therapy. The objective response rate with cabozantinib was 15%, which did not meet the prespecified criteria for statistical significance. However, with cabozantinib, median progression-free survival was not reached [CI 5.7 months—not estimable] compared with a median progression-free survival of only 1.9 months with placebo [CI 1.8–3.6 months] (HR 0.22 [CI 0.13–0.36];  $p < 0.0001$ ). Based on these data, the FDA-approved cabozantinib for the second-line treatment of patients with RAIR DTC who experience disease progression while receiving a VEGFR MKI. Prescribers should be aware that the cabozantinib formulation studied in COSMIC-311, Cabometyx, differs from the cabozantinib formulation, Cometriq, studied in medullary thyroid carcinoma. The most common adverse events in COSMIC-311 were HFS, diarrhea, and fatigue. Dose reductions for toxicity were required in 56% of patients, and 5% of patients discontinued cabozantinib due to intolerable adverse events.

Several other VEGFR MKIs have been studied in RAIR DTC, either in the first line or beyond. All the agents studied have demonstrated clinical activity and generally acceptable safety profiles. These include sunitinib, pazopanib, axitinib, and vandetanib.<sup>1199,1228–1233</sup> These agents are FDA approved for other malignancies, but they have not garnered health authority approvals for the treatment of RAIR DTC. However, there may be patient-specific reasons justifying their use in select cases.

Several studies in China have explored additional MKIs for activity in RAIR thyroid cancer. Donafenib was studied in a small, randomized phase II trial examining two different doses. The objective response rate was 13% in both dose arms, but progression-free survival seemed longer with the higher dose (15.0 vs. 9.4 months, respectively).<sup>1234</sup> Apatinib showed encouraging activity in phase II and real-world settings, leading to the phase III REALITY study.<sup>1235–1237</sup> In REALITY, 92 participants were enrolled and randomized to apatinib or placebo. The objective response rate with apatinib was 54.3%, and median progression-free survival was 22.2 months compared with 4.5 months with placebo. Additionally, 113 patients with RAIR DTC were enrolled in a randomized phase II trial of anlotinib compared with placebo.<sup>1238</sup> There was a significant improvement in median progression-free survival, from 8.4 months in the placebo arm to 40.5 months with anlotinib. Neither of these agents are available for prescription or approved by the FDA for thyroid cancer therapy in the United States.

For patients with NTRK fusion-positive RAIR DTC, what is the optimal first-line therapy?

#### ■ RECOMMENDATION 67

In patients with progressive RAIR DTC harboring an oncogenic *NTRK* fusion, NTRK-targeted therapy is recommended in the first line. (**Strong recommendation, Moderate certainty evidence**)

Neurotrophic receptor tyrosine kinase (*NTRK*) genes, *NTRK 1/2/3*, code for tropomyosin receptor kinase (TRK) proteins, TRK A/B/C.<sup>1239</sup> *NTRK* gene fusions are oncogenic driver alterations seen in multiple pediatric and adult malignancies, including thyroid cancer. A few rare malignancies harbor very high rates of *NTRK* gene fusions (>90%), whereas *NTRK* fusions may be seen at low rates of <1% in many more common cancers, including non-small cell lung cancer (NSCLC), colorectal carcinoma, and melanoma. The prevalence of *NTRK* gene fusion in PTC is approximately 7%.<sup>1240</sup> *NTRK* fusions are seen rarely in more aggressive follicular cell-derived thyroid cancers and ATC. *NTRK* fusions occur more frequently in PTCs diagnosed in children and young adults, at approximately 25%.<sup>1240,1241</sup> *NTRK 3* fusions are most common in thyroid cancer, followed by *NTRK 1* fusions. *NTRK 2* fusions have not yet been identified in thyroid cancer. Importantly, both *NTRK 1* and *3* have multiple 5' fusion partners, which is an important factor in choosing the best NGS test used to identify these alterations.

Larotrectinib is a potent and selective oral small molecule pan-TRK inhibitor. It was studied in a phase I–II program involving children, adolescents, and adults with *NTRK* fusion-positive malignancies. In the initial report, 55 adults and children with 17 different *NTRK* fusion-positive tumor types were enrolled and included in the primary analysis.<sup>1242</sup> The adult dose administered was 100 mg twice daily. The objective response rate by RECIST v1.1, the primary endpoint, was 75%. At the time of data cutoff, median duration of response and progression-free survival had not been reached, but the 1-year progression-free survival rate was 55%. Most adverse events were only grade 1 or 2. Of the grade 3 or higher treatment-related adverse events, the most common were anemia, increased transaminases, weight gain, and decreased neutrophil count. There were no grade 4 or 5 treatment-related adverse events. Only 15% of patients required dose reduction. Larotrectinib is approved by the FDA and other health authorities for the treatment of *NTRK* fusion-positive malignancy.

Updated results in 159 participants with *NTRK* fusion-positive cancers were subsequently reported.<sup>1243</sup> The objective response rate for the entire cohort was 79%; 16% of participants experienced a complete response. Median progression-free survival was 28.3 months. Thirteen participants had brain metastasis at enrollment, including four participants with thyroid cancer. Of these, nine (75%) responded. Of the 159 participants, 24 (16%) had thyroid cancers (RAIR DTC or ATC), making thyroid cancer the most common adult tumor type enrolled. The most recently published results in *NTRK* fusion-positive thyroid cancer details outcomes of 29 thyroid cancer participants.<sup>1244</sup> Twenty patients had PTC, two had FTC, and seven had ATC. *NTRK 3* fusions were slightly more common than *NTRK 1* fusions. In the 21 patients with

evaluable DTC, the objective response rate was 86%, including two participants with a complete response. In the participants with DTC, responses were durable, with median duration of response, progression-free survival, and overall survival not yet reached.

Entrectinib was developed as an MKI targeting TRK A, B and C, as well as the *ROS1* and *ALK* kinases. Entrectinib was studied in a phase I/II program and an integrated analysis of 54 adult participants harboring *NTRK 1, 2, or 3* fusion-driven cancers was reported.<sup>1245</sup> The cohort included five participants with thyroid cancer. The objective response rate of the *NTRK* fusion-positive patients of all tumor types was 57%, with a 7% complete response rate. One of the five thyroid cancer participants experienced a partial response. Median progression-free survival for the whole cohort was 10 months. Forty percent of patients required dose reduction, and 4% of patients discontinued entrectinib due to treatment-related adverse events. These data led to FDA approval for entrectinib for *NTRK* fusion-positive solid tumors and *ROS-1* fusion-positive NSCLC.

The most recent updated analysis of entrectinib in adults with *NTRK* fusion-positive solid tumors is available in abstract form.<sup>1246</sup> This cohort included 150 patients with sarcoma, NSCLC cancer, secretory carcinoma, thyroid cancer, and other cancers. The objective response rate for the entire cohort was 61.3%, with a median progression-free survival of 13.8 months. Ten of the 16 (62.5%) participants with thyroid cancer responded. The median duration of response across tumor types ranged from 5.6 to 44.2 months.

In a rare tumor setting such as *NTRK* fusion-positive advanced thyroid cancer, opportunities to conduct clinical trials are limited. Nonetheless, in view of the available data, larotrectinib appears to be the preferred agent for treating patients with *NTRK* fusion-positive advanced thyroid cancer. Similarly, no robust data are available to help decide when to initiate gene-specific therapy. Because the studies were “basket trials” for patients with multiple tumor types, RAIR disease criteria for patients with thyroid cancer were not specified, and while the protocols required measurable disease by RECIST v1.1, disease progression prior to enrollment was not required. Immediate initiation of treatment may not be necessary in patients with *NTRK* fusion-positive thyroid cancer with low-volume disease that is asymptomatic and very slowly progressive, even if RAIR. However, when patients have clinically meaningful disease progression, the risk–benefit calculation involved in considering the initiation of treatment differs from that with *VEGFR* MKI therapy, due to the relatively favorable toxicity profile of larotrectinib and entrectinib. Future study devoted to optimizing the role for TRK-specific treatment in *NTRK* fusion-positive thyroid cancer, including involving the patient voice in decision-making, is needed.

For patients with RET fusion-positive RAIR DTC, what is the optimal first-line therapy?

#### ■ RECOMMENDATION 68

In patients with progressive RAIR DTC harboring an oncogenic *RET* fusion, RET-targeted therapy is recommended in the first line. (*Strong recommendation, Moderate certainty evidence*)

*RE*arranged during Transfection (*RET*) codes for a receptor tyrosine kinase that, when activated by its ligand, signals through several pathways, including the RAS-MAPK and PI3K-AKT pathways.<sup>1247,1248</sup> *RET* is activated in thyroid cancers via two distinct mechanisms: point mutations in MTC and gene fusions in DTC. While *CCDC6* (coil-coil domain 6) and *NCOA4* (nuclear coactivator 4) are the most common 5′ fusion partners with *RET* in thyroid cancers, more than 25 5′ fusion partners have now been identified. As with identifying *NTRK* fusions in thyroid cancers, the fact that *RET* also has numerous 5′ fusion partners makes it critical to select an NGS assay optimized for identifying oncogenic gene rearrangements with all possible 5′ fusion partners when conducting biomarker testing for treatment decision-making. *RET* fusions occur in approximately 10–15% of PTCs but are more common in pediatric and young cases and in radiation-induced thyroid cancers.<sup>261,1249–1254</sup> *RET* fusions are less common in PDTC or ATC.

Many *VEGFR* MKIs, such as cabozantinib, lenvatinib, sorafenib, and vandetanib, inhibit *RET* along with other kinases, including *VEGFR 1–3*.<sup>1255</sup> MKIs have been studied in multiple *RET*-driven cancers with mixed success. Activity led to approvals of vandetanib and cabozantinib in MTC.<sup>1256–1259</sup> It is thought that the efficacy of *VEGFR* MKIs in *RET*-driven cancers is limited by insufficient anti-*RET* activity ascribed to the dose-limiting adverse events. In *RET*-driven cancers treated with vandetanib and cabozantinib, acquired resistance can arise due to the emergence of on-target *RET V804M/L* mutations. This mutation at the “gatekeeper” residue blocks drug binding in the kinase pocket, leading to loss of treatment efficacy.<sup>1260</sup>

Selpercatinib is an oral highly specific and potent *RET* kinase inhibitor, with limited off-target activity against other kinases, especially *VEGFR2*.<sup>1260</sup> The drug was designed to inhibit the wildtype *RET* kinase present in *RET* fusion-positive cancers, as well as to inhibit all the known *RET* mutations present in MTCs. Selpercatinib also was designed to overcome the *RET V804M/L* “gatekeeper” resistance mutations and has good central nervous system penetration. LIBRETTO-001 was a phase I/II clinical trial enrolling adolescents and adults with *RET*-driven NSCLC, advanced thyroid cancers and other solid tumors.<sup>1261,1262</sup> Three thyroid cancer cohorts enrolled participants with (i) *RET*-mutant MTC previously treated with vandetanib and/or cabozantinib, (ii) *RET*-mutant MTC who had not received prior vandetanib or cabozantinib, and (iii) *RET* fusion-positive DTC. Radiographical tumor progression was not an explicit inclusion criterion, although systemic therapy had to be warranted. Objective response rate was the primary endpoint. Nineteen participants with *RET* fusion-positive DTC were enrolled, 13 with PTC, 3 with PDTC, and 1 with OTC (2 with ATC also were enrolled). Six (32%) of the participants with DTC had brain metastases. Six distinct 5′ *RET* fusion partners were involved, with *CCDC6* and *NCOA4* being the most common. The objective response rate in NMTC was 79% [CI 54–94], including a partial response in one of the two patients with ATC. The 1-year duration of response was 71% [CI 39–88], and 1-year progression-free survival 64% [CI 37–82].

Consistent with selpercatinib’s specificity for the *RET* kinase, the drug was overall well tolerated. Most adverse

events were grades 1 and 2. The most common grade 3 or 4 treatment-related adverse events seen in 10% or more of participants were hypertension and increased alanine aminotransferase. There were no deaths attributed to selpercatinib. Similarly high response rates, durability, and tolerability were seen in LIBRETTO-001's two MTC cohorts and NSCLC cohorts, including in tumors harboring the *RET* V804M/L gatekeeper resistance mutation and in participants with brain metastases.<sup>1261–1263</sup> Selpercatinib received FDA and other health authority approvals. The FDA's specific approval for selpercatinib is for adults with *RET* fusion-positive NSCLC, for adult and pediatric patients at least 12 years of age with *RET*-mutant MTC, and for *RET* fusion-positive RAI-refractory DTC who require systemic therapy.

Pralsetinib is another *RET* kinase-specific oral small molecule inhibitor, like selpercatinib, designed to have potent anti-*RET* activity with minimal off-*RET* kinase activity. Pralsetinib was studied in ARROW, a phase I/II trial enrolling adults with *RET*-driven solid tumors and the phase II efficacy results in participants who received the recommended phase II dose, 400 mg once daily, have been reported.<sup>1264,1265</sup> Three thyroid cancer cohorts were evaluated, including patients with (i) *RET*-mutant MTC that previously had received vandetanib and/or cabozantinib, (ii) treatment-naïve *RET*-mutant MTC, and (iii) *RET* fusion-positive thyroid cancer. Forty-five percent of the participants with *RET* fusion-positive thyroid cancer had brain metastases. Of the nine participants with *RET* fusion-positive thyroid cancer who had measurable disease, eight responses were seen for an objective response rate of 89% [CI 52–100]. The 1-year duration of response was 86% [CI 60–100], and one-year progression-free survival was 81%.

Pralsetinib was well tolerated; adverse events were primarily grade 1 or 2. Grade 3 or higher treatment-related adverse events that occurred in 10% of participants or more were hypertension, neutropenia, lymphopenia, and anemia. Dose interruptions due to adverse events were necessary in 54% of patients, and dose discontinuations due to treatment-related adverse events occurred in 4% of patients. Pralsetinib received FDA line-agnostic approval in patients with *RET* fusion-positive NSCLC and *RET* fusion-positive thyroid cancer who require systemic therapy and are RAI-refractory. While the initially accelerated FDA approval for pralsetinib included *RET*-mutant MTC, its approval was subsequently withdrawn because a required confirmatory phase study would not be feasible.

There are no data available to help guide the decision to initiate gene-specific therapy in *RET* fusion-positive thyroid cancer. As with TRK-directed therapy, the *RET*-specific targeted therapies are generally well tolerated. Thus, there is not as strong a rationale to delay initiation of treatment because of concerns surrounding treatment-related toxicity and impact on QoL when patients with RAI RAI *RET* fusion-positive DTC have clinically meaningful disease progression.

For patients with *ALK* fusion-positive RAI RAI DTC, what is the optimal first-line therapy?

#### ■ RECOMMENDATION 69

In patients with progressive RAI RAI DTC harboring an oncogenic *ALK* fusion, anaplastic lymphoma kinase (*ALK*)-

targeted therapy is recommended in the first line. (**Strong recommendation, Low certainty evidence**)

Oncogenic kinase fusions involving *ALK* have been reported rarely in PTCs, PDTs and ATCs, with higher rates occurring in patients previously exposed to radiation.<sup>261,665,680,681,1266,1267</sup> The most frequent 5' fusion partners with *ALK* are striatin and echinoderm microtubule-associated protein-like 4, both of which contain coil-coil domains leading to homodimerization, constitutive *ALK* phosphorylation, and activation. While *ALK*-targeted therapy has been studied extensively in *ALK* fusion-positive NSCLC, the rarity of *ALK* fusion-positive thyroid cancers precludes standard clinical trial approaches. Case reports have detailed impressive efficacy of *ALK*-specific therapies, such as crizotinib, alectinib, and lorlatinib, in several patients with *ALK* fusion-positive RAI RAI DTC.<sup>1202,1268–1270</sup>

For patients with *BRAF*<sup>V600E</sup> mutation-positive RAI RAI DTC, what is the optimal first-line therapy?

#### ■ RECOMMENDATION 70

- In patients with progressive RAI RAI DTC harboring an oncogenic *BRAF*<sup>V600E</sup> mutation, *BRAF*<sup>V600E</sup>-directed therapy may be considered in the first line for patients who are poor candidates for lenvatinib. (**Conditional recommendation, Moderate certainty evidence**)
- BRAF*-directed treatment is recommended in patients with *BRAF*<sup>V600E</sup> mutation-positive RAI RAI DTC who have progressed on or did not tolerate one or more prior MKI therapies. (**Strong recommendation, Moderate certainty evidence**)
- Currently approved *BRAF*-directed therapies are not recommended in DTCs harboring non-V600 *BRAF* alterations. (**Strong recommendation, Moderate certainty evidence**)

In view of the high rate of oncogenic *BRAF*<sup>V600E</sup> mutations driving PTCs, *BRAF*<sup>V600E</sup>-specific targeted therapy is appealing in thyroid cancer. However, to date, large-scale trials investigating *BRAF*-targeted therapy in *BRAF*<sup>V600E</sup> mutation-positive RAI RAI DTC have not been completed. Several small studies have demonstrated activity with this approach. The *BRAF* kinase inhibitor, vemurafenib, was evaluated in a multicenter phase II trial involving two cohorts.<sup>1271</sup> Cohort 1 enrolled 26 participants with RAI RAI PTC harboring *BRAF*<sup>V600E</sup> mutations who had not received prior VEGFR MKI therapy and cohort 2 enrolled 25 *BRAF*<sup>V600E</sup> mutation-positive participants who had previously received VEGFR MKI therapy. The primary endpoint was the objective response rate, which was 39% in cohort 1 and 27% in cohort 2. Median progression-free survival was 18.2 months [CI 15.5–29.3] in cohort 1 and 8.9 months [CI 5.5–not estimated] in cohort 2. Grade 3 or 4 adverse events were encountered in 66.7% of participants, the most common of which were cutaneous squamous cell carcinoma, lymphopenia, and increased gamma glutamyl transferase.

A multicenter randomized phase II trial compared dabrafenib monotherapy with dabrafenib/trametinib combination therapy for *BRAF*-mutated RAI RAI DTC with progressive disease by RECIST v1.1.<sup>1272</sup> Fifty-three participants were enrolled, 26 to the monotherapy arm and 27 to the combination arm. One participant's tumor had a *BRAF*<sup>K601E</sup> mutation; all others harbored a *BRAF*<sup>V600E</sup> mutation. Prior

treatments with up to three prior MKIs were allowed, and most participants had received at least one prior MKI. The primary endpoint, objective response rate, was defined as the rate of minor, partial, and complete responses. With monotherapy, the objective response rate was 46%. With combination therapy, the objective response rate was 48%. Median progression-free survival with monotherapy was 10.7 months [CI 3.8–34.7] and 15.1 months [CI 12.3–37.3] with the combination. Grade 3 adverse events occurred in 58% of patients receiving dabrafenib and in 48% of patients receiving dabrafenib plus trametinib. There were no grade 4 or 5 adverse events. Dose reductions and discontinuations due to adverse events occurred in 23% and 56%, and 19% and 22% of patients in each group, respectively. Thus, combination therapy was not superior to monotherapy in this randomized phase II DTC trial, a result that differed from the results of randomized phase III data in melanoma.<sup>1273–1275</sup>

A similar BRAF-targeted approach investigated the BRAF inhibitor, encorafenib, plus mitogen-activated protein kinase (MEK) inhibitor, binimetinib, in a phase II open-label single-arm multicenter Japanese trial enrolling patients with previously treated *BRAF*<sup>V600</sup>-mutated thyroid cancers. Eight of 17 patients with DTC (47.1%) experienced an objective response, with a 12-month progression-free survival rate of 79.0%.<sup>1276</sup>

Currently, a global randomized, placebo-controlled phase III study evaluating dabrafenib plus trametinib in adult participants with *BRAF*<sup>V600E</sup> mutation-positive RAIR DTC (who progressed following prior VEGFR MKI therapy) is underway (NCT04940052). During this trial, dabrafenib plus trametinib has garnered tissue-agnostic FDA approval for adults and children with *BRAF*<sup>V600E</sup> mutation-positive solid tumors who have progressed following prior treatment and who have no satisfactory alternative treatment options. This approval was based on the Rare Oncology Agnostic Research and NCI-MATCH program enrolling multiple cohorts treated with open-label dabrafenib plus trametinib, which together accruing 131 adult and 36 pediatric participants with *BRAF*<sup>V600E</sup> mutation-positive solid tumors.<sup>1277–1281</sup> A total of 54 adult participants (41% [CI 33–50]) experienced an objective response. In the 36 pediatric participants, the objective response rate was 25% [CI 12–42]; duration of response was ≥6 months for 78% of patients and ≥24 months for 44% of patients. The most common (≥20%) adverse reactions in adult patients were pyrexia, fatigue, nausea, rash, chills, headache, hemorrhage, cough, vomiting, constipation, diarrhea, myalgia, arthralgia, and edema.

Reported objective response and progression-free survival rates in small studies do not establish superior outcomes for *BRAF*<sup>V600E</sup>-targeted therapy versus lenvatinib for progressive DTC. Thus, lenvatinib in general is considered as first-line therapy for patients with RAIR progressive *BRAF*<sup>V600E</sup>-mutated DTC unless contraindications to its use are present or comorbidities suggest higher risk for lenvatinib-related side effects (e.g., fistula formation or uncontrolled hypertension). Dabrafenib plus trametinib is an FDA-approved option for patients with *BRAF*<sup>V600E</sup> mutation-positive cancers as second-line therapy. Its use as a first-line therapy may be considered for patients with comorbidities or who are at high-risk for lenvatinib side effects. Many patients with RAIR progressive *BRAF*<sup>V600E</sup>-mutated will ultimately be

treated with both a MKI and *BRAF*<sup>V600E</sup>-targeted strategy. Ongoing studies will better address this important “order of treatment” question.

It is important to recognize that the efficacy of currently approved BRAF kinase inhibitors, which block the signaling of the monomeric BRAF kinase activated by *BRAF*<sup>V600E</sup> mutations, is limited to tumors driven by class 1 *BRAF* mutations, predominately *BRAF*<sup>V600E</sup>.<sup>1282</sup> Dabrafenib or vemurafenib has no role in the treatment of tumors harboring *BRAF* class 2 or 3 alterations (e.g., *BRAF* mutation at codon 601 or *BRAF* gene fusions), which signal as dimers, not monomers. Not only are these therapies ineffective at blocking activated *BRAF* dimers, they can also paradoxically increase BRAF signaling in this context<sup>1283</sup> and drive cancer progression. Newer treatments with broader efficacy across the spectrum of BRAF monomers and dimers, including *BRAF* non-V600E class 2 or 3 alterations, are under development.<sup>1284</sup>

For patients with RAIR DTC harboring other potentially actionable targets, what is the optimal first-line therapy?

#### ■ RECOMMENDATION 71

In patients with progressive RAIR DTC harboring other potentially actionable non-*NTRK/RET/ALK/BRAF*<sup>V600E</sup> targets, enrollment in a clinical trial or first-line lenvatinib is suggested. (*Conditional recommendation, Low certainty evidence*)

Other oncogenic targets potentially amenable to drug therapy can be identified in genomic analysis of RAIR DTC. For example, *N/H/K RAS* mutations are frequently present in FTCs, FVPTCs, and PDTCs and lead to upregulation of the MAPK signaling pathway.<sup>261,674,1285–1287</sup> As such, *RAS* mutations represent attractive oncogenic targets for pharmacologic intervention. *KRAS* G12C accounts for approximately 40% of all *KRAS* mutations in solid tumors, and now two *KRAS* G12C-specific inhibitors, sotorasib and adagrasib, have received FDA approvals for the treatment of *KRAS* G12C mutation-positive NSCLC.<sup>1288,1289</sup> Both agents have activity limited specifically to the *KRAS* G12C mutation alone. While not approved for DTC, their use could be considered if this mutation is identified.

Although not a direct inhibitor of *RAS* signaling, tipifarnib is an inhibitor of farnesyl transferase that can interfere with *HRAS* protein function, and it has been studied in *HRAS* mutation-positive malignancies.<sup>1290</sup> This phase II trial in patients with advanced, unresectable or metastatic, relapsed and/or refractory tumors that carry *HRAS* mutations included 13 patients with thyroid cancer. While promising activity was seen in *HRAS* mutation-positive head and neck squamous cell carcinoma and other malignancies, none of 13 patients with *HRAS* mutation-positive thyroid cancer included in the trial responded to treatment.

A broader approach targeting MAPK pathway activation also has been studied, due to the frequency of oncogenic *BRAF* and *RAS* mutations. A phase II trial investigated selumetinib, a small-molecule inhibitor of the MEK-1/2 MAPK kinases, in 39 participants with RAIR DTC.<sup>1291</sup> While genotyping was not required for enrollment, 12 of 26 tumors tested for *BRAF*<sup>V600E</sup> were positive. With only one response seen, and a median progression-free survival of 8 months, further study was not warranted. More research is needed to exploit the potential for blocking other oncogenic *RAS* mutations, and several novel approaches are being actively studied.

The PI3K/Akt/mTOR pathway is frequently dysregulated in FTC and PDTC.<sup>665,1292–1295</sup> PI3K inhibitors have been developed in oncology, including buparlisib, an oral pan-class I inhibitor. The TUTOR network conducted a multicenter phase II trial of buparlisib in 43 patients with progressive RAI-FTC and PDTC.<sup>1296</sup> The primary endpoint of this study was the progression-free survival at 6 months, with a 50% progression-free survival at 6 months defined as success. Thirty-five percent of the advanced thyroid cancers studied by NGS testing harbored alterations activating the PI3K pathway. The 6-month rate of progression-free survival with buparlisib was 41.7% [CI 7.7–55.5], but no patients achieved a RECIST-defined response, even though eight patients harbored an activating PI3K alteration. Thus, buparlisib has not undergone further development in DTC,

Targeting mTOR directly has also been explored as a treatment approach for RAI-refractory DTC. Everolimus has been studied in several phase II trials, resulting in objective response rates ranging from 0% to 5%, and median progression-free survival ranging from 9 to 12.9 months.<sup>1297–1299</sup> Little activity was seen, even in patients harboring PI3K/Akt/mTOR alterations. The limited activity of everolimus as a single agent has not justified further study. Combined mTOR inhibition with other agents has also been studied. In a randomized phase II trial, the addition of pasireotide long-acting release to everolimus did not improve outcomes.<sup>1300</sup> More promise has been seen with combining mTOR inhibition with VEGFR MKI treatment. A single institution phase II trial of sorafenib plus temsirolimus for patients with advanced DTC enrolled 36 patients.<sup>1301</sup> With 8 of 36 (22%) patients responding, the study did not meet its primary goal of an objective response rate of at least 25%, but it did set the stage for further study. A subsequent single institution phase II trial of sorafenib with everolimus reported an objective response rate of 60% in 28 patients with RAI-FTC.<sup>1302</sup> Nine

of these patients had OTC, and seven responded, prompting an Alliance for Clinical Trials in Oncology randomized phase II trial evaluating sorafenib with or without everolimus in patients with RAI-OTC (NCT02143726). This study has completed accrual; results are only available in abstract form.<sup>1303</sup> While progression-free survival was significantly improved with sorafenib plus everolimus, compared with sorafenib alone, objective response rate and overall survival were similar between the two arms. In view of the frequency of PI3K/Akt/mTOR pathway upregulation in advanced DTC and the number of potential pharmacologic opportunities to disrupt this pathway, more studies exploiting this therapeutic target are needed.


What is the approach for patients with progressive RAI-FTC who progress on first-line therapy or cannot tolerate first-line therapy?

While response rates to first-line therapies can be high, and medications can be well tolerated, no current therapies are curative, and treatment resistance is nearly universal. In addition, some patients cannot tolerate the medications due to side effects and/or toxicities. Thus, determination of the timing and type of second-line treatment, and/or whether such therapy should be pursued, requires careful discussion with the patient. Figure 9 outlines the general approach for second-line therapies in the following section as an application of the DATA framework.

What is the optimal approach to address disease progression in RAI-FTC on gene-specific therapy?

#### RECOMMENDATION 72

- A. Whenever feasible, surgical or core tumor biopsy to allow for NGS testing to identify potential molecular mechanisms of acquired resistance should be performed. (*Good Practice Statement*)



**FIG. 9.** DATA framework for treatment of patients with progression on (or intolerance to) first-line therapy for RAI-FTC metastatic DTC. 1) Biopsy of progressive disease when acquired resistance emerges is advised to evaluate for potentially actionable resistant mechanisms. 2) If targeted therapy or clinical trial is not available, cabozantinib or another MKI may be considered in patients treated with lenvatinib first-line. 3) Dabrafenib plus trametinib is FDA-approved for solid tumors with *BRAF*<sup>V600E</sup> mutation who have progressed on prior treatment. Dabrafenib plus trametinib was not superior to dabrafenib alone in progressive DTC; thus, dabrafenib monotherapy may be considered. 4) Enrollment in a treatment clinical trial when available is encouraged. Other third-line options may include lenvatinib, cabozantinib, or sorafenib if not already received. FDA, U.S. Food and Drug Administration.

- B. Surgical or core biopsy is preferred over ctDNA analysis, which may be considered for patients in whom tumor biopsy is not possible. (*Conditional recommendation, Low certainty evidence*)

In the gene-specific treatment setting, there are two basic types of resistance: primary resistance and acquired resistance. Primary resistance is defined by disease progression without an initial response to treatment. Teasing out the mechanisms of primary resistance to gene-specific treatment can be challenging, particularly because large datasets are generally needed to identify predictive biomarkers. Acquired resistance is defined as disease progression during treatment after an initial response. In the setting of gene-specific treatment, patients usually have biomarker testing by an NGS assay prior to beginning treatment. When disease progression occurs, tumor or “liquid” ctDNA biopsies for NGS testing can be performed to search for an acquired alteration (not present in the baseline studies) that may explain the development of resistance.

In *NTRK* fusion-positive cancers, both on- and off-target mechanisms of resistance to TRK-specific therapies have been identified.<sup>1304</sup> *NTRK* mutations that alter the conformation of the TRK kinase binding pocket have been found in tumors that have developed acquired resistance. These *NTRK* acquired resistance mutations are paralogous to mutations responsible for acquired resistance previously described in *ALK* and *ROS1* fusion-positive NSCLCs. Off-target resistance mechanisms also have emerged, typically non-*NTRK* alterations that upregulate other oncogenic pathways, such as emergence of *MET* amplification, *BRAF*<sup>V600E</sup> mutations, and *KRAS* hotspot mutations. In the RET-specific treatment setting, similar on- and off-target acquired resistance has emerged.<sup>1305–1307</sup> In some patients, despite NGS testing, no mechanism of acquired resistance is identified. More than one acquired resistance mechanism emerges in some patients. Hence, polyclonal resistance may develop, likely because of tumor heterogeneity.<sup>1307,1308</sup> Polyclonal acquired resistance presents a particularly difficult treatment challenge.

Next-generation TRK inhibitors have been developed to overcome on-target resistance, and studies are underway.<sup>1309</sup> As is the case when targeting *ALK* and other oncogenic fusion-driven cancers, sequential TRK- and RET-specific treatments may become necessary to extend the benefits of gene-specific therapy beyond the first line, particularly to address on-target acquired resistance. On the other hand, bypass pathway mechanisms of resistance that activate a secondary oncogenic pathway pose a challenging problem. In theory, therapeutically targeting both pathways with combined gene-specific inhibitors may be possible. In the absence of clinical trials that determine safe combination dosing strategies, tolerability and efficacy, combined targeted therapy options are not generally available.

Oligo-progressive metastatic disease may be seen as a pattern of acquired resistance to gene-specific treatment. A focal approach, such as resection or SBRT (if feasible), plus continuation of the gene-specific treatment may extend the length of clinical benefit of the gene-specific treatment beyond this initial episode of disease progression.<sup>1310</sup> Drug-specific recommendations for holding treatment perioperatively and/or during radiation should be observed.

What is the role of immunotherapy in RAIR DTC?

#### ■ RECOMMENDATION 73

Immune checkpoint inhibitors or other forms of immunotherapy may be offered in selected cases, such as when tumors harbor a high tumor mutational burden or are mismatch repair deficient. (*Conditional recommendation, Low certainty evidence*)

The success of ICIs across multiple malignancies has prompted interest in using ICIs for the treatment of RAIR DTC. In solid tumor oncology, the lead immunotherapy approaches involve targeting the PD-1/PD-L1 and CTLA4 immune checkpoint axes. Multiple investigations have evaluated biomarkers predictive of response to ICIs across the spectrum of malignancies.<sup>1311</sup> PD-L1 expression in the tumor microenvironment correlates with response in a variety of cancers. In addition, solid tumors that are MSI-H or dMMR have demonstrated high response rates to ICIs. Tumor mutational burden is another strong predictor of response to ICIs.<sup>1177,1311,1312</sup> The hypothesis that rich peri- and intratumoral infiltration of CD8<sup>+</sup> T cells (representing) responds to ICIs whereas “cold” tumors are unlikely to respond has been demonstrated in multiple settings.<sup>1313,1314</sup>

The strong immunogenicity of normal thyroid tissue, exemplified by Hashimoto thyroiditis and autoimmune-mediated hypothyroidism, prompted early interest in the tumor microenvironment of thyroid cancers. PD-L1 positivity in DTC ranges from 25% to 67% and seems to correlate with more aggressive disease.<sup>1178,1181,1182,1315–1317</sup> Analyses of tumor-infiltrating T cells, including regulatory T cells, indicate that some DTCs do indeed harbor a “hot” tumor microenvironment, especially in more aggressive disease.<sup>1182,1318,1319</sup> On the contrary, DTCs typically do not demonstrate a high tumor mutational burden. DTCs are rarely MSI-H, though they may uncommonly harbor a dMMR signature.<sup>665,1320</sup>

Several clinical trials investigating ICIs in advanced thyroid cancer have been conducted. KEYNOTE-028 was a single-arm, multicenter “basket” trial evaluating the anti-PD-1 monoclonal antibody pembrolizumab in PD-L1-positive advanced solid tumors.<sup>1321</sup> Of the 475 patients enrolled, 22 had thyroid cancer. In these 22 patients, an objective response rate of 9% was seen, which was one of the lowest response rates found across the 20 solid tumor types enrolled. Median progression-free survival in the patients with thyroid cancer was 6.8 months. This study incorporated analysis of PD-L1 staining, tumor mutational burden, and T cell-inflamed gene-expression profile. Together and separately, these three biomarkers were predictive of outcomes, but the presence of the biomarkers and correlation with response was not analyzed and reported for the individual cancer histologies. KEYNOTE-158 was a subsequent multicenter phase II basket trial of pembrolizumab in ten different advanced solid tumor histologies.<sup>1177,1322</sup> The primary endpoint was objective response rate, and a key exploratory endpoint was the association of tumor mutational burden with response. One hundred and three patients with thyroid cancer were enrolled. The objective response rate was similarly disappointing, with only 6.8% of patients responding. Based on these results, pembrolizumab was not advanced as a standard of care treatment for patients with RAIR DTC. However, based on KEYNOTE-158, the FDA approved pembrolizumab for the treatment of adult and pediatric patients with any type of solid tumor that is unresectable, or metastatic that has progressed on other standard

therapies, if that lesion is tumor mutational burden-high (determined by an FDA-approved test). Thus, pembrolizumab may be considered a treatment option for the uncommon RAI DTC patient with tumor mutational burden-high disease that has progressed on standard of care treatment, such as first- and second-line kinase inhibitor therapy.

Efforts are underway to couple ICIs with other agents that may enhance their efficacy. One successful strategy in several tumor types involves adding a VEGFR MKI to ICI treatment based in promising preclinical data.<sup>1323–1325</sup> Definitive clinical trials investigating the addition of VEGFR MKI to ICI therapy have been conducted in several tumor types.<sup>1326,1327</sup> In RAI DTC, several small studies have yielded intriguing data, including a multicenter phase II trial of lenvatinib plus pembrolizumab in two cohorts: patients with treatment-naïve progressive RAI DTC and patients with RAI DTC that has progressed on lenvatinib.<sup>1328</sup> While activity of lenvatinib plus pembrolizumab in the first-line patients did not seem superior to the activity of lenvatinib alone (demonstrated in SELECT) when pembrolizumab was added as a salvage approach to patients who experienced disease progression on lenvatinib, the objective response rate was 14%. A second multicenter phase II trial has explored this combination in patients with PDC and ATC. Early published data and abstract presentation suggest promising activity.<sup>1329</sup> Other early data explored VEGFR MKI treatment with cabozantinib coupled the ICI combination ipilimumab and nivolumab in progressive RAI-refractory DTC; results were less promising.<sup>1330</sup> Investigations aimed at improved understanding of immune control of RAI-refractory DTC and new immunotherapy clinical trials, including investigation of chimeric antigen receptor T cell therapy, are currently ongoing (NCT04420754).

For patients with RAI DTC, what is the role for kinase inhibitor redifferentiation therapy?

#### ■ RECOMMENDATION 74

- A. Redifferentiation by MAPK pathway blockade in patients with progressive RAI DTC harboring targetable mutations may be considered in selected patients. Clinical trial participation is encouraged. (*Conditional recommendation, Low certainty evidence*)
- B. Redifferentiation approaches in adjuvant RAI treatment for patients with high-risk, non-gene selected DTC are not recommended. (*Strong recommendation, Moderate certainty evidence*)

RAI remains a mainstay of treatment for patients with metastatic DTC. Approaches that re-differentiate thyroid cells to enhance RAI uptake or that increase RAI retention to improve RAI treatment outcomes have long been an area of research and clinical interest. Prior efforts include use of demethylating agents and retinoic acids (for redifferentiation) and lithium (to enhance retention) either have not progressed through clinical trials or have not been shown major impact to date.

One consequence of MAPK pathway upregulation that is particularly common in DTC is suppression of thyroid hormone biosynthesis gene expression. As a result, *NIS* and *TPO* expression involved in facilitating iodine uptake and organification are suppressed.<sup>1331,1332</sup> Preclinical studies

demonstrated that disruption of MAPK can increase <sup>124</sup>I uptake *in vitro* and *in vivo* in thyroid cancer mouse models driven by *BRAF*<sup>V600E</sup> expression.<sup>1333,1334</sup> These studies led to a single-institution, single-arm study exploring the pharmacologic inhibition of the MAPK pathway in patients with RAI DTC to reverse refractoriness to RAI.<sup>1335</sup> In this study, 20 patients with metastatic DTC meeting at least one of three definitions of RAI-refractory disease were treated with the MEK inhibitor, selumetinib, for 4 weeks. During the fourth week, <sup>124</sup>I PET was performed. If this scan indicated that at least one lesion was predicted to reach a threshold absorbed dose of at least 2000 cGy, the patient continued selumetinib until receiving up to 11.1 GBq (300 mCi), based on dosimetry. Eight patients met the threshold for RAI. Five of the 20 enrolled patients met criteria for confirmed partial response by RECIST v1.1. Of interest, all five patients with *NRAS*-mutated tumors met the <sup>124</sup>I threshold for treatment, while only one of nine patients with tumors harboring *BRAF* mutations met the threshold for treatment. One patient with wild type and one patient with *RET* fusion-positive disease also met criteria for RAI treatment. This pilot study established the proof-of-principle that MAPK inhibition can stimulate RAI uptake in RAI DTC in a subset of cancers distinguished by MAPK activation. A subsequent multicenter phase II trial investigated selumetinib for redifferentiation in patients with DTC with RAI RECIST-measurable disease that had progressed within the previous 12 months.<sup>1336</sup> Participants were treated with selumetinib for 28 days, followed by <sup>123</sup>I SPECT/CT. Participants deemed to have sufficient RAI uptake continued selumetinib for two more weeks and then received 5.5 GBq (150 mCi). The primary endpoint was progression-free survival at 12 months among patients receiving RAI. A sample size of 60 was planned, but the trial was closed early due to slow enrollment, with only 28 patients evaluable. Eleven (39.3%) were deemed to have sufficient <sup>123</sup>I uptake for RAI treatment. In patients receiving RAI, the 12-month progression-free survival rate was 64.8%, which the authors considered promising since all participants had disease progression within 12 months at study entry.

Another small single-institution feasibility study investigating the *BRAF* inhibitor, dabrafenib, in RAI *BRAF*<sup>V600E</sup>-mutant PTC followed.<sup>1337</sup> This study enrolled 10 patients with RAI *BRAF*<sup>V600E</sup>-mutant PTC who were treated with the *BRAF* inhibitor, dabrafenib, for 4 weeks. In the last week, patients underwent a low-dose <sup>131</sup>I WBS. Those patients with evidence of uptake continued dabrafenib for 2 weeks and received an empirical activity of 5.5 GBq (150 mCi). The primary endpoint was rate of new RAI uptake after treatment with dabrafenib. Six of the 10 patients demonstrated new RAI uptake and received RAI treatment. Of these, two patients met criteria for partial response by RECIST v1.1. Vemurafenib was investigated in a single-institution pilot trial of 12 patients with RAI-refractory *BRAF*<sup>V600E</sup>-mutant PTC. Two patients stopped treatment due to toxicity; <sup>124</sup>I PET predicted absorption of at least 2000 cGy in at least one target lesion among four patients who were treated with RAI. At 6 months, two of these patients experienced partial response by RECIST v1.1. Beyond evaluating vemurafenib's potential to increase RAI uptake in *BRAF*<sup>V600E</sup> mutant tumors, this study also studied mechanistic questions of redifferentiation. Three patients underwent paired pre- and on-vemurafenib biopsies on which RNAseq was performed and *BRAF*/*RAS* and thyroid differentiation scores (TDS) were determined. Paired biopsies

confirmed pharmacologic reprogramming by inhibition of MAPK output that was accompanied by increasing BRAF/RAS TDS scores.<sup>1338</sup>

A single-institution retrospective series of 13 patients with RAI R DTC treated with targeted therapy provides further support for the potential for MAPK blockade to reverse refractoriness to RAI in patients with *BRAF*- and *RAS*-mutated DTC. Thirteen patients were treated with either selected BRAF or MEK inhibitors. Nine patients were treated with RAI, three of whom achieved a partial response.<sup>1339</sup> The first multicenter study examining redifferentiation in metastatic disease completed to date is MERAIODE: A Redifferentiation Phase II Trial with Dabrafenib and Trametinib Followed by Radioactive Iodine in *BRAF*<sup>V600E</sup> mutation-positive RAI R DTC.<sup>1340</sup> This study enrolled 24 patients who received dabrafenib plus trametinib and underwent diagnostic WBS on day 28. After 35 days, patients received an empirical rhTSH-stimulated administration of 5.5 GBq (150 mCi). The primary endpoint was the objective response rate by RECIST v1.1 at 6 months. It was 38%. The biochemical response rate in patients without TgAb, defined as a suppressed Tg decrease of 50% or more, was 47%. Most adverse events were grade 1 or 2, and no grade 4 or 5 adverse events were seen. MERAIODE enrolled a second cohort of patients with *11N/H/K RAS*-mutated RAI R DTC who were treated with trametinib alone followed by an rhTSH-stimulated empirical administration of 5.5 GBq (150 mCi).<sup>1340</sup> Two of the 10 patients evaluable for response at 6 months derived a partial response by RECIST v1.1 criteria.

The mechanisms of resistance to redifferentiation with MAPK inhibition are not fully understood; preclinical models investigating monomeric BRAF inhibition in *BRAF*<sup>V600E</sup> mutation-positive DTC have shown a potential role for up-regulation of epidermal growth factor receptor 3 (ErbB3) expression and MAPK and PI3K/Akt pathway reactivation.<sup>1341</sup> This finding led to a small single-institution exploratory study of vemurafenib plus the anti-ErbB3 monoclonal antibody, CDX-3379, for redifferentiation in *BRAF*<sup>V600E</sup> mutation-positive RAI R DTC. Seven patients were enrolled. Of the six patients evaluable for RECIST v1.1 response, two experienced a partial response at 6 months. The authors concluded that further evaluation of BRAF-directed therapy with ErbB3 inhibition for redifferentiation is warranted.

While redifferentiation studies thus far have focused mainly on BRAF- and RAS-specific inhibition, case reports have detailed the potential for TRK- and RET-targeted therapies to promote redifferentiation in *NTRK* and *RET* fusion-positive RAI R DTC.<sup>1342–1344</sup> The rarity of *NTRK* fusion-positive PTC poses a challenge to execute conventional clinical trials to investigate TRK inhibition for redifferentiation; however, study of *RET* inhibition for redifferentiation of RAI R *RET* fusion-positive PTC is now underway (NCT05668962). Currently, redifferentiation therapy is only considered for individuals with tumors harboring *BRAF* or *RAS*-mutations.

The potential ability of a MEK inhibitor alone to enhance RAI uptake during initial therapy in patients with high-risk DTC has been studied in a randomized prospective study, ASTRA trial.<sup>778</sup> This was an international multicenter phase III placebo-controlled, double-blind trial that randomized 233 patients with post-thyroidectomy high-risk DTC to receive selumetinib or placebo (in a 2:1 ratio) for 5 weeks. On treatment days 29–31, rhTSH-stimulated <sup>131</sup>I (100 mCi/3.7 GBq) was administered,

followed by 5 days of selumetinib or placebo. The primary endpoint was complete response rate at 18 months. Post-thyroidectomy high-risk DTC was defined by demonstrating at least one of the following pathological features: primary tumor >4 cm, gross extrathyroidal extension (T4 disease), and at least one metastatic lymph node ≥1 cm or involvement of ≥5 lymph nodes (any size). ASTRA was not an up-front gene-selected trial. Excellent response was determined at 18 months in three consecutive stages: stage I, serum Tg <1 ng/mL without TSH stimulation and neck ultrasound showing no structural disease; stage II, following rhTSH stimulation, serum Tg level <1 ng/mL and no evidence of thyroid cancer on diagnostic WBS; and stage III, no evidence of thyroid cancer by cross-sectional imaging. No statistically significant difference in complete response rate 18 months after RAI was observed (selumetinib *n* = 62 [40%]; placebo = 53 [38%]; OR 1.07 [CI 0.61–1.87]; *p* = 0.8205). Thus, while not supporting use of MEK inhibitor redifferentiation in a non-genotype-selected but high-risk population, ASTRA has established benchmarks, including a well-thought-out definition of complete response to adjuvant RAI for use in future studies.<sup>778</sup>

Despite promising results with improved RAI uptake and tumor response in some contexts, more studies are needed to define the clinical benefit of redifferentiation, potential side effects, and populations appropriate for redifferentiation-directed therapy.

What is the role of cytotoxic chemotherapy in RAI R DTC?

#### ■ RECOMMENDATION 75

Cytotoxic chemotherapy can be considered in patients with RAI R DTC with metastatic, rapidly progressive, symptomatic, and/or imminently threatening disease not amenable to control through other approaches. Use within the context of a therapeutic clinical trial is preferred. (*Conditional recommendation, Low certainty evidence*)

Although doxorubicin was approved for use in thyroid cancer by the FDA in 1974 and has some utility in ATC, historically, cytotoxic chemotherapy has produced disappointing results when used to treat RAI R DTC.<sup>1345</sup> Cytotoxic chemotherapy, however, may have selective benefit in patients unresponsive to kinase inhibitors.<sup>1346</sup> Data are limited and primarily anecdotal.

What is the optimal approach for patients with oligometastatic RAI R DTC?

#### ■ RECOMMENDATION 76

For patients with RAI R DTC with solitary or oligometastases (two to five lesions), focal ablative treatment may be considered. Optimal treatment approaches may be best addressed in a multidisciplinary setting. (*Conditional recommendation, Low certainty evidence*)

Surgery, RFA, and PEI are also addressed for patients with locally residual or recurrent DTC in **Recommendations 52–54**. This section will focus on approaches to solitary or oligometastatic and/or symptomatic metastatic RAI R DTC. Lung metastases are the most common distant metastases seen in advanced DTC, and bone metastases are the second most common, occurring in approximately 25% of patients.<sup>765,1347</sup> Distant metastases are frequently non-RAI-avid and are associated with poor long-term survival.<sup>765,1348</sup> When distant metastases in DTC are solitary or oligometastatic, treatment with local modalities

including surgery, thermo-ablation, and radiation, or a combination of approaches, may be warranted.<sup>1137</sup> The best treatment must consider multiple factors related to the patient and disease status. Local treatment for a relatively slow-growing solitary or oligometastatic RAIR DTC may offer the benefits of local control and improved survival but must be weighed against the morbidity of such approaches. Thus, there is no single established approach for local treatment. Instead, a tailored approach, developed by a multidisciplinary team, taking into account the overall disease burden, pace of disease progression, symptoms or impending symptoms, and potential anatomical complications may optimize outcomes for each individual patient, allow for delay in the start of systemic therapy with kinase inhibitors, and even lead to cure in rare cases.<sup>1349–1354</sup>

Oligometastatic disease has been variably defined in the literature. Some define it as two to five metastatic deposits that may be limited to one to two organs, whereas others have proposed more dynamic models incorporating lesions emerging either synchronously or metachronously, and including progressive disease.<sup>1354–1358</sup> Traditionally, local treatment for any burden of metastatic disease was considered palliative. However, clinical data supporting a role for aggressive local treatment in improving progression-free and overall survival, deepening response to systemic therapy, and salvaging patients developing solitary/oligo-progressive disease in the course of systemic therapy have emerged.<sup>1356,1358–1361</sup> Data elaborated specifically in thyroid cancer are limited; treatment of oligometastatic RAIR DTC has been described primarily in case reports and small series.<sup>1362–1367</sup> Because many RAIR DTCs grow slowly, local treatment for oligometastatic disease has the potential to offer significant clinical benefit, which may be difficult to discern.

While no randomized prospective controlled trial has been conducted to evaluate the role of metastectomy in oligometastatic RAIR DTC, several analyses of pulmonary metastectomy demonstrate the potential for a survival benefit with surgery.<sup>1366,1367</sup> A single-center retrospective review included 43 patients with RAIR DTC submitted to pulmonary metastectomy; for those who underwent a complete (R0) resection, disease-specific survival at 5 and 10 years was 100% and 77%, respectively. A similarly long survival rate was seen in a SEER registry analysis of patients with thyroid cancer with lung metastasis who underwent resection.<sup>1367</sup> In this analysis, survival benefit was also seen in patients with bone metastasis who underwent resection. Metastectomy in patients with solitary bone metastasis also appears to be associated with excellent long-term overall survival.<sup>1368</sup>

SBRT, also termed stereotactic ablative radiotherapy (SABR), is a radiation technique that delivers high doses of radiation to small tumor targets using highly conformal techniques. SABR has been used to treat cancer deposits in the lungs, brain, liver, adrenal glands, and bones, and it has been studied in NSCLC, prostate, breast and colorectal cancers.<sup>1354</sup> One international multicenter phase II trial, SABR-COMET, enrolled patients with multiple solid tumor types.<sup>1356,1369</sup> SABR-COMET randomized 99 patients with one to five oligometastases to receive SABR to all metastases versus standard palliative radiotherapy administered for symptom relief or to prevent an impending complication. Median overall survival in the SABR-treated group was 50 months, compared

with 28 months in the control arm (stratified log-rank test  $p = 0.006$ ; HR, 0.47 [CI 0.27–0.81]). While the rate of  $\geq$ grade 2 adverse events was higher in the SABR arm, there was no difference in patient-reported QoL.<sup>1370</sup> Phase III trials are now underway, including SABR-COMET-3 (ClinicalTrials.gov identifier: NCT03862911), SABR-COMET-10 (ClinicalTrials.gov identifier: NCT03721341), and the CORE trial (ClinicalTrials.gov identifier: NCT02759783). Enrollment of patients with thyroid cancer into these studies is to be advised.

Thermal ablative techniques, such as RFA, cryoablation, and microwave ablation, have become common treatments for lung metastases and other metastatic sites in various solid tumors.<sup>1371,1372</sup> Randomized trials of thermal ablation in RAI-refractory DTC have not been conducted, but a retrospective review of patients with lung metastasis treated across the TUTHYREF network has been reported.<sup>1373</sup> RFA was employed most frequently, followed by cryoablation and then microwave ablation. While most patients had treatment of multiple metastases, one patient with a solitary lung metastasis remained disease-free at last follow-up. Overall survival for all 47 patients treated was 79% [CI 66–91] at 3 years.<sup>1373</sup> Treatment with thermal ablation, whether by cryoablation or RFA, in patients with solitary/oligometastatic bone metastasis has also been shown to yield excellent disease control, especially for lesions 2 cm or smaller.<sup>1374,1375</sup>

When solitary/oligo-progressive disease emerges during kinase inhibitor therapy, an ablative treatment approach may be considered if the site is amenable. To date, thyroid cancer-specific data are limited, but a single-center retrospective series of patients with *ALK/ROS1/RET*-rearranged NSCLC with solitary/oligo-progressive disease on TKI therapy treated with radiation, surgery, or percutaneous thermal ablation has been reported.<sup>1361</sup> TKIs were held during local therapy in many, but not all cases, and then resumed after ablative therapy was completed. The authors concluded that this approach facilitated clinically meaningful extension of TKI therapy beyond the initial date of disease progression.

What is the optimal treatment approach for patients with site-specific symptomatic RAIR DTC?

#### ■ RECOMMENDATION 77

For patients with symptomatic RAIR DTC, local treatment is suggested. Surgery, radiotherapy, and percutaneous thermo-ablative approaches are available to treat individual symptomatic sites of disease. (*Conditional recommendation, Moderate certainty evidence*)

Patients with symptomatic unresectable and/or metastatic RAIR DTC are optimally reviewed in a multidisciplinary setting. Treatment decision-making should be individualized and consider the overall disease burden, pace of disease progression, symptoms or impending symptoms, and potential anatomical complications. In many cases, treatment goals are palliative. Local therapies, including surgery, cementoplasty/vertebroplasty, radiotherapy or thermal ablation, should be considered for symptomatic or anatomically threatening lesions (such as for the prevention or palliation of airway or aerodigestive tract obstruction or hemorrhage; symptomatic mediastinal, hilar, or lung lesions; and symptomatic bone lesions).<sup>1359</sup> The site of metastases, extent of disease, presence of symptoms or impending functional impact

of the metastasis, and the role of RAI should be considered when making treatment decisions.

While prospective controlled trials are lacking, palliative radiotherapy is well tolerated and effective at producing durable local control in many cases. SBRT is generally the preferred modality for lung lesions and may be used for disease locations. One single-institution retrospective series reported outcomes of 53 patients with various thyroid cancer diagnoses treated using palliative radiotherapy.<sup>1376</sup> In this series, 21 patients received SBRT for lung metastases, and 34 patients were treated for bone metastases. In the lung metastases group, median local control of the treated lesion(s) was 187 months, and median progression-free survival and overall-survival were, respectively, 16 and 245 months. In the bone metastases group, median local control of the treated lesion(s) was 98 months, and median progression-free survival and overall-survival were, respectively, 24 and 50 months. Radiotherapy was well tolerated, without significant adverse events. The impact of treatment on symptoms, such as cough, dyspnea, hemoptysis, or pain, was not reported. A second small single-institution retrospective series similarly reported disease control from palliative radiotherapy in DTC.<sup>1377</sup> This group also noted control of symptoms related to the treatment lesions.

Bone metastases in DTC are typically osteolytic and highly destructive to bone structural integrity and cause frequent skeletal-related events (including pathological fracture, spinal cord compression, and pain), impairing QoL and survival.<sup>1378,1379</sup> Bone metastases are seen in a higher percentage of patients with FTC, OTC, and PDTC than in patients with PTC.<sup>1380,1381</sup> Mutational analysis in a single-institution study revealed *TERT* promoter mutations in 72% of cases, *RAS* mutations in 40%, and *BRAF*<sup>V600E</sup> mutations in 20%. Median overall survival can be quite long for patients with a solitary bone metastasis, whereas expected overall survival with multisite disease is less than 10 years.<sup>1135,1368,1372,1382,1383</sup> Multivariable analysis identified RAI-avidity and treatment with radiotherapy as significant predictors of improved survival.

Symptomatic vertebral metastases are best approached by a multidisciplinary team. Indications for palliative surgery include vertebral metastases associated with spinal cord compression or impending compression and risk of fracture in weight-bearing long-bone metastases.<sup>1368,1379,1380</sup> Postoperative radiotherapy is typically administered to reduce the risk of local recurrence. Cementoplasty is a palliative approach involving CT-guided percutaneous injection of poly-methyl methacrylate cement into an osteolytic lesion. The goal of cementoplasty is to fill the defect in order to enhance mechanical stability of the bone and rapidly reduce pain. Cementoplasty may be used alone or in combination with other local treatment such as surgery or external radiation therapy. Cementoplasty may be complicated by cement leakage, although such episodes are usually not clinically significant.<sup>1359,1372,1380</sup>

Other percutaneous approaches (e.g., RFA, cryotherapy, and microwave ablation) are alternatives to radiotherapy for symptomatic metastases. These techniques can be particularly helpful to salvage sites of disease after progression following prior radiotherapy and for patients who are poor candidates for surgery. Several retrospective series

examining the rate of local control of treated lesions, especially lung and bone metastases, and patient survival have been published, but data examining patient-reported outcomes, such as symptom control, are scarce.<sup>1372,1373,1384</sup> RFA is more commonly used in treating lung, bone, and liver metastases, although some consider cryoablation preferable for treating bone metastases, because it is associated with less post-procedural pain compared with RFA and avoids electrical conduction.<sup>1359</sup> Advantages of RFA include its minimally invasive nature, repeatability, and low morbidity. RFA has limitations: it should not be used for lesions >3 cm or for lesions in proximity to large blood vessels (which promote heat loss, thus reducing efficacy) or to the pleura (which raises the risk of pneumothorax).

Cryoablation is another local treatment involving percutaneous insertion of one or more probes into the tumor.<sup>1359</sup> Freezing is achieved by circulation of argon under pressure, causing the destruction of cell membranes and denaturation of proteins, leading to cell death. One anatomical advantage of cryoablation is the ability to visualize the zone of freezing. In addition, risk to some anatomical obstacles such as neural tissue can be minimized by temperature control or by using carbon dioxide or saline injection to move structures out of the way. Morbidity is generally limited, and larger tumor volumes can be addressed by the insertion of more than one probe. One drawback is the high cost of the needles and the rare gas.

Microwave ablation, like RFA, uses electromagnetic current to increase intra-tumoral temperature based on micromovement of water molecules.<sup>1359,1385</sup> Heating is faster and can achieve higher temperatures than RFA. Theoretical advantages include the possibility of treating lesions >3 cm and avoiding heat loss by thermal convection from adjacent large vessels. Microwave ablation has been studied most extensively in liver metastases, particularly among patients with colorectal carcinoma, but data are emerging with microwave ablation in other metastatic settings, include bone for metastasis.<sup>1386–1389</sup>

When should bone-directed agents be considered for patients with DTC?

#### ■ RECOMMENDATION 78

- A. In patients with RAI R DTC with symptomatic and/or multiple bone metastases, treatment with a bone modifying agent is recommended to decrease the risk of skeletal-related events. (**Strong recommendation, Low certainty evidence**)
- B. A bone-modifying agent dosing schedule of every 3 months may be considered due to a reduction in the risk of adverse events, especially osteonecrosis of the jaw, compared with monthly dosing, but may increase the risk of symptomatic skeletal events. (**Conditional recommendation, low certainty evidence**)

Bone metastases in advanced RAI R DTC are common and are a poor prognostic factor.<sup>765,1347</sup> Skeletal-related events, such as spinal cord compression, pathological fracture, need for external beam radiation therapy and/or surgery, and hypercalcemia, are a major cause of morbidity and can cause pain, impaired mobility, and financial burden.

Bisphosphonates, particularly zoledronic acid, and the RANKL inhibitor, denosumab, have been studied extensively in patients with solid tumor with bone metastases, but large-scale clinical trials have not been carried out in DTC. One small single-institutional experience studying patients with DTC/bone metastases has been reported.<sup>1137</sup> Patients with thyroid cancer have been enrolled in several randomized controlled trials investigating zoledronic acid.<sup>1349–1351</sup> Most data in solid tumors are in patients with castration-resistant prostate cancer, breast cancer, and NSCLC.

Randomized controlled trials in patients with bone metastases from solid tumors have shown consistently that bisphosphonates (e.g., zoledronic acid) reduce the incidence of skeletal-related events, and zoledronic acid is the most effective agent. Common adverse events include nephrotoxicity, acute phase reactions, and hypocalcemia. Less common ones include osteonecrosis of the jaw and atypical femur fractures. In addition, zoledronic acid must be dose-reduced based on renal function and is contraindicated for individuals with a GFR <30 mL/mL due to risks of acute nephrotoxicity.

The RANKL-targeted monoclonal antibody, denosumab, has been studied to prevent skeletal-related events in a range of solid tumors, including breast, prostate cancer, and lung cancers. Non-inferiority randomized controlled trials have compared denosumab with zoledronic acid.<sup>1352,1353</sup> In addition, several pooled analyses have been conducted.<sup>1351,1354</sup> These suggest that denosumab delays time to skeletal-related events and worsening of pain more effectively than does zoledronic acid, but there were no differences in overall survival or disease progression between the two agents. Denosumab has an adverse event profile like that of zoledronic acid overall, including osteonecrosis of the jaw and risk of atypical fractures. Denosumab causes more frequent serious hypocalcemia compared with zoledronic acid but is less nephrotoxic. Additional benefits with denosumab include the convenience of subcutaneous administration (as compared with intravenous administration for zoledronic acid) and reduced need for renal function monitoring. Hypocalcemia is more common in patients with renal failure treated with denosumab.

Cost-effectiveness of denosumab compared with zoledronic acid has been studied.<sup>1355</sup> While the direct cost of denosumab is higher than that of zoledronic acid, this was offset by reduced costs related to bone complications. Quality-adjusted life-year and net monetary benefit analyses favored denosumab from the perspectives of society and payers. Extending the dosing interval from 4 to 12 weeks for zoledronic acid and denosumab, especially to decrease the risk of osteonecrosis of the jaw, has been explored in noninferiority trials.<sup>1356–1359</sup> Overall, most data support the 12-week schedule, although concern has been raised regarding a potential risk of increased symptomatic skeletal events with the 12-week dosing schedule that might not be definitively detected in a noninferiority trial.<sup>1360</sup> A head-to-head study, the REDUSE trial comparing every 4-week to every 12-week dosing of denosumab for patients with bone metastases with a primary endpoint of serious skeletal events, is underway (NCT02051218).

Bone-directed agents often are administered for several years in patients with bone metastases, though randomized controlled trials generally have evaluated treatment durations of 1–2 years. A recent systematic review of studies evaluating bone-directed therapies beyond 2 years suggests that the incidence of osteonecrosis of the jaw increases after 2 years, while the rates of

clinically significant hypocalcemia and nephrotoxicity were low, and atypical femoral fractures were rare.<sup>1361</sup> However, most data were retrospective and limited to subgroup analyses.

What is the best treatment for patients with brain metastases?

#### ■ RECOMMENDATION 79

- A. Resection and/or SBRT are the mainstays of therapy for central nervous system metastases. (*Conditional recommendation, Low-certainty evidence*)
- B. RAI can be considered if central nervous system metastases concentrate RAI. If RAI is planned, SBRT and concomitant glucocorticoid therapy are recommended prior to RAI therapy to minimize the effects of a potential TSH induced increase in tumor size and RAI induced inflammatory response. (*Good Practice Statement*)

Brain metastases typically occur in older patients with more advanced disease and are associated with a poor prognosis.<sup>1390</sup> Surgical resection and SBRT are the mainstays of therapy.<sup>1390–1392</sup> There are few data showing efficacy of RAI. For patients with few (one to three) brain metastases, SBRT is as effective as surgery and can be repeated in case of the appearance of new brain lesions. It is usually well tolerated, and brain necrosis that occurs in less than 10% of cases is usually limited and without clinical consequences; thus, patient outcome depends mostly on the progression rate of extracerebral lesions.<sup>1393,1394</sup>

Stereotactic radiation therapy is preferred to whole brain irradiation because life expectancy in patients with brain metastases may be prolonged, and stereotactic irradiation induces less short- and long-term toxicity compared with whole brain irradiation (fatigue, headache, cognitive decline, and behavioral changes). It may be effective even in patients with multiple brain lesions.

Who should be considered for clinical trials?

#### ■ RECOMMENDATION 80

Patients should be counseled to consider enrolling in prospective clinical trials based upon specific eligibility requirements for given studies and the likelihood that the patient will benefit from participation. Clinicians considering referral of patients for trials should review available treatment options and eligibility criteria, preferably through discussions with personnel at the trial center and review of materials at the website [www.clinicaltrials.gov](http://www.clinicaltrials.gov). (*Good Practice Statement*)

A therapeutic clinical trial is a systematic investigation of the effectiveness and safety of a new, modified, or combination of treatments, potentially including medications, surgery, radiation therapy, and/or other novel or revised approaches. A broad variety of such trials may be ongoing, and they can generally be identified through online databases such as [www.clinicaltrials.gov](http://www.clinicaltrials.gov). Referral recommendations are informed through direct contact with the institutions conducting studies of particular interest to assure trial availability and patient eligibility. Enrollment into clinical trials is associated with lower overall cancer-specific mortality for patients with common cancers, even within contexts in which approved, and “standard of care” therapies already

exist.<sup>1395</sup> The reasons for this association are unclear, but there is no evidence to suggest that trial participation is deleterious to patients, and it may be beneficial.

Participation in a clinical trial should be considered in any situation where there is no effective standard of care, or when a standard of care is being compared with a promising new or investigational approach. Adjuvant therapy trials may be appropriate for patients at high risk of recurrence following primary treatment who wish to pursue aggressive therapy. For patients with RAIR DTC that is locally advanced or metastatic, clinical trials are appropriate in the setting of disease that is considered progressive by RECIST criteria. This is particularly true if progression occurred after use of an approved therapy.

#### Considerations managing pregnant patients with DTC

##### ■ RECOMMENDATION 81

- A. In most pregnant patients, surgery can be safely delayed until after delivery. Exceptions include rare patients for whom there is concern for significant disease progression. If necessary, surgery may be performed in the second trimester of pregnancy. *(Conditional recommendation, Low certainty evidence)*
- B. For pregnant patients diagnosed with DTC during pregnancy, monitoring with neck ultrasound at least once in early second trimester and more often if clinically indicated is appropriate. Cross-sectional imaging using MRI may be performed in selected cases. Imaging modalities that require ionizing radiation should not be performed other than in exceptional circumstances. *(Conditional recommendation, Low certainty evidence)*
- C. TSH goals for pregnant patients, in general, are the same TSH as determined preconception. Thyroxine dose may be adjusted toward less TSH suppression if there are concerns that excess thyroxine may have an adverse impact on the pregnancy. TSH should be monitored approximately every 4 weeks until 16–20 weeks of gestation and at least once between 26 and 32 weeks of gestation. *(Good Practice Statement)*
- D. Monitoring using neck ultrasound and Tg is appropriate for pregnant patients who have an incomplete response to therapy. If cross-sectional imaging is needed, MRI should be performed. Pregnant patients in excellent or indeterminate response categories should be monitored as for nonpregnant patients. *(Conditional recommendation, Low certainty evidence)*

The potential adverse impact of thyroid cancer treatments on pregnancy and fertility, as well as the impact of pregnancy on the onset and progression of DTC, has been the focus of several studies.<sup>885,898,1396–1406</sup> Human chorionic gonadotropin (hCG), elevated throughout pregnancy, stimulates the luteinizing hormone/hCG receptor but also is a weak stimulator of the TSH receptor, which is responsible for the increased level of free thyroxine and reduced TSH seen in the first trimester of normal pregnancy.<sup>1396</sup> This endogenous stimulation of the TSH receptor during

pregnancy could potentially result in stimulation of the growth of thyroid cancer in pregnancy and drive earlier treatment.

Several studies have examined the impact of pregnancy on the onset and progression of DTC. In women with treated DTC, pregnancy has not been associated with an increased level of progression or recurrence. In a retrospective study of 235 women with DTC with term pregnancies after initial treatment for DTC (1997–2015), structural disease recurrence or progression was seen in only 5% of patients (11/235) when they were evaluated 3–12 months after delivery.<sup>1397</sup> Among the women with no evidence of structural disease before pregnancy, none progressed; among those with structural disease, 29% progressed (11/35), but therapy in the first year was only required in 8% (3/35). A retrospective analysis was performed of 19 women with PTC (most with T1aPTC [68%]) who were diagnosed immediately before or in the early stages of pregnancy and who delayed surgery until after delivery.<sup>1398</sup> Serial neck ultrasounds did not demonstrate clinically significant progression of their tumors. Most women (16/19) underwent elective surgery at a median of 12 months after diagnosis. The predominance of small initial tumors may not make these findings generalizable to women with more advanced DTC.

In a study of 124 women with DTC and lung metastases, outcomes were compared between those who became pregnant ( $N = 37$ ) and those who did not ( $N = 87$ ).<sup>1399</sup> There was no difference in the 5- and 10-year progression-free survival in these groups, indicating that even in women with lung metastases, pregnancy was not associated with worse outcomes. A study designed to determine if pregnancy influences thyroid cancer stage and outcome utilized the California tumor registry and identified women with thyroid cancer and a pregnancy 5 years prior to, or 9 months after, the diagnosis. Tumor histopathology, stage, and status at last follow-up and 5-year disease-specific survival were evaluated. No differences in any of the outcomes were identified in 301 recently pregnant women versus 903 matched nonpregnant women. A meta-analysis of 10 studies of women with previously treated DTC who became pregnant showed no overall difference in the risk of recurrence associated with pregnancy, including in two studies of patients with distant metastases.<sup>1400</sup> A propensity score-matched retrospective cohort study of women in China with DTC who became pregnant showed that there was no impact of pregnancy on progression-free survival.<sup>1401</sup>

Numerous studies have examined the impact of thyroid cancer treatment on obstetrical complications and outcomes. In a retrospective observational study examining women in South Korea, 7232 women with a diagnosis of thyroid cancer had similar obstetrical complications and outcomes in comparison to a control group of women without thyroid cancer.<sup>1402</sup> The only obstetrical complication that was increased in women with thyroid cancer was postpartum hemorrhage (OR 1.23 [CI 1.15–1.32]). Another retrospective study using data from a large U.S. database (US HCUP-NIS) of women delivering between 1999 and 2014 found no significant differences in obstetrical complications or outcomes in women with thyroid cancer, except for an increase in blood transfusions and venous thrombosis. A retrospective cohort study in China of 154 women with thyroid cancer who had term pregnancies compared with matched controls found no overall

difference in obstetrical complications or outcomes, except for an increased risk of invasive placentation.<sup>1403</sup>

A long-standing recommendation after RAI therapy for hyperthyroidism or thyroid cancer has been to wait at least 6 months after therapy before becoming pregnant. Several observational studies have provided a basis for recommendations around the timing of pregnancy after <sup>131</sup>I therapy. A large retrospective study from Korea, a population-based cohort, utilizing the Health Insurance Review and Assessment database identified 10,842 women with thyroid cancer who then became pregnant.<sup>885</sup> They assessed the impact of surgery or surgery and RAI on obstetrical complications and pregnancy outcomes. Overall, there was no increased incidence if pregnancy occurred greater than 6 months after RAI was given. When pregnancy occurred less than 6 months after RAI was administered, there was a small but significant increase in congenital malformations in the offspring, with an OR of 1.74 [CI 1.01–2.97]. A retrospective study of 212 singleton pregnancies in women with thyroid cancer compared with controls found a higher rate of late miscarriages, but this finding was not significant when adjusted for a higher rate of TPO antibody positivity.<sup>1404</sup> The women with thyroid cancer had greater gestational weight gain but no increase in gestational diabetes, and there was no impact on neonatal thyroid function. RAI therapy should not be administered in recently lactating patients (see **Recommendation 43**).

In pregnant women with a new diagnosis of thyroid cancer, or after detection of a recurrence, the impact of delaying thyroid cancer treatment until after delivery has been assessed. Several small retrospective studies have followed pregnant women with thyroid cancer who delayed surgery until after delivery to determine the influence of pregnancy on tumor progression. A study of 19 women with PTC were followed through pregnancy using serial neck ultrasounds. An increase in tumor volume was observed in 26% of women, but there were no clinically relevant changes, and 16/19 underwent elective surgery at a median time of 12 months post-delivery.<sup>1398</sup> An international cohort study highlighted that thyroid cancer constitutes ~6–10% of cancer diagnoses during pregnancy; in this population, 29/35 (83%) underwent surgery during pregnancy.<sup>1405</sup> Most tumors (57%) were <2 cm in diameter, and lymph nodes were present in 26%. There were no adverse obstetrical or neonatal complications. These studies indicate that in most pregnant women with newly diagnosed DTC or recurrence of their DTC, there is rarely significant progression, and it is safe to defer surgery until after delivery. If there is a decision to move forward with surgery during pregnancy, this appears to be safe. In general, it is recommended in the second trimester.

Thyroxine dose requirements increase in most pregnant women with hypothyroid, especially those who are athyretic.<sup>898</sup> A concern has been raised whether the higher thyroxine doses of pregnant women with thyroid cancer may impact obstetrical complications. According to a retrospective cohort study of women with thyroid cancer on thyroxine up to 2 years before pregnancy, a TSH <0.10 was associated with an increase in preterm delivery compared with control, with an OR of 2.14 [CI 1.51–2.78].<sup>1406</sup> Although data are limited, women with DTC and a TSH level in the reference range did not have increased obstetrical complications.

### Cancer survivorship

According to the National Cancer Institute of the National Institutes of Health, an individual is considered a cancer survivor from the time of diagnosis, through life.<sup>1407</sup> Cancer survivors can include those free of disease and living beyond cancer treatment, individuals free of cancer experiencing the sequelae of treatment, as well as those living with active tumor. Untoward consequences associated with their diagnosis of cancer are not limited to those with living with side effects of treatment or with uncontrolled cancer. Several aspects affect QoL among thyroid cancer survivors. We focus on those related to a thyroid cancer diagnosis *per se*; management of hypothyroidism is discussed in other ATA guidelines.

What are long-term survivorship concerns related to initial thyroid cancer therapy?

#### ■ RECOMMENDATION 82

Patients should be made aware of potential long-term side effects of treatments and monitored with appropriate intervention and/or referrals during follow-up. (**Good Practice Statement**)

Shared decision-making between the patient and the treating clinical team is essential and is particularly important prior to initiating a treatment plan, including active surveillance. Because complications can impact QoL even after a thyroid cancer is in complete remission or during years of stability, the potential for impact on long-term QoL should be discussed and carefully weighed prior to initiating therapy. Potential long-term complications of RAI and those of non-RAI medical therapies are discussed in detail in their individual recommendations. Potential long-term consequences of thyroid cancer surgery include the following.

**Hoarseness/voice change.** Thyroidectomy with or without central neck dissection involves manipulation of the larynx for intubation to allow for general anesthesia and relevant nerves and muscles that may alter the voice on a temporary or permanent basis. Postsurgical voice change is very common for these reasons, even when relevant nerves such as the recurrent laryngeal nerve and external branch of the superior laryngeal nerve are preserved and deemed to be functional by laryngeal exam. Voice change has been reported in over 30% of patients in the long term, even without nerve injury.<sup>1408</sup> Vocal fold paralysis may occur from nerve injury during surgery. The incidence of vocal fold paralysis after thyroid surgery is variable and may be related to surgeon volume/experience with thyroid surgery. Dhillon et al.<sup>1409</sup> reported a 2.9% incidence of temporary and 0.2% permanent vocal fold paralysis in nerves that could be preserved in a single high-volume thyroid surgeon's hands. When a patient has a voice change that impacts QoL, referral should be made to a laryngologist who works in tandem with a speech language pathologist to help the patient achieve the best voice possible.<sup>583</sup> In some cases, patients also may experience aspiration, which also can be managed by this team. Bilateral injury to the recurrent laryngeal nerves may result in dyspnea and the need for a tracheostomy. Every effort should be made to avoid this challenging situation by avoiding a total thyroidectomy when the initial thyroid lobe removal results in a known recurrent laryngeal nerve injury.

**Hypoparathyroidism.** The parathyroid glands may be injured or inadvertently removed during thyroid surgery. The risk of hypoparathyroidism varies with surgeon experience. The rate of temporary hypoparathyroidism has been reported to be 14–43%, and the rate of permanent hypoparathyroidism estimated to be 1–25%.<sup>1410</sup> Those patients who are not adequately supported with calcium and vitamin D supplements may experience paresthesias in their extremities and in severe cases tetany or cardiac arrhythmia. Even when adequately supplemented, Bergenfelz et al. have reported that patients experiencing permanent hypoparathyroidism after total thyroidectomy for benign disease are at an increased risk for renal insufficiency and a cardiovascular event if they had known cardiovascular disease at the time of thyroidectomy.<sup>1411</sup> Also, compared with patients without permanent hypoparathyroidism, the risk of death was significantly higher among patients with permanent hypoparathyroidism.<sup>1412</sup> Preservation of viable parathyroid glands during thyroid surgery is of critical importance.

**Scar/cosmesis.** The cervical scar that results from thyroid surgery is a result of multiple factors that are both surgical technique and patient-related. Many studies have reported that the appearance of the cervical scar after thyroid surgery has a significant QoL impact on patients, especially within the first few years after surgery.<sup>584,585</sup> Management of the scar and lessening its impact should be a focus for the thyroid surgeon. There are also remote access surgical options available for carefully selected patients that will avoid a neck scar.

**Neck tightness and dysphagia.** Many patients experience a “tight neck” from scarring and fibrosis that can occur after thyroid surgery (“post-thyroidectomy central compartment syndrome”). If it occurs, this is most noticeable in the first 3 months post-op but may persist longer. This tightness may also result in a globus sensation or dysphagia which mostly reverts back to the preoperative baseline by 2–3 months.<sup>586</sup> Massage and neck range of motion exercises in the immediate postoperative period may help to minimize this effect.<sup>587</sup>

How should financial hardship caused by thyroid cancer be addressed?

#### ■ RECOMMENDATION 83

- A. Patients should be informed that resources exist for patients and families impacted by financial burden due to a diagnosis of thyroid cancer. (*Good Practice Statement*)
- B. Clinicians should know that many patients diagnosed with thyroid cancer experience financial burden engendered by the costs of cancer diagnosis, treatment, and monitoring. Clinicians should discuss these topics with patients and their families. (*Good Practice Statement*)

The substantial cost of thyroid cancer care can place a burden on thyroid cancer survivors and their families. Patients diagnosed with thyroid cancer are at risk for financial hardship (i.e., financial toxicity).<sup>1413–1415</sup> A study evaluating bankruptcy in Washington State found that patients diagnosed with thyroid cancer are 3.46 times more likely to file for bankruptcy than people without cancer (the second largest difference when compared with other cancer types).<sup>1416</sup> In addition, compared with individuals without cancer, thyroid cancer survivors experience

higher unemployment 2 years after diagnosis and lower income at 2 and 4 years after diagnosis.<sup>1417</sup> In one study from the Netherlands, older age, greater fatigue, and lower education were associated with unemployment.<sup>1418</sup> Medical costs can lead to differing financial burdens based on factors such as patient age, socioeconomic status, and race/ethnicity. Prior studies have found that Black and Hispanic patients with thyroid cancer are at elevated risk for food insecurity.<sup>1419</sup> In the United States, younger patient age is commonly associated with more cancer-related financial hardship, likely because older patients have access to Medicare. In contrast, among low-aculturated Hispanic women as compared with high-aculturated Hispanic women, financial hardship has been seen across all age groups.<sup>1420</sup> Financial hardship contributes to poor QoL. In a study of 1743 adult thyroid cancer survivors in the United States, financial difficulties were associated with increased anxiety and depression.<sup>1415</sup> Clinicians should be aware that some patients diagnosed with thyroid cancer suffer financial hardships due to the costs of cancer diagnosis, treatment, and monitoring. Clinicians should employ approaches to testing, treatment, and monitoring that are most cost effective for a patient and reduce the financial barriers to care.<sup>1421</sup> Patient education should address financial services, social work, and when available, care coordinators.

What are the critical psychosocial concerns of thyroid cancer survivors?

#### ■ RECOMMENDATION 84

- A. Thyroid cancer survivors should be informed that services are available to support psychosocial needs related to having a cancer diagnosis. (*Good Practice Statement*)
- B. Clinicians treating patients diagnosed with thyroid cancer should be prepared to help patients manage the psychosocial implications of thyroid cancer diagnosis and management. (*Good Practice Statement*)

Thyroid cancer survivors may have long-term and under-addressed psychosocial concerns, including worse QoL, distress, and cancer-related worry. Although there has been some variability in findings and measures used, several reports show that irrespective of prognosis, many patients with thyroid cancer report worse QoL.<sup>468,1422–1424</sup> One study found that self-reported QoL among thyroid cancer survivors is similar or worse than the QoL of survivors with other cancer types.<sup>1425</sup> Patients with thyroid cancer diagnosed at a younger age, with comorbidities, with preexisting depression, who overestimate mortality risk, who have a fear of recurrence, who have persistent disease, and who have side effects or complications from their thyroid cancer treatment are more likely to report worse QoL.<sup>941,1426–1435</sup> One study suggested that cancer-related fatigue is associated with both worse QoL and distress.<sup>1436</sup> Another study found that with thyroid cancer, younger patient age, more comorbidities, history of depression, and report of thyroid hormone suppression correlated with moderate to severe post-treatment fatigue.<sup>1437</sup> A recent systematic review suggested that QoL was better in patients undergoing hemithyroidectomy versus total thyroidectomy when measured shortly after the procedure (less than 6 months), but long-term data were less certain, and prospective data are limited.<sup>1438</sup> There are mixed findings surrounding whether more intensive treatment adversely impacts QoL.<sup>396,398,1439,1440</sup>

One important consideration of measures of QoL has been the need for their validation in patients with thyroid cancer. Recently, the EORTC QoL group has developed and validated a QoL tool for patients with thyroid cancer (EORTC QLQ-THY34), including in a recent phase IV study.<sup>1441,1442</sup> Use of this validated scale has the potential to provide important insights to inform better understanding of the their psychosocial well-being.

Distress related to a thyroid cancer diagnosis can remain high for many years after diagnosis.<sup>1443,1444</sup> Studies have found that cancer-related worry is prevalent among thyroid cancer survivors; for a substantial proportion of patients, it can become long-standing.<sup>990,1443,1445</sup> A study in 941 Canadian cancer survivors found that cancer-related worry was greatest in younger cancer survivors and in patients with confirmed or suspected residual disease.<sup>1443</sup> However, even in 2215 disease-free patients 2–4 years post-diagnosis, there were concerns about death (41%), harms from treatment (44%), impaired QoL (55%), family at risk (58%), and cancer recurrence (63%). Female patients, younger patients, those with a lower education, and racial/ethnic minorities are more likely to report cancer-related worry.<sup>990</sup> Studies suggest that patient worry can impact both clinician and patient treatment choices.<sup>1446–1448</sup>

Despite clinician awareness of high levels of worry, distress, and worse QoL among thyroid cancer survivors, many clinicians do not pursue management considerations beyond the clinician–patient clinic visit. Hence, many patients report unmet psychosocial support needs.<sup>1449–1453</sup> In a survey of 2000 patients with thyroid cancer, just 9% reported receiving support addressing worry about recurrence, 12% counseling to manage distress, and 10% information about coping strategies.<sup>1454</sup> High-quality information resources should be offered to patients, including, but not limited to, details surrounding online support groups (e.g., ThyCa: Thyroid Cancer Survivors' Association, Inc.), general information on cancer distress (e.g., the NCCN patient guidelines on cancer distress), thyroid cancer–specific information on cancer distress and coping (e.g., ASCO's Thyroid Cancer: Coping with Treatment and the NCI's Thyroid Cancer-Patient Version), as well as access to local resources, such as hospital social work and/or psychology services.<sup>1443,1455–1458</sup>

### Acknowledgments

The task force wishes to thank Ms. Amanda Perl, former Executive Director, American Thyroid Association; Ms. Pam Mechler, current Executive Director of American Thyroid Association; Ms. Kelly Hoff and Ms. Becky Schierman, Assistants to the task force, and Chandler Atchison, research librarian, for their constant help and support, as well as Ms. Vicki Wright for her assistance in article preparation. We would like to thank the members of the ATA Guidelines Steering Committee and the full ATA membership for their careful review and suggestions for the draft article that led to detailed consideration and modifications during final revisions prior to journal submission, as well as our patient advocate (G.B.) who served as a full voting member of the task force.

The following groups reviewed and endorsed the final document: the ATA BOD, American Association of Endocrine Surgeons, Asia Oceania Thyroid Association, American Head and Neck Society, Canadian Society of Otolaryngology-Head and Neck Surgery, China Thyroid Association, Endocrine Society, Endocrine Society of

Australia, Guangzhou First People's Hospital, International Association Endocrine Surgeons, International Federation of Head and Neck Oncologic Societies, International Thyroid Oncology Group, and Latin American Thyroid Society.

### Disclaimer

It is our goal in formulating these guidelines, and the ATA's goal in providing support for the development of these guidelines, that they assist in the clinical care of patients and share what we believe is current, rational, and optimal medical practice. In some circumstances, it may be apparent that the level of care recommended may be best provided in limited centers with specific expertise. Finally, it is not the intent of these guidelines to replace individual decision-making, the wishes of the patient or family, or clinical judgment.

### Authors' Contributions

M.D.R.: Conceptualization, project administration and supervision, writing—original draft, writing—review and editing, and visualization. J.A.S.: Conceptualization, project administration and supervision, writing—original draft, writing—review and editing, and visualization. Z.B.: Writing—original draft, writing—review and editing, and visualization. L.B.: Writing—original draft, writing—review and editing, and visualization. G.B.: Writing—original draft, writing—review and editing, and visualization. G.A.B.: Writing—original draft, writing—review and editing, and visualization. P.L.B.: Writing—original draft, writing—review and editing, and visualization. R.C.: Methodology, data curation, validation, writing—original draft, writing—review and editing, and visualization. R.R.F.: Writing—original draft, writing—review and editing, and visualization. W.G.: Writing—original draft, writing—review and editing, and visualization. E.G.G.: Writing—original draft, writing—review and editing, and visualization. M.H.: Writing—original draft, writing—review and editing, and visualization. S.M.L.: Writing—original draft, writing—review and editing, and visualization. A.M.L.: Writing—original draft, writing—review and editing, and visualization. J.O.: Writing—original draft, writing—review and editing, and visualization. J.A.R.: Writing—original draft, writing—review and editing, and visualization. B.R.: Writing—original draft, writing—review and editing, and visualization. D.L.S.: Writing—original draft, writing—review and editing, and visualization. R.P.T.: Writing—original draft, writing—review and editing, and visualization. L.J.W.: Writing—original draft, writing—review and editing, and visualization.

### Funding Information

These guidelines were funded by the ATA without support from any commercial sources.

### Author Disclosure Statement

These guidelines were funded by the American Thyroid Association without support from any commercial sources. MDR and JAS have no significant financial or competing interests to disclose.

## DISCLOSURE STATEMENT

<i>First Name</i>	<i>Last Name</i>	<i>Disclosures Noted</i>	<i>Is this relationship relevant?</i>	<i>Mitigation Measures</i>
Matthew	Ringel	None	N/A	
Julie Ann	Sosa	Research Support: Subcontract from MD Anderson Cancer Center funded by Exelixis and Eli Lilly for MTC registry. Consultant: Member and ATA representative, Data Monitoring Committee of the Medullary Thyroid Cancer Consortium Registry	No	
Zubair	Baloch	None	N/A	
Lindsay	Bischoff	None	N/A	
Gary	Bloom	Commercial Interest: Eli Lilly travel grant	Yes	Recusal from recommendation voting where COI is relevant.
Gregory	Brent	None	N/A	
Pamela	Brock	None	N/A	
Lyn				
Robert	Flavell	Commercial Interest: Co-Founder, Tiller Therapeutics. Value < \$5000. Commercial Research Grants from Bristol-Myers-Squibb and Fibrogen	No	
Whitney	Goldner	Commercial interest: Roche: Site PI of multicenter study/ Siemen's: Site PI of multicenter study. Does not get paid directly - research costs are paid to institution.	No	
Elizabeth	Gardner	Research Support: Elizabeth Grubbs oversees institutional research funding from by Exelixis and Eli Lilly for MTC registry	No	
	Grubbs			
Megan	Haymart	None	N/A	
Steven	Larson	Commercial Interest: Commercial research grants from Y-mAbs Therapeutics, Inc., Genentech, Inc., WILEX AG, Telix Pharmaceuticals Limited, and Regeneron Pharmaceuticals, Inc.; Inventor of issued patents both currently unlicensed and licensed by MSK to Samus Therapeutics, Inc., Elucida Oncology, Inc., and Y-mAbs Therapeutics, Inc Serves or has served as a consultant both compensated and uncompensated to Cynvec LLC, Eli Lilly & Co., Prescient Therapeutics Limited, Advanced Innovative Partners, LLC, Gerson Lehrman Group, Progenics Pharmaceuticals, Inc., Exini, Inc., and Janssen Pharmaceuticals, Inc Holding ownership interest/equity in Elucida Oncology, Inc.; and holding stock in ImaginAb, Inc., and Y-mAbs Therapeutics	Yes	Recusal from recommendation voting where COI is relevant.
Angela	Leung	None	No	
Joseph	Osborne	Consultant: Siemens Healthineer	No	
John	Ridge	None	N/A	
Bruce	Robinson	Consultant: Advisory Board for Eisai, Lilly and Exelixis	Yes	Recusal from recommendation voting where COI is relevant.
David	Steward	None	N/A	
Ralph	Tufano	Commercial Interest and Consultant: Medtronic Category C Commercial Interest and Consultant: Stryker Medical-(terminated 4/1/2023) Pulse Biosciences Category D Commercial Interest and Consultant: RGS Health Care Category B Commercial Interest and Consultant: RGS Health Care Category B	Yes	Recusal from recommendation voting where COI is relevant.
Lori	Wirth	Consultant: Bayer Healthcare Consultant: Blueprint Medicines Consultant: Eli Lilly Research Support: Eli Lilly Consultant: Exelixis Consultant: Coherus Biosciences Consultant: Morphic Therapeutic terminated 12/2021) Consultant: EMD Serono Consultant: Illumina Consultant: Nested Therapeutics Consultant: PDS Biotechnology DSMC Member: PDS Biotechnology Research Support: Ellipses Consultant: Ellipses Research Support: Novartis Consultant: Novartis Consultant: Merck	Yes	Recusal from recommendation voting where COI is relevant.

**Supplementary Material**

Supplementary Figure S1  
Supplementary Figure S2  
Supplementary Figure S3

**References**

- Sherma SI. Thyroid carcinoma. *Lancet* 2003;361(9356): 501–511.
- Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. *CA: A Cancer Journal for Clinicians* 2024;74(1): 12–49; doi: 10.3322/caac.21820
- Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. *CA Cancer J Clin* 2014;64(1):9–29; doi: 10.3322/caac.21208
- Davies L, Welch HG. Current thyroid cancer trends in the United States. *JAMA Otolaryngol Head Neck Surg* 2014; 140(4):317–322; doi: 10.1001/jamaoto.2014.1

5. Leenhardt L, Bernier MO, Boin-Pineau MH, et al. Advances in diagnostic practices affect thyroid cancer incidence in France. *Eur J Endocrinol* 2004;150(2):133–139.
6. Yu J. Trends in the incidence of thyroid cancer among US persons from 2000 to 2019. *Eur J Cancer Prev* 2024;33(1):5–10; doi: 10.1097/cej.0000000000000827
7. Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. *American Thyroid Association. Arch Intern Med* 1996;156(19):2165–2172.
8. Francis GL, Waguespack SG, Bauer AJ, et al; American Thyroid Association Guidelines Task Force. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. *Thyroid* 2015;25(7):716–759; doi: 10.1089/thy.2014.0460
9. Lewis MH, Gohagan JK, Merenstein DJ. The locality rule and the physician's dilemma: Local medical practices vs the national standard of care. *JAMA* 2007;297(23):2633–2637; doi: 10.1001/jama.297.23.2633
10. Harrison MB, Graham ID, van den Hoek J, et al. Guideline adaptation and implementation planning: A prospective observational study. *Implement Sci* 2013;8:49–63.
11. Carlson RW, Larsen JK, McClure J, et al. International adaptations of NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 2014;12(5):643–648; doi: 10.6004/jnccn.2014.0068
12. Cooper DS, Doherty GM, Haugen BR, et al; American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* 2006;16(2):109–142.
13. Cooper DS, Doherty GM, Haugen BR, et al; American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* 2009;19(11):1167–1214; doi: 10.1089/thy.2009.0110
14. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid* 2016;26(1):1–133; doi: 10.1089/thy.2015.0020
15. Chou R, Dana T, Haymart MR, et al. Active surveillance versus thyroid surgery for differentiated thyroid cancer: A systematic review. *Thyroid* 2022;32(4):351–367; doi: 10.1089/thy.2021.0539
16. Chou R, Dana T, Brent GA, et al. Serum thyroglobulin measurement following surgery without radioactive iodine for differentiated thyroid cancer: A systematic review. *Thyroid* 2022;32(6):613–639; doi: 10.1089/thy.2021.0666
17. Qaseem A, Kansagara D, Lin JS, et al; Clinical Guidelines Committee of the American College of Physicians. The development of clinical guidelines and guidance statements by the clinical guidelines committee of the American college of physicians: Update of methods. *Ann Intern Med* 2019;170(12):863–870; doi: 10.7326/m18-3290
18. Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. In *Clinical Practice Guidelines We Can Trust*. (Graham R, Mancher M, Miller Wolman D, et al. eds.) National Academies Press: Washington, DC; 2011.
19. World Health Organization. Decision-making for guideline development at WHO. WHO; 2014.
20. Harris RP, Helfand M, Woolf SH, et al; Methods Work Group, Third U.S. Preventive Services Task Force. Reprint of: Current methods of the U.S. preventive services task force: A review of the process. *Am J Prev Med* 2020;58(3):316–331; doi: 10.1016/j.amepre.2020.01.001
21. Higgins JP, Savović J, Page MJ, et al. Assessing risk of bias in a randomized trial. In: *Cochrane Handbook for Systematic Reviews of Interventions*. Cochrane; 2019; pp. 205–228.
22. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336(7650):924–926; doi: 10.1136/bmj.39489.470347.AD
23. Dewidar O, Lotfi T, Langendam MW, et al; eCOVID-19 recommendations map collaborators. Good or best practice statements: Proposal for the operationalisation and implementation of GRADE guidance. *BMJ Evid Based Med* 2023;28(3):189–196; doi: 10.1136/bmjebm-2022-111962
24. WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours, 5th ed. International Agency for Research on Cancer: Lyon, France; 2025. (WHO classification of tumours series, vol. 10).
25. Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. *Endocrinol Metab Clin North Am* 2014;43(2):401–421; doi: 10.1016/j.ecl.2014.02.010
26. Tuttle RM. Distinguishing remnant ablation from adjuvant treatment in differentiated thyroid cancer. *Lancet Diabetes Endocrinol* 2019;7(1):7–8; doi: 10.1016/S2213-8587(18)30335-8
27. Tuttle M, Haugen B, Shah J, et al. Thyroid-differentiated and anaplastic carcinoma. In: *AJCC Cancer Staging Manual*, 8th ed. (Amin MB, Greene F, Byrd DR eds.) Springer International: New York, NY; 2017.
28. Cirocchi R, Trastulli S, Randolph J, et al. Total or near-total thyroidectomy versus subtotal thyroidectomy for multinodular non-toxic goitre in adults. *Cochrane Database Syst Rev* 2015;2015(8):CD010370; doi: 10.1002/14651858.CD010370.pub2
29. Mizrachi A, Shaha AR. Lymph node dissection for differentiated thyroid cancer. *Mol Imaging Radionucl Ther* 2017;26(Suppl 1):10–15; doi: 10.4274/2017.26.suppl.02
30. Agrawal N, Evasovich MR, Kandil E, et al. Indications and extent of central neck dissection for papillary thyroid cancer: An American Head and Neck Society Consensus Statement. *Head Neck* 2017;39(7):1269–1279; doi: 10.1002/hed.24715
31. Stack BC, Jr, Ferris RL, Goldenberg D, et al; American Thyroid Association Surgical Affairs Committee. American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. *Thyroid* 2012;22(5):501–508; doi: 10.1089/thy.2011.0312
32. Carty SE, Cooper DS, Doherty GM, et al; American Head and Neck Society. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. *Thyroid* 2009;19(11):1153–1158; doi: 10.1089/thy.2009.0159

33. Sturgeon C, Yang A, Elaraj D. Surgical management of lymph node compartments in papillary thyroid cancer. *Surg Oncol Clin N Am* 2016;25(1):17–40; doi: 10.1016/j.soc.2015.08.013
34. Rosai J, DeLellis RA, Carcangui ML, et al. *Tumors of The Thyroid Gland*. Armed Forces Institute of Pathology: Washington, DC; 2014.
35. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin* 2020;70(1):7–30; doi: 10.3322/caac.21590
36. Baloch ZW, Asa SL, Barletta JA, et al. Overview of the 2022 WHO classification of thyroid neoplasms. *Endocr Pathol* 2022;33(1):27–63; doi: 10.1007/s12022-022-09707-3
37. Kim K, Kim JK, Lee CR, et al. Comparison of long-term prognosis for differentiated thyroid cancer according to the 7th and 8th editions of the AJCC/UICC TNM staging system. *Ther Adv Endocrinol Metab* 2020;11:2042018820921019; doi: 10.1177/2042018820921019
38. Fagin JA, Nikiforov YE. Progress in thyroid cancer genomics: A 40-year journey. *Thyroid* 2023;33(11):1271–1286; doi: 10.1089/thy.2023.0045
39. Landa I, Cabanillas ME. Genomic alterations in thyroid cancer: Biological and clinical insights. *Nat Rev Endocrinol* 2024;20(2):93–110; doi: 10.1038/s41574-023-00920-6
40. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: Evidence for distinct molecular pathways in thyroid follicular carcinoma. *J Clin Endocrinol Metab* 2003;88(5):2318–2326; doi: 10.1210/jc.2002-021907
41. Jalaly JB, Baloch ZW. Hurthle-cell neoplasms of the thyroid: An algorithmic approach to pathologic diagnosis in light of molecular advances. *Semin Diagn Pathol* 2020;37(5):234–242; doi: 10.1053/j.semdp.2020.03.004
42. Mete O, Asa SL. Oncocytes, oxyphils, Hurthle, and Askanazy cells: Morphological and molecular features of oncocytic thyroid nodules. *Endocr Pathol* 2010;21(1):16–24; doi: 10.1007/s12022-009-9102-2
43. Juhlin C, Mete O, Baloch ZW. The 2022 WHO classification of thyroid tumors: Novel concepts in nomenclature and grading. *Endocr Relat Cancer* 2023;30(2):e220293; doi: 10.1530/ERC-22-0293
44. Gopal RK, Kübler K, Calvo SE, et al. Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hurthle cell carcinoma. *Cancer Cell* 2018;34(2):242–255.e5; doi: 10.1016/j.ccell.2018.06.013
45. Ganly I, Makarov V, Deraje S, et al. Integrated genomic analysis of Hurthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes. *Cancer Cell* 2018;34(2):256–270.e5; doi: 10.1016/j.ccell.2018.07.002
46. Zhou X, Zheng Z, Chen C, et al. Clinical characteristics and prognostic factors of Hurthle cell carcinoma: A population based study. *BMC Cancer* 2020;20(1):407; doi: 10.1186/s12885-020-06915-0
47. Grani G, Lamartina L, Durante C, et al. Follicular thyroid cancer and Hurthle cell carcinoma: Challenges in diagnosis, treatment, and clinical management. *Lancet Diabetes Endocrinol* 2018;6(6):500–514; doi: 10.1016/S2213-8587(17)30325-X
48. Goffredo P, Roman SA, Sosa JA. Hurthle cell carcinoma: A population-level analysis of 3311 patients. *Cancer* 2013;119(3):504–511; doi: 10.1002/ncr.27770
49. Phitayakorn R, McHenry CR. Follicular and Hurthle cell carcinoma of the thyroid gland. *Surg Oncol Clin N Am* 2006;15(3):603–623, ix-x.
50. Ozlem Kucuk N, Kulak H, Tokmak E, et al. Hurthle cell carcinoma: A clinicopathological study of thirteen cases. *Nucl Med Commun* 2006;27(4):377–379.
51. Lazzi S, Spina D, Als C, et al. Oncocytic (Hurthle cell) tumors of the thyroid: Distinct growth patterns compared with clinicopathological features. *Thyroid* 1999;9(2):97–103.
52. Stojadinovic A, Ghossein RA, Hoos A, et al. Hurthle cell carcinoma: A critical histopathologic appraisal. *J Clin Oncol* 2001;19(10):2616–2625; doi: 10.1200/JCO.2001.19.10.2616
53. Bischoff LA, Ganly I, Fugazzola L, et al. Molecular alterations and comprehensive clinical management of oncocytic thyroid carcinoma: A review and multidisciplinary 2023 update. *JAMA Otolaryngol Head Neck Surg* 2024;150(3):265–272; doi: 10.1001/jamaoto.2023.4323
54. Chiba T. Molecular pathology of thyroid tumors: Essential points to comprehend regarding the latest WHO classification. *Biomedicines* 2024;12(4):712; doi: 10.3390/biomedicines12040712
55. Lukovic J, Petrovic I, Liu Z, et al. Oncocytic papillary thyroid carcinoma and oncocytic poorly differentiated thyroid carcinoma: Clinical features, uptake, and response to radioactive iodine therapy, and outcome. *Front Endocrinol (Lausanne)* 2021;12:795184; doi: 10.3389/fendo.2021.795184
56. Xu B, Ghossein RA. Advances in thyroid pathology: High grade follicular cell-derived thyroid carcinoma and anaplastic thyroid carcinoma. *Adv Anat Pathol* 2023;30(1):3–10; doi: 10.1097/pap.0000000000000380
57. Ghossein R, Katabi N, Dogan S, et al. Papillary thyroid carcinoma tall cell subtype (PTC-TC) and high-grade differentiated thyroid carcinoma tall cell phenotype (HGDT-TC) have different clinical behaviour: A retrospective study of 1456 patients. *Histopathology* 2024;84(7):1130–1138; doi: 10.1111/his.15157
58. Harahap AS, Roren RS, Imtiyaz S. A comprehensive review and insights into the new entity of differentiated high-grade thyroid carcinoma. *Curr Oncol* 2024;31(6):3311–3328; doi: 10.3390/currenco131060252
59. Poma AM, Macerola E, Ghossein RA, et al. Prevalence of differentiated high-grade thyroid carcinoma among well-differentiated tumors: A systematic review and meta-analysis. *Thyroid* 2024;34(3):314–323; doi: 10.1089/thy.2023.0350
60. Abrosimova A, Sidorin AV, Shinkarkina AP. [High-grade thyroid cancer]. *Arkh Patol* 2014;76(2):48–54.
61. Baloch Z, LiVolsi VA. Fifty years of thyroid pathology: Concepts and developments. *Hum Pathol* 2020;95:46–54; doi: 10.1016/j.humpath.2019.09.008
62. Shafique K, Baloch Z. Risk stratification of papillary thyroid carcinoma and its variants; from clinicopathologic features to molecular profiling. *Diagnostic Histopathology* 2019;25(5):143–153; doi: 10.1016/j.mpdhp.2019.02.001
63. Lee YK, Kim D, Shin DY, et al. The prognosis of papillary thyroid cancer with initial distant metastasis is strongly associated with extensive extrathyroidal extension: A retrospective cohort study. *Ann Surg Oncol* 2019;26(7):2200–2209; doi: 10.1245/s10434-019-07314-x

64. Ibrahimspasic T, Xu B, Landa I, et al. Genomic alterations in fatal forms of non-anaplastic thyroid cancer: Identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence. *Clin Cancer Res* 2017;23(19):5970–5980; doi: 10.1158/1078-0432.CCR-17-1183
65. Xu B, Ghossein R. Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma. *Endocr Pathol* 2016;27(3):205–212; doi: 10.1007/s12022-016-9445-4
66. Xu B, Wang L, Tuttle RM, et al. Prognostic impact of extent of vascular invasion in low-grade encapsulated follicular cell-derived thyroid carcinomas: A clinicopathologic study of 276 cases. *Hum Pathol* 2015;46(12):1789–1798; doi: 10.1016/j.humpath.2015.08.015
67. Taylor T, Specker B, Robbins J, et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. *Ann Intern Med* 1998;129(8):622–627.
68. Cracolici V, Cipriani NA. High-grade non-anaplastic thyroid carcinomas of follicular cell origin: A review of poorly differentiated and high-grade differentiated carcinomas. *Endocr Pathol* 2023;34(1):34–47; doi: 10.1007/s12022-023-09752-6
69. Chowdhury R, Alsayegh R, Forest VI, et al. Ki-67 labelling index as a predictor of invasive features in thyroid cancer: Retrospective analysis and implications. *Curr Oncol* 2024;31(7):4030–4037; doi: 10.3390/curroncol31070300
70. Ragazzi M, Besutti G, Mancuso P, et al. Accuracy of World Health Organisation-grade parameters (necrosis and mitotic activity) and foci of vascular invasion in predicting prognosis of papillary thyroid carcinoma. A case-control validation study. *Histopathology* 2024;85(1):62–74; doi: 10.1111/his.15173
71. Walczyk A, Kopczyński J, Gąsior-Periczak D, et al. Poorly differentiated thyroid cancer in the context of the revised 2015 American Thyroid Association guidelines and the updated American Joint Committee on Cancer/Tumor-Node-Metastasis staging system (eighth edition). *Clin Endocrinol (Oxf)* 2019;91(2):331–339; doi: 10.1111/cen.13910
72. Romei C, Tacito A, Molinaro E, et al. Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience. *Oncol Lett* 2018;15(6):9174–9182; doi: 10.3892/ol.2018.8470
73. Higashino M, Ayani Y, Terada T, et al. Clinical features of poorly differentiated thyroid papillary carcinoma. *Auris Nasus Larynx* 2019;46(3):437–442; doi: 10.1016/j.anl.2018.10.001
74. Yu MG, Rivera J, Jimeno C. Poorly differentiated thyroid carcinoma: 10-year experience in a southeast Asian population. *Endocrinol Metab (Seoul)* 2017;32(2):288–295; doi: 10.3803/EnM.2017.32.2.288
75. Tallini G. Poorly differentiated thyroid carcinoma. Are we there yet? *Endocr Pathol* 2011;22(4):190–194; doi: 10.1007/s12022-011-9176-5
76. Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: A paradigm shift to reduce overtreatment of indolent tumors. *JAMA Oncol* 2016;2(8):1023–1029; doi: 10.1001/jamaoncol.2016.0386
77. Haugen BR, Sawka AM, Alexander EK, et al. American Thyroid Association guidelines on the management of thyroid nodules and differentiated thyroid cancer task force review and recommendation on the proposed renaming of encapsulated follicular variant papillary thyroid carcinoma without invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features. *Thyroid* 2017;27(4):481–483; doi: 10.1089/thy.2016.0628
78. Caulley L, Eskander A, Yang W, et al. Trends in diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features and total thyroidectomies for patients with papillary thyroid neoplasms. *JAMA Otolaryngol Head Neck Surg* 2022;148(2):99–106; doi: 10.1001/jamaoto.2021.3277
79. Paja M, Zafon C, Iglesias C, et al. Rate of non-invasive follicular thyroid neoplasms with papillary-like nuclear features depends on pathologist's criteria: A multicentre retrospective Southern European study with prolonged follow-up. *Endocrine* 2021;73(1):131–140; doi: 10.1007/s12020-021-02610-7
80. Parente DN, Kluijfhout WP, Bongers PJ, et al. Clinical safety of renaming encapsulated follicular variant of papillary thyroid carcinoma: Is NIFTP truly benign? *World J Surg* 2018;42(2):321–326; doi: 10.1007/s00268-017-4182-5
81. Rana C, Vuong HG, Nguyen TQ, et al. The incidence of noninvasive follicular thyroid neoplasm with papillary-like nuclear features: A meta-analysis assessing worldwide impact of the reclassification. *Thyroid* 2021;31(10):1502–1513; doi: 10.1089/thy.2021.0158
82. Turan G, Ozkara SK. Pathological findings of the retrospective diagnosis of NIFTP (non-invasive follicular thyroid neoplasm with papillary-like nuclear features) in 84 cases from Turkey and systematic review. *Ann Diagn Pathol* 2021;53(1):151764; doi: 10.1016/j.anndiagpath.2021.151764
83. Nikiforov YE, Baloch ZW, Hodak SP, et al. Change in diagnostic criteria for noninvasive follicular thyroid neoplasm with papillary-like nuclear features. *JAMA Oncol* 2018;4(8):1125–1126; doi: 10.1001/jamaoncol.2018.1446
84. Xu B, Farhat N, Barletta JA, et al. Should subcentimeter non-invasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category? *Endocrine* 2018;59(1):143–150; doi: 10.1007/s12020-017-1484-1
85. Xu B, Reznik E, Tuttle RM, et al. Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocyctic features. *Endocrine* 2019;64(1):97–108; doi: 10.1007/s12020-019-01848-6
86. Paniza ACJ, Mendes TB, Viana MDB, et al. Revised criteria for diagnosis of NIFTP reveals a better correlation with tumor biological behavior. *Endocr Connect* 2019;8(11):1529–1538; doi: 10.1530/EC-19-0459
87. Cho U, Mete O, Kim MH, et al. Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: The impact of rigid criteria to distinguish non-invasive follicular thyroid neoplasm with papillary-like nuclear features. *Mod Pathol* 2017;30(6):810–825; doi: 10.1038/modpathol.2017.9
88. Basolo F, Macerola E, Ugolini C, et al. The molecular landscape of noninvasive follicular thyroid neoplasm

- with papillary-like nuclear features (NIFTP): A literature review. *Adv Anat Pathol* 2017;24(5):252–258; doi: 10.1097/PAP.000000000000163
89. Chu YH, Sadow PM. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): Diagnostic updates and molecular advances. *Semin Diagn Pathol* 2020;37(5):213–218; doi: 10.1053/j.semmp.2020.06.001
  90. Lloyd RV, Asa SL, LiVolsi VA, et al. The evolving diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). *Hum Pathol* 2018;74:1–4; doi: 10.1016/j.humpath.2017.12.027
  91. Zhao L, Dias-Santagata D, Sadow PM, et al. Cytological, molecular, and clinical features of noninvasive follicular thyroid neoplasm with papillary-like nuclear features versus invasive forms of follicular variant of papillary thyroid carcinoma. *Cancer Cytopathol* 2017;125(5):323–331; doi: 10.1002/cncy.21839
  92. Kuchareczko A, Kopczyński J, Kowalik A, et al. Are molecular tests necessary to diagnose NIFTP? *Genes Cancer* 2021;12:39–50; doi: 10.18632/genescancer.213
  93. Pool C, Walter V, Bann D, et al. Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). *Virchows Arch* 2019;474(3):341–351; doi: 10.1007/s00428-018-02512-6
  94. Borrelli N, Denaro M, Ugolini C, et al. miRNA expression profiling of ‘noninvasive follicular thyroid neoplasms with papillary-like nuclear features’ compared with adenomas and infiltrative follicular variants of papillary thyroid carcinomas. *Mod Pathol* 2017;30(1):39–51; doi: 10.1038/modpathol.2016.157
  95. Coyne C, Nikiforov YE. RAS mutation-positive follicular variant of papillary thyroid carcinoma arising in a struma ovarii. *Endocr Pathol* 2010;21(2):144–147; doi: 10.1007/s12022-009-9097-8
  96. Thompson LDR, Poller DN, Kakudo K, et al. An international interobserver variability reporting of the nuclear scoring criteria to diagnose noninvasive follicular thyroid neoplasm with papillary-like nuclear features: A validation study. *Endocr Pathol* 2018;29(3):242–249; doi: 10.1007/s12022-018-9520-0
  97. Rosario PW, Mourão GF. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): A review for clinicians. *Endocr Relat Cancer* 2019;26(5):R259–R266; doi: 10.1530/erc-19-0048
  98. Kwon MR, Shin JH, Hahn SY, et al. Histogram analysis of greyscale sonograms to differentiate between the subtypes of follicular variant of papillary thyroid cancer. *Clin Radiol* 2018;73(6):591.e1–591.e7; doi: 10.1016/j.crad.2017.12.008
  99. Kim TH, Lee M, Kwon AY, et al. Molecular genotyping of the non-invasive encapsulated follicular variant of papillary thyroid carcinoma. *Histopathology* 2018;72(4):648–661; doi: 10.1111/his.13401
  100. Lee M, Powers AE, Morris LGT, et al. Reversal in thyroid cancer incidence trends in the United States, 2000–2017. *Thyroid* 2020;30(8):1226–1227; doi: 10.1089/thy.2020.0321
  101. Van den Bruel A, Francart J, Dubois C, et al. Regional variation in thyroid cancer incidence in Belgium is associated with variation in thyroid imaging and thyroid disease management. *J Clin Endocrinol Metab* 2013;98(10):4063–4071; doi: 10.1210/jc.2013-1705
  102. Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”—screening and overdiagnosis. *N Engl J Med* 2014;371(19):1765–1767; doi: 10.1056/NEJMp1409841
  103. Haymart MR, Banerjee M, Reyes-Gastelum D, et al. Thyroid ultrasound and the increase in diagnosis of low-risk thyroid cancer. *J Clin Endocrinol Metab* 2019;104(3):785–792; doi: 10.1210/jc.2018-01933
  104. Kitahara CM, Sosa JA. Understanding the ever-changing incidence of thyroid cancer. *Nat Rev Endocrinol* 2020;16(11):617–618; doi: 10.1038/s41574-020-00414-9
  105. Vaccarella S, Franceschi S, Bray F, et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. *N Engl J Med* 2016;375(7):614–617; doi: 10.1056/NEJMp1604412
  106. Pereira M, Williams VL, Hallanger Johnson J, et al. Thyroid cancer incidence trends in the United States: Association with changes in professional guideline recommendations. *Thyroid* 2020;30(8):1132–1140; doi: 10.1089/thy.2019.0415
  107. Tessler FN, Middleton WD, Grant EG, et al. ACR thyroid imaging, reporting and data System (TI-RADS): White Paper of the ACR TI-RADS Committee. *J Am Coll Radiol* 2017;14(5):587–595; doi: 10.1016/j.jacr.2017.01.046
  108. Bibbins-Domingo K, Grossman DC, Curry SJ, et al; US Preventive Services Task Force. Screening for thyroid cancer: US preventive services task force recommendation statement. *JAMA* 2017;317(18):1882–1887; doi: 10.1001/jama.2017.4011
  109. Shi X, Liu R, Basolo F, et al. Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. *J Clin Endocrinol Metab* 2016;101(1):264–274; doi: 10.1210/jc.2015-2917
  110. Lim H, Devesa SS, Sosa JA, et al. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. *JAMA* 2017;317(13):1338–1348; doi: 10.1001/jama.2017.2719
  111. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. *N Engl J Med* 1997;336(13):897–904; doi: 10.1056/NEJM199703273361301
  112. Pacini F, Vorontsova T, Demidchik EP, et al. Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: Comparison with naturally occurring thyroid carcinoma in Italy and France. *J Clin Endocrinol Metab* 1997;82(11):3563–3569; doi: 10.1210/jcem.82.11.4367
  113. Kitahara CM, Preston DL, Neta G, et al. Occupational radiation exposure and thyroid cancer incidence in a cohort of U.S. radiologic technologists, 1983–2013. *Int J Cancer* 2018;143(9):2145–2149; doi: 10.1002/ijc.31270
  114. Muirhead CR, O’Hagan JA, Haylock RG, et al. Mortality and cancer incidence following occupational radiation exposure: Third analysis of the National Registry for Radiation Workers. *Br J Cancer* 2009;100(1):206–212; doi: 10.1038/sj.bjc.6604825
  115. Fromme H, Becher G, Hilger B, et al. Brominated flame retardants - Exposure and risk assessment for the general population. *Int J Hyg Environ Health* 2016;219(1):1–23; doi: 10.1016/j.ijheh.2015.08.004
  116. Stapleton HM, Sharma S, Getzinger G, et al. Novel and high volume use flame retardants in US couches reflective of the 2005 PentaBDE phase out. *Environ Sci Technol* 2012;46(24):13432–13439; doi: 10.1021/es303471d

117. van der Veen I, de Boer J. Phosphorus flame retardants: Properties, production, environmental occurrence, toxicity and analysis. *Chemosphere* 2012;88(10):1119–1153; doi: 10.1016/j.chemosphere.2012.03.067
118. Aschebrook-Kilfoy B, DellaValle CT, Purdue M, et al. Polybrominated diphenyl ethers and thyroid cancer risk in the Prostate, Colorectal, Lung, and Ovarian Cancer Screening Trial cohort. *Am J Epidemiol* 2015;181(11):883–888; doi: 10.1093/aje/kwu358
119. Hoffman K, Lorenzo A, Butt CM, et al. Exposure to flame retardant chemicals and occurrence and severity of papillary thyroid cancer: A case-control study. *Environ Int* 2017;107:235–242; doi: 10.1016/j.envint.2017.06.021
120. Green M. *Flame Retardant Chemicals: Technologies and Global Markets*. BCC Research: Wellesley, MA; 2015.
121. Hellgren LS, Stenman A, Paulsson JO, et al. Prognostic utility of the Ki-67 labeling index in follicular thyroid tumors: A 20-year experience from a tertiary thyroid center. *Endocr Pathol* 2022;33(2):231–242; doi: 10.1007/s12022-022-09714-4
122. Ito Y, Miyauchi A. Prognostic factors of papillary and follicular carcinomas based on pre-, intra-, and post-operative findings. *Eur Thyroid J* 2024;13(5):e240196; doi: 10.1530/etj-24-0196
123. Kakudo K, Wakasa T, Ohta Y, et al. Prognostic classification of thyroid follicular cell tumors using Ki-67 labeling index: Risk stratification of thyroid follicular cell carcinomas. *Endocr J* 2015;62(1):1–12; doi: 10.1507/endocrj.EJ14-0293
124. Schultz KAP, Williams GM, Kamihara J, et al. DICER1 and associated conditions: Identification of at-risk individuals and recommended surveillance strategies. *Clin Cancer Res* 2018;24(10):2251–2261; doi: 10.1158/1078-0432.Ccr-17-3089
125. Correa R, Salpea P, Stratakis CA. Carney complex: an update. *Eur J Endocrinol* 2015;173(4):M85–M97; doi: 10.1530/eje-15-0209
126. Takemoto M, Yokote K. Preface to management guideline for Werner syndrome 2020. *Geriatr Gerontol Int* 2021;21(2):131–132; doi: 10.1111/ggi.14074
127. Daly MB, Pal T, Berry MP, et al; CGC. Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 2021;19(1):77–102; doi: 10.6004/jnccn.2021.0001
128. Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: Systematic review and revised diagnostic criteria. *J Natl Cancer Inst* 2013;105(21):1607–1616; doi: 10.1093/jnci/djt277
129. Ngeow J, Mester J, Rybicki LA, et al. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. *J Clin Endocrinol Metab* 2011;96(12):E2063–E71; doi: 10.1210/jc.2011-1616
130. Laury AR, Bongiovanni M, Tille JC, et al. Thyroid pathology in PTEN-hamartoma tumor syndrome: Characteristic findings of a distinct entity. *Thyroid* 2011;21(2):135–144; doi: 10.1089/thy.2010.0226
131. Chernock RD, Rivera B, Borrelli N, et al. Poorly differentiated thyroid carcinoma of childhood and adolescence: A distinct entity characterized by DICER1 mutations. *Mod Pathol* 2020;33(7):1264–1274; doi: 10.1038/s41379-020-0458-7
132. Lee YA, Im SW, Jung KC, et al. Predominant DICER1 pathogenic variants in pediatric follicular thyroid carcinomas. *Thyroid* 2020;30(8):1120–1131; doi: 10.1089/thy.2019.0233
133. Wasserman JD, Sabbaghian N, Fahiminiya S, et al. DICER1 mutations are frequent in adolescent-onset papillary thyroid carcinoma. *J Clin Endocrinol Metab* 2018;103(5):2009–2015; doi: 10.1210/jc.2017-02698
134. Rutter MM, Jha P, Schultz KA, et al. DICER1 mutations and differentiated thyroid carcinoma: Evidence of a direct association. *J Clin Endocrinol Metab* 2016;101(1):1–5; doi: 10.1210/jc.2015-2169
135. Stewart DR, Best AF, Williams GM, et al. Neoplasm risk among individuals with a pathogenic germline variant in DICER1. *J Clin Oncol* 2019;37(8):668–676; doi: 10.1200/JCO.2018.78.4678
136. Cetta F, Montalto G, Gori M, et al. Germline mutations of the APC gene in patients with familial adenomatous polyposis-associated thyroid carcinoma: Results from a European cooperative study. *J Clin Endocrinol Metab* 2000;85(1):286–292; doi: 10.1210/jcem.85.1.6254
137. Harach HR, Williams GT, Williams ED. Familial adenomatous polyposis associated thyroid carcinoma: A distinct type of follicular cell neoplasm. *Histopathology* 1994;25(6):549–561.
138. Cameselle-García S, Abdulkader-Nallib I, Sánchez-Ares M, et al. Cribriform morular thyroid carcinoma: Clinicopathological and molecular basis for both a preventive and therapeutic approach for a rare tumor (Review). *Oncol Rep* 2024;52(3):119; doi: 10.3892/or.2024.8778
139. Hirokawa M, Maekawa M, Kuma S, et al. Cribriform-morular variant of papillary thyroid carcinoma—cytological and immunocytochemical findings of 18 cases. *Diagn Cytopathol* 2010;38(12):890–896; doi: 10.1002/dc.21309
140. Jung CK, Choi YJ, Lee KY, et al. The cytological, clinical, and pathological features of the cribriform-morular variant of papillary thyroid carcinoma and mutation analysis of CTNNB1 and BRAF genes. *Thyroid* 2009;19(8):905–913; doi: 10.1089/thy.2008.0332
141. Koo JS, Jung W, Hong SW. Cytologic characteristics and beta-catenin immunocytochemistry on smear slide of cribriform-morular variant of papillary thyroid carcinoma. *Acta Cytol* 2011;55(1):13–18; doi: 10.1159/000320856
142. Boyraz B, Sadow PM, Asa SL, et al. Cribriform-morular thyroid carcinoma is a distinct thyroid malignancy of uncertain cytogenesis. *Endocr Pathol* 2021;32(3):327–335; doi: 10.1007/s12022-021-09683-0
143. Ito Y, Miyauchi A, Ishikawa H, et al. Our experience of treatment of cribriform morular variant of papillary thyroid carcinoma; difference in clinicopathological features of FAP-associated and sporadic patients. *Endocr J* 2011;58(8):685–689.
144. DeBoy EA, Nicosia AM, Liyanarachchi S, et al. Telomere-lengthening germline variants predispose to a syndromic papillary thyroid cancer subtype. *Am J Hum Genet* 2024;111(6):1114–1124; doi: 10.1016/j.ajhg.2024.04.006
145. DeBoy EA, Tassia MG, Schratz KE, et al. Familial clonal hematopoiesis in a long telomere syndrome. *N Engl J Med* 2023;388(26):2422–2433; doi: 10.1056/NEJMoa2300503
146. Srivastava A, Miao B, Skopelitou D, et al. A germline mutation in the POT1 gene is a candidate for familial

- non-medullary thyroid cancer. *Cancers (Basel)* 2020; 12(6):1441; doi: 10.3390/cancers12061441
147. He H, Li W, Comiskey DF, et al. A truncating germline mutation of *TINF2* in individuals with thyroid cancer or melanoma results in longer telomeres. *Thyroid* 2020; 30(2):204–213; doi: 10.1089/thy.2019.0156
  148. Chen B, Yan Y, Wang H, et al. Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies. *Aging Cell* 2023; 22(7):e13874; doi: 10.1111/accel.13874
  149. Li J, An C, Zheng H, et al. Leukocyte telomere length and risk of papillary thyroid carcinoma. *J Clin Endocrinol Metab* 2019;104(7):2712–2718; doi: 10.1210/jc.2018-02471
  150. He H, Li W, Wu D, et al. Ultra-rare mutation in long-range enhancer predisposes to thyroid carcinoma with high penetrance. *PLoS One* 2013;8(5):e61920; doi: 10.1371/journal.pone.0061920
  151. He H, Bronisz A, Liyanarachchi S, et al. *SRGAP1* is a candidate gene for papillary thyroid carcinoma susceptibility. *J Clin Endocrinol Metab* 2013;98(5):E973–E80; doi: 10.1210/jc.2012-3823
  152. Wang Y, Liyanarachchi S, Miller KE, et al. Identification of rare variants predisposing to thyroid cancer. *Thyroid* 2019;29(7):946–955; doi: 10.1089/thy.2018.0736
  153. Bychkovsky BL, Agaoglu NB, Horton C, et al. Differences in cancer phenotypes among frequent *CHEK2* variants and implications for clinical care-checking *CHEK2*. *JAMA Oncol* 2022;8(11):1598–1606; doi: 10.1001/jamaoncol.2022.4071
  154. Siołek M, Cybulski C, Gašior-Periczak D, et al. *CHEK2* mutations and the risk of papillary thyroid cancer. *Int J Cancer* 2015;137(3):548–552; doi: 10.1002/ijc.29426
  155. Brock P, Liyanarachchi S, Nieminen TT, et al. *CHEK2* founder variants and thyroid cancer risk. *Thyroid* 2024; 34(4):477–483; doi: 10.1089/thy.2023.0529
  156. Charkes ND. On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds. *Thyroid* 2006;16(2):181–186; doi: 10.1089/thy.2006.16.181
  157. Capezzone M, Sagnella A, Pilli T, et al. Role of age at diagnosis in defining potential familial nonmedullary thyroid cancer in Kindreds with two affected members. *J Clin Endocrinol Metab* 2021;106(2):e855–e865; doi: 10.1210/clinem/dgaa798
  158. Klubo-Gwiedzinska J, Yang L, Merkel R, et al. Results of screening in familial non-medullary thyroid cancer. *Thyroid* 2017;27(8):1017–1024; doi: 10.1089/thy.2016.0668
  159. Capezzone M, Robenshtok E, Cantara S, et al. Familial non-medullary thyroid cancer: A critical review. *J Endocrinol Invest* 2021;44(5):943–950; doi: 10.1007/s40618-020-01435-x
  160. Moses W, Weng J, Kebebew E. Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer. *Thyroid* 2011;21(4):367–371; doi: 10.1089/thy.2010.0256
  161. Park YJ, Ahn HY, Choi HS, et al. The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases. *Thyroid* 2012;22(4):356–362; doi: 10.1089/thy.2011.0163
  162. Wang X, Cheng W, Li J, et al. Endocrine tumours: Familial nonmedullary thyroid carcinoma is a more aggressive disease: A systematic review and meta-analysis. *Eur J Endocrinol* 2015;172(6):R253–R62; doi: 10.1530/eje-14-0960
  163. Capezzone M, Marchisotta S, Cantara S, et al. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. *Endocr Relat Cancer* 2008;15(4):1075–1081; doi: 10.1677/ERC-08-0080
  164. Robenshtok E, Tzvetov G, Grozinsky-Glasberg S, et al. Clinical characteristics and outcome of familial nonmedullary thyroid cancer: A retrospective controlled study. *Thyroid* 2011;21(1):43–48; doi: 10.1089/thy.2009.0406
  165. Cao J, Chen C, Chen C, et al. Clinicopathological features and prognosis of familial papillary thyroid carcinoma—a large-scale, matched, case-control study. *Clin Endocrinol (Oxf)* 2016;84(4):598–606; doi: 10.1111/cen.12859
  166. Lincoln SE, Nussbaum RL, Kurian AW, et al. Yield and utility of germline testing following tumor sequencing in patients with cancer. *JAMA Netw Open* 2020;3(10):e2019452; doi: 10.1001/jamanetworkopen.2020.19452
  167. Kuzbari Z, Bandlamudi C, Loveday C, et al. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. *Ann Oncol* 2023;34(3):215–227; doi: 10.1016/j.annonc.2022.12.003
  168. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. *Am J Med* 1994;97(5):418–428; doi: 10.1016/0002-9343(94)90321-2
  169. De Fiori E, Rampinelli C, Turco F, et al. Role of operator experience in ultrasound-guided fine-needle aspiration biopsy of the thyroid. *Radiol Med* 2010;115(4):612–618; doi: 10.1007/s11547-010-0528-x
  170. Jeong EY, Kim HL, Ha EJ, et al. Computer-aided diagnosis system for thyroid nodules on ultrasonography: Diagnostic performance and reproducibility based on the experience level of operators. *Eur Radiol* 2019;29(4):1978–1985; doi: 10.1007/s00330-018-5772-9
  171. Kovatch KJ, Reyes-Gastelum D, Sipos JA, et al. Physician confidence in neck ultrasonography for surveillance of differentiated thyroid cancer recurrence. *JAMA Otolaryngol Head Neck Surg* 2020;147(2):166–172; doi: 10.1001/jamaoto.2020.4471
  172. Kumbhar SS, O'Malley RB, Robinson TJ, et al. Why thyroid surgeons are frustrated with radiologists: Lessons learned from pre- and postoperative US. *Radiographics* 2016;36(7):2141–2153; doi: 10.1148/rg.2016150250
  173. Leenhardt L, Erdogan MF, Hegedus L, et al. 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. *Eur Thyroid J* 2013;2(3):147–159; doi: 10.1159/000354537
  174. Houlton JJ, Sun GH, Fernandez N, et al. Thyroid fine-needle aspiration: Does case volume affect diagnostic yield and interpretation? *Arch Otolaryngol Head Neck Surg* 2011;137(11):1136–1139; doi: 10.1001/archoto.2011.185
  175. Sosa JA, Bowman HM, Tielsch JM, et al. The importance of surgeon experience for clinical and economic

- outcomes from thyroidectomy. *Ann Surg* 1998;228(3):320–330.
176. Loyo M, Tufano RP, Gourin CG. National trends in thyroid surgery and the effect of volume on short-term outcomes. *Laryngoscope* 2013;123(8):2056–2063; doi: 10.1002/lary.23923
  177. Stavrakis AI, Ituarte PH, Ko CY, et al. Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery. *Surgery* 2007;142(6):887–899; doi: 10.1016/j.surg.2007.09.003
  178. Tuggle CT, Roman S, Udelsman R, et al. Same-day thyroidectomy: A review of practice patterns and outcomes for 1,168 procedures in New York State. *Ann Surg Oncol* 2011;18(4):1035–1040; doi: 10.1245/s10434-010-1398-0
  179. Tuggle CT, Roman SA, Wang TS, et al. Pediatric endocrine surgery: Who is operating on our children? *Surgery* 2008;144(6):869–877; discussion 877; doi: 10.1016/j.surg.2008.08.033
  180. Sosa JA, Wang TS, Yeo HL, et al. The maturation of a specialty: Workforce projections for endocrine surgery. *Surgery* 2007;142(6):876–883; doi: 10.1016/j.surg.2007.09.005
  181. Melfa G, Porello C, Cocorullo G, et al. Surgeon volume and hospital volume in endocrine neck surgery: How many procedures are needed for reaching a safety level and acceptable costs? A systematic narrative review. *G Chir* 2018;39(1):5–11; doi: 10.11138/gchir/2018.39.1.005
  182. Al-Qurayshi Z, Robins R, Hauch A, et al. Association of surgeon volume with outcomes and cost savings following thyroidectomy: A national forecast. *JAMA Otolaryngol Head Neck Surg* 2016;142(1):32–39; doi: 10.1001/jamaoto.2015.2503
  183. Liang TJ, Liu SI, Mok KT, et al. Associations of volume and thyroidectomy outcomes: A nationwide study with systematic review and meta-analysis. *Otolaryngol Head Neck Surg* 2016;155(1):65–75; doi: 10.1177/0194599816634627
  184. Aspinall S, Oweis D, Chadwick D. Effect of surgeons' annual operative volume on the risk of permanent hypoparathyroidism, recurrent laryngeal nerve palsy and haematoma following thyroidectomy: Analysis of United Kingdom registry of endocrine and thyroid surgery (UKRETS). *Langenbecks Arch Surg* 2019;404(4):421–430; doi: 10.1007/s00423-019-01798-7
  185. Lorenz K, Raffaeli M, Barczyński M, et al. Volume, outcomes, and quality standards in thyroid surgery: An evidence-based analysis-European Society of Endocrine Surgeons (ESES) positional statement. *Langenbecks Arch Surg* 2020;405(4):401–425; doi: 10.1007/s00423-020-01907-x
  186. Meltzer C, Klau M, Gurushanthaiah D, et al. Surgeon volume in thyroid surgery: Surgical efficiency, outcomes, and utilization. *Laryngoscope* 2016;126(11):2630–2639; doi: 10.1002/lary.26119
  187. Nouraei SA, Virk JS, Middleton SE, et al. A national analysis of trends, outcomes and volume-outcome relationships in thyroid surgery. *Clin Otolaryngol* 2017;42(2):354–365; doi: 10.1111/coa.12730
  188. Adkisson CD, Howell GM, McCoy KL, et al. Surgeon volume and adequacy of thyroidectomy for differentiated thyroid cancer. *Surgery* 2014;156(6):1453–1459; discussion 1460; doi: 10.1016/j.surg.2014.08.024
  189. Adam MA, Thomas S, Youngwirth L, et al. Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes? *Ann Surg* 2017;265(2):402–407; doi: 10.1097/sla.0000000000001688
  190. Song JSA, Moolman N, Burrell S, et al. Use of radioiodine-131 scan to measure influence of surgical discipline, practice, and volume on residual thyroid tissue after total thyroidectomy for differentiated thyroid carcinoma. *Head Neck* 2018;40(10):2129–2136; doi: 10.1002/hed.25204
  191. Youngwirth LM, Adam MA, Scheri RP, et al. Patients treated at low-volume centers have higher rates of incomplete resection and compromised outcomes: analysis of 31,129 patients with papillary thyroid cancer. *Ann Surg Oncol* 2016;23(2):403–409; doi: 10.1245/s10434-015-4867-7
  192. Hauch A, Al-Qurayshi Z, Randolph G, et al. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. *Ann Surg Oncol* 2014;21(12):3844–3852; doi: 10.1245/s10434-014-3846-8
  193. Hall SF, Irish JC, Griffiths RJ, et al. Explaining the variation in surgical practice for differentiated thyroid cancer in Ontario, Canada. *JAMA Otolaryngol Head Neck Surg* 2019;145(10):949–954; doi: 10.1001/jamaoto.2019.2304
  194. Haymart MR, Banerjee M, Yang D, et al. Referral patterns for patients with high-risk thyroid cancer. *Endocr Pract* 2013;19(4):638–643; doi: 10.4158/ep12288.Or
  195. Haymart MR, Banerjee M, Yang D, et al. The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer. *Cancer* 2013;119(2):259–265; doi: 10.1002/cncr.27721
  196. Papaleontiou M, Gauger PG, Haymart MR. Referral of older thyroid cancer patients to a high-volume surgeon: Results of a multidisciplinary physician survey. *Endocr Pract* 2017;23(7):808–815; doi: 10.4158/ep171788.Or
  197. Schuessler KM, Banerjee M, Yang D, et al. Surgeon training and use of radioactive iodine in stage I thyroid cancer patients. *Ann Surg Oncol* 2013;20(3):733–738; doi: 10.1245/s10434-012-2745-0
  198. Wallner LP, Reyes-Gastelum D, Hamilton AS, et al. Patient-perceived lack of choice in receipt of radioactive iodine for treatment of differentiated thyroid cancer. *J Clin Oncol* 2019;37(24):2152–2161; doi: 10.1200/jco.18.02228
  199. Nam-Goong IS, Kim HY, Gong G, et al. Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: Correlation with pathological findings. *Clin Endocrinol (Oxf)* 2004;60(1):21–28.
  200. Grebe SK, Hay ID. Thyroid cancer nodal metastases: Biologic significance and therapeutic considerations. *Surg Oncol Clin N Am* 1996;5(1):43–63.
  201. Scheumann GF, Gimm O, Wegener G, et al. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. *World J Surg* 1994;18(4):559–567.
  202. Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. *Thyroid* 2003;13(4):381–387; doi: 10.1089/105072503321669875
  203. Chow SM, Law SC, Chan JK, et al. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. *Cancer* 2003;98(1):31–40; doi: 10.1002/cncr.11442

204. Hay ID, Grant CS, van Heerden JA, et al. Papillary thyroid microcarcinoma: A study of 535 cases observed in a 50-year period. *Surgery* 1992;112(6):1139–1146.
205. Qubain SW, Nakano S, Baba M, et al. Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. *Surgery* 2002;131(3):249–256.
206. Arturi F, Russo D, Giuffrida D, et al. Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. *J Clin Endocrinol Metab* 1997;82(5):1638–1641; doi: 10.1210/jcem.82.5.4062
207. Liu W, Yan X, Dong Z, et al. A mathematical model to assess the effect of residual positive lymph nodes on the survival of patients with papillary thyroid microcarcinoma. *Front Oncol* 2022;12:855830; doi: 10.3389/fonc.2022.855830
208. Beom Heo D, Piao Y, Hee Lee J, et al. Completion thyroidectomy may not be required for papillary thyroid carcinoma with multifocality, lymphovascular invasion, extrathyroidal extension to the strap muscles, or five or more central lymph node micrometastasis. *Oral Oncol* 2022;134:106115; doi: 10.1016/j.oraloncology.2022.106115
209. Solorzano CC, Carneiro DM, Ramirez M, et al. Surgeon-performed ultrasound in the management of thyroid malignancy. *Am Surg* 2004;70(7):576–580.
210. Shimamoto K, Satake H, Sawaki A, et al. Preoperative staging of thyroid papillary carcinoma with ultrasonography. *Eur J Radiol* 1998;29(1):4–10.
211. Stulak JM, Grant CS, Farley DR, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. *Arch Surg* 2006;141(5):489–494; doi: 10.1001/archsurg.141.5.489
212. Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. *Surgery* 2003;134(6):946–954.
213. O’Connell K, Yen TW, Quiroz F, et al. The utility of routine preoperative cervical ultrasonography in patients undergoing thyroidectomy for differentiated thyroid cancer. *Surgery* 2013;154(4):697–701; doi: 10.1016/j.surg.2013.06.040
214. Leboulleux S, Girard E, Rose M, et al. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. *J Clin Endocrinol Metab* 2007;92(9):3590–3594; doi: 10.1210/jc.2007-0444
215. Ni X, Xu S, Zhan W, et al. A risk stratification model for metastatic lymph nodes of papillary thyroid cancer: A retrospective study based on sonographic features. *Front Endocrinol (Lausanne)* 2022;13:942569; doi: 10.3389/fendo.2022.942569
216. Chung SR, Baek JH, Rho YH, et al. Sonographic diagnosis of cervical lymph node metastasis in patients with thyroid cancer and comparison of European and Korean guidelines for stratifying the risk of malignant lymph node. *Korean J Radiol* 2022;23(11):1102–1111; doi: 10.3348/kjr.2022.0358
217. Kuna SK, Bracic I, Tesic V, et al. Ultrasonographic differentiation of benign from malignant neck lymphadenopathy in thyroid cancer. *J Ultrasound Med* 2006;25(12):1531–1537.
218. Park JH, Lee YS, Kim BW, et al. Skip lateral neck node metastases in papillary thyroid carcinoma. *World J Surg* 2012;36(4):743–747; doi: 10.1007/s00268-012-1476-5
219. Chung J, Kim EK, Lim H, et al. Optimal indication of thyroglobulin measurement in fine-needle aspiration for detecting lateral metastatic lymph nodes in patients with papillary thyroid carcinoma. *Head Neck* 2014;36(6):795–801; doi: 10.1002/hed.23371
220. Grani G, Fumarola A. Thyroglobulin in lymph node fine-needle aspiration wash-out: A systematic review and meta-analysis of diagnostic accuracy. *J Clin Endocrinol Metab* 2014;99(6):1970–1982; doi: 10.1210/jc.2014-1098
221. Pak K, Suh S, Hong H, et al. Diagnostic values of thyroglobulin measurement in fine-needle aspiration of lymph nodes in patients with thyroid cancer. *Endocrine* 2015;49(1):70–77; doi: 10.1007/s12020-014-0410-z
222. Wang SR, Li QL, Tian F, et al. Diagnostic value of multiple diagnostic methods for lymph node metastases of papillary thyroid carcinoma: A systematic review and meta-analysis. *Front Oncol* 2022;12:990603; doi: 10.3389/fonc.2022.990603
223. Zhu XH, Zhou JN, Qian YY, et al. Diagnostic values of thyroglobulin in lymph node fine-needle aspiration wash-out: A systematic review and meta-analysis diagnostic values of FNA-Tg. *Endocr J* 2020;67(2):113–123; doi: 10.1507/endocrj.EJ18-0558
224. Blažeković I, Romić M, Bosak Butković M, et al. Thyroglobulin measurement in needle aspiration for detection of recurrences and neck metastases in patients with differentiated thyroid carcinoma: Significance of anti-Tg antibodies. *Acta Clin Croat* 2020;59(Suppl 1):9–17; doi: 10.20471/acc.2020.59.s1.01
225. Martins-Costa MC, Maciel RMB, Kasamatsu TS, et al. Clinical impact of thyroglobulin (Tg) and Tg autoantibody (TgAb) measurements in needle washouts of neck lymph node biopsies in the management of patients with papillary thyroid carcinoma. *Arch Endocrinol Metab* 2017;61(2):108–114; doi: 10.1590/2359-3997000000241
226. Duval M, Zanella AB, Cristo AP, et al. Impact of serum TSH and anti-thyroglobulin antibody levels on lymph node fine-needle aspiration thyroglobulin measurements in differentiated thyroid cancer patients. *Eur Thyroid J* 2017;6(6):292–297; doi: 10.1159/000479682
227. Lamartina L, Bidault S, Hadoux J, et al. Can preoperative ultrasound predict extrathyroidal extension of differentiated thyroid cancer? *Eur J Endocrinol* 2021;185(1):13–22; doi: 10.1530/EJE-21-0091
228. Xing Z, Qiu Y, Yang Q, et al. Thyroid cancer neck lymph nodes metastasis: Meta-analysis of US and CT diagnosis. *Eur J Radiol* 2020;129:109103; doi: 10.1016/j.ejrad.2020.109103
229. Lu G, Chen L. Cervical lymph node metastases in papillary thyroid cancer: Preoperative staging with ultrasound and/or computed tomography. *Medicine (Baltimore)* 2022;101(9):e28909; doi: 10.1097/md.00000000000028909
230. Stephenson BM, Wheeler MH, Clark OH. The role of total thyroidectomy in the management of differentiated thyroid cancer. *Curr Opin Gen Surg* 1994;2:53–59.
231. Cho SJ, Suh CH, Baek JH, et al. Diagnostic performance of CT in detection of metastatic cervical lymph nodes in patients with thyroid cancer: A systematic review and meta-analysis. *Eur Radiol* 2019;29(9):4635–4647; doi: 10.1007/s00330-019-06036-8
232. Cho SJ, Suh CH, Baek JH, et al. Diagnostic performance of MRI to detect metastatic cervical lymph nodes in

- patients with thyroid cancer: A systematic review and meta-analysis. *Clin Radiol* 2020;75(7):562.e1–562.e10; doi: 10.1016/j.crad.2020.03.025
233. Padovani RP, Kasamatsu TS, Nakabashi CC, et al. One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy. *Thyroid* 2012;22(9):926–930; doi: 10.1089/thy.2012.0099
  234. Sohn SY, Choi JH, Kim NK, et al. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment. *Thyroid* 2014;24(5):872–877; doi: 10.1089/thy.2013.0238
  235. Mishra A, Pradhan PK, Gambhir S, et al. Preoperative contrast-enhanced computerized tomography should not delay radioiodine ablation in differentiated thyroid carcinoma patients. *J Surg Res* 2015;193(2):731–737; doi: 10.1016/j.jss.2014.07.065
  236. Kim DH, Kim SJ. Diagnostic role of F-18 FDG PET/CT for preoperative lymph node staging in thyroid cancer patients; A systematic review and metaanalysis. *Clin Imaging* 2020;65:100–107; doi: 10.1016/j.clinimag.2020.04.030
  237. Kim K, Shim SR, Lee SW, et al. Diagnostic values of F-18 FDG PET or PET/CT, CT, and US for preoperative lymph node staging in thyroid cancer: A network meta-analysis. *Br J Radiol* 2021;94(1120):20201076; doi: 10.1259/bjr.20201076
  238. Andersen PE, Kinsella J, Loree TR, et al. Differentiated carcinoma of the thyroid with extrathyroidal extension. *Am J Surg* 1995;170(5):467–470.
  239. Zhang L, Liu J, Wang P, et al. Impact of gross strap muscle invasion on outcome of differentiated thyroid cancer: Systematic review and meta-analysis. *Front Oncol* 2020; 10:1687; doi: 10.3389/fonc.2020.01687
  240. Lesnik D, Cunnane ME, Zurakowski D, et al. Papillary thyroid carcinoma nodal surgery directed by a preoperative radiographic map utilizing CT scan and ultrasound in all primary and reoperative patients. *Head Neck* 2014; 36(2):191–202; doi: 10.1002/hed.23277
  241. Yeh M, Bernet V, Ferris R, et al; American Thyroid Association Surgical Affairs Committee Writing Task Force. American Thyroid Association statement on preoperative imaging for thyroid cancer surgery. *Thyroid* 2015;25(1):3–14.
  242. Spencer CA, Bergoglio LM, Kazarosyan M, et al. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. *J Clin Endocrinol Metab* 2005;90(10):5566–5575; doi: 10.1210/jc.2005-0671
  243. Patel A, Shostrom V, Treude K, et al. Serum thyroglobulin: Preoperative levels and factors affecting postoperative optimal timing following total thyroidectomy. *Int J Endocrinol* 2019;2019:1384651; doi: 10.1155/2019/1384651
  244. Rigbi S, Joshua BZ, Baraf L, et al. Thyroglobulin is a poor predictor of differentiated thyroid cancer in patients who undergo surgery for thyroid nodular diseases. *Eur Arch Otorhinolaryngol* 2023;280(3):1311–1319; doi: 10.1007/s00405-022-07678-z
  245. Scheffler P, Forest VI, Leboeuf R, et al. Serum thyroglobulin improves the sensitivity of the McGill Thyroid Nodule Score for well-differentiated thyroid cancer. *Thyroid* 2014;24(5):852–857; doi: 10.1089/thy.2013.0191
  246. Kim H, Park SY, Choe JH, et al. Preoperative serum thyroglobulin and its correlation with the burden and extent of differentiated thyroid cancer. *Cancers (Basel)* 2020; 12(3):625; doi: 10.3390/cancers12030625
  247. Patell R, Mikhael A, Tabet M, et al. Assessing the utility of preoperative serum thyroglobulin in differentiated thyroid cancer: A retrospective cohort study. *Endocrine* 2018;61(3):506–510; doi: 10.1007/s12020-018-1643-z
  248. McLeod DS, Cooper DS, Ladenson PW, et al; The National Thyroid Cancer Treatment Cooperative Study Group. Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. *Thyroid* 2014;24(1):35–42; doi: 10.1089/thy.2013.0062
  249. Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. *Endocr Relat Cancer* 2013;20(4):603–610.
  250. Landa I, Ganly I, Chan TA, et al. Frequent somatic TERT promoter mutations in thyroid cancer: Higher prevalence in advanced forms of the disease. *J Clin Endocrinol Metab* 2013;98(9):E1562–E1566; doi: 10.1210/jc.2013-2383
  251. Vinagre J, Almeida A, Populo H, et al. Frequency of TERT promoter mutations in human cancers. *Nat Commun* 2013;4:2185; doi: 10.1038/ncomms3185
  252. Ebina A, Togashi Y, Baba S, et al. TERT promoter mutation and extent of thyroidectomy in patients with 1-4 cm intrathyroidal papillary carcinoma. *Cancers (Basel)* 2020; 12(8):2115; doi: 10.3390/cancers12082115
  253. Lee J, Ha EJ, Roh J, et al. Presence of TERT +/- BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma. *Surgery* 2021;170(3):743–747; doi: 10.1016/j.surg.2021.03.056
  254. Song YS, Lim JA, Choi H, et al. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. *Cancer* 2016;122(9): 1370–1379; doi: 10.1002/cncr.29934
  255. Lukyanov SA, Titov SE, Kozorezova ES, et al. Prediction of the aggressive clinical course of papillary thyroid carcinoma based on fine needle aspiration biopsy molecular testing. *Int J Mol Sci* 2024;25(13):7090; doi: 10.3390/ijms25137090
  256. Abdulhaleem M, Bandargal S, Pusztaszeri MP, et al. The impact of BRAF V600E mutation allele frequency on the histopathological characteristics of thyroid cancer. *Cancers (Basel)* 2023;16(1):113; doi: 10.3390/cancers16010113
  257. Craig S, Stretch C, Farshidfar F, et al. A clinically useful and biologically informative genomic classifier for papillary thyroid cancer. *Front Endocrinol (Lausanne)* 2023; 14:1220617; doi: 10.3389/fendo.2023.1220617
  258. Leandro-Garcia LJ, Landa I. Mechanistic insights of thyroid cancer progression. *Endocrinology* 2023;164(9): bqad118; doi: 10.1210/endo/bqad118
  259. Mady LJ, Grimes MC, Khan NI, et al. Molecular profile of locally aggressive well differentiated thyroid cancers. *Sci Rep* 2020;10(1):8031; doi: 10.1038/s41598-020-64635-8

260. Liu R, Bishop J, Zhu G, et al. Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: Genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. *JAMA Oncol* 2017;3(2):202–208; doi: 10.1001/jamaoncol.2016.3288
261. Agrawal N, Akbani R, Aksoy BA, et al. Integrated genomic characterization of papillary thyroid carcinoma. *Cell* 2014;159(3):676–690; doi: 10.1016/j.cell.2014.09.050
262. Efanov AA, Brenner AV, Bogdanova TI, et al. Investigation of the relationship between radiation dose and gene mutations and fusions in post-Chernobyl thyroid cancer. *J Natl Cancer Inst* 2018;110(4):371–378; doi: 10.1093/jnci/djx209
263. Xu B, Tuttle RM, Sabra MM, et al. Primary thyroid carcinoma with low-risk histology and distant metastases: Clinicopathologic and molecular characteristics. *Thyroid* 2017;27(5):632–640; doi: 10.1089/thy.2016.0582
264. Labourier E, Fahey TJ. 3rd., Preoperative molecular testing in thyroid nodules with Bethesda VI cytology: Clinical experience and review of the literature. *Diagn Cytopathol* 2021;49(4):E175–E180; doi: 10.1002/dc.24637
265. Chiosea S, Hodak SP, Yip L, et al. Molecular profiling of 50 734 Bethesda III–VI thyroid nodules by ThyroSeq v3: Implications for personalized management. *J Clin Endocrinol Metab* 2023;108(11):2999–3008; doi: 10.1210/clinem/dgad220
266. Tang AL, Kloos RT, Aunins B, et al. Pathologic features associated with molecular subtypes of well-differentiated thyroid cancer. *Endocr Pract* 2021;27(3):206–211; doi: 10.1016/j.eprac.2020.09.003
267. Yip L, Gooding WE, Nikitski A, et al. Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case-control study. *Cancer* 2021;127(11):1779–1787; doi: 10.1002/cncr.33421
268. Liu JB, Ramonell KM, Carty SE, et al. Association of comprehensive thyroid cancer molecular profiling with tumor phenotype and cancer-specific outcomes. *Surgery* 2023;173(1):252–259; doi: 10.1016/j.surg.2022.05.048
269. Kurtom S, Liu JB, Doerfler WR, et al. Tumor size and molecular risk group are associated with differentiated thyroid cancer recurrence. *Surgery* 2025;177:108838; doi: 10.1016/j.surg.2024.06.066
270. Liu JB, Baugh KA, Ramonell KM, et al. Molecular testing predicts incomplete response to initial therapy in differentiated thyroid carcinoma without lateral neck or distant metastasis at presentation: Retrospective cohort study. *Thyroid* 2023;33(6):705–714; doi: 10.1089/thy.2023.0060
271. Kim KJ, Kim SG, Tan J, et al. BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. *Eur J Cancer* 2020;124:161–169; doi: 10.1016/j.ejca.2019.10.017
272. Fukuoka O, Sugitani I, Ebina A, et al. Natural history of asymptomatic papillary thyroid microcarcinoma: Time-dependent changes in calcification and vascularity during active surveillance. *World J Surg* 2016;40(3):529–537; doi: 10.1007/s00268-015-3349-1
273. Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. *World J Surg* 2010;34(1):28–35; doi: 10.1007/s00268-009-0303-0
274. Ito Y, Miyauchi A, Kihara M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. *Thyroid* 2014;24(1):27–34; doi: 10.1089/thy.2013.0367
275. Kong SH, Ryu J, Kim MJ, et al. Longitudinal assessment of quality of life according to treatment options in low-risk papillary thyroid microcarcinoma patients: Active surveillance or immediate surgery (Interim Analysis of MAeSTro). *Thyroid* 2019;29(8):1089–1096; doi: 10.1089/thy.2018.0624
276. Moon JH, Kim JH, Lee EK, et al. Study protocol of multicenter prospective cohort study of active surveillance on papillary thyroid microcarcinoma (MAeSTro). *Endocrinol Metab (Seoul)* 2018;33(2):278–286; doi: 10.3803/EnM.2018.33.2.278
277. Nagaoka R, Ebina A, Toda K, et al. Multifocality and progression of papillary thyroid microcarcinoma during active surveillance. *World J Surg* 2021;45(9):2769–2776; doi: 10.1007/s00268-021-06185-2
278. Oda H, Miyauchi A, Ito Y, et al. Incidences of unfavorable events in the management of low-risk papillary microcarcinoma of the thyroid by active surveillance versus immediate surgery. *Thyroid* 2016;26(1):150–155; doi: 10.1089/thy.2015.0313
279. Rosario PW, Mourao GF, Calsolari MR. Active surveillance in adults with low-risk papillary thyroid microcarcinomas: A prospective study. *Horm Metab Res* 2019;51(11):703–708; doi: 10.1055/a-1015-6684
280. Sakai T, Sugitani I, Ebina A, et al. Active surveillance for T1bN0M0 papillary thyroid carcinoma. *Thyroid* 2019;29(1):59–63; doi: 10.1089/thy.2018.0462
281. Sasaki T, Miyauchi A, Ito Y, et al. Marked decrease over time in conversion surgery after active surveillance of low-risk papillary thyroid microcarcinoma. *Thyroid* 2021;31(2):217–223; doi: 10.1089/thy.2020.0319
282. Sugitani I, Toda K, Yamada K, et al. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: Our treatment strategies and outcomes. *World J Surg* 2010;34(6):1222–1231; doi: 10.1007/s00268-009-0359-x
283. Jeon MJ, Lee YM, Sung TY, et al. Quality of life in patients with papillary thyroid microcarcinoma managed by active surveillance or lobectomy: A cross-sectional study. *Thyroid* 2019;29(7):956–962; doi: 10.1089/thy.2018.0711
284. Nakamura T, Miyauchi A, Ito Y, et al. Quality of life in patients with low-risk papillary thyroid microcarcinoma: Active surveillance versus immediate surgery. *Endocr Pract* 2020;26(12):1451–1457; doi: 10.4158/EP-2020-0201
285. Kim HI, Jang HW, Ahn HS, et al. High serum TSH level is associated with progression of papillary thyroid microcarcinoma during active surveillance. *J Clin Endocrinol Metab* 2018;103(2):446–451; doi: 10.1210/jc.2017-01775
286. Kwon H, Oh HS, Kim M, et al. Active surveillance for patients with papillary thyroid microcarcinoma: A single center's experience in Korea. *J Clin Endocrinol Metab* 2017;102(6):1917–1925; doi: 10.1210/jc.2016-4026
287. Molinaro E, Campopiano MC, Pieruzzi L, et al. Active surveillance in papillary thyroid microcarcinomas is feasible and safe: Experience at a single Italian Center. *J*

- Clin Endocrinol Metab 2020;105(3):e172–e180; doi: 10.1210/clinem/dgz113
288. Oh HS, Ha J, Kim HI, et al. Active surveillance of low-risk papillary thyroid microcarcinoma: A multi-center cohort study in Korea. *Thyroid* 2018;28(12):1587–1594; doi: 10.1089/thy.2018.0263
  289. Sanabria A. Active surveillance in thyroid microcarcinoma in a Latin-American cohort. *JAMA Otolaryngol Head Neck Surg* 2018;144(10):947–948; doi: 10.1001/jamaoto.2018.1663
  290. Tuttle RM, Fagin JA, Minkowitz G, et al. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. *JAMA Otolaryngol Head Neck Surg* 2017;143(10):1015–1020; doi: 10.1001/jamaoto.2017.1442
  291. Ho AS, Luu M, Zalt C, et al. Mortality risk of nonoperative papillary thyroid carcinoma: A corollary for active surveillance. *Thyroid* 2019;29(10):1409–1417; doi: 10.1089/thy.2019.0060
  292. Kuo EJ, Wu JX, Li N, et al. Nonoperative management of differentiated thyroid cancer in California: A population-level analysis of 29,978 patients. *Endocr Pract* 2017;23(10):1262–1269; doi: 10.4158/EP171933.OR
  293. Lin JK, Sakoda LC, Darbinian J, et al. Risk of mortality between untreated and treated papillary thyroid cancer: A matched cohort analysis. *Ann Otol Rhinol Laryngol* 2020;129(3):265–272; doi: 10.1177/0003489419885403
  294. Megwalu UC. Observation versus thyroidectomy for papillary thyroid microcarcinoma in the elderly. *J Laryngol Otol* 2017;131(2):173–176; doi: 10.1017/S0022215116009762
  295. Jin M, Kim HI, Ha J, et al. Tumor volume doubling time in active surveillance of papillary thyroid microcarcinoma: A multicenter cohort study in Korea. *Thyroid* 2021;31(10):1494–1501; doi: 10.1089/thy.2021.0094
  296. Moon JH, Ryu CH, Cho SW, et al. Effect of initial treatment choice on 2-year quality of life in patients with low-risk papillary thyroid microcarcinoma. *J Clin Endocrinol Metab* 2021;106(3):724–735; doi: 10.1210/clinem/dgaa889
  297. Sanabria A. Experience with active surveillance of thyroid low-risk carcinoma in a developing country. *Thyroid* 2020;30(7):985–991; doi: 10.1089/thy.2019.0522
  298. Altshuler B, Bikas A, Pappa T, et al. Nonoperative, active surveillance of larger malignant and suspicious thyroid nodules. *J Clin Endocrinol Metab* 2024;109(8):1996–2002; doi: 10.1210/clinem/dgae082
  299. Ho AS, Kim S, Zalt C, et al. Expanded parameters in active surveillance for low-risk papillary thyroid carcinoma: A nonrandomized controlled trial. *JAMA Oncol* 2022;8(11):1588–1596; doi: 10.1001/jamaoncol.2022.3875
  300. Smulever A, Pitoia F. High rate incidence of post-surgical adverse events in patients with low-risk papillary thyroid cancer who did not accept active surveillance. *Endocrine* 2020;69(3):587–595; doi: 10.1007/s12020-020-02310-8
  301. Smulever A, Pitoia F. Active surveillance in papillary thyroid carcinoma: Not easily accepted but possible in Latin America. *Arch Endocrinol Metab* 2019;63(5):462–469; doi: 10.20945/2359-399700000168
  302. Rosenthal MS, Angelos P, Cooper DS, et al; American Thyroid Association Ethics Advisory Committee. Clinical and professional ethics guidelines for the practice of thyroidology. *Thyroid* 2013;23(10):1203–1210; doi: 10.1089/thy.2013.0124
  303. Lee EK, Moon JH, Hwangbo Y, et al. Progression of low-risk papillary thyroid microcarcinoma during active surveillance: Interim analysis of a multicenter prospective cohort study of active surveillance on papillary thyroid microcarcinoma in Korea. *Thyroid* 2022;32(11):1328–1336; doi: 10.1089/thy.2021.0614
  304. Ren Y, Lu C, Xu S. Ultrasound-guided thermal ablation for papillary thyroid microcarcinoma: The devil is in the details. *Int J Hyperthermia* 2023;40(1):2278823; doi: 10.1080/02656736.2023.2278823
  305. Orloff LA, Noel JE, Stack BC, Jr, et al. Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Associazione Medici Endocrinologi, British Association of Endocrine and Thyroid Surgeons, European Thyroid Association, Italian Society of Endocrine Surgery Units, Korean Society of Thyroid Radiology, Latin American Thyroid Society, and Thyroid Nodules Therapies Association. *Head Neck* 2022;44(3):633–660; doi: 10.1002/hed.26960
  306. Santos GPL, Kulcsar MAV, Capelli FA, et al. Brazilian consensus on the application of thermal ablation for treatment of thyroid nodules: A task force statement by the Brazilian Society of Interventional Radiology and Endovascular Surgery (SOBRICE), Brazilian Society of Head and Neck Surgery (SBCCP), and Brazilian Society of Endocrinology and Metabolism (SBEM). *Arch Endocrinol Metab* 2024;68:e230263; doi: 10.20945/2359-4292-2023-0263
  307. Choi Y, Jung SL. Efficacy and safety of thermal ablation techniques for the treatment of primary papillary thyroid microcarcinoma: A systematic review and meta-analysis. *Thyroid* 2020;30(5):720–731; doi: 10.1089/thy.2019.0707
  308. Gao X, Yang Y, Wang Y, et al. Efficacy and safety of ultrasound-guided radiofrequency, microwave and laser ablation for the treatment of T1N0M0 papillary thyroid carcinoma on a large scale: A systematic review and meta-analysis. *Int J Hyperthermia* 2023;40(1):2244713; doi: 10.1080/02656736.2023.2244713
  309. Zhang M, Luo Y, Zhang Y, et al. Efficacy and safety of ultrasound-guided radiofrequency ablation for treating low-risk papillary thyroid microcarcinoma: A prospective study. *Thyroid* 2016;26(11):1581–1587; doi: 10.1089/thy.2015.0471
  310. Cho SJ, Baek SM, Lim HK, et al. Long-term follow-up results of ultrasound-guided radiofrequency ablation for low-risk papillary thyroid microcarcinoma: More than 5-year follow-up for 84 tumors. *Thyroid* 2020;30(12):1745–1751; doi: 10.1089/thy.2020.0106
  311. Teng DK, Li WH, Du JR, et al. Effects of microwave ablation on papillary thyroid microcarcinoma: A five-year follow-up report. *Thyroid* 2020;30(12):1752–1758; doi: 10.1089/thy.2020.0049
  312. Zhang M, Tufano RP, Russell JO, et al. Ultrasound-guided radiofrequency ablation versus surgery for low-risk papillary thyroid microcarcinoma: Results of over 5 years' follow-up. *Thyroid* 2020;30(3):408–417; doi: 10.1089/thy.2019.0147
  313. Yan L, Lan Y, Xiao J, et al. Long-term outcomes of radiofrequency ablation for unifocal low-risk papillary

- thyroid microcarcinoma: A large cohort study of 414 patients. *Eur Radiol* 2021;31(2):685–694; doi: 10.1007/s00330-020-07128-6
314. Li X, Yan L, Xiao J, et al. Long-term outcomes and risk factors of radiofrequency ablation for T1N0M0 papillary thyroid carcinoma. *JAMA Surg* 2024;159(1):51–58; doi: 10.1001/jamasurg.2023.5202
  315. Yan L, Zhang M, Song Q, et al. Clinical outcomes of radiofrequency ablation for multifocal papillary thyroid microcarcinoma versus unifocal papillary thyroid microcarcinoma: A propensity-matched cohort study. *Eur Radiol* 2022;32(2):1216–1226; doi: 10.1007/s00330-021-08133-z
  316. Yang J, Tang L, Qiu Y, et al. Ultrasound-guided ablation for T1N0M0 papillary thyroid carcinoma adjacent and non-adjacent danger triangle area: A retrospective comparative study. *Int J Hyperthermia* 2024;41(1):2419904; doi: 10.1080/02656736.2024.2419904
  317. Dong P, Teng DK, Sui GQ, et al. Long-term efficacy of microwave ablation for multifocal papillary thyroid microcarcinoma: A 5-year follow-up study. *Eur Radiol* 2024;34(1):715–723; doi: 10.1007/s00330-023-10117-0
  318. Hay ID, Lee RA, Kaggal S, et al. Long-term results of treating with ethanol ablation 15 adult patients with cT1aN0 papillary thyroid microcarcinoma. *J Endocr Soc* 2020;4(11):bvaa135; doi: 10.1210/jendso/bvaa135
  319. Ahmadi S, Gonzalez JM, Talbott M, et al. Patient preferences around extent of surgery in low-risk thyroid cancer: A discrete choice experiment. *Thyroid* 2020;30(7):1044–1052; doi: 10.1089/thy.2019.0590
  320. Bilimoria KY, Brentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. *Ann Surg* 2007;246(3):375–381; doi: 10.1097/SLA.0b013e31814697d9
  321. Grant CS, Hay ID, Gough IR, et al. Local recurrence in papillary thyroid carcinoma: Is extent of surgical resection important? *Surgery* 1988;104(6):954–962.
  322. Hay ID, Grant CS, Bergstralh EJ, et al. Unilateral total lobectomy: Is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? *Surgery* 1998;124(6):958–964; doi: S0039606098003717
  323. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. *J Clin Endocrinol Metab* 2001;86(4):1447–1463; doi: 10.1210/jcem.86.4.7407
  324. Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: Effect of therapy. *Endocr Pract* 2000;6(6):469–476; doi: 10.4158/EP.6.6.469
  325. Matsuzaki K, Sugino K, Masudo K, et al. Thyroid lobectomy for papillary thyroid cancer: Long-term follow-up study of 1,088 cases. *World J Surg* 2014;38(1):68–79; doi: 10.1007/s00268-013-2224-1
  326. Barney BM, Hitchcock YJ, Sharma P, et al. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. *Head Neck* 2011;33(5):645–649; doi: 10.1002/hed.21504
  327. Mendelsohn AH, Elashoff DA, Abemayor E, et al. Surgery for papillary thyroid carcinoma: Is lobectomy enough? *Arch Otolaryngol Head Neck Surg* 2010;136(11):1055–1061; doi: 10.1001/archoto.2010.181
  328. Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. *Ann Surg Oncol* 2005;12(1):81–89; doi: 10.1007/s10434-004-1165-1
  329. Nixon IJ, Ganly I, Patel SG, et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. *Surgery* 2012;151(4):571–579; doi: 10.1016/j.surg.2011.08.016
  330. Adam MA, Pura J, Gu L, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: An analysis of 61,775 patients. *Ann Surg* 2014;260(4):601–605; doi: 10.1097/SLA.0000000000000925
  331. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. *Thyroid* 1999;9(5):421–427.
  332. Kiernan CM, Whiteside MA, Solorzano CC. Cancer registries: Can we improve the quality of thyroid cancer data? *Ann Surg Oncol* 2017;24(5):1202–1207; doi: 10.1245/s10434-016-5612-6
  333. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. *Surgery* 1993;114(6):1050–1057.
  334. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. *World J Surg* 2002;26(8):879–885; doi: 10.1007/s00268-002-6612-1
  335. Bojoga A, Koot A, Bonenkamp J, et al. The impact of the extent of surgery on the long-term outcomes of patients with low-risk differentiated non-medullary thyroid cancer: A systematic meta-analysis. *J Clin Med* 2020;9(7):2316; doi: 10.3390/jcm9072316
  336. Gartland RM, Lubitz CC. Impact of extent of surgery on tumor recurrence and survival for papillary thyroid cancer patients. *Ann Surg Oncol* 2018;25(9):2520–2525; doi: 10.1245/s10434-018-6550-2
  337. Rodriguez Schaap PM, Botti M, Otten RHJ, et al. Hemithyroidectomy versus total thyroidectomy for well differentiated T1-2 N0 thyroid cancer: Systematic review and meta-analysis. *BJS Open* 2020;4(6):987–994; doi: 10.1002/bjs5.50359
  338. Chan S, Karamali K, Kolodziejczyk A, et al. Systematic review of recurrence rate after hemithyroidectomy for low-risk well-differentiated thyroid cancer. *Eur Thyroid J* 2020;9(2):73–84; doi: 10.1159/000504961
  339. Vargas-Pinto S, Romero Arenas MA. Lobectomy compared to total thyroidectomy for low-risk papillary thyroid cancer: A systematic review. *J Surg Res* 2019;242:244–251; doi: 10.1016/j.jss.2019.04.036
  340. Zhang C, Li Y, Li J, et al. Total thyroidectomy versus lobectomy for papillary thyroid cancer: A systematic review and meta-analysis. *Medicine (Baltimore)* 2020;99(6):e19073; doi: 10.1097/MD.00000000000019073
  341. Rajjoub SR, Yan H, Calcaterra NA, et al. Thyroid lobectomy is not sufficient for T2 papillary thyroid cancers. *Surgery* 2018;163(5):1134–1143; doi: 10.1016/j.surg.2017.12.026
  342. Barbaro D, Basili G, Materazzi G. Total thyroidectomy vs. lobectomy in differentiated thyroid cancer: Is there a reasonable size cut-off for decision? A narrative review. *Gland Surg* 2021;10(7):2275–2283; doi: 10.21037/gS-21-242
  343. Guo MY, Wiseman JJ, Wiseman SM. Current surgical treatment of intermediate risk differentiated thyroid cancer: A systematic review. *Expert Rev Anticancer Ther* 2021;21(2):205–220; doi: 10.1080/14737140.2021.1850280

344. Wang X, Zheng X, Zhu J, et al. Impact of extent of surgery on long-term prognosis of follicular thyroid carcinoma without extrathyroidal extension and distant metastasis. *World J Surg* 2022;46(1):104–111; doi: 10.1007/s00268-021-06337-4
345. Yamazaki H, Sugino K, Katoh R, et al. Outcomes for minimally invasive follicular thyroid carcinoma in relation to the change in age stratification in the AJCC 8th Edition. *Ann Surg Oncol* 2021;28(7):3576–3583; doi: 10.1245/s10434-020-09397-3
346. Kuba S, Yamanouchi K, Hayashida N, et al. Total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer: Comparative analysis after propensity score matching: A multicenter study. *Int J Surg* 2017;38:143–148; doi: 10.1016/j.ijso.2016.09.083
347. Matsuura D, Yuan A, Harris V, et al. Surgical management of low-/intermediate-risk node negative thyroid cancer: A single-institution study using propensity matching analysis to compare thyroid lobectomy and total thyroidectomy. *Thyroid* 2022;32(1):28–36; doi: 10.1089/thy.2021.0356
348. Geron Y, Benbassat C, Shteinshneider M, et al. Long-term outcome after hemithyroidectomy for papillary thyroid cancer: A comparative study and review of the literature. *Cancers (Basel)* 2018;11(1):26; doi: 10.3390/cancers11010026
349. Kim MJ, Lee MC, Lee GH, et al. Extent of surgery did not affect recurrence during 7-years follow-up in papillary thyroid cancer sized 1-4 cm: Preliminary results. *Clin Endocrinol (Oxf)* 2017;87(1):80–86; doi: 10.1111/cen.13336
350. Ma T, Wang H, Liu J, et al. Should contralateral nodules be an indication of total or completion thyroidectomy for patients with unilateral papillary thyroid carcinoma? *Front Endocrinol (Lausanne)* 2021;12:723631; doi: 10.3389/fendo.2021.723631
351. Choi JB, Lee SG, Kim MJ, et al. Oncologic outcomes in patients with 1-cm to 4-cm differentiated thyroid carcinoma according to extent of thyroidectomy. *Head Neck* 2019;41(1):56–63; doi: 10.1002/hed.25356
352. Merten MM, Foster T, Lyden M, et al. Favorable early outcomes with thyroid lobectomy for low-risk papillary thyroid cancer: The Mayo Clinic experience. *Am Surg* 2021;87(9):1374–1378; doi: 10.1177/00031348211038557
353. Zhang LZ, Xu JJ, Ge XY, et al. Pathological analysis and surgical modalities selection of cT1N0M0 solitary papillary thyroid carcinoma in the isthmus. *Gland Surg* 2021;10(8):2445–2454; doi: 10.21037/gs-21-357
354. Xue S, Wang P, Liu J, et al. Total thyroidectomy may be more reasonable as initial surgery in unilateral multifocal papillary thyroid microcarcinoma: A single-center experience. *World J Surg Oncol* 2017;15(1):62; doi: 10.1186/s12957-017-1130-7
355. Kim SK, Park I, Woo JW, et al. Total thyroidectomy versus lobectomy in conventional papillary thyroid microcarcinoma: Analysis of 8,676 patients at a single institution. *Surgery* 2017;161(2):485–492; doi: 10.1016/j.surg.2016.07.037
356. Jo YJ, Choi HR, Park SH, et al. Extent of thyroid surgery for clinically node-negative papillary thyroid carcinoma with confirmed nodal metastases after prophylactic central neck dissection: A 15-year experience in a single center. *Ann Surg Treat Res* 2020;99(4):197–204; doi: 10.4174/astr.2020.99.4.197
357. Di Filippo L, Giugliano G, Tagliabue M, et al. Total thyroidectomy versus lobectomy: Surgical approach to T1-T2 papillary thyroid cancer. *Acta Otorhinolaryngol Ital* 2020;40(4):254–261; doi: 10.14639/0392-100X-N0608
358. Ji YB, Song CM, Kim D, et al. Efficacy of hemithyroidectomy in papillary thyroid carcinoma with minimal extrathyroidal extension. *Eur Arch Otorhinolaryngol* 2019;276(12):3435–3442; doi: 10.1007/s00405-019-05598-z
359. Zhao H, Cui L. Extent of surgery and the prognosis of unilateral papillary thyroid microcarcinoma. *Front Endocrinol (Lausanne)* 2021;12:655608; doi: 10.3389/fendo.2021.655608
360. Wu Z, Xiao Y, Ming J, et al. Reevaluation of criteria and establishment of models for total thyroidectomy in differentiated thyroid cancer. *Front Oncol* 2021;11:691341; doi: 10.3389/fonc.2021.691341
361. Liu J, Zhang Z, Huang H, et al. Total thyroidectomy versus lobectomy for intermediate-risk papillary thyroid carcinoma: A single-institution matched-pair analysis. *Oral Oncol* 2019;90:17–22; doi: 10.1016/j.oraloncology.2019.01.010
362. Xu S, Huang H, Wang X, et al. Long-term outcomes of lobectomy for papillary thyroid carcinoma with high-risk features. *Br J Surg* 2021;108(4):395–402; doi: 10.1093/bjs/znaa129
363. Tsui KP, Kwan WY, Chow TL. Total vs hemithyroidectomy for intermediate risk papillary thyroid cancer: A 23-year retrospective study in a tertiary center. *Am J Otolaryngol* 2019;40(3):431–434; doi: 10.1016/j.amjoto.2019.04.001
364. Suman P, Razdan SN, Wang CE, et al. Thyroid lobectomy for T1b-T2 papillary thyroid cancer with high-risk features. *J Am Coll Surg* 2020;230(1):136–144; doi: 10.1016/j.jamcollsurg.2019.09.021
365. Carhill AA, Litofsky DR, Ross DS, et al. Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987-2012. *J Clin Endocrinol Metab* 2015;100(9):3270–3279; doi: 10.1210/JC.2015-1346
366. Kluijfhout WP, Pasternak JD, Lim J, et al. Frequency of high-risk characteristics requiring total thyroidectomy for 1-4 cm well-differentiated thyroid cancer. *Thyroid* 2016;26(6):820–824; doi: 10.1089/thy.2015.0495
367. Lang BH, Wong CKH. Lobectomy is a more cost-effective option than total thyroidectomy for 1 to 4 cm papillary thyroid carcinoma that do not possess clinically recognizable high-risk features. *Ann Surg Oncol* 2016;23(11):3641–3652; doi: 10.1245/s10434-016-5280-6
368. Carmel Neiderman NN, Duek I, Ravia A, et al. The incidence of postoperative re-stratification for recurrence in well-differentiated thyroid cancer—a retrospective cohort study. *Gland Surg* 2021;10(8):2354–2367; doi: 10.21037/gs-21-105
369. Puttergill B, Khan S, Christakis I, et al. Thyroid lobectomy for low-risk thyroid cancers. *Ann R Coll Surg Engl* 2022;104(2):113–116; doi: 10.1308/rcsann.2021.0058
370. Craig SJ, Bysice AM, Nakoneshny SC, et al. The identification of intraoperative risk factors can reduce, but not exclude, the need for completion thyroidectomy in low-risk papillary thyroid cancer patients. *Thyroid* 2020;30(2):222–228; doi: 10.1089/thy.2019.0274
371. Moore EC, Zolin S, Krishnamurthy V, et al. Need for completion thyroidectomy in patients undergoing lobectomy for indeterminate and high-risk nodules: Impact of

- intra-operative findings and final pathology. *World J Surg* 2020;44(2):408–416; doi: 10.1007/s00268-019-05189-3
372. Hirshoren N, Kaganov K, Weinberger JM, et al. Thyroidectomy practice after implementation of the 2015 American Thyroid Association guidelines on surgical options for patients with well-differentiated thyroid carcinoma. *JAMA Otolaryngol Head Neck Surg* 2018;144(5):427–432; doi: 10.1001/jamaoto.2018.0042
  373. Toumi A, DiGennaro C, Vahdat V, et al. Trends in thyroid surgery and guideline-concordant care in the United States, 2007–2018. *Thyroid* 2021;31(6):941–949; doi: 10.1089/thy.2020.0643
  374. Adhami M, Bhatt CR, Grodski S, et al. Less extensive surgery for low-risk papillary thyroid cancers post 2015 American Thyroid Association guidelines in an Australian tertiary centre. *Eur J Surg Oncol* 2021;47(11):2781–2787; doi: 10.1016/j.ejso.2021.06.018
  375. Wrenn SM, Wang TS, Toumi A, et al. Practice patterns for surgical management of low-risk papillary thyroid cancer from 2014 to 2019: A CESQIP analysis. *Am J Surg* 2021;221(2):448–454; doi: 10.1016/j.amjsurg.2020.07.032
  376. Kuo LE, Angell TE, Pandian TK, et al. Completion thyroidectomy is less common following updated 2015 American Thyroid Association Guidelines. *Ann Surg Oncol* 2021;28(1):484–491; doi: 10.1245/s10434-020-08709-x
  377. Dobrinja C, Samardzic N, Giudici F, et al. Hemithyroidectomy versus total thyroidectomy in the intermediate-risk differentiated thyroid cancer: the Italian Societies of Endocrine Surgeons and Surgical Oncology Multicentric Study. *Updates Surg* 2021;73(5):1909–1921; doi: 10.1007/s13304-021-01140-1
  378. Czarniecka A, Zeman M, Wozniak G, et al. Therapeutic strategy in low-risk papillary thyroid carcinoma - long-term results of the first single-center prospective non-randomized trial between 2011 and 2015. *Front Endocrinol (Lausanne)* 2021;12:718833; doi: 10.3389/fendo.2021.718833
  379. Leong D, Ng K, Nguyen H, et al. Preoperative ultrasound characteristics in determining the likelihood of requiring completion thyroidectomy for cytologically confirmed (Bethesda VI) papillary thyroid tumors with 1 - 4 cm in diameter. *Asian J Surg* 2022;45(1):197–201; doi: 10.1016/j.asjsur.2021.04.037
  380. Raffaelli M, Sessa L, De Crea C, et al. Is it possible to intraoperatively modulate the extent of thyroidectomy in small papillary thyroid carcinoma? *Surgery* 2021;169(1):77–81; doi: 10.1016/j.surg.2020.04.043
  381. Marshall R, Alexander D, Fleming J, et al. Utility of intraoperative frozen sections of thyroid tissue in the age of molecular testing. *Clin Otolaryngol* 2021;46(5):991–997; doi: 10.1111/coa.13766
  382. Staubitz JI, Elmrich I, Musholt PB, et al; Prospective Evaluation Study Thyroid Surgery (PETS) 2 study group. Targeted use of intraoperative frozen-section analysis lowers the frequency of completion thyroidectomy. *BJS Open* 2021;5(2):zraa058; doi: 10.1093/bjsopen/zraa058
  383. Kandil E, Krishnan B, Noureldine SI, et al. Hemithyroidectomy: A meta-analysis of postoperative need for hormone replacement and complications. *ORL J Otorhinolaryngol Relat Spec* 2013;75(1):6–17; doi: 10.1159/000345498
  384. Kandil E, Noureldine SI, Abbas A, et al. The impact of surgical volume on patient outcomes following thyroid surgery. *Surgery* 2013;154(6):1346–1352; doi: 10.1016/j.surg.2013.04.068
  385. Ducloux A, Peix JL, Colin C, et al; CATHY Study Group. Influence of experience on performance of individual surgeons in thyroid surgery: Prospective cross sectional multicentre study. *Bmj* 2012;344:d8041.
  386. Verloop H, Louwerens M, Schoones JW, et al. Risk of hypothyroidism following hemithyroidectomy: Systematic review and meta-analysis of prognostic studies. *J Clin Endocrinol Metab* 2012;97(7):2243–2255; doi: 10.1210/jc.2012-1063
  387. Ha TK, Kim DW, Park HK, et al. Factors influencing the successful maintenance of euthyroidism after lobectomy in patients with papillary thyroid microcarcinoma: A single-center study. *Endocr Pract* 2019;25(10):1035–1040; doi: 10.4158/EP-2019-0153
  388. Cox C, Bosley M, Southerland LB, et al. Lobectomy for treatment of differentiated thyroid cancer: Can patients avoid postoperative thyroid hormone supplementation and be compliant with the American Thyroid Association guidelines? *Surgery* 2018;163(1):75–80; doi: 10.1016/j.surg.2017.04.039
  389. Lee DY, Seok J, Jeong WJ, et al. Prediction of thyroid hormone supplementation after thyroid lobectomy. *J Surg Res* 2015;193(1):273–278; doi: 10.1016/j.jss.2014.07.003
  390. Wilson M, Patel A, Goldner W, et al. Postoperative thyroid hormone supplementation rates following thyroid lobectomy. *Am J Surg* 2020;220(5):1169–1173; doi: 10.1016/j.amjsurg.2020.06.052
  391. Xiao L, Wu J, Jiang L, et al. Is thyroid hormone supplementation avoidable for patients with low-risk papillary thyroid cancer after thyroid lobectomy? A two-center observational study. *Clin Endocrinol (Oxf)* 2022;96(3):413–418; doi: 10.1111/cen.14580
  392. Xu S, Huang Y, Huang H, et al. Optimal serum thyrotropin level for patients with papillary thyroid carcinoma after lobectomy. *Thyroid* 2022;32(2):138–144; doi: 10.1089/thy.2021.0404
  393. Na YM, Cho JS, Park MH. Levothyroxine cessation after thyroid lobectomy for papillary thyroid cancer can be achieved at the same rate as that for benign tumors regardless of the duration of thyroid-stimulating hormone suppression. *Anticancer Res* 2021;41(11):5713–5721; doi: 10.21873/anticancer.15387
  394. Bischoff L, Haymart MR. Optimal thyrotropin following lobectomy for papillary thyroid cancer: Does it exist? *Thyroid* 2022;32(2):117–118; doi: 10.1089/thy.2021.0617
  395. Bae MR, Nam SH, Roh JL, et al. Thyroid stimulating hormone suppression and recurrence after thyroid lobectomy for papillary thyroid carcinoma. *Endocrine* 2022;75(2):487–494; doi: 10.1007/s12020-021-02911-x
  396. Nickel B, Tan T, Cvejic E, et al. Health-related quality of life after diagnosis and treatment of differentiated thyroid cancer and association with type of surgical treatment. *JAMA Otolaryngol Head Neck Surg* 2019;145(3):231–238; doi: 10.1001/jamaoto.2018.3870
  397. Li J, Xue LB, Gong XY, et al. Risk factors of deterioration in quality of life scores in thyroid cancer patients after thyroidectomy. *Cancer Manag Res* 2019;11:10593–10598; doi: 10.2147/CMAR.S235323

398. Chen W, Li J, Peng S, et al. Association of total thyroidectomy or thyroid lobectomy with the quality of life in patients with differentiated thyroid cancer with low to intermediate risk of recurrence. *JAMA Surg* 2022;157(3):200–209; doi: 10.1001/jamasurg.2021.6442
399. Rosato L, Pacini F, Panier S, et al. Post-thyroidectomy chronic asthenia: Self-deception or disease? *Endocrine* 2015;48(2):615–620; doi: 10.1007/s12020-014-0353-4
400. Schumm MA, Shu ML, Hughes EG, et al. Prognostic value of preoperative molecular testing and implications for initial surgical management in thyroid nodules harboring suspected (Bethesda V) or Known (Bethesda VI) Papillary Thyroid Cancer. *JAMA Otolaryngol Head Neck Surg* 2023;149(8):735–742; doi: 10.1001/jamaoto.2023.1494
401. Chen JY, Huang NS, Wei WJ, et al. The efficacy and safety of surufatinib combined with anti PD-1 antibody toripalimab in neoadjuvant treatment of locally advanced differentiated thyroid cancer: A phase II study. *Ann Surg Oncol* 2023;30(12):7172–7180; doi: 10.1245/s10434-023-14031-z
402. Russell M, Gild ML, Wirth LJ, et al. Neoadjuvant therapy to improve resectability of advanced thyroid cancer: A real-world experience. *Head Neck* 2024;46(10):2496–2507; doi: 10.1002/hed.27735
403. Erdem E, Gulcelik MA, Kuru B, et al. Comparison of completion thyroidectomy and primary surgery for differentiated thyroid carcinoma. *Eur J Surg Oncol* 2003;29(9):747–749; doi: 10.1016/j.ejso.2003.08.006
404. Tan MP, Agarwal G, Reeve TS, et al. Impact of timing on completion thyroidectomy for thyroid cancer. *Br J Surg* 2002;89(6):802–804; doi: 10.1046/j.1365-2168.2002.02068.x
405. Untch BR, Palmer FL, Ganly I, et al. Oncologic outcomes after completion thyroidectomy for patients with well-differentiated thyroid carcinoma. *Ann Surg Oncol* 2014;21(4):1374–1378; doi: 10.1245/s10434-013-3428-1
406. Giordano D, Botti C, Piana S, et al. Postoperative hypoparathyroidism after completion thyroidectomy for well-differentiated thyroid cancer. *Eur J Endocrinol* 2021;185(3):413–419; doi: 10.1530/EJE-21-0353
407. Brauer PR, Reddy CA, Burkey BB, et al. A national comparison of postoperative outcomes in completion thyroidectomy and total thyroidectomy. *Otolaryngol Head Neck Surg* 2021;164(3):566–573; doi: 10.1177/0194599820951165
408. Barbesino G, Goldfarb M, Parangi S, et al. Thyroid lobe ablation with radioactive iodine as an alternative to completion thyroidectomy after hemithyroidectomy in patients with follicular thyroid carcinoma: Long-term follow-up. *Thyroid* 2012;22(4):369–376; doi: 10.1089/thy.2011.0198
409. Santra A, Bal S, Mahargan S, et al. Long-term outcome of lobar ablation versus completion thyroidectomy in differentiated thyroid cancer. *Nucl Med Commun* 2011;32(1):52–58; doi: 10.1097/MNM.0b013e328340e74c
410. Ritter A, Bachar G, Hirsch D, et al. Natural history of contralateral nodules after lobectomy in patients with papillary thyroid carcinoma. *J Clin Endocrinol Metab* 2018;103(2):407–414; doi: 10.1210/jc.2017-01616
411. Harries V, Wang LY, McGill M, et al. Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma? *Surgery* 2020;167(1):10–17; doi: 10.1016/j.surg.2019.03.031
412. Qu N, Zhang L, Ji QH, et al. Number of tumor foci predicts prognosis in papillary thyroid cancer. *BMC Cancer* 2014;14:914; doi: 10.1186/1471-2407-14-914
413. Wang F, Yu X, Shen X, et al. The prognostic value of tumor multifocality in clinical outcomes of papillary thyroid cancer. *J Clin Endocrinol Metab* 2017;102(9):3241–3250; doi: 10.1210/jc.2017-00277
414. Coca-Pelaz A, Rodrigo JP, Shah JP, et al. Hürthle cell carcinoma of the thyroid gland: Systematic review and meta-analysis. *Adv Ther* 2021;38(10):5144–5164; doi: 10.1007/s12325-021-01876-7
415. Wang X, Zheng X, Zhu J, et al. Radioactive iodine therapy does not improve cancer-specific survival in Hürthle cell carcinoma of the thyroid. *J Clin Endocrinol Metab* 2022;107(11):3144–3151; doi: 10.1210/clinem/dgac448
416. Abiri A, Goshtasbi K, Torabi SJ, et al. Outcomes and trends of treatments in high-risk differentiated thyroid cancer. *Otolaryngol Head Neck Surg* 2023;168(4):745–753; doi: 10.1177/01945998221095720
417. Abiri A, Nguyen T, Goshtasbi K, et al. A comparative analysis of treatment efficacy in intermediate-risk thyroid cancer. *Eur Arch Otorhinolaryngol* 2023;280(5):2525–2533; doi: 10.1007/s00405-023-07832-1
418. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. *CA Cancer J Clin* 2017;67(2):93–99; doi: 10.3322/caac.21388
419. Lang BH, Shek TW, Wan KY. Does microscopically involved margin increase disease recurrence after curative surgery in papillary thyroid carcinoma? *J Surg Oncol* 2016;113(6):635–639; doi: 10.1002/jso.24194
420. Danilovic DLS, Castroneves LA, Suemoto CK, et al. Is there a difference between minimal and gross extension into the strap muscles for the risk of recurrence in papillary thyroid carcinomas? *Thyroid* 2020;30(7):1008–1016; doi: 10.1089/thy.2019.0753
421. Sanabria A, Rojas A, Arevalo J, et al. Microscopically positive surgical margins and local recurrence in thyroid cancer: A meta-analysis. *Eur J Surg Oncol* 2019;45(8):1310–1316; doi: 10.1016/j.ejso.2019.02.007
422. Wang LY, Ghossein R, Palmer FL, et al. Microscopic positive margins in differentiated thyroid cancer is not an independent predictor of local failure. *Thyroid* 2015;25(9):993–998; doi: 10.1089/thy.2015.0141
423. Ruel E, Thomas S, Perkins JM, et al. The impact of pathologically positive lymph nodes in the clinically negative neck: An analysis of 39,301 patients with papillary thyroid cancer. *Ann Surg Oncol* 2017;24(7):1935–1942; doi: 10.1245/s10434-016-5719-9
424. Lee YM, Park JH, Cho JW, et al. The definition of lymph node micrometastases in pathologic N1a papillary thyroid carcinoma should be revised. *Surgery* 2019;165(3):652–656; doi: 10.1016/j.surg.2018.09.015
425. Furtado MdS, Rosario PW, Calsolari MR. Persistent and recurrent disease in patients with papillary thyroid carcinoma with clinically apparent (cN1), but not extensive, lymph node involvement and without other factors for poor prognosis. *Arch Endocrinol Metab* 2015;59(4):285–291; doi: 10.1590/2359-3997000000081
426. Kim SK, Park I, Woo JW, et al. Predictive factors for lymph node metastasis in papillary thyroid microcarcinoma. *Ann Surg Oncol* 2016;23(9):2866–2873; doi: 10.1245/s10434-016-5225-0

427. Ryu YJ, Cho JS, Yoon JH, et al. Identifying risk factors for recurrence of papillary thyroid cancer in patients who underwent modified radical neck dissection. *World J Surg Oncol* 2018;16(1):205; doi: 10.1186/s12957-018-1496-1
428. Lee YC, Na SY, Park GC, et al. Occult lymph node metastasis and risk of regional recurrence in papillary thyroid cancer after bilateral prophylactic central neck dissection: A multi-institutional study. *Surgery* 2017; 161(2):465–471; doi: 10.1016/j.surg.2016.07.031
429. Veronese N, Luchini C, Nottegar A, et al. Prognostic impact of extra-nodal extension in thyroid cancer: A meta-analysis. *J Surg Oncol* 2015;112(8):828–833; doi: 10.1002/jso.24070
430. Lang BH, Shek TW, Wan KY. Impact of microscopic extra-nodal extension (ENE) on locoregional recurrence following curative surgery for papillary thyroid carcinoma. *J Surg Oncol* 2016;113(5):526–531; doi: 10.1002/jso.24180
431. Roh JL, Park JW, Jeong J, et al. Extranodal extension of lymph node metastasis as a prognostic indicator of recurrence and survival in papillary thyroid carcinoma. *J Surg Oncol* 2017;116(4):450–458; doi: 10.1002/jso.24713
432. Cao J, Hu JL, Chen C, et al. Vascular invasion is an independent prognostic factor for distant recurrence-free survival in papillary thyroid carcinoma: A matched-case comparative study. *J Clin Pathol* 2016;69(10):872–877; doi: 10.1136/jclinpath-2015-203547
433. Lee YM, Lee YH, Song DE, et al. Prognostic impact of further treatments on distant metastasis in patients with minimally invasive follicular thyroid carcinoma: Verification using inverse probability of treatment weighting. *World J Surg* 2017;41(1):138–145; doi: 10.1007/s00268-016-3608-9
434. Wreesmann VB, Nixon IJ, Rivera M, et al. Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma. *Thyroid* 2015;25(5):503–508; doi: 10.1089/thy.2015.0052
435. Wei S, LiVolsi VA, Baloch ZW. Pathology of thyroglossal duct: An institutional experience. *Endocr Pathol* 2015; 26(1):75–79; doi: 10.1007/s12022-015-9354-y
436. Zizic M, Faquin W, Stephen AE, et al. Upper neck papillary thyroid cancer (UPTC): A new proposed term for the composite of thyroglossal duct cyst-associated papillary thyroid cancer, pyramidal lobe papillary thyroid cancer, and Delphian node papillary thyroid cancer metastasis. *Laryngoscope* 2016;126(7):1709–1714; doi: 10.1002/lary.25824
437. Isaacson G. Sistrunk centennial: Evolution of a classic operation. *Laryngoscope* 2020;130(2):E45–E47; doi: 10.1002/lary.27914
438. Sistrunk WE. The surgical treatment of cysts of the thyroglossal tract. *Ann Surg* 1920;71(2):121–122 2; doi: 10.1097/00000658-192002000-00002
439. Sistrunk WE. The Mikulicz operation for resection of the colon: Its advantages and dangers. *Ann Surg* 1928;88(3): 597–606; doi: 10.1097/00000658-192809000-00029
440. Pellegriti G, Lumera G, Malandrino P, et al. Thyroid cancer in thyroglossal duct cysts requires a specific approach due to its unpredictable extension. *J Clin Endocrinol Metab* 2013;98(2):458–465; doi: 10.1210/jc.2012-1952
441. Thompson LDR, Herrera HB, Lau SK. Thyroglossal duct cyst carcinomas: A clinicopathologic series of 22 cases with staging recommendations. *Head Neck Pathol* 2017; 11(2):175–185; doi: 10.1007/s12105-016-0757-y
442. Chen L, Wu YH, Lee CH, et al. Prophylactic central neck dissection for papillary thyroid carcinoma with clinically uninvolved central neck lymph nodes: A systematic review and meta-analysis. *World J Surg* 2018;42(9): 2846–2857; doi: 10.1007/s00268-018-4547-4
443. Wang TS, Cheung K, Farrokhyar F, et al. A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer. *Ann Surg Oncol* 2013;20(11): 3477–3483; doi: 10.1245/s10434-013-3125-0
444. Hughes DT, Rosen JE, Evans DB, et al. Prophylactic central compartment neck dissection in papillary thyroid cancer and effect on locoregional recurrence. *Ann Surg Oncol* 2018;25(9):2526–2534; doi: 10.1245/s10434-018-6528-0
445. Nixon IJ, Wang LY, Ganly I, et al. Outcomes for patients with papillary thyroid cancer who do not undergo prophylactic central neck dissection. *Br J Surg* 2016;103(3): 218–225; doi: 10.1002/bjs.10036
446. Zhao W, You L, Hou X, et al. The effect of prophylactic central neck dissection on locoregional recurrence in papillary thyroid cancer after total thyroidectomy: A systematic review and meta-analysis: PCND for the locoregional recurrence of papillary thyroid cancer. *Ann Surg Oncol* 2017;24(8):2189–2198; doi: 10.1245/s10434-016-5691-4
447. Qu H, Sun GR, Liu Y, et al. Clinical risk factors for central lymph node metastasis in papillary thyroid carcinoma: A systematic review and meta-analysis. *Clin Endocrinol (Oxf)* 2015;83(1):124–132; doi: 10.1111/cen.12583
448. Lee YS, Lim YS, Lee JC, et al. Clinical implication of the number of central lymph node metastasis in papillary thyroid carcinoma: Preliminary report. *World J Surg* 2010; 34(11):2558–2563; doi: 10.1007/s00268-010-0749-0
449. Koo BS, Choi EC, Park YH, et al. Occult contralateral central lymph node metastases in papillary thyroid carcinoma with unilateral lymph node metastasis in the lateral neck. *J Am Coll Surg* 2010;210(6):895–900; doi: 10.1016/j.jamcollsurg.2010.01.037
450. Kim KE, Kim EK, Yoon JH, et al. Preoperative prediction of central lymph node metastasis in thyroid papillary microcarcinoma using clinicopathologic and sonographic features. *World J Surg* 2013;37(2):385–391; doi: 10.1007/s00268-012-1826-3
451. Likhterov I, Reis LL, Urken ML. Central compartment management in patients with papillary thyroid cancer presenting with metastatic disease to the lateral neck: Anatomic pathways of lymphatic spread. *Head Neck* 2017; 39(5):853–859; doi: 10.1002/hed.24568
452. Miller JE, Al-Attar NC, Brown OH, et al. Location and causation of residual lymph node metastasis after surgical treatment of regionally advanced differentiated thyroid cancer. *Thyroid* 2018;28(5):593–600; doi: 10.1089/thy.2017.0434
453. Robinson TJ, Thomas S, Dinan MA, et al. How many lymph nodes are enough? Assessing the adequacy of lymph node yield for papillary thyroid cancer. *J Clin Oncol* 2016; 34(28):3434–3439; doi: 10.1200/jco.2016.67.6437
454. Heaton CM, Chang JL, Orloff LA. Prognostic implications of lymph node yield in central and lateral neck dissections for well-differentiated papillary thyroid carcinoma. *Thyroid* 2016;26(3):434–440; doi: 10.1089/thy.2015.0318
455. Amit M, Tam S, Boonsripitayanon M, et al. Association of lymph node density with survival of patients with

- papillary thyroid cancer. *JAMA Otolaryngol Head Neck Surg* 2018;144(2):108–114; doi: 10.1001/jamaoto.2017.2416
456. Lee YM, Sung TY, Kim WB, et al. Risk factors for recurrence in patients with papillary thyroid carcinoma undergoing modified radical neck dissection. *Br J Surg* 2016; 103(8):1020–1025; doi: 10.1002/bjs.10144
  457. Ryu YJ, Cho JS, Park MH, et al. Identifying risk factors of recurrence for clinically node negative papillary thyroid carcinoma with pathologic N1a. *BMC Surg* 2019; 19(1):78; doi: 10.1186/s12893-019-0541-5
  458. Lee SH, Roh JL, Gong G, et al. Risk factors for recurrence after treatment of N1b papillary thyroid carcinoma. *Ann Surg* 2019;269(5):966–971; doi: 10.1097/SLA.0000000000002710
  459. Nam SH, Roh JL, Gong G, et al. Nodal factors predictive of recurrence after thyroidectomy and neck dissection for papillary thyroid carcinoma. *Thyroid* 2018;28(1):88–95; doi: 10.1089/thy.2017.0334
  460. Lee J, Lee SG, Kim K, et al. Clinical value of lymph node ratio integration with the 8(th) edition of the UICC TNM classification and 2015 ATA risk stratification systems for recurrence prediction in papillary thyroid cancer. *Sci Rep* 2019;9(1):13361; doi: 10.1038/s41598-019-50069-4
  461. Griffin MJ, Baik FM, Brandwein-Weber M, et al. Positive lymph node counts in American Thyroid Association low-risk papillary thyroid carcinoma patients. *World J Surg* 2020;44(6):1892–1897; doi: 10.1007/s00268-020-05399-0
  462. O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. *Cochrane Database Syst Rev* 2009;3(3):CD001431–C117.
  463. Feldman-Stewart D, Capirci C, Brennenstuhl S, et al. Information for decision making by patients with early-stage prostate cancer: A comparison across 9 countries. *Med Decis Making* 2011;31(5):754–766; doi: 10.1177/0272989X10395029
  464. Haynes RB, McKibbin KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. *Lancet* 1996;348(9024): 383–386; doi: 10.1016/s0140-6736(96)01073-2
  465. Weiss SM, Wengert PA, Jr, Martinez EM, et al. Patient satisfaction with decision-making for breast cancer therapy. *Ann Surg Oncol* 1996;3(3):285–289.
  466. Street RL, Jr, Voigt B. Patient participation in deciding breast cancer treatment and subsequent quality of life. *Med Decis Making* 1997;17(3):298–306.
  467. Abdul-Sater L, Henry M, Majdan A, et al. What are thyroidectomy patients really concerned about? *Otolaryngol Head Neck Surg* 2011;144(5):685–690; doi: 10.1177/0194599811399556
  468. Husson O, Haak HR, Oranje WA, et al. Health-related quality of life among thyroid cancer survivors: A systematic review. *Clin Endocrinol (Oxf)* 2011;75(4):544–554; doi: 10.1111/j.1365-2265.2011.04114.x
  469. Stojadinovic A, Shaha AR, Orlikoff RF, et al. Prospective functional voice assessment in patients undergoing thyroid surgery. *Ann Surg* 2002;236(6):823–832.
  470. Soylu L, Ozbas S, Uslu HY, et al. The evaluation of the causes of subjective voice disturbances after thyroid surgery. *Am J Surg* 2007;194(3):317–322; doi: 10.1016/j.amjsurg.2006.10.009
  471. Wilson JA, Deary IJ, Millar A, et al. The quality of life impact of dysphonia. *Clin Otolaryngol Allied Sci* 2002; 27(3):179–182.
  472. Jones SM, Carding PN, Drinnan MJ. Exploring the relationship between severity of dysphonia and voice-related quality of life. *Clin Otolaryngol* 2006;31(5):411–417; doi: 10.1111/j.1749-4486.2006.01291.x
  473. Munch S, deKryger L. A piece of my mind. Moral wounds: Complicated complications. *JAMA* 2001;285(9): 1131–1132.
  474. Cohen SM, Kim J, Roy N, et al. Prevalence and causes of dysphonia in a large treatment-seeking population. *Laryngoscope* 2012;122(2):343–348; doi: 10.1002/lary.22426
  475. Singer MC, Iverson KC, Terris DJ. Thyroidectomy-related malpractice claims. *Otolaryngol Head Neck Surg* 2012;146(3):358–361; doi: 10.1177/0194599811430898
  476. Chandrasekhar SS, Randolph GW, Seidman MD, et al; American Academy of Otolaryngology-Head and Neck Surgery. Clinical practice guideline: Improving voice outcomes after thyroid surgery. *Otolaryngol Head Neck Surg* 2013; 148(6 Suppl):S1–S37; doi: 10.1177/0194599813487301
  477. Farrag TY, Samlan RA, Lin FR, et al. The utility of evaluating true vocal fold motion before thyroid surgery. *Laryngoscope* 2006;116(2):235–238; doi: 10.1097/01.mlg.0000191472.02720.1f
  478. Roh JL, Yoon YH, Park CI. Recurrent laryngeal nerve paralysis in patients with papillary thyroid carcinomas: Evaluation and management of resulting vocal dysfunction. *Am J Surg* 2009;197(4):459–465; doi: 10.1016/j.amjsurg.2008.04.017
  479. Randolph GW, Kamani D. The importance of preoperative laryngoscopy in patients undergoing thyroidectomy: Voice, vocal cord function, and the preoperative detection of invasive thyroid malignancy. *Surgery* 2006; 139(3):357–362; doi: 10.1016/j.surg.2005.08.009
  480. Eadie TL, Kapsner M, Rosenzweig J, et al. The role of experience on judgments of dysphonia. *J Voice* 2010; 24(5):564–573; doi: 10.1016/j.jvoice.2008.12.005
  481. Rowe-Jones JM, Rosswick RP, Leighton SE. Benign thyroid disease and vocal cord palsy. *Ann R Coll Surg Engl* 1993;75(4):241–244.
  482. Shin JJ, Grillo HC, Mathisen D, et al. The surgical management of goiter: Part I. Preoperative evaluation. *Laryngoscope* 2011;121(1):60–67; doi: 10.1002/lary.21084
  483. Bergenfelz A, Jansson S, Kristoffersson A, et al. Complications to thyroid surgery: Results as reported in a database from a multicenter audit comprising 3,660 patients. *Langenbecks Arch Surg* 2008;393(5):667–673; doi: 10.1007/s00423-008-0366-7
  484. Green KM, de Carpentier JP. Are pre-operative vocal fold checks necessary? *J Laryngol Otol* 1999;113(7): 642–644.
  485. Cheng SP, Lee JJ, Liu TP, et al. Preoperative ultrasonography assessment of vocal cord movement during thyroid and parathyroid surgery. *World J Surg* 2012;36(10): 2509–2515; doi: 10.1007/s00268-012-1674-1
  486. Terris DJ, Snyder S, Carneiro-Pla D, et al; American Thyroid Association Surgical Affairs Committee Writing Task Force. American Thyroid Association statement on outpatient thyroidectomy. *Thyroid* 2013;23(10):1193–1202; doi: 10.1089/thy.2013.0049
  487. Dralle H, Sekulla C, Haerting J, et al. Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery. *Surgery* 2004; 136(6):1310–1322; doi: 10.1016/j.surg.2004.07.018
  488. Shindo ML, Caruana S, Kandil E, et al. Management of invasive well-differentiated thyroid cancer an American

- Head and Neck society consensus statement. *Head Neck* 2014;36(10):1379–1390; doi: 10.1002/hed.23619
489. Haddad RI, Bischoff L, Ball D, et al. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2022;20(8):925–951; doi: 10.6004/jncn.2022.0040
  490. Falk SA, McCaffrey TV. Management of the recurrent laryngeal nerve in suspected and proven thyroid cancer. *Otolaryngol Head Neck Surg* 1995;113(1):42–48.
  491. Jatzko GR, Lisborg PH, Muller MG, et al. Recurrent nerve palsy after thyroid operations—principal nerve identification and a literature review. *Surgery* 1994;115(2):139–144.
  492. Lo CY, Kwok KF, Yuen PW. A prospective evaluation of recurrent laryngeal nerve paralysis during thyroidectomy. *Arch Surg* 2000;135(2):204–207.
  493. Curran AJ, Smyth D, Sheehan SJ, et al. Recurrent laryngeal nerve dysfunction following carotid endarterectomy. *J R Coll Surg Edinb* 1997;42(3):168–170.
  494. Rosenthal LH, Benninger MS, Deeb RH. Vocal fold immobility: A longitudinal analysis of etiology over 20 years. *Laryngoscope* 2007;117(10):1864–1870; doi: 10.1097/MLG.0b013e3180de4d49
  495. Kriskovich MD, Apfelbaum RI, Haller JR. Vocal fold paralysis after anterior cervical spine surgery: Incidence, mechanism, and prevention of injury. *Laryngoscope* 2000;110(9):1467–1473; doi: 10.1097/00005537-200009000-00011
  496. Benninger MS, Crumley RL, Ford CN, et al. Evaluation and treatment of the unilateral paralyzed vocal fold. *Otolaryngol Head Neck Surg* 1994;111(4):497–508.
  497. Grundfast KM, Harley E. Vocal cord paralysis. *Otolaryngol Clin North Am* 1989;22(3):569–597.
  498. Chan WF, Lang BH, Lo CY. The role of intraoperative neuromonitoring of recurrent laryngeal nerve during thyroidectomy: A comparative study on 1000 nerves at risk. *Surgery* 2006;140(6):866–872; doi: 10.1016/j.surg.2006.07.017
  499. Randolph GW, Dralle H, Abdullah H, et al; International Intraoperative Monitoring Study Group. Electrophysiologic recurrent laryngeal nerve monitoring during thyroid and parathyroid surgery: International standards guideline statement. *Laryngoscope* 2011;121(Suppl 1):S1–S16; doi: 10.1002/lary.21119
  500. Sturgeon C, Sturgeon T, Angelos P. Neuromonitoring in thyroid surgery: Attitudes, usage patterns, and predictors of use among endocrine surgeons. *World J Surg* 2009;33(3):417–425; doi: 10.1007/s00268-008-9724-4
  501. Musholt TJ, Clerici T, Dralle H, et al; Interdisciplinary Task Force Guidelines of the German Association of Endocrine Surgeons. German Association of Endocrine Surgeons practice guidelines for the surgical treatment of benign thyroid disease. *Langenbecks Arch Surg* 2011;396(5):639–649; doi: 10.1007/s00423-011-0774-y
  502. Horne SK, Gal TJ, Brennan JA. Prevalence and patterns of intraoperative nerve monitoring for thyroidectomy. *Otolaryngol Head Neck Surg* 2007;136(6):952–956; doi: 10.1016/j.otohns.2007.02.011
  503. Sadowski SM, Soardo P, Leuchter I, et al. Systematic use of recurrent laryngeal nerve neuromonitoring changes the operative strategy in planned bilateral thyroidectomy. *Thyroid* 2013;23(3):329–333; doi: 10.1089/thy.2012.0368
  504. Goretzki PE, Schwarz K, Brinkmann J, et al. The impact of intraoperative neuromonitoring (IONM) on surgical strategy in bilateral thyroid diseases: Is it worth the effort? *World J Surg* 2010;34(6):1274–1284; doi: 10.1007/s00268-009-0353-3
  505. Melin M, Schwarz K, Lammers BJ, et al. IONM-guided goiter surgery leading to two-stage thyroidectomy—indication and results. *Langenbecks Arch Surg* 2013;398(3):411–418; doi: 10.1007/s00423-012-1032-7
  506. Barczyński M, Randolph GW, Cernea CR, et al; International Neural Monitoring Study Group. External branch of the superior laryngeal nerve monitoring during thyroid and parathyroid surgery: International Neural Monitoring Study Group standards guideline statement. *Laryngoscope* 2013;123(Suppl 4):S1–S14; doi: 10.1002/lary.24301
  507. Cirocchi R, Arezzo A, D'Andrea V, et al. Intraoperative neuromonitoring versus visual nerve identification for prevention of recurrent laryngeal nerve injury in adults undergoing thyroid surgery. *Cochrane Database Syst Rev* 2019;1(1):Cd012483; doi: 10.1002/14651858.CD012483.pub2
  508. Calò PG, Medas F, Gordini L, et al. Interpretation of intraoperative recurrent laryngeal nerve monitoring signals: The importance of a correct standardization. *Int J Surg* 2016;28(Suppl 1):S54–S8; doi: 10.1016/j.ijssu.2015.12.039
  509. Brajcich BC, McHenry CR. The utility of intraoperative nerve monitoring during thyroid surgery. *J Surg Res* 2016;204(1):29–33; doi: 10.1016/j.jss.2016.04.039
  510. Mizuno K, Takeuchi M, Kanazawa Y, et al. Recurrent laryngeal nerve paralysis after thyroid cancer surgery and intraoperative nerve monitoring. *Laryngoscope* 2019;129(8):1954–1960; doi: 10.1002/lary.27698
  511. Akici M, Cilekar M, Yilmaz S, et al. Should intraoperative nerve monitoring be used routinely in primary thyroid surgeries? *Pak J Med Sci* 2020;36(2):276–280; doi: 10.12669/pjms.36.2.1054
  512. Staubitz JJ, Watzka F, Poplawski A, et al; EUROCRINE® Council. Effect of intraoperative nerve monitoring on postoperative vocal cord palsy rates after thyroidectomy: European multicentre registry-based study. *BJS Open* 2020;4(5):821–829; doi: 10.1002/bjs.5.50310
  513. Bergenfelz A, Salem AF, Jacobsson H, et al; Steering Committee for the Scandinavian Quality Register for Thyroid, Parathyroid and Adrenal Surgery (SQRTPA). Risk of recurrent laryngeal nerve palsy in patients undergoing thyroidectomy with and without intraoperative nerve monitoring. *Br J Surg* 2016;103(13):1828–1838; doi: 10.1002/bjs.10276
  514. Vasileiadis I, Karatzas T, Charitoudis G, et al. Association of intraoperative neuromonitoring with reduced recurrent laryngeal nerve injury in patients undergoing total thyroidectomy. *JAMA Otolaryngol Head Neck Surg* 2016;142(10):994–1001; doi: 10.1001/jamaoto.2016.1954
  515. Kai H, Xixia L, Miaoyun L, et al. Intraoperative nerve monitoring reduces recurrent laryngeal nerve injury in geriatric patients undergoing thyroid surgery. *Acta Otolaryngol* 2017;137(12):1275–1280; doi: 10.1080/00016489.2017.1354397
  516. Ling Y, Zhao J, Zhao Y, et al. Role of intraoperative neuromonitoring of recurrent laryngeal nerve in thyroid and parathyroid surgery. *J Int Med Res* 2020;48(9):300060520952646; doi: 10.1177/0300060520952646
  517. Xie Q, Wang P, Yan H, et al. Feasibility and effectiveness of intraoperative nerve monitoring in total endoscopic thyroidectomy for thyroid cancer. *J Laparoendosc*

- Adv Surg Tech A 2016;26(2):109–115; doi: 10.1089/lap.2015.0401
518. Wu SY, Shen HY, Duh QY, et al. Routine intraoperative neuromonitoring of the recurrent laryngeal nerve to facilitate complete resection and ensure safety in thyroid cancer surgery. *Am Surg* 2018;84(12):1882–1888.
  519. Pei M, Zhu S, Zhang C, et al. The value of intraoperative nerve monitoring against recurrent laryngeal nerve injury in thyroid reoperations. *Medicine (Baltimore)* 2021;100(51):e28233; doi: 10.1097/MD.00000000000028233
  520. Prete FP, Sgaramella LI, Di Meo G, et al. Introducing routine intraoperative nerve monitoring in a high-volume endocrine surgery centre: A health technology assessment. *Updates Surg* 2021;73(6):2263–2273; doi: 10.1007/s13304-021-01104-5
  521. Duong W, Grigorian A, Farzaneh C, et al. Nerve monitoring decreases recurrent laryngeal nerve injury risk for neoplasm-related thyroidectomy. *Am J Surg* 2022;223(5):918–922; doi: 10.1016/j.amjsurg.2021.10.013
  522. Leonard-Murali S, Ivanics T, Nasser H, et al. Intraoperative nerve monitoring in thyroidectomies for malignancy: Does it matter? *Am Surg* 2022;88(6):1187–1194; doi: 10.1177/0003134821991967
  523. Kim J, Graves CE, Jin C, et al. Intraoperative nerve monitoring is associated with a lower risk of recurrent laryngeal nerve injury: A national analysis of 17,610 patients. *Am J Surg* 2021;221(2):472–477; doi: 10.1016/j.amjsurg.2020.10.013
  524. Mahoney RC, Vossler JD, Murayama KM, et al. Predictors and consequences of recurrent laryngeal nerve injury during open thyroidectomy: An American College of Surgeons National Surgical Quality Improvement Project database analysis. *Am J Surg* 2021;221(1):122–126; doi: 10.1016/j.amjsurg.2020.07.023
  525. Abdelhamid A, Aspinall S. Intraoperative nerve monitoring in thyroid surgery: Analysis of United Kingdom registry of endocrine and thyroid surgery database. *Br J Surg* 2021;108(2):182–187; doi: 10.1093/bjs/znaa081
  526. Schneider R, Sekulla C, Machens A, et al. Postoperative vocal fold palsy in patients undergoing thyroid surgery with continuous or intermittent nerve monitoring. *Br J Surg* 2015;102(11):1380–1387; doi: 10.1002/bjs.9889
  527. Brauckhoff K, Vik R, Sandvik L, et al. Impact of EMG changes in continuous vagal nerve monitoring in high-risk endocrine neck surgery. *World J Surg* 2016;40(3):672–680; doi: 10.1007/s00268-015-3368-y
  528. Sinclair CF, Tellez MJ, Ulkatan S. Continuous laryngeal adductor reflex versus intermittent nerve monitoring in neck endocrine surgery. *Laryngoscope* 2021;131(1):230–236; doi: 10.1002/lary.28710
  529. Schneider R, Machens A, Sekulla C, et al. Superiority of continuous over intermittent intraoperative nerve monitoring in preventing vocal cord palsy. *Br J Surg* 2021;108(5):566–573; doi: 10.1002/bjs.11901
  530. Wang T, Kim HY, Wu CW, et al. Analyzing cost-effectiveness of neural-monitoring in recurrent laryngeal nerve recovery course in thyroid surgery. *Int J Surg* 2017;48:180–188; doi: 10.1016/j.ijssu.2017.10.003
  531. Rocke DJ, Goldstein DP, de Almeida JR. A cost-utility analysis of recurrent laryngeal nerve monitoring in the setting of total thyroidectomy. *JAMA Otolaryngol Head Neck Surg* 2016;142(12):1199–1205; doi: 10.1001/jamaoto.2016.2860
  532. Lee E, Lee K, Yu HW, et al. Comparison of recurrent laryngeal nerve identification time in the lower central triangle during thyroid surgery using neurophysiological mapping and monitoring. *Medicina (Kaunas)* 2021;57(8):748; doi: 10.3390/medicina57080748
  533. Maneprasopchoke P, Chongkolwatana C, Pongsapich W, et al. Intraoperative nerve monitoring in thyroid surgery: Analysis of recurrent laryngeal nerve identification and operative time. *Laryngoscope Investig Otolaryngol* 2021;6(2):354–361; doi: 10.1002/lio2.543
  534. Feng AL, Puram SV, Singer MC, et al. Increased prevalence of neural monitoring during thyroidectomy: Global surgical survey. *Laryngoscope* 2020;130(4):1097–1104; doi: 10.1002/lary.28210
  535. Lorente-Poch L, Sancho JJ, Ruiz S, et al. Importance of *in situ* preservation of parathyroid glands during total thyroidectomy. *Br J Surg* 2015;102(4):359–367; doi: 10.1002/bjs.9676
  536. Friedman AD, Burns JA, Heaton JT, et al. Early versus late injection medialization for unilateral vocal cord paralysis. *Laryngoscope* 2010;120(10):2042–2046; doi: 10.1002/lary.21097
  537. Randolph GW, Clark OH. Principles in Thyroid Surgery. In: *Surgery of the Thyroid and Parathyroid Glands*. (Randolph GW., ed.) Elsevier: Philadelphia; 2013; pp. 273–293.
  538. Schneider R, Randolph GW, Dionigi G, et al. International neural monitoring study group guideline 2018 part I: Staging bilateral thyroid surgery with monitoring loss of signal. *Laryngoscope* 2018;128(Suppl 3):S1–S17; doi: 10.1002/lary.27359
  539. Fundakowski CE, Hales NW, Agrawal N, et al. Surgical management of the recurrent laryngeal nerve in thyroidectomy: American Head and Neck Society Consensus Statement. *Head Neck* 2018;40(4):663–675; doi: 10.1002/hed.24928
  540. Patel KN, Yip L, Lubitz CC, et al. The American Association of Endocrine Surgeons guidelines for the definitive surgical management of thyroid disease in adults. *Ann Surg* 2020;271(3):e21–e93; doi: 10.1097/sla.0000000000003580
  541. Cavicchi O, Burgio L, Cioccoloni E, et al. Intraoperative intermittent neuromonitoring of inferior laryngeal nerve and staged thyroidectomy: Our experience. *Endocrine* 2018;62(3):560–565; doi: 10.1007/s12020-018-1739-5
  542. Calò PG, Medas F, Conzo G, et al. Intraoperative neuro-monitoring in thyroid surgery: Is the two-staged thyroidectomy justified? *Int J Surg* 2017;41(Suppl 1):S13–Ss20; doi: 10.1016/j.ijssu.2017.02.001
  543. Stopa M, Barczyński M. Prognostic value of intraoperative neural monitoring of the recurrent laryngeal nerve in thyroid surgery. *Langenbecks Arch Surg* 2017;402(6):957–964; doi: 10.1007/s00423-016-1441-0
  544. Cipolla C, Vieni S, Genova P, et al. Value of neurostimulation plus laryngeal palpation to predict postoperative vocal fold motility. *J Surg Res* 2021;267:506–511; doi: 10.1016/j.jss.2021.06.003
  545. Gurleyik E, Dogan S, Cetin F, et al. Visual and electrophysiological identification of the external branch of superior laryngeal nerve in redo thyroid surgery compared with primary thyroid surgery. *Ann Surg Treat Res* 2019;96(6):269–274; doi: 10.4174/astr.2019.96.6.269
  546. Kartal K, Aygun N, Celayir MF, et al. Intraoperative neuro-monitoring in thyroid surgery: An efficient tool to avoid

- bilateral vocal cord palsy. *Ear Nose Throat J* 2021; 100(5\_suppl):694S–699S; doi: 10.1177/0145561320906325
547. Al-Qurayshi Z, Kandil E, Randolph GW. Cost-effectiveness of intraoperative nerve monitoring in avoidance of bilateral recurrent laryngeal nerve injury in patients undergoing total thyroidectomy. *Br J Surg* 2017;104(11): 1523–1531; doi: 10.1002/bjs.10582
548. Donatini G, Danion J, Zerrweck C, et al. single dose steroid injection after loss of signal (LOS) during thyroid surgery is effective to recover electric signal avoiding vocal cord palsy and the need of staged thyroidectomy: Prospective evaluation on 702 patients. *World J Surg* 2020;44(2):417–425; doi: 10.1007/s00268-019-05295-2
549. Wu CW, Dionigi G, Barczynski M, et al. International neuromonitoring study group guidelines 2018: Part II: Optimal recurrent laryngeal nerve management for invasive thyroid cancer-incorporation of surgical, laryngeal, and neural electrophysiologic data. *Laryngoscope* 2018; 128(Suppl 3):S18–Ss27; doi: 10.1002/lary.27360
550. Cernea CR, Ferraz AR, Nishio S, et al. Surgical anatomy of the external branch of the superior laryngeal nerve. *Head Neck* 1992;14(5):380–383; doi: 10.1002/hed.2880140507
551. Cernea CR, Ferraz AR, Furlani J, et al. Identification of the external branch of the superior laryngeal nerve during thyroidectomy. *Am J Surg* 1992;164(6):634–639; doi: 10.1016/s0002-9610(05)80723-8
552. Kim MR, Park YJ, Park BW, et al. Can voice pitch be preserved in patients after transoral endoscopic thyroidectomy vestibular approach? *J Clin Med* 2020;9(9):2777; doi: 10.3390/jcm9092777
553. Iwata AJ, Liddy W, Barczyński M, et al. Superior laryngeal nerve signal attenuation influences voice outcomes in thyroid surgery. *Laryngoscope* 2021;131(6):1436–1442; doi: 10.1002/lary.29413
554. Cheruiyot I, Kipkorir V, Henry BM, et al. Surgical anatomy of the external branch of the superior laryngeal nerve: A systematic review and meta-analysis. *Langenbecks Arch Surg* 2018;403(7):811–823; doi: 10.1007/s00423-018-1723-9
555. Masuoka H, Miyauchi A, Higashiyama T, et al. Prospective randomized study on injury of the external branch of the superior laryngeal nerve during thyroidectomy comparing intraoperative nerve monitoring and a conventional technique. *Head Neck* 2015;37(10):1456–1460; doi: 10.1002/hed.23778
556. Uludag M, Aygun N, Kartal K, et al. Is intraoperative neural monitoring necessary for exploration of the superior laryngeal nerve? *Surgery* 2017;161(4):1129–1138; doi: 10.1016/j.surg.2016.10.026
557. Yuan Q, Zheng L, Hou J, et al. Visual identification and neuromonitoring vs. no sighting the external branch of the superior laryngeal nerve in thyroid surgery: A randomized clinical trial. *Updates Surg* 2022;74(2): 727–734; doi: 10.1007/s13304-021-01138-9
558. Uludag M, Aygun N, Kartal K, et al. Contribution of intraoperative neural monitoring to preservation of the external branch of the superior laryngeal nerve: A randomized prospective clinical trial. *Langenbecks Arch Surg* 2017;402(6):965–976; doi: 10.1007/s00423-016-1544-7
559. Barczyński M, Konturek A, Stopa M, et al. Randomized controlled trial of visualization versus neuromonitoring of the external branch of the superior laryngeal nerve during thyroidectomy. *World J Surg* 2012;36(6): 1340–1347; doi: 10.1007/s00268-012-1547-7
560. Lee J, Fraser S, Glover A, et al. Prospective evaluation of the utility of routine neuromonitoring for an established thyroid surgical practice. *ANZ J Surg* 2017;87(10): E138–Ee142; doi: 10.1111/ans.13606
561. Gurleyik E, Gurleyik G. Intraoperative monitoring of external branch of the superior laryngeal nerve: Functional identification, motor integrity, and its role on vocal cord function. *J Invest Surg* 2018;31(6):509–514; doi: 10.1080/08941939.2017.1362489
562. Engelsman AF, Warhurst S, Fraser S, et al. Influence of neural monitoring during thyroid surgery on nerve integrity and postoperative vocal function. *BJS Open* 2018; 2(3):135–141; doi: 10.1002/bjs.50
563. Aygün N, Uludağ M, İsgör A. Contribution of intraoperative neuromonitoring to the identification of the external branch of superior laryngeal nerve. *Turk J Surg* 2017; 33(3):169–174; doi: 10.5152/turksurg.2017.3645
564. Aleksova L, Ali MM, Chakarov DI, et al. Identification of the external branch of the superior laryngeal nerve during thyroid surgery. *Folia Med (Plovdiv)* 2018;60(1): 154–157; doi: 10.1515/folmed-2017-0083
565. Hurtado-López LM, Díaz-Hernández PI, Basurto-Kuba E, et al. Efficacy of intraoperative neuro-monitoring to localize the external branch of the superior laryngeal nerve. *Thyroid* 2016;26(1):174–178; doi: 10.1089/thy.2015.0190
566. Del Rio P, Bonati E, Loderer T, et al. Can we routinely identify the external branch of the superior laryngeal nerves with neural monitoring? A prospective report on 176 consecutive nerves at risk. *Updates Surg* 2021;73(6): 2275–2281; doi: 10.1007/s13304-021-01084-6
567. Dedivitis RA, Aires FT, Cernea CR. Hypoparathyroidism after thyroidectomy: Prevention, assessment and management. *Curr Opin Otolaryngol Head Neck Surg* 2017;25(2):142–146; doi: 10.1097/moo.0000000000000346
568. Su A, Gong Y, Wei T, et al. A new classification of parathyroid glands to evaluate *in situ* preservation or autotransplantation during thyroid surgery. *Medicine (Baltimore)* 2018;97(48):e13231; doi: 10.1097/md.00000000000013231
569. Iorio O, Petrozza V, De Gori A, et al. Parathyroid autotransplantation during thyroid surgery. where we are? a systematic review on indications and results. *J Invest Surg* 2019;32(7):594–601; doi: 10.1080/08941939.2018.1441344
570. Wang B, Zhu CR, Liu H, et al. The effectiveness of parathyroid gland autotransplantation in preserving parathyroid function during thyroid surgery for thyroid neoplasms: A meta-analysis. *PLoS One* 2019;14(8): e0221173; doi: 10.1371/journal.pone.0221173
571. Abbaci M, De Leeuw F, Breuskin I, et al. Parathyroid gland management using optical technologies during thyroidectomy or parathyroidectomy: A systematic review. *Oral Oncol* 2018;87:186–196; doi: 10.1016/j.oraloncology.2018.11.011
572. Benmiloud F, Godiris-Petit G, Gras R, et al. Association of autofluorescence-based detection of the parathyroid glands during total thyroidectomy with postoperative hypocalcemia risk: Results of the PARAFUO multicenter randomized clinical trial. *JAMA Surg* 2020;155(2): 106–112; doi: 10.1001/jamasurg.2019.4613
573. Dip F, Falco J, Verna S, et al. Randomized controlled trial comparing white light with near-infrared

- autofluorescence for parathyroid gland identification during total thyroidectomy. *J Am Coll Surg* 2019;228(5):744–751; doi: 10.1016/j.jamcollsurg.2018.12.044
574. Barbieri D, Indelicato P, Vinciguerra A, et al. Autofluorescence and indocyanine green in thyroid surgery: A systematic review and meta-analysis. *Laryngoscope* 2021; 131(7):1683–1692; doi: 10.1002/lary.29297
575. Lu W, Chen Q, Zhang P, et al. Near-infrared autofluorescence imaging in thyroid surgery: A systematic review and meta-analysis. *J Invest Surg* 2022;35(9):1723–1732; doi: 10.1080/08941939.2022.2095468
576. Silver Karcioğlu AL, Triponez F, Solórzano CC, et al. Emerging imaging technologies for parathyroid gland identification and vascular assessment in thyroid surgery: A review from the American Head and Neck Society Endocrine Surgery section. *JAMA Otolaryngol Head Neck Surg* 2023;149(3):253–260; doi: 10.1001/jamaoto.2022.4421
577. Li Y, Jian WH, Guo ZM, et al. A meta-analysis of carbon nanoparticles for identifying lymph nodes and protecting parathyroid glands during surgery. *Otolaryngol Head Neck Surg* 2015;152(6):1007–1016; doi: 10.1177/0194599815580765
578. Wang L, Yang D, Lv JY, et al. Application of carbon nanoparticles in lymph node dissection and parathyroid protection during thyroid cancer surgeries: A systematic review and meta-analysis. *Onco Targets Ther* 2017;10:1247–1260; doi: 10.2147/ott.S131012
579. Xu S, Li Z, Xu M, et al. The role of carbon nanoparticle in lymph node detection and parathyroid gland protection during thyroidectomy for non-anaplastic thyroid carcinoma—a meta-analysis. *PLoS One* 2020;15(11):e0223627; doi: 10.1371/journal.pone.0223627
580. Orloff LA, Wiseman SM, Bernet VJ, et al. American thyroid association statement on postoperative hypoparathyroidism: Diagnosis, prevention, and management in adults. *Thyroid* 2018;28(7):830–841; doi: 10.1089/thy.2017.0309
581. Li Z, Fei Y, Li Z, et al. Outcome of parathyroid function after total thyroidectomy when calcium supplementation is administered routinely versus exclusively to symptomatic patients: A prospective randomized clinical trial. *Endocrine* 2022;75(2):583–592; doi: 10.1007/s12020-021-02921-9
582. Soh TCF, Ong QJ, Yip HM. Complications of neck drains in thyroidectomies: A systematic review and meta-analysis. *Laryngoscope* 2021;131(3):690–700; doi: 10.1002/lary.29077
583. Dhillon VK, Randolph GW, Stack BC, Jr, et al. Immediate and partial neural dysfunction after thyroid and parathyroid surgery: Need for recognition, laryngeal exam, and early treatment. *Head Neck* 2020;42(12):3779–3794; doi: 10.1002/hed.26472
584. Best AR, Shipchandler TZ, Cordes SR. Midcervical scar satisfaction in thyroidectomy patients. *Laryngoscope* 2017;127(5):1247–1252; doi: 10.1002/lary.26177
585. Kurumety SK, Helenowski IB, Goswami S, et al. Post-thyroidectomy neck appearance and impact on quality of life in thyroid cancer survivors. *Surgery* 2019;165(6):1217–1221; doi: 10.1016/j.surg.2019.03.006
586. Vardaxi C, Tsetsos N, Koliastasi A, et al. Swallowing disorders after thyroidectomy: A systematic review and meta-analysis. *Eur Arch Otorhinolaryngol* 2022;279(9):4213–4227; doi: 10.1007/s00405-022-07386-8
587. Lippi L, Turco A, Moalli S, et al. Role of prehabilitation and rehabilitation on functional recovery and quality of life in thyroid cancer patients: A comprehensive review. *Cancers (Basel)* 2023;15(18):4502; doi: 10.3390/cancers15184502
588. Carty SE, Doherty GM, Inabnet WB, III, et al; Surgical Affairs Committee Of The American Thyroid Association. American Thyroid Association statement on the essential elements of interdisciplinary communication of perioperative information for patients undergoing thyroid cancer surgery. *Thyroid* 2012;22(4):395–399; doi: 10.1089/thy.2011.0423
589. Meltzer CJ, Irish J, Angelos P, et al. American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. *Head Neck* 2019;41(4):843–856; doi: 10.1002/hed.25526
590. Chambers AJ, Pasieka JL, Temple WJ. Improvement in the accuracy of reporting key prognostic and anatomic findings during thyroidectomy by using a novel Web-based synoptic operative reporting system. *Surgery* 2009; 146(6):1090–1098; doi: 10.1016/j.surg.2009.09.032
591. Iyer NG, Nixon IJ, Palmer F, et al. Electronic synoptic operative reporting for thyroid surgery using an electronic data management system: Potential for prospective multicenter data collection. *Ann Surg Oncol* 2011;18(3):762–766; doi: 10.1245/s10434-010-1361-0
592. Dos Reis LL, Tuttle RM, Alon E, et al. What is the gold standard for comprehensive interinstitutional communication of perioperative information for thyroid cancer patients? A comparison of existing electronic health records with the current American Thyroid Association recommendations. *Thyroid* 2014;24(10):1466–1472; doi: 10.1089/thy.2014.0209
593. Moore MD, Postma E, Gray KD, et al. Less is more: The impact of multidisciplinary thyroid conference on the treatment of well-differentiated thyroid carcinoma. *World J Surg* 2018;42(2):343–349; doi: 10.1007/s00268-017-4308-9
594. Mete O, Asa SL, Baloch ZW, et al. Protocol for the Examination of Specimens From Patients With Carcinomas of the Thyroid Gland. March 2023. Available from: [https://documents.cap.org/documents/Thyroid\\_4.4.0.0.REL\\_CAPCP.pdf?\\_gl=1\\*b9gdkq\\*\\_ga\\*ODk0Mjc5Mzg5LjE3NDYwNDQyNTY\\*\\_ga\\_97ZFJSQQ0X\\*czE3NDg4Njc4MTIkbzYkZzEkdDE3NDg4Njc4NDgkajI0JGwwJGgw](https://documents.cap.org/documents/Thyroid_4.4.0.0.REL_CAPCP.pdf?_gl=1*b9gdkq*_ga*ODk0Mjc5Mzg5LjE3NDYwNDQyNTY*_ga_97ZFJSQQ0X*czE3NDg4Njc4MTIkbzYkZzEkdDE3NDg4Njc4NDgkajI0JGwwJGgw).
595. Shaha AR, Migliacci JC, Nixon IJ, et al. Stage migration with the new American Joint Committee on Cancer (AJCC) staging system (8th edition) for differentiated thyroid cancer. *Surgery* 2019;165(1):6–11; doi: 10.1016/j.surg.2018.04.078
596. Lechner MG, Bernardo AC, Lampe A, et al. Changes in stage distribution and disease-specific survival in differentiated thyroid cancer with transition to American Joint Committee on Cancer 8th edition: A systematic review and meta-analysis. *Oncologist* 2021;26(2):e251–e260; doi: 10.1634/theoncologist.2020-0306
597. Manzardo OA, Cellini M, Indirli R, et al. TNM 8th edition in thyroid cancer staging: Is there an improvement in predicting recurrence? *Endocr Relat Cancer* 2020;27(6):325–336; doi: 10.1530/ERC-19-0412
598. Gan T, Huang B, Chen Q, et al. Risk of recurrence in differentiated thyroid cancer: A population-based comparison of the 7th and 8th editions of the American Joint

- Committee on Cancer staging systems. *Ann Surg Oncol* 2019;26(9):2703–2710; doi: 10.1245/s10434-019-07275-1
599. Chereau N, Dautier E, Godiris-Petit G, et al. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population. *Langenbecks Arch Surg* 2018; 403(3):325–332; doi: 10.1007/s00423-018-1657-2
  600. Carvalho AY, Kohler HF, Gomes CC, et al. Predictive factors of recurrence of papillary thyroid microcarcinomas: Analysis of 2,538 patients. *Int Arch Otorhinolaryngol* 2021;25(4):e585–e593; doi: 10.1055/s-0040-1722253
  601. Ywata de Carvalho A, Kohler HF, Gomes CC, et al. Predictive factors for recurrence of papillary thyroid carcinoma: Analysis of 4,085 patients. *Acta Otorhinolaryngol Ital* 2021; 41(3):236–242; doi: 10.14639/0392-100X-N1412
  602. van Velsen EFS, Stegenga MT, van Kemenade FJ, et al. Evaluating the 2015 American Thyroid Association risk stratification system in high-risk papillary and follicular thyroid cancer patients. *Thyroid* 2019;29(8):1073–1079; doi: 10.1089/thy.2019.0053
  603. Qu N, Zhang L, Wu WL, et al. Bilaterality weighs more than unilateral multifocality in predicting prognosis in papillary thyroid cancer. *Tumour Biol* 2016;37(7): 8783–8789; doi: 10.1007/s13277-015-4533-5
  604. Genpeng L, Jianyong L, Jiaying Y, et al. Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer. *Medicine (Baltimore)* 2018;97(5):e9619; doi: 10.1097/MD.00000000000009619
  605. Woo J, Kim H, Kwon H. Impact of multifocality on the recurrence of papillary thyroid carcinoma. *J Clin Med* 2021;10(21):5144; doi: 10.3390/jcm10215144
  606. Kim H, Kwon H, Moon BI. Association of multifocality with prognosis of papillary thyroid carcinoma: A systematic review and meta-analysis. *JAMA Otolaryngol Head Neck Surg* 2021;147(10):847–854; doi: 10.1001/jamaoto.2021.1976
  607. Zhang T, He L, Wang Z, et al. The differences between multifocal and unifocal papillary thyroid carcinoma in unilateral lobe: A meta-analysis. *Front Oncol* 2021;11: 657237; doi: 10.3389/fonc.2021.657237
  608. Cui L, Feng D, Zhu C, et al. Clinical outcomes of multifocal papillary thyroid cancer: A systematic review and meta-analysis. *Laryngoscope Invest Otolaryngol* 2022; 7(4):1224–1234; doi: 10.1002/lio2.824
  609. Loveday C, Josephs K, Chubb D, et al. p.Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer. *J Clin Endocrinol Metab* 2018;103(11):4275–4282; doi: 10.1210/jc.2017-02529
  610. Mete O, Asa SL. Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. *Mod Pathol* 2011;24(12): 1545–1552; doi: 10.1038/modpathol.2011.119
  611. Wagner K, Abraham E, Tran B, et al. Lymphovascular invasion and risk of recurrence in papillary thyroid carcinoma. *ANZ J Surg* 2020;90(9):1727–1732; doi: 10.1111/ans.16202
  612. O'Neill CJ, Vaughan L, Learoyd DL, et al. Management of follicular thyroid carcinoma should be individualised based on degree of capsular and vascular invasion. *Eur J Surg Oncol* 2011;37(2):181–185; doi: 10.1016/j.ejso.2010.11.005
  613. Huang CC, Hsueh C, Liu FH, et al. Diagnostic and therapeutic strategies for minimally and widely invasive follicular thyroid carcinomas. *Surg Oncol* 2011;20(1):1–6; doi: 10.1016/j.suronc.2009.06.006
  614. Collini P, Sampietro G, Pilotti S. Extensive vascular invasion is a marker of risk of relapse in encapsulated non-Hurthle cell follicular carcinoma of the thyroid gland: A clinicopathological study of 18 consecutive cases from a single institution with a 11-year median follow-up. *Histopathology* 2004;44(1):35–39.
  615. Sugino K, Ito K, Nagahama M, et al. Prognosis and prognostic factors for distant metastases and tumor mortality in follicular thyroid carcinoma. *Thyroid* 2011;21(7): 751–757; doi: 10.1089/thy.2010.0353
  616. Falvo L, Catania A, D'Andrea V, et al. Prognostic importance of histologic vascular invasion in papillary thyroid carcinoma. *Ann Surg* 2005;241(4):640–646.
  617. Gardner RE, Tuttle RM, Burman KD, et al. Prognostic importance of vascular invasion in papillary thyroid carcinoma. *Arch Otolaryngol Head Neck Surg* 2000;126(3): 309–312.
  618. Nishida T, Katayama S, Tsujimoto M. The clinicopathological significance of histologic vascular invasion in differentiated thyroid carcinoma. *Am J Surg* 2002;183(1): 80–86; doi: 10.1016/s0002-9610(01)00843-1
  619. Vuong HG, Kondo T, Duong UNP, et al. Prognostic impact of vascular invasion in differentiated thyroid carcinoma: A systematic review and meta-analysis. *Eur J Endocrinol* 2017;177(2):207–216; doi: 10.1530/EJE-17-0260
  620. Yamazaki H, Sugino K, Katoh R, et al. Role of the degree of vascular invasion in predicting prognosis of follicular thyroid carcinoma. *J Clin Endocrinol Metab* 2024;109(5): 1291–1300; doi: 10.1210/clinem/dgad689
  621. Kim WG, Kim TY, Kim TH, et al. Follicular and Hurthle cell carcinoma of the thyroid in iodine-sufficient area: Retrospective analysis of Korean multicenter data. *Korean J Intern Med* 2014;29(3):325–333; doi: 10.3904/kjim.2014.29.3.325
  622. Ito Y, Hirokawa M, Masuoka H, et al. Prognostic factors for follicular thyroid carcinoma: The importance of vascular invasion. *Endocr J* 2022;69(9):1149–1156; doi: 10.1507/endocrj.EJ22-0077
  623. Chindris AM, Casler JD, Bernet VJ, et al. Clinical and molecular features of Hurthle cell carcinoma of the thyroid. *J Clin Endocrinol Metab* 2015;100(1):55–62; doi: 10.1210/jc.2014-1634
  624. Ghossein RA, Hiltzik DH, Carlson DL, et al. Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: A clinicopathologic study of 50 cases. *Cancer* 2006;106(8):1669–1676; doi: 10.1002/cncr.21825
  625. Jin M, Kim ES, Kim BH, et al. Clinicopathological characteristics and disease-free survival in patients with Hurthle cell carcinoma: A multicenter cohort study in South Korea. *Endocrinol Metab (Seoul)* 2021;36(5): 1078–1085; doi: 10.3803/EnM.2021.1151
  626. Stojadinovic A, Hoos A, Ghossein RA, et al. Hurthle cell carcinoma: A 60-year experience. *Ann Surg Oncol* 2002; 9(2):197–203; doi: 10.1007/bf02557374
  627. Wenter V, Albert NL, Unterrainer M, et al. Clinical impact of follicular oncocytic (Hurthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma. *Eur J Nucl Med Mol Imaging* 2021; 48(2):449–460; doi: 10.1007/s00259-020-04952-2

628. Bishop JA, Wu G, Tufano RP, et al. Histological patterns of locoregional recurrence in Hurthle cell carcinoma of the thyroid gland. *Thyroid* 2012;22(7):690–694; doi: 10.1089/thy.2011.0407
629. Randolph GW, Duh QY, Heller KS, et al; American Thyroid Association Surgical Affairs Committee's Taskforce on Thyroid Cancer Nodal Surgery. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. *Thyroid* 2012;22(11):1144–1152; doi: 10.1089/thy.2012.0043
630. Xue S, Zhang L, Wang P, et al. Predictive factors of recurrence for multifocal papillary thyroid microcarcinoma with Braf(v600e) mutation: A single center study of 1,207 Chinese patients. *Front Endocrinol (Lausanne)* 2019;10:407; doi: 10.3389/fendo.2019.00407
631. Bardet S, Ciappuccini R, Quak E, et al. Prognostic value of microscopic lymph node involvement in patients with papillary thyroid cancer. *J Clin Endocrinol Metab* 2015;100(1):132–140; doi: 10.1210/jc.2014-1199
632. Park YM, Wang SG, Lee JC, et al. Metastatic lymph node status in the central compartment of papillary thyroid carcinoma: A prognostic factor of locoregional recurrence. *Head Neck* 2016;38(Suppl 1):E1172–E6; doi: 10.1002/hed.24186
633. Adam MA, Pura J, Goffredo P, et al. Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. *J Clin Oncol* 2015;33(21):2370–2375; doi: 10.1200/JCO.2014.59.8391
634. Schneider DF, Mazeh H, Chen H, et al. Lymph node ratio predicts recurrence in papillary thyroid cancer. *Oncologist* 2013;18(2):157–162; doi: 10.1634/theoncologist.2012-0240
635. Haglund F, Garvin S, Ihre-Lundgren C, et al. Detailed lymph node sectioning of papillary thyroid carcinoma specimen increases the number of pN1a patients. *Endocr Pathol* 2016;27(4):346–351; doi: 10.1007/s12022-016-9438-3
636. Chereau N, Buffet C, Tresallet C, et al. Recurrence of papillary thyroid carcinoma with lateral cervical node metastases: Predictive factors and operative management. *Surgery* 2016;159(3):755–762; doi: 10.1016/j.surg.2015.08.033
637. Wu MH, Shen WT, Gosnell J, et al. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer. *Head Neck* 2015;37(9):1336–1343; doi: 10.1002/hed.23747
638. Edge SB, Byrd DR, Compton CC, et al. *Thyroid Cancer Staging*. In: *AJCC Cancer Staging Manual*. Springer-Verlag: New York; 2010; pp. 59–64.
639. Su HK, Wenig BM, Haser GC, et al. Inter-observer variation in the pathologic identification of minimal extrathyroidal extension in papillary thyroid carcinoma. *Thyroid* 2016;26(4):512–517; doi: 10.1089/thy.2015.0508
640. Li G, Li R, Song L, et al. Implications of extrathyroidal extension invading only the strap muscles in papillary thyroid carcinomas. *Thyroid* 2020;30(1):57–64; doi: 10.1089/thy.2018.0801
641. Seifert R, Schafers MA, Heitplatz B, et al. Minimal extrathyroid extension in papillary micro carcinoma of the thyroid is an independent risk factor for relapse through lymph node and distant metastases. *J Nucl Med* 2021;62(12):1702–1709; doi: 10.2967/jnumed.121.261898
642. Diker-Cohen T, Hirsch D, Shimon I, et al. Impact of minimal extra-thyroid extension in differentiated thyroid cancer: Systematic review and meta-analysis. *J Clin Endocrinol Metab* 2018; doi: 10.1210/jc.2018-00081
643. Kluijfhout WP, Pasternak JD, Kwon JS, et al. Microscopic positive tumor margin does not increase the risk of recurrence in patients with T1-T2 well-differentiated thyroid cancer. *Ann Surg Oncol* 2016;23(5):1446–1451; doi: 10.1245/s10434-015-4998-x
644. Lee CI, Kutlu O, Khan ZF, et al. Margin positivity and survival in papillary thyroid microcarcinoma: A national cancer database analysis. *J Am Coll Surg* 2021;233(4):537–544; doi: 10.1016/j.jamcollsurg.2021.06.011
645. Khan ZF, Kutlu O, Picado O, et al. Margin positivity and survival outcomes: A review of 14,471 patients with 1-cm to 4-cm papillary thyroid carcinoma. *J Am Coll Surg* 2021;232(4):545–550; doi: 10.1016/j.jamcollsurg.2020.12.018
646. Mercado CE, Drew PA, Morris CG, et al. Positive surgical margins in favorable-stage differentiated thyroid cancer. *Am J Clin Oncol* 2018;41(12):1168–1171; doi: 10.1097/COC.0000000000000444
647. Henke LE, Pfeifer JD, Baranski TJ, et al. Long-term outcomes of follicular variant vs classic papillary thyroid carcinoma. *Endocr Connect* 2018;7(12):1226–1235; doi: 10.1530/EC-18-0264
648. Tunca F, Sormaz IC, Iscan Y, et al. Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma. *J Endocrinol Invest* 2015;38(12):1327–1334; doi: 10.1007/s40618-015-0376-6
649. Trimboli P, Piccardo A, Signore A, et al. Patient age is an independent risk factor of relapse of differentiated thyroid carcinoma and improves the performance of the American thyroid association stratification system. *Thyroid* 2020;30(5):713–719; doi: 10.1089/thy.2019.0688
650. van Velsen EFS, Peeters RP, Stegenga MT, et al. The influence of age on disease outcome in 2015 ATA high-risk differentiated thyroid cancer patients. *Eur J Endocrinol* 2021;185(3):421–429; doi: 10.1530/eje-21-0365
651. Zuhur SS, Aggul H, Çelik M, et al. Can age at diagnosis and sex improve the performance of the American Thyroid Association risk stratification system for prediction of structural persistent and recurrent disease in patients with differentiated thyroid carcinoma? A multicenter study. *Endocr Pract* 2022;28(1):30–35; doi: 10.1016/j.eprac.2021.09.001
652. Shah S, Boucai L. Effect of age on response to therapy and mortality in patients with thyroid cancer at high risk of recurrence. *J Clin Endocrinol Metab* 2018;103(2):689–697; doi: 10.1210/jc.2017-02255
653. Alzahrani AS, Mukhtar N. Incomplete response to therapy in intermediate- and high-risk thyroid cancer. *Endocrine* 2022;78(3):531–542; doi: 10.1007/s12020-022-03187-5
654. Grani G, Gentili M, Siciliano F, et al. A data-driven approach to refine predictions of differentiated thyroid cancer outcomes: A prospective multicenter study. *J Clin Endocrinol Metab* 2023;108(8):1921–1928; doi: 10.1210/clinem/dgad075
655. Pitoia F, Jerkovich F, Smulever A, et al. Should age at diagnosis be included as an additional variable in the risk

- of recurrence classification system in patients with differentiated thyroid cancer. *Eur Thyroid J* 2017;6(3): 160–166; doi: 10.1159/000453450
656. Banerjee M, Reyes-Gastelum D, Haymart MR. Treatment-free survival in patients with differentiated thyroid cancer. *J Clin Endocrinol Metab* 2018;103(7):2720–2727; doi: 10.1210/je.2018-00511
657. Chen B, Shi Y, Xu Y, et al. The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis. *Clin Endocrinol (Oxf)* 2021;94(5):731–742; doi: 10.1111/cen.14316
658. Moon S, Song YS, Kim YA, et al. Effects of Coexistent BRAF(V600E) and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: A meta-analysis. *Thyroid* 2017;27(5):651–660; doi: 10.1089/thy.2016.0350
659. Vuong HG, Altibi AMA, Duong UNP, et al. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—A meta-analysis. *Clin Endocrinol (Oxf)* 2017;87(5):411–417; doi: 10.1111/cen.13413
660. Liu R, Zhu G, Tan J, et al. Genetic trio of BRAF and TERT alterations and rs2853669TT in papillary thyroid cancer aggressiveness. *J Natl Cancer Inst* 2024;116(5): 694–701; doi: 10.1093/jnci/djad265
661. Song YS, Lim JA, Min HS, et al. Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer. *Eur J Endocrinol* 2017;177(6): 465–473; doi: 10.1530/EJE-17-0456
662. Shen X, Liu R, Xing M. A six-genotype genetic prognostic model for papillary thyroid cancer. *Endocr Relat Cancer* 2017;24(1):41–52; doi: 10.1530/ERC-16-0402
663. Krishnamoorthy GP, Davidson NR, Leach SD, et al. EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC. *Cancer Discov* 2019;9(2):264–281; doi: 10.1158/2159-8290.CD-18-0606
664. Simoes-Pereira J, Moura MM, Marques IJ, et al. The role of EIF1AX in thyroid cancer tumorigenesis and progression. *J Endocrinol Invest* 2019;42(3):313–318; doi: 10.1007/s40618-018-0919-8
665. Landa I, Ibrahimasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. *J Clin Invest* 2016;126(3): 1052–1066; doi: 10.1172/JCI85271
666. Bandargal S, Chen T, Pusztaszeri MP, et al. Prognostic indicators of EIF1AX-mutated thyroid tumor malignancy and cancer aggressiveness. *Cancers (Basel)* 2022;14(24): 6097; doi: 10.3390/cancers14246097
667. Xu GJ, Loberg MA, Gallant JN, et al. Molecular signature incorporating the immune microenvironment enhances thyroid cancer outcome prediction. *Cell Genom* 2023;3(10):100409; doi: 10.1016/j.xgen.2023.100409
668. Chung JH. BRAF and TERT promoter mutations: Clinical application in thyroid cancer. *Endocr J* 2020;67(6): 577–584; doi: 10.1507/endocrj.EJ20-0063
669. Agarwal S, Gupta S, Raj R. Identification of potential targetable genes in papillary, follicular, and anaplastic thyroid carcinoma using bioinformatics analysis. *Endocrine* 2024;86(1):255–267; doi: 10.1007/s12020-024-03836-x
670. Romei C, Elisei R. A narrative review of genetic alterations in primary thyroid epithelial cancer. *Int J Mol Sci* 2021;22(4):1726; doi: 10.3390/ijms22041726
671. Alzumaili BA, Fisch AS, Faquin WC, et al. Detection of RAS p.Q61R by immunohistochemistry in practice: A clinicopathologic study of 217 thyroid nodules with molecular correlates. *Endocr Pathol* 2024;35(3):219–229; doi: 10.1007/s12022-024-09821-4
672. Yip L, Nikiforova MN, Yoo JY, et al. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: A study of 1510 patients. *Ann Surg* 2015; 262(3):519–525; discussion 524-5; doi: 10.1097/SLA.0000000000001420
673. Legrand MA, Raverot G, Nicolino M, et al. GNAS mutated thyroid carcinoma in a patient with Mc Cune Albright syndrome. *Bone Rep* 2020;13:100299; doi: 10.1016/j.bonr.2020.100299
674. Yoo SK, Lee S, Kim SJ, et al. Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers. *PLoS Genet* 2016;12(8): e1006239; doi: 10.1371/journal.pgen.1006239
675. Kim K, Jeon S, Kim TM, et al. Immune gene signature delineates a subclass of papillary thyroid cancer with unfavorable clinical outcomes. *Cancers (Basel)* 2018; 10(12):494; doi: 10.3390/cancers10120494
676. Jung SH, Kim MS, Jung CK, et al. Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma. *Oncotarget* 2016;7(43):69638–69648; doi: 10.18632/oncotarget.11922
677. Jeong SH, Hong HS, Lee EH, et al. Analysis of RAS mutation in thyroid nodular hyperplasia and follicular neoplasm in a Korean population. *Endocrinol Diabetes Metab* 2018;1(4):e00040; doi: 10.1002/edm2.40
678. Landa I. Re: “Risk stratification using a novel genetic classifier including PLEKHS1 Promoter mutations for differentiated thyroid cancer with distant metastasis” by Jung et al. *Thyroid* 2021;31(4):703–704; doi: 10.1089/thy.2020.0728
679. Jung CK, Jung SH, Jeon S, et al. Risk stratification using a novel genetic classifier including PLEKHS1 promoter mutations for differentiated thyroid cancer with distant metastasis. *Thyroid* 2020;30(11):1589–1600; doi: 10.1089/thy.2019.0459
680. Kelly LM, Barila G, Liu P, et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. *Proc Natl Acad Sci U S A* 2014;111(11):4233–4238; doi: 10.1073/pnas.1321937111
681. Panebianco F, Nikitski AV, Nikiforova MN, et al. Characterization of thyroid cancer driven by known and novel ALK fusions. *Endocr Relat Cancer* 2019;26(11):803–814; doi: 10.1530/erc-19-0325
682. Arndt A, Steinestel K, Rump A, et al. Anaplastic lymphoma kinase (ALK) gene rearrangements in radiation-related human papillary thyroid carcinoma after the Chernobyl accident. *J Pathol Clin Res* 2018;4(3):175–183; doi: 10.1002/cjp2.102
683. Latteyer S, Tiedje V, König K, et al. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer. *Endocrine* 2016;54(3):733–741; doi: 10.1007/s12020-016-1080-9
684. Weiss LM, Funari VA. NTRK fusions and Trk proteins: What are they and how to test for them. *Hum Pathol* 2021;112:59–69; doi: 10.1016/j.humpath.2021.03.007

685. Lee YC, Chen JY, Huang CJ, et al. Detection of NTRK1/3 rearrangements in papillary thyroid carcinoma using immunohistochemistry, fluorescent *in situ* hybridization, and next-generation sequencing. *Endocr Pathol* 2020;31(4):348–358; doi: 10.1007/s12022-020-09648-9
686. Chu YH, Dias-Santagata D, Farahani AA, et al. Clinico-pathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC). *Mod Pathol* 2020; 33(11):2186–2197; doi: 10.1038/s41379-020-0574-4
687. Seethala RR, Chiosea SI, Liu CZ, et al. Clinical and morphologic features of ETV6-NTRK3 translocated papillary thyroid carcinoma in an adult population without radiation exposure. *Am J Surg Pathol* 2017;41(4):446–457; doi: 10.1097/PAS.0000000000000814
688. Bae JS, Jung SH, Hirokawa M, et al. High prevalence of DICER1 mutations and low frequency of gene fusions in pediatric follicular-patterned tumors of the thyroid. *Endocr Pathol* 2021;32(3):336–346; doi: 10.1007/s12022-021-09688-9
689. de Kock L, Bah I, Revil T, et al. Deep sequencing reveals spatially distributed distinct hot spot mutations in DICER1-related multinodular goiter. *J Clin Endocrinol Metab* 2016; 101(10):3637–3645; doi: 10.1210/jc.2016-1328
690. Juhlin CC, Stenman A, Zedenius J. Macrofollicular variant follicular thyroid tumors are DICER1 mutated and exhibit distinct histological features. *Histopathology* 2021;79(4):661–666; doi: 10.1111/his.14416
691. Ghossein CA, Dogan S, Farhat N, et al. Expanding the spectrum of thyroid carcinoma with somatic DICER1 mutation: A survey of 829 thyroid carcinomas using MSK-IMPACT next-generation sequencing platform. *Virchows Arch* 2022;480(2):293–302; doi: 10.1007/s00428-021-03212-4
692. Beg S, Siraj AK, Jehan Z, et al. PTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinoma. *Br J Cancer* 2015;112(12):1938–1943; doi: 10.1038/bjc.2015.169
693. Karunamurthy A, Panebianco F, S JH, et al. Prevalence and phenotypic correlations of EIF1AX mutations in thyroid nodules. *Endocr Relat Cancer* 2016;23(4):295–301; doi: 10.1530/ERC-16-0043
694. Alzahrani AS, Murugan AK, Qasem E, et al. Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer. *Endocrine* 2019;63(1):94–100; doi: 10.1007/s12020-018-1762-6
695. Whaley RD, Gupta S, Manninen MC, et al. Clinicopathologic and molecular analysis of 15 pediatric and young adult patients with high-grade non-anaplastic thyroid carcinoma. *Endocr Pathol* 2024;35(4):397–410; doi: 10.1007/s12022-024-09842-z
696. Zhao Y. A novel mutation in PTEN in anaplastic thyroid carcinoma: A case report. *Biomed Rep* 2024;21(2):127; doi: 10.3892/br.2024.1815
697. Jitpasutham T, Andrianus S, Gubbiotti M, et al. Thyroid nodules with DICER1 mutation or PTEN alteration: A comparative cytologic, clinical, and molecular study of 117 FNA cases. *Cancer Cytopathol* 2024;132(6):370–385; doi: 10.1002/cncy.22811
698. Belaiche A, Morand GB, Turkdogan S, et al. Molecular markers in follicular and oncocytic thyroid carcinomas: Clinical application of molecular genetic testing. *Curr Oncol* 2024;31(10):5919–5928; doi: 10.3390/currenco131100441
699. Wong KS. Unraveling Hurthle cell lesions of the thyroid using molecular findings. *Cancer Cytopathol* 2022; 130(6):405–406; doi: 10.1002/cncy.22567
700. Sasanakietkul T, Murtha TD, Javid M, et al. Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer. *Mol Cell Endocrinol* 2018;469:23–37; doi: 10.1016/j.mce.2017.05.022
701. Celano M, Rosignolo F, Maggisano V, et al. MicroRNAs as biomarkers in thyroid carcinoma. *Int J Genomics* 2017;2017:6496570; doi: 10.1155/2017/6496570
702. Park JL, Kim SK, Jeon S, et al. MicroRNA profile for diagnostic and prognostic biomarkers in thyroid cancer. *Cancers (Basel)* 2021;13(4):632; doi: 10.3390/cancers13040632
703. Maximo V, Melo M, Zhu Y, et al. Genomic profiling of primary and metastatic thyroid cancers. *Endocr Relat Cancer* 2024;31(2):e230144; doi: 10.1530/ERC-23-0144
704. Nilubol N, Zhang L, Kebebew E. Multivariate analysis of the relationship between male sex, disease-specific survival, and features of tumor aggressiveness in thyroid cancer of follicular cell origin. *Thyroid* 2013;23(6): 695–702; doi: 10.1089/thy.2012.0269
705. Park J, Kim K, Lim DJ, et al. Male sex is not an independent risk factor for recurrence of differentiated thyroid cancer: A propensity score-matching study. *Sci Rep* 2021;11(1):14908; doi: 10.1038/s41598-021-94461-5
706. O'Neill RJ, Abd Elwahab S, Kerin MJ, et al. Association of BMI with clinicopathological features of papillary thyroid cancer: A systematic review and meta-analysis. *World J Surg* 2021;45(9):2805–2815; doi: 10.1007/s00268-021-06193-2
707. Economides A, Giannakou K, Mamais I, et al. Association between aggressive clinicopathologic features of papillary thyroid carcinoma and body mass index: A systematic review and meta-analysis. *Front Endocrinol (Lausanne)* 2021;12:692879; doi: 10.3389/fendo.2021.692879
708. Kitahara CM, Pfeiffer RM, Sosa JA, et al. Impact of overweight and obesity on US papillary thyroid cancer incidence trends (1995–2015). *J Natl Cancer Inst* 2020; 112(8):810–817; doi: 10.1093/jnci/djz202
709. Greca A, Grau L, Arbet J, et al. Anthropometric, dietary, and lifestyle factors and risk of advanced thyroid cancer: The NIH-AARP diet and health cohort study. *Clin Endocrinol (Oxf)* 2023;99(6):586–597; doi: 10.1111/cen.14970
710. Tuttle RM, Leboeuf R. Follow up approaches in thyroid cancer: A risk adapted paradigm. *Endocrinol Metab Clin North Am* 2008;37(2):419–435; doi: 10.1016/j.ecl.2008.02.008
711. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: A European perspective. *Eur J Endocrinol* 2004;150(2): 105–112.
712. Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: Using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. *Thyroid* 2010;20(12):1341–1349; doi: 10.1089/thy.2010.0178
713. Vaisman F, Momesso D, Bulzico DA, et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. *Clin Endocrinol (Oxf)* 2012;77(1):132–138; doi: 10.1111/j.1365-2265.2012.04342.x

714. Berger F, Friedrich U, Knesewitsch P, et al. Diagnostic <sup>131</sup>I whole-body scintigraphy 1 year after thyroablative therapy in patients with differentiated thyroid cancer: Correlation of results to the individual risk profile and long-term follow-up. *Eur J Nucl Med Mol Imaging* 2011; 38(3):451–458; doi: 10.1007/s00259-010-1657-0
715. Malandrino P, Latina A, Marescalco S, et al. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. *J Clin Endocrinol Metab* 2011;96(6):1703–1709; doi: 10.1210/jc.2010-2695
716. Soyuluk O, Boztepe H, Aral F, et al. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment. *Thyroid* 2011;21(12):1301–1308; doi: 10.1089/thy.2011.0122
717. Piccardo A, Arecco F, Morbelli S, et al. Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levothyroxine suppressive treatment in low-risk differentiated thyroid cancer. *J Endocrinol Invest* 2010;33(2):83–87.
718. Castagna MG, Brilli L, Pilli T, et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. *J Clin Endocrinol Metab* 2008;93(1):76–81; doi: 10.1210/jc.2007-1404
719. Kloos RT. Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values. *J Clin Endocrinol Metab* 2010; 95(12):5241–5248; doi: 10.1210/jc.2010-1500
720. Han JM, Kim WB, Yim JH, et al. Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment. *Thyroid* 2012;22(8):784–790; doi: 10.1089/thy.2011.0322
721. Rosario PW, Furtado MS, Mineiro Filho AF, et al. Value of repeat stimulated thyroglobulin testing in patients with differentiated thyroid carcinoma considered to be free of disease in the first year after ablation. *Thyroid* 2012; 22(5):482–486; doi: 10.1089/thy.2011.0214
722. Brassard M, Borget I, Edet-Sanson A, et al; THYRDIAG Working Group. Long-term follow-up of patients with papillary and follicular thyroid cancer: A prospective study on 715 patients. *J Clin Endocrinol Metab* 2011; 96(5):1352–1359; doi: 10.1210/jc.2010-2708
723. Pelttari H, Valimaki MJ, Loyttyniemi E, et al. Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: A 16-year follow-up study. *Eur J Endocrinol* 2010; 163(5):757–763; doi: 10.1530/EJE-10-0553
724. Klubo-Gwiedzinska J, Burman KD, Van Nostrand D, et al. Does an undetectable rhTSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission? *Clin Endocrinol (Oxf)* 2011;74(1):111–117; doi: 10.1111/j.1365-2265.2010.03898.x
725. Crocetti U, Durante C, Attard M, et al. Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients. *Thyroid* 2008;18(10):1049–1053; doi: 10.1089/thy.2008.0160
726. Torlontano M, Attard M, Crocetti U, et al. Follow-up of low risk patients with papillary thyroid cancer: Role of neck ultrasonography in detecting lymph node metastases. *J Clin Endocrinol Metab* 2004;89(7):3402–3407; doi: 10.1210/jc.2003-031521
727. Verburg FA, Stokkel MP, Duren C, et al. No survival difference after successful (<sup>131</sup>I) ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging* 2010;37(2):276–283; doi: 10.1007/s00259-009-1315-6
728. Giovanella L, Maffioli M, Ceriani L, et al. Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma. *Clin Chem Lab Med* 2009;47(8):1001–1004; doi: 10.1515/CCLM.2009.216
729. Castagna MG, Maino F, Cipri C, et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. *Eur J Endocrinol* 2011;165(3):441–446; doi: 10.1530/EJE-11-0466
730. Vaisman F, Saha A, Fish S, et al. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. *Clin Endocrinol (Oxf)* 2011;75(1):112–119; doi: 10.1111/j.1365-2265.2011.04002.x
731. Barres B, Kelly A, Kwiatkowski F, et al. Stimulated thyroglobulin and thyroglobulin reduction index predict excellent response in differentiated thyroid cancers. *J Clin Endocrinol Metab* 2019;104(8):3462–3472; doi: 10.1210/jc.2018-02680
732. Momesso DP, Vaisman F, Yang SP, et al. Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine. *J Clin Endocrinol Metab* 2016;101(7):2692–2700; doi: 10.1210/jc.2015-4290
733. Kelly A, Barres B, Kwiatkowski F, et al. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients. *PLoS One* 2019;14(8):e0221298; doi: 10.1371/journal.pone.0221298
734. Park S, Jeon MJ, Oh HS, et al. Changes in serum thyroglobulin levels after lobectomy in patients with low-risk papillary thyroid cancer. *Thyroid* 2018;28(8):997–1003; doi: 10.1089/thy.2018.0046
735. Ritter A, Mizrachi A, Bachar G, et al. Detecting recurrence following lobectomy for thyroid cancer: Role of thyroglobulin and thyroglobulin antibodies. *J Clin Endocrinol Metab* 2020;105(6):dgaa152; doi: 10.1210/clinem/dgaa152
736. Lee YJ, Kim DW, Shin GW, et al. Appropriate frequency and interval of neck ultrasonography surveillance during the first 10 years after total thyroidectomy in patients with papillary thyroid carcinoma. *Front Endocrinol (Lausanne)* 2018;9:79; doi: 10.3389/fendo.2018.00079
737. Torlontano M, Crocetti U, Augello G, et al. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, <sup>131</sup>I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. *J Clin Endocrinol Metab* 2006; 91(1):60–63; doi: 10.1210/jc.2005-1185

738. Zhao H, Li H. Meta-analysis of ultrasound for cervical lymph nodes in papillary thyroid cancer: Diagnosis of central and lateral compartment nodal metastases. *Eur J Radiol* 2019;112:14–21; doi: 10.1016/j.ejrad.2019.01.006
739. Rondeau G, Fish S, Hann LE, et al. Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. *Thyroid* 2011;21(8):845–853; doi: 10.1089/thy.2011.0011
740. Shin JH, Han BK, Ko EY, et al. Sonographic findings in the surgical bed after thyroidectomy: Comparison of recurrent tumors and nonrecurrent lesions. *J Ultrasound Med* 2007;26(10):1359–1366.
741. Frates MC, Parziale MP, Alexander EK, et al. Role of sonographic characteristics of thyroid bed lesions identified following thyroidectomy in the diagnosis or exclusion of recurrent cancer. *Radiology* 2021;299(2):374–380; doi: 10.1148/radiol.2021201596
742. Oltmann SC, Schneider DF, Chen H, et al. All thyroid ultrasound evaluations are not equal: Sonographers specialized in thyroid cancer correctly label clinical N0 disease in well differentiated thyroid cancer. *Ann Surg Oncol* 2015;22(2):422–428; doi: 10.1245/s10434-014-4089-4
743. Yang SP, Bach AM, Tuttle RM, et al. Serial neck ultrasound is more likely to identify false-positive abnormalities than clinically significant disease in low-risk papillary thyroid cancer patients. *Endocr Pract* 2015;21(12):1372–1379; doi: 10.4158/ep15851.Or
744. Nordell F, Hallal G, Asp P, et al. Optimization of follow-up in patients with papillary thyroid cancer who show no evidence of disease 9–12 months after treatment. *BJS Open* 2021;5(6):zrab119; doi: 10.1093/bjsopen/zrab119
745. Leboulleux S, Schroeder PR, Schlumberger M, et al. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. *Nat Clin Pract Endocrinol Metab* 2007;3(2):112–121; doi: 10.1038/hcpndmet0402
746. Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. *J Clin Endocrinol Metab* 2005;90(10):5723–5729; doi: 10.1210/jc.2005-0285
747. Bardet S, Malville E, Rame JP, et al. Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. *Eur J Endocrinol* 2008;158(4):551–560; doi: 10.1530/EJE-07-0603
748. Mansour J, Sagiv D, Alon E, et al. Prognostic value of lymph node ratio in metastatic papillary thyroid carcinoma. *J Laryngol Otol* 2018;132(1):8–13; doi: 10.1017/s0022215117002250
749. Seok J, Ryu CH, Park SY, et al. Factors affecting central node metastasis and metastatic lymph node ratio in papillary thyroid cancer. *Otolaryngol Head Neck Surg* 2021;165(4):519–527; doi: 10.1177/0194599821991465
750. Bachelot A, Cailleux AF, Klain M, et al. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. *Thyroid* 2002;12(8):707–711; doi: 10.1089/105072502760258686
751. Spencer C, Fatemi S, Singer P, et al. Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. *Thyroid* 2010;20(6):587–595; doi: 10.1089/thy.2009.0338
752. Torres MR, Nobrega Neto SH, Rosas RJ, et al. Thyroglobulin in the washout fluid of lymph-node biopsy: What is its role in the follow-up of differentiated thyroid carcinoma? *Thyroid* 2014;24(1):7–18; doi: 10.1089/thy.2013.0244
753. Frasoldati A, Toschi E, Zini M, et al. Role of thyroglobulin measurement in fine-needle aspiration biopsies of cervical lymph nodes in patients with differentiated thyroid cancer. *Thyroid* 1999;9(2):105–111.
754. Pacini F, Fugazzola L, Lippi F, et al. Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: A clue to the diagnosis of metastatic differentiated thyroid cancer. *J Clin Endocrinol Metab* 1992;74(6):1401–1404; doi: 10.1210/jcem.74.6.1592886
755. Snozek CL, Chambers EP, Reading CC, et al. Serum thyroglobulin, high-resolution ultrasound, and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases. *J Clin Endocrinol Metab* 2007;92(11):4278–4281; doi: 10.1210/jc.2007-1075
756. Boi F, Baghino G, Atzeni F, et al. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. *J Clin Endocrinol Metab* 2006;91(4):1364–1369; doi: 10.1210/jc.2005-1705
757. Wang Y, Duan Y, Zhou M, et al. The diagnostic value of thyroglobulin in fine-needle aspiration of metastatic lymph nodes in patients with papillary thyroid cancer and its influential factors. *Surg Oncol* 2021;39:101666; doi: 10.1016/j.suronc.2021.101666
758. Jiang HJ, Hsiao PJ. Clinical application of the ultrasound-guided fine needle aspiration for thyroglobulin measurement to diagnose lymph node metastasis from differentiated thyroid carcinoma-literature review. *Kaohsiung J Med Sci* 2020;36(4):236–243; doi: 10.1002/kjm2.12173
759. Farina E, Monari F, Tallini G, et al. Unusual thyroid carcinoma metastases: A case series and literature review. *Endocr Pathol* 2016;27(1):55–64; doi: 10.1007/s12022-015-9410-7
760. Tuttle RM, Ahuja S, Avram AM, et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. *Mary Ann Liebert, Inc.*; 2019.
761. Mu Z, Zhang X, Sun D, et al. Characterizing genetic alterations related to radioiodine avidity in metastatic thyroid cancer. *J Clin Endocrinol Metab* 2024;109(5):1231–1240; doi: 10.1210/clinem/dgad697
762. Laschinsky C, Theurer S, Herold T, et al. Molecular markers are associated with onset of radioiodine refractoriness in patients with papillary thyroid carcinoma. *J Nucl Med* 2023;64(12):1865–1868; doi: 10.2967/jnumed.123.266044
763. Boucai L, Saqena M, Kuo F, et al. Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy. *Clin Cancer Res* 2023;29(8):1620–1630; doi: 10.1158/1078-0432.CCR-22-2882
764. Cao J, Zhu X, Sun Y, et al. The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor

- curative effect of radioiodine therapy in papillary thyroid cancer. *Eur J Nucl Med Mol Imaging* 2022;49(10):3470–3481; doi: 10.1007/s00259-022-05820-x
765. Soe MH, Chiang JM, Flavell RR, et al. Non-iodine-avid disease is highly prevalent in distant metastatic differentiated thyroid cancer with papillary histology. *J Clin Endocrinol Metab* 2022;107(8):e3206–e3216; doi: 10.1210/clinem/dgac305
766. Liu Y, Wang J, Hu X, et al. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy. *Drug Resist Updat* 2023;68:100939; doi: 10.1016/j.drug.2023.100939
767. Schwartz C, Bonnetain F, Dabakuyo S, et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. *J Clin Endocrinol Metab* 2012;97(5):1526–1535; doi: 10.1210/jc.2011-2512
768. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. *Thyroid* 2006;16(12):1229–1242; doi: 10.1089/thy.2006.16.1229
769. Jonklaas J, Cooper DS, Ain KB, et al; National Thyroid Cancer Treatment Cooperative Study Group. Radioiodine therapy in patients with stage I differentiated thyroid cancer. *Thyroid* 2010;20(12):1423–1424; doi: 10.1089/thy.2010.0308
770. Leboulleux S, Bournaud C, Chougnet CN, et al. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer. *N Engl J Med* 2022;386(10):923–932; doi: 10.1056/NEJMoa2111953
771. Dehbi HM, Mallick U, Wadsley J, et al. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. *Lancet Diabetes Endocrinol* 2019;7(1):44–51; doi: 10.1016/s2213-8587(18)30306-1
772. Matrone A, Gambale C, Piaggi P, et al. Postoperative thyroglobulin and neck ultrasound in the risk re-stratification and decision to perform 131I ablation. *J Clin Endocrinol Metab* 2017;102(3):893–902; doi: 10.1210/jc.2016-2860
773. Kazaure HS, Roman SA, Sosa JA. Insular thyroid cancer: A population-level analysis of patient characteristics and predictors of survival. *Cancer* 2012;118(13):3260–3267; doi: 10.1002/cncr.26638
774. Kazaure HS, Roman SA, Sosa JA. Aggressive variants of papillary thyroid cancer: Incidence, characteristics and predictors of survival among 43,738 patients. *Ann Surg Oncol* 2012;19(6):1874–1880; doi: 10.1245/s10434-011-2129-x
775. Ruel E, Thomas S, Dinan M, et al. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. *J Clin Endocrinol Metab* 2015;100(4):1529–1536; doi: 10.1210/jc.2014-4332
776. Lamartina L, Durante C, Filetti S, et al. Low-risk differentiated thyroid cancer and radioiodine remnant ablation: A systematic review of the literature. *J Clin Endocrinol Metab* 2015;100(5):1748–1761; doi: 10.1210/jc.2014-3882
777. Verburg FA, Flux G, Giovanella L, et al. Differentiated thyroid cancer patients potentially benefitting from post-operative I-131 therapy: A review of the literature of the past decade. *Eur J Nucl Med Mol Imaging* 2020;47(1):78–83; doi: 10.1007/s00259-019-04479-1
778. Ho AL, Dedecjus M, Wirth LJ, et al; ASTRA investigator group. Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer: A phase III, randomized, placebo-controlled trial (ASTRA). *J Clin Oncol* 2022;40(17):1870–1878; doi: 10.1200/jco.21.00714
779. Tian T, Qi Z, Huang S, et al. Radioactive iodine therapy decreases the recurrence of intermediate-risk PTC with low thyroglobulin levels. *J Clin Endocrinol Metab* 2023;108(8):2033–2041; doi: 10.1210/clinem/dgad045
780. Podnos YD, Smith DD, Wagman LD, et al. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. *J Surg Oncol* 2007;96(1):3–7; doi: 10.1002/jso.20656
781. Lassmann M, Reiners C, Luster M. Dosimetry and thyroid cancer: The individual dosage of radioiodine. *Endocr Relat Cancer* 2010;17(3):R161–R172; doi: 10.1677/ERC-10-0071
782. Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. *J Nucl Med* 2006;47(10):1587–1591.
783. Kulkarni K, Van Nostrand D, Atkins F, et al. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. *Thyroid* 2006;16(10):1019–1023; doi: 10.1089/thy.2006.16.1019
784. Klubo-Gwiedzinska J, Van Nostrand D, Atkins F, et al. Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer. *J Clin Endocrinol Metab* 2011;96(10):3217–3225; doi: 10.1210/jc.2011-0494
785. Besic N, Schwarzbartl-Pevce A, Videgar-Kralj B, et al. Treatment and outcome of 32 patients with distant metastases of Hürthle cell thyroid carcinoma: A single-institution experience. *BMC Cancer* 2016;16:162; doi: 10.1186/s12885-016-2179-3
786. Oluic B, Paunovic I, Loncar Z, et al. Survival and prognostic factors for survival, cancer specific survival and disease free interval in 239 patients with Hurthle cell carcinoma: A single center experience. *BMC Cancer* 2017;17(1):371; doi: 10.1186/s12885-017-3370-x
787. Yang Q, Zhao Z, Zhong G, et al. Effect of adjuvant radioactive iodine therapy on survival in rare oxyphilic subtype of thyroid cancer (Hürthle cell carcinoma). *PeerJ* 2019;7:e7458; doi: 10.7717/peerj.7458
788. Jillard CL, Youngwirth L, Scheri RP, et al. Radioactive iodine treatment is associated with improved survival for patients with Hürthle cell carcinoma. *Thyroid* 2016;26(7):959–964; doi: 10.1089/thy.2016.0246
789. Haigh PI, Urbach DR. The treatment and prognosis of Hurthle cell follicular thyroid carcinoma compared with its non-Hurthle cell counterpart. *Surgery* 2005;138(6):1152–1157.
790. Lopez-Penabad L, Chiu AC, Hoff AO, et al. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid. *Cancer* 2003;97(5):1186–1194; doi: 10.1002/cncr.11176
791. Lee J, Yun MJ, Nam KH, et al. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. *Thyroid* 2010;20(2):173–179; doi: 10.1089/thy.2009.0187
792. Fallahi B, Beiki D, Takavar A, et al. Low versus high radioiodine dose in postoperative ablation of residual thyroid

- tissue in patients with differentiated thyroid carcinoma: A large randomized clinical trial. *Nucl Med Commun* 2012; 33(3):275–282; doi: 10.1097/MNM.0b013e32834e306a
793. Karam M, Gianoukakis A, Feustel PJ, et al. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. *Nucl Med Commun* 2003;24(5):489–495.
  794. Xiao J, Yun C, Cao J, et al. A pre-ablative thyroid-stimulating hormone with 30-70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients. *Sci Rep* 2021;11(1):1348; doi: 10.1038/s41598-020-80015-8
  795. Vrachimis A, Riemann B, Mäder U, et al. Endogenous TSH levels at the time of (131)I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality. *Eur J Nucl Med Mol Imaging* 2016;43(2):224–231; doi: 10.1007/s00259-015-3223-2
  796. Robbins RJ, Driedger A, Magner J, U.S. and Canadian Thyrogen Compassionate Use Program Investigator Group. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. *Thyroid* 2006;16(11):1121–1130; doi: 10.1089/thy.2006.16.1121
  797. Tu J, Wang S, Huo Z, et al. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: A meta-analysis. *Radiother Oncol* 2014;110(1):25–30; doi: 10.1016/j.radonc.2013.12.018
  798. Pak K, Cheon GJ, Kang KW, et al. The effectiveness of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer: A meta-analysis of randomized controlled trials. *J Korean Med Sci* 2014;29(6):811–817; doi: 10.3346/jkms.2014.29.6.811
  799. Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. *N Engl J Med* 2012;366(18):1674–1685; doi: 10.1056/NEJMoa1109589
  800. Taieb D, Sebag F, Cherenko M, et al. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): A randomized controlled study. *Clin Endocrinol (Oxf)* 2009;71(1):115–123; doi: 10.1111/j.1365-2265.2008.03424.x
  801. Tala H, Robbins R, Fagin JA, et al. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. *J Clin Endocrinol Metab* 2011;96(7):2105–2111; doi: 10.1210/jc.2011-0305
  802. Klubo-Gwiedzinska J, Burman KD, Van Nostrand D, et al. Radioiodine treatment of metastatic thyroid cancer: Relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. *Thyroid* 2012;22(3):310–317; doi: 10.1089/thy.2011.0235
  803. Sawka AM, Ibrahim-Zada I, Galacgac P, et al. Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: A systematic review. *Thyroid* 2010;20(10):1129–1138; doi: 10.1089/thy.2010.0055
  804. Pluijmen MJ, Eustatia-Rutten C, Goslings BM, et al. Effects of low-iodide diet on postsurgical radioiodine ablation therapy in patients with differentiated thyroid carcinoma. *Clin Endocrinol (Oxf)* 2003;58(4):428–435.
  805. Morris LF, Wilder MS, Waxman AD, et al. Reevaluation of the impact of a stringent low-iodine diet on ablation rates in radioiodine treatment of thyroid carcinoma. *Thyroid* 2001; 11(8):749–755; doi: 10.1089/10507250152484583
  806. Morsch EP, Vanacor R, Furlanetto TW, et al. Two weeks of a low-iodine diet are equivalent to 3 weeks for lowering urinary iodine and increasing thyroid radioactive iodine uptake. *Thyroid* 2011;21(1):61–67; doi: 10.1089/thy.2010.0232
  807. Tala Jury HP, Castagna MG, Fioravanti C, et al. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. *J Clin Endocrinol Metab* 2010;95(1):230–237; doi: 10.1210/jc.2009-1624
  808. Sohn SY, Choi JY, Jang HW, et al. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer. *Thyroid* 2013;23(6):741–747; doi: 10.1089/thy.2012.0136
  809. Bartel TB, Magrefteh S, Avram AM, et al. SNMMI procedure standard for scintigraphy for differentiated thyroid cancer. *J Nucl Med Technol* 2020;48(3):202–209.
  810. Li JH, He ZH, Bansal V, et al. Low iodine diet in differentiated thyroid cancer: A review. *Clin Endocrinol (Oxf)* 2016;84(1):3–12; doi: 10.1111/cen.12846
  811. Lim CY, Kim JY, Yoon MJ, et al. Effect of a low iodine diet vs. restricted iodine diet on postsurgical preparation for radioiodine ablation therapy in thyroid carcinoma patients. *Yonsei Med J* 2015;56(4):1021–1027; doi: 10.3349/ymj.2015.56.4.1021
  812. Al Nozha OM, Vautour L, How J. Life-threatening hyponatremia following a low-iodine diet: A case report and review of all reported cases. *Endocr Pract* 2011;17(5):e113–e117; doi: 10.4158/EP11045.CR
  813. Hilditch TE, Dempsey MF, Bolster AA, et al. Self-stunning in thyroid ablation: Evidence from comparative studies of diagnostic 131I and 123I. *Eur J Nucl Med Mol Imaging* 2002;29(6):783–788; doi: 10.1007/s00259-002-0785-6
  814. Dam HQ, Kim SM, Lin HC, et al. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning. *Radiology* 2004;232(2):527–533; doi: 10.1148/radiol.2322030528
  815. Sisson JC, Avram AM, Lawson SA, et al. The so-called stunning of thyroid tissue. *J Nucl Med* 2006;47(9):1406–1412.
  816. Silberstein EB. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. *J Nucl Med* 2007;48(7):1043–1046; doi: 10.2967/jnumed.107.040311
  817. Mandel SJ, Shankar LK, Benard F, et al. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. *Clin Nucl Med* 2001;26(1):6–9; doi: 10.1097/00003072-200101000-00002
  818. Avram AM, Zukotynski K, Nadel HR, et al. Management of differentiated thyroid cancer: The standard of care. *J Nucl Med* 2022;63(2):189–195; doi: 10.2967/jnumed.121.262402
  819. Wong KK, Sisson JC, Koral KF, et al. Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT/CT.

- AJR Am J Roentgenol 2010;195(3):730–736; doi: 10.2214/AJR.09.3458
820. Avram AM, Fig LM, Frey KA, et al. Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: What is the impact on staging? *J Clin Endocrinol Metab* 2013;98(3):1163–1171; doi: 10.1210/jc.2012-3630
821. Avram AM, Esfandiari NH, Wong KK. Preablation 131-I scans with SPECT/CT contribute to thyroid cancer risk stratification and 131-I therapy planning. *J Clin Endocrinol Metab* 2015;100(5):1895–1902; doi: 10.1210/jc.2014-4043
822. Avram AM, Rosculet N, Esfandiari NH, et al. Differentiated thyroid cancer outcomes after surgery and activity-adjusted 131I theragnostics. *Clin Nucl Med* 2019;44(1):11–20; doi: 10.1097/rlu.0000000000002321
823. Van Nostrand D, Aiken M, Atkins F, et al. The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer. *Thyroid* 2009;19(8):849–855; doi: 10.1089/thy.2008.0419
824. Chen MK, Yasrebi M, Samii J, et al. The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer. *Thyroid* 2012;22(3):304–309; doi: 10.1089/thy.2011.0203
825. Song H, Mosci C, Akatsu H, et al. Diagnostic 123I whole body scan prior to ablation of thyroid remnant in patients with papillary thyroid cancer: Implications for clinical management. *Clin Nucl Med* 2018;43(10):705–709; doi: 10.1097/rlu.0000000000002246
826. Campenni A, Giovannella L, Pignata SA, et al. Undetectable or low (<1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients. *Oncotarget* 2018;9(25):17491–17500; doi: 10.18632/oncotarget.24766
827. Park EK, Chung JK, Lim IH, et al. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. *Eur J Nucl Med Mol Imaging* 2009;36(2):172–179; doi: 10.1007/s00259-008-0912-0
828. Fatourehchi V, Hay ID, Mullan BP, et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? *Thyroid* 2000;10(7):573–577.
829. Tharp K, Israel O, Hausmann J, et al. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. *Eur J Nucl Med Mol Imaging* 2004;31(10):1435–1442; doi: 10.1007/s00259-004-1565-2
830. Maruoka Y, Abe K, Baba S, et al. Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma. *Radiology* 2012;265(3):902–909; doi: 10.1148/radiol.12112108
831. Barwick T, Murray I, Megadmi H, et al. Single photon emission computed tomography (SPECT)/computed tomography using Iodine-123 in patients with differentiated thyroid cancer: Additional value over whole body planar imaging and SPECT. *Eur J Endocrinol* 2010;162(6):1131–1139; doi: 10.1530/EJE-09-1023
832. Grewal RK, Tuttle RM, Fox J, et al. The effect of post-therapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. *J Nucl Med* 2010;51(9):1361–1367; doi: 10.2967/jnumed.110.075960
833. Schmidt D, Linke R, Uder M, et al. Five months' follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT/CT at the first radioablation. *Eur J Nucl Med Mol Imaging* 2010;37(4):699–705; doi: 10.1007/s00259-009-1299-2
834. Schmidt D, Szikszai A, Linke R, et al. Impact of 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation. *J Nucl Med* 2009;50(1):18–23; doi: 10.2967/jnumed.108.052746
835. Xue YL, Qiu ZL, Song HJ, et al. Value of <sup>131</sup>I SPECT/CT for the evaluation of differentiated thyroid cancer: A systematic review of the literature. *Eur J Nucl Med Mol Imaging* 2013;40(5):768–778; doi: 10.1007/s00259-012-2310-x
836. Chong A, Seo Y, Bang JI, et al. Clinical implications of adding SPECT/CT to radioiodine whole-body scan in patients with differentiated thyroid cancer: A systematic review and meta-analysis. *Clin Nucl Med* 2024;49(3):215–225; doi: 10.1097/RLU.0000000000004953
837. Sisson JC, Freitas J, McDougall IR, et al; American Thyroid Association Taskforce On Radioiodine Safety. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: Practice recommendations of the American Thyroid Association. *Thyroid* 2011;21(4):335–346; doi: 10.1089/thy.2010.0403
838. United States Nuclear Regulatory Commission. NRC information notice 2017-02: Best practice concepts for patient release. NRC; 2017.
839. Silberstein EB, Alavi A, Balon HR, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. *J Nucl Med* 2012;53(10):1633–1651; doi: 10.2967/jnumed.112.105148
840. National Council on Radiation Protection and Measurements. NCRP Report No. 155: Management of radionuclide therapy patients. NCRP; 2007.
841. Release of patients after therapy with unsealed radionuclides. *Ann ICRP* 2004;34(2):v-vi, 1–v79; doi: 10.1016/j.icrp.2004.08.001
842. Liu B, Peng W, Huang R, et al. Thyroid cancer: Radiation safety precautions in 131I therapy based on actual biokinetic measurements. *Radiology* 2014;273(1):211–219; doi: 10.1148/radiol.14132234
843. Dewji SA, Bellamy M, Hertel N, et al. Assessment of the point-source method for estimating dose rates to members of the public from exposure to patients with 131I thyroid treatment. *Health Phys* 2015;109(3):233–241; doi: 10.1097/hp.0000000000000327
844. Grewal RK, Larson SM, Pentlow CE, et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. *J Nucl Med* 2009;50(10):1605–1610; doi: 10.2967/jnumed.108.061382
845. Nakada K, Ishibashi T, Takei T, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? *J Nucl Med* 2005;46(2):261–266. doi:46/2/261
846. Liu B, Kuang A, Huang R, et al. Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: A prospective, randomized, single-blind, controlled trial. *J Nucl Med* 2010;51(4):618–623; doi: 10.2967/jnumed.109.071449
847. Campanhã D, Pereira LE, Alves FA, et al. Bethanechol used to prevent salivary gland dysfunction in patients submitted to radioactive iodine therapy: A double blind,

- placebo-controlled, randomized study. *J Stomatol Oral Maxillofac Surg* 2022;123(5):e626–e630; doi: 10.1016/j.jormas.2021.12.014
848. Jaguar GC, Lima EN, Kowalski LP, et al. Double blind randomized prospective trial of bethanechol in the prevention of radiation-induced salivary gland dysfunction in head and neck cancer patients. *Radiother Oncol* 2015; 115(2):253–256; doi: 10.1016/j.radonc.2015.03.017
849. Walter MA, Turtzsch CP, Schindler C, et al. The dental safety profile of high-dose radioiodine therapy for thyroid cancer: Long-term results of a longitudinal cohort study. *J Nucl Med* 2007;48(10):1620–1625; doi: 10.2967/jnumed.107.042192
850. Kloos RT, Duvuuri V, Jhiang SM, et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. *J Clin Endocrinol Metab* 2002;87(12):5817–5820; doi: 10.1210/jc.2002-020210
851. Brown AP, Chen J, Hitchcock YJ, et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. *J Clin Endocrinol Metab* 2008;93(2):504–515; doi: 10.1210/jc.2007-1154
852. Rubino C, de VF, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. *Br J Cancer* 2003;89(9):1638–1644; doi: 10.1038/sj.bjc.6601319
853. Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: A systematic review and meta-analysis. *Thyroid* 2009;19(5):451–457; doi: 10.1089/thy.2008.0392
854. Subramanian S, Goldstein DP, Parlea L, et al. Second primary malignancy risk in thyroid cancer survivors: A systematic review and meta-analysis. *Thyroid* 2007;17(12):1277–1288; doi: 10.1089/thy.2007.0171
855. Sandeep TC, Strachan MW, Reynolds RM, et al. Second primary cancers in thyroid cancer patients: A multinational record linkage study. *J Clin Endocrinol Metab* 2006;91(5):1819–1825; doi: 10.1210/jc.2005-2009
856. Almeida JP, Sanabria AE, Lima EN, et al. Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. *Head Neck* 2011;33(5):686–690; doi: 10.1002/hed.21520
857. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. *Thyroid* 2003;13(3):265–271; doi: 10.1089/105072503321582060
858. Jentzen W, Balschuweit D, Schmitz J, et al. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET/(CT) imaging. *Eur J Nucl Med Mol Imaging* 2010;37(12):2298–2306; doi: 10.1007/s00259-010-1532-z
859. Van Nostrand D, Bandaru V, Chennupati S, et al. Radiopharmacokinetics of radioiodine in the parotid glands after the administration of lemon juice. *Thyroid* 2010; 20(10):1113–1119; doi: 10.1089/thy.2009.0429
860. Kulkarni K, Van Nostrand D, Atkins F, et al. Does lemon juice increase radioiodine reaccumulation within the parotid glands more than if lemon juice is not administered? *Nucl Med Commun* 2014;35(2):210–216.
861. Bomeli SR, Schaitkin B, Carrau RL, et al. Interventional sialendoscopy for treatment of radioiodine-induced sialadenitis. *Laryngoscope* 2009;119(5):864–867; doi: 10.1002/lary.20140
862. Prendes BL, Orloff LA, Eisele DW. Therapeutic sialendoscopy for the management of radioiodine sialadenitis. *Arch Otolaryngol Head Neck Surg* 2012;138(1):15–19; doi: 10.1001/archoto.2011.215
863. Bhayani MK, Acharya V, Kongkiatkamon S, et al. Sialendoscopy for patients with radioiodine-induced sialadenitis and xerostomia. *Thyroid* 2015;25(7):834–838; doi: 10.1089/thy.2014.0572
864. Reinecke MJ, Ahlers G, Burchert A, et al. Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma—a critical review and evaluation of the existing evidence. *Eur J Nucl Med Mol Imaging* 2022;49(9):3247–3256.
865. Teng CJ, Hu YW, Chen SC, et al. Use of radioactive iodine for thyroid cancer and risk of second primary malignancy: A nationwide population-based study. *J Natl Cancer Inst* 2016;108(2):djv314; doi: 10.1093/jnci/djv314
866. Pasqual E, Schonfeld S, Morton LM, et al. Association between radioactive iodine treatment for pediatric and young adulthood differentiated thyroid cancer and risk of second primary malignancies. *J Clin Oncol* 2022;40(13):1439–1449; doi: 10.1200/jco.21.01841
867. Yu CY, Saeed O, Goldberg AS, et al. A systematic review and meta-analysis of subsequent malignant neoplasm risk after radioactive iodine treatment of thyroid cancer. *Thyroid* 2018;28(12):1662–1673; doi: 10.1089/thy.2018.0244
868. Molenaar RJ, Sidana S, Radivoyevitch T, et al. Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer. *J Clin Oncol* 2018; 36(18):1831–1839; doi: 10.1200/JCO.2017.75.0232
869. Iyer NG, Morris LG, Tuttle RM, et al. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. *Cancer* 2011;117(19):4439–4446; doi: 10.1002/cncr.26070
870. Seo GH, Kong KA, Kim BS, et al. Radioactive iodine treatment for children and young adults with thyroid cancer in South Korea: A population-based study. *J Clin Endocrinol Metab* 2021;106(7):e2580–e2588.
871. Seo GH, Cho YY, Chung JH, et al. Increased risk of leukemia after radioactive iodine therapy in patients with thyroid cancer: A nationwide, population-based study in Korea. *Thyroid* 2015;25(8):927–934; doi: 10.1089/thy.2014.0557
872. Tran TV, Rubino C, Allodji R, et al. Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment. *Br J Cancer* 2022;127(12):2118–2124; doi: 10.1038/s41416-022-01982-5
873. Chen AY, Levy L, Goepfert H, et al. The development of breast carcinoma in women with thyroid carcinoma. *Cancer* 2001;92(2):225–231; doi: 10.1002/1097-0142(20010715)92:2<225::AID-CNCR1313>3.0.CO;2-B
874. Luster M, Clarke SE, Dietlein M, et al; European Association of Nuclear Medicine (EANM). Guidelines for radioiodine therapy of differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging* 2008;35(10):1941–1959; doi: 10.1007/s00259-008-0883-1
875. Benua RS, Cicale NR, Sonenberg M, et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. *Am J Roentgenol Radium Ther Nucl Med* 1962;87:171–182.
876. Burns R, O’Herlihy C, Smyth PP. The placenta as a compensatory iodine storage organ. *Thyroid* 2011;21(5):541–546; doi: 10.1089/thy.2010.0203

877. Sun Y, Han Y, Qian M, et al. Defending effects of iodide transfer in placental barrier against maternal iodine deficiency. *Thyroid* 2021;31(3):509–518; doi: 10.1089/thy.2020.0510
878. Mégier C, Dumery G, Luton D. Iodine and thyroid maternal and fetal metabolism during pregnancy. *Metabolites* 2023;13(5):633; doi: 10.3390/metabo13050633
879. Sawka AM, Lakra DC, Lea J, et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. *Clin Endocrinol (Oxf)* 2008;69(3):479–490; doi: 10.1111/j.1365-2265.2008.03222.x
880. Vini L, Hyer S, Al-Saadi A, et al. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. *Postgrad Med J* 2002;78(916):92–93.
881. Dottorini ME, Lomuscio G, Mazzucchelli L, et al. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. *J Nucl Med* 1995;36(1):21–27.
882. Wu JX, Young S, Ro K, et al. Reproductive outcomes and nononcologic complications after radioactive iodine ablation for well-differentiated thyroid cancer. *Thyroid* 2015;25(1):133–138; doi: 10.1089/thy.2014.0343
883. Ohori NP, Schoedel KE. Variability in the atypia of undetermined significance/follicular lesion of undetermined significance diagnosis in the Bethesda System for Reporting Thyroid Cytopathology: Sources and recommendations. *Acta Cytol* 2011;55(6):492–498.
884. Garsi JP, Schlumberger M, Rubino C, et al. Therapeutic administration of 131I for differentiated thyroid cancer: Radiation dose to ovaries and outcome of pregnancies. *J Nucl Med* 2008;49(5):845–852.
885. Kim HO, Lee K, Lee SM, et al. Association between pregnancy outcomes and radioactive iodine treatment after thyroidectomy among women with thyroid cancer. *JAMA Intern Med* 2020;180(1):54–61; doi: 10.1001/jamainternmed.2019.4644
886. Martin CJ, Marengo M, Vassileva J, et al. Guidance on prevention of unintended and accidental radiation exposures in nuclear medicine. *J Radiol Prot* 2019;39(3):665–695; doi: 10.1088/1361-6498/ab19d8
887. Mattsson S, Johansson L, Leide Svegborn S, et al; ICRP. Radiation dose to patients from radiopharmaceuticals: A compendium of current information related to frequently used substances. *Ann ICRP* 2015;44(2 Suppl):7–321; doi: 10.1177/0146645314558019
888. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: Mechanisms, findings, and radiation dosimetry. *J Nucl Med* 2000;41(5):863–873.
889. Gorman CA. Radioiodine and pregnancy. *Thyroid* 1999;9(7):721–726; doi: 10.1089/thy.1999.9.721
890. Advisory Committee on Medical Uses of Isotopes (ACMUI) Sub-Committee on Nursing Mother Guidelines for the Medical Administration of Radioactive Materials. January 2019. Available from: <https://www.nrc.gov/docs/ML1903/ML19038A498.pdf>.
891. Bernard N, Jantzen H, Becker M, et al; French Network of Regional Pharmacovigilance Centres. Severe adverse effects of bromocriptine in lactation inhibition: A pharmacovigilance survey. *BJOG* 2015;122(9):1244–1251; doi: 10.1111/1471-0528.13352
892. Wichers M, Benz E, Palmedo H, et al. Testicular function after radioiodine therapy for thyroid carcinoma. *Eur J Nucl Med* 2000;27(5):503–507.
893. Hyer S, Vini L, O’Connell M, et al. Testicular dose and fertility in men following I(131) therapy for thyroid cancer. *Clin Endocrinol (Oxf)* 2002;56(6):755–758.
894. Ceccarelli C, Battisti P, Gasperi M, et al. Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer. *J Nucl Med* 1999;40(10):1716–1721.
895. Soltani S, Aghaee A, Rasoul Zakavi S, et al. Effects of radioiodine therapy on fertility indicators among men with differentiated thyroid cancer: A cohort study. *Int J Reprod Biomed* 2023;21(5):387–394; doi: 10.18502/ijrm.v21i5.13472
896. Bourcigaux N, Rubino C, Berthaud I, et al. Impact on testicular function of a single ablative activity of 3.7 GBq radioactive iodine for differentiated thyroid carcinoma. *Hum Reprod* 2018;33(8):1408–1416; doi: 10.1093/humrep/dey222
897. Clement SC, Peeters RP, Ronckers CM, et al. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma—a systematic review. *Cancer Treat Rev* 2015;41(10):925–934; doi: 10.1016/j.ctrv.2015.09.001
898. Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. *Thyroid* 2017;27(3):315–389; doi: 10.1089/thy.2016.0457
899. Sarkar SD, Beierwaltes WH, Gill SP, et al. Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. *J Nucl Med* 1976;17(6):460–464.
900. Mazzaferri EL. Gonadal damage from 131I therapy for thyroid cancer. *Clin Endocrinol (Oxf)* 2002;57(3):313–314.
901. Huang N, Zeng L, Yan J, et al. Analysis of *in vitro* fertilization/intracytoplasmic sperm injection outcomes in infertile women with a history of thyroid cancer: A retrospective study. *Reprod Biol Endocrinol* 2021;19(1):82; doi: 10.1186/s12958-021-00763-8
902. van Velsen EFS, Visser WE, van den Berg SAA, et al. Longitudinal analysis of the effect of radioiodine therapy on ovarian reserve in females with differentiated thyroid cancer. *Thyroid* 2020;30(4):580–587; doi: 10.1089/thy.2019.0504
903. Yaish I, Azem F, Gutfeld O, et al. A single radioactive iodine treatment has a deleterious effect on ovarian reserve in women with thyroid cancer: Results of a prospective pilot study. *Thyroid* 2018;28(4):522–527; doi: 10.1089/thy.2017.0442
904. Evranos B, Faki S, Polat SB, et al. Effects of radioactive iodine therapy on ovarian reserve: A prospective pilot study. *Thyroid* 2018;28(12):1702–1707; doi: 10.1089/thy.2018.0129
905. Radowsky JS, Howard RS, Burch HB, et al. Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome. *Thyroid* 2014;24(2):241–244; doi: 10.1089/thy.2012.0567
906. Tsang RW, Brierley JD, Simpson WJ, et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. *Cancer* 1998;82(2):375–388.
907. Kiess AP, Agrawal N, Brierley JD, et al. External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society. *Head Neck* 2016;38(4):493–498; doi: 10.1002/hed.24357

908. Biermann M, Pixberg M, Riemann B, et al; MSDS study group. Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer - results after 874 patient-years of follow-up in the MSDS-trial. *Nuklearmedizin* 2009;48(3):89–98; quiz N15; doi: 10.3413/nukmed-0221
909. Brierley J, Tsang R, Panzarella T, et al. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. *Clin Endocrinol (Oxf)* 2005;63(4):418–427; doi: 10.1111/j.1365-2265.2005.02358.x
910. Schwartz DL, Lobo MJ, Ang KK, et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: Outcomes and morbidity with conformal treatment. *Int J Radiat Oncol Biol Phys* 2009;74(4):1083–1091; doi: 10.1016/j.ijrobp.2008.09.023
911. Lee EK, Lee YJ, Jung YS, et al. Postoperative simultaneous integrated boost-intensity modulated radiation therapy for patients with locoregionally advanced papillary thyroid carcinoma: Preliminary results of a phase II trial and propensity score analysis. *J Clin Endocrinol Metab* 2015;100(3):1009–1017; doi: 10.1210/jc.2014-3242
912. Lee NK, Kim CY, Baek SK, et al. The role of adjuvant radiation therapy for locoregionally advanced papillary thyroid carcinoma. *Oncology* 2016;90(4):209–214; doi: 10.1159/000444393
913. Vulpe H, Kwan JYY, McNiven A, et al. Patterns of failure in anaplastic and differentiated thyroid carcinoma treated with intensity-modulated radiotherapy. *Curr Oncol* 2017;24(3):e226–e232; doi: 10.3747/co.24.3551
914. Tam S, Amit M, Boonsripitayanon M, et al. Adjuvant external beam radiotherapy in locally advanced differentiated thyroid cancer. *JAMA Otolaryngol Head Neck Surg* 2017;143(12):1244–1251; doi: 10.1001/jamaoto.2017.2077
915. Besic N, Dremelj M, Pilko G. Locoregional disease control after external beam radiotherapy in 91 patients with differentiated thyroid carcinoma and pT4 tumor stage—a single institution experience. *Radiol Oncol* 2018;52(4):453–460; doi: 10.2478/raon-2018-0038
916. Kim TH, Chung KW, Lee YJ, et al. The effect of external beam radiotherapy volume on locoregional control in patients with locoregionally advanced or recurrent nonanaplastic thyroid cancer. *Radiat Oncol* 2010;5:69; doi: 10.1186/1748-717x-5-69
917. Romesser PB, Sherman EJ, Shaha AR, et al. External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. *J Surg Oncol* 2014;110(4):375–382; doi: 10.1002/jso.23656
918. Adilbay D, Yuan A, Romesser PB, et al. Well-differentiated thyroid cancer: Who should get postoperative radiation? *Ann Surg Oncol* 2022;29(9):5582–5590; doi: 10.1245/s10434-022-11898-2
919. Makita K, Hamamoto Y, Tsuruoka S, et al. Treatment intensity and control rates in combining external-beam radiotherapy and radioactive iodine therapy for metastatic or recurrent differentiated thyroid cancer. *Int J Clin Oncol* 2020;25(4):691–697; doi: 10.1007/s10147-019-01591-y
920. Goffredo P, Robinson TJ, Youngwirth LM, et al. Intensity-modulated radiation therapy use for the localized treatment of thyroid cancer: Nationwide practice patterns and outcomes. *Endocrine* 2016;53(3):761–773; doi: 10.1007/s12020-016-0937-2
921. Megwalu UC, Orloff LA, Ma Y. Adjuvant external beam radiotherapy for locally invasive papillary thyroid cancer. *Head Neck* 2019;41(6):1719–1724; doi: 10.1002/hed.25639
922. Jacomina LE, Jacinto JKM, Co LBA, et al. The Role of postoperative external beam radiotherapy for differentiated thyroid carcinoma: A systematic review and meta-analysis. *Head Neck* 2020;42(8):2181–2193; doi: 10.1002/hed.26133
923. Dicuonzo S, Pedretti S, Mangoni M, et al. Adjuvant radiotherapy and radioiodine treatment for locally advanced differentiated thyroid cancer: Systematic review and meta-analysis. *Tumori* 2021;107(6):489–497; doi: 10.1177/0300891621996817
924. Beckham TH, Romesser PB, Groen AH, et al. Intensity-modulated radiation therapy with or without concurrent chemotherapy in nonanaplastic thyroid cancer with unresectable or gross residual disease. *Thyroid* 2018;28(9):1180–1189; doi: 10.1089/thy.2018.0214
925. Lamartina L, Godbert Y, Nascimento C, et al; with the support of the TUTHYREF network. Locally unresectable differentiated thyroid cancer: Outcomes and perspectives. *Endocrine* 2020;69(1):133–141; doi: 10.1007/s12020-020-02245-0
926. Romesser PB, Sherman EJ, Whiting K, et al. Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. *Cancer* 2021;127(22):4161–4170; doi: 10.1002/cncr.33804
927. Brabant G. Thyrotropin suppressive therapy in thyroid carcinoma: What are the targets? *J Clin Endocrinol Metab* 2008;93(4):1167–1169; doi: 10.1210/jc.2007-2228
928. McGriff NJ, Csako G, Gourgiotis L, et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. *Ann Med* 2002;34(7–8):554–564.
929. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry. *Thyroid* 1998;8(9):737–744.
930. Diessl S, Holzberger B, Mader U, et al. Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. *Clin Endocrinol (Oxf)* 2012;76(4):586–592; doi: 10.1111/j.1365-2265.2011.04272.x
931. Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. *Thyroid* 2010;20(2):135–146; doi: 10.1089/thy.2009.0311
932. Hovens GC, Stokkel MP, Kievit J, et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. *J Clin Endocrinol Metab* 2007;92(7):2610–2615; doi: 10.1210/jc.2006-2566
933. Pujol P, Daures JP, Nsakala N, et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. *J Clin Endocrinol Metab* 1996;81(12):4318–4323; doi: 10.1210/jcem.81.12.8954034
934. Klubo-Gwiedzinska J, Auh S, Gershengorn M, et al. Association of thyrotropin suppression with survival outcomes in patients with intermediate- and high-risk differentiated thyroid cancer. *JAMA Netw Open* 2019;2(2):e187754; doi: 10.1001/jamanetworkopen.2018.7754

935. Tian T, Huang R, Liu B. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment? *Endocrine* 2019;65(1):149–154; doi: 10.1007/s12020-019-01914-z
936. Sugitani I, Fujimoto Y. Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. *J Clin Endocrinol Metab* 2010;95(10):4576–4583; doi: 10.1210/jc.2010-0161
937. Lee MC, Kim MJ, Choi HS, et al. Postoperative thyroid-stimulating hormone levels did not affect recurrence after thyroid lobectomy in patients with papillary thyroid cancer. *Endocrinol Metab (Seoul)* 2019;34(2):150–157; doi: 10.3803/EnM.2019.34.2.150
938. Park JH, Lee YM, Lee YH, et al. The prognostic value of serum thyroid-stimulating hormone level post-lobectomy in low- and intermediate-risk papillary thyroid carcinoma. *J Surg Oncol* 2018;118(3):390–396; doi: 10.1002/jso.25164
939. Gubbi S, Al-Jundi M, Foerster P, et al. The effect of thyrotropin suppression on survival outcomes in patients with differentiated thyroid cancer: A systematic review and meta-analysis. *Thyroid* 2024;34(6):674–686; doi: 10.1089/thy.2023.0711
940. De Carlucci D, Jr, Tavares MR, Obara MT, et al. Thyroid function after unilateral total lobectomy: Risk factors for postoperative hypothyroidism. *Arch Otolaryngol Head Neck Surg* 2008;134(10):1076–1079; doi: 10.1001/archotol.134.10.1076
941. Li J, Zhang B, Bai Y, et al. Health-related quality of life analysis in differentiated thyroid carcinoma patients after thyroidectomy. *Sci Rep* 2020;10(1):5765; doi: 10.1038/s41598-020-62731-3
942. Schumm MA, Lechner MG, Shu ML, et al. Frequency of thyroid hormone replacement after lobectomy for differentiated thyroid cancer. *Endocr Pract* 2021;27(7):691–697; doi: 10.1016/j.eprac.2021.01.004
943. Barranco H, Fazendin J, Lindeman B, et al. Thyroid hormone replacement following lobectomy: Long-term institutional analysis 15 years after surgery. *Surgery* 2023;173(1):189–192; doi: 10.1016/j.surg.2022.05.044
944. Sugitani I, Fujimoto Y, Yamada K. Association between serum thyrotropin concentration and growth of asymptomatic papillary thyroid microcarcinoma. *World J Surg* 2014;38(3):673–678; doi: 10.1007/s00268-013-2335-8
945. Kim HI, Jin M, Ko NG, et al. Effect of TSH levels during active surveillance of PTMC according to age. *Endocr Relat Cancer* 2022;29(4):191–200; doi: 10.1530/ERC-21-0403
946. Lee JY, Kim JH, Kim YK, et al. US predictors of papillary thyroid microcarcinoma progression at active surveillance. *Radiology* 2023;309(1):e230006; doi: 10.1148/radiol.230006
947. Yamamoto M, Miyauchi A, Ito Y, et al. Active surveillance outcomes of patients with low-risk papillary thyroid microcarcinoma according to levothyroxine treatment status. *Thyroid* 2023;33(10):1182–1189; doi: 10.1089/thy.2023.0046
948. Somwaru LL, Arnold AM, Joshi N, et al. High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over. *J Clin Endocrinol Metab* 2009;94(4):1342–1345; doi: 10.1210/jc.2008-1696
949. Mammen JS, McGready J, Oxman R, et al. Thyroid hormone therapy and risk of thyrotoxicosis in community-resident older adults: Findings from the Baltimore longitudinal study of aging. *Thyroid* 2015;25(9):979–986; doi: 10.1089/thy.2015.0180
950. Yavuz DG, Yazan CD, Hekimsoy Z, et al. Assessment of attainment of recommended TSH levels and levothyroxine compliance in differentiated thyroid cancer patients. *Clin Endocrinol (Oxf)* 2022;97(6):833–840; doi: 10.1111/cen.14787
951. Toft AD. Clinical practice. Subclinical hyperthyroidism. *N Engl J Med* 2001;345(7):512–516; doi: 10.1056/NEJMcp010145
952. Panico A, Lupoli GA, Fonderico F, et al. Osteoporosis and thyrotropin-suppressive therapy: Reduced effectiveness of alendronate. *Thyroid* 2009;19(5):437–442; doi: 10.1089/thy.2008.0428
953. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. *N Engl J Med* 1994;331(19):1249–1252; doi: 10.1056/NEJM199411103311901
954. Papaleontiou M, Levine DA, Reyes-Gastelum D, et al. Thyroid hormone therapy and incident stroke. *J Clin Endocrinol Metab* 2021;106(10):e3890–e3900; doi: 10.1210/clinem/dgab444
955. Evron JM, Hummel SL, Reyes-Gastelum D, et al. Association of thyroid hormone treatment intensity with cardiovascular mortality among US Veterans. *JAMA Netw Open* 2022;5(5):e2211863; doi: 10.1001/jamanetworkopen.2022.11863
956. Sugitani I, Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: A prospective controlled study. *Surgery* 2011;150(6):1250–1257; doi: 10.1016/j.surg.2011.09.013
957. Chen CH, Chen JF, Yang BY, et al. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma. *J Formos Med Assoc* 2004;103(6):442–447.
958. Mazziotti G, Formenti AM, Frara S, et al. High prevalence of radiological vertebral fractures in women on thyroid-stimulating hormone-suppressive therapy for thyroid carcinoma. *J Clin Endocrinol Metab* 2018;103(3):956–964; doi: 10.1210/jc.2017-01986
959. Papaleontiou M, Banerjee M, Reyes-Gastelum D, et al. Risk of osteoporosis and fractures in patients with thyroid cancer: A case-control study in U.S. Veterans. *Oncologist* 2019;24(9):1166–1173; doi: 10.1634/theoncologist.2019-0234
960. Ku EJ, Yoo WS, Lee EK, et al. Effect of TSH suppression therapy on bone mineral density in differentiated thyroid cancer: A systematic review and meta-analysis. *J Clin Endocrinol Metab* 2021;106(12):3655–3667; doi: 10.1210/clinem/dgab539
961. Heemstra KA, Hamdy NA, Romijn JA, et al. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. *Thyroid* 2006;16(6):583–591; doi: 10.1089/thy.2006.16.583
962. Wang LY, Smith AW, Palmer FL, et al. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. *Thyroid* 2015;25(3):300–307; doi: 10.1089/thy.2014.0287

963. Klein Hesselink EN, Klein Hesselink MS, de Bock GH, et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: An observational study. *J Clin Oncol* 2013;31(32):4046–4053; doi: 10.1200/JCO.2013.49.1043
964. Algeciras-Schimmich A. Thyroglobulin measurement in the management of patients with differentiated thyroid cancer. *Crit Rev Clin Lab Sci* 2018;55(3):205–218; doi: 10.1080/10408363.2018.1450830
965. Evans C, Tennant S, Perros P. Thyroglobulin in differentiated thyroid cancer. *Clin Chim Acta* 2015;444:310–317; doi: 10.1016/j.cca.2014.10.035
966. Spencer CA, Lopresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. *Nat Clin Pract Endocrinol Metab* 2008;4(4):223–233; doi: 10.1038/ncpendmet0757
967. Giovanella L, Feldt-Rasmussen U, Verburg FA, et al. Thyroglobulin measurement by highly sensitive assays: Focus on laboratory challenges. *Clin Chem Lab Med* 2015;53(9):1301–1314; doi: 10.1515/cclm-2014-0813
968. Spencer CA. Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). *J Clin Endocrinol Metab* 2011;96(12):3615–3627.
969. Taylor KP, Parkington D, Bradbury S, et al. Concordance between thyroglobulin antibody assays. *Ann Clin Biochem* 2011;48(Pt 4):367–369; doi: 10.1258/acb.2011.010248
970. Verburg FA, Waschle K, Reiners C, et al. Heterophile antibodies rarely influence the measurement of thyroglobulin and thyroglobulin antibodies in differentiated thyroid cancer patients. *Horm Metab Res* 2010;42(10):736–739; doi: 10.1055/s-0030-1254132
971. Giovanella L, Clark PM, Chiovato L, et al. Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: A clinical position paper. *Eur J Endocrinol* 2014;171(2):R33–R46; doi: 10.1530/eje-14-0148
972. Giovanella L, Treglia G, Sadeghi R, et al. Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: A meta-analysis. *J Clin Endocrinol Metab* 2014;99(2):440–447; doi: 10.1210/jc.2013-3156
973. Giovanella L, Castellana M, Trimboli P. Unstimulated high-sensitive thyroglobulin is a powerful prognostic predictor in patients with thyroid cancer. *Clin Chem Lab Med* 2019;58(1):130–137; doi: 10.1515/cclm-2019-0654
974. Angell TE, Spencer CA, Rubino BD, et al. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. *Thyroid* 2014;24(7):1127–1133; doi: 10.1089/thy.2013.0691
975. Verburg FA, Mäder U, Giovanella L, et al. Low or undetectable basal thyroglobulin levels obviate the need for neck ultrasound in differentiated thyroid cancer patients after total thyroidectomy and (131)I ablation. *Thyroid* 2018;28(6):722–728; doi: 10.1089/thy.2017.0352
976. Ringel MD, Nabhan F. Approach to follow-up of the patient with differentiated thyroid cancer and positive anti-thyroglobulin antibodies. *J Clin Endocrinol Metab* 2013;98(8):3104–3110; doi: 10.1210/jc.2013-1412
977. Giovanella L. Circulating biomarkers for the detection of tumor recurrence in the postsurgical follow-up of differentiated thyroid carcinoma. *Curr Opin Oncol* 2020;32(1):7–12; doi: 10.1097/cco.0000000000000588
978. Giovanella L, Verburg FA, Trimboli P, et al. Measuring thyroglobulin in patients with thyroglobulin autoantibodies: Evaluation of the clinical impact of BRAHMS Kryptor® Tg-minirecovery test in a large series of patients with differentiated thyroid carcinoma. *Clin Chem Lab Med* 2019;57(8):1185–1191; doi: 10.1515/cclm-2018-1390
979. Matrone A, Latrofa F, Torregrossa L, et al. Changing trend of thyroglobulin antibodies in patients with differentiated thyroid cancer treated with total thyroidectomy without (131) I ablation. *Thyroid* 2018;28(7):871–879; doi: 10.1089/thy.2018.0080
980. Bueno F, Falcone MGG, Peñaloza MA, et al. Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer. *Endocrine* 2020;67(2):387–396; doi: 10.1007/s12020-019-02112-7
981. Zavala LF, Barra MI, Olmos R, et al. In properly selected patients with differentiated thyroid cancer, antithyroglobulin antibodies decline after thyroidectomy and their sole presence should not be an indication for radioiodine ablation. *Arch Endocrinol Metab* 2019;63(3):293–299; doi: 10.20945/2359-399700000123
982. Sun D, Zheng X, He X, et al. Prognostic value and dynamics of antithyroglobulin antibodies for differentiated thyroid carcinoma. *Biomark Med* 2020;14(18):1683–1692; doi: 10.2217/bmm-2019-0432
983. Ora M, Nazar AH, Mishra P, et al. Clinical outcome of patients with differentiated thyroid cancer and raised antithyroglobulin antibody levels: A retrospective study. *Thyroid Res* 2021;14(1):8; doi: 10.1186/s13044-021-00099-w
984. Noel JE, Thatipamala P, Hung KS, et al. Pre-operative antithyroid antibodies in differentiated thyroid cancer. *Endocr Pract* 2021;27(11):1114–1118; doi: 10.1016/j.eprac.2021.06.014
985. Yin N, Sherman SI, Pak Y, et al; National Thyroid Cancer Treatment Cooperative Study Group. The *de novo* detection of anti-thyroglobulin antibodies and differentiated thyroid cancer recurrence. *Thyroid* 2020;30(10):1490–1495; doi: 10.1089/thy.2019.0791
986. Scappaticcio L, Trimboli P, Verburg FA, et al. Significance of “*de novo*” appearance of thyroglobulin antibodies in patients with differentiated thyroid cancer. *Int J Biol Markers* 2020;35(3):41–49; doi: 10.1177/1724600820931517
987. Qiu ZL, Shen CT, Sun ZK, et al. Lung metastases from papillary thyroid cancer with persistently negative thyroglobulin and elevated thyroglobulin antibody levels during radioactive iodine treatment and follow-up: Long-term outcomes and prognostic indicators. *Front Endocrinol (Lausanne)* 2019;10:903; doi: 10.3389/fendo.2019.00903
988. National Cancer Institute. NCI dictionary of cancer terms: Complete remission. 2023. Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/complete-remission> [Last accessed: March 30 2024].
989. Hedman C, Strang P, Djärv T, et al. Anxiety and fear of recurrence despite a good prognosis: An interview study with differentiated thyroid cancer patients. *Thyroid* 2017;27(11):1417–1423; doi: 10.1089/thy.2017.0346
990. Papaleontiou M, Reyes-Gastelum D, Gay BL, et al. Worry in thyroid cancer survivors with a favorable prognosis. *Thyroid* 2019;29(8):1080–1088; doi: 10.1089/thy.2019.0163
991. Durante C, Montesano T, Torlontano M, et al; PTC Study Group. Papillary thyroid cancer: Time course of

- recurrences during postsurgery surveillance. *J Clin Endocrinol Metab* 2013;98(2):636–642; doi: 10.1210/jc.2012-3401
992. Kim H, Kim TH, Choe JH, et al. Patterns of initial recurrence in completely resected papillary thyroid carcinoma. *Thyroid* 2017;27(7):908–914; doi: 10.1089/thy.2016.0648
993. Mukhtar N, Aljamei H, Aljomaiah A, et al. Natural course of the American Thyroid Association response to therapy statuses (dynamic risk stratification) in differentiated thyroid cancer. *Eur Thyroid J* 2021;10(3):198–207; doi: 10.1159/000511708
994. Schlumberger M, Leboulleux S, Catargi B, et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. *Lancet Diabetes Endocrinol* 2018;6(8):618–626; doi: 10.1016/s2213-8587(18)30113-x
995. Seejore K, Gerrard GE, Gill VM, et al. Can we discharge dynamically risk-stratified low-risk (excellent response to treatment) thyroid cancer patients after 5 years of follow-up? *Clin Oncol (R Coll Radiol)* 2019;31(4):219–224; doi: 10.1016/j.clon.2019.01.005
996. Epstein S, McEachern R, Khot R, et al. Papillary thyroid carcinoma recurrence: Low yield of neck ultrasound with an undetectable serum thyroglobulin level. *J Ultrasound Med* 2018;37(10):2325–2331; doi: 10.1002/jum.14580
997. Grani G, Ramundo V, Falcone R, et al. Thyroid cancer patients with no evidence of disease: The need for repeat neck ultrasound. *J Clin Endocrinol Metab* 2019;104(11):4981–4989; doi: 10.1210/jc.2019-00962
998. Peiling Yang S, Bach AM, Tuttle RM, et al. Frequent screening with serial neck ultrasound is more likely to identify false-positive abnormalities than clinically significant disease in the surveillance of intermediate risk papillary thyroid cancer patients without suspicious findings on follow-up ultrasound evaluation. *J Clin Endocrinol Metab* 2015;100(4):1561–1567; doi: 10.1210/jc.2014-3651
999. Sek KS, Tsang I, Lee XY, et al. Frequent neck US in papillary thyroid cancer likely detects non-actionable findings. *Clin Endocrinol (Oxf)* 2021;94(3):504–512; doi: 10.1111/cen.14325
1000. Seejore K, Mulla O, Gerrard GE, et al. Outcomes of 756 patients with differentiated thyroid cancer and excellent response to treatment: An evidence-based paradigm for long-term surveillance strategies. *Clin Endocrinol (Oxf)* 2022;96(3):395–401; doi: 10.1111/cen.14549
1001. Banerjee M, Wiebel JL, Guo C, et al. Use of imaging tests after primary treatment of thyroid cancer in the United States: Population based retrospective cohort study evaluating death and recurrence. *Bmj* 2016;354:i3839; doi: 10.1136/bmj.i3839
1002. Wang LY, Roman BR, Migliacci JC, et al. Cost-effectiveness analysis of papillary thyroid cancer surveillance. *Cancer* 2015;121(23):4132–4140; doi: 10.1002/ncr.29633
1003. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. *J Clin Endocrinol Metab* 2003;88(4):1433–1441.
1004. Torlontano M, Crocetti U, D'Aloiso L, et al. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. *Eur J Endocrinol* 2003;148(1):19–24.
1005. Sol B, Bravenboer B, Velkeniers B, et al. Undetectable thyroglobulin makes (123)I whole-body scan and stimulated thyroglobulin obsolete in follow-up care of differentiated thyroid cancer: A retrospective study. *Thyroid Res* 2021;14(1):23; doi: 10.1186/s13044-021-00114-0
1006. Kohlfuerst S, Igerc I, Lobnig M, et al. Posttherapeutic (131)I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen. *Eur J Nucl Med Mol Imaging* 2009;36(6):886–893; doi: 10.1007/s00259-008-1044-2
1007. Lee SW. SPECT/CT in the treatment of differentiated thyroid cancer. *Nucl Med Mol Imaging* 2017;51(4):297–303; doi: 10.1007/s13139-017-0473-x
1008. Zilioli V, Peli A, Panarotto MB, et al. Differentiated thyroid carcinoma: Incremental diagnostic value of (131)I SPECT/CT over planar whole body scan after radioiodine therapy. *Endocrine* 2017;56(3):551–559; doi: 10.1007/s12020-016-1086-3
1009. Hassan FU, Mohan HK. Clinical utility of SPECT/CT imaging post-radioiodine therapy: Does it enhance patient management in thyroid cancer? *Eur Thyroid J* 2015;4(4):239–245; doi: 10.1159/000435836
1010. Spanu A, Nuvoli S, Gelo I, et al. Role of diagnostic (131)I SPECT/CT in long-term follow-up of patients with papillary thyroid microcarcinoma. *J Nucl Med* 2018;59(10):1510–1515; doi: 10.2967/jnumed.117.204636
1011. Spanu A, Nuvoli S, Marongiu A, et al. Neck lymph node metastasis detection in patients with differentiated thyroid carcinoma (DTC) in long-term follow-up: A (131)I-SPECT/CT study. *BMC Cancer* 2020;20(1):239; doi: 10.1186/s12885-020-06744-1
1012. Mauguen A, Grewal RK, Augensen F, et al. The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): A regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients. *Eur J Nucl Med Mol Imaging* 2023;50(10):2971–2983; doi: 10.1007/s00259-023-06240-1
1013. Wierts R, Brans B, Havekes B, et al. Dose-response relationship in differentiated thyroid cancer patients undergoing radioiodine treatment assessed by means of 124I PET/CT. *J Nucl Med* 2016;57(7):1027–1032; doi: 10.2967/jnumed.115.168799
1014. Plyku D, Hobbs RF, Wu D, et al. I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: Correlation of patient-specific lesional dosimetry to treatment response. *Ann Nucl Med* 2022;36(3):213–223; doi: 10.1007/s12149-021-01655-y
1015. Dittmann M, Gonzalez Carvalho JM, Rahbar K, et al. Incremental diagnostic value of [(18)F]tetrafluoroborate PET-CT compared to [(131)I]iodine scintigraphy in recurrent differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging* 2020;47(11):2639–2646; doi: 10.1007/s00259-020-04727-9
1016. Lawhn-Heath C, Yom SS, Liu C, et al. Gallium-68 prostate-specific membrane antigen [(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: A feasibility study. *EJNMMI Res* 2020;10(1):128; doi: 10.1186/s13550-020-00720-3
1017. Ocak M, Demirci E, Kabasakal L, et al. Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid

- cancer. *Nucl Med Commun* 2013;34(11):1084–1089; doi: 10.1097/MNM.0b013e328364eaab
1018. Freudenberg LS, Jentzen W, Stahl A, et al. Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging* 2011;38(Suppl 1):S48–S56; doi: 10.1007/s00259-011-1773-5
1019. Van Nostrand D, Moreau S, Bandaru VV, et al. (124)I positron emission tomography versus (131)I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer. *Thyroid* 2010;20(8):879–883; doi: 10.1089/thy.2009.0430
1020. Phan HT, Jager PL, Paans AM, et al. The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging* 2008;35(5):958–965; doi: 10.1007/s00259-007-0660-6
1021. Wu D, Yili D, Heimlich SL, et al. (124)I positron emission tomography/computed tomography versus conventional radioiodine imaging in differentiated thyroid cancer: A review. *Thyroid* 2019;29(11):1523–1535; doi: 10.1089/thy.2018.0598
1022. Gulec SA, Kuker RA, Goryawala M, et al. (124)I PET/CT in patients with differentiated thyroid cancer: Clinical and quantitative image analysis. *Thyroid* 2016;26(3):441–448; doi: 10.1089/thy.2015.0482
1023. Santhanam P, Taieb D, Solnes L, et al. Utility of I-124 PET/CT in identifying radioiodine avid lesions in differentiated thyroid cancer: A systematic review and meta-analysis. *Clin Endocrinol (Oxf)* 2017;86(5):645–651; doi: 10.1111/cen.13306
1024. Qichang W, Lin B, Gege Z, et al. Diagnostic performance of 18F-FDG-PET/CT in DTC patients with thyroglobulin elevation and negative iodine scintigraphy: A meta-analysis. *Eur J Endocrinol* 2019;181(2):93–102; doi: 10.1530/eje-19-0261
1025. Araz M, Soydal Ç, Özkan E, et al. Role of thyroglobulin doubling time in differentiated thyroid cancer and its relationship with demographic-histopathologic risk factors and (18)f-fluorodeoxyglucose positron emission tomography/computed tomography parameters. *Cancer Biother Radiopharm* 2021;36(5):425–432; doi: 10.1089/cbr.2019.3203
1026. Albano D, Tulchinsky M, Dondi F, et al. The role of Tg kinetics in predicting 2-[(18)F]-FDG PET/CT results and overall survival in patients affected by differentiated thyroid carcinoma with detectable Tg and negative 131I-scan. *Endocrine* 2021;74(2):332–339; doi: 10.1007/s12020-021-02755-5
1027. Albano D, Tulchinsky M, Dondi F, et al. Thyroglobulin doubling time offers a better threshold than thyroglobulin level for selecting optimal candidates to undergo localizing [(18)F]FDG PET/CT in non-iodine avid differentiated thyroid carcinoma. *Eur J Nucl Med Mol Imaging* 2021;48(2):461–468; doi: 10.1007/s00259-020-04992-8
1028. Wang H, Dai H, Li Q, et al. Investigating (18)F-FDG PET/CT parameters as prognostic markers for differentiated thyroid cancer: A systematic review. *Front Oncol* 2021;11:648658; doi: 10.3389/fonc.2021.648658
1029. Albano D, Dondi F, Mazzeletti A, et al. Prognostic role of 2-[(18)F]FDG PET/CT metabolic volume parameters in patients affected by differentiated thyroid carcinoma with high thyroglobulin level. Negative (131)I WBS and Positive 2-[(18)F]-FDG PET/CT. *Diagnostics (Basel)* 2021;11(12); doi: 10.3390/diagnostics11122189
1030. Giovanella L, Trimboli P, Verburg FA, et al. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. *Eur J Nucl Med Mol Imaging* 2013;40(6):874–880; doi: 10.1007/s00259-013-2370-6
1031. Leboulleux S, Schroeder PR, Busaidy NL, et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. *J Clin Endocrinol Metab* 2009;94(4):1310–1316; doi: 10.1210/jc.2008-1747
1032. Lee SG, Lee WK, Lee HS, et al. Practical performance of the 2015 American Thyroid Association guidelines for predicting tumor recurrence in patients with papillary thyroid cancer in South Korea. *Thyroid* 2017;27(2):174–181; doi: 10.1089/thy.2016.0252
1033. Grani G, Zatelli MC, Alfò M, et al. Real-world performance of the American Thyroid Association risk estimates in predicting 1-year differentiated thyroid cancer outcomes: A prospective multicenter study of 2000 patients. *Thyroid* 2021;31(2):264–271; doi: 10.1089/thy.2020.0272
1034. Jammah AA, AlSadhan IM, Alyusuf EY, et al. The American Thyroid Association risk stratification and long-term outcomes of differentiated thyroid cancer: A 20-year follow-up of patients in Saudi Arabia. *Front Endocrinol (Lausanne)* 2023;14:1256232; doi: 10.3389/fendo.2023.1256232
1035. Ozkan E, Soydal C, Nak D, et al. Dynamic risk stratification for predicting the recurrence in differentiated thyroid cancer. *Nucl Med Commun* 2017;38(12):1055–1059; doi: 10.1097/mnm.0000000000000766
1036. Lee YM, Cho JW, Hong SJ, et al. Dynamic risk stratification in papillary thyroid carcinoma measuring 1 to 4 cm. *J Surg Oncol* 2018;118(4):636–643; doi: 10.1002/jso.25182
1037. Cano-Palomares A, Castells I, Capel I, et al. Response to initial therapy of differentiated thyroid cancer predicts the long-term outcome better than classical risk stratification systems. *Int J Endocrinol* 2014;2014:591285; doi: 10.1155/2014/591285
1038. Hong CM, Lee WK, Jeong SY, et al. Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation. *Nucl Med Commun* 2014;35(11):1119–1126; doi: 10.1097/mnm.0000000000000183
1039. Kowalska A, Walczyk A, Pałyga I, et al. The delayed risk stratification system in the risk of differentiated thyroid cancer recurrence. *PLoS One* 2016;11(4):e0153242; doi: 10.1371/journal.pone.0153242
1040. Jeon MJ, Kim M, Park S, et al. A follow-up strategy for patients with an excellent response to initial therapy for differentiated thyroid carcinoma: Less is better. *Thyroid* 2018;28(2):187–192; doi: 10.1089/thy.2017.0130
1041. Pérez-Fernández L, Sastre J, Zafón C, et al. Validation of dynamic risk stratification and impact of BRAF in risk assessment of thyroid cancer, a nation-wide multicenter study. *Front Endocrinol (Lausanne)* 2022;13:1071775; doi: 10.3389/fendo.2022.1071775
1042. Pitoia F, Jerkovich F. Dynamic risk assessment in patients with differentiated thyroid cancer. *Endocr Relat Cancer* 2019;26(10):R553–R566; doi: 10.1530/erc-19-0213
1043. Pitoia F, Jerkovich F, Urciuoli C, et al. Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low

- and Intermediate Risk of Recurrence. *Thyroid* 2015; 25(11):1235–1242; doi: 10.1089/thy.2015.0121
1044. Cuéllar DI, De Los Reyes A, Llamas-Olier A. Modified dynamic risk stratification system further predicts individual outcome in patients with intermediate-risk papillary thyroid cancer. *Ann Endocrinol (Paris)* 2023;84(2): 242–248; doi: 10.1016/j.ando.2022.03.003
  1045. Tian T, Kou Y, Huang R, et al. Prognosis of high-risk papillary thyroid cancer patients with pre-ablation stimulated TG <1 NG/ML. *Endocr Pract* 2019;25(3):220–225; doi: 10.4158/ep-2018-0436
  1046. Yoon J, Yoon JH, Han K, et al. Ultrasonography surveillance in papillary thyroid carcinoma patients after total thyroidectomy according to dynamic risk stratification. *Endocrine* 2020;69(2):347–357; doi: 10.1007/s12020-020-02347-9
  1047. Abelleira E, Jerkovich F. Dynamic risk assessment in patients with differentiated thyroid cancer. *Rev Endocr Metab Disord* 2024;25(1):79–93; doi: 10.1007/s11154-023-09857-7
  1048. Trimboli P, Zilioli V, Imperiali M, et al. High-sensitive basal serum thyroglobulin 6-12 months after thyroid ablation is strongly associated with early response to therapy and event-free survival in patients with low-to-intermediate risk differentiated thyroid carcinomas. *Eur J Endocrinol* 2017;176(5):497–504; doi: 10.1530/eje-16-1011
  1049. Cho JW, Lee YM, Lee YH, et al. Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients. *Clin Endocrinol (Oxf)* 2018;89(1):100–109; doi: 10.1111/cen.13721
  1050. Park JH, Moon GS, Nam KT, et al. Optimal timing of initiating dynamic risk stratification during the early postoperative period in patients with differentiated thyroid carcinoma after thyroidectomy and radioactive iodine remnant ablation. *Ann Surg Oncol* 2021;28(11):6580–6589; doi: 10.1245/s10434-021-09721-5
  1051. Pałyga I, Rumian M, Kosel A, et al. The frequency of differentiated thyroid cancer recurrence in 2302 patients with excellent response to primary therapy. *J Clin Endocrinol Metab* 2024;109(2):e569–e578; doi: 10.1210/clinem/dgad571
  1052. Lee JH, Chung YS, Lee YD. A variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study. *Head Neck* 2017; 39(4):767–771; doi: 10.1002/hed.24684
  1053. Giordano D, Frasoldati A, Gabrielli E, et al. Long-term outcomes of central neck dissection for cN0 papillary thyroid carcinoma. *Am J Otolaryngol* 2017;38(5): 576–581; doi: 10.1016/j.amjoto.2017.06.004
  1054. Kruijff S, Petersen JF, Chen P, et al. Patterns of structural recurrence in papillary thyroid cancer. *World J Surg* 2014;38(3):653–659; doi: 10.1007/s00268-013-2286-0
  1055. Lang BH, Shek TW, Chan AO, et al. Significance of size of persistent/recurrent central nodal disease on surgical morbidity and response to therapy in reoperative neck dissection for papillary thyroid carcinoma. *Thyroid* 2017; 27(1):67–73; doi: 10.1089/thy.2016.0337
  1056. Bosset M, Bonjour M, Castellnou S, et al. Long-term outcome of lobectomy for thyroid cancer. *Eur Thyroid J* 2021;10(6):486–494; doi: 10.1159/000510620
  1057. Misra S, Meiyappan S, Heus L, et al. Patients' experiences following local-regional recurrence of thyroid cancer: A qualitative study. *J Surg Oncol* 2013;108(1):47–51; doi: 10.1002/jso.23345
  1058. Robenshtok E, Fish S, Bach A, et al. Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients. *J Clin Endocrinol Metab* 2012; 97(8):2706–2713; doi: 10.1210/jc.2012-1553
  1059. Ito Y, Higashiyama T, Takamura Y, et al. Prognosis of patients with papillary thyroid carcinoma showing post-operative recurrence to the central neck. *World J Surg* 2011;35(4):767–772; doi: 10.1007/s00268-010-0924-3
  1060. Uchida H, Imai T, Kikumori T, et al. Long-term results of surgery for papillary thyroid carcinoma with local recurrence. *Surg Today* 2013;43(8):848–853; doi: 10.1007/s00595-012-0353-z
  1061. Newman KD, Black T, Heller G, et al. Differentiated thyroid cancer: Determinants of disease progression in patients <21 years of age at diagnosis: A report from the Surgical Discipline Committee of the Children's Cancer Group. *Ann Surg* 1998;227(4):533–541.
  1062. Robie DK, Dinauer CW, Tuttle RM, et al. The impact of initial surgical management on outcome in young patients with differentiated thyroid cancer. *J Pediatr Surg* 1998; 33(7):1134–1140; doi: 10.1016/s0022-3468(98)90546-2
  1063. Merdad M, Eskander A, Kroeker T, et al. Predictors of level II and Vb neck disease in metastatic papillary thyroid cancer. *Arch Otolaryngol Head Neck Surg* 2012; 138(11):1030–1033; doi: 10.1001/2013.jamaoto.393
  1064. Eskander A, Merdad M, Freeman JL, et al. Pattern of spread to the lateral neck in metastatic well-differentiated thyroid cancer: A systematic review and meta-analysis. *Thyroid* 2013;23(5):583–592; doi: 10.1089/thy.2012.0493
  1065. Onuma AE, Beal EW, Nabhan F, et al. Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer: 13-year follow-up. *Ann Surg Oncol* 2019; 26(6):1737–1743; doi: 10.1245/s10434-019-07263-5
  1066. Kalaitzidou S, Papadakis G, Saper A, et al. Outcomes of surgery and radioiodine treatment for neck recurrence in papillary thyroid cancer. *J Buon* 2020;25(1):383–388.
  1067. Lamartina L, Borget I, Mirghani H, et al. Surgery for neck recurrence of differentiated thyroid cancer: Outcomes and risk factors. *J Clin Endocrinol Metab* 2017; 102(3):1020–1031; doi: 10.1210/jc.2016-3284
  1068. Fontenot TE, Deniwar A, Bhatia P, et al. Percutaneous ethanol injection vs reoperation for locally recurrent papillary thyroid cancer: A systematic review and pooled analysis. *JAMA Otolaryngol Head Neck Surg* 2015; 141(6):512–518; doi: 10.1001/jamaoto.2015.0596
  1069. Frich PS, Sigstad E, Berstad AE, et al. Long-term efficacy of ethanol ablation as treatment of metastatic lymph nodes from papillary thyroid carcinoma. *J Clin Endocrinol Metab* 2022;107(5):e2141–e2147; doi: 10.1210/clinem/dgab907
  1070. Heilo A, Sigstad E, Fagerlid KH, et al. Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma. *J Clin Endocrinol Metab* 2011;96(9):2750–2755; doi: 10.1210/jc.2010-2952
  1071. Hay ID, Lee RA, Davidge-Pitts C, et al. Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected "recurrent" neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy. *Surgery* 2013;154(6):1448–1454; doi: 10.1016/j.surg.2013.07.007
  1072. Toe S, Argüelles I, Serra G, et al. Ultrasound-guided percutaneous ethanol ablation for the management of

- recurrent thyroid cancer: Evaluation of efficacy and impact on disease course. *Int J Thyroidol* 2020;13(2):128–141; doi: 10.11106/ijt.2020.13.2.128
1073. Kim SY, Kim SM, Chang H, et al. Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid cancer. *Eur Arch Otorhinolaryngol* 2017;274(9):3497–3501; doi: 10.1007/s00405-017-4660-2
1074. Park KW, Shin JH, Han BK, et al. Inoperable symptomatic recurrent thyroid cancers: Preliminary result of radiofrequency ablation. *Ann Surg Oncol* 2011;18(9):2564–2568; doi: 10.1245/s10434-011-1619-1
1075. Baek JH, Kim YS, Sung JY, et al. Locoregional control of metastatic well-differentiated thyroid cancer by ultrasound-guided radiofrequency ablation. *AJR Am J Roentgenol* 2011;197(2):W331–W336; doi: 10.2214/AJR.10.5345
1076. Lee SJ, Jung SL, Kim BS, et al. Radiofrequency ablation to treat loco-regional recurrence of well-differentiated thyroid carcinoma. *Korean J Radiol* 2014;15(6):817–826; doi: 10.3348/kjr.2014.15.6.817
1077. Kim JH, Yoo WS, Park YJ, et al. Efficacy and safety of radiofrequency ablation for treatment of locally recurrent thyroid cancers smaller than 2 cm. *Radiology* 2015;276(3):909–918; doi: 10.1148/radiol.15140079
1078. Guang Y, Luo Y, Zhang Y, et al. Efficacy and safety of percutaneous ultrasound guided radiofrequency ablation for treating cervical metastatic lymph nodes from papillary thyroid carcinoma. *J Cancer Res Clin Oncol* 2017;143(8):1555–1562; doi: 10.1007/s00432-017-2386-6
1079. Suh CH, Baek JH, Choi YJ, et al. Efficacy and safety of radiofrequency and ethanol ablation for treating locally recurrent thyroid cancer: A systematic review and meta-analysis. *Thyroid* 2016;26(3):420–428; doi: 10.1089/thy.2015.0545
1080. Chung SR, Baek JH, Choi YJ, et al. Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer. *Eur Radiol* 2019;29(9):4897–4903; doi: 10.1007/s00330-019-06063-5
1081. Choi Y, Jung SL, Bae JS, et al. Comparison of efficacy and complications between radiofrequency ablation and repeat surgery in the treatment of locally recurrent thyroid cancers: A single-center propensity score matching study. *Int J Hyperthermia* 2019;36(1):359–367; doi: 10.1080/02656736.2019.1571248
1082. Tufano RP, Pace-Asciak P, Russell JO, et al. Update of radiofrequency ablation for treating benign and malignant thyroid nodules. The future is now. *Front Endocrinol (Lausanne)* 2021;12:698689; doi: 10.3389/fendo.2021.698689
1083. Chung SR, Suh CH, Baek JH, et al. Safety of radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: A systematic review and meta-analysis. *Int J Hyperthermia* 2017;33(8):920–930; doi: 10.1080/02656736.2017.1337936
1084. Jasim S, Patel KN, Randolph G, et al. American association of clinical endocrinology disease state clinical review: The clinical utility of minimally invasive interventional procedures in the management of benign and malignant thyroid lesions. *Endocr Pract* 2022;28(4):433–448; doi: 10.1016/j.eprac.2022.02.011
1085. Papini E, Bizzarri G, Bianchini A, et al. Percutaneous ultrasound-guided laser ablation is effective for treating selected nodal metastases in papillary thyroid cancer. *J Clin Endocrinol Metab* 2013;98(1):E92–E97; doi: 10.1210/jc.2012-2991
1086. Mauri G, Cova L, Ierace T, et al. Treatment of metastatic lymph nodes in the neck from papillary thyroid carcinoma with percutaneous laser ablation. *Cardiovasc Intervent Radiol* 2016;39(7):1023–1030; doi: 10.1007/s00270-016-1313-6
1087. Guo Y, Li Z, Wang S, et al. Single-fiber laser ablation in treating selected metastatic lymph nodes of papillary thyroid carcinoma and benign cold thyroid nodules-preliminary results. *Lasers Surg Med* 2020;52(5):408–418; doi: 10.1002/lsm.23150
1088. Hirsch D, Gorshtein A, Robenshtok E, et al. Second radioiodine treatment: Limited benefit for differentiated thyroid cancer with locoregional persistent disease. *J Clin Endocrinol Metab* 2018;103(2):469–476; doi: 10.1210/jc.2017-01790
1089. Hung ML, Wu JX, Li N, et al. Association of radioactive iodine administration after reoperation with outcomes among patients with recurrent or persistent papillary thyroid cancer. *JAMA Surg* 2018;153(12):1098–1104; doi: 10.1001/jamasurg.2018.2659
1090. Piccardo A, Puntoni M, Bottoni G, et al. Differentiated thyroid cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy. *Eur J Nucl Med Mol Imaging* 2017;44(6):926–934; doi: 10.1007/s00259-016-3593-0
1091. Haymart MR, Muenz DG, Stewart AK, et al. Disease severity and radioactive iodine use for thyroid cancer. *J Clin Endocrinol Metab* 2013;98(2):678–686; doi: 10.1210/jc.2012-3160
1092. Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. *Thyroid* 2009;19(12):1381–1391; doi: 10.1089/thy.2009.1611
1093. Higashi T, Nishii R, Yamada S, et al. Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: A retrospective statistical analysis of 198 cases. *J Nucl Med* 2011;52(5):683–689; doi: 10.2967/jnumed.110.081059
1094. Yim JH, Kim WB, Kim EY, et al. Adjuvant radioactive therapy after reoperation for locoregionally recurrent papillary thyroid cancer in patients who initially underwent total thyroidectomy and high-dose remnant ablation. *J Clin Endocrinol Metab* 2011;96(12):3695–3700; doi: 10.1210/jc.2011-1270
1095. Van Nostrand D, Atkins F, Yeganeh F, et al. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. *Thyroid* 2002;12(2):121–134; doi: 10.1089/105072502753522356
1096. Chiesa C, Castellani MR, Vellani C, et al. Individualized dosimetry in the management of metastatic differentiated thyroid cancer. *Q J Nucl Med Mol Imaging* 2009;53(5):546–561.
1097. Lawhn-Heath C, Hope TA, Martinez J, et al. Dosimetry in radionuclide therapy: The clinical role of measuring radiation dose. *Lancet Oncol* 2022;23(2):e75–e87.
1098. Verburg FA, Hanscheid H, Biko J, et al. Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: Initial experience. *Eur J Nucl Med Mol Imaging* 2010;37(5):896–903; doi: 10.1007/s00259-009-1303-x
1099. Van Nostrand D, Atkins F, Moreau S, et al. Utility of the radioiodine whole-body retention at 48 hours for modifying empiric activity of 131-iodine for the treatment of metastatic well-differentiated thyroid carcinoma. *Thyroid* 2009;19(10):1093–1098; doi: 10.1089/thy.2008.0339

1100. Dorn R, Kopp J, Vogt H, et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: Largest safe dose using a risk-adapted approach. *J Nucl Med* 2003;44(3):451–456.
1101. Maxon H. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. *The Quarterly Journal of Nuclear Medicine and Molecular Imaging* 1999; 43(4):313.
1102. Holst JP, Burman KD, Atkins F, et al. Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. *Thyroid* 2005;15(12):1321–1331; doi: 10.1089/thy.2005.15.1321
1103. Vermandel M, Debruyne P, Beron A, et al. Management of patients with renal failure undergoing dialysis during 131I therapy for thyroid cancer. *J Nucl Med* 2020;61(8): 1161–1170.
1104. Luster M, Lassmann M, Freudenberg LS, et al. Thyroid cancer in childhood: Management strategy, including dosimetry and long-term results. *Hormones (Athens)* 2007;6(4):269–278. -
1105. Verburg FA, Biko J, Diessl S, et al. I-131 activities as high as safely administrable (AHASA) for the treatment of children and adolescents with advanced differentiated thyroid cancer. *J Clin Endocrinol Metab* 2011;96(8): E1268–E1271; doi: 10.1210/jc.2011-0520
1106. Lee JJ, Chung JK, Kim SE, et al. Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma. *Ann Nucl Med* 2008; 22(9):727–734; doi: 10.1007/s12149-007-0179-8
1107. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. *N Engl J Med* 1983; 309(16):937–941; doi: 10.1056/NEJM198310203091601
1108. Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. *J Nucl Med* 1998;39(9):1531–1536.
1109. Deandreis D, Rubino C, Tala H, et al. Comparison of empiric versus whole-body/-blood clearance dosimetry-based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer. *J Nucl Med* 2017;58(5):717–722.
1110. Van Nostrand D. Prescribed activity of 131I therapy in differentiated thyroid cancer. *J Nucl Med* 2017;58(5): 697–699; doi: 10.2967/jnumed.116.188862
1111. Reiners C, Biko J, Haenscheid H, et al. Twenty-five years after Chernobyl: Outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 2013;98(7):3039–3048; doi: 10.1210/jc.2013-1059
1112. Jentzen W, Freudenberg L, Eising EG, et al. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. *J Nucl Med* 2008;49(6): 1017–1023; doi: 10.2967/jnumed.107.047159
1113. Weber M, Binse I, Nagarajah J, et al. The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer. *Q J Nucl Med Mol Imaging* 2019;63(3):235–252.
1114. Durski JM, Hruska CB, Bogsrud TV, et al. 123I scan with whole-body retention measurement at 48 hours for simplified dosimetry before 131I treatment of metastatic thyroid cancer. *Clin Nucl Med* 2021;46(3):e151–e153.
1115. Hänscheid H, Lassmann M, Luster M, et al. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. *Endocr Relat Cancer* 2009;16(4):1283–1289; doi: 10.1677/ERC-09-0076
1116. Schlumberger M, Lacroix L, Russo D, et al. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. *Nat Clin Pract Endocrinol Metab* 2007;3(3):260–269; doi: 10.1038/ncpendmet0449
1117. Van Nostrand D, Khorjekar GR, O’Neil J, et al. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET. *J Nucl Med* 2012;53(3):359–362; doi: 10.2967/jnumed.111.096016
1118. Plyku D, Hobbs RF, Huang K, et al. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in 124I PET/CT-based dosimetry for 131I therapy of metastatic differentiated thyroid cancer. *J Nucl Med* 2017;58(7):1146–1154.
1119. Luster M, Lassmann M, Haenscheid H, et al. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 2000;85(10):3640–3645; doi: 10.1210/jcem.85.10.6903
1120. Gomes-Lima CJ, Chittimoju S, Wehbeh L, et al. Metastatic differentiated thyroid cancer survival is unaffected by mode of preparation for 131I administration. *J Endocr Soc* 2022;6(5):bvac032.
1121. Potzi C, Moameni A, Karanikas G, et al. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. *Clin Endocrinol (Oxf)* 2006; 65(4):519–523; doi: 10.1111/j.1365-2265.2006.02626.x
1122. Vargas GE, Uy H, Bazan C, et al. Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. *J Clin Endocrinol Metab* 1999;84(11):3867–3871; doi: 10.1210/jcem.84.11.6161
1123. Braga M, Ringel MD, Cooper DS. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. *J Clin Endocrinol Metab* 2001; 86(11):5148–5151; doi: 10.1210/jcem.86.11.8055
1124. Song H-J, Qiu Z-L, Shen C-T, et al. Pulmonary metastases in differentiated thyroid cancer: Efficacy of radioiodine therapy and prognostic factors. *Eur J Endocrinol* 2015;173(3):399–408.
1125. Ball JE, Alpers JB, Lewallen CG, et al. Radiation pneumonitis and fibrosis: A complication of radioiodine treatment of pulmonary metastases from cancer of the thyroid\*. *The Journal of Clinical Endocrinology & Metabolism* 1957; 17(11):1263–1276; doi: 10.1210/jcem-17-11-1263
1126. Hebestreit H, Biko J, Drozd V, et al. Pulmonary fibrosis in youth treated with radioiodine for juvenile thyroid cancer and lung metastases after Chernobyl. *Eur J Nucl Med Mol Imaging* 2011;38(9):1683–1690; doi: 10.1007/s00259-011-1841-x
1127. Ronga G, Filesi M, Montesano T, et al. Lung metastases from differentiated thyroid carcinoma. A 40 years’ experience. *Q J Nucl Med Mol Imaging* 2004;48(1):12–19.
1128. Schlumberger M, Challeton C, de VF, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. *J Nucl Med* 1996;37(4):598–605.
1129. Ilgan S, Karacalioglu AO, Pabuscu Y, et al. Iodine-131 treatment and high-resolution CT: Results in patients with lung metastases from differentiated thyroid carcinoma. *Eur*

- J Nucl Med Mol Imaging 2004;31(6):825–830; doi: 10.1007/s00259-004-1460-x
1130. Hod N, Hagag P, Baumer M, et al. Differentiated thyroid carcinoma in children and young adults: Evaluation of response to treatment. *Clin Nucl Med* 2005;30(6):387–390.
  1131. Fatourehchi V, Hay ID, Javedan H, et al. Lack of impact of radioiodine therapy in Tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. *J Clin Endocrinol Metab* 2002;87(4):1521–1526; doi: 10.1210/jcem.87.4.8373
  1132. Ma C, Kuang A, Xie J. Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases. *Cochrane Database Syst Rev* 2009;2009(1):CD006988–C38; doi: 10.1002/14651858.CD006988.pub2
  1133. Sabra MM, Grewal RK, Tala H, et al. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans. *Thyroid* 2012;22(9):877–883; doi: 10.1089/thy.2011.0429
  1134. Bernier MO, Leenhardt L, Hoang C, et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. *J Clin Endocrinol Metab* 2001;86(4):1568–1573; doi: 10.1210/jcem.86.4.7390
  1135. Jannin A, Lamartina L, Moutarde C, et al. Bone metastases from differentiated thyroid carcinoma: Heterogenous tumor response to radioactive Iodine therapy and overall survival. *Eur J Nucl Med Mol Imaging* 2022;49(7):2401–2413; doi: 10.1007/s00259-022-05697-w
  1136. Qiu Z-L, Song H-J, Xu Y-H, et al. Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer. *J Clin Endocrinol Metab* 2011;96(10):3078–3086.
  1137. Wu D, Gomes Lima CJ, Moreau SL, et al. Improved survival after multimodal approach with 131I treatment in patients with bone metastases secondary to differentiated thyroid cancer. *Thyroid* 2019;29(7):971–978.
  1138. Pacini F, Agate L, Elisei R, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: Comparison of patients treated with high (131)I activities versus untreated patients. *J Clin Endocrinol Metab* 2001;86(9):4092–4097; doi: 10.1210/jcem.86.9.7831
  1139. van Tol KM, Jager PL, de Vries EG, et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. *Eur J Endocrinol* 2003;148(6):589–596.
  1140. Kabasakal L, Selcuk NA, Shafipour H, et al. Treatment of iodine-negative thyroglobulin-positive thyroid cancer: Differences in outcome in patients with macrometastases and patients with micrometastases. *Eur J Nucl Med Mol Imaging* 2004;31(11):1500–1504; doi: 10.1007/s00259-004-1516-y
  1141. Padovani RP, Robenshtok E, Brokhin M, et al. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. *Thyroid* 2012;22(8):778–783; doi: 10.1089/thy.2011.0522
  1142. Yim JH, Kim EY, Bae KW, et al. Long-term consequence of elevated thyroglobulin in differentiated thyroid cancer. *Thyroid* 2013;23(1):58–63; doi: 10.1089/thy.2011.0487
  1143. Miyauchi A, Kudo T, Miya A, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. *Thyroid* 2011;21(7):707–716; doi: 10.1089/thy.2010.0355
  1144. Huang SH, Wang PW, Huang YE, et al. Sequential follow-up of serum thyroglobulin and whole body scan in thyroid cancer patients without initial metastasis. *Thyroid* 2006;16(12):1273–1278; doi: 10.1089/thy.2006.16.1273
  1145. Schlumberger M, Mancusi F, Baudin E, et al. 131I therapy for elevated thyroglobulin levels. *Thyroid* 1997;7(2):273–276.
  1146. Ma C, Xie J, Kuang A. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results? *J Nucl Med* 2005;46(7):1164–1170.
  1147. Koh JM, Kim ES, Ryu JS, et al. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: Comparative study. *Clin Endocrinol (Oxf)* 2003;58(4):421–427.
  1148. Sinha P, Conrad GR, West HC. Response of thyroglobulin to radioiodine therapy in thyroglobulin-elevated negative iodine scintigraphy (TENIS) syndrome. *Anticancer Res* 2011;31(6):2109–2112.
  1149. Baudin E, Do CC, Cailleux AF, et al. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. *J Clin Endocrinol Metab* 2003;88(3):1107–1111; doi: 10.1210/jc.2002-021365
  1150. Pineda JD, Lee T, Ain K, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. *J Clin Endocrinol Metab* 1995;80(5):1488–1492; doi: 10.1210/jcem.80.5.7744991
  1151. Alzahrani AS, Mohamed G, Al SA, et al. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer. *J Endocrinol Invest* 2005;28(6):540–546.
  1152. Kim WG, Ryu JS, Kim EY, et al. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan. *J Clin Endocrinol Metab* 2010;95(3):1169–1173; doi: 10.1210/jc.2009-1567
  1153. Biko J, Reiners C, Kreissl MC, et al. Favourable course of disease after incomplete remission on (131)I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up. *Eur J Nucl Med Mol Imaging* 2011;38(4):651–655; doi: 10.1007/s00259-010-1669-9
  1154. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. *J Clin Endocrinol Metab* 2006;91(8):2892–2899; doi: 10.1210/jc.2005-2838
  1155. Van Nostrand D. Radioiodine refractory differentiated thyroid cancer: Time to update the classifications. *Thyroid* 2018;28(9):1083–1093; doi: 10.1089/thy.2018.0048
  1156. Gulec SA, Ahuja S, Avram AM, et al. A joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on current diagnostic and theranostic

- approaches in the management of thyroid cancer. *Thyroid* 2021;31(7):1009–1019; doi: 10.1089/thy.2020.0826
1157. Fugazzola L, Elisei R, Fuhrer D, et al. 2019 European Thyroid Association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. *Eur Thyroid J* 2019;8(5):227–245.
1158. Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. *J Clin Endocrinol Metab* 2006;91(2):498–505; doi: 10.1210/jc.2005-1534
1159. Deandreis D, Al GA, Leboulleux S, et al. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? *Endocr Relat Cancer* 2011;18(1):159–169; doi: 10.1677/ERC-10-0233
1160. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur J Cancer* 2009; 45(2):228–247; doi: 10.1016/j.ejca.2008.10.026
1161. Sabra MM, Sherman EJ, Tuttle RM. Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. *Cancer* 2017;123(15):2955–2964; doi: 10.1002/cncr.30690
1162. Giovanella L, Garo ML, Albano D, et al. The role of thyroglobulin doubling time in differentiated thyroid cancer: A meta-analysis. *Endocr Connect* 2022;11(4):e210648; doi: 10.1530/ec-21-0648
1163. Lubitz CC, Sadow PM, Daniels GH, et al. Progress in treating advanced thyroid cancers in the era of targeted therapy. *Thyroid* 2021;31(10):1451–1462; doi: 10.1089/thy.2020.0962
1164. Leboulleux S, Lamartina L, Hadoux J, et al. Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer. *Expert Opin Investig Drugs* 2022; 31(7):669–679; doi: 10.1080/13543784.2022.2071696
1165. Stransky N, Cerami E, Schalm S, et al. The landscape of kinase fusions in cancer. *Nat Commun* 2014;5:4846; doi: 10.1038/ncomms5846
1166. Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nat Med* 2017; 23(6):703–713; doi: 10.1038/nm.4333
1167. Toda S, Hiroshima Y, Iwasaki H, et al. Genomic landscape and clinical features of advanced thyroid carcinoma: A national database study in Japan. *J Clin Endocrinol Metab* 2024;109(11):2784–2792; doi: 10.1210/clinem/dgae271
1168. Chakravarty D, Johnson A, Sklar J, et al. Somatic genomic testing in patients with metastatic or advanced cancer: ASCO Provisional Clinical Opinion. *J Clin Oncol* 2022;40(11):1231–1258; doi: 10.1200/jco.21.02767
1169. Shonka DC, Jr, Ho A, Chintakuntlawar AV, et al. American Head and Neck Society Endocrine Surgery section and international thyroid oncology group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. *Head Neck* 2022;44(6):1277–1300; doi: 10.1002/hed.27025
1170. Sorokin M, Rabushko E, Rozenberg JM, et al. Clinically relevant fusion oncogenes: Detection and practical implications. *Ther Adv Med Oncol* 2022;14:17588359221144108; doi: 10.1177/17588359221144108
1171. Zagzag J, Pollack A, Dultz L, et al. Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. *Surgery* 2013;154(6):1199–1204; discussion 12045; doi: 10.1016/j.surg.2013.06.020
1172. Routhier CA, Mochel MC, Lynch K, et al. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. *Hum Pathol* 2013;44(11): 2563–2570; doi: 10.1016/j.humpath.2013.06.018
1173. Dvorak K, Aggeler B, Palting J, et al. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: Impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma. *Pathology* 2014;46(6):509–517; doi: 10.1097/pat.000000000000119
1174. Ilie MI, Lassalle S, Long-Mira E, et al. Diagnostic value of immunohistochemistry for the detection of the BRAF (V600E) mutation in papillary thyroid carcinoma: Comparative analysis with three DNA-based assays. *Thyroid* 2014;24(5):858–866; doi: 10.1089/thy.2013.0302
1175. Oh HS, Kwon H, Park S, et al. Comparison of immunohistochemistry and direct Sanger sequencing for detection of the BRAF(V600E) mutation in thyroid neoplasm. *Endocrinol Metab (Seoul)* 2018;33(1):62–69; doi: 10.3803/EnM.2018.33.1.62
1176. Rashid FA, Tabassum S, Khan MS, et al. VE1 immunohistochemistry is an adjunct tool for detection of BRAF (V600E) mutation: Validation in thyroid cancer patients. *J Clin Lab Anal* 2021;35(2):e23628; doi: 10.1002/jcla.23628
1177. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. *Lancet Oncol* 2020; 21(10):1353–1365; doi: 10.1016/s1470-2045(20)30445-9
1178. Shobab L, Gomes-Lima C, Zeymo A, et al. Clinical, pathological, and molecular profiling of radioactive iodine refractory differentiated thyroid cancer. *Thyroid* 2019; 29(9):1262–1268; doi: 10.1089/thy.2019.0075
1179. Shao C, Li G, Huang L, et al. Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors. *JAMA Netw Open* 2020; 3(10):e2025109; doi: 10.1001/jamanetworkopen.2020.25109
1180. Genutis LK, Tomsic J, Bundschuh RA, et al. Microsatellite instability occurs in a subset of follicular thyroid cancers. *Thyroid* 2019;29(4):523–529; doi: 10.1089/thy.2018.0655
1181. Chowdhury S, Veyhl J, Jessa F, et al. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. *Oncotarget* 2016;7(22):32318–32328; doi: 10.18632/oncotarget.8698
1182. Bastman JJ, Serracino HS, Zhu Y, et al. Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer. *J Clin Endocrinol Metab* 2016;101(7):2863–2873; doi: 10.1210/jc.2015-4227
1183. Mehnert JM, Varga A, Brose MS, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. *BMC Cancer* 2019;19(1):196; doi: 10.1186/s12885-019-5380-3

1184. Bettgowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med* 2014;6(224):224ra24; doi: 10.1126/scitranslmed.3007094
1185. Condello V, Macerola E, Ugolini C, et al. Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma. *Head Neck* 2018;40(8):1752–1758; doi: 10.1002/hed.25155
1186. Wijewardene AA, Chehade M, Gild ML, et al. Translational utility of liquid biopsies in thyroid cancer management. *Cancers (Basel)* 2021;13(14):3443; doi: 10.3390/cancers13143443
1187. Brose MS, Nutting CM, Jarzab B, et al; DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. *Lancet* 2014;384(9940):319–328; doi: 10.1016/S0140-6736(14)60421-9
1188. Brose MS, Schlumberger M, Jeffers M, et al. Analysis of biomarkers and association with clinical outcomes in patients with differentiated thyroid cancer: Subanalysis of the sorafenib phase III DECISION Trial. *Clin Cancer Res* 2019;25(24):7370–7380; doi: 10.1158/1078-0432.Ccr-18-3439
1189. Shen CT, Qiu ZL, Luo QY. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: A meta-analysis. *Endocr Relat Cancer* 2014;21(2):253–261; doi: 10.1530/erc-13-0438
1190. Kim M, Kim TH, Shin DY, et al; Korean Thyroid Cancer Study Group (KTCSCG). Tertiary care experience of sorafenib in the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma: A Korean multicenter study. *Thyroid* 2018;28(3):340–348; doi: 10.1089/thy.2017.0356
1191. Oh HS, Shin DY, Kim M, et al. Extended real-world observation of patients treated with sorafenib for radioactive iodine-refractory differentiated thyroid carcinoma and impact of lenvatinib salvage treatment: A Korean multicenter study. *Thyroid* 2019;29(12):1804–1810; doi: 10.1089/thy.2019.0246
1192. Feng G, Luo Y, Zhang Q, et al. Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): A systematic review and meta-analysis. *Endocrine* 2020;68(1):56–63; doi: 10.1007/s12020-019-02167-6
1193. Koehler VF, Berg E, Adam P, et al. Real-world efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer. *Thyroid* 2021;31(10):1531–1541; doi: 10.1089/thy.2021.0091
1194. Schlumberger M, Tahara M, Wirth LJ. Lenvatinib in radioiodine-refractory thyroid cancer. *N Engl J Med* 2015;372(19):1868; doi: 10.1056/NEJMc1503150
1195. Gianoukakis AG, Dutcus CE, Batty N, et al. Prolonged duration of response in lenvatinib responders with thyroid cancer. *Endocr Relat Cancer* 2018;25(6):699–704; doi: 10.1530/erc-18-0049
1196. Zheng X, Xu Z, Ji Q, et al. A randomized, phase III study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer. *Clin Cancer Res* 2021;27(20):5502–5509; doi: 10.1158/1078-0432.Ccr-21-0761
1197. Tahara M, Schlumberger M, Elisei R, et al. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. *Eur J Cancer* 2017;75:213–221; doi: 10.1016/j.ejca.2017.01.013
1198. Berdelou A, Borget I, Godbert Y, et al. Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. *Thyroid* 2018;28(1):72–78; doi: 10.1089/thy.2017.0205
1199. Locati LD, Piovesan A, Durante C, et al. Real-world efficacy and safety of lenvatinib: Data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. *Eur J Cancer* 2019;118:35–40; doi: 10.1016/j.ejca.2019.05.031
1200. Kish JK, Chatterjee D, Wan Y, et al. Lenvatinib and subsequent therapy for radioactive iodine-refractory differentiated thyroid cancer: a real-world study of clinical effectiveness in the United States. *Adv Ther* 2020;37(6):2841–2852; doi: 10.1007/s12325-020-01362-6
1201. Rendl G, Sipos B, Becherer A, et al. Real-world data for lenvatinib in radioiodine-refractory differentiated thyroid cancer (RELEVANT): A retrospective multicentric analysis of clinical practice in Austria. *Int J Endocrinol* 2020;2020:8834148; doi: 10.1155/2020/8834148
1202. Aydemirli MD, Kapiteijn E, Ferrier KRM, et al. Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data. *Eur J Endocrinol* 2020;182(2):131–138; doi: 10.1530/eje-19-0763
1203. Masaki C, Sugino K, Saito N, et al. Efficacy and limitations of lenvatinib therapy for radioiodine-refractory differentiated thyroid cancer: Real-world experiences. *Thyroid* 2020;30(2):214–221; doi: 10.1089/thy.2019.0221
1204. Porcelli T, Luongo C, Sessa F, et al. Long-term management of lenvatinib-treated thyroid cancer patients: A real-life experience at a single institution. *Endocrine* 2021;73(2):358–366; doi: 10.1007/s12020-021-02634-z
1205. Kim M, Jin M, Jeon MJ, et al. Lenvatinib compared with sorafenib as a first-line treatment for radioactive iodine-refractory, progressive, differentiated thyroid carcinoma: Real-world outcomes in a multicenter retrospective cohort study. *Thyroid* 2023;33(1):91–99; doi: 10.1089/thy.2022.0054
1206. Worden F, Rajkovic-Hooley O, Reynolds N, et al. Real-world treatment patterns and clinical outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with first line lenvatinib monotherapy in the United States. *Endocrine* 2024;84(2):663–669; doi: 10.1007/s12020-023-03638-7
1207. Kawalec P, Malinowska-Lipień I, Brzostek T, et al. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: A systematic review and indirect comparison with sorafenib. *Expert Rev Anticancer Ther* 2016;16(12):1303–1309; doi: 10.1080/14737140.2016.1247697
1208. Verburg FA, Amthauer H, Binse I, et al. Questions and controversies in the clinical application of tyrosine kinase inhibitors to treat patients with radioiodine-refractory differentiated thyroid carcinoma: Expert perspectives. *Horm Metab Res* 2021;53(3):149–160; doi: 10.1055/a-1380-4154
1209. Brose MS, Worden FP, Newbold KL, et al. Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial. *J Clin Oncol* 2017;35(23):2692–2699; doi: 10.1200/jco.2016.71.6472
1210. Tahara M, Kiyota N, Hoff AO, et al. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory

- differentiated thyroid cancer. *Eur J Cancer* 2021;147:51–57; doi: 10.1016/j.ejca.2020.12.032
1211. Taylor MH, Takahashi S, Capdevila J, et al. Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. *Thyroid* 2021;31(8):1226–1234; doi: 10.1089/thy.2020.0779
  1212. Kiyota N, Tahara M, Robinson B, et al. Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial. *Cancer* 2022;128(12):2281–2287; doi: 10.1002/cncr.34181
  1213. Fukuda N, Toda K, Ohmoto A, et al. Baseline tumour size as a prognostic factor for radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. *Anticancer Res* 2021;41(3):1683–1691; doi: 10.21873/anticancer.14932
  1214. Suzuki C, Kiyota N, Imamura Y, et al. Exploratory analysis to predict optimal tumor burden for starting lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. *Front Oncol* 2021;11:638123; doi: 10.3389/fonc.2021.638123
  1215. Giani C, Valerio L, Bongiovanni A, et al. Safety and quality-of-life data from an Italian expanded access program of lenvatinib for treatment of thyroid cancer. *Thyroid* 2021;31(2):224–232; doi: 10.1089/thy.2020.0276
  1216. Brose MS, Panaseykin Y, Konda B, et al. A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. *J Clin Endocrinol Metab* 2022;107(3):776–787; doi: 10.1210/clinem/dgab731
  1217. Tahara M, Brose MS, Wirth LJ, et al. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. *Eur J Cancer* 2019;106:61–68; doi: 10.1016/j.ejca.2018.10.002
  1218. Mikoshiba T, Sekimizu M, Kono T, et al. Utility and optimal management of planned drug holidays during lenvatinib treatment in patients with unresectable differentiated thyroid cancer: A real-world multi-center study. *Endocrine* 2024;85(2):777–785; doi: 10.1007/s12020-024-03744-0
  1219. Wirth LJ, Durante C, Topliss DJ, et al. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer: Treatment optimization for maximum clinical benefit. *Oncologist* 2022;27(7):565–572; doi: 10.1093/oncolo/oyac065
  1220. Brose MS, Frenette CT, Keefe SM, et al. Management of sorafenib-related adverse events: A clinician's perspective. *Semin Oncol* 2014;41 (Suppl 2):S1–S16; doi: 10.1053/j.seminoncol.2014.01.001
  1221. Cabanillas ME, Takahashi S. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. *Semin Oncol* 2019;46(1):57–64; doi: 10.1053/j.seminoncol.2018.11.004
  1222. De Leo A, Di Simone E, Spano A, et al. Nursing management and adverse events in thyroid cancer treatments with tyrosine kinase inhibitors. A narrative review. *Cancers (Basel)* 2021;13(23):5961; doi: 10.3390/cancers13235961
  1223. Wirth LJ, Tahara M, Robinson B, et al. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). *Cancer* 2018;124(11):2365–2372; doi: 10.1002/cncr.31344
  1224. Valerio L, Giani C, Agate L, et al. Prevalence and risk factors of developing fistula or organ perforation in patients treated with lenvatinib for radioiodine-refractory thyroid cancer. *Eur Thyroid J* 2021;10(5):399–407; doi: 10.1159/000514182
  1225. Xie WJ, Zhang S, Su L, et al. The efficacy and safety of lenvatinib in the treatment of solid tumors: An up-to-date meta-analysis. *Future Oncol* 2021;17(6):745–754; doi: 10.2217/fon-2020-0327
  1226. Cabanillas ME, de Souza JA, Geyer S, et al. Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: Results of a multicenter phase ii international thyroid oncology group trial. *J Clin Oncol* 2017;35(29):3315–3321; doi: 10.1200/jco.2017.73.0226
  1227. Brose MS, Robinson B, Sherman SI, et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2021;22(8):1126–1138; doi: 10.1016/s1470-2045(21)00332-6
  1228. Atallah V, Hocquet A, Do Cao C, et al. Activity and safety of sunitinib in patients with advanced radioiodine refractory thyroid carcinoma: A retrospective analysis of 57 patients. *Thyroid* 2016;26(8):1085–1092; doi: 10.1089/thy.2015.0648
  1229. Ravaud A, de la Fouchardière C, Caron P, et al. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: Mature data from the THYSU study. *Eur J Cancer* 2017;76:110–117; doi: 10.1016/j.ejca.2017.01.029
  1230. Bible KC, Menefee ME, Lin CJ, et al. An international phase 2 study of pazopanib in progressive and metastatic thyroglobulin antibody negative radioactive iodine refractory differentiated thyroid cancer. *Thyroid* 2020;30(9):1254–1262; doi: 10.1089/thy.2019.0269
  1231. de la Fouchardière C, Godbert Y, Dalban C, et al; PAZO-THYR investigators. Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZO-THYR. *Eur J Cancer* 2021;157:153–164; doi: 10.1016/j.ejca.2021.07.029
  1232. Cohen EE, Tortorici M, Kim S, et al. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: Long-term outcomes and pharmacokinetic/pharmacodynamic analyses. *Cancer Chemother Pharmacol* 2014;74(6):1261–1270; doi: 10.1007/s00280-014-2604-8
  1233. Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 2 trial. *Lancet Oncol* 2012;13(9):897–905; doi: 10.1016/S1470-2045(12)70335-2
  1234. Lin YS, Yang H, Ding Y, et al. Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: Results of a randomized, multicenter phase II trial. *Thyroid* 2021;31(4):607–615; doi: 10.1089/thy.2020.0235
  1235. Lin YS, Zhang X, Wang C, et al. Long-term results of a phase II trial of apatinib for progressive radioiodine refractory differentiated thyroid cancer. *J Clin Endocrinol Metab* 2021;106(8):e3027–e3036; doi: 10.1210/clinem/dgab196

1236. Qiu X, Cheng L, Sa R, et al. Initial or salvage treatment with apatinib shows promise against radioiodine-refractory differentiated thyroid carcinoma. *Eur Thyroid J* 2022;11(2):e210065; doi: 10.1530/etj-21-0065
1237. Lin Y, Qin S, Li Z, et al. Apatinib vs placebo in patients with locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: The REALITY randomized clinical trial. *JAMA Oncol* 2022;8(2):242–250; doi: 10.1001/jamaoncol.2021.6268
1238. Chi Y, Gao M, Zhang Y, et al. 2650 Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial. *Annals of Oncology* 2020;31:S1347; doi: 10.1016/j.annonc.2020.10.259
1239. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. *Nat Rev Clin Oncol* 2018;15(12):731–747; doi: 10.1038/s41571-018-0113-0
1240. Pekova B, Sykorova V, Mastnikova K, et al. NTRK fusion genes in thyroid carcinomas: Clinicopathological characteristics and their impacts on prognosis. *Cancers (Basel)* 2021;13(8):1932; doi: 10.3390/cancers13081932
1241. Prasad ML, Vyas M, Horne MJ, et al. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. *Cancer* 2016;122(7):1097–1107; doi: 10.1002/ncr.29887
1242. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. *N Engl J Med* 2018;378(8):731–739; doi: 10.1056/NEJMoal714448
1243. Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials. *Lancet Oncol* 2020;21(4):531–540; doi: 10.1016/s1470-2045(19)30856-3
1244. Waguespack SG, Drilon A, Lin JJ, et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. *Eur J Endocrinol* 2022;186(6):631–643; doi: 10.1530/eje-21-1259
1245. Doebele RC, Drilon A, Paz-Ares L, et al; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials. *Lancet Oncol* 2020;21(2):271–282; doi: 10.1016/s1470-2045(19)30691-6
1246. Krzakowski M, Lu S, Cousin S, et al. Updated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. *Jco* 2022;40(16\_suppl):3099–3099.
1247. Santoro M, Moccia M, Federico G, et al. RET gene fusions in malignancies of the thyroid and other tissues. *Genes (Basel)* 2020;11(4):424; doi: 10.3390/genes11040424
1248. Salvatore D, Santoro M, Schlumberger M. The importance of the RET gene in thyroid cancer and therapeutic implications. *Nat Rev Endocrinol* 2021;17(5):296–306; doi: 10.1038/s41574-021-00470-9
1249. Pekova B, Sykorova V, Dvorakova S, et al. RET, NTRK, ALK, BRAF, and MET fusions in a large cohort of pediatric papillary thyroid carcinomas. *Thyroid* 2020;30(12):1771–1780; doi: 10.1089/thy.2019.0802
1250. Zhu Z, Ciampi R, Nikiforova MN, et al. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: Effects of the detection methods and genetic heterogeneity. *J Clin Endocrinol Metab* 2006;91(9):3603–3610; doi: 10.1210/jc.2006-1006
1251. Chu YH, Wirth LJ, Farahani AA, et al. Clinicopathologic features of kinase fusion-related thyroid carcinomas: An integrative analysis with molecular characterization. *Mod Pathol* 2020;33(12):2458–2472; doi: 10.1038/s41379-020-0638-5
1252. Leeman-Neill RJ, Brenner AV, Little MP, et al. RET/PTC and PAX8/PPAR $\gamma$  chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. *Cancer* 2013;119(10):1792–1799; doi: 10.1002/ncr.27893
1253. Mitsutake N, Fukushima T, Matsuse M, et al. BRAF (V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: A different oncogenic profile from Chernobyl. *Sci Rep* 2015;5:16976; doi: 10.1038/srep16976
1254. Vanden Borre P, Schrock AB, Anderson PM, et al. Pediatric, adolescent, and young adult thyroid carcinoma harbors frequent and diverse targetable genomic alterations, including kinase fusions. *Oncologist* 2017;22(3):255–263; doi: 10.1634/theoncologist.2016-0279
1255. Subbiah V, Yang D, Velcheti V, et al. State-of-the-art strategies for targeting RET-dependent cancers. *J Clin Oncol* 2020;38(11):1209–1221; doi: 10.1200/jco.19.02551
1256. Wells SA, Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. *J Clin Oncol* 2012;30(2):134–141; doi: 10.1200/jco.2011.35.5040
1257. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. *J Clin Oncol* 2013;31(29):3639–3646; doi: 10.1200/jco.2012.48.4659
1258. Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: An open-label, single-centre, phase 2, single-arm trial. *Lancet Oncol* 2016;17(12):1653–1660; doi: 10.1016/s1470-2045(16)30562-9
1259. Hida T, Velcheti V, Reckamp KL, et al. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma. *Lung Cancer* 2019;138:124–130; doi: 10.1016/j.lungcan.2019.09.011
1260. Wirth LJ, Kohno T, Udagawa H, et al. Emergence and targeting of acquired and hereditary resistance to multikinase RET inhibition in patients with RET-altered cancer. *JCO Precis Oncol* 2019;3; doi: 10.1200/po.19.00189
1261. Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. *N Engl J Med* 2020;383(9):813–824; doi: 10.1056/NEJMoa2005653
1262. Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. *N Engl J Med* 2020;383(9):825–835; doi: 10.1056/NEJMoa2005651
1263. Subbiah V, Gainor JF, Oxnard GR, et al. Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial. *Clin Cancer Res* 2021;27(15):4160–4167; doi: 10.1158/1078-0432.Ccr-21-0800
1264. Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): A multi-cohort, open-label, phase 1/2 study. *Lancet Oncol* 2021;22(7):959–969; doi: 10.1016/s1470-2045(21)00247-3
1265. Subbiah V, Hu MI, Wirth LJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): A multi-cohort, open-label, registrational, phase 1/2 study. *Lancet Diabetes Endocrinol* 2021;9(8):491–501; doi: 10.1016/s2213-8587(21)00120-0

1266. Bastos AU, de Jesus AC, Cerutti JM. ETV6-NTRK3 and STRN-ALK kinase fusions are recurrent events in papillary thyroid cancer of adult population. *Eur J Endocrinol* 2018;178(1):83–91; doi: 10.1530/eje-17-0499
1267. Chou A, Fraser S, Toon CW, et al. A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. *Am J Surg Pathol* 2015;39(5):652–659; doi: 10.1097/pas.0000000000000368
1268. de Salins V, Loganadane G, Joly C, et al. Complete response in anaplastic lymphoma kinase-rearranged oncogenic thyroid cancer: A case report and review of literature. *World J Clin Oncol* 2020;11(7):495–503; doi: 10.5306/wjco.v11.i7.495
1269. Demeure MJ, Aziz M, Rosenberg R, et al. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target. *World J Surg* 2014;38(6):1296–1305; doi: 10.1007/s00268-014-2485-3
1270. Lee H, Krishnan V, Wirth LJ, et al. Case report of CCDC149-ALK fusion: A novel genetic alteration and a clinically relevant target in metastatic papillary thyroid carcinoma. *Thyroid* 2022;32(12):1580–1585; doi: 10.1089/thy.2022.0389
1271. Brose MS, Cabanillas ME, Cohen EE, et al. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: A non-randomised, multicentre, open-label, phase 2 trial. *Lancet Oncol* 2016;17(9):1272–1282; doi: 10.1016/s1470-2045(16)30166-8
1272. Busaidy NL, Konda B, Wei L, et al. Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: Results of a randomized, phase 2, open-label multicenter trial. *Thyroid* 2022;32(10):1184–1192; doi: 10.1089/thy.2022.0115
1273. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. *N Engl J Med* 2014;371(20):1877–1888; doi: 10.1056/NEJMoa1406037
1274. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. *Lancet* 2015;386(9992):444–451; doi: 10.1016/s0140-6736(15)60898-4
1275. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. *N Engl J Med* 2015;372(1):30–39; doi: 10.1056/NEJMoa1412690
1276. Tahara M, Kiyota N, Imai H, et al. A phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan. *Thyroid* 2024;34(4):467–476; doi: 10.1089/thy.2023.0547
1277. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: Updated analysis from the phase II ROAR basket study. *Ann Oncol* 2022;33(4):406–415; doi: 10.1016/j.annonc.2021.12.014
1278. Wen PY, Stein A, van den Bent M, et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): A multicentre, open-label, single-arm, phase 2, basket trial. *Lancet Oncol* 2022;23(1):53–64; doi: 10.1016/s1470-2045(21)00578-7
1279. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. *J Clin Oncol* 2018;36(1):7–13; doi: 10.1200/JCO.2017.73.6785
1280. Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial. *Lancet Oncol* 2020;21(9):1234–1243; doi: 10.1016/s1470-2045(20)30321-1
1281. Bouffet E, Geoerger B, Moertel C, et al. Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600-mutant low-grade glioma. *J Clin Oncol* 2023;41(3):664–674; doi: 10.1200/jco.22.01000
1282. Dankner M, Wang Y, Fazlzad R, et al. Clinical activity of mitogen-activated protein kinase-targeted therapies in patients with non-V600 BRAF-mutant tumors. *JCO Precis Oncol* 2022;6:e2200107; doi: 10.1200/po.22.00107
1283. Yao Z, Torres NM, Tao A, et al. BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. *Cancer Cell* 2015;28(3):370–383; doi: 10.1016/j.ccell.2015.08.001
1284. Maji L, Teli G, Raghavendra NM, et al. An updated literature on BRAF inhibitors (2018–2023). *Mol Divers* 2024;28(4):2689–2730; doi: 10.1007/s11030-023-10699-3
1285. Fukahori M, Yoshida A, Hayashi H, et al. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: New insights from a single center and a large patient cohort. *Thyroid* 2012;22(7):683–689; doi: 10.1089/thy.2011.0261
1286. Volante M, Rapa I, Gandhi M, et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. *J Clin Endocrinol Metab* 2009;94(12):4735–4741; doi: 10.1210/jc.2009-1233
1287. Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of Ras mutations. *Am J Clin Pathol* 2003;120(1):71–77; doi: 10.1309/nd8d-9laj-trct-g6qd
1288. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. *N Engl J Med* 2021;384(25):2371–2381; doi: 10.1056/NEJMoa2103695
1289. Jänne PA, Sabari JK, Spira AI. Adagrasib in non-small-cell lung cancer. Reply. *N Engl J Med* 2022;387(13):1238–1239; doi: 10.1056/NEJM2210539
1290. Ho AL, Brana I, Haddad R, et al. Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations. *J Clin Oncol* 2021;39(17):1856–1864; doi: 10.1200/jco.20.02903
1291. Hayes DN, Lucas AS, Tanvetyanon T, et al. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. *Clin Cancer Res* 2012;18(7):2056–2065; doi: 10.1158/1078-0432.CCR-11-0563
1292. Liu Z, Hou P, Ji M, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. *J Clin Endocrinol Metab* 2008;93(8):3106–3116; doi: 10.1210/jc.2008-0273
1293. Paes JE, Ringel MD. viii, ix., Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. *Endocrinol Metab Clin North Am* 2008;37(2):375–387; doi: 10.1016/j.ecl.2008.01.001

1294. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. *Cancer Res* 2009;69(11):4885–4893; doi: 10.1158/0008-5472.CAN-09-0727
1295. Soares P, Lima J, Preto A, et al. Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. *Curr Genomics* 2011;12(8):609–617; doi: 10.2174/138920211798120853
1296. Borson-Chazot F, Dantony E, Illouz F, et al. Effect of Buparlisib, a Pan-Class I PI3K inhibitor, in refractory follicular and poorly differentiated thyroid cancer. *Thyroid* 2018;28(9):1174–1179; doi: 10.1089/thy.2017.0663
1297. Lim SM, Chang H, Yoon MJ, et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. *Ann Oncol* 2013;24(12):3089–3094; doi: 10.1093/annonc/mdt379
1298. Schneider TC, de Wit D, Links TP, et al. Everolimus in patients with advanced follicular-derived thyroid cancer: Results of a phase II clinical trial. *J Clin Endocrinol Metab* 2017;102(2):698–707; doi: 10.1210/jc.2016-2525
1299. Hanna GJ, Busaidy NL, Chau NG, et al. Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: A phase II study. *Clin Cancer Res* 2018; 24(7):1546–1553; doi: 10.1158/1078-0432.Ccr-17-2297
1300. Bauman JE, Chen Z, Zhang C, et al. A multicenter randomized phase ii study of single agent efficacy and optimal combination sequence of everolimus and pasireotide LAR in advanced thyroid cancer. *Cancers (Basel)* 2022;14(11):2639; doi: 10.3390/cancers14112639
1301. Sherman EJ, Dunn LA, Ho AL, et al. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. *Cancer* 2017;123(21):4114–4121; doi: 10.1002/cncr.30861
1302. Sherman EJ, Ho AL, Fury MG, et al. Combination of everolimus and sorafenib in the treatment of thyroid cancer: Update on phase II study. *Jco* 2015;33(15\_suppl): 6069–6069; doi: 10.1200/jco.2015.33.15\_suppl.6069
1303. Sherman EJ, Foster NR, Su YB, et al. Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hürthle cell thyroid cancer (HCC) (Alliance A091302/ITOG 1706). *Jco* 2021;39(15\_suppl):6076–6076; doi: 10.1200/JCO.2021.39.15\_suppl.6076
1304. Harada G, Drilon A. TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults. *Cancer Genet* 2022; 264–265:33–39; doi: 10.1016/j.cancergen.2022.03.002
1305. Lin JJ, Liu SV, McCoach CE, et al. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. *Ann Oncol* 2020; 31(12):1725–1733; doi: 10.1016/j.annonc.2020.09.015
1306. Shen T, Hu X, Liu X, et al. The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib. *NPJ Precis Oncol* 2021;5(1):48; doi: 10.1038/s41698-021-00188-x
1307. Rosen EY, Won HH, Zheng Y, et al. The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. *Nat Commun* 2022;13(1):1450.
1308. Solomon BJ, Tan L, Lin JJ, et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. *J Thorac Oncol* 2020; 15(4):541–549; doi: 10.1016/j.jtho.2020.01.006
1309. Yun MR, Kim DH, Kim SY, et al. Repotrectinib exhibits potent antitumor activity in treatment-naïve and solvent-front-mutant ROS1-rearranged non-small cell lung cancer. *Clin Cancer Res* 2020;26(13):3287–3295; doi: 10.1158/1078-0432.Ccr-19-2777
1310. Cozzi S, Ali E, Bardoscia L, et al. Stereotactic body radiation therapy (SBRT) for oligorecurrent/oligoprogressive mediastinal and hilar lymph node metastasis: A systematic review. *Cancers (Basel)* 2022;14(11):2680; doi: 10.3390/cancers14112680
1311. Ritterhouse LL, Gogakos T. Molecular biomarkers of response to cancer immunotherapy. *Clin Lab Med* 2022; 42(3):469–484; doi: 10.1016/j.cll.2022.05.004
1312. Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nat Genet* 2019;51(2): 202–206; doi: 10.1038/s41588-018-0312-8
1313. Daud AI, Loo K, Pauli ML, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. *J Clin Invest* 2016;126(9):3447–3452; doi: 10.1172/jci87324
1314. Gajewski TF, Corrales L, Williams J, et al. Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment. *Adv Exp Med Biol* 2017;1036:19–31; doi: 10.1007/978-3-319-67577-0\_2
1315. Severson JJ, Serracino HS, Mateescu V, et al. PD-1+Tim-3+ CD8+ T lymphocytes display varied degrees of functional exhaustion in patients with regionally metastatic differentiated thyroid cancer. *Cancer Immunol Res* 2015;3(6):620–630; doi: 10.1158/2326-6066.Cir-14-0201
1316. Rosenbaum MW, Gigliotti BJ, Pai SI, et al. PD-L1 and IDO1 are expressed in poorly differentiated thyroid carcinoma. *Endocr Pathol* 2018;29(1):59–67; doi: 10.1007/s12022-018-9514-y
1317. Wan B, Deng P, Dai W, et al. Association between programmed cell death ligand 1 expression and thyroid cancer: A meta-analysis. *Medicine (Baltimore)* 2021;100(14): e25315; doi: 10.1097/md.00000000000025315
1318. French JD, Weber ZJ, Fretwell DL, et al. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. *J Clin Endocrinol Metab* 2010;95(5): 2325–2333; doi: 10.1210/jc.2009-2564
1319. Cunha LL, Morari EC, Guihen AC, et al. Infiltration of a mixture of different immune cells may be related to molecular profile of differentiated thyroid cancer. *Endocr Relat Cancer* 2012;19(3):L31–L6; doi: 10.1530/erc-11-0285
1320. Steiniche T, Ladekarl M, Georgsen JB, et al. Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers. *Future Sci OA* 2020;6(8):Fso616; doi: 10.2144/fsoa-2020-0063
1321. Ott PA, Bang YJ, Piha-Paul SA, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. *J Clin Oncol* 2019;37(4):318–327; doi: 10.1200/jco.2018.78.2276
1322. Oh DY, Algazi A, Capdevila J, et al. Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study. *Cancer* 2023;129(8):1195–1204; doi: 10.1002/cncr.34657

1323. Kimura T, Kato Y, Ozawa Y, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. *Cancer Sci* 2018;109(12):3993–4002; doi: 10.1111/cas.13806
1324. Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. *PLoS One* 2019; 14(2):e0212513; doi: 10.1371/journal.pone.0212513
1325. Adachi Y, Kamiyama H, Ichikawa K, et al. Inhibition of FGFR reactivates IFN $\gamma$  signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies. *Cancer Res* 2022;82(2): 292–306; doi: 10.1158/0008-5472.Can-20-2426
1326. Makker V, Colombo N, Casado Herraz A, et al; Study 309–KEYNOTE-775 Investigators. Lenvatinib plus pembrolizumab for advanced endometrial cancer. *N Engl J Med* 2022;386(5):437–448; doi: 10.1056/NEJMoa2108330
1327. Motzer R, Alekseev B, Rha SY, et al; CLEAR Trial Investigators. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. *N Engl J Med* 2021;384(14):1289–1300; doi: 10.1056/NEJMoa2035716
1328. French JD, Haugen BR, Worden FP, et al. Combination targeted therapy with pembrolizumab and lenvatinib in progressive, radioiodine-refractory differentiated thyroid cancers. *Clin Cancer Res* 2024;30(17):3757–3767; doi: 10.1158/1078-0432.CCR-23-3417
1329. Dierks C, Seufert J, Aumann K, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. *Thyroid* 2021;31(7):1076–1085; doi: 10.1089/thy.2020.0322
1330. Konda B, Sherman E, Massarelli E, et al. Cabozantinib in combination with nivolumab and ipilimumab in patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) whose cancer progressed after one prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy: Interim results of a multicenter phase 2 national cancer institute (NCI)-international thyroid oncology group (ITOG) trial (nci#10240). *Thyroid*<sup>®</sup> 2022; 32(S1):P-1-A-135; doi: 10.1089/thy.2022.29137.abstracts
1331. Liu J, Liu Y, Lin Y, et al. Radioactive iodine-refractory differentiated thyroid cancer and redifferentiation therapy. *Endocrinol Metab (Seoul)* 2019;34(3):215–225; doi: 10.3803/EnM.2019.34.3.215
1332. Lamartina L, Anizan N, Dupuy C, et al. Redifferentiation-facilitated radioiodine therapy in thyroid cancer. *Endocr Relat Cancer* 2021;28(10):T179–Tt191; doi: 10.1530/erc-21-0024
1333. Chakravarty D, Santos E, Ryder M, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. *J Clin Invest* 2011;121(12):4700–4711; doi: 10.1172/JCI46382
1334. Nagarajah J, Le M, Knauf JA, et al. Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. *J Clin Invest* 2016;126(11):4119–4124; doi: 10.1172/JCI89067
1335. Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. *N Engl J Med* 2013;368(7):623–632; doi: 10.1056/NEJMoa1209288
1336. Wadsley J, Ainsworth G, Coulson AB, et al. Results of the SEL-I-METRY Phase II trial on resensitization of advanced iodine refractory differentiated thyroid cancer to radioiodine therapy. *Thyroid* 2023;33(9):1119–1123; doi: 10.1089/thy.2022.0707
1337. Rothenberg SM, McFadden DG, Palmer EL, et al. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. *Clin Cancer Res* 2015;21(5):1028–1035; doi: 10.1158/1078-0432.CCR-14-2915
1338. Dunn LA, Sherman EJ, Baxi SS, et al. Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers. *J Clin Endocrinol Metab* 2019;104(5):1417–1428; doi: 10.1210/jc.2018-01478
1339. Jaber T, Waguespack SG, Cabanillas ME, et al. Targeted therapy in advanced thyroid cancer to resensitize tumors to radioactive iodine. *J Clin Endocrinol Metab* 2018; 103(10):3698–3705; doi: 10.1210/jc.2018-00612
1340. Leboulleux S, Benisvy D, Taieb D, et al. MERAIODE: A phase II redifferentiation trial with Trametinib and (131)I in metastatic radioactive iodine refractory RAS mutated differentiated thyroid cancer. *Thyroid* 2023;33(9): 1124–1129; doi: 10.1089/thy.2023.0240
1341. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. *Cancer Discov* 2013;3(5):520–533; doi: 10.1158/2159-8290.Cd-12-0531
1342. Groussin L, Clerc J, Huillard O. Larotrectinib-enhanced radioactive iodine uptake in advanced thyroid cancer. *N Engl J Med* 2020;383(17):1686–1687; doi: 10.1056/NEJMc2023094
1343. Lee YA, Lee H, Im SW, et al. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. *J Clin Invest* 2021; 131(18):e144847; doi: 10.1172/jci144847
1344. Groussin L, Theodon H, Bessiene L, et al. Redifferentiating effect of larotrectinib in NTRK-rearranged advanced radioactive-iodine refractory thyroid cancer. *Thyroid* 2022;32(5):594–598; doi: 10.1089/thy.2021.0524
1345. Droz JP, Schlumberger M, Rougier P, et al. Chemotherapy in metastatic nonanaplastic thyroid cancer: Experience at the Institut Gustave-Roussy. *Tumori* 1990;76(5):480–483.
1346. Spano JP, Vano Y, Vignot S, et al. GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma. *Med Oncol* 2012;29(3):1421–1428; doi: 10.1007/s12032-011-0070-2
1347. Toraih EA, Hussein MH, Zerfaoui M, et al. Site-specific metastasis and survival in papillary thyroid cancer: The importance of brain and multi-organ disease. *Cancers (Basel)* 2021;13(7):1625; doi: 10.3390/cancers13071625
1348. Wilhelm A, Conroy PC, Calthorpe L, et al. Disease-specific survival trends for patients presenting with differentiated thyroid cancer and distant metastases in the United States, 1992–2018. *Thyroid* 2023;33(1):63–73; doi: 10.1089/thy.2022.0353
1349. Bulfamante AM, Lori E, Bellini MI, et al. Advanced differentiated thyroid cancer: A complex condition needing a tailored approach. *Front Oncol* 2022;12:954759; doi: 10.3389/fonc.2022.954759
1350. Stojadinovic A, Shoup M, Ghossein RA, et al. The role of operations for distantly metastatic well-differentiated thyroid carcinoma. *Surgery* 2002;131(6):636–643; doi: 10.1067/msy.2002.124732
1351. Ruers T, Punt C, Van Coevorden F, et al; Arbeitsgruppe Lebermetastasen und—tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO) and the National Cancer Research Institute Colorectal Clinical

- Study Group (NCRI CCSG). Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: A randomized EORTC Intergroup phase II study (EORTC 40004). *Ann Oncol* 2012;23(10):2619–2626; doi: 10.1093/annonc/mds053
1352. Gomez DR, Blumenschein GR, Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study. *Lancet Oncol* 2016;17(12):1672–1682; doi: 10.1016/s1470-2045(16)30532-0
1353. Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase ii trial. *J Clin Oncol* 2018;36(5):446–453; doi: 10.1200/jco.2017.75.4853
1354. Tan VS, Palma DA. Top ten lessons learned from trials in oligometastatic cancers. *Cancer Res Treat* 2023;55(1):5–14; doi: 10.4143/crt.2022.1460
1355. Hellman S, Weichselbaum RR. Oligometastases. *J Clin Oncol* 1995;13(1):8–10; doi: 10.1200/jco.1995.13.1.8
1356. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial. *Lancet* 2019;393(10185):2051–2058; doi: 10.1016/s0140-6736(18)32487-5
1357. deSouza NM, Tempany CM. A risk-based approach to identifying oligometastatic disease on imaging. *Int J Cancer* 2019;144(3):422–430; doi: 10.1002/ijc.31793
1358. Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. *Lancet Oncol* 2020;21(1):e18–e28; doi: 10.1016/s1470-2045(19)30718-1
1359. Bonichon F, Buy X, Godbert Y, et al. Local treatment of metastases from differentiated thyroid cancer. *Ann Endocrinol (Paris)* 2015;76(Suppl 1):1s40–1s46; doi: 10.1016/s0003-4266(16)30013-0
1360. Iyengar P, Kavanagh BD, Wardak Z, et al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. *J Clin Oncol* 2014;32(34):3824–3830; doi: 10.1200/jco.2014.56.7412
1361. Hubbeling H, Choudhury N, Flynn J, et al. Outcomes with local therapy and tyrosine kinase inhibition in patients with ALK/ROS1/RET-rearranged lung cancers. *JCO Precis Oncol* 2022;6:e2200024; doi: 10.1200/po.22.00024
1362. Basu S, Borde CR, Abhyankar A. Advantages of surgical extirpation in addition to radioiodine therapy in differentiated thyroid carcinoma patients with a solitary large-volume skeletal metastasis with small-volume oligometastatic disease in the rest of the whole body. *J Cancer Res Ther* 2012;8(4):656–657; doi: 10.4103/0973-1482.106595
1363. Ginzburg S, Reddy M, Veloski C, et al. Papillary thyroid carcinoma metastases presenting as ipsilateral adrenal mass and renal cyst. *Urol Case Rep* 2015;3(6):221–222; doi: 10.1016/j.eucr.2015.08.007
1364. Fode MM, Høyer M. Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. *Radiother Oncol* 2015;114(2):155–160; doi: 10.1016/j.radonc.2014.12.003
1365. Crombé A, Buy X, Godbert Y, et al. 23 lung metastases treated by radiofrequency ablation over 10 years in a single patient: Successful oncological outcome of a metastatic cancer without altered respiratory function. *Cardiovasc Intervent Radiol* 2016;39(12):1779–1784; doi: 10.1007/s00270-016-1445-8
1366. Moneke I, Kaifi JT, Kloeser R, et al. Pulmonary metastasectomy for thyroid cancer as salvage therapy for radioactive iodine-refractory metastases. *Eur J Cardiothorac Surg* 2018;53(3):625–630; doi: 10.1093/ejcts/ezx367
1367. Zhong M, Khan FZ, He X, et al. Impact of lung metastasis versus metastasis of bone, brain, or liver on overall survival and thyroid cancer-specific survival of thyroid cancer patients: A population-based study. *Cancers (Basel)* 2022;14(13):3133; doi: 10.3390/cancers14133133
1368. Fragnaud H, Mattei JC, Le Nail LR, et al. Mid and long-term overall survival after carcinologic resections of thyroid cancer bone metastases. *Front Surg* 2022;9:965951; doi: 10.3389/fsurg.2022.965951
1369. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET Phase II Randomized Trial. *J Clin Oncol* 2020;38(25):2830–2838; doi: 10.1200/jco.20.00818
1370. Olson R, Senan S, Harrow S, et al. Quality of life outcomes after stereotactic ablative radiation therapy (SABR) versus standard of care treatments in the oligometastatic setting: A secondary analysis of the SABR-COMET randomized trial. *Int J Radiat Oncol Biol Phys* 2019;105(5):943–947; doi: 10.1016/j.ijrobp.2019.08.041
1371. de Baere T, Tselikas L, Woodrum D, et al. Evaluating cryoablation of metastatic lung tumors in patients—safety and efficacy: The ECLIPSE Trial—Interim Analysis at 1 Year. *J Thorac Oncol* 2015;10(10):1468–1474; doi: 10.1097/jto.0000000000000632
1372. Cazzato RL, Bonichon F, Buy X, et al. Over ten years of single-institution experience in percutaneous image-guided treatment of bone metastases from differentiated thyroid cancer. *Eur J Surg Oncol* 2015;41(9):1247–1255; doi: 10.1016/j.ejso.2015.06.005
1373. Bonichon F, de Baere T, Berdelou A, et al. Percutaneous thermal ablation of lung metastases from thyroid carcinomas. A retrospective multicenter study of 107 nodules. On behalf of the TUTHYREF network. *Endocrine* 2021;72(3):798–808; doi: 10.1007/s12020-020-02580-2
1374. Cazzato RL, Garmon J, Caudrelier J, et al. Percutaneous radiofrequency ablation of painful spinal metastasis: A systematic literature assessment of analgesia and safety. *Int J Hyperthermia* 2018;34(8):1272–1281; doi: 10.1080/02656736.2018.1425918
1375. Autrusseau PA, Schneegans O, Koch G, et al. Safety and efficacy of percutaneous cryoablation of extraspinal thyroid cancer bone metastases with curative intent: Single-center experience with a median follow-up of more than 5 years. *J Vasc Interv Radiol* 2022;33(7):797–804; doi: 10.1016/j.jvir.2022.03.016
1376. Samhoury L, Kriz J, Elsayad K, et al. The role of radiotherapy for patients with thyroid cancer in the modern era. *Anticancer Res* 2020;40(6):3379–3386; doi: 10.21873/anticancer.14321
1377. So K, Smith RE, Davis SR. Radiotherapy in well-differentiated thyroid cancer: Is it underutilized? *ANZ J Surg* 2016;86(9):696–700; doi: 10.1111/ans.13374

1378. Farooki A, Leung V, Tala H, et al. Skeletal-related events due to bone metastases from differentiated thyroid cancer. *J Clin Endocrinol Metab* 2012;97(7):2433–2439; doi: 10.1210/jc.2012-1169
1379. Kato S, Demura S, Murakami H, et al. Medium to long-term clinical outcomes of spinal metastasectomy. *Cancers (Basel)* 2022;14(12):2852; doi: 10.3390/cancers14122852
1380. Iñiguez-Ariza NM, Bible KC, Clarke BL. Bone metastases in thyroid cancer. *J Bone Oncol* 2020;21:100282; doi: 10.1016/j.jbo.2020.100282
1381. Khired ZA, Hussein MH, Jishu JA, et al. Osseous metastases in thyroid cancer: Unveiling risk factors, disease outcomes, and treatment impact. *Cancers (Basel)* 2023; 15(14):3557; doi: 10.3390/cancers15143557
1382. Kondraciuk JD, Rice SL, Zhou X, et al. Thyroid cancer bone metastasis: Survival and genomic characteristics of a large tertiary care cohort. *Clin Nucl Med* 2019;44(8): e465–e471; doi: 10.1097/rlu.0000000000002626
1383. Slook O, Levy S, Slutzky-Shraga I, et al. Long-term outcomes and prognostic factors in patients with differentiated thyroid carcinoma and bone metastases. *Endocr Pract* 2019;25(5):427–437; doi: 10.4158/ep-2018-0465
1384. Barat M, Tselikas L, de Baère T, et al. Thermal-ablation of vertebral metastases prevents adverse events in patients with differentiated thyroid carcinoma. *Eur J Radiol* 2019; 119:108650; doi: 10.1016/j.ejrad.2019.108650
1385. de Baere T, Deschamps F. New tumor ablation techniques for cancer treatment (microwave, electroporation). *Diagn Interv Imaging* 2014;95(7–8):677–682; doi: 10.1016/j.diii.2014.04.001
1386. De Cobelli F, Calandri M, Della Corte A, et al. Multi-institutional analysis of outcomes for thermosphere microwave ablation treatment of colorectal liver metastases: The SMAC study. *Eur Radiol* 2022;32(6):4147–4159; doi: 10.1007/s00330-021-08497-2
1387. Mimmo A, Pegoraro F, Rhaïem R, et al. Microwave ablation for colorectal liver metastases: A systematic review and pooled oncological analyses. *Cancers (Basel)* 2022; 14(5):1305; doi: 10.3390/cancers14051305
1388. Wang B, Zhang K, Zhang X, et al. Microwave ablation combined with cementoplasty under real-time temperature monitoring in the treatment of 82 patients with recurrent spinal metastases after radiotherapy. *BMC Musculoskelet Disord* 2022;23(1):1025; doi: 10.1186/s12891-022-05999-y
1389. Motaghi M, England RW, Nejad NH, et al. Assessing long-term locoregional control of spinal osseous metastases after microwave ablation. *J Clin Neurosci* 2022;104: 48–55; doi: 10.1016/j.jocn.2022.07.025
1390. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. *J Clin Endocrinol Metab* 1997;82(11):3637–3642; doi: 10.1210/jcem.82.11.4386
1391. McWilliams RR, Giannini C, Hay ID, et al. Management of brain metastases from thyroid carcinoma: A study of 16 pathologically confirmed cases over 25 years. *Cancer* 2003;98(2):356–362; doi: 10.1002/encr.11488
1392. Henriques de FB, Godbert Y, Soubeyran I, et al. Brain metastases from thyroid carcinoma: A retrospective study of 21 patients. *Thyroid* 2014;24(2):270–276; doi: 10.1089/thy.2013.0061
1393. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. *J Clin Oncol* 2011;29(2):134–141; doi: 10.1200/JCO.2010.30.1655
1394. Achrol AS, Rennert RC, Anders C, et al. Brain metastases. *Nat Rev Dis Primers* 2019;5(1):5; doi: 10.1038/s41572-018-0055-y
1395. Chow CJ, Habermann EB, Abraham A, et al. Does enrollment in cancer trials improve survival? *J Am Coll Surg* 2013; 216(4):774–780; doi: 10.1016/j.jamcollsurg.2012.12.036
1396. Hershman JM. Physiological and pathological aspects of the effect of human chorionic gonadotropin on the thyroid. *Best Pract Res Clin Endocrinol Metab* 2004;18(2): 249–265; doi: 10.1016/j.beem.2004.03.010
1397. Rakhlin L, Fish S, Tuttle RM. Response to therapy status is an excellent predictor of pregnancy-associated structural disease progression in patients previously treated for differentiated thyroid cancer. *Thyroid* 2017;27(3): 396–401; doi: 10.1089/thy.2016.0501
1398. Oh HS, Kim WG, Park S, et al. Serial neck ultrasonographic evaluation of changes in papillary thyroid carcinoma during pregnancy. *Thyroid* 2017;27(6):773–777; doi: 10.1089/thy.2016.0618
1399. Xi C, Zhang Q, Song HJ, et al. Pregnancy does not affect the prognoses of differentiated thyroid cancer patients with lung metastases. *J Clin Endocrinol Metab* 2021; 106(8):e3185–e3197; doi: 10.1210/clinem/dgab111
1400. Shan R, Li X, Tao M, et al. Pregnancy and the disease recurrence of patients previously treated for differentiated thyroid cancer: A systematic review and meta analysis. *Chin Med J (Engl)* 2024;137(5):547–555; doi: 10.1097/CM9.0000000000003008
1401. Xiao WC, Li X, Shan R, et al. Pregnancy and progression of differentiated thyroid cancer: A propensity score-matched retrospective cohort study. *J Clin Endocrinol Metab* 2024;109(3):837–843; doi: 10.1210/clinem/dgad557
1402. Cho GJ, Kim SY, Lee HC, et al. Risk of adverse obstetric outcomes and the abnormal growth of offspring in women with a history of thyroid cancer. *Thyroid* 2019; 29(6):879–885; doi: 10.1089/thy.2018.0283
1403. Liu D, Wei Y, Zhao Y, et al. Obstetric outcomes in thyroid cancer survivors: A retrospective cohort study. *Int J Gynaecol Obstet* 2021;155(1):119–124; doi: 10.1002/ijgo.13571
1404. Yuan X, Zhao J, Wang J, et al. Pregnancy outcomes and neonatal thyroid function in women with thyroid cancer: A retrospective study. *BMC Pregnancy Childbirth* 2023; 23(1):383; doi: 10.1186/s12884-023-05588-4
1405. Boucek J, de Haan J, Halaska MJ, et al; International Network on Cancer, Infertility, and Pregnancy. Maternal and obstetrical outcome in 35 cases of well-differentiated thyroid carcinoma during pregnancy. *Laryngoscope* 2018; 128(6):1493–1500; doi: 10.1002/lary.26936
1406. Lemieux P, Yamamoto JM, Nerenberg KA, et al. Thyroid laboratory testing and management in women on thyroid replacement before pregnancy and associated pregnancy outcomes. *Thyroid* 2021;31(5):841–849; doi: 10.1089/thy.2020.0609
1407. National Cancer Institute, Office of Cancer Survivorship. Definitions: Survivorship terms. Available from: <https://cancercontrol.cancer.gov/ocs/definitions#:~:text=Survivorship%20Terms,and%20those%20free%20of%20cancer> [Last accessed: November 7].
1408. Li C, Lopez B, Fligor S, et al. Long-term voice changes after thyroidectomy: Results from a validated survey. *Surgery* 2021;170(6):1687–1691; doi: 10.1016/j.surg.2021.04.060

1409. Dhillon VK, Rettig E, Noureldine SI, et al. The incidence of vocal fold motion impairment after primary thyroid and parathyroid surgery for a single high-volume academic surgeon determined by pre- and immediate postoperative fiberoptic laryngoscopy. *Int J Surg* 2018;56:73–78; doi: 10.1016/j.ijss.2018.06.014
1410. Pasiaka JL, Wentworth K, Yeo CT, et al. Etiology and pathophysiology of hypoparathyroidism: A narrative review. *J Bone Miner Res* 2022;37(12):2586–2601; doi: 10.1002/jbmr.4714
1411. Bergenfelz A, Nordenström E, Almquist M. Morbidity in patients with permanent hypoparathyroidism after total thyroidectomy. *Surgery* 2020;167(1):124–128; doi: 10.1016/j.surg.2019.09.010
1412. Almquist M, Ivarsson K, Nordenström E, et al. Mortality in patients with permanent hypoparathyroidism after total thyroidectomy. *Br J Surg* 2018;105(10):1313–1318; doi: 10.1002/bjs.10843
1413. Barrows CE, Belle JM, Fleishman A, et al. Financial burden of thyroid cancer in the United States: An estimate of economic and psychological hardship among thyroid cancer survivors. *Surgery* 2020;167(2):378–384; doi: 10.1016/j.surg.2019.09.010
1414. Broekhuis JM, Li C, Chen HW, et al. Patient-reported financial burden in thyroid cancer. *J Surg Res* 2021;266:160–167; doi: 10.1016/j.jss.2021.03.051
1415. Mongelli MN, Giri S, Peipert BJ, et al. Financial burden and quality of life among thyroid cancer survivors. *Surgery* 2020;167(3):631–637; doi: 10.1016/j.surg.2019.11.014
1416. Ramsey S, Blough D, Kirchoff A, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. *Health Aff (Millwood)* 2013;32(6):1143–1152; doi: 10.1377/hlthaff.2012.1263
1417. Ratzon NZ, Uziely B, de Boer AG, et al. Unemployment risk and decreased income two and four years after thyroid cancer diagnosis: A population-based study. *Thyroid* 2016;26(9):1251–1258; doi: 10.1089/thy.2015.0608
1418. Tamminga SJ, Bultmann U, Husson O, et al. Employment and insurance outcomes and factors associated with employment among long-term thyroid cancer survivors: a population-based study from the PROFILES registry. *Qual Life Res* 2016;25(4):997–1005; doi: 10.1007/s11136-015-1135-z
1419. Berger MH, Lin HW, Bhattacharyya N. A national evaluation of food insecurity in a head and neck cancer population. *Laryngoscope* 2021;131(5):E1539–E1542; doi: 10.1002/lary.29188
1420. Chen DW, Reyes-Gastelum D, Veenstra CM, et al. Financial hardship among Hispanic women with thyroid cancer. *Thyroid* 2021;31(5):752–759; doi: 10.1089/thy.2020.0497
1421. Wu JX, Beni CE, Zanoocco KA, et al. Cost-effectiveness of long-term every three-year versus annual postoperative surveillance for low-risk papillary thyroid cancer. *Thyroid* 2015;25(7):797–803; doi: 10.1089/thy.2014.0617
1422. Goswami S, Mongelli M, Peipert BJ, et al. Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data. *Surgery* 2018;164(5):986–992; doi: 10.1016/j.surg.2018.06.042
1423. Wang T, Jiang M, Ren Y, et al. Health-related quality of life of community thyroid cancer survivors in Hangzhou, China. *Thyroid* 2018;28(8):1013–1023; doi: 10.1089/thy.2017.0213
1424. Lubitz CC, De Gregorio L, Fingeret AL, et al. Measurement and variation in estimation of quality of life effects of patients undergoing treatment for papillary thyroid carcinoma. *Thyroid* 2017;27(2):197–206; doi: 10.1089/thy.2016.0260
1425. Applewhite MK, James BC, Kaplan SP, et al. Quality of life in thyroid cancer is similar to that of other cancers with worse survival. *World J Surg* 2016;40(3):551–561; doi: 10.1007/s00268-015-3300-5
1426. Buttner M, Locati LD, Pinto M, et al. Quality of life in patients with hypoparathyroidism after treatment for thyroid cancer. *J Clin Endocrinol Metab* 2020;105(12):dga597; doi: 10.1210/clinem/dga597
1427. Chan WL, Choi HC, Lang B, et al. Health-related quality of life in Asian differentiated thyroid cancer survivors. *Cancer Control* 2021;28:10732748211029726; doi: 10.1177/10732748211029726
1428. Chen DW, Reyes-Gastelum D, Wallner LP, et al. Disparities in risk perception of thyroid cancer recurrence and death. *Cancer* 2020;126(7):1512–1521; doi: 10.1002/cncr.32670
1429. Goldfarb M, Casillas J. Thyroid cancer-specific quality of life and health-related quality of life in young adult thyroid cancer survivors. *Thyroid* 2016;26(7):923–932; doi: 10.1089/thy.2015.0589
1430. Goswami S, Peipert BJ, Mongelli MN, et al. Clinical factors associated with worse quality-of-life scores in United States thyroid cancer survivors. *Surgery* 2019;166(1):69–74; doi: 10.1016/j.surg.2019.01.034
1431. Hedman C, Djarv T, Strang P, et al. Effect of thyroid-related symptoms on long-term quality of life in patients with differentiated thyroid carcinoma: a population-based study in Sweden. *Thyroid* 2017;27(8):1034–1042; doi: 10.1089/thy.2016.0604
1432. Lee JI, Kim SH, Tan AH, et al. Decreased health-related quality of life in disease-free survivors of differentiated thyroid cancer in Korea. *Health Qual Life Outcomes* 2010;8:101; doi: 10.1186/1477-7525-8-101
1433. Mols F, Schoormans D, Smit JWA, et al. Age-related differences in health-related quality of life among thyroid cancer survivors compared with a normative sample: Results from the PROFILES registry. *Head Neck* 2018;40(10):2235–2245; doi: 10.1002/hed.25325
1434. Vissers PA, Thong MS, Pouwer F, et al. The impact of comorbidity on health-related quality of life among cancer survivors: analyses of data from the PROFILES registry. *J Cancer Surviv* 2013;7(4):602–613; doi: 10.1007/s11764-013-0299-1
1435. Papaleontiou M, Evron JM, Esfandiari NH, et al. Patient report of recurrent and persistent thyroid cancer. *Thyroid* 2020;30(9):1297–1305; doi: 10.1089/thy.2019.0652
1436. Husson O, Nieuwlaet WA, Oranje WA, et al. Fatigue among short- and long-term thyroid cancer survivors: Results from the population-based PROFILES registry. *Thyroid* 2013;23(10):1247–1255; doi: 10.1089/thy.2013.0015
1437. Hughes DT, Reyes-Gastelum D, Kovatch KJ, et al. Energy level and fatigue after surgery for thyroid cancer: A population-based study of patient-reported outcomes. *Surgery* 2020;167(1):102–109; doi: 10.1016/j.surg.2019.04.068
1438. Bach K, Ansari P, Ansari H, et al. Health-related quality of life in patients with low-risk differentiated thyroid cancer: a systematic review examining the extent of thyroidectomy. *Thyroid* 2024;34(1):14–25; doi: 10.1089/thy.2023.0328
1439. Almeida JP, Vartanian JG, Kowalski LP. Clinical predictors of quality of life in patients with initial differentiated thyroid cancers. *Arch Otolaryngol Head Neck Surg* 2009;135(4):342–346; doi: 10.1001/archoto.2009.16

1440. Bongers PJ, Greenberg CA, Hsiao R, et al. Differences in long-term quality of life between hemithyroidectomy and total thyroidectomy in patients treated for low-risk differentiated thyroid carcinoma. *Surgery* 2020;167(1):94–101; doi: 10.1016/j.surg.2019.04.060
1441. Singer S, Jordan S, Locati LD, et al; EORTC Quality of Life Group, the EORTC Head and Neck Cancer Group, and the EORTC Endocrine Task Force. The EORTC module for quality of life in patients with thyroid cancer: Phase III. *Endocr Relat Cancer* 2017;24(4):197–207; doi: 10.1530/erc-16-0530
1442. Singer S, Al-Ibraheem A, Pinto M, et al. International phase IV field study for the reliability and validity of the European Organisation for Research and Treatment of Cancer Thyroid Cancer Module EORTC QLQ-THY34. *Thyroid* 2023; 33(9):1078–1089; doi: 10.1089/thy.2023.0221
1443. Bresner L, Banach R, Rodin G, et al. Cancer-related worry in Canadian thyroid cancer survivors. *J Clin Endocrinol Metab* 2015;100(3):977–985; doi: 10.1210/jc.2014-3169
1444. Roerink SH, de Ridder M, Prins J, et al. High level of distress in long-term survivors of thyroid carcinoma: Results of rapid screening using the distress thermometer. *Acta Oncol* 2013;52(1):128–137; doi: 10.3109/0284186X.2012.723822
1445. Jackson Levin N, Zhang A, Reyes-Gastelum D, et al. Change in worry over time among Hispanic women with thyroid cancer. *J Cancer Surviv* 2022;16(4):844–852; doi: 10.1007/s11764-021-01078-8
1446. Hughes DT, Reyes-Gastelum D, Ward KC, et al. Barriers to the use of active surveillance for thyroid cancer results of a physician survey. *Ann Surg* 2022;276(1):e40–e47; doi: 10.1097/SLA.0000000000004417
1447. Papaleontiou M, Banerjee M, Yang D, et al. Factors that influence radioactive iodine use for thyroid cancer. *Thyroid* 2013;23(2):219–224; doi: 10.1089/thy.2012.0380
1448. Pitt SC, Saucke MC, Roman BR, et al. The influence of emotions on treatment decisions about low-risk thyroid cancer: a qualitative study. *Thyroid* 2021;31(12):1800–1807; doi: 10.1089/thy.2021.0323
1449. Banach R, Bartes B, Farnell K, et al. Results of the Thyroid Cancer Alliance international patient/survivor survey: Psychosocial/informational support needs, treatment side effects and international differences in care. *Hormones (Athens)* 2013;12(3):428–438; doi: 10.1007/BF03401308
1450. Husson O, Mols F, Oranje WA, et al. Unmet information needs and impact of cancer in (long-term) thyroid cancer survivors: Results of the PROFILES registry. *Psychooncology* 2014;23(8):946–952; doi: 10.1002/pon.3514
1451. Hyun YG, Alhashemi A, Fazelzad R, et al. A systematic review of unmet information and psychosocial support needs of adults diagnosed with thyroid cancer. *Thyroid* 2016;26(9):1239–1250; doi: 10.1089/thy.2016.0039
1452. James BC, Aschebrook-Kilfoy B, White MG, et al. Quality of life in thyroid cancer-assessment of physician perceptions. *J Surg Res* 2018;226:94–99; doi: 10.1016/j.jss.2017.11.069
1453. Papaleontiou M, Zebrack B, Reyes-Gastelum D, et al. Physician management of thyroid cancer patients' worry. *J Cancer Surviv* 2021;15(3):418–426; doi: 10.1007/s11764-020-00937-0
1454. Morley S, Goldfarb M. Support needs and survivorship concerns of thyroid cancer patients. *Thyroid* 2015;25(6):649–656; doi: 10.1089/thy.2015.0032
1455. American Society of Clinical Oncology (ASCO). Thyroid Cancer: Coping with Treatment. Available from: <https://www.cancer.net/cancer-types/thyroid-cancer/coping-with-treatment> [Last accessed: November 7 2023].
1456. National Cancer Institute. Thyroid Cancer—Patient Version. Available from: <https://www.cancer.gov/types/thyroid> [Last accessed: November 7 2023].
1457. National Comprehensive Cancer Network (NCCN). Guidelines for patients. Distress during cancer care. NCCN; 2020, pp. 1–38.
1458. ThyCa. Thyroid Cancer Survivors' Association, Inc. Available from: <https://www.thyca.org/> [Last accessed: September 12 2023].

Address correspondence to:

*Julie Ann Sosa, MD, MA, FACS*

*Department of Surgery*

*University of California San Francisco (UCSF)*

*Suite S320*

*513 Parnassus Avenue*

*San Francisco*

*CA 94143*

*USA*

*E-mail: Julie.sosa@ucsf.edu*